<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<html>
 <body>
  <pmc-articleset>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Pharmacol Rev
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Pharmacol. Rev
      </journal-id>
      <journal-id journal-id-type="hwp">
       pharmrev
      </journal-id>
      <journal-id journal-id-type="pmc">
       Pharmacol Rev
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       PharmRev
      </journal-id>
      <journal-title-group>
       <journal-title>
        Pharmacological Reviews
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0031-6997
      </issn>
      <issn pub-type="epub">
       1521-0081
      </issn>
      <publisher>
       <publisher-name>
        The American Society for Pharmacology and Experimental Therapeutics
       </publisher-name>
       <publisher-loc>
        Bethesda, MD
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       31537750
      </article-id>
      <article-id pub-id-type="pmc">
       6782023
      </article-id>
      <article-id pub-id-type="publisher-id">
       PHARMREV_017129
      </article-id>
      <article-id pub-id-type="doi">
       10.1124/pr.118.017129
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review Articles
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
       </article-title>
       <alt-title alt-title-type="short">
        Novel Therapeutic Approaches Targeting the RAS
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Arendse
         </surname>
         <given-names>
          Lauren B.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Danser
         </surname>
         <given-names>
          A. H. Jan
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Poglitsch
         </surname>
         <given-names>
          Marko
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Touyz
         </surname>
         <given-names>
          Rhian M.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Burnett
         </surname>
         <given-names>
          John C.
         </given-names>
         <suffix>
          Jr.
         </suffix>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Llorens-Cortes
         </surname>
         <given-names>
          Catherine
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ehlers
         </surname>
         <given-names>
          Mario R.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Sturrock
         </surname>
         <given-names>
          Edward D.
         </given-names>
        </name>
       </contrib>
       <aff>
        Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa (L.B.A., E.D.S.); Division of Pharmacology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands (A.H.J.D.); Attoquant Diagnostics, Vienna, Austria (M.P.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (R.M.T.); Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota (J.C.B.); Institut National de la Santé et de la Recherche Médicale, Paris, France (C.L.-C.); and Clinical Trials Group, Immune Tolerance Network, San Francisco, California (M.R.E.)
       </aff>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Barker
         </surname>
         <given-names>
          Eric L.
         </given-names>
        </name>
        <role>
         ASSOCIATE EDITOR
        </role>
       </contrib>
      </contrib-group>
      <author-notes>
       <corresp>
        <bold>
         Address correspondence to:
        </bold>
        Edward D. Sturrock,
        <addr-line>
         Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town 7925, South Africa.
        </addr-line>
        E-mail:
        <email>
         edward.sturrock@uct.ac.za
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        10
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <month>
        10
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <month>
        10
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>
       71
      </volume>
      <issue>
       4
      </issue>
      <fpage>
       539
      </fpage>
      <lpage>
       570
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2019 by The Author(s)
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>
         This is an open access article distributed under the
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          CC BY-NC Attribution 4.0 International license
         </ext-link>
         .
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="pr.118.017129.pdf" xlink:title="pdf">
      </self-uri>
      <self-uri xlink:href="pr.118.017129_thumb.jpg" xlink:role="icon">
      </self-uri>
      <abstract>
       <p>
        Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT
        <sub>
         1
        </sub>
        R) blockers, current therapies for hypertension and related cardiovascular diseases are still inadequate. Identification of additional components of the RAS and associated vasoactive pathways, as well as new structural and functional insights into established targets, have led to novel therapeutic approaches with the potential to provide improved cardiovascular protection and better blood pressure control and/or reduced adverse side effects. The simultaneous modulation of several neurohumoral mediators in key interconnected blood pressure–regulating pathways has been an attractive approach to improve treatment efficacy, and several novel approaches involve combination therapy or dual-acting agents. In addition, increased understanding of the complexity of the RAS has led to novel approaches aimed at upregulating the ACE2/angiotensin-(1-7)/Mas axis to counter-regulate the harmful effects of the ACE/angiotensin II/angiotensin III/AT
        <sub>
         1
        </sub>
        R axis. These advances have opened new avenues for the development of novel drugs targeting the RAS to better treat hypertension and heart failure. Here we focus on new therapies in preclinical and early clinical stages of development, including novel small molecule inhibitors and receptor agonists/antagonists, less conventional strategies such as gene therapy to suppress angiotensinogen at the RNA level, recombinant ACE2 protein, and novel bispecific designer peptides.
       </p>
      </abstract>
      <abstract abstract-type="graphical">
       <p>
        <fig fig-type="featured" id="absf1" orientation="portrait" position="float">
         <graphic xlink:href="pr.118.017129absf1">
         </graphic>
        </fig>
       </p>
      </abstract>
      <counts>
       <page-count count="32">
       </page-count>
      </counts>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         DJS Export
        </meta-name>
        <meta-value>
         v1
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="s1" sec-type="intro">
     <title>
      I. Introduction
     </title>
     <p>
      Cardiovascular disease is responsible for more than 30% of all deaths worldwide, most of which occur in developing countries (
      <xref ref-type="bibr" rid="B23">
       Benjamin et al., 2017
      </xref>
      ). Hypertension is the main risk factor for cardiovascular disease; despite the availability of more than 100 commercial drugs and drug combinations for treating hypertension, a substantial proportion of the hypertensive population has uncontrolled or suboptimally controlled hypertension (
      <xref ref-type="bibr" rid="B233">
       Oparil and Schmieder, 2015
      </xref>
      ). This contributes to the growing global burden of cardiovascular disease (
      <xref ref-type="bibr" rid="B232">
       Oparil et al., 2018
      </xref>
      ). In addition, patients receiving treatment may suffer from significant side effects such as angiotensin-converting enzyme (ACE) inhibitor–induced persistent cough and, more rarely, life-threatening angioedema (
      <xref ref-type="bibr" rid="B304">
       Simon et al., 1992
      </xref>
      ;
      <xref ref-type="bibr" rid="B4">
       Agah et al., 1997
      </xref>
      ;
      <xref ref-type="bibr" rid="B19">
       Bas, 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B316">
       Stone and Brown, 2017
      </xref>
      ). Suboptimal control of hypertension is associated with target organ damage leading to heart failure, ischemic heart disease, stroke, kidney dysfunction, retinopathy, and vascular dementia, all of which are major causes of disability and premature death. Hence, there is a growing need for novel antihypertensive and cardiovascular drugs that are effective, affordable, and safe with no adverse side effects and that reduce the need for the administration of multiple drugs.
     </p>
     <p>
      Blood pressure and cardiovascular function are regulated by multiple interacting systems, including in large part the enzyme-catalyzed formation and degradation of vasoactive peptides and hormones in overlapping regulatory systems (
      <xref ref-type="fig" rid="F1">
       Fig. 1
      </xref>
      ). Peptidases and receptors within these systems are important drug targets for the treatment of various cardiovascular diseases, including hypertension, heart failure, and coronary artery syndrome.
     </p>
     <fig id="F1" orientation="portrait" position="float">
      <label>
       Fig. 1.
      </label>
      <caption>
       <p>
        Outline of the systems involved in blood pressure regulation. Vasoconstrictor and vasodilator peptides are shown in red and blue rectangles, respectively. Vasopeptidases responsible for the production or degradation of vasoactive peptides are shown in colored spheres (ACE, APP, ECE, and NEP). Production of the vasoconstrictor peptides Ang II and ET-1 (red rectangles) in the RAS and endothelin system, respectively, lead to vasoconstriction, aldosterone secretion, and sodium retention. Bradykinin and NPs (ANP, BNP, and CNP) are potent vasodilatory peptides that counter-regulate the effects of Ang II and ET-1. The vasoactive peptides mediate their physiologic effect via a range of receptors (AT
        <sub>
         1
        </sub>
        R, AT
        <sub>
         2
        </sub>
        R, B
        <sub>
         1
        </sub>
        R, B
        <sub>
         2
        </sub>
        R, ET
        <sub>
         A
        </sub>
        R, ET
        <sub>
         B
        </sub>
        R, NPR-A, NPR-B, and NPR-C).
       </p>
      </caption>
      <graphic xlink:href="pr.118.017129f1">
      </graphic>
     </fig>
    </sec>
    <sec id="s2">
     <title>
      II. Vasoactive Systems Controlling Blood Pressure and Cardiovascular Function
     </title>
     <sec id="s3">
      <title>
       A. The Renin-Angiotensin System
      </title>
      <p>
       The systemic renin-angiotensin system (RAS) plays a central role in regulating extracellular fluid volume and arterial vasoconstriction (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       ). A reduction in renal blood flow or blood sodium levels leads to the release of renin into the circulation, mostly from renal juxtaglomerular cells in the walls of the afferent arterioles of the kidney (
       <xref ref-type="bibr" rid="B63">
        Davis and Freeman, 1976
       </xref>
       ). Renin, an aspartyl protease, is responsible for hydrolyzing the serum globulin, angiotensinogen, releasing the peptide angiotensin I (Ang I; Ang 1-10) (
       <xref ref-type="bibr" rid="B238">
        Page and Helmer, 1940
       </xref>
       ). Ang I is then converted to the potent vasoconstrictor, angiotensin II (Ang II; Ang 1-8), by the zinc metalloprotease, ACE, which is highly expressed by endothelial and epithelial cells in the vasculature, kidneys, and lungs (
       <xref ref-type="bibr" rid="B305">
        Skeggs et al., 1956
       </xref>
       ) and shed into the circulation by unknown proteases (
       <xref ref-type="bibr" rid="B76">
        Ehlers et al., 1996
       </xref>
       ;
       <xref ref-type="bibr" rid="B371">
        Woodman et al., 2000
       </xref>
       ). Ang II, the main vasoactive peptide of angiotensin metabolites in the systemic RAS, elicits its downstream physiologic and pathophysiological effects predominantly via the angiotensin II type 1 receptor (AT
       <sub>
        1
       </sub>
       R), which is ubiquitously expressed in the cardiovascular system. Binding to AT
       <sub>
        1
       </sub>
       R results in vasoconstriction and aldosterone secretion, leading to salt and water retention and ultimately increasing arterial blood pressure. The RAS is regulated by a negative feedback loop whereby Ang II reduces renin gene transcription and renal renin secretion by interacting directly with the juxtaglomerular cells (
       <xref ref-type="bibr" rid="B213">
        Naftilan and Oparil, 1978
       </xref>
       ), decreasing the flux through the pathway. Ang II can also mediate vasodilatory effects by binding to the angiotensin II type 2 receptor (AT
       <sub>
        2
       </sub>
       R). However, this receptor is only expressed at very low levels in the cardiovascular system of healthy adults. The Ang II receptors are reviewed in
       <xref ref-type="bibr" rid="B66">
        de Gasparo et al. (2000)
       </xref>
       .
      </p>
      <p>
       Drugs targeting various components of the systemic RAS, including renin inhibitors, ACE inhibitors, and angiotensin II type 1 receptor blockers (ARBs), are used to treat cardiovascular diseases (
       <xref ref-type="bibr" rid="B9">
        Atlas, 2007
       </xref>
       ;
       <xref ref-type="bibr" rid="B199">
        Mentz et al., 2013
       </xref>
       ). All of these drugs are primarily designed to block and/or reduce the detrimental effects of Ang II. There is, however, increasing evidence that in addition to Ang II, many other angiotensin peptides including Ang III (Ang 2-8), Ang 1-7, Ang 1-9, Ang 3-7, and Ang 3-8 have important physiologic effects. Multiple amino-, endo-, and carboxypeptidases are involved in producing a range of angiotensin metabolites (
       <xref ref-type="fig" rid="F2">
        Fig. 2A
       </xref>
       ), responsible for the activation and/or inhibition of numerous receptors that lead to downstream physiologic effects.
      </p>
      <fig id="F2" orientation="portrait" position="float">
       <label>
        Fig. 2.
       </label>
       <caption>
        <p>
         (A) Angiotensin metabolism. Angiotensin peptides are shown as colored spheres (AGT and Ang metabolites). Peptidases responsible for peptide cleavage are indicated (ACE, ACE2, AP, CHY, DAP, and NEP). Receptors for vasoactive peptides responsible for mediating vasoconstrictive and counteractive vasodilatory responses are indicated in colored rectangles (AT
         <sub>
          1
         </sub>
         R, AT
         <sub>
          2
         </sub>
         R, and Mas). (B) Schematic showing the counter-regulatory effects of the Ang 1
         <bold>
          -
         </bold>
         7/Mas, Ang 1
         <bold>
          -
         </bold>
         9/AT
         <sub>
          2
         </sub>
         R, and Ang II/AT
         <sub>
          2
         </sub>
         R pathways on the Ang II/AT
         <sub>
          1
         </sub>
         R pathway. AGT, angiotensinogen; AP, aminopeptidase; CHY, chymase; DAP, dipeptidyl aminopeptidase.
        </p>
       </caption>
       <graphic xlink:href="pr.118.017129f2">
       </graphic>
      </fig>
      <p>
       The cardiovascular protective peptide Ang 1-7 leads to vasodilatory, antiproliferative, and anti-inflammatory effects mediated via the G protein–coupled receptor (GPCR) Mas (
       <xref ref-type="bibr" rid="B287">
        Santos et al., 2018
       </xref>
       ). Ang 1-7 is produced via the peptidase-mediated cleavage of Ang I, Ang 1
       <bold>
        -
       </bold>
       9, or Ang II (
       <xref ref-type="fig" rid="F2">
        Fig. 2A
       </xref>
       ). Several peptidases can form Ang 1-7, including neprilysin (NEP), ACE homolog ACE2, vascular endothelium prolyl endopeptidase, and smooth muscle thimet oligopeptidase (
       <xref ref-type="bibr" rid="B366">
        Welches et al., 1993
       </xref>
       ;
       <xref ref-type="bibr" rid="B38">
        Chappell et al., 1995
       </xref>
       ;
       <xref ref-type="bibr" rid="B352">
        Vickers et al., 2002
       </xref>
       ). Activation of the ACE2/Ang 1-7/Mas axis leads to cardiovascular and renal-protective actions that counter-regulate the harmful actions of the ACE/Ang II/AT
       <sub>
        1
       </sub>
       R pathway (reviewed in
       <xref ref-type="bibr" rid="B284">
        Santos et al., 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B136">
        Jiang et al., 2014
       </xref>
       ; and
       <xref ref-type="bibr" rid="B241">
        Patel et al., 2016
       </xref>
       ) (
       <xref ref-type="fig" rid="F2">
        Fig. 2B
       </xref>
       ). There is also accumulating evidence that additional receptors, including AT
       <sub>
        2
       </sub>
       R (
       <xref ref-type="bibr" rid="B356">
        Walters et al., 2005
       </xref>
       ;
       <xref ref-type="bibr" rid="B228">
        Ohshima et al., 2014
       </xref>
       ;
       <xref ref-type="bibr" rid="B301">
        Shimada et al., 2015
       </xref>
       ) and Mas-related GPCR member D (
       <xref ref-type="bibr" rid="B102">
        Gembardt et al., 2008
       </xref>
       ;
       <xref ref-type="bibr" rid="B171">
        Lautner et al., 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B325">
        Tetzner et al., 2016
       </xref>
       ), can function as Ang 1-7 receptors and that receptors for Ang II and Ang 1-7 constitute an intricate crossregulated signaling network (reviewed in
       <xref ref-type="bibr" rid="B145">
        Karnik et al., 2017
       </xref>
       ). A recent study suggested that Ang 1-7 acts as a biased agonist of AT
       <sub>
        1
       </sub>
       R, promoting
       <italic>
        β
       </italic>
       -arrestin activation while behaving as a competitive antagonist for detrimental AT
       <sub>
        1
       </sub>
       R pathways initiated by Ang II (
       <xref ref-type="bibr" rid="B100">
        Galandrin et al., 2016
       </xref>
       ). In addition,
       <xref ref-type="bibr" rid="B386">
        Yu et al. (2016)
       </xref>
       showed that the metabolite Ang 1-5 displays cardioprotective properties, stimulating the release of the cardioprotective atrial natriuretic peptide (ANP) via the Mas axis similarly to its parent peptide Ang 1-7. Ang 1-7 is currently in clinical trials to treat diabetic foot ulcers and cancer based on its ability to stimulate wound healing and hematopoietic progenitor cells, respectively (
       <xref ref-type="bibr" rid="B264">
        Rodgers et al., 2015
       </xref>
       ;
       <xref ref-type="bibr" rid="B290">
        Savage et al., 2016
       </xref>
       ;
       <xref ref-type="bibr" rid="B244">
        Pinter et al., 2018
       </xref>
       ), further exemplifying the diverse functions of this peptide and the RAS.
      </p>
      <p>
       ACE2 also plays a role in the conversion of Ang I to Ang 1
       <bold>
        -
       </bold>
       9 (albeit with much lower efficiency than conversion of Ang II to Ang 1
       <bold>
        -
       </bold>
       7), an additional counter-regulatory peptide that reduces adverse cardiovascular remodeling, cardiomyocyte hypertrophy, and cardiac fibrosis in various animal models of hypertension and myocardial infarction after subcutaneous administration (
       <xref ref-type="bibr" rid="B222">
        Ocaranza et al., 2010
       </xref>
       ,
       <xref ref-type="bibr" rid="B223">
        2014
       </xref>
       ;
       <xref ref-type="bibr" rid="B89">
        Flores-Muñoz et al., 2011
       </xref>
       ,
       <xref ref-type="bibr" rid="B90">
        2012
       </xref>
       ). These beneficial effects were blocked by coadministration of an AT
       <sub>
        2
       </sub>
       R antagonist but not a Mas antagonist, suggesting that these counter-regulatory effects, independent of the ACE2/Ang 1
       <bold>
        -
       </bold>
       7/Mas axis, are mediated through AT
       <sub>
        2
       </sub>
       R (
       <xref ref-type="bibr" rid="B89">
        Flores-Muñoz et al., 2011
       </xref>
       ,
       <xref ref-type="bibr" rid="B90">
        2012
       </xref>
       ). In addition,
       <xref ref-type="bibr" rid="B81">
        Fattah et al. (2016)
       </xref>
       showed that gene therapy with Ang 1
       <bold>
        -
       </bold>
       9 is cardioprotective in a murine model of myocardial infarction. Ang 1
       <bold>
        -
       </bold>
       9 is also a competitive inhibitor of ACE, thereby decreasing Ang II levels and, like Ang 1
       <bold>
        -
       </bold>
       7, has been shown to potentiate bradykinin effects via the B
       <sub>
        2
       </sub>
       receptor (B
       <sub>
        2
       </sub>
       R) (
       <xref ref-type="bibr" rid="B131">
        Jackman et al., 2002
       </xref>
       ). Angiotensin metabolites, including Ang 1
       <bold>
        -
       </bold>
       7, Ang 3
       <bold>
        -
       </bold>
       7, and Ang 3
       <bold>
        -
       </bold>
       8, also display unique pharmacological effects in biologic processes beyond blood pressure regulation and cardiovascular function, including brain function, dopamine regulation, and insulin secretion (
       <xref ref-type="bibr" rid="B375">
        Wright et al. 1993
       </xref>
       ;
       <xref ref-type="bibr" rid="B317">
        Stragier et al., 2005
       </xref>
       ;
       <xref ref-type="bibr" rid="B85">
        Ferreira et al., 2007
       </xref>
       ).
      </p>
      <p>
       ARBs and ACE inhibitors alter the peptide fluxes through the systemic RAS by elevating renin secretion, although ACE inhibitors in particular lead to a prominent increase in plasma levels of Ang 1
       <bold>
        -
       </bold>
       7, potentiating their antihypertensive and cardioprotective effects (
       <xref ref-type="table" rid="T1">
        Table 1
       </xref>
       ). ACE is the primary enzyme responsible for the degradation of Ang 1
       <bold>
        -
       </bold>
       7 (
       <xref ref-type="bibr" rid="B37">
        Chappell et al., 1998
       </xref>
       ), which further explains the increase in Ang 1
       <bold>
        -
       </bold>
       7 and Ang 1
       <bold>
        -
       </bold>
       9 plasma levels associated with ACE inhibitors. An undesirable effect of ACE inhibition is the increase in renin secretion and consequently the flux through the RAS due to suppression of the Ang II–mediated negative feedback loop. These processes lead to decreased pharmacologic efficacy of ACE inhibitors during long-term treatment caused by incomplete inhibition of Ang II formation while Ang I is abundantly present as a substrate for ACE due to a high plasma renin activity. This results in a new steady state where Ang II levels are no longer suppressed, whereas Ang 1
       <bold>
        -
       </bold>
       7 levels are elevated (
       <xref ref-type="table" rid="T1">
        Table 1
       </xref>
       ). ACE inhibitors are very effective in many cardiovascular diseases and are the first-line treatment of heart failure, myocardial infarction, and nephropathy unless ACE inhibitors are poorly tolerated. ARBs were not found to be superior to ACE inhibitors for these conditions and are recommended when ACE inhibitors are not tolerated (
       <xref ref-type="bibr" rid="B245">
        Pitt et al., 2000
       </xref>
       ;
       <xref ref-type="bibr" rid="B53">
        Dahlöf et al., 2002
       </xref>
       ;
       <xref ref-type="bibr" rid="B108">
        Granger et al., 2003
       </xref>
       ;
       <xref ref-type="bibr" rid="B388">
        Yusuf et al., 2008
       </xref>
       ). More recently, ACE2 activators, AT
       <sub>
        2
       </sub>
       R agonists, and Mas agonists have been investigated in preclinical models as antihypertensive agents to oppose harmful effects of the RAS (
       <xref ref-type="bibr" rid="B324">
        Tamargo et al., 2015
       </xref>
       ).
      </p>
      <table-wrap id="T1" orientation="portrait" position="float">
       <label>
        TABLE 1
       </label>
       <caption>
        <p>
         Effects of antihypertensive drug classes on plasma vasoactive peptide levels and renin activity
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th colspan="1" rowspan="1">
           Drug Class
          </th>
          <th align="center" colspan="1" rowspan="1">
           Ang I
          </th>
          <th align="center" colspan="1" rowspan="1">
           Ang II
          </th>
          <th align="center" colspan="1" rowspan="1">
           Ang 1
           <bold>
            -
           </bold>
           7
          </th>
          <th align="center" colspan="1" rowspan="1">
           BK 1-9
          </th>
          <th align="center" colspan="1" rowspan="1">
           ANP, BNP
          </th>
          <th align="center" colspan="1" rowspan="1">
           PRC
          </th>
          <th align="center" colspan="1" rowspan="1">
           PRA
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td colspan="1" rowspan="1">
           ARB
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           ACEi
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           C-ACEi
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           NEPi
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           ACEi/NEPi
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           ARNI
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           AGT-siRNA
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓↓
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           DRI
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓↓
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           APAi
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           rhACE2
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↓↓
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           =
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
          <td align="center" colspan="1" rowspan="1">
           ↑↑
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          Upward arrows indicate upregulation, downward arrows indicate downregulation, and equal signs indicate no change. ACEi, ACE inhibitor; ACEi/NEPi, dual ACE and NEP inhibitor; AGT-siRNA, angiotensinogen siRNA; APAi, amino peptidase A inhibitor; C-ACEi, C-domain–selective ACE inhibitor; DRI, direct renin inhibitor; NEPi, NEP inhibitor; PRA, plasma renin activity; PRC, plasma renin concentration.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </sec>
     <sec id="s4">
      <title>
       B. The Kinin System
      </title>
      <p>
       The kinin system is a key hormonal pathway that counter-regulates an overactive RAS. Kinin peptides, of which the best-known member is bradykinin (BK 1
       <bold>
        -
       </bold>
       9), are potent vasodilators and important inflammatory mediators generated from kininogen precursors by the serine protease, kallikrein (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       ) (
       <xref ref-type="bibr" rid="B257">
        Regoli and Barabé, 1980
       </xref>
       ;
       <xref ref-type="bibr" rid="B140">
        Kakoki and Smithies, 2009
       </xref>
       ). Bradykinin causes vasodilation, induces prostaglandin production, and increases vascular permeability and fluid extravasation. Two kinin receptors have been identified: B
       <sub>
        1
       </sub>
       R and B
       <sub>
        2
       </sub>
       R (
       <xref ref-type="bibr" rid="B173">
        Leeb-Lundberg et al., 2005
       </xref>
       ). The vasodilatory effects of bradykinin are predominantly mediated through B
       <sub>
        2
       </sub>
       R, which is constitutively expressed in most tissues and is abundant in vascular endothelial cells. B
       <sub>
        1
       </sub>
       R is minimally expressed in healthy tissue but is induced by tissue injury and plays a role in chronic pain and inflammation.
      </p>
      <p>
       Bradykinin is cleaved into inactive fragments by ACE and several other peptidases, including aminopeptidase P (APP), NEP, endothelin-converting enzyme (ECE)-1, ACE2, carboxypeptidase N, and dipeptidyl peptidase IV (
       <xref ref-type="bibr" rid="B306">
        Skidgel et al., 1984
       </xref>
       ;
       <xref ref-type="bibr" rid="B122">
        Hoang and Turner, 1997
       </xref>
       ;
       <xref ref-type="bibr" rid="B165">
        Kuoppala et al., 2000
       </xref>
       ;
       <xref ref-type="bibr" rid="B96">
        Fryer et al., 2008
       </xref>
       ) (
       <xref ref-type="fig" rid="F3">
        Fig. 3
       </xref>
       ). ACE is the major bradykinin-metabolizing enzyme in human blood plasma (
       <xref ref-type="bibr" rid="B165">
        Kuoppala et al., 2000
       </xref>
       ) and accordingly, treatment with ACE inhibitors results in a substantial increase in bradykinin levels, potentiating their vasodilatory and antihypertensive effects. There is also crosstalk between the RAS and the kinin system, and the benefits of ACE inhibition can be partially attributed to an intracellular inhibitor-induced ACE-mediated signaling cascade that leads to changes in gene expression and potentiation of the bradykinin response by inhibiting the desensitization of B
       <sub>
        2
       </sub>
       R (
       <xref ref-type="bibr" rid="B24">
        Benzing et al., 1999
       </xref>
       ;
       <xref ref-type="bibr" rid="B191">
        Marcic et al., 1999
       </xref>
       ;
       <xref ref-type="bibr" rid="B331">
        Tom et al., 2001
       </xref>
       ;
       <xref ref-type="bibr" rid="B111">
        Guimarães et al., 2011
       </xref>
       ). Bradykinin potentiation is, however, a double-edged sword: although the potent vasodilatory effects of ACE inhibitors can be attributed in part to increased levels of bradykinin, excessive bradykinin potentiation seems to be associated with the principle side effects caused by ACE inhibitors. The major side effect is persistent cough. It was also thought that ACE inhibitor–associated angioedema is due to increased bradykinin (
       <xref ref-type="bibr" rid="B127">
        Israili and Hall, 1992
       </xref>
       ;
       <xref ref-type="bibr" rid="B94">
        Fox et al., 1996
       </xref>
       ) but recent clinical studies do not support this (
       <xref ref-type="bibr" rid="B318">
        Straka et al., 2017
       </xref>
       ). Considering the functional interactions between the RAS and kinin systems, there is growing interest in developing new drugs that target both systems, which would have greater efficacy than targeting only one system.
      </p>
      <fig id="F3" orientation="portrait" position="float">
       <label>
        Fig. 3.
       </label>
       <caption>
        <p>
         Bradykinin metabolism. Bradykinin peptides are shown as colored spheres. Peptidases responsible for peptide cleavage are indicated (ACE, ACE2, APP, CPN, DPPIV, and NEP). Bradykinin receptors B
         <sub>
          1
         </sub>
         R and B
         <sub>
          2
         </sub>
         R are indicated in green rectangles. CPN, carboxypeptidase N; DPP-IV, dipeptidyl peptidase IV.
        </p>
       </caption>
       <graphic xlink:href="pr.118.017129f3">
       </graphic>
      </fig>
     </sec>
     <sec id="s5">
      <title>
       C. The Natriuretic Peptide System
      </title>
      <p>
       Natriuretic peptides (NPs) are a family of structurally related signaling molecules that signal through activation of guanylyl cyclases. They have natriuretic and vascular smooth muscle–relaxing activity and regulate cardiovascular, skeletal, and kidney function. In general, NPs are cardiovascular protective and lower blood pressure, maintain fluid volume homeostasis, and reduce cardiovascular fibrosis (reviewed in
       <xref ref-type="bibr" rid="B239">
        Pandey, 2005
       </xref>
       ). There are three forms of NPs, ANP, B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), all of which are processed from preprohormones to mature forms that contain a C-terminal disulphide ring structure. ANP is expressed and stored primarily in granules in the atria, but it is expressed at lower levels in other tissues, including the ventricles and kidney. ANP release is primarily stimulated by atrial wall stretching (
       <xref ref-type="bibr" rid="B65">
        de Bold et al., 1986
       </xref>
       ;
       <xref ref-type="bibr" rid="B75">
        Edwards et al., 1988
       </xref>
       ) but can also be stimulated by cardiac transmural pressure as well as various hormone stimuli (
       <xref ref-type="bibr" rid="B166">
        Lachance et al., 1986
       </xref>
       ;
       <xref ref-type="bibr" rid="B313">
        Stasch et al., 1989
       </xref>
       ;
       <xref ref-type="bibr" rid="B310">
        Soualmia et al., 1997
       </xref>
       ), such as endothelin, Ang 1
       <bold>
        -
       </bold>
       9, and Ang 1
       <bold>
        -
       </bold>
       7. Although BNP was originally isolated from the brain and is commonly referred to as brain NP, it is predominantly expressed in the ventricles of the heart, where it is transcriptionally regulated by cardiac wall stretching. Both ANP and BNP plasma levels can be elevated up to 100-fold in patients with heart failure (
       <xref ref-type="bibr" rid="B46">
        Cody et al., 1986
       </xref>
       ;
       <xref ref-type="bibr" rid="B252">
        Raine et al., 1986
       </xref>
       ;
       <xref ref-type="bibr" rid="B208">
        Mukoyama et al., 1991
       </xref>
       ;
       <xref ref-type="bibr" rid="B186">
        Maisel et al., 2002
       </xref>
       ;
       <xref ref-type="bibr" rid="B1">
        Abassi et al., 2004
       </xref>
       ). In contrast, CNP is found at low levels in the heart, and its plasma levels are generally unchanged during heart failure (
       <xref ref-type="bibr" rid="B364">
        Wei et al., 1993
       </xref>
       ). Rather, CNP is expressed at high concentrations in chondrocytes, where it regulates bone growth (
       <xref ref-type="bibr" rid="B113">
        Hagiwara et al., 1994
       </xref>
       ). In addition, CNP is believed to be an endothelium-derived hyperpolarizing factor, mediating relaxation in the vascular wall (
       <xref ref-type="bibr" rid="B354">
        Villar et al., 2007
       </xref>
       ).
      </p>
      <p>
       The complexity of the NP system is further increased by the presence of three types of natriuretic peptide receptors (NPRs). The classification and specific roles of these receptors have been extensively reviewed (
       <xref ref-type="bibr" rid="B239">
        Pandey, 2005
       </xref>
       ). Briefly, NPR-A [particulate guanylyl cyclase A (pGC-A)] and NPR-B are transmembrane guanylate cyclases and are primarily responsible for the physiologic effects of NPs. ANP and BNP activate NPR-A and CNP activates NPR-B, leading to the production of second-messenger cGMP. NPR-C serves as a clearance receptor for all three peptides indiscriminately, mediating NP internalization followed by lysosomal degradation. In addition to receptor-mediated clearance, all three NPs are cleared rapidly from the extracellular matrix by NEP (
       <xref ref-type="bibr" rid="B247">
        Potter, 2011
       </xref>
       ), a glycosylated neutral zinc endopeptidase expressed at high levels in the proximal tubule cells of the kidney.
      </p>
      <p>
       Because of the counter-regulatory actions of the NPs on detrimental Ang II/AT
       <sub>
        1
       </sub>
       R effects, augmentation of the NP system has been explored as an additional therapeutic strategy for the treatment of hypertension and cardiovascular disease. Intravenous administration of recombinant forms of ANP and BNP can improve the clinical status of patients with heart failure (
       <xref ref-type="bibr" rid="B47">
        Colucci et al., 2000
       </xref>
       ;
       <xref ref-type="bibr" rid="B320">
        Suwa et al., 2005
       </xref>
       ;
       <xref ref-type="bibr" rid="B117">
        Hata et al., 2008
       </xref>
       ;
       <xref ref-type="bibr" rid="B224">
        O’Connor et al., 2011
       </xref>
       ), but increased rates of hypotension and short half-lives have restricted their routine clinical use. NP analogs (M-ANP, cenderitide-NP, and PL-3994 (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)), which are more resistant to enzymatic degradation and act as NPR agonists, are currently undergoing clinical testing. The other approach investigated extensively to increase circulating NP levels is NEP inhibition. Under normal conditions, NPR-C and NEP make similar contributions to NP clearance (
       <xref ref-type="bibr" rid="B229">
        Okolicany et al., 1992
       </xref>
       ;
       <xref ref-type="bibr" rid="B39">
        Charles et al., 1996
       </xref>
       ); however, in pathologic conditions, in which NP levels are elevated and clearance receptors may be saturated, NEP plays a more significant role and inhibition of NEP is sufficient to elevate NP levels (
       <xref ref-type="bibr" rid="B116">
        Hashimoto et al., 1994
       </xref>
       ). Nevertheless, despite the successful development of potent NEP inhibitors effective at increasing NP levels, NEP inhibition has only proved useful for blood pressure control and cardiovascular function when combined with inhibition of the RAS (reviewed in
       <xref ref-type="bibr" rid="B33">
        Campbell, 2017
       </xref>
       ) and is discussed in more detail below.
      </p>
     </sec>
     <sec id="s6">
      <title>
       D. The Endothelin System
      </title>
      <p>
       The endothelin system (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       ) functions together with the RAS to maintain blood pressure and vascular tone. Preproendothelin-1 is a precursor of proendothelin-1, produced largely by endothelial cells, and is processed by furan convertase to the 38-amino-acid peptide big endothelin-1 (
       <xref ref-type="bibr" rid="B128">
        Itoh et al., 1988
       </xref>
       ;
       <xref ref-type="bibr" rid="B69">
        Denault et al., 1995
       </xref>
       ). Big endothelin-1 is then cleaved by another zinc metallopeptidase, ECE-1 (
       <xref ref-type="bibr" rid="B322">
        Takahashi et al., 1993
       </xref>
       ), to produce endothelin-1 (ET-1), a 21-amino-acid vasoactive peptide (
       <xref ref-type="bibr" rid="B379">
        Yanagisawa et al., 1988
       </xref>
       ;
       <xref ref-type="bibr" rid="B151">
        Kimura et al., 1989
       </xref>
       ) that mediates its potent vasoconstrictor actions via the GPCRs endothelin receptors A and B (ET
       <sub>
        A
       </sub>
       R and ET
       <sub>
        B
       </sub>
       R, respectively) (
       <xref ref-type="bibr" rid="B133">
        Jandeleit-Dahm, 2006
       </xref>
       ;
       <xref ref-type="bibr" rid="B206">
        Motte et al., 2006
       </xref>
       ), which, much like the angiotensin receptors AT
       <sub>
        1
       </sub>
       R and AT
       <sub>
        2
       </sub>
       R, exert opposing effects on vasoregulation and cell growth. ET
       <sub>
        A
       </sub>
       R mediates the predominant responses associated with pathologic conditions, including potent prolonged vasoconstriction as a result of irreversible ET-1 binding (
       <xref ref-type="bibr" rid="B275">
        Rubanyi and Polokoff, 1994
       </xref>
       ;
       <xref ref-type="bibr" rid="B147">
        Kedzierski and Yanagisawa, 2001
       </xref>
       ). In contrast, endothelial ET
       <sub>
        B
       </sub>
       R mediates nitric oxide–mediated vasorelaxation and functions as a clearance receptor, facilitating removal of ET-1 from the circulation for lysosomal degradation (
       <xref ref-type="bibr" rid="B30">
        Bremnes et al., 2000
       </xref>
       ). There are multiple complex interactions between the RAS and the endothelin systems, including a positive dual-feedback system: Ang II increases expression of preproendothelin-1 mRNA and functional ECE-1 activity, leading to an increase in ET-1 levels (
       <xref ref-type="bibr" rid="B125">
        Imai et al., 1992
       </xref>
       ;
       <xref ref-type="bibr" rid="B18">
        Barton et al., 1997
       </xref>
       ;
       <xref ref-type="bibr" rid="B272">
        Rossi et al., 1999
       </xref>
       ). However, in some clinical conditions such as preeclampsia, ET-1 activation was associated with reduced levels of renin and aldosterone and increased mean arterial pressure (
       <xref ref-type="bibr" rid="B351">
        Verdonk et al., 2015
       </xref>
       ). The natriuretic and endothelin systems are also linked by a feedback mechanism whereby ET-1 stimulates the release of NPs, which in turn suppress the actions of the endothelin system (
       <xref ref-type="bibr" rid="B313">
        Stasch et al., 1989
       </xref>
       ). ET-1 is degraded by NEP (
       <xref ref-type="bibr" rid="B353">
        Vijayaraghavan et al., 1990
       </xref>
       ); thus, the vasodilatory effect of elevated NP levels caused by NEP inhibitors may be counter-regulated by increased levels of ET-1.
      </p>
      <p>
       The endothelin system has been a target for therapeutic intervention due to its pathophysiological role in hypertension, pulmonary arterial hypertension, heart failure, renal disease, and diabetes. ET
       <sub>
        A
       </sub>
       R/ET
       <sub>
        B
       </sub>
       R and selective ET
       <sub>
        A
       </sub>
       R antagonists, such as bosentan, macitentan, and ambrisentan, are used clinically for the treatment of pulmonary arterial hypertension, but their use is associated with side effects, including edema, anemia, increased risk of heart failure, and hepatic transaminitis (
       <xref ref-type="bibr" rid="B363">
        Wei et al., 2016
       </xref>
       ;
       <xref ref-type="bibr" rid="B237">
        Packer et al., 2017
       </xref>
       ). Based on the dual-feedback system linking the endothelin system and the RAS, dual AT
       <sub>
        1
       </sub>
       R/ET
       <sub>
        A
       </sub>
       R antagonists have been developed and tested in the clinic for pulmonary arterial hypertension, essential hypertension, and chronic kidney disease (
       <xref ref-type="bibr" rid="B212">
        Murugesan et al., 2002
       </xref>
       ,
       <xref ref-type="bibr" rid="B211">
        2005
       </xref>
       ;
       <xref ref-type="bibr" rid="B221">
        Neutel et al., 2008
       </xref>
       ;
       <xref ref-type="bibr" rid="B155">
        Komers and Plotkin, 2016
       </xref>
       ;
       <xref ref-type="bibr" rid="B154">
        Komers et al., 2017
       </xref>
       ); however, it is still to be established whether the protective benefits outweigh the risk of adverse reactions. ECE-1 inhibitors as well as dual ECE-1/NEP inhibitors have also been developed but showed poor efficacy in humans (
       <xref ref-type="bibr" rid="B70">
        Dickstein et al., 2004
       </xref>
       ).
      </p>
     </sec>
     <sec id="s7">
      <title>
       E. General Biochemical Features of Vasoactive Peptide Hormone Cascades
      </title>
      <p>
       Biochemical processes involved in the generation of vasoactive hormones and peptides are complex and involve the mechanisms of hormone formation and secretion. For the peptide cascades addressed in this article, two distinct mechanisms that can be described in terms of stoichiometric relations and localization of the corresponding precursor hormones. Whereas endothelins and NPs are typically generated by intracellular processing or membrane-bound enzymes locally in tissues (
       <xref ref-type="bibr" rid="B278">
        Russell and Davenport, 1999
       </xref>
       ), angiotensins and bradykinins are derived from primarily liver-secreted precursor peptides that are abundantly present in plasma, serving as a virtually inexhaustible source for the formation of active hormone molecules throughout the body. Angiotensinogen levels in human plasma range between 50 and 150
       <italic>
        µ
       </italic>
       g/ml (1–3
       <italic>
        µ
       </italic>
       M); women have much higher plasma angiotensinogen concentrations, especially during pregnancy (
       <xref ref-type="bibr" rid="B351">
        Verdonk et al., 2015
       </xref>
       ). Plasma concentrations for the bradykinin precursors, low molecular weight and high molecular weight kininogen, were reported to be in the low micromolar range (
       <xref ref-type="bibr" rid="B152">
        Kleniewski, 1979
       </xref>
       ;
       <xref ref-type="bibr" rid="B167">
        Lalmanach et al., 2010
       </xref>
       ). Therefore, plasma concentrations of both the bradykinin and the angiotensin precursor are more than 100,000-fold higher than plasma concentration for BK 1
       <bold>
        -
       </bold>
       9 and Ang I, which are reported to be in the low picomolar range. This allows for virtually unlimited hormone synthesis within the plasma compartment. However, formation of bradykinin and angiotensin in the circulation is determined by the tightly regulated concentration and activity of the enzymes kallikrein and renin. Ang I and BK 1
       <bold>
        -
       </bold>
       9 are continuously produced by plasma renin and kallikrein throughout the body while being simultaneously converted to other downstream metabolites by a variety of soluble proteases including ACE and aminopeptidases, representing the major metabolic pathways in human plasma. Although the enzymatic composition of plasma is similar throughout the body, local peptide hormone levels can be different due to tissue expression of enzymes and receptors producing, converting, or binding certain peptide metabolites and thereby modifying the baseline peptide hormone profile that is established by intrinsic peptide formation within the plasma compartment.
      </p>
      <p>
       Drugs interfering with proteases involved in hormone metabolism directly affect formation and degradation rates of peptide products and substrates. Depending on the site of target expression, pharmacodynamic effects might be seen in plasma or limited to tissue sites, which requires careful selection of analytic approaches when aiming to establish relationships between pharmacodynamics and physiologic effects.
      </p>
     </sec>
    </sec>
    <sec id="s8">
     <title>
      III. Therapeutic Targets of the Renin-Angiotensin System and Associated Pathways
     </title>
     <p>
      ACE inhibitors, the first drugs targeting the RAS, have been used effectively for the treatment of a wide range of indications related to hypertension, cardiovascular disease, and renal disease for over 30 years. Since the discovery of the first ACE inhibitors and later the development of ARBs, there has been growing interest in the development of inhibitors that target other structurally related vasopeptidases as well as other receptors for vasoactive peptides. Driven largely by the success of RAS blockade but also the observation that suppression of the RAS does not, in many cases, lead to an adequate reduction in blood pressure, extensive effort has gone into developing therapies that target multiple vasoactive pathways controlling blood pressure and cardiovascular function.
     </p>
     <sec id="s9">
      <title>
       A. Angiotensin-Converting Enzyme
      </title>
      <p>
       ACE (also known as peptidyl dipeptidase; EC 3.4.15.1) is a type I membrane-anchored zinc dipeptidyl carboxypeptidase responsible for the cleavage of a diverse set of substrates, including angiotensin peptides, bradykinin, substance P, and gonadotropin-releasing hormone or luteinizing hormone-releasing hormone. ACE exists as two isoforms, somatic ACE and testes ACE, that are transcribed from the same gene in a tissue-specific manner. Somatic ACE is a 1227-amino-acid protein that is expressed widely, particularly in endothelial and epithelial cells. Testes ACE is a smaller form consisting of 701 amino acids expressed only in sperm cells. Both isoforms consist of a heavily glycosylated ectodomain that can be shed from the membrane. Plasma ACE is derived from endothelial ACE by shedding a 1203-amino-acid isoform of 150–180 kDa. The concentration of ACE in human plasma is reported to range between 36 and 288 ng/ml (260–2076 pM), which is an almost 200-fold molar excess compared with Ang I, its major substrate within the RAS (
       <xref ref-type="bibr" rid="B80">
        Fagyas et al., 2014
       </xref>
       ). Despite this excess of enzyme over its substrate, soluble ACE likely has limited impact on tissue Ang II levels, which might be more dependent on the local conversion of Ang I to Ang II by endothelial ACE in direct proximity to AT
       <sub>
        1
       </sub>
       R (
       <xref ref-type="bibr" rid="B56">
        Danser et al., 2007
       </xref>
       ). The ectodomain of somatic ACE consists of two homologous catalytically active domains, the N and C domains, whereas the ectodomain of testes ACE consists of only the C domain (
       <xref ref-type="bibr" rid="B311">
        Soubrier et al., 1988
       </xref>
       ). Crystal structures of individual N and C domains reveal that they are ellipsoid in shape and mostly
       <italic>
        α
       </italic>
       -helical (
       <xref ref-type="bibr" rid="B217">
        Natesh et al., 2003
       </xref>
       ;
       <xref ref-type="bibr" rid="B50">
        Corradi et al., 2006
       </xref>
       ). The catalytic zinc ion is buried deep in the active-site cavity and a chloride ion is typically observed at each of the two chloride binding sites. The active site contains the conserved HEXXH zinc binding motif, containing the two histidine residues that coordinate the zinc ion together with a conserved glutamate residue and a water molecule that is displaced upon ligand coordination (
       <xref ref-type="bibr" rid="B370">
        Williams et al., 1994
       </xref>
       ). The N and C domains display distinct but overlapping substrate specificity and physiologic functions, differences in chloride dependence, and distinct glycosylation patterns (
       <xref ref-type="bibr" rid="B365">
        Wei et al., 1992
       </xref>
       ;
       <xref ref-type="bibr" rid="B231">
        O’Neill et al., 2008
       </xref>
       ). Both domains catalyze the degradation of bradykinin with similar efficiency and both N-domain and C-domain knockout mice show similar bradykinin plasma levels as wild-type mice (
       <xref ref-type="bibr" rid="B341">
        van Esch et al., 2005
       </xref>
       ;
       <xref ref-type="bibr" rid="B26">
        Bernstein et al., 2011
       </xref>
       ), suggesting that bradykinin cleavage by one domain can effectively compensate for the absence of the other domain. In contrast, the C domain is the primary site for Ang II formation and is essential and sufficient for controlling blood pressure in vivo (
       <xref ref-type="bibr" rid="B139">
        Junot et al., 2001
       </xref>
       ;
       <xref ref-type="bibr" rid="B341">
        van Esch et al., 2005
       </xref>
       ;
       <xref ref-type="bibr" rid="B98">
        Fuchs et al., 2008
       </xref>
       ;
       <xref ref-type="bibr" rid="B26">
        Bernstein et al., 2011
       </xref>
       ;
       <xref ref-type="bibr" rid="B32">
        Burger et al., 2014
       </xref>
       ). The N domain is the primary site for the clearance of the tetrapeptide
       <italic>
        N
       </italic>
       -acetyl-Ser–Asp–Lys–Pro (Ac-SDKP) (
       <xref ref-type="bibr" rid="B12">
        Azizi et al., 1999
       </xref>
       ;
       <xref ref-type="bibr" rid="B139">
        Junot et al., 2001
       </xref>
       ;
       <xref ref-type="bibr" rid="B97">
        Fuchs et al., 2004
       </xref>
       ), a potent anti-inflammatory and antifibrotic peptide. Consequently, it may be desirable to selectively target individual domains, and several domain-specific residues within the active site have been identified that are important for conferring domain selectivity (
       <xref ref-type="fig" rid="F4">
        Fig. 4
       </xref>
       ) (
       <xref ref-type="bibr" rid="B358">
        Watermeyer et al., 2008
       </xref>
       ,
       <xref ref-type="bibr" rid="B359">
        2010
       </xref>
       ;
       <xref ref-type="bibr" rid="B162">
        Kröger et al., 2009
       </xref>
       ). To date, there are more than 30 structures of the individual domains in complex with a variety of peptides and inhibitors.
      </p>
      <fig id="F4" orientation="portrait" position="float">
       <label>
        Fig. 4.
       </label>
       <caption>
        <p>
         A schematic diagram of ACE active sites [Schechter and Berger nomenclature (
         <xref ref-type="bibr" rid="bib397">
          Schechter and Berger, 1967
         </xref>
         )] showing the subsite binding pockets accommodating the residues on either side of the ZBG of peptide substrates. ACE domain-specific amino acid residues important for conferring domain selectivity are shown within the relevant subsites of the ACE active site.
        </p>
       </caption>
       <graphic xlink:href="pr.118.017129f4">
       </graphic>
      </fig>
     </sec>
     <sec id="s10">
      <title>
       B. Angiotensin-Converting Enzyme 2
      </title>
      <p>
       Another important peptidase in the RAS is ACE2 (also known as ACE-related carboxypeptidase; EC 3.4.17.23), a type I membrane-anchored zinc carboxypeptidase (
       <xref ref-type="bibr" rid="B73">
        Donoghue et al., 2000
       </xref>
       ;
       <xref ref-type="bibr" rid="B329">
        Tipnis et al., 2000
       </xref>
       ). ACE2 cleaves multiple substrates including vasoactive peptides involved in the pathology of cardiovascular disease. ACE2 converts Ang II to Ang 1
       <bold>
        -
       </bold>
       7 by removing the C-terminal phenylalanine residue (
       <xref ref-type="bibr" rid="B329">
        Tipnis et al., 2000
       </xref>
       ;
       <xref ref-type="bibr" rid="B352">
        Vickers et al., 2002
       </xref>
       ) and is thus a major component of the counter-regulatory axis of the RAS (
       <xref ref-type="bibr" rid="B284">
        Santos et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="B287">
        2018
       </xref>
       ). ACE2 also acts on Ang I to produce Ang 1
       <bold>
        -
       </bold>
       9, albeit with lower efficiency. This ACE2-dependent formation of Ang 1
       <bold>
        -
       </bold>
       9 is particularly relevant during ACE inhibition, where Ang I is abundantly present as a substrate in humans and ACE2 treatment might result in a profound increase of Ang 1
       <bold>
        -
       </bold>
       9 (
       <xref ref-type="bibr" rid="B22">
        Basu et al., 2017
       </xref>
       ). In addition to these angiotensin peptide substrates within the RAS, it is very likely that Ang III and Ang IV, sharing their C terminus with the preferred ACE2 substrate Ang II, serve as additional ACE2 substrates, but this still needs to be demonstrated in vivo. Other ACE2 substrates include des-Arg9-bradykinin, apelin-13, and dynorphin A-(1-13) (
       <xref ref-type="bibr" rid="B352">
        Vickers et al., 2002
       </xref>
       ); in addition to its catalytic functions, ACE2 also has noncatalytic functions, acting as a functional receptor for the coronavirus that causes severe acute respiratory syndrome (
       <xref ref-type="bibr" rid="B178">
        Li et al., 2003
       </xref>
       ,
       <xref ref-type="bibr" rid="B177">
        2005
       </xref>
       ) and playing a role in amino acid transport (
       <xref ref-type="bibr" rid="B161">
        Kowalczuk et al., 2008
       </xref>
       ).
      </p>
      <p>
       ACE2 is predominantly localized on endothelial cells and is widely expressed within tissues, including the heart, kidneys, testes, brain, intestine, and lungs (
       <xref ref-type="bibr" rid="B329">
        Tipnis et al., 2000
       </xref>
       ). ACE2 is an 805-amino-acid protein with a single catalytic domain that shares ∼60% and ∼40% sequence identity with the N and C domains of somatic ACE, respectively. The transmembrane region and cytoplasmic tail of ACE2 is distinct from ACE, sharing close homology with collectrin, a molecular chaperone of a renal amino acid transporter B
       <sup>
        0
       </sup>
       AT1 (
       <xref ref-type="bibr" rid="B55">
        Danilczyk et al., 2006
       </xref>
       ) and ACE2 indeed acts as a chaperone for the same amino acid transporter in the small intestine where collectrin is not expressed (
       <xref ref-type="bibr" rid="B161">
        Kowalczuk et al., 2008
       </xref>
       ). Like ACE, the glycosylated ectodomain of ACE2 is shed from the membrane and released into circulation: ACE2 is shed by the disintegrin and metalloprotease ADAM 17 (
       <xref ref-type="bibr" rid="B168">
        Lambert et al., 2005
       </xref>
       ), although the enzymes responsible for ACE shedding have not yet been identified.
      </p>
      <p>
       In humans, circulating ACE2 is not detectable in healthy individuals and its presence is highly associated with cardiovascular risk factors. In a study involving 534 healthy subjects, ACE2 activity was detectable in 40 subjects only, whereas soluble ACE2 levels were below the assay detection limit of 2.7 pM in the remaining 494 subjects. The 40 subjects having mean ACE2 levels of 33.0 pM showed a stronger exposure to cardiovascular risk factors including abdominal adiposity, hypertension, and elevated fasting glucose and lipid levels (
       <xref ref-type="bibr" rid="B259">
        Rice et al., 2006
       </xref>
       ). Serum ACE2 activity is increased in patients with heart failure while correlating with the severity of heart failure (
       <xref ref-type="bibr" rid="B78">
        Epelman et al., 2008
       </xref>
       ) and was reported to predict the combined clinical endpoint of all-cause mortality, heart failure hospitalization, and heart transplantation in a cohort of 113 stable patients with chronic systolic heart failure (
       <xref ref-type="bibr" rid="B77">
        Epelman et al., 2009
       </xref>
       ).
      </p>
      <p>
       The catalytic domain of ACE2 consists of two subdomains linked together by a hinge region. Comparison of inhibitor-bound and free X-ray structures reveals that a hinge-bending motion, resulting in changes to the relative position of the subdomains, is important for catalysis (
       <xref ref-type="bibr" rid="B334">
        Towler et al., 2004
       </xref>
       ). These structures have also revealed insights into the observed selectivity of ACE2 relative to ACE, showing that a single amino acid substitution in ACE2 hinders the S
       <sub>
        2
       </sub>
       ′ subsite. This explains why ACE2 acts as a carboxypeptidase rather than a peptidyl dipeptidase like ACE and why conventional ACE inhibitors such as lisinopril and captopril do not inhibit ACE2. Structure-based methods have been used to develop allosteric ACE2 activators by exploiting conformational differences observed in ACE2 crystal structures (
       <xref ref-type="bibr" rid="B121">
        Hernández Prada et al., 2008
       </xref>
       ;
       <xref ref-type="bibr" rid="B104">
        Gjymishka et al., 2010
       </xref>
       ). These activators bind to surface-binding pockets in the hinge region, locking the protein in an active conformation. ACE2 activators have shown antihypertensive and cardioprotective effects in a range of rodent models (
       <xref ref-type="bibr" rid="B287">
        Santos et al., 2018
       </xref>
       ). Other approaches to increase ACE2 activity, with the aim of activating the ACE2/Ang 1
       <bold>
        -
       </bold>
       7/Mas axis, have included viral overexpression of ACE2 (
       <xref ref-type="bibr" rid="B109">
        Grobe et al., 2007
       </xref>
       ) and oral or intravenous administration of recombinant ACE2 (
       <xref ref-type="bibr" rid="B300">
        Shenoy et al., 2014
       </xref>
       ) (discussed in more detail in section VII). In addition to its effect on alternative RAS activation, ACE2 efficiently degrades Ang II, which in turn reduces the detrimental effects of Ang II/AT
       <sub>
        1
       </sub>
       R signaling, explaining why recombinant ACE2 has shown efficacy in many Ang II infusion models. Importantly, understanding the dynamics of the RAS in response to ACE2 administration or activation in vivo as well as the crosstalk of ACE2 with other pharmacologic treatments targeting the RAS may be of major importance to achieve therapeutic efficacy in complex pathologic settings in vivo.
      </p>
     </sec>
     <sec id="s11">
      <title>
       C. Neprilysin
      </title>
      <p>
       NEP (also known as neutral endopeptidase 24.11, enkephalinase, or CD10; EC 3.4.24.11) is a type II membrane-anchored zinc-dependent endopeptidase originally purified from the brush borders of rabbit kidneys (
       <xref ref-type="bibr" rid="B148">
        Kerr and Kenny, 1974
       </xref>
       ). This widely expressed enzyme is tethered to the cell surface and has a large C-terminal extracellular catalytic domain responsible for the cleavage of a variety of physiologically active peptides including NPs, Ang I, Ang II, bradykinin, ET-1, adrenomedullin, enkephalins, substance P, insulin, gastrin, and amyloid-
       <italic>
        β
       </italic>
       peptide (
       <xref ref-type="bibr" rid="B188">
        Malfroy et al., 1978
       </xref>
       ;
       <xref ref-type="bibr" rid="B268">
        Roques et al., 1980
       </xref>
       ,
       <xref ref-type="bibr" rid="B269">
        1993
       </xref>
       ;
       <xref ref-type="bibr" rid="B79">
        Erdös and Skidgel, 1989
       </xref>
       ;
       <xref ref-type="bibr" rid="B338">
        Turner and Tanzawa, 1997
       </xref>
       ;
       <xref ref-type="bibr" rid="B130">
        Iwata et al., 2001
       </xref>
       ;
       <xref ref-type="bibr" rid="B302">
        Shirotani et al., 2001
       </xref>
       ).
      </p>
      <p>
       Several crystal structures of the soluble ectodomain in complex with various inhibitors have provided insight into the structure and specificity of NEP (
       <xref ref-type="bibr" rid="B225">
        Oefner et al., 2000
       </xref>
       ,
       <xref ref-type="bibr" rid="B227">
        2004
       </xref>
       ,
       <xref ref-type="bibr" rid="B226">
        2007
       </xref>
       ;
       <xref ref-type="bibr" rid="B279">
        Sahli et al., 2005
       </xref>
       ;
       <xref ref-type="bibr" rid="B106">
        Glossop et al., 2011
       </xref>
       ;
       <xref ref-type="bibr" rid="B293">
        Schiering et al., 2016
       </xref>
       ). The ectodomain consists of two
       <italic>
        α
       </italic>
       -helical lobes linked by interlacing polypeptide chains. The large lobe is structurally similar to zinc-dependent bacterial endopeptidases such as thermolysin, and it contains the catalytic zinc binding motif HEXXH and other conserved motifs and residues involved in zinc coordination, catalysis, and ligand binding (
       <xref ref-type="bibr" rid="B225">
        Oefner et al., 2000
       </xref>
       ). The smaller lobe, absent in related bacterial enzymes, acts as a molecular sieve, limiting the size of ligands to about 3000 Da (
       <xref ref-type="bibr" rid="B225">
        Oefner et al., 2000
       </xref>
       ). NEP has a large flexible active site with broader substrate specificity than ACE. The prime side of the binding pocket is primarily responsible for substrate potency and selectivity. The S
       <sub>
        1
       </sub>
       ′ pocket displays the most stringent specificity and preferentially binds aromatic or other large hydrophobic groups (
       <xref ref-type="bibr" rid="B180">
        Llorens et al., 1980
       </xref>
       ;
       <xref ref-type="bibr" rid="B268">
        Roques et al., 1980
       </xref>
       ). The large S
       <sub>
        2
       </sub>
       ′ subsite, extending into the solvent region, has broader specificity. There is fluidity between the S
       <sub>
        1
       </sub>
       ′ and S
       <sub>
        2
       </sub>
       ′ subsites, with the side chains of residues dividing the two pockets shifting to accommodate large groups at either site. Consequently, however, the simultaneous binding of large groups at both subsites is unfavorable and would require a substantial induced fit requiring backbone motion (
       <xref ref-type="bibr" rid="B227">
        Oefner et al., 2004
       </xref>
       ).
      </p>
     </sec>
     <sec id="s12">
      <title>
       D. Endothelin-Converting Enzyme-1
      </title>
      <p>
       ECE-1 (EC 3.4.24.71), named for its role in the hydrolysis of endothelins, is widely distributed in mammalian tissue, with particularly high levels of expression in the cardiovascular, reproductive, and endocrine systems (
       <xref ref-type="bibr" rid="B157">
        Korth et al., 1999
       </xref>
       ). ECE-1 belongs to the same family of proteins as NEP and their ectodomains have overlapping specificity and a high degree of structural similarity, with an overall sequence identity of 40% (
       <xref ref-type="bibr" rid="B31">
        Bur et al., 2001
       </xref>
       ). There is one crystal structure of ECE-1 available, which shows phosphoramidon bound within the active site (
       <xref ref-type="bibr" rid="B294">
        Schulz et al., 2009
       </xref>
       ), revealing that the NEP and ECE-1 active sites share a high degree of conservation. Structure–activity relationship (SAR) studies on a series of phosphinic inhibitors by
       <xref ref-type="bibr" rid="B138">
        Jullien et al. (2010)
       </xref>
       revealed the following differences in ECE-1 and NEP specificity: 1) ECE-1 can tolerate a bulky group at the S
       <sub>
        1
       </sub>
       ′ and S
       <sub>
        2
       </sub>
       ′ sites, whereas NEP can only tolerate a bulky group at one of these sites; and 2) ECE-1 can tolerate a stereocenter in the
       <italic>
        S
       </italic>
       or
       <italic>
        R
       </italic>
       configuration at C
       <italic>
        α
       </italic>
       in the P
       <sub>
        1
       </sub>
       ′ position, whereas NEP can only tolerate a stereocenter in the
       <italic>
        S
       </italic>
       configuration at this position.
      </p>
     </sec>
     <sec id="s13">
      <title>
       E. Aminopeptidase A
      </title>
      <p>
       Aminopeptidase A (APA; EC 3.4.11.7) is a 160-kDa homodimeric type II membrane-bound monozinc aminopeptidase. APA hydrolyzes the N-terminal glutamate or aspartate residue from peptidic substrates such as Ang II or cholecystokinin-8 in vitro (
       <xref ref-type="bibr" rid="B214">
        Nagatsu et al., 1970
       </xref>
       ;
       <xref ref-type="bibr" rid="B120">
        Healy and Wilk, 1993
       </xref>
       ) and in vivo in the brain (
       <xref ref-type="bibr" rid="B200">
        Migaud et al., 1996
       </xref>
       ;
       <xref ref-type="bibr" rid="B393">
        Zini et al., 1996
       </xref>
       ) and its activity is enhanced by Ca
       <sup>
        2+
       </sup>
       (
       <xref ref-type="bibr" rid="B105">
        Glenner et al., 1962
       </xref>
       ). APA is expressed in various tissues such as the intestinal and renal brush border epithelial cells and vascular endothelium and within the brain (
       <xref ref-type="bibr" rid="B181">
        Lojda and Gossrau, 1980
       </xref>
       ). This enzyme has also been identified in several brain nuclei involved in the control of body fluid homeostasis and cardiovascular functions (
       <xref ref-type="bibr" rid="B394">
        Zini et al., 1997
       </xref>
       ). Using the crystal structure of leukotriene-A4 hydrolase (EC 3.3.2.6) (
       <xref ref-type="bibr" rid="B328">
        Thunnissen et al., 2001
       </xref>
       ) as a template and functional information collected from site-directed mutagenesis studies on APA, a three-dimensional (3D) model of the mouse APA ectodomain from residues 79 to 559, including the active site of the enzyme, was built (
       <xref ref-type="bibr" rid="B273">
        Rozenfeld et al., 2002
       </xref>
       ). In this model, the zinc atom is coordinated by the two histidine residues (His 385 and His 389) of the consensus sequence HEXXH, Glu 408, and a water molecule (
       <xref ref-type="bibr" rid="B357">
        Wang and Cooper, 1993
       </xref>
       ;
       <xref ref-type="bibr" rid="B348">
        Vazeux et al., 1996
       </xref>
       ). Analysis of the APA 3D model complexed with an APA inhibitor, 4-amino-4-phosphobutyric acid (GluPO
       <sub>
        3
       </sub>
       H
       <sub>
        2
       </sub>
       ) (
       <xref ref-type="bibr" rid="B174">
        Lejczak et al., 1993
       </xref>
       ) showed that Tyr 471 is involved in transition state stabilization (
       <xref ref-type="bibr" rid="B346">
        Vazeux et al., 1997
       </xref>
       ). The model also demonstrated an interaction between the N-terminal amine of GluPO
       <sub>
        3
       </sub>
       H
       <sub>
        2
       </sub>
       and two glutamate residues of APA: Glu 352 in the GAMEN motif conserved among monozinc aminopeptidases and Glu 215, which is responsible for APA exopeptidase specificity (
       <xref ref-type="bibr" rid="B347">
        Vazeux et al., 1998
       </xref>
       ;
       <xref ref-type="bibr" rid="B274">
        Rozenfeld et al., 2003
       </xref>
       ). Ca
       <sup>
        2+
       </sup>
       was then introduced into the 3D model of APA and was localized at the bottom of the S
       <sub>
        1
       </sub>
       subsite where it interacts with the acidic side chains of Asp 213 and Asp 218, ensuring acidic APA substrate specificity (
       <xref ref-type="bibr" rid="B107">
        Goto et al., 2007
       </xref>
       ;
       <xref ref-type="bibr" rid="B43">
        Claperon et al., 2008
       </xref>
       ). The crystal structure of human APA (residues 76–956) was recently resolved (
       <xref ref-type="bibr" rid="B383">
        Yang et al., 2013
       </xref>
       ) and a comparison of this structure with the 3D homology mouse APA model showed a perfect overlap for the APA active site and the same structural organization of the S
       <sub>
        1
       </sub>
       subsite. The S
       <sub>
        1
       </sub>
       subsite of APA displays the most stringent specificity and was optimally blocked by an acidic amino-acid residue such a glutamate, leading to the development of the first specific and selective APA inhibitor, EC33 [(3
       <italic>
        S
       </italic>
       )-3-amino-4-sulfanyl-butane-1-sulfonic acid] (
       <xref ref-type="bibr" rid="B40">
        Chauvel et al., 1994
       </xref>
       ). The S
       <sub>
        1
       </sub>
       ′ subsite is hydrophobic, whereas the S
       <sub>
        2
       </sub>
       ′ subsite preferentially recognizes negatively charged residues derived from aspartic acid, leading to the design of APA inhibitors with subnanomolar inhibitory potency (
       <xref ref-type="bibr" rid="B62">
        David et al., 1999
       </xref>
       ).
      </p>
     </sec>
     <sec id="s14">
      <title>
       F. Angiotensin II Receptors
      </title>
      <p>
       AT
       <sub>
        1
       </sub>
       R and AT
       <sub>
        2
       </sub>
       R are members of the seven-transmembrane domain superfamily of GPCRs and have a 34% nucleic acid sequence homology. The single AT
       <sub>
        1
       </sub>
       R gene in humans is located on chromosome 3 and encodes a 359-amino-acid protein. In rodents, however, there are two subtypes, AT
       <sub>
        1
       </sub>
       R a and AT
       <sub>
        1
       </sub>
       R b (located on chromosomes 17 and 2, respectively), which are highly conserved in the coding region (
       <xref ref-type="bibr" rid="B282">
        Sandberg et al., 1992
       </xref>
       ). AT
       <sub>
        1
       </sub>
       R is widely expressed and well conserved between species (
       <xref ref-type="bibr" rid="B66">
        de Gasparo et al., 2000
       </xref>
       ). Ang II activates a number of signaling pathways, such as G protein–mediated (Gq and Gi), Janus kinase/signal transducers and activators of transcription, and mitogen-activated protein kinase or extracellular signal-regulated kinase pathways, causing hypertension, endothelial dysfunction, vascular remodeling, and end organ damage. In addition, there is G protein–independent signaling through the adapter proteins
       <italic>
        β
       </italic>
       -arrestin 1 and
       <italic>
        β
       </italic>
       -arrestin 2 that can have distinct functional and physiologic consequences (
       <xref ref-type="bibr" rid="B253">
        Rajagopal et al., 2010
       </xref>
       ). AT
       <sub>
        1
       </sub>
       R conformations stabilized by
       <italic>
        β
       </italic>
       -arrestin–biased peptide agonists differ from Ang II–induced conformations. These agonists have had a significant impact on AT
       <sub>
        1
       </sub>
       R pharmacology and alter the intracellular trafficking of the receptor in addition to the activation of the
       <italic>
        β
       </italic>
       -arrestin–mediated signaling pathway (
       <xref ref-type="bibr" rid="B215">
        Namkung et al., 2016
       </xref>
       ).
      </p>
      <p>
       AT
       <sub>
        1
       </sub>
       R forms homo- and heterodimers with other GPCRs and many of these dimers have been linked to altered ability to activate G protein and/or
       <italic>
        β
       </italic>
       -arrestin (
       <xref ref-type="bibr" rid="B3">
        AbdAlla et al., 2000
       </xref>
       ;
       <xref ref-type="bibr" rid="B114">
        Hansen et al., 2004
       </xref>
       ;
       <xref ref-type="bibr" rid="B333">
        Tóth et al., 2018
       </xref>
       ). Ang II and Ang III have a similar binding affinity for AT
       <sub>
        1
       </sub>
       R and AT
       <sub>
        2
       </sub>
       R, and thus the expression of these receptors regulates which receptor subtype mediates responses to Ang II and Ang III (
       <xref ref-type="bibr" rid="B250">
        Rabey et al., 2010
       </xref>
       ;
       <xref ref-type="bibr" rid="B29">
        Bosnyak et al., 2011
       </xref>
       ). Moreover, crosstalk between AT
       <sub>
        1
       </sub>
       R and AT
       <sub>
        2
       </sub>
       R results in stimulation of one receptor modulating the expression of the other (
       <xref ref-type="bibr" rid="B2">
        AbdAlla et al., 2001
       </xref>
       ).
      </p>
      <p>
       The high-resolution crystal structure of human AT
       <sub>
        1
       </sub>
       R in complex with its selective antagonist ZD7155 [5,7-Diethyl-3,4-dihydro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,6-naphthyridin-2(1H)-one] (precursor to the antihypertensive candesartan) has provided fundamental insights into the structure–function relationship of the receptor (
       <xref ref-type="bibr" rid="B391">
        Zhang et al., 2015
       </xref>
       ). Surprisingly, three residues (Arg 167, Tyr 35, and Trp 84) that have not previously been shown to make interactions with ligands made important contacts with the antagonist. In addition, mutagenesis and docking studies revealed residues that were critical for peptide and nonpeptide binding. Exploitation of these interactions paves the way for new mechanistic studies and therapeutic strategies.
      </p>
      <p>
       The AT
       <sub>
        2
       </sub>
       R gene, located on human chromosome X, encodes the 363-amino-acid GPCR with a molecular mass of 41 kDa (
       <xref ref-type="bibr" rid="B141">
        Kambayashi et al., 1993
       </xref>
       ). In contrast to AT
       <sub>
        1
       </sub>
       R, the activation of phosphatases such as mitogen-activated protein kinase phosphatase 1 and protein phosphatase 2 is an important signaling mechanism for AT
       <sub>
        2
       </sub>
       R (
       <xref ref-type="bibr" rid="B144">
        Kang et al., 1995
       </xref>
       ;
       <xref ref-type="bibr" rid="B378">
        Yamada et al., 1996
       </xref>
       ). Furthermore, AT
       <sub>
        2
       </sub>
       R couples to G
       <sub>
        i
       </sub>
       proteins and stimulates ion channel currents (
       <xref ref-type="bibr" rid="B143">
        Kang et al., 1994
       </xref>
       ). The crystal structures of the AT
       <sub>
        2
       </sub>
       R in complex with AT
       <sub>
        2
       </sub>
       R and AT
       <sub>
        1
       </sub>
       R/AT
       <sub>
        2
       </sub>
       R ligands showed helix 8 in a noncanonical position that stabilizes the active state of the GPCR. Moreover, interaction of H8 with H5 and H6 prevented binding of G proteins and
       <italic>
        β
       </italic>
       -arrestins, providing a molecular basis for its alternative G-protein signaling (
       <xref ref-type="bibr" rid="B390">
        Zhang et al., 2017
       </xref>
       ). Although the signaling mechanism of AT
       <sub>
        2
       </sub>
       R is not fully understood, there are similarities between the AT
       <sub>
        2
       </sub>
       R and Mas signaling, such as the involvement of SH2-containing protein tyrosine phosphotases SHP-1/SHP-2 and phosphoinositide 3-kinase/AKT/endothelial nitric oxide synthase (
       <xref ref-type="bibr" rid="B296">
        Seguin et al., 2012
       </xref>
       ). In addition, AT
       <sub>
        2
       </sub>
       R and Mas can form heterodimers and Ang 1
       <bold>
        -
       </bold>
       7 effects are blocked by AT
       <sub>
        2
       </sub>
       R antagonists. Physiologically, the levels of AT
       <sub>
        2
       </sub>
       R expression are low; however, expression levels have been found to be higher during development, disappearing in adult rats except in the brain, ovary and uterus (
       <xref ref-type="bibr" rid="B48">
        Cook et al., 1991
       </xref>
       ;
       <xref ref-type="bibr" rid="B201">
        Millan et al., 1991
       </xref>
       ;
       <xref ref-type="bibr" rid="B249">
        Pucell et al., 1991
       </xref>
       ;
       <xref ref-type="bibr" rid="B309">
        Song et al., 1992
       </xref>
       ;
       <xref ref-type="bibr" rid="B175">
        Lenkei et al., 1997
       </xref>
       ), and liver and kidney of rats compared with those in neonates (
       <xref ref-type="bibr" rid="B387">
        Yu et al., 2010
       </xref>
       ). Gene expression of AT
       <sub>
        2
       </sub>
       R is regulated by numerous factors, including intracellular calcium and protein kinase C (
       <xref ref-type="bibr" rid="B150">
        Kijima et al., 1996
       </xref>
       ), interleukin-1
       <italic>
        β
       </italic>
       and insulin (
       <xref ref-type="bibr" rid="B142">
        Kambayashi et al., 1996
       </xref>
       ), and multiple growth factors (
       <xref ref-type="bibr" rid="B124">
        Ichiki et al., 1995
       </xref>
       ). AT
       <sub>
        2
       </sub>
       R mediates a variety of protective actions such as immune modulation and antifibrotic, anti-inflammatory, neuroprotective, neuroregeneration, antihypertensive, and antiapoptotic actions (
       <xref ref-type="bibr" rid="B216">
        Namsolleck et al., 2014
       </xref>
       ;
       <xref ref-type="bibr" rid="B315">
        Steckelings et al., 2017
       </xref>
       ). Thus, a number of AT
       <sub>
        2
       </sub>
       R agonists have been developed for therapeutic intervention and will provide important information about the future prospect of drugs targeting the AT
       <sub>
        2
       </sub>
       R (
       <xref ref-type="bibr" rid="B286">
        Santos et al., 2019
       </xref>
       ).
      </p>
     </sec>
     <sec id="s15">
      <title>
       G. Mas Receptor
      </title>
      <p>
       Mas (also called MAS1 proto-oncogene) was the first identified member of the Mas-related GPCR subfamily of proteins and consists of seven transmembrane domains typical of GPCRs (reviewed in
       <xref ref-type="bibr" rid="B13">
        Bader et al., 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="B14">
        2018
       </xref>
       ). It was first described as an oncogene, based on a human oncogene assay in which the human
       <italic>
        MAS
       </italic>
       gene was purified from a tumor that was induced in a nude mouse by injecting the animal with NIH 3T3 cells cotransfected with DNA purified from a human tumor (
       <xref ref-type="bibr" rid="B385">
        Young et al., 1986
       </xref>
       ). However, further studies showed that Mas can only transform cells when artificially overexpressed (
       <xref ref-type="bibr" rid="B251">
        Rabin et al., 1987
       </xref>
       ;
       <xref ref-type="bibr" rid="B344">
        van’t Veer et al., 1993
       </xref>
       ), suggesting that it is not an oncogene as initially reported. Mas was originally proposed to be the functional receptor for Ang II (
       <xref ref-type="bibr" rid="B132">
        Jackson et al., 1988
       </xref>
       ), but this was also later disproved by subsequent signaling experiments (
       <xref ref-type="bibr" rid="B7">
        Ambroz et al., 1991
       </xref>
       ), cloning of AT
       <sub>
        1
       </sub>
       R (
       <xref ref-type="bibr" rid="B210">
        Murphy et al., 1991
       </xref>
       ;
       <xref ref-type="bibr" rid="B288">
        Sasaki et al., 1991
       </xref>
       ), and the discovery that Mas and AT
       <sub>
        1
       </sub>
       R interact directly, explaining the indirect involvement of Mas in Ang II signaling (
       <xref ref-type="bibr" rid="B158">
        Kostenis et al., 2005
       </xref>
       ). In 2003, Mas was identified as the functional receptor of Ang 1
       <bold>
        -
       </bold>
       7 responsible for the beneficial physiologic effects of Ang 1
       <bold>
        -
       </bold>
       7 (
       <xref ref-type="bibr" rid="B285">
        Santos et al., 2003
       </xref>
       ), making it a key component of the counter-regulatory axis of the RAS and a potential target for therapeutic intervention. Subsequent studies provided additional evidence supporting this, showing that the specific labeling of tissues/cell lines by labeled Ang 1
       <bold>
        -
       </bold>
       7 is lost in Mas-deficient animals/cells (
       <xref ref-type="bibr" rid="B323">
        Tallant et al., 2005
       </xref>
       ;
       <xref ref-type="bibr" rid="B95">
        Fraga-Silva et al., 2008
       </xref>
       ;
       <xref ref-type="bibr" rid="B172">
        Leal et al., 2009
       </xref>
       ). However, recent extensive biochemical studies were unable to support the direct interaction between Ang 1
       <bold>
        -
       </bold>
       7 and Mas (
       <xref ref-type="bibr" rid="B99">
        Gaidarov et al., 2018
       </xref>
       ), bringing into question whether Ang 1
       <bold>
        -
       </bold>
       7 is indeed the endogenous agonist of this receptor. In addition to Ang 1
       <bold>
        -
       </bold>
       7, several putative Mas agonists including AVE 0991 [3-ethyl-1-[3-[4-[(5-formyl-4-methoxy-2-phenylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylurea] (
       <xref ref-type="bibr" rid="B369">
        Wiemer et al., 2002
       </xref>
       ) and CGEN-856S [amino acid sequence: FLGYSIYLNRKRRGDPAFKRRLRD] (
       <xref ref-type="bibr" rid="B243">
        Pinheiro et al., 2004
       </xref>
       ;
       <xref ref-type="bibr" rid="B291">
        Savergnini et al., 2010
       </xref>
       ) and antagonists A-779 (D-Ala7 Ang 1-7) (
       <xref ref-type="bibr" rid="B283">
        Santos et al., 1994
       </xref>
       ) and D-Pro7 Ang 1-7 (
       <xref ref-type="bibr" rid="B285">
        Santos et al., 2003
       </xref>
       ) have been used to study the actions of Mas, although a rigorous analysis of their Mas binding affinity is lacking. These Mas agonists have shown a range of cardioprotective effects in animal models (reviewed by
       <xref ref-type="bibr" rid="B13">
        Bader et al., 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="B14">
        2018
       </xref>
       ). Other endogenous peptides able to act as Mas agonists have also been reported (
       <xref ref-type="bibr" rid="B134">
        Jankowski et al., 2011
       </xref>
       ;
       <xref ref-type="bibr" rid="B330">
        Tirupula et al., 2014
       </xref>
       ;
       <xref ref-type="bibr" rid="B386">
        Yu et al., 2016
       </xref>
       ) and like many other GPCRs, Mas displays biased agonism with different ligands activating different downstream pathways (
       <xref ref-type="bibr" rid="B13">
        Bader et al., 2014
       </xref>
       ;
       <xref ref-type="bibr" rid="B146">
        Karnik et al., 2015
       </xref>
       ). Potential downstream signaling pathways of Mas stimulated by Ang 1
       <bold>
        -
       </bold>
       7 and related analogs include the phospholipase A2 pathway to generate arachidonic acid (
       <xref ref-type="bibr" rid="B285">
        Santos et al., 2003
       </xref>
       ) and the phosphoinositide 3-kinase/AKT pathway leading to the activation of endothelial nitric oxide synthase (
       <xref ref-type="bibr" rid="B281">
        Sampaio et al., 2007
       </xref>
       ;
       <xref ref-type="bibr" rid="B183">
        Lopez Verrilli et al., 2012
       </xref>
       ;
       <xref ref-type="bibr" rid="B292">
        Savergnini et al., 2013
       </xref>
       ;
       <xref ref-type="bibr" rid="B326">
        Than et al., 2013
       </xref>
       ). Ang 1
       <bold>
        -
       </bold>
       7 activation of Mas in glomerular mesangial cells is cAMP dependent and is thought to mediate a protective action in experimental models of renal injury (
       <xref ref-type="bibr" rid="B179">
        Liu et al., 2012
       </xref>
       ). Mas-mediated activation of the phospholipase C/Ca
       <sup>
        2+
       </sup>
       signaling pathway has been reported for other agonists, including the endogenous ligand neuropeptide FF, but not for Ang 1
       <bold>
        -
       </bold>
       7 (
       <xref ref-type="bibr" rid="B299">
        Shemesh et al., 2008
       </xref>
       ;
       <xref ref-type="bibr" rid="B392">
        Zhang et al., 2012
       </xref>
       ;
       <xref ref-type="bibr" rid="B330">
        Tirupula et al., 2014
       </xref>
       ). Mas is expressed at the highest levels in the brain and testis and has been found at low levels in a wide range of other organs; the functions of Mas and other GPCRs in various tissue was reviewed in
       <xref ref-type="bibr" rid="B13">
        Bader et al. (2014)
       </xref>
       . There are currently no high-resolution structures of any of the Mas-related GPCRs.
      </p>
     </sec>
    </sec>
    <sec id="s16">
     <title>
      IV. Targeting Angiotensin-Converting Enzyme, Neprilysin, and Endothelin-Converting Enzyme-1 with Vasopeptidase Inhibitors
     </title>
     <p>
      The structural similarity between ACE, NEP, and ECE-1 and overlapping substrate specificity has enabled the development of single molecules that target two or even three of these enzymes. Remarkably, the design of current-generation ACE inhibitors as well as vasopeptidase inhibitors that have entered clinical trials to date has been achieved with limited knowledge of the sequences and 3D structures of the enzymes. Rather, the first ACE inhibitors were designed based on the expected functional homology of ACE with carboxypeptidase A (
      <xref ref-type="bibr" rid="B52">
       Cushman et al., 1977
      </xref>
      ). Despite this misconception, ACE inhibitors are a successful class of drugs in cardiovascular disease, although failure to appreciate the two-domain structure of ACE has contributed, at least in part, to the adverse event profile of these drugs. Development of NEP inhibitors dates to the 1980s and was largely based on the homology between NEP and the better characterized bacterial metalloendopeptidase thermolysin. Several selective NEP inhibitors have been described, including thiorphan (
      <xref ref-type="bibr" rid="B268">
       Roques et al., 1980
      </xref>
      ), ecadotril, candoxatril, and sacubitril, but these inhibitors showed poor efficacy in the clinic (
      <xref ref-type="bibr" rid="B8">
       Ando et al., 1995
      </xref>
      ;
      <xref ref-type="bibr" rid="B44">
       Cleland and Swedberg, 1998
      </xref>
      ). Although it had been ascertained that NEP inhibition leads to elevated NP, adrenomedullin, and bradykinin levels, which have vasorelaxant, natriuretic, and cardioprotective actions, clinical studies also confirmed that NEP inhibition increased Ang II and ET-1 levels, which possibly counteract the therapeutic effects (
      <xref ref-type="bibr" rid="B86">
       Ferro et al., 1998
      </xref>
      ;
      <xref ref-type="bibr" rid="B361">
       Weber, 2001
      </xref>
      ;
      <xref ref-type="bibr" rid="B266">
       Roksnoer et al., 2015
      </xref>
      ). Given that Ang I is a better NEP substrate than Ang II (
      <xref ref-type="bibr" rid="B260">
       Rice et al., 2004
      </xref>
      ), Ang II is increased in the presence of NEP inhibitors primarily by increasing Ang I levels (allowing more Ang I to II conversion by ACE) and secondly by blocking NEP-mediated Ang II degradation. The next progression from this was to establish whether the additional suppression of Ang II production (and later ET-1) would be effective. This was supported by a study demonstrating that combining an NEP inhibitor with an ACE inhibitor reduced blood pressure in hypertensive rats to a greater extent than either inhibitor administered alone (
      <xref ref-type="bibr" rid="B297">
       Seymour et al., 1991
      </xref>
      ). A similar result was later reported in humans (
      <xref ref-type="bibr" rid="B82">
       Favrat et al., 1995
      </xref>
      ), setting the stage for the development of dual ACE/NEP vasopeptidase inhibitors, a new class of drugs for the treatment of hypertension.
     </p>
     <sec id="s17">
      <title>
       A. Dual Angiotensin-Converting Enzyme/Neprilysin Inhibitors
      </title>
      <p>
       The dual ACE/NEP inhibitors were the first vasopeptidase inhibitors to enter clinical trials. They were developed to simultaneously block the ACE-mediated formation of the vasoconstrictor Ang II and the NEP-mediated degradation of NP vasodilators. Eleven dual ACE/NEP inhibitors have been tested to varying extents in the clinic (
       <xref ref-type="bibr" rid="B71">
        Dimitropoulos et al., 2010
       </xref>
       ). Of these, omapatrilat progressed the furthest but eventually failed to obtain U.S. Food and Drug Administration (FDA) approval after large phase III clinical trials, due to a reported increased risk of angioedema.
      </p>
      <p>
       The early dual inhibitors were designed rationally based on specific ACE and NEP inhibitors. Combining a P
       <sub>
        1
       </sub>
       ′ benzyl group, known to be important for NEP inhibition, with a P
       <sub>
        2
       </sub>
       ′ proline group as seen in the first ACE inhibitors (e.g., captopril) led to a series of potent mercaptoacyl dipeptides with dual inhibitory activity (
       <xref ref-type="bibr" rid="B261">
        Robl et al., 1994
       </xref>
       ;
       <xref ref-type="bibr" rid="B337">
        Turcaud et al., 1995
       </xref>
       ). Further SAR studies to optimize for in vivo activity led to conformationally restricted dipeptide mimetics and, eventually, omapatrilat, a 7,6-fused bicyclic thiazepinone (
       <xref ref-type="bibr" rid="B263">
        Robl et al., 1997
       </xref>
       ). Omapatrilat displayed potent inhibition in the low nanomolar range against both ACE and NEP in vitro, as well as chronic potent antihypertensive and cardioprotective effects in experimental models of hypertension and heart failure (
       <xref ref-type="bibr" rid="B263">
        Robl et al., 1997
       </xref>
       ,
       <xref ref-type="bibr" rid="B262">
        1999
       </xref>
       ;
       <xref ref-type="bibr" rid="B336">
        Trippodo et al., 1998
       </xref>
       ;
       <xref ref-type="bibr" rid="B126">
        Intengan and Schiffrin, 2000
       </xref>
       ;
       <xref ref-type="bibr" rid="B248">
        Pu et al., 2002
       </xref>
       ).
      </p>
      <p>
       Early preliminary clinical data were also promising: tested doses of omapatrilat showed more potent antihypertensive effects than any other drug class tested and appeared to be effective in improving cardiac function in patients with heart failure. However, there were concerns about omapatrilat-associated angioedema. To further study the efficacy and safety of omapatrilat, large randomized clinical trials were undertaken to assess the efficacy and safety profile of omapatrilat in patients with hypertension and heart failure, compared with the conventional ACE inhibitor enalapril (
       <xref ref-type="bibr" rid="B45">
        Coats, 2002
       </xref>
       ). The OCTAVE (Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril) trial, including more than 25,000 hypertensive patients, showed antihypertensive efficacy of omapatrilat but, disappointingly, the rate of angioedema was 3-fold higher than observed for enalapril (2.17% vs. 0.68%) and cases of angioedema tended to occur earlier and be more severe in the omapatrilat group (
       <xref ref-type="bibr" rid="B159">
        Kostis et al., 2004
       </xref>
       ). OVERTURE (Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events) was carried out in 5770 patients and showed that omapatrilat was as good as, but no better than, enalapril at reducing primary endpoint events in patients with heart failure (
       <xref ref-type="bibr" rid="B235">
        Packer et al., 2002
       </xref>
       ). Although the incidence of angioedema was lower in OVERTURE than OCTAVE, the rate of angioedema was still higher in the omapatrilat group (0.8% vs. 0.5%). Based on the OVERTURE and OCTAVE trials, the FDA concluded that the benefits of treating patients with hypertension or heart failure with omapatrilat did not outweigh the risks (
       <xref ref-type="bibr" rid="B389">
        Zanchi et al., 2003
       </xref>
       ).
      </p>
      <p>
       Since both ACE and NEP contribute to the breakdown of bradykinin, and bradykinin accumulation is associated with angioedema (
       <xref ref-type="bibr" rid="B94">
        Fox et al., 1996
       </xref>
       ;
       <xref ref-type="bibr" rid="B203">
        Molinaro et al., 2002
       </xref>
       ), it was thought that the increased risk of this serious, potentially life-threatening complication would also affect other dual ACE/NEP inhibitors, halting the development of this once-promising class of drugs. Although it is conceivable that changing the relative levels of ACE and NEP inhibition could improve the efficacy and safety profiles of these dual inhibitors, and some promising early-stage clinical trials of other inhibitors were reported in the years after the omapatrilat studies (
       <xref ref-type="bibr" rid="B10">
        Azizi et al., 2006
       </xref>
       ;
       <xref ref-type="bibr" rid="B137">
        Johnson et al., 2006
       </xref>
       ), large-scale trials of other inhibitors have not been conducted. It is also worth noting that omapatrilat had off-target effects that may have contributed to its poor side effect profile, which could differ from off-target effects of other inhibitors in this class. After omapatrilat’s failure in the clinic, it was discovered that omapatrilat inhibits a third zinc metallopeptidase involved in bradykinin inactivation, APP (
       <italic>
        K
       </italic>
       <sub>
        i
       </sub>
       of 0.25
       <italic>
        µ
       </italic>
       M) (
       <xref ref-type="bibr" rid="B319">
        Sulpizio et al., 2005
       </xref>
       ;
       <xref ref-type="bibr" rid="B96">
        Fryer et al., 2008
       </xref>
       ).
       <xref ref-type="bibr" rid="B96">
        Fryer et al. (2008)
       </xref>
       showed that bradykinin is degraded in rats with an enzyme rank efficacy of ACE &gt; APP &gt;&gt; NEP, suggesting that APP inhibition may contribute significantly to the increase in kinin-mediated side effects observed for omapatrilat. More recent enzyme and structural data has confirmed that omapatrilat is a nonselective potent inhibitor of both ACE domains, interacting with conserved residues within the N and C domain active sites (
       <xref ref-type="bibr" rid="bib398">
        Cozier et al., 2018
       </xref>
       ). Dual ACE/NEP inhibitors also result in the elevation of other peptides such as ET-1 which, like bradykinin, increase endothelial nitric oxide levels, which may also contribute to angioedema and other adverse effects, including flushing.
      </p>
     </sec>
     <sec id="s18">
      <title>
       B. Dual Neprilysin/Endothelin-Converting Enzyme-1 Inhibitors
      </title>
      <p>
       Dual NEP/ECE-1 inhibitors were also explored to increase the efficacy of NEP inhibition: the inhibition of ECE-1 prevents the formation of ET-1, thereby avoiding the accumulation of ET-1 observed during the inhibition of NEP, the primary enzyme responsible for ET-1 degradation (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       ). The discovery that phosphoramidon inhibited ECE-1 in addition to NEP initiated the development of other NEP/ECE-1 dual inhibitors (
       <xref ref-type="bibr" rid="B377">
        Xu et al., 1994
       </xref>
       ;
       <xref ref-type="bibr" rid="B164">
        Kukkola et al., 1995
       </xref>
       ). However, the most advanced dual ECE-1/NEP inhibitor daglutril (SLV 306), despite effectively elevating plasma NP and big ET-1 levels in a dose-dependent manner, was ineffective at lowering systemic blood pressure in clinical studies (
       <xref ref-type="bibr" rid="B70">
        Dickstein et al., 2004
       </xref>
       ), suggesting that effective antihypertensive treatment must incorporate blockade of the RAS.
      </p>
     </sec>
     <sec id="s19">
      <title>
       C. Triple Angiotensin-Converting Enzyme/Neprilysin/Endothelin-Converting Enzyme-1 Inhibitors
      </title>
      <p>
       Another strategy is to simultaneously block the RAS, NP degradation, and ET-1 formation with triple ACE/NEP/ECE-1 inhibitors. These inhibitors are expected to show improved efficacy over dual inhibitors, reducing the need for polypharmacy, but once again safety issues are a concern. The most extensively studied triple vasopeptidase inhibitor, CGS-35601 [L-tryptophan, N-[[1-[[(2S)-2-mercapto-4-methyl-1-oxopentyl]amino]-cyclopentyl]carbonyl]], is an
       <italic>
        α
       </italic>
       -mercaptodipeptide with a central cyclic non-natural amino acid and a P
       <sub>
        2
       </sub>
       ′ tryptophan that is accommodated in the S
       <sub>
        2
       </sub>
       ′ site of all three enzymes. CGS-35601 showed good efficacy in various rat models of hypertension; in addition, although treatment resulted in significant accumulation of bradykinin, nitric oxide levels were substantially reduced compared with treatment with omapatrilat (
       <xref ref-type="bibr" rid="B59">
        Daull et al., 2005
       </xref>
       ,
       <xref ref-type="bibr" rid="B60">
        2006b
       </xref>
       ). It is yet to be shown whether the decrease in plasma ET-1 concentration and associated reduction in nitric oxide release can compensate for elevated bradykinin levels. Even though preclinical testing of CGS-35601 in rats showed no toxic effects (
       <xref ref-type="bibr" rid="B61">
        Daull et al., 2006a
       </xref>
       ), no triple vasopeptidase inhibitors have yet been tested in humans. The effect of these broad-spectrum inhibitors on vasopeptide levels will need to be carefully evaluated due to the complexity of these interconnected pathways. Off-target effects will also need to be minimized to ensure that the activity of additional enzymes involved in kinin inactivation, such as APP and carboxypeptidase N, is not affected.
      </p>
      <p>
       Adverse reactions associated with ACE inhibitors and vasopeptidase inhibitors are likely due to undesired effects on peptide levels besides Ang II, particularly bradykinin, but other peptides such as ET-1, substance P, and so forth may also contribute. Adverse effects occur in up to 28% of patients (
       <xref ref-type="bibr" rid="B314">
        Steckelings et al., 2001
       </xref>
       ;
       <xref ref-type="bibr" rid="B362">
        Weber and Messerli, 2008
       </xref>
       ), which is astounding considering that ACE inhibitors have been routinely used to treat large numbers of patients for decades. Although current evidence suggests that vasopeptidase inhibitors are potentially more effective than conventional ACE inhibitors, the safety profile remains a concern.
      </p>
      <p>
       ACE inhibitors and vasopeptidase inhibitors that target both the N and C domains of ACE were tested clinically prior to knowledge of the different roles of these ACE domains. Now that it is well established that the C domain is predominantly responsible for Ang II formation in vivo and that both domains inactivate bradykinin at a similar rate, selectively inhibiting the C domain has the potential to reduce the accumulation of bradykinin levels and other peptides cleaved by the N domain during ACE inhibitor treatment.
      </p>
      <p>
       Multiple crystal structures of inhibitors in complex with the individual ACE N and C domains, NEP, and ECE-1 have provided molecular insights into enzyme specificity and function. This, together with increased knowledge of the integrated network between the RAS, NPS, kallikrein-kinin system, and endothelin system and several decades of SAR studies on these enzymes, provides a strong foundation for the design of next-generation inhibitors.
      </p>
     </sec>
    </sec>
    <sec id="s20">
     <title>
      V. Angiotensin-Converting Enzyme C-Domain–Selective Vasopeptidase Inhibitors
     </title>
     <sec id="s21">
      <title>
       A. C-Domain–Selective Angiotensin-Converting Enzyme Inhibitors
      </title>
      <p>
       Knowledge of the ACE sequence and 3D structures of the individual domains has facilitated the development of both N- and C-domain–selective ACE inhibitors. N-domain–selective inhibitors may prove useful for indications such as fibrosis, where it would be beneficial to inhibit N-domain–specific Ac-SDKP formation without affecting blood pressure (
       <xref ref-type="bibr" rid="B72">
        Dive et al., 1999
       </xref>
       ;
       <xref ref-type="bibr" rid="B74">
        Douglas et al., 2014
       </xref>
       ;
       <xref ref-type="bibr" rid="B87">
        Fienberg et al., 2018
       </xref>
       ). In vitro mutagenesis studies, in which C-domain–specific residues are systematically mutated to their N-domain counterparts (or vice versa), have provided valuable information on residue–inhibitor interactions important for conferring domain selectivity (
       <xref ref-type="bibr" rid="B358">
        Watermeyer et al., 2008
       </xref>
       ;
       <xref ref-type="bibr" rid="B162">
        Kröger, et al., 2009
       </xref>
       ;
       <xref ref-type="bibr" rid="B359">
        Watermeyer et al., 2010
       </xref>
       ) (
       <xref ref-type="fig" rid="F4">
        Fig. 4
       </xref>
       ).
      </p>
      <p>
       Several inhibitors, typically derivatives of nonselective ACE inhibitors, have been developed that show greater than two orders of magnitude selectivity for the C domain in vitro. These compounds include the ketomethylene inhibitors kAW and kAF (
       <xref ref-type="bibr" rid="B220">
        Nchinda et al., 2006b
       </xref>
       ;
       <xref ref-type="bibr" rid="B358">
        Watermeyer et al., 2008
       </xref>
       ) derived from the moderately C-selective compound kAP (
       <xref ref-type="bibr" rid="B6">
        Almquist et al., 1980
       </xref>
       ;
       <xref ref-type="bibr" rid="B68">
        Deddish et al., 1998
       </xref>
       ), phosphinic inhibitor RXPA380 (
       <xref ref-type="bibr" rid="B103">
        Georgiadis et al., 2003
       </xref>
       ;
       <xref ref-type="bibr" rid="B162">
        Kröger, et al., 2009
       </xref>
       ), and carboxylic inhibitor LisW (
       <xref ref-type="bibr" rid="B219">
        Nchinda et al., 2006a
       </xref>
       ;
       <xref ref-type="bibr" rid="B359">
        Watermeyer et al., 2010
       </xref>
       ), derived from the conventional inhibitor lisinopril (
       <xref ref-type="fig" rid="F5">
        Fig. 5
       </xref>
       ). Crystal structures of these inhibitors in complex with the C domain reveal that a bulky hydrophobic residue that binds to the S
       <sub>
        2
       </sub>
       ′ pocket is a common feature of these inhibitors, typically conferring ∼30- to 70-fold of the observed C-domain selectivity (
       <xref ref-type="bibr" rid="B49">
        Corradi et al., 2007
       </xref>
       ;
       <xref ref-type="bibr" rid="B358">
        Watermeyer et al., 2008
       </xref>
       ,
       <xref ref-type="bibr" rid="B359">
        2010
       </xref>
       ). Mutational data suggest that cooperative effects of a number of C-domain–specific residues within the S
       <sub>
        2
       </sub>
       ′ subsite contribute to the selectivity of these compounds, but additional residues in other subsites also play a role. Several bradykinin-potentiating peptides, the first compounds identified for their antihypertensive properties, also display C-domain selectivity (
       <xref ref-type="bibr" rid="B51">
        Cotton et al., 2002
       </xref>
       ). The structures of the most selective bradykinin-potentiating peptide, BPPb, in complex with the C domain (
       <xref ref-type="bibr" rid="B192">
        Masuyer et al., 2012
       </xref>
       ) and N domain, together with mutagenesis studies, have provided a structural basis for the selectivity of these peptides (
       <xref ref-type="bibr" rid="bib395">
        Sturrock et al., 2019
       </xref>
       ), providing additional insights for the design of selective inhibitors.
      </p>
      <fig id="F5" orientation="portrait" position="float">
       <label>
        Fig. 5.
       </label>
       <caption>
        <p>
         (A) Chemical structures of C-domain–selective inhibitors and the corresponding in vitro inhibition constants for the N and C domains. (B) Overlay of C-domain–selective inhibitors bound to the active site of the C domain from crystal structures [PDB codes 3BKK (kAF), 3BKL (kAW), 2OC2 (RXPA380), and 3L3N (LisW)]. (C) Overlay of crystal structures of ACE N and C domains in complex with lisinopril is shown in yellow (N domain) and green (C domain) (PDB codes 2C6N and 1O86 respectively) and the ACE C domain in complex with LisW in purple (PDB code 3L3N). C-domain unique residues are shown in cyan with corresponding N-domain residues in orange. Cdom, C domain; Ndom, N domain; PDB, Protein Data Bank.
        </p>
       </caption>
       <graphic xlink:href="pr.118.017129f5">
       </graphic>
      </fig>
      <p>
       Ex vivo and in vivo studies with LisW, the most extensively studied C-domain–selective inhibitor, have further confirmed that C-domain–selective inhibition is pharmacologically relevant, resulting in unique vasopeptide metabolism profiles compared with nonselective ACE inhibitors. A study in hypertensive mice that express active human renin showed that LisW reduced blood pressure and Ang II levels similarly to lisinopril without increasing bradykinin levels (
       <xref ref-type="bibr" rid="B32">
        Burger et al., 2014
       </xref>
       ). Another study in rat myocardial infarction determined the pharmacodynamic effects of LisW on angiotensin metabolites and Ac-SDKP levels (
       <xref ref-type="bibr" rid="B298">
        Sharp et al., 2015
       </xref>
       ). Lisinopril, but not LisW, decreased Ang 1
       <bold>
        -
       </bold>
       5/Ang 1
       <bold>
        -
       </bold>
       7 ratios and Ac-SDKP levels. This confirms that LisW inhibits the C domain selectively, since Ang 1
       <bold>
        -
       </bold>
       7 and Ac-SDKP are N-domain–selective substrates (
       <xref ref-type="bibr" rid="B68">
        Deddish et al., 1998
       </xref>
       ).
      </p>
      <p>
       Based on the in vivo data for LisW, C-domain–selective ACE inhibitors offer hope for a new generation of ACE inhibitors with improved safety but are unlikely to offer improved efficacy unless combined with other drugs. This class of inhibitors is yet to be tested in the clinic.
      </p>
     </sec>
     <sec id="s22">
      <title>
       B. Dual Angiotensin-Converting Enzyme C-Domain–Selective/Endothelin-Converting Enzyme-1 Inhibitors
      </title>
      <p>
       <xref ref-type="bibr" rid="B138">
        Jullien et al. (2010)
       </xref>
       have taken this concept one step further, developing dual ACE C-domain–selective/ECE-1 inhibitors. These inhibitors are designed to inhibit the formation of vasoconstrictors Ang II and ET-1, while leaving the ACE N domain and NEP free to degrade bradykinin (
       <xref ref-type="bibr" rid="B138">
        Jullien et al., 2010
       </xref>
       ). Structure-based design, initially based on the structures of the C-domain–selective inhibitor RXPA380 and dual NEP/ECE-1 inhibitor phosphoramidon, led to a series of phosphinic tripeptides. The stereochemistry of the bulky bicyclic P
       <sub>
        1
       </sub>
       ′ residue proved to be important for discriminating between ECE-1 and NEP, as illustrated by the differences in inhibition constants observed for compounds FI and FII (
       <xref ref-type="fig" rid="F6">
        Fig. 6
       </xref>
       ). The unusual
       <italic>
        R
       </italic>
       configuration of the P
       <sub>
        1
       </sub>
       ′ residue in FII was highly selective for ECE-1 over NEP and maintained potent ACE C-domain activity.
      </p>
      <fig id="F6" orientation="portrait" position="float">
       <label>
        Fig. 6.
       </label>
       <caption>
        <p>
         (A) Chemical structures of C-domain–selective phosphinic tripeptides FI and FII, showing residue positions relative to the zinc binding group together with the in vitro inhibition data for NEP, ECE-1, and ACE N and C domains. (B) FI and FII bound to the active sites of the ACE N and C domains: FI bound to the N domain and C domain in green and cyan, respectively; FII bound to the N domain and C domain shown in yellow and black, respectively. C-domain unique residues within the active site are shown in cyan with corresponding N-domain residues in orange.
        </p>
       </caption>
       <graphic xlink:href="pr.118.017129f6">
       </graphic>
      </fig>
      <p>
       The crystal structures of both the ACE C domain and N domain in complex with these compounds unexpectedly reveal that the bulky P
       <sub>
        1
       </sub>
       ′ group is accommodated by the S
       <sub>
        2
       </sub>
       ′ pocket in all four structures, highlighting the fluidity between the S
       <sub>
        1
       </sub>
       ′ and S
       <sub>
        2
       </sub>
       ′ pockets and the S
       <sub>
        2
       </sub>
       ′ pocket’s ability to accommodate conformationally diverse, bulky hydrophobic groups (
       <xref ref-type="fig" rid="F6">
        Fig. 6
       </xref>
       ) (
       <xref ref-type="bibr" rid="B5">
        Akif et al., 2011
       </xref>
       ;
       <xref ref-type="bibr" rid="bib396">
        Masuyer et al., 2014
       </xref>
       ). Another surprising finding was that an additional FII inhibitor molecule occupied the C-domain active site, binding on the nonprime side of the first molecule. FII, the most promising dual ACE C-domain–selective/ECE-1 inhibitor, displayed 230-fold C-domain selectivity and 480-fold selectivity for ECE-1 over NEP. Administration of FII to hypertensive rats resulted in antihypertensive effects (
       <xref ref-type="bibr" rid="B138">
        Jullien et al., 2010
       </xref>
       ), but the effect of FII on bradykinin levels and metabolism of other vasoactive peptides was not reported. This compound displays high selectivity for the C domains over the N domain, but it still inhibits the N domain in the nanomolar range, and there is only a 10-fold difference between the
       <italic>
        K
       </italic>
       <sub>
        i
       </sub>
       for the N domain and ECE-1. Confirmation that this inhibitor results in a distinct peptide metabolism profile compared with conventional dual ACE/ECE-1 inhibitors in vivo is also still to be reported.
      </p>
     </sec>
     <sec id="s23">
      <title>
       C. Dual Angiotensin-Converting Enzyme C-Domain–Selective/Neprilysin Inhibitors
      </title>
      <p>
       It may be unnecessary to leave both the ACE N domain and NEP free to degrade bradykinin: since ACE is the primary bradykinin-metabolizing enzyme (
       <xref ref-type="bibr" rid="B96">
        Fryer et al., 2008
       </xref>
       ), the N domain may compensate sufficiently for the C domain in preventing the buildup of dangerous levels of bradykinin. Consequently, dual ACE C-domain–selective/NEP inhibitors could offer a promising alternative for the treatment of hypertension and cardiovascular disease by potentiating NP levels in addition to blocking Ang II formation.
      </p>
     </sec>
    </sec>
    <sec id="s24">
     <title>
      VI. Angiotensin Receptor–Neprilysin Inhibitors: A Current Perspective
     </title>
     <p>
      There are parallels between dual ACE C-domain–selective/NEP inhibitors and the dual-acting angiotensin-receptor/NEP inhibitor (LCZ696 or sacubitril/valsartan, called Entresto; Novartis, East Hanover, NJ), a novel drug formulation containing equimolar amounts of the ARB valsartan and the NEP inhibitor sacubitril, which is a prodrug. Sacubitril/valsartan is the first in a new class of drugs that combines NEP inhibition together with Ang II receptor blockade (
      <xref ref-type="bibr" rid="B110">
       Gu et al., 2010
      </xref>
      ;
      <xref ref-type="bibr" rid="B277">
       Ruilope et al., 2010
      </xref>
      ;
      <xref ref-type="bibr" rid="B195">
       McMurray et al., 2013
      </xref>
      ;
      <xref ref-type="bibr" rid="B345">
       Vardeny et al., 2014
      </xref>
      ). Similar to dual ACE C-domain–selective/NEP inhibitors, this drug combination serves to enhance NEP activity while inhibiting the detrimental effects of the RAS, with no effect on bradykinin and other NEP-derived vasoprotective factors. Sacubitril/valsartan has been evaluated in the management of hypertension, heart failure with reduced ejection fraction (HFrEF), and heart failure with preserved ejection fraction (HFpEF) and has demonstrated clinical efficacy in the reduction of blood pressure in patients with essential hypertension and without HFpEF and a reduction in hospitalizations and mortality for patients with HFrEF. The landmark clinical trial, PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), showed that sacubitril/valsartan was significantly more effective for the treatment of heart failure with HFrEF compared with enalapril (
      <xref ref-type="bibr" rid="B196">
       McMurray et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B202">
       Mogensen et al., 2018
      </xref>
      ). In 2015, sacubitril/valsartan was approved by the FDA for the treatment of HFrEF and the drug is now included in American (
      <xref ref-type="bibr" rid="B380">
       Yancy et al., 2016
      </xref>
      ) and European (
      <xref ref-type="bibr" rid="B246">
       Ponikowski et al., 2016
      </xref>
      ) clinical guidelines for the treatment of heart failure.
     </p>
     <p>
      Despite the robust evidence of clinical benefit seen in the PARADIGM-HF trial, as well as inclusion of the drug in clinical guidelines, this medication is approved in the United States for the treatment of heart failure only and prescribing of this new therapeutic has been slow. This has been ascribed to the phenomenon of “clinical inertia” (
      <xref ref-type="bibr" rid="B135">
       Jarcho, 2019
      </xref>
      ), which is driven by clinician unfamiliarity, reluctance to switch stable patients, safety concerns, and payer-reimbursement issues (
      <xref ref-type="bibr" rid="B289">
       Sauer et al., 2019
      </xref>
      ). A recent study estimated that ∼28,484 deaths could be prevented each year in the United States with optimal implementation of sacubitril/valsartan therapy (
      <xref ref-type="bibr" rid="B91">
       Fonarow et al., 2016
      </xref>
      ); thus, because the potential reduction in mortality could be substantial, there have been calls that a paradigm shift is warranted in clinical practice (
      <xref ref-type="bibr" rid="B289">
       Sauer et al., 2019
      </xref>
      ). The PIONEER-HF study (comparison of sacubitril/valsartan versus enalapril on effect on nt-pro-bnp in patients stabilized from an acute heart failure episode), which showed that treatment with sacubitril/valsartan produced a significantly greater reduction in N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels than enalapril without increasing the rates of major adverse events in patients hospitalized with acute decompensated heart failure (
      <xref ref-type="bibr" rid="B350">
       Velazquez et al., 2019
      </xref>
      ), may help in overcoming the clinical inertia (
      <xref ref-type="bibr" rid="B135">
       Jarcho, 2019
      </xref>
      ). The angiotensin receptor–neprilysin inhibitor (ARNI) has shown considerable cardiovascular benefit and absolute risk reduction compared with the standard-of-care treatment in the PARADIGM (
      <xref ref-type="bibr" rid="B382">
       Yandrapalli et al., 2018
      </xref>
      ) and PIONEER-HF (
      <xref ref-type="bibr" rid="B205">
       Morrow et al., 2019
      </xref>
      ;
      <xref ref-type="bibr" rid="B350">
       Velazquez et al., 2019
      </xref>
      ) trials. The composite endpoint, which was explored as part of a prespecified exploratory analysis, consisted of death, rehospitalization for heart failure (hospital stay &gt;24 hours), requirement for a left ventricular assist device insertion, or listing for a cardiac transplantation. Furthermore, a recent meta-analysis of data from the PARADIGM-HF trial (
      <xref ref-type="bibr" rid="B312">
       Srivastava et al., 2018
      </xref>
      ) showed that the 5-year estimated number needed to treat for the primary outcome of cardiovascular death or heart failure hospitalization with ARNI therapy incremental to ACE inhibitor therapy in the overall cohort was 14. This value is considered clinically meaningful and supports guideline recommendations for use of ARNI therapy among eligible patients with HFrEF. The therapeutic role of ARNI in HFpEF is still unclear and currently under investigation.
     </p>
     <p>
      However, the effects of long-term NEP inhibition are yet to be established. NEP is responsible for the metabolism of many peptides; thus, chronic inhibition may have a range of physiologic effects. Indeed, too much NEP inhibition over and above angiotensin receptor blockade may increase ET-1 chronically, thereby diminishing the blood pressure–lowering potential of this combination, most likely because ET-1 upregulates sodium-hydrogen exchanger 3 in the kidney and constrictor ET
      <sub>
       B
      </sub>
      R in the vascular wall (
      <xref ref-type="bibr" rid="B266">
       Roksnoer et al., 2015
      </xref>
      ). Chronic NEP inhibition may additionally influence Alzheimer disease progression due to NEP’s role in the degradation of amyloid-
      <italic>
       β
      </italic>
      peptides. To date,
      <italic>
       β
      </italic>
      -amyloid concentration has not been shown to be increased in cerebrospinal fluid in healthy volunteers treated with sacubitril/valsartan (
      <xref ref-type="bibr" rid="B169">
       Langenickel et al., 2016
      </xref>
      ), and there was no increase in cognitive defects versus enalapril in the PARADIGM-HF trial (
      <xref ref-type="bibr" rid="B35">
       Cannon et al., 2017
      </xref>
      ). The PERSPECTIVE trial evaluates the efficacy and safety of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction. It will collect data on long-term cognitive effects in patients with chronic heart failure treated with sacubitril/valsartan or valsartan (
      <xref ref-type="bibr" rid="B289">
       Sauer et al., 2019
      </xref>
      ). Furthermore, sacubitril/valsartan may have an effect on inflammation, polyneuropathy, bronchial reactivity, and cancer, as recently reviewed in detail (
      <xref ref-type="bibr" rid="B33">
       Campbell, 2017
      </xref>
      ). Long-term clinical data from treatment with sacubitril/valsartan will provide information on both the beneficial and adverse effects of chronic inhibition, which will be important for the development of new vasopeptidase inhibitors.
     </p>
     <p>
      Potential future indications of sacubitril/valsartan include myocardial infarction, HFpEF, (diabetic) nephropathy, and stroke. ARNI attenuated adverse cardiac remodeling and dysfunction after myocardial infarction in rats compared with the ACE inhibitor perindopril (
      <xref ref-type="bibr" rid="B156">
       Kompa et al., 2018
      </xref>
      ), and it preserved left ventricular ejection fraction after myocardial infarction in rabbits, whereas valsartan did not (
      <xref ref-type="bibr" rid="B332">
       Torrado et al., 2018
      </xref>
      ). Studies in patients with HFpEF showed that after 12 weeks of treatment, ARNI lowered NT-proBNP more strongly than valsartan (
      <xref ref-type="bibr" rid="B308">
       Solomon et al., 2012
      </xref>
      ). HFpEF accounts for a large percentage of patients with heart failure and is associated with significant morbidity and mortality. Current medications are suboptimal and new therapies are being sought including sacubitril/valsartan. The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy and safety of the sacubitril/valsartan combination compared with valsartan (
      <xref ref-type="bibr" rid="B307">
       Solomon et al., 2017
      </xref>
      ). PARAGON-HF is an event-driven trial and all randomized patients will be followed up until at least 1847 total heart failure hospitalizations and cardiovascular deaths occur. The study, which is ongoing, will provide important information on the potential therapeutic use of sacubitril/valsartan in HFpEF.
     </p>
     <p>
      ARNI may also be effective in cardiovascular disease associated with diabetes. In rats made diabetic with streptozotocin, the NEP inhibitor thiorphan combined with an ARB prevented functional renal decline, improving glomerulosclerosis, fibrosis, and inflammation versus ARB alone (
      <xref ref-type="bibr" rid="B267">
       Roksnoer et al., 2016b
      </xref>
      ;
      <xref ref-type="bibr" rid="B187">
       Malek et al., 2019
      </xref>
      ). Secondary analysis of patients with heart failure and type 2 diabetes in the PARADIGM-HF trial also revealed that ARNI attenuated the effect of diabetes to accelerate renal deterioration (
      <xref ref-type="bibr" rid="B54">
       Damman et al., 2018
      </xref>
      ;
      <xref ref-type="bibr" rid="B236">
       Packer et al., 2018
      </xref>
      ). Yet ARNI displayed similar effects on kidney function and albuminuria as irbesartan in patients with chronic kidney diseases, although it did display superior blood pressure effects (
      <xref ref-type="bibr" rid="B119">
       Haynes et al., 2018
      </xref>
      ). Remarkably, complete prevention of stroke was obtained with ARNI, but not valsartan, in stroke-prone spontaneously hypertensive rats (SHRs) (
      <xref ref-type="bibr" rid="B276">
       Rubattu et al., 2018
      </xref>
      ), although
      <xref ref-type="bibr" rid="B15">
       Bai et al. (2015)
      </xref>
      observed that ARNI prevented ischemic brain damage after middle cerebral artery occlusion in a much more marked manner than valsartan.
     </p>
     <p>
      Given these promising effects, a full understanding of the mechanisms of action of ARNI is urgently needed. Studies often report an increase in BNP and a decrease in NT-proBNP. The latter is the inactive side-product yielded upon cleavage of proBNP into biologically active BNP. Elevated serum NT-proBNP is a well known marker for heart failure severity, as it is associated with increased risk of mortality and hospitalization. NT-proBNP is not degraded by NEP and thus has a longer half-life than BNP. A decrease in NT-proBNP levels suggests reduced pro-BNP production due to reduced cardiac wall tension (e.g., due to blood pressure lowering), whereas an increase in BNP either suggests the opposite or might be due to NEP inhibition. Hence, a combination of blood pressure lowering and NEP inhibition may even result in no change in BNP levels. Furthermore, the decreases in NT-proBNP and rises in BNP that have been reported might also be an assay artifact, due to the fact that ARNI promotes peptide glycosylation, thereby affecting the assays of NT-proBNP and BNP: NT-proBNP would become invisible, while proBNP would additionally be detected in BNP assays (
      <xref ref-type="bibr" rid="B271">
       Røsjø et al., 2015
      </xref>
      ). Another complicating factor is that BNP of all NPs is the least susceptible to degradation by NEP and thus acts as an endogenous inhibitor of NEP. If so, patients with elevated BNP levels already undergo NEP inhibition, and accordingly may be less responsive to ARNI (
      <xref ref-type="bibr" rid="B355">
       Vodovar et al., 2015
      </xref>
      ).
     </p>
    </sec>
    <sec id="s25">
     <title>
      VII. Recombinant Angiotensin-Converting Enzyme 2 as a Therapeutic Intervention
     </title>
     <p>
      The enzymatic conversion of the proinflammatory, profibrotic vasoconstrictor Ang II into the anti-inflammatory antifibrotic and cardioprotective vasodilator Ang 1
      <bold>
       -
      </bold>
      7 appears to be a reasonable therapeutic approach for treating conditions in which Ang II has been shown to be involved in the pathologic mechanism and Ang 1
      <bold>
       -
      </bold>
      7 could mediate protective effects. Therefore, recombinant human angiotensin-converting enzyme 2 (rhACE2) is currently considered for treating acute respiratory distress syndrome and pulmonary arterial hypertension. In a safety and tolerability study in healthy volunteers, single doses between 100 and 1200
      <italic>
       µ
      </italic>
      g/kg rhACE2 were administered intravenously, revealing a plasma half-life of the enzyme in the range of 10 hours with peak plasma concentrations up to 20
      <italic>
       µ
      </italic>
      g/ml (223 nM) for the highest-dose cohort. Plasma levels stayed in the range of 1
      <italic>
       µ
      </italic>
      g/ml (11.2 nM) until 24 hours after administration of a single dose of 400
      <italic>
       µ
      </italic>
      g/kg (
      <xref ref-type="bibr" rid="B115">
       Haschke et al., 2013
      </xref>
      ). Compared with the undetectable levels of ACE2 present in healthy volunteers (&lt;2.7 pM) (
      <xref ref-type="bibr" rid="B259">
       Rice et al., 2006
      </xref>
      ), a more that 4000-fold increase of circulating ACE2 levels is achieved until at least 24 hours after administration of a moderate intravenous dose of the recombinant enzyme. Although no significant decrease in blood pressure could be detected in healthy volunteers, the treatment showed the expected biochemical in vivo effects—that is, a profound suppression of circulating Ang II, while Ang 1
      <bold>
       -
      </bold>
      7 and Ang 1
      <bold>
       -
      </bold>
      5 levels were increased (
      <xref ref-type="bibr" rid="B115">
       Haschke et al., 2013
      </xref>
      ).
     </p>
     <p>
      In a recent pilot trial conducted in patients with acute respiratory distress syndrome (
      <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">
       ClinicalTrials.gov
      </ext-link>
      identifier NCT01597635), ACE2-mediated conversion of Ang II to Ang 1
      <bold>
       -
      </bold>
      7 and Ang 1
      <bold>
       -
      </bold>
      5 could be confirmed and the compound was well tolerated. Although a trend for reduced interleukin-6 levels was reported for rhACE2-treated subjects, no significant changes were observed in the ratio of partial pressure of arterial oxygen to fraction of inspired oxygen, oxygenation index, or sequential organ failure assessment score. The study was terminated after including 39 of 60 patients, as an interim analysis revealed the unlikeliness to reach a significant outcome. Primary outcomes including safety and tolerability were successfully reached. A rapid modulation of angiotensin metabolite levels was also observed in individual patients with circulating Ang II levels up to 600 pM, indicating that pharmacologic efficacy can be achieved at a state of high RAS activity. One reason for the lack of effect might be the large heterogeneity in baseline RAS activity in this population, although this does reflect reality (
      <xref ref-type="bibr" rid="B149">
       Khan et al., 2017
      </xref>
      ). Given that ACE2-mediated Ang 1
      <bold>
       -
      </bold>
      7 formation critically depends on the availability of Ang II as its primary substrate, patient stratification on the basis of renin or Ang II might be a reasonable approach to enhance the therapeutic efficacy observed for a treatment aiming to reduce Ang II levels while promoting the alternative RAS via increased Ang 1
      <bold>
       -
      </bold>
      7 formation.
     </p>
     <p>
      Two studies investigating the intravenous administration of rhACE2 are currently recruiting patients. The first is conducted in human healthy volunteers under acute hypoxia and exercise (NCT03000686) in a placebo-controlled crossover design, in which modification of pulmonary artery systolic pressure by rhACE2 serves as the primary outcome. The second study is an open-label dose escalation study for rhACE2 (NCT03177603) in patients with pulmonary arterial hypertension, in which changes in pulmonary vascular resistance, cardiac output, and mean pulmonary artery pressure in response to rhACE2 serve as primary outcome measures.
     </p>
     <p>
      Endogenous ACE2 is predominantly expressed on endothelial surfaces and in a variety of tissues, including the heart, kidney, and lung (
      <xref ref-type="bibr" rid="B329">
       Tipnis et al., 2000
      </xref>
      ). Angiotensin metabolites are continuously generated in blood plasma, which is a process mainly driven by kidney-derived renin, hepatic angiotensinogen, and membrane-bound ACE and aminopeptidases. Indeed, endothelial surfaces play a key role in generating a local RAS by modifying the angiotensin mix supplied by the blood. In its natural environment, ACE2 is likely to compete with AT
      <sub>
       1
      </sub>
      R for local Ang II. To what extent this balanced system is affected by an excess of rhACE2 in the circulation at different states of RAS activity (e.g., how such high amounts of rhACE2 affect the plasma angiotensin substrate supply for endothelial surfaces in the absence and presence of compensatory mechanisms) is obviously critical for the clinical success of rhACE2 and requires further investigation.
     </p>
    </sec>
    <sec id="s26">
     <title>
      VIII. Regulation of Hypertension by Central-Acting Aminopeptidase A Inhibitors
     </title>
     <p>
      Several decades of investigation have provided evidence for the existence of a brain RAS and its involvement in the control of cardiovascular functions (
      <xref ref-type="bibr" rid="B349">
       Veerasingham and Raizada, 2003
      </xref>
      ;
      <xref ref-type="bibr" rid="B280">
       Sakai and Sigmund, 2005
      </xref>
      ). All of the components of the systemic RAS—the precursor, angiotensinogen; the enzymes, renin, ACE, ACE2, APA, and aminopeptidase N (APN); the peptides, Ang I, Ang II, Ang III, and Ang 1
      <bold>
       -
      </bold>
      7; and the receptors, AT
      <sub>
       1
      </sub>
      R and AT
      <sub>
       2
      </sub>
      R as well as Mas—are present within the brain (reviewed in
      <xref ref-type="bibr" rid="B175">
       Lenkei et al., 1997
      </xref>
      ;
      <xref ref-type="bibr" rid="B374">
       Wright and Harding, 1997
      </xref>
      ; and
      <xref ref-type="bibr" rid="B287">
       Santos et al., 2018
      </xref>
      ). Whether they are of local origin or derived from plasma remains a matter of debate (
      <xref ref-type="bibr" rid="B303">
       Sigmund et al., 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B342">
       van Thiel et al., 2017
      </xref>
      ).
     </p>
     <p>
      Brain RAS hyperactivity has been implicated in the development and maintenance of hypertension in several experimental and genetic animal models of hypertension, such as SHRs, deoxycorticosterone acetate (DOCA)-salt rats, and transgenic mice overexpressing both angiotensinogen and renin human genes (
      <xref ref-type="bibr" rid="B21">
       Basso et al., 1981
      </xref>
      ;
      <xref ref-type="bibr" rid="B101">
       Ganten et al., 1983
      </xref>
      ;
      <xref ref-type="bibr" rid="B64">
       Davisson et al., 1998
      </xref>
      ). Among the bioactive peptides of the RAS, Ang II and Ang III display similar affinities for AT
      <sub>
       1
      </sub>
      R (
      <xref ref-type="bibr" rid="B373">
       Wright and Harding, 1995
      </xref>
      ). When injected into the brain, these peptides similarly increase blood pressure and arginine-vasopressin release (
      <xref ref-type="bibr" rid="B242">
       Phillips, 1987
      </xref>
      ;
      <xref ref-type="bibr" rid="B393">
       Zini et al., 1996
      </xref>
      ;
      <xref ref-type="bibr" rid="B256">
       Reaux et al., 1999
      </xref>
      ). However, because Ang II is converted into Ang III in vivo, the nature of the effector peptide of the brain RAS remains to be defined.
     </p>
     <p>
      Using radiolabeled angiotensins in the presence or absence of specific and selective APA and APN inhibitors, EC33 (
      <xref ref-type="bibr" rid="B40">
       Chauvel et al., 1994
      </xref>
      ) and PC18 [(2
      <italic>
       S
      </italic>
      )-2-amino-4-methylsulfanyl butane thiol] (
      <xref ref-type="bibr" rid="B92">
       Fournié-Zaluski et al., 1992
      </xref>
      ), respectively, administered by the intracerebroventricular route, brain APA was shown to generate Ang III from Ang II by removing the N-terminal aspartate residue, whereas APN (EC 3.4.11.2), another membrane-bound zinc metalloprotease, metabolized Ang III into Ang IV (
      <xref ref-type="bibr" rid="B393">
       Zini et al., 1996
      </xref>
      ). The use of EC33 and PC18 injected alone by the central route showed that endogenous Ang III, rather than Ang II, is one of the main effector peptides of the brain RAS in the control of blood pressure and arginine-vasopressin release (
      <xref ref-type="bibr" rid="B393">
       Zini et al., 1996
      </xref>
      ;
      <xref ref-type="bibr" rid="B256">
       Reaux et al., 1999
      </xref>
      ;
      <xref ref-type="bibr" rid="B376">
       Wright et al., 2003
      </xref>
      ;
      <xref ref-type="bibr" rid="B93">
       Fournie-Zaluski et al., 2004
      </xref>
      ). Brain Ang III exerts a tonic stimulatory control over blood pressure in two experimental models of hypertension: the SHR (
      <xref ref-type="bibr" rid="B256">
       Reaux et al., 1999
      </xref>
      ;
      <xref ref-type="bibr" rid="B189">
       Marc et al., 2012
      </xref>
      ) and the DOCA-salt rat (
      <xref ref-type="bibr" rid="B93">
       Fournie-Zaluski et al., 2004
      </xref>
      ), with both models exhibiting hyperactivity of the brain RAS. The activity of the systemic RAS is normal in the SHR model and depressed in DOCA-salt rats (characterized by low plasma renin levels and high plasma arginine-vasopressin levels), accounting for the resistance of hypertensive DOCA-salt rats to treatment by systemic RAS blockers.
     </p>
     <p>
      Brain APA, the enzyme responsible for generating brain Ang III, therefore constitutes a promising target for hypertension treatment, justifying the development of potent and selective APA inhibitors as central-acting antihypertensive agents. A prodrug of EC33, RB150 (4,4-dithio-{bis[(3
      <italic>
       S
      </italic>
      )-3-aminobutyl sulfonic acid]}), renamed firibastat, was developed for clinical use (
      <xref ref-type="bibr" rid="B93">
       Fournie-Zaluski et al., 2004
      </xref>
      ). This compound is composed of two molecules of EC33 linked by a disulfide bridge. Orally administered RB150 crosses the intestinal, hepatic, and blood–brain barriers. Upon brain entry, the disulfide bridge is rapidly cleaved by brain reductases to generate two active molecules of EC33, which inhibit brain APA activity, block the formation of brain Ang III (
      <xref ref-type="bibr" rid="B93">
       Fournie-Zaluski et al., 2004
      </xref>
      ), and decrease blood pressure and arginine-vasopressin release in alert hypertensive rats (
      <xref ref-type="bibr" rid="B27">
       Bodineau et al., 2008
      </xref>
      ;
      <xref ref-type="bibr" rid="B190">
       Marc et al., 2018
      </xref>
      ). The RB150/firibastat-induced blood pressure decrease is due to the following: 1) decreases in sympathetic tone and, consequently, vascular resistance; 2) a decrease in arginine-vasopressin release into the bloodstream from the posterior pituitary, reducing extracellular volume; and 3) an improvement in baroreflex function (
      <xref ref-type="fig" rid="F7">
       Fig. 7
      </xref>
      ) (
      <xref ref-type="bibr" rid="B27">
       Bodineau et al., 2008
      </xref>
      ;
      <xref ref-type="bibr" rid="B189">
       Marc et al., 2012
      </xref>
      ;
      <xref ref-type="bibr" rid="B123">
       Huang et al., 2013
      </xref>
      ). No blood pressure effect was noted in normotensive rats, showing that RB150/firibastat is an antihypertensive agent and not a hypotensive agent. Moreover, the blood pressure decrease was greater in hypertensive DOCA-salt rats than in SHRs, suggesting that RB150/firibastat may be especially effective in salt-dependent hypertension.
     </p>
     <fig id="F7" orientation="portrait" position="float">
      <label>
       Fig. 7.
      </label>
      <caption>
       <p>
        Mode of action of the APA inhibitor prodrug RB150/firibastat on the control of blood pressure in hypertensive rats. After oral administration, the disulfide bridge enables RB150 to cross the blood–brain barrier and to enter the brain. At the opposite, EC33 is not able to enter the brain. In the brain, the disulfide bridge of RB150 is cleaved by brain reductases generating two active molecules of EC33. EC33 subsequently inhibits brain APA activity and blocks the formation of brain Ang III, known to exert, in brain structures (PVN, SON, PPit, NTS, and RVLM), a stimulatory action on the control of blood pressure in hypertensive rats. This results in a blood pressure decrease via a decrease in arginine-vasopressin release and sympathetic neuron activity and an improvement of the baroreflex function. The red dashed lines represent the neuronal angiotensinergic pathways in the adult rat brain. MnPO, median preoptic nucleus; NTS, nucleus of the solitary tract; OVLT, organum vasculosum of the lamina terminalis; PPit, posterior pituitary; PVN, paraventricular nucleus; RVLM, rostral ventrolateral medulla; SFO, subfornical organ; SON, supraoptic nucleus.
       </p>
      </caption>
      <graphic xlink:href="pr.118.017129f7">
      </graphic>
     </fig>
     <p>
      Together, these data led to the first evaluation of RB150/firibastat in humans. Clinical studies in healthy volunteers, in single ascending oral doses (phase Ia) and multiple oral doses (phase Ib), have shown that RB150/firibastat is well tolerated (
      <xref ref-type="bibr" rid="B16">
       Balavoine et al., 2014
      </xref>
      ) up to 750 mg twice daily for 7 days. Two phase II clinical trials were then conducted. The first, a phase IIa trial carried out in 34 hypertensive patients (grade I and II), was a randomized double-blind study comparing the effect of RB150 (250 mg twice daily for 1 week, then 500 mg twice daily for 3 weeks) to placebo (
      <xref ref-type="bibr" rid="B11">
       Azizi et al., 2017
      </xref>
      ). In the intention-to-treat population, daytime ambulatory systolic blood pressure (SBP) and office SBP decreased by 2.7 and 4.7 mm Hg, respectively, after 4 weeks of firibastat treatment versus placebo, but the difference between the groups was not statistically significant (
      <italic>
       P
      </italic>
      = 0.157 and
      <italic>
       P
      </italic>
      = 0.151, respectively). In the per-protocol population (
      <italic>
       n
      </italic>
      = 29 patients), firibastat treatment induced a larger decrease in daytime ambulatory SBP (median, −9.4 mm Hg; interquartile range, −12.5 to −3.0) in patients with a basal value of daytime ambulatory SBP between 154 and 172 mm Hg, whereas placebo treatment did not induce any change (median, 0.75 mm Hg; interquartile range, −5.5 to −1.9). In the multiple linear regression analysis for the per-protocol population, only treatment with firibastat (
      <italic>
       P
      </italic>
      = 0.06) and baseline daytime ambulatory SBP (
      <italic>
       P
      </italic>
      = 0.01) were associated with changes in daytime ambulatory SBP. This suggests that the more the basal daytime ambulatory SBP is elevated, the more the firibastat-induced SBP decrease is apparent. This is in agreement with the observation that, in experimental models of hypertension, firibastat acted as an antihypertensive agent and not as a hypotensive agent. This study showed that RB150/firibastat treatment was safe and tended to decrease daytime ambulatory SBP, but not significantly (
      <xref ref-type="bibr" rid="B11">
       Azizi et al., 2017
      </xref>
      ), possibly due to the small number of patients and the short duration of treatment. These data were used to guide the design of a large phase IIb clinical trial, NEW-HOPE (Novel Evaluation with QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins), carried out in 250 overweight hypertensive patients (SBP 145–170 mm Hg), 50% of whom were self-identified African Americans or Hispanics. In patients receiving firibastat for 2 months (250 mg twice daily orally for 2 weeks, then 500 mg twice daily; 25 mg hydrochlorothiazide daily could be added after 1 month if SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg), a significant blood pressure–lowering efficacy and a safe tolerability profile were observed (NCT03198793) (
      <xref ref-type="bibr" rid="B83">
       Ferdinand et al., 2018
      </xref>
      ).
     </p>
     <p>
      If the proof of concept of firibastat efficacy is confirmed in pivotal phase III trials, RB150/firibastat could constitute the first of a new class of centrally acting antihypertensive agents. Firibastat may be especially effective in African Americans who are poorly responsive to blockers of the systemic RAS and who are salt sensitive with high plasma arginine-vasopressin levels and low plasma renin activity.
     </p>
    </sec>
    <sec id="s27">
     <title>
      IX. Targeting Angiotensinogen: Antisense Oligonucleotides and Small Interfering RNA
     </title>
     <p>
      Since all angiotensins stem from angiotensinogen, deleting angiotensinogen will diminish the stimulation of all angiotensin receptors, including AT
      <sub>
       2
      </sub>
      R and Mas. Circulating angiotensinogen is derived from the liver, and it is generally believed that additional angiotensinogen production occurs in the brain, kidney, and adipose tissue (
      <xref ref-type="bibr" rid="B34">
       Campbell and Habener, 1986
      </xref>
      ;
      <xref ref-type="bibr" rid="B327">
       Thomas and Sernia, 1988
      </xref>
      ;
      <xref ref-type="bibr" rid="B194">
       Matsusaka et al., 2012
      </xref>
      ). Although it is attractive to speculate that this angiotensinogen contributes to “local” angiotensin production, direct evidence that tissue angiotensin generation occurs independently of liver angiotensinogen is still lacking. Indeed, deleting renal angiotensinogen unexpectedly did not affect renal angiotensin levels at baseline or under pathophysiological conditions (
      <xref ref-type="bibr" rid="B194">
       Matsusaka et al., 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="B193">
       2014
      </xref>
      ). Future studies should address brain and adipose tissue angiotensin levels in the absence of hepatic angiotensinogen to solve this issue (
      <xref ref-type="bibr" rid="B340">
       Uijl et al., 2018
      </xref>
      ). Such studies require highly sensitive angiotensin assays, since brain angiotensin levels in particular are extremely low (
      <xref ref-type="bibr" rid="B342">
       van Thiel et al., 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B182">
       Lombard-Banek et al., 2019
      </xref>
      ).
     </p>
     <p>
      In humans, circulating angiotensinogen levels are in the micromolar range (i.e., close to the
      <italic>
       K
      </italic>
      <sub>
       m
      </sub>
      of its reaction with renin) and 5 to 6 orders of magnitude above the levels of circulating Ang II. Circulating, liver-derived angiotensinogen diffuses slowly into the interstitial space and hence contributes to tissue angiotensin production (e.g., in the heart and vascular wall) (
      <xref ref-type="bibr" rid="B67">
       de Lannoy et al., 1997
      </xref>
      ). Upregulation of angiotensinogen levels, such as in subjects carrying the T235 allele of the angiotensinogen gene or in pregnant women (due to the fact that estrogen stimulates angiotensinogen synthesis) (
      <xref ref-type="bibr" rid="B295">
       Schunkert et al., 1997
      </xref>
      ;
      <xref ref-type="bibr" rid="B57">
       Danser et al., 1998
      </xref>
      ), results in renin downregulation, thereby normalizing angiotensin generation. In contrast, renin upregulation, as occurs in patients with heart failure, particularly during treatment with diuretics and RAS blockers, diminishes angiotensinogen and, if excessive, may result in near-complete angiotensinogen depletion (
      <xref ref-type="bibr" rid="B58">
       Danser et al., 1997
      </xref>
      ;
      <xref ref-type="bibr" rid="B153">
       Klotz et al., 2009
      </xref>
      ). Such depletion tends to occur earlier at the tissue level rather than in the circulation (
      <xref ref-type="bibr" rid="B153">
       Klotz et al., 2009
      </xref>
      ). Nevertheless, the inverse relationship between renin and angiotensinogen allows angiotensin levels to remain intact over a wide range of angiotensinogen levels, even in patients with angiotensinogen levels that are &lt;25% of normal (
      <xref ref-type="bibr" rid="B58">
       Danser et al., 1997
      </xref>
      ;
      <xref ref-type="bibr" rid="B153">
       Klotz et al., 2009
      </xref>
      ). Of interest, mice display angiotensinogen levels that are at most a few percent of those in humans, and they still display similar angiotensin levels to humans. This is due to the fact that their renin levels are several orders of magnitude higher than those in humans (
      <xref ref-type="bibr" rid="B342">
       van Thiel et al., 2017
      </xref>
      ). Here it is important to realize that humans are also capable of upregulating renin levels several hundredfold (
      <xref ref-type="bibr" rid="B17">
       Balcarek et al., 2014
      </xref>
      ), thereby compensating for significant angiotensinogen depletion. Taken together, this implies that to suppress angiotensin levels in blood plasma, angiotensinogen depletion should be substantial (most likely &gt;90%), whereas suppression of angiotensins at the tissue level may already occur at less impressive angiotensinogen reductions.
     </p>
     <p>
      Currently, suppression of angiotensinogen can be achieved by interference at the RNA level with oligonucleotides (
      <xref ref-type="fig" rid="F8">
       Fig. 8
      </xref>
      ). Antisense oligonucleotides (ASOs) are single-stranded synthetic nucleic acids that are complementary to a specific mRNA region (
      <xref ref-type="bibr" rid="B360">
       Watts and Corey, 2012
      </xref>
      ). Once hybridized, mRNA degradation occurs, thereby abrogating protein (angiotensinogen) synthesis. ASOs generally consisting of 15–30 nucleotides and are highly unstable; thus, chemical modifications are required to increase nuclease resistance. Such modifications may also help to increase RNA affinity and selectivity. Furthermore, conjugation to a hepatocyte-targeting ligand [triantennary
      <italic>
       N
      </italic>
      -acetylgalactosamine (GalNAc)] facilitates selective accumulation in the liver, thereby increasing potency 10- to 30-fold (
      <xref ref-type="bibr" rid="B209">
       Mullick et al., 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B258">
       Ren et al., 2018
      </xref>
      ). GalNAc binds to the asialoglycoprotein receptor on hepatocytes, allowing transport and release of the ASO into the intracellular compartment (
      <xref ref-type="bibr" rid="B176">
       Levin, 2019
      </xref>
      ). Without GalNAc, the ASOs may also accumulate outside the liver, for example, in the above-mentioned putative angiotensinogen-synthesizing organs. Small interfering RNA (siRNA) shares with ASOs the principle of oligonucleotide binding to a target RNA through Watson-Crick base pairing. Yet siRNA is double stranded (increasing stability) and, once in the cell, one strand (the “passenger” strand) is lost, whereas the other strand (the “guide” strand) is loaded into the RNA-induced silencing complex (RISC). RISC is a protein complex that allows the guide strand to bind to a complementary RNA region, after which an enzyme (Argonaute) that is part of RISC cleaves the mRNA. GalNAc conjugation can be applied to siRNA as well, which in the case of siRNA for proprotein convertase subtilisin/kexin type 9 (PCSK9)–enabled biannual dosing to suppress PCSK9 (
      <xref ref-type="bibr" rid="B255">
       Ray et al., 2017
      </xref>
      ). If true for angiotensinogen as well, this might revolutionize hypertension pharmacotherapy, particularly in patients who are nonadherent.
     </p>
     <fig id="F8" orientation="portrait" position="float">
      <label>
       Fig. 8.
      </label>
      <caption>
       <p>
        Overview of AGT suppression using siRNAs. siRNAs enter the cell and are incorporated into the RISC in the cytoplasm. The RISC complex with the active guide strand binds the complementary sequence within the target mRNA, resulting in Argonaut 2–mediated cleavage and subsequent AGT mRNA degradation. AGT, angiotensinogen.
       </p>
      </caption>
      <graphic xlink:href="pr.118.017129f8">
      </graphic>
     </fig>
     <p>
      Early studies with angiotensinogen ASOs administered by intracerebroventricular injection in the brain of SHRs showed a modest reduction of angiotensinogen levels in the hypothalamus (from ≈60 to ≈40 pmol/g), but not in the brainstem, cortex, midbrain, or cerebellum (
      <xref ref-type="bibr" rid="B368">
       Wielbo et al., 1995
      </xref>
      ). Remarkably, baseline brain angiotensinogen levels were comparable in all brain regions and corresponded to &lt;5% of blood plasma angiotensinogen levels. These data argue against angiotensinogen expression in selected brain nuclei, and they favor the presence of trapped plasma angiotensinogen in the brain. Furthermore, brainstem Ang II levels decreased marginally from 70 to 60 pg/g after angiotensinogen ASO administration (
      <xref ref-type="bibr" rid="B112">
       Gyurko et al., 1993
      </xref>
      ), yet blood pressure decreased by &gt;35 mm Hg. It remains difficult to link this large hypotensive effect to the inconsistent or even absent changes in brain angiotensinogen and Ang II; thus, before concluding that this reflects exclusive interference with brain angiotensinogen expression, these studies should now be repeated with the current, more selective, potent and stable angiotensinogen ASOs. Recent studies evaluated such ASOs and siRNAs in various rat models (
      <xref ref-type="bibr" rid="B209">
       Mullick et al., 2017
      </xref>
      ) and mice (
      <xref ref-type="bibr" rid="B384">
       Ye et al., 2019
      </xref>
      ) and also compared the GalNAc-conjugated and nonconjugated variants.
     </p>
     <p>
      In mice, hepatocyte-specific angiotensinogen deficiency abolished angiotensinogen accumulation in proximal tubules and greatly diminished renal Ang II levels, supporting the concept that renal angiotensin generation depends on liver-derived angiotensinogen (
      <xref ref-type="bibr" rid="B265">
       Roksnoer et al., 2016a
      </xref>
      ). In rats, both GalNAc-conjugated and unconjugated angiotensinogen ASO suppressed circulating angiotensinogen, although only the unconjugated ASO additionally suppressed renal and adipose angiotensinogen mRNA. Nevertheless, both the GalNAc-conjugated ASO and siRNA effectively lowered blood pressure in SHRs (
      <xref ref-type="bibr" rid="B209">
       Mullick et al., 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B339">
       Uijl et al., 2019
      </xref>
      ), suggesting that interference with renal or adipose angiotensinogen is not required for this effect. This was also true for lipid nanoparticle-encapsulated angiotensinogen siRNA delivered to the liver in SHRs (
      <xref ref-type="bibr" rid="B230">
       Olearczyk et al., 2014
      </xref>
      ). Unexpectedly, GalNAc-conjugated angiotensinogen ASO also lowered blood pressure in SHRs fed 8% salt, whereas classic RAS blockers are ineffective in this model (
      <xref ref-type="bibr" rid="B209">
       Mullick et al., 2017
      </xref>
      ). Moreover, GalNAc-conjugated angiotensinogen ASO did not induce renal dysfunction (reflected by reduced creatinine clearance) in rats with 5/6 nephrectomy, unlike both nonconjugated angiotensinogen ASO and captopril (
      <xref ref-type="bibr" rid="B209">
       Mullick et al., 2017
      </xref>
      ). The authors speculated that the preservation of renal angiotensinogen in the 5/6 nephrectomy model with GalNAc-conjugated angiotensinogen ASO might have prevented kidney function deterioration, but failed to support this concept by determining renal angiotensin levels under the various conditions. Renal angiotensinogen production is unlikely to underlie the effectiveness of GalNAc-conjugated angiotensinogen ASO in SHRs fed 8% salt. Finally, unconjugated angiotensinogen ASO slowed polycystic kidney disease in various polycystic kidney disease mouse models (
      <xref ref-type="bibr" rid="B254">
       Ravichandran et al., 2015
      </xref>
      ;
      <xref ref-type="bibr" rid="B88">
       Fitzgibbon et al., 2018
      </xref>
      ). Since this approach lowered both renal and hepatic angiotensinogen expression, as well as angiotensinogen in serum, it cannot be concluded to what degree this was due to interference with renal angiotensinogen, although it is likely to be due to suppression of renal Ang II. Clearly, future studies combining GalNAc-conjugated and unconjugated angiotensinogen ASO/siRNA together with renal Ang II measurements in various models are needed to finally settle the issue of renal angiotensinogen versus hepatic angiotensinogen contributing to renal angiotensin generation.
     </p>
     <p>
      In summary, angiotensinogen ASO and siRNA show promising results in rodent models for hypertension and kidney failure. Their long-lasting effects are particularly exciting, and if translated to a clinical application of at most a few administrations per year, may help to eliminate nonadherence. Yet major hurdles remain with regard to both safety (e.g., immune responses, liver toxicity, nonspecific effects, what to do in situations where RAS activity is acutely needed, etc.) and efficacy, particularly in the context of common comorbidities such as heart failure and chronic kidney disease, and in combination with other RAS blockers.
     </p>
    </sec>
    <sec id="s28">
     <title>
      X. Dual Receptor Activation of Particulate Guanylyl Cyclase A and Mas
     </title>
     <p>
      In contemporary drug discovery, an emerging strategy is the design and development of bispecific therapeutics. A bispecific drug, as either a small molecule or peptide, targets two independent signaling pathways. Importantly, the goal of bispecific drugs is to achieve therapeutic synergy that transcends the effects of single-pathway activation. As an example, this concept has been supported by the approval of the small molecule sacubitril/valsartan for heart failure, which has also demonstrated efficacy in hypertension (
      <xref ref-type="bibr" rid="B277">
       Ruilope et al., 2010
      </xref>
      ;
      <xref ref-type="bibr" rid="B195">
       McMurray et al., 2013
      </xref>
      ).
     </p>
     <p>
      Most recently, advances in peptide engineering have been employed to design and develop novel designer peptides that target pGC-A (
      <xref ref-type="bibr" rid="B198">
       Meems and Burnett, 2016
      </xref>
      ;
      <xref ref-type="bibr" rid="B42">
       Chen et al., 2018
      </xref>
      ). This molecular target is well recognized to mediate cardiorenal protection in cardiovascular disease, via its second-messenger cGMP, for which the cardiac hormones ANP and BNP are its endogenous ligands. Indeed, stimulation of the pGC-A/cGMP pathway results in a number of biologic properties, including natriuresis, diuresis, blood pressure lowering, inhibition of cardiomyocyte hypertrophy and fibroblast proliferation, browning of white adipocytes with enhanced energy utilization, suppression of inflammatory cytokines and T cells, and inhibition of aldosterone (
      <xref ref-type="bibr" rid="B28">
       Bordicchia et al., 2012
      </xref>
      ;
      <xref ref-type="bibr" rid="B184">
       Ma et al., 2013
      </xref>
      ;
      <xref ref-type="bibr" rid="B163">
       Kuhn, 2016
      </xref>
      ).
      <xref ref-type="bibr" rid="B36">
       Cataliotti et al. (2011)
      </xref>
      also reported that chronic activation of pGC-A by adenoviral BNP gene delivery in SHRs reduced blood pressure and attenuated cardiac hypertrophy and diastolic dysfunction. In human heart failure, chronic pGC-A augmentation with daily subcutaneous BNP injections improved cardiorenal function and clinical symptoms (
      <xref ref-type="bibr" rid="B41">
       Chen et al., 2012
      </xref>
      ).
     </p>
     <p>
      A second but separate molecular target in cardiorenal therapeutics is the Mas. Mas activation mediates antiapoptotic, anti-inflammatory, vasodilatory, antithrombotic, and AT
      <sub>
       1
      </sub>
      R antagonizing actions by activation via its ligand Ang 1
      <bold>
       -
      </bold>
      7 and its second-messenger cAMP (
      <xref ref-type="bibr" rid="B285">
       Santos et al., 2003
      </xref>
      ;
      <xref ref-type="bibr" rid="B335">
       Trask and Ferrario, 2007
      </xref>
      ). In addition to cAMP activation, other downstream pathways activated by Ang 1
      <bold>
       -
      </bold>
      7/Mas include the phospholipase A2 pathway (
      <xref ref-type="bibr" rid="B285">
       Santos et al., 2003
      </xref>
      ) and the phosphoinositide 3-kinase/AKT pathway (
      <xref ref-type="bibr" rid="B281">
       Sampaio et al., 2007
      </xref>
      ;
      <xref ref-type="bibr" rid="B183">
       Lopez Verrilli et al., 2012
      </xref>
      ;
      <xref ref-type="bibr" rid="B292">
       Savergnini et al., 2013
      </xref>
      ;
      <xref ref-type="bibr" rid="B326">
       Than et al., 2013
      </xref>
      ). This Ang 1
      <bold>
       -
      </bold>
      7/Mas axis also has cardiorenal protective actions in models of hypertension and heart failure (
      <xref ref-type="bibr" rid="B204">
       Mori et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B343">
       van Twist et al., 2014
      </xref>
      ). The therapeutic development of Mas has been limited, however, by the rapid in vivo degradation of Ang 1
      <bold>
       -
      </bold>
      7 (
      <xref ref-type="bibr" rid="B129">
       Iusuf et al., 2008
      </xref>
      ).
     </p>
     <p>
      A first-in-class bispecific designer peptide that cotargets Mas and pGC-A in one peptide entity was recently engineered (
      <xref ref-type="bibr" rid="B197">
       Meems et al., 2019
      </xref>
      ). This designer peptide NPA7 replaces the 9-amino-acid N terminus of BNP1-32 with the Mas agonist Ang 1
      <bold>
       -
      </bold>
      7 (
      <xref ref-type="fig" rid="F9">
       Fig. 9
      </xref>
      ). The goal was to create a bispecific drug (i.e., NPA7) that would possess greater systemic and renal vasodilating, natriuretic, diuretic, and cardiac unloading properties compared with either Ang 1
      <bold>
       -
      </bold>
      7 or BNP alone and which potentially would have beneficial efficacy for the treatment of cardiovascular disease such as hypertension and heart failure.
     </p>
     <fig id="F9" orientation="portrait" position="float">
      <label>
       Fig. 9.
      </label>
      <caption>
       <p>
        NPA7 is a single peptide entity that coactivates the Mas and pGC-A receptors and their second messengers cAMP and cGMP, respectively. NPA7 incorporates key amino acids from BNP1-32 (a pGC-A activator) and Ang 1
        <bold>
         -
        </bold>
        7 (a Mas activator), resulting in a novel bispecific first-in-class bispecific peptide. GC, guanylyl cyclase; URO, urodilatin.
       </p>
      </caption>
      <graphic xlink:href="pr.118.017129f9">
      </graphic>
     </fig>
     <p>
      In a recent report, pGC-A and Mas activation by NPA7 was validated and it was shown that NPA7 is biologically active in vivo with potent and more sustained cardiorenal actions that go beyond Mas or pGC-A alone (
      <xref ref-type="bibr" rid="B197">
       Meems et al., 2019
      </xref>
      ). Further validation of stimulation of both receptors in vitro was shown and increases in the second messengers of pGC-A and Mas in HEK293 cells with increases in cGMP and cAMP, respectively, were demonstrated. Importantly, blockade of Mas attenuated the hemodynamic, natriuretic, and diuretic responses to NPA7 in vivo, underscoring the important activation of Mas by NPA7. These findings are the first studies of a novel and unique Mas activator that possesses Ang 1
      <bold>
       -
      </bold>
      7 properties, hence generating in vitro and in vivo actions that represent alternative RAS activation together with pGC-A targeting.
     </p>
     <p>
      NPA7 as a therapeutic has implications for the treatment of cardiovascular disease, especially for those disease states in which RAS activation plays a pivotal role (i.e., hypertension and heart failure). Hypertension and heart failure have neurohumoral imbalance, which is characterized by a relative NP deficiency with excessive RAS activation (
      <xref ref-type="bibr" rid="B118">
       Hawkridge et al., 2005
      </xref>
      ;
      <xref ref-type="bibr" rid="B185">
       Macheret et al., 2012
      </xref>
      ). Treatment with drugs that target both the pGC-A receptor system and Mas have the potential to restore this imbalance. Indeed, studies have reported that chronic pGC-A receptor activation in human heart failure is associated with improved cardiorenal function, left ventricular function and/or structure, and overall clinical outcomes (
      <xref ref-type="bibr" rid="B41">
       Chen et al., 2012
      </xref>
      ). Long-term treatment with Ang 1
      <bold>
       -
      </bold>
      7 in experimental models of cardiovascular disease improves cardiac function mice and prevents cardiomyocyte hypertrophy, apoptosis, and fibrosis (
      <xref ref-type="bibr" rid="B204">
       Mori et al., 2014
      </xref>
      ;
      <xref ref-type="bibr" rid="B240">
       Papinska et al., 2016
      </xref>
      ). Therefore, NPA7 may not only improve hemodynamic function, diuresis and natriuresis in the short term but may have wide potential application in cardiovascular, renal, and metabolic diseases when chronically used. Thus, future studies are needed to address the full therapeutic potential of this first-in-class peptide and the concept of optimizing therapy with bivalency.
     </p>
    </sec>
    <sec id="s29">
     <title>
      XI. Conclusion
     </title>
     <p>
      Blockers of the RAS have profoundly influenced clinical medicine. In particular, ACE inhibitors have had a major impact on cardiovascular medicine, especially in the treatment of heart failure, hypertension, and ischemic heart disease (
      <xref ref-type="bibr" rid="B84">
       Ferrario and Mullick, 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B232">
       Oparil et al., 2018
      </xref>
      ). Many major evidence-based cardiovascular guidelines recommend ACE inhibitors as first-line therapy, at least for heart failure and hypertension (
      <xref ref-type="bibr" rid="B270">
       Rosendorff et al., 2015
      </xref>
      ;
      <xref ref-type="bibr" rid="B381">
       Yancy et al., 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B367">
       Whelton et al., 2018
      </xref>
      ;
      <xref ref-type="bibr" rid="B372">
       Wright et al., 2018
      </xref>
      ). However, despite enormous therapeutic advances in the management of these conditions, patients treated with ACE inhibitors are still at increased risk for cardiovascular morbidity and premature death (
      <xref ref-type="bibr" rid="B207">
       Moukarbel and Solomon, 2008
      </xref>
      ). Reasons for this are multifactorial, including the fact that the “ideal ACE inhibitor” has yet to be developed. Clinically, this was addressed, in part, with the development of vasopeptidase inhibitors such as omapatrilat, a dual inhibitor of ACE and NEP (
      <xref ref-type="bibr" rid="B218">
       Nawarskas et al., 2001
      </xref>
      ;
      <xref ref-type="bibr" rid="B321">
       Tabrizchi, 2001
      </xref>
      ;
      <xref ref-type="bibr" rid="B170">
       Lapointe and Rouleau, 2002
      </xref>
      ).
     </p>
     <p>
      These drugs had the promise of being highly effective in the treatment of endothelial dysfunction, atherosclerosis, hypertension, and heart failure and were termed by some as the “super ACE inhibitors.” However, large clinical trials did not live up to the expectations and omapatrilat failed to obtain FDA approval as a result of the high incidence of angioedema, which has also been associated with ACE inhibitors and to a lesser extent with ARBs and ARB/NEP inhibitors (
      <xref ref-type="bibr" rid="B234">
       Owens and Oliphant, 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B160">
       Kostis et al., 2018
      </xref>
      ), especially in African Americans, smokers, women, older individuals, and patients with previous drug rash or reaction, seasonal allergies, or use of immunosuppressive drugs.
     </p>
     <p>
      Although the exact causes of vasopeptidase inhibitor– and ACE inhibitor–induced angioedema remain elusive, evidence suggests that this may be due to the excess bradykinin formation owing to inhibition of both the domains of ACE (
      <xref ref-type="bibr" rid="B20">
       Baş et al., 2015
      </xref>
      ;
      <xref ref-type="bibr" rid="B19">
       Bas, 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B316">
       Stone and Brown, 2017
      </xref>
      ;
      <xref ref-type="bibr" rid="B318">
       Straka et al., 2017
      </xref>
      ). Accordingly, the potential benefits of selective inhibition of the ACE C domain that primarily inhibits production of Ang II from Ang I, while at the same time reducing side effects by preventing bradykinin buildup via continued bradykinin degradation by an intact N domain, seem attractive. The ACE N domain also regulates the breakdown of other peptides, including amyloid-
      <italic>
       β
      </italic>
      peptide, tetrapeptide Ac-SDKP, and GnRH, hence maintaining a functional N domain to prevent accumulation of amyloid-
      <italic>
       β
      </italic>
      peptide, and other peptides may have additional cardiovascular protective and health benefits (
      <xref ref-type="bibr" rid="B25">
       Bernstein et al., 2012
      </xref>
      ).
     </p>
     <p>
      Nevertheless, even having an ideal ACE inhibitor without side effects may not be sufficient to treat all patients, given the multiple counter-regulatory mechanisms within the RAS that allow Ang II levels to return to their original status even in the presence of ACE inhibition. Hence, we need alternative RAS blockers like angiotensinogen ASO and siRNA, which are capable of significantly suppressing/eliminating RAS activity, even when renin is upregulated, simply because it removes the substrate from which all angiotensins stem. This approach (siRNA, in particular) additionally has the advantage of an exceptional long half-life, allowing application to be limited to a few times per year, thus offering the possibility to simultaneously combat nonadherence. Of course, a matter of debate remains how far one should suppress the RAS, since we cannot live without a functional RAS—too much RAS blockade will yield the well known side effects observed in trials applying multiple RAS blockers at the same time, such as hypotension, renal dysfunction, and hyperkalemia. The optimal degree of RAS suppression is unlikely to be identical in all patients and undoubtedly requires individualization of therapy. In other words, there is a need for significant or even “complete” RAS blockade in some patients, but a modest degree of RAS blockade might be sufficient in others. Alternative options would be to either combine classic RAS blockers with drugs that interfere with other hormonal systems that are known to be involved in hypertension, to upregulate the so-called protective arm of the RAS, or to aim at RAS blockade at one specific location (e.g., in the brain with firibastat), normalizing brain RAS hyperactivity and consequently regulating sympathetic tone, baroreflex function, and arginine-vasopressin release. Here, exciting new developments are currently taking place, such as the combination of an ACE C-domain–selective inhibitor with an NEP inhibitor, which increases NP levels by inhibiting breakdown to inactive fragments. Theoretically, this constitutes a second opportunity to create a “super ACE inhibitor” that is now safe for widespread use in the clinic. The combination of an ARB with an NEP inhibitor is already a clinical reality with proven superior effectiveness versus single RAS blockade. Recombinant ACE2 and brain-selective APA inhibition are currently being tested clinically in pulmonary arterial hypertension and overweight patients with hypertension, respectively, based on the concept that ACE2 degrades Ang II and upregulates the protective Ang 1
      <bold>
       -
      </bold>
      7, whereas APA blockade prevents brain AT
      <sub>
       1
      </sub>
      R stimulation by Ang III. Finally, dual Mas/pGC-A activation has shown promising results in animal studies and should now be taken to the next step. Taken together, our possibilities to improve and extend classic RAS blockade are rapidly expanding and should eventually result in novel treatment modalities with superior efficacy, diminished side effects, reduced dosing frequency, enhanced brain specificity, and/or the capacity to upregulate protective mechanisms.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="supported-by" id="FN1">
       <p>
        This work was supported by the British Heart Foundation [Grants RG/13/7/30099, RE/13/5/30177, and CH/4/29762 (to R.M.T.)], the
        <funding-source>
         National Institutes of Health
        </funding-source>
        National Heart, Lung and Blood Institute [Grants R01-HL36634 and R01-HL134668 (to J.C.B.)], and the South African National Research Foundation [Grants CPRR160331161352 and EQ160511164723 (to E.D.S.)].
       </p>
      </fn>
      <fn fn-type="other" id="FN2">
       <p>
        <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1124/pr.118.017129">
         https://doi.org/10.1124/pr.118.017129
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We gratefully acknowledge Vinasha Ramasamy for assistance with figure preparation.
      </p>
     </ack>
     <glossary>
      <title>
       Abbreviations
      </title>
      <def-list list-content="abbreviations">
       <def-item>
        <term id="G1">
         3D
        </term>
        <def>
         <p>
          three-dimensional
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G2">
         Ac-SDKP
        </term>
        <def>
         <p>
          <italic>
           N
          </italic>
          -acetyl-Ser–Asp–Lys–Pro
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G3">
         ACE
        </term>
        <def>
         <p>
          angiotensin-converting enzyme
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G4">
         Ang
        </term>
        <def>
         <p>
          angiotensin
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G5">
         ANP
        </term>
        <def>
         <p>
          atrial natriuretic peptide
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G6">
         APA
        </term>
        <def>
         <p>
          aminopeptidase A
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G7">
         APN
        </term>
        <def>
         <p>
          aminopeptidase N
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G8">
         APP
        </term>
        <def>
         <p>
          aminopeptidase P
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G9">
         ARB
        </term>
        <def>
         <p>
          angiotensin II receptor blocker
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G10">
         ARNI
        </term>
        <def>
         <p>
          angiotensin receptor–neprilysin inhibitor
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G11">
         ASO
        </term>
        <def>
         <p>
          antisense oligonucleotide
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G12">
         AT
         <sub>
          1
         </sub>
         R
        </term>
        <def>
         <p>
          angiotensin II type 1 receptor
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G13">
         AT
         <sub>
          2
         </sub>
         R
        </term>
        <def>
         <p>
          angiotensin II type 2 receptor
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G14">
         B
         <sub>
          1
         </sub>
         R
        </term>
        <def>
         <p>
          B
          <sub>
           1
          </sub>
          receptor
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G15">
         B
         <sub>
          2
         </sub>
         R
        </term>
        <def>
         <p>
          B
          <sub>
           2
          </sub>
          receptor
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G16">
         BK
        </term>
        <def>
         <p>
          bradykinin
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G17">
         BNP
        </term>
        <def>
         <p>
          B-type natriuretic peptide
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G18">
         CNP
        </term>
        <def>
         <p>
          C-type natriuretic peptide
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G19">
         DOCA
        </term>
        <def>
         <p>
          deoxycorticosterone acetate
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G20">
         EC33
        </term>
        <def>
         <p>
          (3
          <italic>
           S
          </italic>
          )-3-amino-4-sulfanyl-butane-1-sulfonic acid
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G21">
         ECE
        </term>
        <def>
         <p>
          endothelin-converting enzyme
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G22">
         ET
        </term>
        <def>
         <p>
          endothelin
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G23">
         ET
         <sub>
          A
         </sub>
         R
        </term>
        <def>
         <p>
          endothelin receptor A
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G24">
         ET
         <sub>
          B
         </sub>
         R
        </term>
        <def>
         <p>
          endothelin receptor B
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G25">
         FDA
        </term>
        <def>
         <p>
          U.S. Food and Drug Administration
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G26">
         GalNAc
        </term>
        <def>
         <p>
          triantennary
          <italic>
           N
          </italic>
          -acetylgalactosamine
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G27">
         GPCR
        </term>
        <def>
         <p>
          G protein–coupled receptor
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G28">
         HFpEF
        </term>
        <def>
         <p>
          heart failure with preserved ejection fraction
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G29">
         HFrEF
        </term>
        <def>
         <p>
          heart failure with reduced ejection fraction
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G31">
         NEP
        </term>
        <def>
         <p>
          neprilysin (neutral endopeptidase)
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G32">
         NP
        </term>
        <def>
         <p>
          natriuretic peptide
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G33">
         NPR
        </term>
        <def>
         <p>
          natriuretic peptide receptor
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G34">
         NT-proBNP
        </term>
        <def>
         <p>
          N-terminal pro–B-type natriuretic peptide
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G35">
         PC18
        </term>
        <def>
         <p>
          (2
          <italic>
           S
          </italic>
          )-2-amino-4-methylsulfanyl butane thiol
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G36">
         pGC-A
        </term>
        <def>
         <p>
          particulate guanylyl cyclase A
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G37">
         RAS
        </term>
        <def>
         <p>
          renin-angiotensin system
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G38">
         RB150
        </term>
        <def>
         <p>
          4,4-dithio-{bis[(3
          <italic>
           S
          </italic>
          )-3-aminobutyl sulfonic acid]}
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G39">
         rhACE2
        </term>
        <def>
         <p>
          recombinant human angiotensin-converting enzyme 2
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G40">
         RISC
        </term>
        <def>
         <p>
          RNA-induced silencing complex
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G41">
         SAR
        </term>
        <def>
         <p>
          structure–activity relationship
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G42">
         SBP
        </term>
        <def>
         <p>
          systolic blood pressure
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G43">
         SHR
        </term>
        <def>
         <p>
          spontaneously hypertensive rat
         </p>
        </def>
       </def-item>
       <def-item>
        <term id="G44">
         siRNA
        </term>
        <def>
         <p>
          small interfering RNA
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
     <notes>
      <title>
       Authorship Contributions
      </title>
      <p>
       <italic>
        Wrote or contributed to the writing of the manuscript:
       </italic>
       Arendse, Danser, Poglitsch, Touyz, Burnett, Llorens-Cortes, Ehlers, Sturrock.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Abassi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Karram
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ellaham
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Winaver
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hoffman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance
        </article-title>
        .
        <source>
         Pharmacol Ther
        </source>
        <volume>
         102
        </volume>
        :
        <fpage>
         223
        </fpage>
        –
        <lpage>
         241
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15246247
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B2">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           AbdAlla
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lother
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Abdel-tawab
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Quitterer
          </surname>
          <given-names>
           U
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         The angiotensin II AT2 receptor is an AT1 receptor antagonist
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         276
        </volume>
        :
        <fpage>
         39721
        </fpage>
        –
        <lpage>
         39726
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11507095
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B3">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           AbdAlla
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lother
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Quitterer
          </surname>
          <given-names>
           U
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         407
        </volume>
        :
        <fpage>
         94
        </fpage>
        –
        <lpage>
         98
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10993080
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B4">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Agah
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bandi
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Guntupalli
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome
        </article-title>
        .
        <source>
         Intensive Care Med
        </source>
        <volume>
         23
        </volume>
        :
        <fpage>
         793
        </fpage>
        –
        <lpage>
         796
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9290997
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B5">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Akif
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwager
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Anthony
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Czarny
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beau
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide
        </article-title>
        .
        <source>
         Biochem J
        </source>
        <volume>
         436
        </volume>
        :
        <fpage>
         53
        </fpage>
        –
        <lpage>
         59
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21352096
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B6">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Almquist
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chao
          </surname>
          <given-names>
           WR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ellis
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Johnson
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1980
        </year>
        )
        <article-title>
         Synthesis and biological activity of a ketomethylene analogue of a tripeptide inhibitor of angiotensin converting enzyme
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         23
        </volume>
        :
        <fpage>
         1392
        </fpage>
        –
        <lpage>
         1398
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         6256550
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B7">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ambroz
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Clark
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Catt
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1991
        </year>
        )
        <article-title>
         The mas oncogene enhances angiotensin-induced [Ca2+]i responses in cells with pre-existing angiotensin II receptors
        </article-title>
        .
        <source>
         Biochim Biophys Acta
        </source>
        <volume>
         1133
        </volume>
        :
        <fpage>
         107
        </fpage>
        –
        <lpage>
         111
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1721543
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B8">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ando
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rahman
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Butler
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Senn
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Floras
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         26
        </volume>
        :
        <fpage>
         1160
        </fpage>
        –
        <lpage>
         1166
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7498988
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B9">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Atlas
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition
        </article-title>
        .
        <source>
         J Manag Care Pharm
        </source>
        <volume>
         13
        </volume>
        (
        <issue>
         Suppl B
        </issue>
        ):
        <fpage>
         9
        </fpage>
        –
        <lpage>
         20
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17970613
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B10">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Azizi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bissery
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Peyrard
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Guyene
          </surname>
          <given-names>
           TT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ozoux
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Floch
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ménard
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans
        </article-title>
        .
        <source>
         Clin Pharmacol Ther
        </source>
        <volume>
         79
        </volume>
        :
        <fpage>
         49
        </fpage>
        –
        <lpage>
         61
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16413241
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B11">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Azizi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Courand
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Denolle
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zhygalina
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Delsart
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Amar
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lantelme
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Deplanque
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mounier-Vehier
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Balavoine
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         [OP. 4A. 08] A randomized double-blind placebo controlled crossover study to compare QGC001, a brain aminopeptidase A inhibitor, with placebo in patients with grade I/II essential hypertension (Abstract)
        </article-title>
        .
        <source>
         J Hypertens
        </source>
        <volume>
         35
        </volume>
        :
        <fpage>
         e36
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B12">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Azizi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ezan
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Reny
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wdzieczak-Bakala
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gerineau
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ménard
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         33
        </volume>
        :
        <fpage>
         879
        </fpage>
        –
        <lpage>
         886
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10082503
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B13">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alenina
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Andrade-Navarro
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         MAS and its related G protein-coupled receptors, Mrgprs
        </article-title>
        .
        <source>
         Pharmacol Rev
        </source>
        <volume>
         66
        </volume>
        :
        <fpage>
         1080
        </fpage>
        –
        <lpage>
         1105
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25244929
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B14">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alenina
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Young
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RAS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Touyz
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         The meaning of Mas
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         72
        </volume>
        :
        <fpage>
         1072
        </fpage>
        –
        <lpage>
         1075
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30354821
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B15">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bai
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mogi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nakaoka
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kan-No
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tsukuda
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chisaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           XL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kukida
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shan
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yamauchi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage
        </article-title>
        .
        <source>
         Eur J Pharmacol
        </source>
        <volume>
         762
        </volume>
        :
        <fpage>
         293
        </fpage>
        –
        <lpage>
         298
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26057694
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B16">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Balavoine
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Azizi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bergerot
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           De Mota
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Patouret
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase A inhibitor prodrug
        </article-title>
        .
        <source>
         Clin Pharmacokinet
        </source>
        <volume>
         53
        </volume>
        :
        <fpage>
         385
        </fpage>
        –
        <lpage>
         395
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24337978
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B17">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Balcarek
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sevá Pessôa
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bryson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Azizi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ménard
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Garrelds
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McGeehan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Reeves
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Griffith
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AHJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         63
        </volume>
        :
        <fpage>
         942
        </fpage>
        –
        <lpage>
         950
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24470465
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B18">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Barton
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shaw
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           d’Uscio
          </surname>
          <given-names>
           LV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Moreau
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lüscher
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ET
         <sub>
          A
         </sub>
         receptors for endothelin regulation
        </article-title>
        .
        <source>
         Biochem Biophys Res Commun
        </source>
        <volume>
         238
        </volume>
        :
        <fpage>
         861
        </fpage>
        –
        <lpage>
         865
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9325182
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B19">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bas
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         The angiotensin-converting-enzyme-induced angioedema
        </article-title>
        .
        <source>
         Immunol Allergy Clin North Am
        </source>
        <volume>
         37
        </volume>
        :
        <fpage>
         183
        </fpage>
        –
        <lpage>
         200
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27886906
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B20">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Baş
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Greve
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Stelter
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Havel
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Strassen
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rotter
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Veit
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schossow
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hapfelmeier
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kehl
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         A randomized trial of icatibant in ACE-inhibitor-induced angioedema
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         372
        </volume>
        :
        <fpage>
         418
        </fpage>
        –
        <lpage>
         425
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25629740
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B21">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Basso
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ruiz
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mangiarua
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Taquini
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1981
        </year>
        )
        <article-title>
         Renin-like activity in the rat brain during the development of DOC-salt hypertension
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         3
        </volume>
        :
        <fpage>
         II
        </fpage>
        -
        <lpage>
         14-II-17
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B22">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Basu
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Poglitsch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yogasundaram
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Thomas
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rowe
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Roles of angiotensin peptides and recombinant human ACE2 in heart failure
        </article-title>
        .
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         69
        </volume>
        :
        <fpage>
         805
        </fpage>
        –
        <lpage>
         819
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28209222
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B23">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Benjamin
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Blaha
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chiuve
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cushman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Das
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Deo
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Ferranti
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Floyd
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fornage
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gillespie
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          American Heart Association Statistics Committee and Stroke Statistics Subcommittee
         </collab>
        </person-group>
        (
        <year>
         2017
        </year>
        ) Heart disease and stroke statistics-2017 update: a report from the American Heart Association [published correction appears in
        <italic>
         Circulation
        </italic>
        (2017)
        <bold>
         135
        </bold>
        :e646 and
        <bold>
         136
        </bold>
        :e196].
        <italic>
         Circulation
        </italic>
        135:e146–e603.
       </mixed-citation>
      </ref>
      <ref id="B24">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Benzing
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fleming
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Blaukat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Müller-Esterl
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Busse
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         99
        </volume>
        :
        <fpage>
         2034
        </fpage>
        –
        <lpage>
         2040
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10209009
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B25">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bernstein
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ong
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Blackwell
          </surname>
          <given-names>
           WL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shah
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Giani
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gonzalez-Villalobos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shen
          </surname>
          <given-names>
           XZ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fuchs
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Touyz
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme
        </article-title>
        .
        <source>
         Pharmacol Rev
        </source>
        <volume>
         65
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         46
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23257181
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B26">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bernstein
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shen
          </surname>
          <given-names>
           XZ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gonzalez-Villalobos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Billet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Okwan-Duodu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ong
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fuchs
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE)
        </article-title>
        .
        <source>
         Curr Opin Pharmacol
        </source>
        <volume>
         11
        </volume>
        :
        <fpage>
         105
        </fpage>
        –
        <lpage>
         111
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21130035
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B27">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bodineau
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Frugière
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marc
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inguimbert
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fassot
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Balavoine
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         51
        </volume>
        :
        <fpage>
         1318
        </fpage>
        –
        <lpage>
         1325
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18362226
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B28">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bordicchia
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Amri
          </surname>
          <given-names>
           EZ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ailhaud
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dessì-Fulgheri
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Takahashi
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sarzani
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Collins
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes
        </article-title>
        .
        <source>
         J Clin Invest
        </source>
        <volume>
         122
        </volume>
        :
        <fpage>
         1022
        </fpage>
        –
        <lpage>
         1036
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22307324
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B29">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bosnyak
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jones
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Christopoulos
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Aguilar
          </surname>
          <given-names>
           MI
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Thomas
          </surname>
          <given-names>
           WG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Widdop
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors
        </article-title>
        .
        <source>
         Clin Sci (Lond)
        </source>
        <volume>
         121
        </volume>
        :
        <fpage>
         297
        </fpage>
        –
        <lpage>
         303
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21542804
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B30">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bremnes
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Paasche
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mehlum
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sandberg
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bremnes
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Attramadal
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         Regulation and intracellular trafficking pathways of the endothelin receptors
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         275
        </volume>
        :
        <fpage>
         17596
        </fpage>
        –
        <lpage>
         17604
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10747877
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B31">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bur
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dale
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oefner
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         A three-dimensional model of endothelin-converting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP)
        </article-title>
        .
        <source>
         Protein Eng
        </source>
        <volume>
         14
        </volume>
        :
        <fpage>
         337
        </fpage>
        –
        <lpage>
         341
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11438756
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B32">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Burger
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Reudelhuber
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mahajan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chibale
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Touyz
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension
        </article-title>
        .
        <source>
         Clin Sci (Lond)
        </source>
        <volume>
         127
        </volume>
        :
        <fpage>
         57
        </fpage>
        –
        <lpage>
         63
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24506807
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B33">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Campbell
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Long-term neprilysin inhibition—implications for ARNIs
        </article-title>
        .
        <source>
         Nat Rev Cardiol
        </source>
        <volume>
         14
        </volume>
        :
        <fpage>
         171
        </fpage>
        –
        <lpage>
         186
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27974807
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B34">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Campbell
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Habener
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1986
        </year>
        )
        <article-title>
         Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat
        </article-title>
        .
        <source>
         J Clin Invest
        </source>
        <volume>
         78
        </volume>
        :
        <fpage>
         31
        </fpage>
        –
        <lpage>
         39
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         3013940
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B35">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cannon
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jhund
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kristensen
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Køber
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rouleau
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          PARADIGM-HF Investigators and Committees
         </collab>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction
        </article-title>
        .
        <source>
         Eur J Heart Fail
        </source>
        <volume>
         19
        </volume>
        :
        <fpage>
         129
        </fpage>
        –
        <lpage>
         137
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27868321
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B36">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cataliotti
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tonne
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bellavia
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Martin
          </surname>
          <given-names>
           FL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oehler
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harders
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Campbell
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Peng
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Russell
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Malatino
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         123
        </volume>
        :
        <fpage>
         1297
        </fpage>
        –
        <lpage>
         1305
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21403100
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B37">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chappell
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pirro
          </surname>
          <given-names>
           NT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sykes
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1998
        </year>
        )
        <article-title>
         Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         31
        </volume>
        :
        <fpage>
         362
        </fpage>
        –
        <lpage>
         367
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9453329
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B38">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chappell
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tallant
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brosnihan
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4. 24.15) in vascular smooth muscle cells
        </article-title>
        .
        <source>
         J Vasc Med Biol
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         129
        </fpage>
        –
        <lpage>
         137
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B39">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Charles
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Espiner
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nicholls
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Richards
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yandle
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Protter
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kosoglou
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep
        </article-title>
        .
        <source>
         Am J Physiol
        </source>
        <volume>
         271
        </volume>
        :
        <fpage>
         R373
        </fpage>
        –
        <lpage>
         R380
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8770137
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B40">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chauvel
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortès
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Coric
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wilk
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournié-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         37
        </volume>
        :
        <fpage>
         2950
        </fpage>
        –
        <lpage>
         2957
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7915326
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B41">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           HH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Glockner
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schirger
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cataliotti
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Redfield
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Burnett
          </surname>
          <given-names>
           JC
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide
        </article-title>
        .
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         60
        </volume>
        :
        <fpage>
         2305
        </fpage>
        –
        <lpage>
         2312
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23122795
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B42">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harty
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Huntley
          </surname>
          <given-names>
           BK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iyer
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heublein
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harders
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Meems
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sangaralingham
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ichiki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         CRRL269: a novel designer and renal-enhancing pGC-A peptide activator
        </article-title>
        .
        <source>
         Am J Physiol Regul Integr Comp Physiol
        </source>
        <volume>
         314
        </volume>
        :
        <fpage>
         R407
        </fpage>
        –
        <lpage>
         R414
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29187381
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B43">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Claperon
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rozenfeld
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iturrioz
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inguimbert
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Okada
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maigret
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Asp
         <sup>
          218
         </sup>
         participates with Asp
         <sup>
          213
         </sup>
         to bind a Ca
         <sup>
          2+
         </sup>
         atom into the S1 subsite of aminopeptidase A: a key element for substrate specificity
        </article-title>
        .
        <source>
         Biochem J
        </source>
        <volume>
         416
        </volume>
        :
        <fpage>
         37
        </fpage>
        –
        <lpage>
         46
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18598240
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B44">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cleland
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swedberg
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <collab>
          The International Ecadotril Multi-centre Dose-ranging Study Investigators
         </collab>
        </person-group>
        (
        <year>
         1998
        </year>
        )
        <article-title>
         Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         351
        </volume>
        :
        <fpage>
         1657
        </fpage>
        –
        <lpage>
         1658
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9620738
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B45">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Coats
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Omapatrilat--the story of Overture and Octave
        </article-title>
        .
        <source>
         Int J Cardiol
        </source>
        <volume>
         86
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12243845
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B46">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cody
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Atlas
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Laragh
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kubo
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Covit
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ryman
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shaknovich
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pondolfino
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Clark
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Camargo
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         1986
        </year>
        )
        <article-title>
         Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion
        </article-title>
        .
        <source>
         J Clin Invest
        </source>
        <volume>
         78
        </volume>
        :
        <fpage>
         1362
        </fpage>
        –
        <lpage>
         1374
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2945832
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B47">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Colucci
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Elkayam
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Horton
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Abraham
          </surname>
          <given-names>
           WT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bourge
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Johnson
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wagoner
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Givertz
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Liang
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Neibaur
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          Nesiritide Study Group
         </collab>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         343
        </volume>
        :
        <fpage>
         246
        </fpage>
        –
        <lpage>
         253
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10911006
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B48">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cook
          </surname>
          <given-names>
           VI
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Grove
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McMenamin
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Carter
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harding
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Speth
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1991
        </year>
        )
        <article-title>
         The AT2 angiotensin receptor subtype predominates in the 18 day gestation fetal rat brain
        </article-title>
        .
        <source>
         Brain Res
        </source>
        <volume>
         560
        </volume>
        :
        <fpage>
         334
        </fpage>
        –
        <lpage>
         336
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1760741
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B49">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Corradi
          </surname>
          <given-names>
           HR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chitapi
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sewell
          </surname>
          <given-names>
           BT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Georgiadis
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380
        </article-title>
        .
        <source>
         Biochemistry
        </source>
        <volume>
         46
        </volume>
        :
        <fpage>
         5473
        </fpage>
        –
        <lpage>
         5478
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17439247
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B50">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Corradi
          </surname>
          <given-names>
           HR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwager
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nchinda
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design
        </article-title>
        .
        <source>
         J Mol Biol
        </source>
        <volume>
         357
        </volume>
        :
        <fpage>
         964
        </fpage>
        –
        <lpage>
         974
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16476442
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B51">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cotton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hayashi
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cuniasse
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vazeux
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ianzer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           De Camargo
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides
        </article-title>
        .
        <source>
         Biochemistry
        </source>
        <volume>
         41
        </volume>
        :
        <fpage>
         6065
        </fpage>
        –
        <lpage>
         6071
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11994001
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib398">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cozier
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Arendse
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwager
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         61
        </volume>
        (
        <issue>
         22
        </issue>
        ):
        <fpage>
         10141
        </fpage>
        –
        <lpage>
         10154
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30372620
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B52">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cushman
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cheung
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sabo
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ondetti
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1977
        </year>
        )
        <article-title>
         Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids
        </article-title>
        .
        <source>
         Biochemistry
        </source>
        <volume>
         16
        </volume>
        :
        <fpage>
         5484
        </fpage>
        –
        <lpage>
         5491
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         200262
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B53">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Dahlöf
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Devereux
          </surname>
          <given-names>
           RB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kjeldsen
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Julius
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beevers
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Faire
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fyhrquist
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ibsen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kristiansson
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lederballe-Pedersen
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          LIFE Study Group
         </collab>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         359
        </volume>
        :
        <fpage>
         995
        </fpage>
        –
        <lpage>
         1003
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11937178
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B54">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Damman
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gori
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Claggett
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jhund
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Senni
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Prescott
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rouleau
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swedberg
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure
        </article-title>
        .
        <source>
         JACC Heart Fail
        </source>
        <volume>
         6
        </volume>
        :
        <fpage>
         489
        </fpage>
        –
        <lpage>
         498
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29655829
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B55">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Danilczyk
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sarao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Remy
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Benabbas
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Stange
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Richter
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Arya
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pospisilik
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Singer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Camargo
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Essential role for collectrin in renal amino acid transport
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         444
        </volume>
        :
        <fpage>
         1088
        </fpage>
        –
        <lpage>
         1091
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17167413
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B56">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AHJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Batenburg
          </surname>
          <given-names>
           WW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van den Meiracker
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Danilov
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?
        </article-title>
        <source>
         Pharmacol Ther
        </source>
        <volume>
         113
        </volume>
        :
        <fpage>
         607
        </fpage>
        –
        <lpage>
         618
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17257685
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B57">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AHJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Derkx
          </surname>
          <given-names>
           FH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hense
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jeunemaître
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Riegger
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schunkert
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1998
        </year>
        )
        <article-title>
         Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels
        </article-title>
        .
        <source>
         J Hypertens
        </source>
        <volume>
         16
        </volume>
        :
        <fpage>
         1879
        </fpage>
        –
        <lpage>
         1883
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9886872
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B58">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AHJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Kesteren
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bax
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tavenier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Derkx
          </surname>
          <given-names>
           FH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Saxena
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schalekamp
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         96
        </volume>
        :
        <fpage>
         220
        </fpage>
        –
        <lpage>
         226
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9236437
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B59">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Daull
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Benrezzak
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Arsenault
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pheng
          </surname>
          <given-names>
           LH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Blouin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cayer
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beaudoin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Belleville
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sirois
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nantel
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats
        </article-title>
        .
        <source>
         Am J Hypertens
        </source>
        <volume>
         18
        </volume>
        :
        <fpage>
         1606
        </fpage>
        –
        <lpage>
         1613
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16364833
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B60">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Daull
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Blouin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Belleville
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beaudoin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Arsenault
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Leonard
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sirois
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nantel
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jeng
          </surname>
          <given-names>
           AY
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Battistini
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006b
        </year>
        )
        <article-title>
         Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats
        </article-title>
        .
        <source>
         Exp Biol Med (Maywood)
        </source>
        <volume>
         231
        </volume>
        :
        <fpage>
         830
        </fpage>
        –
        <lpage>
         833
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16741007
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B61">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Daull
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lepage
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Benrezzak
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cayer
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beaudoin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Belleville
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Blouin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sirois
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nantel
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jeng
          </surname>
          <given-names>
           AY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2006a
        </year>
        )
        <article-title>
         The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats
        </article-title>
        .
        <source>
         Drug Chem Toxicol
        </source>
        <volume>
         29
        </volume>
        :
        <fpage>
         183
        </fpage>
        –
        <lpage>
         202
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16707327
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B62">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           David
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bischoff
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Meudal
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mothé
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           De Mota
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           DaNascimento
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournié-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         42
        </volume>
        :
        <fpage>
         5197
        </fpage>
        –
        <lpage>
         5211
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10602705
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B63">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Davis
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Freeman
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1976
        </year>
        )
        <article-title>
         Mechanisms regulating renin release
        </article-title>
        .
        <source>
         Physiol Rev
        </source>
        <volume>
         56
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         56
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1108062
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B64">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Davisson
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beltz
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cassell
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Johnson
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sigmund
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1998
        </year>
        )
        <article-title>
         The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes
        </article-title>
        .
        <source>
         Circ Res
        </source>
        <volume>
         83
        </volume>
        :
        <fpage>
         1047
        </fpage>
        –
        <lpage>
         1058
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9815152
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B65">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           de Bold
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Bold
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sarda
          </surname>
          <given-names>
           IR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1986
        </year>
        )
        <article-title>
         Functional-morphological studies on in vitro cardionatrin release
        </article-title>
        .
        <source>
         J Hypertens Suppl
        </source>
        <volume>
         4
        </volume>
        :
        <fpage>
         S3
        </fpage>
        –
        <lpage>
         S7
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B66">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           de Gasparo
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Catt
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inagami
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wright
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Unger
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         International Union of Pharmacology. XXIII. The angiotensin II receptors
        </article-title>
        .
        <source>
         Pharmacol Rev
        </source>
        <volume>
         52
        </volume>
        :
        <fpage>
         415
        </fpage>
        –
        <lpage>
         472
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10977869
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B67">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           de Lannoy
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AHJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Kats
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schoemaker
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Saxena
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schalekamp
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         29
        </volume>
        :
        <fpage>
         1240
        </fpage>
        –
        <lpage>
         1251
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9180624
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B68">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Deddish
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marcic
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jackman
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           HZ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Skidgel
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Erdös
          </surname>
          <given-names>
           EG
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1998
        </year>
        )
        <article-title>
         N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         31
        </volume>
        :
        <fpage>
         912
        </fpage>
        –
        <lpage>
         917
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9535414
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B69">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Denault
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Claing
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           D’Orléans-Juste
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sawamura
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kido
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Masaki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Leduc
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Processing of proendothelin-1 by human furin convertase
        </article-title>
        .
        <source>
         FEBS Lett
        </source>
        <volume>
         362
        </volume>
        :
        <fpage>
         276
        </fpage>
        –
        <lpage>
         280
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7729512
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B70">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Dickstein
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           De Voogd
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Miric
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Willenbrock
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mitrovic
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pacher
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Koopman
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure
        </article-title>
        .
        <source>
         Am J Cardiol
        </source>
        <volume>
         94
        </volume>
        :
        <fpage>
         237
        </fpage>
        –
        <lpage>
         239
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15246912
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B71">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Dimitropoulos
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Papakyriakou
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dalkas
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Spyroulias
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         A computational approach to the study of the binding mode of dual ACE/NEP inhibitors
        </article-title>
        .
        <source>
         J Chem Inf Model
        </source>
        <volume>
         50
        </volume>
        :
        <fpage>
         388
        </fpage>
        –
        <lpage>
         396
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20170101
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B72">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cotton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yiotakis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Michaud
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vassiliou
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jiracek
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vazeux
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chauvet
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cuniasse
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         96
        </volume>
        :
        <fpage>
         4330
        </fpage>
        –
        <lpage>
         4335
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10200262
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B73">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Donoghue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hsieh
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Baronas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Godbout
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gosselin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Stagliano
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Donovan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Woolf
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Robison
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jeyaseelan
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
        </article-title>
        .
        <source>
         Circ Res
        </source>
        <volume>
         87
        </volume>
        :
        <fpage>
         E1
        </fpage>
        –
        <lpage>
         E9
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B74">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Douglas
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sharma
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Masuyer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lubbe
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zamora
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chibale
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors
        </article-title>
        .
        <source>
         Clin Sci (Lond)
        </source>
        <volume>
         126
        </volume>
        :
        <fpage>
         305
        </fpage>
        –
        <lpage>
         313
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24015848
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B75">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Edwards
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zimmerman
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwab
          </surname>
          <given-names>
           TR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heublein
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Burnett
          </surname>
          <given-names>
           JC
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        (
        <year>
         1988
        </year>
        )
        <article-title>
         Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor
        </article-title>
        .
        <source>
         Circ Res
        </source>
        <volume>
         62
        </volume>
        :
        <fpage>
         191
        </fpage>
        –
        <lpage>
         195
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2962782
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B76">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ehlers
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwager
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Scholle
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Manji
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brandt
          </surname>
          <given-names>
           WF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Riordan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         Proteolytic release of membrane-bound angiotensin-converting enzyme: role of the juxtamembrane stalk sequence
        </article-title>
        .
        <source>
         Biochemistry
        </source>
        <volume>
         35
        </volume>
        :
        <fpage>
         9549
        </fpage>
        –
        <lpage>
         9559
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8755736
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B77">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Epelman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shrestha
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Troughton
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Francis
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Klein
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tang
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes
        </article-title>
        .
        <source>
         J Card Fail
        </source>
        <volume>
         15
        </volume>
        :
        <fpage>
         565
        </fpage>
        –
        <lpage>
         571
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19700132
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B78">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Epelman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tang
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Van Lente
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Francis
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system
        </article-title>
        .
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         52
        </volume>
        :
        <fpage>
         750
        </fpage>
        –
        <lpage>
         754
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18718423
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B79">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Erdös
          </surname>
          <given-names>
           EG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Skidgel
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1989
        </year>
        )
        <article-title>
         Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones
        </article-title>
        .
        <source>
         FASEB J
        </source>
        <volume>
         3
        </volume>
        :
        <fpage>
         145
        </fpage>
        –
        <lpage>
         151
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2521610
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B80">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fagyas
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Úri
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Siket
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fülöp
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Csató
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Daragó
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Boczán
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bányai
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Szentkirályi
          </surname>
          <given-names>
           IE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maros
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <volume>
         9
        </volume>
        :
        <fpage>
         e87844
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         24691203
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B81">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fattah
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nather
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McCarroll
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hortigon-Vinagre
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zamora
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Flores-Munoz
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McArthur
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zentilin
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Giacca
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Touyz
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Gene therapy with angiotensin-(1-9) preserves left ventricular systolic function after myocardial infarction
        </article-title>
        .
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         68
        </volume>
        :
        <fpage>
         2652
        </fpage>
        –
        <lpage>
         2666
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27978950
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B82">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Favrat
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Burnier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nussberger
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lecomte
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brouard
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Waeber
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brunner
          </surname>
          <given-names>
           HR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension
        </article-title>
        .
        <source>
         J Hypertens
        </source>
        <volume>
         13
        </volume>
        :
        <fpage>
         797
        </fpage>
        –
        <lpage>
         804
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7594444
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B83">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ferdinand
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Balavoine
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Besse
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Black
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Desbrandes
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dittrich
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nesbitt
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Efficacy and safety of a novel antihypertensive pharmacotherapy approach in a high-risk diverse population (Abstract)
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         138
        </volume>
        :
        <fpage>
         e766
        </fpage>
        –
        <lpage>
         e767
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B84">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mullick
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease
        </article-title>
        .
        <source>
         Pharmacol Res
        </source>
        <volume>
         125
        </volume>
        :
        <fpage>
         57
        </fpage>
        –
        <lpage>
         71
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28571891
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B85">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ferreira
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Souza Dos Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Campagnole-Santos
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         Angiotensin-(3-7) pressor effect at the rostral ventrolateral medulla
        </article-title>
        .
        <source>
         Regul Pept
        </source>
        <volume>
         141
        </volume>
        :
        <fpage>
         168
        </fpage>
        –
        <lpage>
         174
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17350116
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B86">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ferro
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Spratt
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Haynes
          </surname>
          <given-names>
           WG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Webb
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1998
        </year>
        )
        <article-title>
         Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         97
        </volume>
        :
        <fpage>
         2323
        </fpage>
        –
        <lpage>
         2330
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9639376
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B87">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fienberg
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cozier
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chibale
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         The design and development of a potent and selective novel diprolyl derivative that binds to the N-domain of angiotensin-I converting enzyme
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         61
        </volume>
        :
        <fpage>
         344
        </fpage>
        –
        <lpage>
         359
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29206036
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B88">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fitzgibbon
          </surname>
          <given-names>
           WR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bunni
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Baicu
          </surname>
          <given-names>
           CF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zile
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mullick
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Saigusa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade
        </article-title>
        .
        <source>
         Am J Physiol Renal Physiol
        </source>
        <volume>
         314
        </volume>
        :
        <fpage>
         F210
        </fpage>
        –
        <lpage>
         F218
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29021226
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B89">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Flores-Muñoz
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Smith
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Haggerty
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Milligan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nicklin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor
        </article-title>
        .
        <source>
         J Physiol
        </source>
        <volume>
         589
        </volume>
        :
        <fpage>
         939
        </fpage>
        –
        <lpage>
         951
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21173078
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B90">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Flores-Muñoz
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Work
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Douglas
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Denby
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dominiczak
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Graham
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nicklin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         59
        </volume>
        :
        <fpage>
         300
        </fpage>
        –
        <lpage>
         307
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22184331
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B91">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fonarow
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hernandez
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Solomon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yancy
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure
        </article-title>
        .
        <source>
         JAMA Cardiol
        </source>
        <volume>
         1
        </volume>
        :
        <fpage>
         714
        </fpage>
        –
        <lpage>
         717
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27437874
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B92">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fournié-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Coric
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Turcaud
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bruetschy
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lucas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Noble
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1992
        </year>
        )
        <article-title>
         Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         35
        </volume>
        :
        <fpage>
         1259
        </fpage>
        –
        <lpage>
         1266
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1348542
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B93">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fournie-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fassot
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Valentin
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Djordjijevic
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Reaux-Le Goazigo
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         101
        </volume>
        :
        <fpage>
         7775
        </fpage>
        –
        <lpage>
         7780
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15136730
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B94">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fox
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lalloo
          </surname>
          <given-names>
           UG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Belvisi
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bernareggi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chung
          </surname>
          <given-names>
           KF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Barnes
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough
        </article-title>
        .
        <source>
         Nat Med
        </source>
        <volume>
         2
        </volume>
        :
        <fpage>
         814
        </fpage>
        –
        <lpage>
         817
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8673930
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B95">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fraga-Silva
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pinheiro
          </surname>
          <given-names>
           SVB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gonçalves
          </surname>
          <given-names>
           ACC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alenina
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RAS
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets
        </article-title>
        .
        <source>
         Mol Med
        </source>
        <volume>
         14
        </volume>
        :
        <fpage>
         28
        </fpage>
        –
        <lpage>
         35
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18026570
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B96">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fryer
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Segreti
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Banfor
          </surname>
          <given-names>
           PN
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Widomski
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Backes
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lin
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ballaron
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cox
          </surname>
          <given-names>
           BF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Trevillyan
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Reinhart
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema
        </article-title>
        .
        <source>
         Br J Pharmacol
        </source>
        <volume>
         153
        </volume>
        :
        <fpage>
         947
        </fpage>
        –
        <lpage>
         955
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18084312
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B97">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fuchs
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Xiao
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cole
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Adams
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Frenzel
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Michaud
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zhao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Keshelava
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Capecchi
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         279
        </volume>
        :
        <fpage>
         15946
        </fpage>
        –
        <lpage>
         15953
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14757757
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B98">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fuchs
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Xiao
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hubert
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Michaud
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Campbell
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Adams
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Capecchi
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bernstein
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         51
        </volume>
        :
        <fpage>
         267
        </fpage>
        –
        <lpage>
         274
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18158355
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B99">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gaidarov
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Adams
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Frazer
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Anthony
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gatlin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Semple
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Unett
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor
        </article-title>
        .
        <source>
         Cell Signal
        </source>
        <volume>
         50
        </volume>
        :
        <fpage>
         9
        </fpage>
        –
        <lpage>
         24
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29928987
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B100">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Galandrin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Denis
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Boularan
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marie
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           M’Kadmi
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pilette
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dubroca
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nicaise
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Seguelas
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           N’Guyen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Cardioprotective angiotensin-(1-7) peptide acts as a natural-biased ligand at the angiotensin II type 1 receptor
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         68
        </volume>
        :
        <fpage>
         1365
        </fpage>
        –
        <lpage>
         1374
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27698068
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B101">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ganten
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hermann
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bayer
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Unger
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lang
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1983
        </year>
        )
        <article-title>
         Angiotensin synthesis in the brain and increased turnover in hypertensive rats
        </article-title>
        .
        <source>
         Science
        </source>
        <volume>
         221
        </volume>
        :
        <fpage>
         869
        </fpage>
        –
        <lpage>
         871
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         6879184
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B102">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gembardt
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Grajewski
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vahl
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schultheiss
          </surname>
          <given-names>
           HP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Walther
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Angiotensin metabolites can stimulate receptors of the Mas-related genes family
        </article-title>
        .
        <source>
         Mol Cell Biochem
        </source>
        <volume>
         319
        </volume>
        :
        <fpage>
         115
        </fpage>
        –
        <lpage>
         123
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18636314
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B103">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Georgiadis
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beau
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Czarny
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cotton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yiotakis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors
        </article-title>
        .
        <source>
         Circ Res
        </source>
        <volume>
         93
        </volume>
        :
        <fpage>
         148
        </fpage>
        –
        <lpage>
         154
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12805239
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B104">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gjymishka
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kulemina
          </surname>
          <given-names>
           LV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shenoy
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Katovich
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ostrov
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Raizada
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Diminazene aceturate is an ACE2 activator and a novel antihypertensive drug
        </article-title>
        .
        <source>
         FASEB J
        </source>
        <volume>
         24
        </volume>
        :
        <fpage>
         1032.3
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B105">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Glenner
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McMILLAN
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Folk
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1962
        </year>
        )
        <article-title>
         A mammalian peptidase specific for the hydrolysis of N-terminal α-L-glutamyl and aspartyl residues
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         194
        </volume>
        :
        <fpage>
         867
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B106">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Glossop
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bazin
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dack
          </surname>
          <given-names>
           KN
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fox
          </surname>
          <given-names>
           DN
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           MacDonald
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mills
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Owen
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Phillips
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Reeves
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ringer
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors
        </article-title>
        .
        <source>
         Bioorg Med Chem Lett
        </source>
        <volume>
         21
        </volume>
        :
        <fpage>
         3404
        </fpage>
        –
        <lpage>
         3406
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21515054
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B107">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Goto
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hattori
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mizutani
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tsujimoto
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         Asparatic acid 221 is critical in the calcium-induced modulation of the enzymatic activity of human aminopeptidase A
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         282
        </volume>
        :
        <fpage>
         37074
        </fpage>
        –
        <lpage>
         37081
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17932029
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B108">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Granger
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McMurray
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yusuf
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Held
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Michelson
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Olofsson
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Östergren
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pfeffer
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swedberg
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <collab>
          CHARM Investigators and Committees
         </collab>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         362
        </volume>
        :
        <fpage>
         772
        </fpage>
        –
        <lpage>
         776
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         13678870
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B109">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Grobe
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Der Sarkissian
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Stewart
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Meszaros
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Raizada
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Katovich
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts
        </article-title>
        .
        <source>
         Clin Sci (Lond)
        </source>
        <volume>
         113
        </volume>
        :
        <fpage>
         357
        </fpage>
        –
        <lpage>
         364
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17600530
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B110">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Noe
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chandra
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Al-Fayoumi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ligueros-Saylan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sarangapani
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maahs
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ksander
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rigel
          </surname>
          <given-names>
           DF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jeng
          </surname>
          <given-names>
           AY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)
        </article-title>
        .
        <source>
         J Clin Pharmacol
        </source>
        <volume>
         50
        </volume>
        :
        <fpage>
         401
        </fpage>
        –
        <lpage>
         414
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19934029
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B111">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Guimarães
          </surname>
          <given-names>
           PB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alvarenga
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Siqueira
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Paredes-Gamero
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sabatini
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Morais
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Reis
          </surname>
          <given-names>
           RI
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Teixeira
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Casarini
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Angiotensin II binding to angiotensin I-converting enzyme triggers calcium signaling
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         57
        </volume>
        :
        <fpage>
         965
        </fpage>
        –
        <lpage>
         972
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21422380
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B112">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gyurko
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wielbo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Phillips
          </surname>
          <given-names>
           MI
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin
        </article-title>
        .
        <source>
         Regul Pept
        </source>
        <volume>
         49
        </volume>
        :
        <fpage>
         167
        </fpage>
        –
        <lpage>
         174
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8134617
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B113">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hagiwara
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sakaguchi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Itakura
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yoshimoto
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Furuya
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tanaka
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hirose
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         269
        </volume>
        :
        <fpage>
         10729
        </fpage>
        –
        <lpage>
         10733
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7908295
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B114">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hansen
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Theilade
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Haunsø
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sheikh
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         279
        </volume>
        :
        <fpage>
         24108
        </fpage>
        –
        <lpage>
         24115
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15056658
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B115">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Haschke
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schuster
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Poglitsch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Loibner
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Salzberg
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bruggisser
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Penninger
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Krähenbühl
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects
        </article-title>
        .
        <source>
         Clin Pharmacokinet
        </source>
        <volume>
         52
        </volume>
        :
        <fpage>
         783
        </fpage>
        –
        <lpage>
         792
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23681967
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B116">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hashimoto
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nakao
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hama
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Imura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mori
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yamaguchi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yasuhara
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hori
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         Clearance mechanisms of atrial and brain natriuretic peptides in rats
        </article-title>
        .
        <source>
         Pharm Res
        </source>
        <volume>
         11
        </volume>
        :
        <fpage>
         60
        </fpage>
        –
        <lpage>
         64
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8140057
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B117">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hata
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Seino
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tsutamoto
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hiramitsu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kaneko
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yoshikawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yokoyama
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tanaka
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mizuno
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nejima
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study
        </article-title>
        .
        <source>
         Circ J
        </source>
        <volume>
         72
        </volume>
        :
        <fpage>
         1787
        </fpage>
        –
        <lpage>
         1793
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18812677
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B118">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hawkridge
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heublein
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bergen
          </surname>
          <given-names>
           HR
          </given-names>
          <suffix>
           3rd
          </suffix>
         </name>
         <name name-style="western">
          <surname>
           Cataliotti
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Burnett
          </surname>
          <given-names>
           JC
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name name-style="western">
          <surname>
           Muddiman
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         102
        </volume>
        :
        <fpage>
         17442
        </fpage>
        –
        <lpage>
         17447
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16293687
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B119">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Haynes
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Judge
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Staplin
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Herrington
          </surname>
          <given-names>
           WG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Storey
          </surname>
          <given-names>
           BC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bethel
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bowman
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brunskill
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cockwell
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hill
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         138
        </volume>
        :
        <fpage>
         1505
        </fpage>
        –
        <lpage>
         1514
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30002098
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B120">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Healy
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wilk
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         Localization of immunoreactive glutamyl aminopeptidase in rat brain. II. Distribution and correlation with angiotensin II
        </article-title>
        .
        <source>
         Brain Res
        </source>
        <volume>
         606
        </volume>
        :
        <fpage>
         295
        </fpage>
        –
        <lpage>
         303
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8490722
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B121">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hernández Prada
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Katovich
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shenoy
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Qi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Castellano
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lampkins
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gubala
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ostrov
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         51
        </volume>
        :
        <fpage>
         1312
        </fpage>
        –
        <lpage>
         1317
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18391097
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B122">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hoang
          </surname>
          <given-names>
           MV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin
        </article-title>
        .
        <source>
         Biochem J
        </source>
        <volume>
         327
        </volume>
        :
        <fpage>
         23
        </fpage>
        –
        <lpage>
         26
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9355729
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B123">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ahmad
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           White
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marc
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Leenen
          </surname>
          <given-names>
           FH
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction
        </article-title>
        .
        <source>
         Cardiovasc Res
        </source>
        <volume>
         97
        </volume>
        :
        <fpage>
         424
        </fpage>
        –
        <lpage>
         431
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23257024
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B124">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ichiki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kambayashi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inagami
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Multiple growth factors modulate mRNA expression of angiotensin II type-2 receptor in R3T3 cells
        </article-title>
        .
        <source>
         Circ Res
        </source>
        <volume>
         77
        </volume>
        :
        <fpage>
         1070
        </fpage>
        –
        <lpage>
         1076
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7586218
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B125">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Imai
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hirata
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Emori
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yanagisawa
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Masaki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marumo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1992
        </year>
        )
        <article-title>
         Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         19
        </volume>
        :
        <fpage>
         753
        </fpage>
        –
        <lpage>
         757
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1592477
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B126">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Intengan
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schiffrin
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         35
        </volume>
        :
        <fpage>
         1221
        </fpage>
        –
        <lpage>
         1225
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10856267
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B127">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Israili
          </surname>
          <given-names>
           ZH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hall
          </surname>
          <given-names>
           WD
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1992
        </year>
        )
        <article-title>
         Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology
        </article-title>
        .
        <source>
         Ann Intern Med
        </source>
        <volume>
         117
        </volume>
        :
        <fpage>
         234
        </fpage>
        –
        <lpage>
         242
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1616218
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B128">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Itoh
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yanagisawa
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ohkubo
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kimura
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kosaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inoue
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ishida
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mitsui
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Onda
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fujino
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         1988
        </year>
        )
        <article-title>
         Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin
        </article-title>
        .
        <source>
         FEBS Lett
        </source>
        <volume>
         231
        </volume>
        :
        <fpage>
         440
        </fpage>
        –
        <lpage>
         444
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         3282927
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B129">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Iusuf
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Henning
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Gilst
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roks
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives
        </article-title>
        .
        <source>
         Eur J Pharmacol
        </source>
        <volume>
         585
        </volume>
        :
        <fpage>
         303
        </fpage>
        –
        <lpage>
         312
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18417117
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B130">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Iwata
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tsubuki
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Takaki
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shirotani
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gerard
          </surname>
          <given-names>
           NP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gerard
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hama
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Saido
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Metabolic regulation of brain Abeta by neprilysin
        </article-title>
        .
        <source>
         Science
        </source>
        <volume>
         292
        </volume>
        :
        <fpage>
         1550
        </fpage>
        –
        <lpage>
         1552
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11375493
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B131">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jackman
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Massad
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sekosan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tan
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brovkovych
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marcic
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Erdös
          </surname>
          <given-names>
           EG
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         39
        </volume>
        :
        <fpage>
         976
        </fpage>
        –
        <lpage>
         981
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12019279
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B132">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jackson
          </surname>
          <given-names>
           TR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Blair
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marshall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Goedert
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hanley
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1988
        </year>
        )
        <article-title>
         The mas oncogene encodes an angiotensin receptor
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         335
        </volume>
        :
        <fpage>
         437
        </fpage>
        –
        <lpage>
         440
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         3419518
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B133">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jandeleit-Dahm
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Dual ACE/NEP inhibitors—more than playing the ACE card
        </article-title>
        .
        <source>
         J Hum Hypertens
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         478
        </fpage>
        –
        <lpage>
         481
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16543904
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B134">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jankowski
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tölle
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Günthner
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Krause
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beyermann
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Welker
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pinheiro
          </surname>
          <given-names>
           SVB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sampaio
          </surname>
          <given-names>
           WO
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects
        </article-title>
        .
        <source>
         FASEB J
        </source>
        <volume>
         25
        </volume>
        :
        <fpage>
         2987
        </fpage>
        –
        <lpage>
         2995
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21628446
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B135">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jarcho
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         PIONEERing the in-hospital initiation of sacubitril-valsartan
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         380
        </volume>
        :
        <fpage>
         590
        </fpage>
        –
        <lpage>
         591
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30726696
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B136">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jiang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dong
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           FF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets
        </article-title>
        .
        <source>
         Nat Rev Cardiol
        </source>
        <volume>
         11
        </volume>
        :
        <fpage>
         413
        </fpage>
        –
        <lpage>
         426
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24776703
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B137">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Johnson
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pearce
          </surname>
          <given-names>
           GL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Danoff
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients
        </article-title>
        .
        <source>
         J Hum Hypertens
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         496
        </fpage>
        –
        <lpage>
         503
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16543907
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B138">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jullien
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Makritis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Georgiadis
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beau
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yiotakis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         53
        </volume>
        :
        <fpage>
         208
        </fpage>
        –
        <lpage>
         220
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19899765
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B139">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Junot
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gonzales
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ezan
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cotton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vazeux
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Michaud
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Azizi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vassiliou
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yiotakis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis
        </article-title>
        .
        <source>
         J Pharmacol Exp Ther
        </source>
        <volume>
         297
        </volume>
        :
        <fpage>
         606
        </fpage>
        –
        <lpage>
         611
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11303049
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B140">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kakoki
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Smithies
          </surname>
          <given-names>
           O
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         The kallikrein-kinin system in health and in diseases of the kidney
        </article-title>
        .
        <source>
         Kidney Int
        </source>
        <volume>
         75
        </volume>
        :
        <fpage>
         1019
        </fpage>
        –
        <lpage>
         1030
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19190676
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B141">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kambayashi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bardhan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Takahashi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tsuzuki
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inui
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hamakubo
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inagami
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         268
        </volume>
        :
        <fpage>
         24543
        </fpage>
        –
        <lpage>
         24546
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8227011
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B142">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kambayashi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nagata
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ichiki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inagami
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         Insulin and insulin-like growth factors induce expression of angiotensin type-2 receptor in vascular-smooth-muscle cells
        </article-title>
        .
        <source>
         Eur J Biochem
        </source>
        <volume>
         239
        </volume>
        :
        <fpage>
         558
        </fpage>
        –
        <lpage>
         565
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8774697
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B143">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Posner
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sumners
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         Angiotensin II type 2 receptor stimulation of neuronal K+ currents involves an inhibitory GTP binding protein
        </article-title>
        .
        <source>
         Am J Physiol
        </source>
        <volume>
         267
        </volume>
        :
        <fpage>
         C1389
        </fpage>
        –
        <lpage>
         C1397
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7977700
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B144">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Richards
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Posner
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sumners
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Modulation of the delayed rectifier K+ current in neurons by an angiotensin II type 2 receptor fragment
        </article-title>
        .
        <source>
         Am J Physiol
        </source>
        <volume>
         268
        </volume>
        :
        <fpage>
         C278
        </fpage>
        –
        <lpage>
         C282
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7840157
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B145">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Karnik
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Singh
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tirupula
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Unal
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22
        </article-title>
        .
        <source>
         Br J Pharmacol
        </source>
        <volume>
         174
        </volume>
        :
        <fpage>
         737
        </fpage>
        –
        <lpage>
         753
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28194766
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B146">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Karnik
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Unal
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kemp
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tirupula
          </surname>
          <given-names>
           KC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Eguchi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vanderheyden
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Thomas
          </surname>
          <given-names>
           WG
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [published correction appears in
         <italic>
          Pharmacol Rev
         </italic>
         (2015)
         <bold>
          67
         </bold>
         :820]
        </article-title>
        .
        <source>
         Pharmacol Rev
        </source>
        <volume>
         67
        </volume>
        :
        <fpage>
         754
        </fpage>
        –
        <lpage>
         819
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26315714
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B147">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kedzierski
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yanagisawa
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Endothelin system: the double-edged sword in health and disease
        </article-title>
        .
        <source>
         Annu Rev Pharmacol Toxicol
        </source>
        <volume>
         41
        </volume>
        :
        <fpage>
         851
        </fpage>
        –
        <lpage>
         876
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11264479
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B148">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kerr
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kenny
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1974
        </year>
        )
        <article-title>
         The purification and specificity of a neutral endopeptidase from rabbit kidney brush border
        </article-title>
        .
        <source>
         Biochem J
        </source>
        <volume>
         137
        </volume>
        :
        <fpage>
         477
        </fpage>
        –
        <lpage>
         488
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         4423492
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B149">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Khan
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Perkins
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hui
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Campbell
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Farber
          </surname>
          <given-names>
           MO
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chlan
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Boustani
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         The confusion assessment method for the ICU-7 delirium severity scale: a novel delirium severity instrument for use in the ICU
        </article-title>
        .
        <source>
         Crit Care Med
        </source>
        <volume>
         45
        </volume>
        :
        <fpage>
         851
        </fpage>
        –
        <lpage>
         857
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28263192
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B150">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kijima
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Matsubara
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Murasawa
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maruyama
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ohkubo
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mori
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inada
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         Regulation of angiotensin II type 2 receptor gene by the protein kinase C-calcium pathway
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         27
        </volume>
        :
        <fpage>
         529
        </fpage>
        –
        <lpage>
         534
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8613198
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B151">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kimura
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kasuya
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sawamura
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shinimi
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sugita
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yanagisawa
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Goto
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Masaki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1989
        </year>
        )
        <article-title>
         Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure-activity relationships of big endothelin-1
        </article-title>
        .
        <source>
         J Cardiovasc Pharmacol
        </source>
        <volume>
         13
        </volume>
        (
        <issue>
         Suppl 5
        </issue>
        ):
        <fpage>
         S5
        </fpage>
        –
        <lpage>
         S7
        </lpage>
        ,
        <comment>
         discussion S18
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B152">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kleniewski
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1979
        </year>
        )
        <article-title>
         Plasma high molecular weight kininogen concentration in health and in chosen impairments of haemostasis. Evidence that plasmin uncovers a new antigenic site in high molecular weight kininogen
        </article-title>
        .
        <source>
         Thromb Haemost
        </source>
        <volume>
         42
        </volume>
        :
        <fpage>
         1046
        </fpage>
        –
        <lpage>
         1055
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         92069
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B153">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Klotz
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Burkhoff
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Garrelds
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Boomsma
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AHJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?
        </article-title>
        <source>
         Eur Heart J
        </source>
        <volume>
         30
        </volume>
        :
        <fpage>
         805
        </fpage>
        –
        <lpage>
         812
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19223317
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B154">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Komers
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gipson
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nelson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Adler
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Srivastava
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Derebail
          </surname>
          <given-names>
           VK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Meyers
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pergola
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           MacNally
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hunt
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET)
        </article-title>
        .
        <source>
         Kidney Int Rep
        </source>
        <volume>
         2
        </volume>
        :
        <fpage>
         654
        </fpage>
        –
        <lpage>
         664
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29142983
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B155">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Komers
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Plotkin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease
        </article-title>
        .
        <source>
         Am J Physiol Regul Integr Comp Physiol
        </source>
        <volume>
         310
        </volume>
        :
        <fpage>
         R877
        </fpage>
        –
        <lpage>
         R884
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27009050
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B156">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kompa
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Weller
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kelly
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Krum
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           von Lueder
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction
        </article-title>
        .
        <source>
         Int J Cardiol
        </source>
        <volume>
         258
        </volume>
        :
        <fpage>
         192
        </fpage>
        –
        <lpage>
         198
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29544929
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B157">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Korth
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bohle
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pinet
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         Cellular distribution of endothelin-converting enzyme-1 in human tissues
        </article-title>
        .
        <source>
         J Histochem Cytochem
        </source>
        <volume>
         47
        </volume>
        :
        <fpage>
         447
        </fpage>
        –
        <lpage>
         462
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10082746
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B158">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kostenis
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Milligan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Christopoulos
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sanchez-Ferrer
          </surname>
          <given-names>
           CF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heringer-Walther
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sexton
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gembardt
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kellett
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Martini
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vanderheyden
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         111
        </volume>
        :
        <fpage>
         1806
        </fpage>
        –
        <lpage>
         1813
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15809376
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B159">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kostis
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Packer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Black
          </surname>
          <given-names>
           HR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schmieder
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Henry
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Levy
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial
        </article-title>
        .
        <source>
         Am J Hypertens
        </source>
        <volume>
         17
        </volume>
        :
        <fpage>
         103
        </fpage>
        –
        <lpage>
         111
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14751650
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B160">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kostis
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shetty
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chowdhury
          </surname>
          <given-names>
           YS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kostis
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         ACE inhibitor-induced angioedema: a review
        </article-title>
        .
        <source>
         Curr Hypertens Rep
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         55
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29884969
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B161">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kowalczuk
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bröer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tietze
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vanslambrouck
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rasko
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bröer
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         A protein complex in the brush-border membrane explains a Hartnup disorder allele
        </article-title>
        .
        <source>
         FASEB J
        </source>
        <volume>
         22
        </volume>
        :
        <fpage>
         2880
        </fpage>
        –
        <lpage>
         2887
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18424768
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B162">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kröger
          </surname>
          <given-names>
           WL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Douglas
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           O’Neill
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme
        </article-title>
        .
        <source>
         Biochemistry
        </source>
        <volume>
         48
        </volume>
        :
        <fpage>
         8405
        </fpage>
        –
        <lpage>
         8412
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19658433
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B163">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kuhn
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Molecular physiology of membrane guanylyl cyclase receptors
        </article-title>
        .
        <source>
         Physiol Rev
        </source>
        <volume>
         96
        </volume>
        :
        <fpage>
         751
        </fpage>
        –
        <lpage>
         804
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27030537
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B164">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kukkola
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Savage
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sakane
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Berry
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bilci
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ghai
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jeng
          </surname>
          <given-names>
           AY
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme
        </article-title>
        .
        <source>
         J Cardiovasc Pharmacol
        </source>
        <volume>
         26
        </volume>
        (
        <issue>
         Suppl 3
        </issue>
        ):
        <fpage>
         S65
        </fpage>
        –
        <lpage>
         S68
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8587470
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B165">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kuoppala
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lindstedt
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Saarinen
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kovanen
          </surname>
          <given-names>
           PT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kokkonen
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma
        </article-title>
        .
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         278
        </volume>
        :
        <fpage>
         H1069
        </fpage>
        –
        <lpage>
         H1074
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10749699
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B166">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lachance
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Garcia
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gutkowska
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cantin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Thibault
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1986
        </year>
        )
        <article-title>
         Mechanisms of release of atrial natriuretic factor. I. Effect of several agonists and steroids on its release by atrial minces
        </article-title>
        .
        <source>
         Biochem Biophys Res Commun
        </source>
        <volume>
         135
        </volume>
        :
        <fpage>
         1090
        </fpage>
        –
        <lpage>
         1098
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2938580
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B167">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lalmanach
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Naudin
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lecaille
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fritz
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Kininogens: more than cysteine protease inhibitors and kinin precursors
        </article-title>
        .
        <source>
         Biochimie
        </source>
        <volume>
         92
        </volume>
        :
        <fpage>
         1568
        </fpage>
        –
        <lpage>
         1579
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20346387
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B168">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lambert
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yarski
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Warner
          </surname>
          <given-names>
           FJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Thornhill
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Parkin
          </surname>
          <given-names>
           ET
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Smith
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         280
        </volume>
        :
        <fpage>
         30113
        </fpage>
        –
        <lpage>
         30119
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15983030
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B169">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Langenickel
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tsubouchi
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ayalasomayajula
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pal
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Valentin
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hinder
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jhee
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gevorkyan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rajman
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects
        </article-title>
        .
        <source>
         Br J Clin Pharmacol
        </source>
        <volume>
         81
        </volume>
        :
        <fpage>
         878
        </fpage>
        –
        <lpage>
         890
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26663387
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B170">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lapointe
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rouleau
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Cardioprotective effects of vasopeptidase inhibitors
        </article-title>
        .
        <source>
         Can J Cardiol
        </source>
        <volume>
         18
        </volume>
        :
        <fpage>
         415
        </fpage>
        –
        <lpage>
         420
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11992135
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B171">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lautner
          </surname>
          <given-names>
           RQ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Villela
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fraga-Silva
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Silva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Verano-Braga
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Costa-Fraga
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jankowski
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jankowski
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sousa
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alzamora
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Discovery and characterization of alamandine: a novel component of the renin-angiotensin system [published correction appears in
         <italic>
          Circ Res
         </italic>
         (2013)
         <bold>
          112
         </bold>
         :e156]
        </article-title>
        .
        <source>
         Circ Res
        </source>
        <volume>
         112
        </volume>
        :
        <fpage>
         1104
        </fpage>
        –
        <lpage>
         1111
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23446738
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B172">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Leal
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pinheiro
          </surname>
          <given-names>
           SV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bordoni
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alenina
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           França
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         The role of angiotensin-(1-7) receptor Mas in spermatogenesis in mice and rats
        </article-title>
        .
        <source>
         J Anat
        </source>
        <volume>
         214
        </volume>
        :
        <fpage>
         736
        </fpage>
        –
        <lpage>
         743
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19438767
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B173">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Leeb-Lundberg
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marceau
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Müller-Esterl
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pettibone
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zuraw
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences
        </article-title>
        .
        <source>
         Pharmacol Rev
        </source>
        <volume>
         57
        </volume>
        :
        <fpage>
         27
        </fpage>
        –
        <lpage>
         77
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15734727
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B174">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lejczak
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           De Choszczak
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kafarski
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         Inhibition of aminopeptidases by phosphonic acid and phosphinic acid analogues of aspartic and glutamic acids
        </article-title>
        .
        <source>
         J Enzyme Inhib
        </source>
        <volume>
         7
        </volume>
        :
        <fpage>
         97
        </fpage>
        –
        <lpage>
         103
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7509873
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B175">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lenkei
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Palkovits
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortès
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review
        </article-title>
        .
        <source>
         Front Neuroendocrinol
        </source>
        <volume>
         18
        </volume>
        :
        <fpage>
         383
        </fpage>
        –
        <lpage>
         439
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9344632
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B176">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Levin
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         Treating disease at the RNA level with oligonucleotides
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         380
        </volume>
        :
        <fpage>
         57
        </fpage>
        –
        <lpage>
         70
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30601736
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B177">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Farzan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harrison
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
        </article-title>
        .
        <source>
         Science
        </source>
        <volume>
         309
        </volume>
        :
        <fpage>
         1864
        </fpage>
        –
        <lpage>
         1868
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16166518
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B178">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Moore
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sui
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Berne
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sullivan
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Greenough
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        :
        <fpage>
         450
        </fpage>
        –
        <lpage>
         454
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B179">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Scholey
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Angiotensin-(1-7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells
        </article-title>
        .
        <source>
         Am J Physiol Renal Physiol
        </source>
        <volume>
         302
        </volume>
        :
        <fpage>
         F784
        </fpage>
        –
        <lpage>
         F790
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22189944
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B180">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Llorens
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gacel
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swerts
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Perdrisot
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournie-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwartz
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1980
        </year>
        )
        <article-title>
         Rational design of enkephalinase inhibitors: substrate specificity of enkephalinase studied from inhibitory potency of various dipeptides
        </article-title>
        .
        <source>
         Biochem Biophys Res Commun
        </source>
        <volume>
         96
        </volume>
        :
        <fpage>
         1710
        </fpage>
        –
        <lpage>
         1716
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7004444
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B181">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lojda
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gossrau
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1980
        </year>
        )
        <article-title>
         Study on aminopeptidase A
        </article-title>
        .
        <source>
         Histochemistry
        </source>
        <volume>
         67
        </volume>
        :
        <fpage>
         267
        </fpage>
        –
        <lpage>
         290
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         6772609
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B182">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lombard-Banek
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swiercz
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marvar
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nemes
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         A microanalytical capillary electrophoresis mass spectrometry assay for quantifying angiotensin peptides in the brain
        </article-title>
        .
        <source>
         Anal Bioanal Chem
        </source>
        <volume>
         411
        </volume>
        :
        <fpage>
         4661
        </fpage>
        –
        <lpage>
         4671
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30953113
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B183">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lopez Verrilli
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rodriguez Fermepín
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Longo Carbajosa
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Landa
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cerrato
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           García
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fernandez
          </surname>
          <given-names>
           BE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gironacci
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Angiotensin-(1-7) through Mas receptor up-regulates neuronal norepinephrine transporter via Akt and Erk1/2-dependent pathways
        </article-title>
        .
        <source>
         J Neurochem
        </source>
        <volume>
         120
        </volume>
        :
        <fpage>
         46
        </fpage>
        –
        <lpage>
         55
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B184">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ma
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ji
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Xiang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Atrial natriuretic peptide suppresses Th17 development through regulation of cGMP-dependent protein kinase and PI3K-Akt signaling pathways
        </article-title>
        .
        <source>
         Regul Pept
        </source>
        <volume>
         181
        </volume>
        :
        <fpage>
         9
        </fpage>
        –
        <lpage>
         16
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23327998
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B185">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Macheret
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heublein
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Costello-Boerrigter
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Boerrigter
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McKie
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bellavia
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mangiafico
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ikeda
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bailey
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Scott
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP
        </article-title>
        .
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         60
        </volume>
        :
        <fpage>
         1558
        </fpage>
        –
        <lpage>
         1565
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23058313
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B186">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Maisel
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Krishnaswamy
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nowak
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McCord
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hollander
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Duc
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Omland
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Storrow
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Abraham
          </surname>
          <given-names>
           WT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          Breathing Not Properly Multinational Study Investigators
         </collab>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         347
        </volume>
        :
        <fpage>
         161
        </fpage>
        –
        <lpage>
         167
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12124404
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B187">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Malek
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sharma
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sankrityayan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gaikwad
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy
        </article-title>
        .
        <source>
         Life Sci
        </source>
        <volume>
         221
        </volume>
        :
        <fpage>
         159
        </fpage>
        –
        <lpage>
         167
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30769114
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B188">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Malfroy
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swerts
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Guyon
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwartz
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1978
        </year>
        )
        <article-title>
         High-affinity enkephalin-degrading peptidase in brain is increased after morphine
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         276
        </volume>
        :
        <fpage>
         523
        </fpage>
        –
        <lpage>
         526
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         214708
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B189">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Marc
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Balavoine
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Michaud
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         60
        </volume>
        :
        <fpage>
         411
        </fpage>
        –
        <lpage>
         418
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22710644
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B190">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Marc
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hmazzou
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Balavoine
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Flahault
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats
        </article-title>
        .
        <source>
         J Hypertens
        </source>
        <volume>
         36
        </volume>
        :
        <fpage>
         641
        </fpage>
        –
        <lpage>
         650
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28968260
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B191">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Marcic
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Deddish
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jackman
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Erdös
          </surname>
          <given-names>
           EG
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         Enhancement of bradykinin and resensitization of its B2 receptor
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         33
        </volume>
        :
        <fpage>
         835
        </fpage>
        –
        <lpage>
         843
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10082496
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib396">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Masuyer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Akif
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Czary
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beau
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwager
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Isaac
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme
        </article-title>
        .
        <source>
         FEBS J
        </source>
        <volume>
         281
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         943
        </fpage>
        –
        <lpage>
         956
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24289879
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B192">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Masuyer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwager
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Isaac
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides
        </article-title>
        .
        <source>
         Sci Rep
        </source>
        <volume>
         2
        </volume>
        :
        <fpage>
         717
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23056909
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B193">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Matsusaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Niimura
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pastan
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shintani
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nishiyama
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ichikawa
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation
        </article-title>
        .
        <source>
         Kidney Int
        </source>
        <volume>
         85
        </volume>
        :
        <fpage>
         1068
        </fpage>
        –
        <lpage>
         1077
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24284520
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B194">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Matsusaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Niimura
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shimizu
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pastan
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Saito
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kobori
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nishiyama
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ichikawa
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Liver angiotensinogen is the primary source of renal angiotensin II
        </article-title>
        .
        <source>
         J Am Soc Nephrol
        </source>
        <volume>
         23
        </volume>
        :
        <fpage>
         1181
        </fpage>
        –
        <lpage>
         1189
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22518004
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B195">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           McMurray
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Packer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Desai
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rizkala
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rouleau
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Solomon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swedberg
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          PARADIGM-HF Committees and Investigators
         </collab>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF)
        </article-title>
        .
        <source>
         Eur J Heart Fail
        </source>
        <volume>
         15
        </volume>
        :
        <fpage>
         1062
        </fpage>
        –
        <lpage>
         1073
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23563576
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B196">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           McMurray
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Packer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Desai
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rizkala
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rouleau
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Solomon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swedberg
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          PARADIGM-HF Investigators and Committees
         </collab>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Angiotensin-neprilysin inhibition versus enalapril in heart failure
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         371
        </volume>
        :
        <fpage>
         993
        </fpage>
        –
        <lpage>
         1004
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25176015
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B197">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Meems
          </surname>
          <given-names>
           LMG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Andersen
          </surname>
          <given-names>
           IA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harty
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harders
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ichiki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heublein
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iyer
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         Design, synthesis, and actions of an innovative bispecific designer peptide
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         73
        </volume>
        :
        <fpage>
         900
        </fpage>
        –
        <lpage>
         909
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30798663
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B198">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Meems
          </surname>
          <given-names>
           LMG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Burnett
          </surname>
          <given-names>
           JC
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Innovative therapeutics: designer natriuretic peptides
        </article-title>
        .
        <source>
         JACC Basic Transl Sci
        </source>
        <volume>
         1
        </volume>
        :
        <fpage>
         557
        </fpage>
        –
        <lpage>
         567
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28497128
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B199">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Mentz
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bakris
          </surname>
          <given-names>
           GL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Waeber
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McMurray
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gheorghiade
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ruilope
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maggioni
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swedberg
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Piña
          </surname>
          <given-names>
           IL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fiuzat
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         The past, present and future of renin-angiotensin aldosterone system inhibition
        </article-title>
        .
        <source>
         Int J Cardiol
        </source>
        <volume>
         167
        </volume>
        :
        <fpage>
         1677
        </fpage>
        –
        <lpage>
         1687
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23121914
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B200">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Migaud
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Durieux
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Viereck
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Soroca-Lucas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournié-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A
        </article-title>
        .
        <source>
         Peptides
        </source>
        <volume>
         17
        </volume>
        :
        <fpage>
         601
        </fpage>
        –
        <lpage>
         607
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8804068
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B201">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Millan
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jacobowitz
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Aguilera
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Catt
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1991
        </year>
        )
        <article-title>
         Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         11440
        </fpage>
        –
        <lpage>
         11444
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1763058
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B202">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Mogensen
          </surname>
          <given-names>
           UM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jhund
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Køber
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Desai
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Packer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rouleau
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Solomon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Effect of sacubitril/valsartan on recurrent events in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF)
        </article-title>
        .
        <source>
         Eur J Heart Fail
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         760
        </fpage>
        –
        <lpage>
         768
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29431251
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B203">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Molinaro
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cugno
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Perez
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lepage
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gervais
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Agostoni
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Adam
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin
        </article-title>
        .
        <source>
         J Pharmacol Exp Ther
        </source>
        <volume>
         303
        </volume>
        :
        <fpage>
         232
        </fpage>
        –
        <lpage>
         237
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12235256
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B204">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Mori
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Patel
          </surname>
          <given-names>
           VB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Abo Alrob
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Basu
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Altamimi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Desaulniers
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wagg
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kassiri
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lopaschuk
          </surname>
          <given-names>
           GD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation
        </article-title>
        .
        <source>
         Circ Heart Fail
        </source>
        <volume>
         7
        </volume>
        :
        <fpage>
         327
        </fpage>
        –
        <lpage>
         339
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24389129
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B205">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Morrow
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Velazquez
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           DeVore
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Prescott
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Duffy
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gurmu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McCague
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rocha
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Braunwald
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
        </article-title>
        .
        <source>
         Eur Heart J
        </source>
        <comment>
         [published ahead of print]
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="B206">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Motte
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McEntee
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Naeije
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Endothelin receptor antagonists
        </article-title>
        .
        <source>
         Pharmacol Ther
        </source>
        <volume>
         110
        </volume>
        :
        <fpage>
         386
        </fpage>
        –
        <lpage>
         414
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16219361
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B207">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Moukarbel
          </surname>
          <given-names>
           GV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Solomon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials
        </article-title>
        .
        <source>
         Curr Heart Fail Rep
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         197
        </fpage>
        –
        <lpage>
         203
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19032914
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B208">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Mukoyama
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nakao
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hosoda
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Suga
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Saito
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ogawa
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shirakami
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jougasaki
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Obata
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yasue
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         1991
        </year>
        )
        <article-title>
         Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide
        </article-title>
        .
        <source>
         J Clin Invest
        </source>
        <volume>
         87
        </volume>
        :
        <fpage>
         1402
        </fpage>
        –
        <lpage>
         1412
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1849149
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B209">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Mullick
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yeh
          </surname>
          <given-names>
           ST
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Graham
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Engelhardt
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Prakash
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Crooke
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         70
        </volume>
        :
        <fpage>
         566
        </fpage>
        –
        <lpage>
         576
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28716988
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B210">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Murphy
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alexander
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Griendling
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Runge
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bernstein
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1991
        </year>
        )
        <article-title>
         Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         351
        </volume>
        :
        <fpage>
         233
        </fpage>
        –
        <lpage>
         236
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2041570
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B211">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Murugesan
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fadnis
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tellew
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Baska
          </surname>
          <given-names>
           RAF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beyer
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Monshizadegan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dickinson
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Valentine
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2′-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         48
        </volume>
        :
        <fpage>
         171
        </fpage>
        –
        <lpage>
         179
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15634011
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B212">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Murugesan
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tellew
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kunst
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fadnis
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cornelius
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Baska
          </surname>
          <given-names>
           RAF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beyer
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Monshizadegan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         45
        </volume>
        :
        <fpage>
         3829
        </fpage>
        –
        <lpage>
         3835
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12190306
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B213">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Naftilan
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oparil
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1978
        </year>
        )
        <article-title>
         Inhibition of renin release from rat kidney slices by the angiotensins
        </article-title>
        .
        <source>
         Am J Physiol
        </source>
        <volume>
         235
        </volume>
        :
        <fpage>
         F62
        </fpage>
        –
        <lpage>
         F68
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         677319
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B214">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Nagatsu
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nagatsu
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yamamoto
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Glenner
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mehl
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1970
        </year>
        )
        <article-title>
         Purification of aminopeptidase A in human serum and degradation of angiotensin II by the purified enzyme
        </article-title>
        .
        <source>
         Biochim Biophys Acta
        </source>
        <volume>
         198
        </volume>
        :
        <fpage>
         255
        </fpage>
        –
        <lpage>
         270
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         4313532
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B215">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Namkung
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Le Gouill
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lukashova
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kobayashi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hogue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Khoury
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Song
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bouvier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Laporte
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using enhanced bystander BRET
        </article-title>
        .
        <source>
         Nat Commun
        </source>
        <volume>
         7
        </volume>
        :
        <fpage>
         12178
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         27397672
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B216">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Namsolleck
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Recarti
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Foulquier
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Steckelings
          </surname>
          <given-names>
           UM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Unger
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         AT(2) receptor and tissue injury: therapeutic implications
        </article-title>
        .
        <source>
         Curr Hypertens Rep
        </source>
        <volume>
         16
        </volume>
        :
        <fpage>
         416
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         24414230
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B217">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Natesh
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwager
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Crystal structure of the human angiotensin-converting enzyme-lisinopril complex
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         421
        </volume>
        :
        <fpage>
         551
        </fpage>
        –
        <lpage>
         554
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12540854
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B218">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Nawarskas
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rajan
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Frishman
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase
        </article-title>
        .
        <source>
         Heart Dis
        </source>
        <volume>
         3
        </volume>
        :
        <fpage>
         378
        </fpage>
        –
        <lpage>
         385
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11975822
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B219">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Nchinda
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chibale
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Redelinghuys
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006a
        </year>
        )
        <article-title>
         Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme
        </article-title>
        .
        <source>
         Bioorg Med Chem Lett
        </source>
        <volume>
         16
        </volume>
        :
        <fpage>
         4616
        </fpage>
        –
        <lpage>
         4619
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16784843
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B220">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Nchinda
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chibale
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Redelinghuys
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006b
        </year>
        )
        <article-title>
         Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors
        </article-title>
        .
        <source>
         Bioorg Med Chem Lett
        </source>
        <volume>
         16
        </volume>
        :
        <fpage>
         4612
        </fpage>
        –
        <lpage>
         4615
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16784850
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B221">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Neutel
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Germino
          </surname>
          <given-names>
           WF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Punzi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McBride
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bryson
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Belder
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Results of a double blind placebo controlled study to evaluate the efficacy and safety of PS433540 in human subjects with hypertension (Abstract)
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         118
        </volume>
        (
        <issue>
         Suppl 18
        </issue>
        ):
        <fpage>
         S886
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B222">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ocaranza
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lavandero
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jalil
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Moya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pinto
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Novoa
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Apablaza
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           González
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hernández
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Varas
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro
        </article-title>
        .
        <source>
         J Hypertens
        </source>
        <volume>
         28
        </volume>
        :
        <fpage>
         1054
        </fpage>
        –
        <lpage>
         1064
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20411619
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B223">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ocaranza
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Moya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Barrientos
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alzamora
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hevia
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Morales
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pinto
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Escudero
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           García
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Novoa
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis
        </article-title>
        .
        <source>
         J Hypertens
        </source>
        <volume>
         32
        </volume>
        :
        <fpage>
         771
        </fpage>
        –
        <lpage>
         783
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24463937
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B224">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           O’Connor
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Starling
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hernandez
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Armstrong
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dickstein
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hasselblad
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heizer
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Komajda
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Massie
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McMurray
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Effect of nesiritide in patients with acute decompensated heart failure [published correction appears in
         <italic>
          N Engl J Med
         </italic>
         (2011)
         <bold>
          365
         </bold>
         :773]
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         365
        </volume>
        :
        <fpage>
         32
        </fpage>
        –
        <lpage>
         43
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21732835
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B225">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Oefner
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           D’Arcy
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hennig
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Winkler
          </surname>
          <given-names>
           FK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dale
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon
        </article-title>
        .
        <source>
         J Mol Biol
        </source>
        <volume>
         296
        </volume>
        :
        <fpage>
         341
        </fpage>
        –
        <lpage>
         349
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10669592
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B226">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Oefner
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pierau
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schulz
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dale
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV
        </article-title>
        .
        <source>
         Acta Crystallogr D Biol Crystallogr
        </source>
        <volume>
         63
        </volume>
        :
        <fpage>
         975
        </fpage>
        –
        <lpage>
         981
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17704566
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B227">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Oefner
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournie-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dale
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Structural analysis of neprilysin with various specific and potent inhibitors
        </article-title>
        .
        <source>
         Acta Crystallogr D Biol Crystallogr
        </source>
        <volume>
         60
        </volume>
        :
        <fpage>
         392
        </fpage>
        –
        <lpage>
         396
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14747736
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B228">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ohshima
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mogi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nakaoka
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iwanami
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Min
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kanno
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tsukuda
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chisaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bai
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           XL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         63
        </volume>
        :
        <fpage>
         e53
        </fpage>
        –
        <lpage>
         e59
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24379178
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B229">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Okolicany
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McEnroe
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Koh
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lewicki
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maack
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1992
        </year>
        )
        <article-title>
         Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor
        </article-title>
        .
        <source>
         Am J Physiol
        </source>
        <volume>
         263
        </volume>
        :
        <fpage>
         F546
        </fpage>
        –
        <lpage>
         F553
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1415584
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B230">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Olearczyk
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Eybye
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yendluri
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Andrews
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bartz
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cully
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tadin-Strapps
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension
        </article-title>
        .
        <source>
         Hypertens Res
        </source>
        <volume>
         37
        </volume>
        :
        <fpage>
         405
        </fpage>
        –
        <lpage>
         412
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24335718
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B231">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           O’Neill
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Redelinghuys
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwager
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         The role of glycosylation and domain interactions in the thermal stability of human angiotensin-converting enzyme
        </article-title>
        .
        <source>
         Biol Chem
        </source>
        <volume>
         389
        </volume>
        :
        <fpage>
         1153
        </fpage>
        –
        <lpage>
         1161
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18713002
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B232">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Oparil
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acelajado
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bakris
          </surname>
          <given-names>
           GL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Berlowitz
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cífková
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dominiczak
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Grassi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jordan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Poulter
          </surname>
          <given-names>
           NR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rodgers
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Hypertension
        </article-title>
        .
        <source>
         Nat Rev Dis Primers
        </source>
        <volume>
         4
        </volume>
        :
        <fpage>
         18014
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29565029
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B233">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Oparil
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schmieder
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         New approaches in the treatment of hypertension
        </article-title>
        .
        <source>
         Circ Res
        </source>
        <volume>
         116
        </volume>
        :
        <fpage>
         1074
        </fpage>
        –
        <lpage>
         1095
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25767291
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B234">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Owens
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oliphant
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Angioedema spotlight: a closer examination of sacubitril/valsartan safety results
        </article-title>
        .
        <source>
         J Am Board Fam Med
        </source>
        <volume>
         30
        </volume>
        :
        <fpage>
         556
        </fpage>
        –
        <lpage>
         557
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28720639
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B235">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Packer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Califf
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Konstam
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Krum
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McMurray
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rouleau
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swedberg
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         106
        </volume>
        :
        <fpage>
         920
        </fpage>
        –
        <lpage>
         926
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12186794
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B236">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Packer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Claggett
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McMurray
          </surname>
          <given-names>
           JJV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rouleau
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Solomon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zile
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
        </article-title>
        .
        <source>
         Lancet Diabetes Endocrinol
        </source>
        <volume>
         6
        </volume>
        :
        <fpage>
         547
        </fpage>
        –
        <lpage>
         554
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29661699
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B237">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Packer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McMurray
          </surname>
          <given-names>
           JJV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Krum
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kiowski
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Massie
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Caspi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pratt
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Petrie
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           DeMets
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kobrin
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          ENABLE Investigators and Committees
         </collab>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials
        </article-title>
        .
        <source>
         JACC Heart Fail
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         317
        </fpage>
        –
        <lpage>
         326
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28449795
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B238">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Page
          </surname>
          <given-names>
           IH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Helmer
          </surname>
          <given-names>
           OM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1940
        </year>
        )
        <article-title>
         A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator
        </article-title>
        .
        <source>
         J Exp Med
        </source>
        <volume>
         71
        </volume>
        :
        <fpage>
         29
        </fpage>
        –
        <lpage>
         42
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19870942
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B239">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pandey
          </surname>
          <given-names>
           KN
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Biology of natriuretic peptides and their receptors
        </article-title>
        .
        <source>
         Peptides
        </source>
        <volume>
         26
        </volume>
        :
        <fpage>
         901
        </fpage>
        –
        <lpage>
         932
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15911062
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B240">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Papinska
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Soto
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Meeks
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rodgers
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling
        </article-title>
        .
        <source>
         Pharmacol Res
        </source>
        <volume>
         107
        </volume>
        :
        <fpage>
         372
        </fpage>
        –
        <lpage>
         380
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26956523
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B241">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Patel
          </surname>
          <given-names>
           VB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zhong
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Grant
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure
        </article-title>
        .
        <source>
         Circ Res
        </source>
        <volume>
         118
        </volume>
        :
        <fpage>
         1313
        </fpage>
        –
        <lpage>
         1326
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27081112
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B242">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Phillips
          </surname>
          <given-names>
           MI
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1987
        </year>
        )
        <article-title>
         Functions of angiotensin in the central nervous system
        </article-title>
        .
        <source>
         Annu Rev Physiol
        </source>
        <volume>
         49
        </volume>
        :
        <fpage>
         413
        </fpage>
        –
        <lpage>
         435
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         3551809
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B243">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pinheiro
          </surname>
          <given-names>
           SVB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Simões e Silva
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sampaio
          </surname>
          <given-names>
           WO
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Paula
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mendes
          </surname>
          <given-names>
           EP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bontempo
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pesquero
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Walther
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alenina
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         44
        </volume>
        :
        <fpage>
         490
        </fpage>
        –
        <lpage>
         496
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15326087
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B244">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pinter
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kwanten
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jain
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events
        </article-title>
        .
        <source>
         Clin Cancer Res
        </source>
        <volume>
         24
        </volume>
        :
        <fpage>
         3803
        </fpage>
        –
        <lpage>
         3812
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29610292
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B245">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pitt
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Poole-Wilson
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Segal
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Martinez
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dickstein
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Camm
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Konstam
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Riegger
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Klinger
          </surname>
          <given-names>
           GH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Neaton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         355
        </volume>
        :
        <fpage>
         1582
        </fpage>
        –
        <lpage>
         1587
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10821361
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B246">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ponikowski
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Voors
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Anker
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bueno
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cleland
          </surname>
          <given-names>
           JGF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Coats
          </surname>
          <given-names>
           AJS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Falk
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           González-Juanatey
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harjola
          </surname>
          <given-names>
           VP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jankowska
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          ESC Scientific Document Group
         </collab>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC [published corrections appear in
         <italic>
          Eur Heart J
         </italic>
         (2018)
         <bold>
          39
         </bold>
         :860, 1206]
        </article-title>
        .
        <source>
         Eur Heart J
        </source>
        <volume>
         37
        </volume>
        :
        <fpage>
         2129
        </fpage>
        –
        <lpage>
         2200
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27206819
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B247">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Potter
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Natriuretic peptide metabolism, clearance and degradation
        </article-title>
        .
        <source>
         FEBS J
        </source>
        <volume>
         278
        </volume>
        :
        <fpage>
         1808
        </fpage>
        –
        <lpage>
         1817
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21375692
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B248">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Touyz
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schiffrin
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats
        </article-title>
        .
        <source>
         J Hypertens
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         899
        </fpage>
        –
        <lpage>
         907
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12011651
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B249">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pucell
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hodges
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sen
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bumpus
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Husain
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1991
        </year>
        )
        <article-title>
         Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor
        </article-title>
        .
        <source>
         Endocrinology
        </source>
        <volume>
         128
        </volume>
        :
        <fpage>
         1947
        </fpage>
        –
        <lpage>
         1959
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1848506
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B250">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rabey
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Karamyan
          </surname>
          <given-names>
           VT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Speth
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Distribution of a novel binding site for angiotensins II and III in mouse tissues
        </article-title>
        .
        <source>
         Regul Pept
        </source>
        <volume>
         162
        </volume>
        :
        <fpage>
         5
        </fpage>
        –
        <lpage>
         11
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20171994
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B251">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rabin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Birnbaum
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Young
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Birchmeier
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wigler
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ruddle
          </surname>
          <given-names>
           FH
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1987
        </year>
        )
        <article-title>
         Human ros1 and mas1 oncogenes located in regions of chromosome 6 associated with tumor-specific rearrangements
        </article-title>
        .
        <source>
         Oncogene Res
        </source>
        <volume>
         1
        </volume>
        :
        <fpage>
         169
        </fpage>
        –
        <lpage>
         178
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         3329713
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B252">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Raine
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Erne
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bürgisser
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Müller
          </surname>
          <given-names>
           FB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bolli
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Burkart
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bühler
          </surname>
          <given-names>
           FR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1986
        </year>
        )
        <article-title>
         Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         315
        </volume>
        :
        <fpage>
         533
        </fpage>
        –
        <lpage>
         537
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2942777
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B253">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rajagopal
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rajagopal
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Teaching old receptors new tricks: biasing seven-transmembrane receptors
        </article-title>
        .
        <source>
         Nat Rev Drug Discov
        </source>
        <volume>
         9
        </volume>
        :
        <fpage>
         373
        </fpage>
        –
        <lpage>
         386
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20431569
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B254">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ravichandran
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ozkok
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mullick
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Edelstein
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2
        </article-title>
        .
        <source>
         Am J Physiol Renal Physiol
        </source>
        <volume>
         308
        </volume>
        :
        <fpage>
         F349
        </fpage>
        –
        <lpage>
         F357
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25537744
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B255">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ray
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Landmesser
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Leiter
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kallend
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dufour
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Karakas
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hall
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Troquay
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Turner
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Visseren
          </surname>
          <given-names>
           FL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         376
        </volume>
        :
        <fpage>
         1430
        </fpage>
        –
        <lpage>
         1440
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28306389
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B256">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Reaux
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournie-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           David
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zini
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         Aminopeptidase A inhibitors as potential central antihypertensive agents
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         96
        </volume>
        :
        <fpage>
         13415
        </fpage>
        –
        <lpage>
         13420
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10557335
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B257">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Regoli
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Barabé
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1980
        </year>
        )
        <article-title>
         Pharmacology of bradykinin and related kinins
        </article-title>
        .
        <source>
         Pharmacol Rev
        </source>
        <volume>
         32
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         46
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7015371
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B258">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ren
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sun
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ye
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Han
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Daugherty
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Su
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         (Pro)renin receptor inhibition reprograms hepatic lipid metabolism and protects mice from diet-induced obesity and hepatosteatosis
        </article-title>
        .
        <source>
         Circ Res
        </source>
        <volume>
         122
        </volume>
        :
        <fpage>
         730
        </fpage>
        –
        <lpage>
         741
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29301853
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B259">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rice
          </surname>
          <given-names>
           GI
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jones
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Grant
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Carter
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         48
        </volume>
        :
        <fpage>
         914
        </fpage>
        –
        <lpage>
         920
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17000927
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B260">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rice
          </surname>
          <given-names>
           GI
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Thomas
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Grant
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism
        </article-title>
        .
        <source>
         Biochem J
        </source>
        <volume>
         383
        </volume>
        :
        <fpage>
         45
        </fpage>
        –
        <lpage>
         51
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15283675
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B261">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Robl
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sieber-McMaster
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Asaad
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bird
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Delaney
          </surname>
          <given-names>
           NG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Barrish
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Neubeck
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Natarajan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cohen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rovnyak
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         Mercaptoacyl dipeptides as dual inhibitors of angiotensin converting enzyme and neutral peptidase. Preliminary structure-activity studies
        </article-title>
        .
        <source>
         Bioorg Med Chem Lett
        </source>
        <volume>
         4
        </volume>
        :
        <fpage>
         1783
        </fpage>
        –
        <lpage>
         1789
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B262">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Robl
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sulsky
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sieber-McMaster
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ryono
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cimarusti
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Simpkins
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Karanewsky
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Asaad
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Seymour
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         42
        </volume>
        :
        <fpage>
         305
        </fpage>
        –
        <lpage>
         311
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9925736
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B263">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Robl
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sun
          </surname>
          <given-names>
           CQ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Stevenson
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ryono
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Simpkins
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cimarusti
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dejneka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Slusarchyk
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Stratton
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <volume>
         40
        </volume>
        :
        <fpage>
         1570
        </fpage>
        –
        <lpage>
         1577
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9171867
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B264">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rodgers
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bolton
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Verco
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           diZerega
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         NorLeu
         <sup>
          3
         </sup>
         -angiotensin (1-7) [DSC127] as a therapy for the healing of diabetic foot ulcers
        </article-title>
        .
        <source>
         Adv Wound Care (New Rochelle)
        </source>
        <volume>
         4
        </volume>
        :
        <fpage>
         339
        </fpage>
        –
        <lpage>
         345
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26029484
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B265">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Roksnoer
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heijnen
          </surname>
          <given-names>
           BF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nakano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Peti-Peterdi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Walsh
          </surname>
          <given-names>
           SB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Garrelds
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Gool
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zietse
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Struijker-Boudier
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hoorn
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016a
        </year>
        )
        <article-title>
         On the origin of urinary renin: a translational approach
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         67
        </volume>
        :
        <fpage>
         927
        </fpage>
        –
        <lpage>
         933
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26928805
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B266">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Roksnoer
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Veghel
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Vries
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Garrelds
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bhaggoe
          </surname>
          <given-names>
           UM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Friesema
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Leijten
          </surname>
          <given-names>
           FP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Poglitsch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Domenig
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Clahsen-van Groningen
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats
        </article-title>
        .
        <source>
         Kidney Int
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         109
        </fpage>
        –
        <lpage>
         120
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25830765
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B267">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Roksnoer
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Veghel
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Groningen
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Vries
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Garrelds
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bhaggoe
          </surname>
          <given-names>
           UM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Gool
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Friesema
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Leijten
          </surname>
          <given-names>
           FP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hoorn
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016b
        </year>
        )
        <article-title>
         Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone
        </article-title>
        .
        <source>
         Clin Sci (Lond)
        </source>
        <volume>
         130
        </volume>
        :
        <fpage>
         1209
        </fpage>
        –
        <lpage>
         1220
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27129187
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B268">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournié-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Soroca
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lecomte
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Malfroy
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwartz
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1980
        </year>
        )
        <article-title>
         The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         288
        </volume>
        :
        <fpage>
         286
        </fpage>
        –
        <lpage>
         288
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7001254
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B269">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Noble
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Daugé
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournié-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beaumont
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology
        </article-title>
        .
        <source>
         Pharmacol Rev
        </source>
        <volume>
         45
        </volume>
        :
        <fpage>
         87
        </fpage>
        –
        <lpage>
         146
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8475170
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B270">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rosendorff
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lackland
          </surname>
          <given-names>
           DT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Allison
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Aronow
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Black
          </surname>
          <given-names>
           HR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Blumenthal
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cannon
          </surname>
          <given-names>
           CP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Lemos
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Elliott
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Findeiss
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          American Heart Association; American College of Cardiology; American Society of Hypertension
         </collab>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension
        </article-title>
        .
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         65
        </volume>
        :
        <fpage>
         1998
        </fpage>
        –
        <lpage>
         2038
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25840655
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B271">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Røsjø
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dahl
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jørgensen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Røysland
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brynildsen
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cataliotti
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Christensen
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Høiseth
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hagve
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Omland
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study
        </article-title>
        .
        <source>
         Clin Chem
        </source>
        <volume>
         61
        </volume>
        :
        <fpage>
         1087
        </fpage>
        –
        <lpage>
         1097
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26056354
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B272">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rossi
          </surname>
          <given-names>
           GP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sacchetto
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cesari
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pessina
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         Interactions between endothelin-1 and the renin-angiotensin-aldosterone system
        </article-title>
        .
        <source>
         Cardiovasc Res
        </source>
        <volume>
         43
        </volume>
        :
        <fpage>
         300
        </fpage>
        –
        <lpage>
         307
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10536660
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B273">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rozenfeld
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iturrioz
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maigret
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Contribution of molecular modeling and site-directed mutagenesis to the identification of two structural residues, Arg-220 and Asp-227, in aminopeptidase A
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         277
        </volume>
        :
        <fpage>
         29242
        </fpage>
        –
        <lpage>
         29252
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12042323
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B274">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rozenfeld
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iturrioz
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Okada
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maigret
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Contribution of molecular modeling and site-directed mutagenesis to the identification of a new residue, glutamate 215, involved in the exopeptidase specificity of aminopeptidase A
        </article-title>
        .
        <source>
         Biochemistry
        </source>
        <volume>
         42
        </volume>
        :
        <fpage>
         14785
        </fpage>
        –
        <lpage>
         14793
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14674752
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B275">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rubanyi
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Polokoff
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
        </article-title>
        .
        <source>
         Pharmacol Rev
        </source>
        <volume>
         46
        </volume>
        :
        <fpage>
         325
        </fpage>
        –
        <lpage>
         415
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7831383
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B276">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rubattu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cotugno
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Forte
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Stanzione
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bianchi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Madonna
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marchitti
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Volpe
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat
        </article-title>
        .
        <source>
         J Hypertens
        </source>
        <volume>
         36
        </volume>
        :
        <fpage>
         1902
        </fpage>
        –
        <lpage>
         1914
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29916993
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B277">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ruilope
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dukat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Böhm
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lacourcière
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         375
        </volume>
        :
        <fpage>
         1255
        </fpage>
        –
        <lpage>
         1266
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20236700
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B278">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Russell
          </surname>
          <given-names>
           FD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Davenport
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         Secretory pathways in endothelin synthesis
        </article-title>
        .
        <source>
         Br J Pharmacol
        </source>
        <volume>
         126
        </volume>
        :
        <fpage>
         391
        </fpage>
        –
        <lpage>
         398
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10077230
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B279">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sahli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Frank
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schweizer
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Diederich
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Blum‐Kaelin
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Aebi
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Böhm
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oefner
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dale
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Second‐generation inhibitors for the metalloprotease neprilysin based on bicyclic heteroaromatic scaffolds: synthesis, biological activity, and X‐ray crystal‐structure analysis
        </article-title>
        .
        <source>
         Helv Chim Acta
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         731
        </fpage>
        –
        <lpage>
         750
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B280">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sakai
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sigmund
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Molecular evidence of tissue renin-angiotensin systems: a focus on the brain
        </article-title>
        .
        <source>
         Curr Hypertens Rep
        </source>
        <volume>
         7
        </volume>
        :
        <fpage>
         135
        </fpage>
        –
        <lpage>
         140
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15748539
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B281">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sampaio
          </surname>
          <given-names>
           WO
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Souza dos Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Faria-Silva
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           da Mata Machado
          </surname>
          <given-names>
           LT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schiffrin
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Touyz
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         49
        </volume>
        :
        <fpage>
         185
        </fpage>
        –
        <lpage>
         192
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17116756
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B282">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sandberg
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ji
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Clark
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shapira
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Catt
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1992
        </year>
        )
        <article-title>
         Cloning and expression of a novel angiotensin II receptor subtype
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         267
        </volume>
        :
        <fpage>
         9455
        </fpage>
        –
        <lpage>
         9458
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1374402
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B283">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Campagnole-Santos
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Baracho
          </surname>
          <given-names>
           NC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fontes
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Silva
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Neves
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oliveira
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Caligiorne
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rodrigues
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gropen Júnior
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors
        </article-title>
        .
        <source>
         Brain Res Bull
        </source>
        <volume>
         35
        </volume>
        :
        <fpage>
         293
        </fpage>
        –
        <lpage>
         298
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7850477
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B284">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Verano-Braga
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system
        </article-title>
        .
        <source>
         J Endocrinol
        </source>
        <volume>
         216
        </volume>
        :
        <fpage>
         R1
        </fpage>
        –
        <lpage>
         R17
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23092879
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B285">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Simoes e Silva
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maric
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Silva
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Machado
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Buhr
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heringer-Walther
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pinheiro
          </surname>
          <given-names>
           SV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lopes
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         100
        </volume>
        :
        <fpage>
         8258
        </fpage>
        –
        <lpage>
         8263
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12829792
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B286">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RAS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Verano-Braga
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Canta
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Steckelings
          </surname>
          <given-names>
           UM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         The renin-angiotensin system: going beyond the classical paradigms
        </article-title>
        .
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         316
        </volume>
        :
        <fpage>
         H958
        </fpage>
        –
        <lpage>
         H970
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30707614
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B287">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Santos
          </surname>
          <given-names>
           RAS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sampaio
          </surname>
          <given-names>
           WO
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alzamora
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Motta-Santos
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alenina
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Campagnole-Santos
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         The ACE2/angiotensin-(1–7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1–7)
        </article-title>
        .
        <source>
         Physiol Rev
        </source>
        <volume>
         98
        </volume>
        :
        <fpage>
         505
        </fpage>
        –
        <lpage>
         553
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29351514
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B288">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sasaki
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yamano
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bardhan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iwai
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Murray
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hasegawa
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Matsuda
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inagami
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1991
        </year>
        )
        <article-title>
         Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         351
        </volume>
        :
        <fpage>
         230
        </fpage>
        –
        <lpage>
         233
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2041569
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B289">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sauer
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cole
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jensen
          </surname>
          <given-names>
           BC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pal
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sharma
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yehya
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Vader
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         Practical guidance on the use of sacubitril/valsartan for heart failure
        </article-title>
        .
        <source>
         Heart Fail Rev
        </source>
        <volume>
         24
        </volume>
        :
        <fpage>
         167
        </fpage>
        –
        <lpage>
         176
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30565021
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B290">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Savage
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lovato
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brosnihan
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Miller
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Petty
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Phase II trial of angiotensin-(1-7) for the treatment of patients with metastatic sarcoma
        </article-title>
        .
        <source>
         Sarcoma
        </source>
        <volume>
         2016
        </volume>
        :
        <fpage>
         4592768
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         27895527
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B291">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Savergnini
          </surname>
          <given-names>
           SQ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beiman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lautner
          </surname>
          <given-names>
           RQ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Paula-Carvalho
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Allahdadi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pessoa
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Costa-Fraga
          </surname>
          <given-names>
           FP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fraga-Silva
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cojocaru
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cohen
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         56
        </volume>
        :
        <fpage>
         112
        </fpage>
        –
        <lpage>
         120
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20479330
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B292">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Savergnini
          </surname>
          <given-names>
           SQ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ianzer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Carvalho
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Silva
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Marques
          </surname>
          <given-names>
           FD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Peluso
          </surname>
          <given-names>
           AAB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Beiman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cojocaru
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cohen
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <volume>
         8
        </volume>
        :
        <fpage>
         e57757
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23469229
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib397">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Schechter
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Berger
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1967
        </year>
        )
        <article-title>
         On the size of active proteases. I. Papain
        </article-title>
        .
        <source>
         Biochem Biophys Res Commun
        </source>
        <volume>
         27
        </volume>
        :
        <fpage>
         157
        </fpage>
        –
        <lpage>
         162
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         6035483
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B293">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Schiering
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           D’Arcy
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Villard
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ramage
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Logel
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cumin
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ksander
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wiesmann
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Karki
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mogi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Structure of neprilysin in complex with the active metabolite of sacubitril
        </article-title>
        .
        <source>
         Sci Rep
        </source>
        <volume>
         6
        </volume>
        :
        <fpage>
         27909
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         27302413
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B294">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Schulz
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dale
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Karimi-Nejad
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oefner
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Structure of human endothelin-converting enzyme I complexed with phosphoramidon
        </article-title>
        .
        <source>
         J Mol Biol
        </source>
        <volume>
         385
        </volume>
        :
        <fpage>
         178
        </fpage>
        –
        <lpage>
         187
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18992253
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B295">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Schunkert
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hense
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Derkx
          </surname>
          <given-names>
           FH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kürzinger
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Riegger
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         95
        </volume>
        :
        <fpage>
         39
        </fpage>
        –
        <lpage>
         45
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8994414
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B296">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Seguin
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Villarreal
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ciuffo
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         AT
         <sub>
          2
         </sub>
         receptors recruit c-Src, SHP-1 and FAK upon activation by Ang II in PND15 rat hindbrain
        </article-title>
        .
        <source>
         Neurochem Int
        </source>
        <volume>
         60
        </volume>
        :
        <fpage>
         199
        </fpage>
        –
        <lpage>
         207
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22120166
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B297">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Seymour
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swerdel
          </surname>
          <given-names>
           JN
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Abboa-Offei
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1991
        </year>
        )
        <article-title>
         Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme
        </article-title>
        .
        <source>
         J Cardiovasc Pharmacol
        </source>
        <volume>
         17
        </volume>
        :
        <fpage>
         456
        </fpage>
        –
        <lpage>
         465
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1711608
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B298">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sharp
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Poglitsch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zilla
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Davies
          </surname>
          <given-names>
           NH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats
        </article-title>
        .
        <source>
         J Renin Angiotensin Aldosterone Syst
        </source>
        <volume>
         16
        </volume>
        :
        <fpage>
         1149
        </fpage>
        –
        <lpage>
         1158
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25757657
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B299">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Shemesh
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Toporik
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Levine
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hecht
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rotman
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wool
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dahary
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gofer
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kliger
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Soffer
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Discovery and validation of novel peptide agonists for G-protein-coupled receptors
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         283
        </volume>
        :
        <fpage>
         34643
        </fpage>
        –
        <lpage>
         34649
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18854305
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B300">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Shenoy
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kwon
          </surname>
          <given-names>
           KC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rathinasabapathy
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jin
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Song
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shil
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nair
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Qi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         64
        </volume>
        :
        <fpage>
         1248
        </fpage>
        –
        <lpage>
         1259
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25225206
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B301">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Shimada
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Furukawa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wada
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wei
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tada
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kuwabara
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shikata
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kanematsu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lawton
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kitazato
          </surname>
          <given-names>
           KT
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Angiotensin-(1-7) protects against the development of aneurysmal subarachnoid hemorrhage in mice
        </article-title>
        .
        <source>
         J Cereb Blood Flow Metab
        </source>
        <volume>
         35
        </volume>
        :
        <fpage>
         1163
        </fpage>
        –
        <lpage>
         1168
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25757758
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B302">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Shirotani
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tsubuki
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iwata
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Takaki
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harigaya
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maruyama
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kiryu-Seo
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kiyama
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iwata
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tomita
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         276
        </volume>
        :
        <fpage>
         21895
        </fpage>
        –
        <lpage>
         21901
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11278416
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B303">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sigmund
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Diz
          </surname>
          <given-names>
           DI
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chappell
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         No brain renin-angiotensin system: déjà vu all over again?
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         69
        </volume>
        :
        <fpage>
         1007
        </fpage>
        –
        <lpage>
         1010
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28396531
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B304">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Simon
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Black
          </surname>
          <given-names>
           HR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Moser
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Berland
          </surname>
          <given-names>
           WE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1992
        </year>
        )
        <article-title>
         Cough and ACE inhibitors
        </article-title>
        .
        <source>
         Arch Intern Med
        </source>
        <volume>
         152
        </volume>
        :
        <fpage>
         1698
        </fpage>
        –
        <lpage>
         1700
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1497404
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B305">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Skeggs
          </surname>
          <given-names>
           LT
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name name-style="western">
          <surname>
           Kahn
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shumway
          </surname>
          <given-names>
           NP
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1956
        </year>
        )
        <article-title>
         The preparation and function of the hypertensin-converting enzyme
        </article-title>
        .
        <source>
         J Exp Med
        </source>
        <volume>
         103
        </volume>
        :
        <fpage>
         295
        </fpage>
        –
        <lpage>
         299
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         13295487
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B306">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Skidgel
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Engelbrecht
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Johnson
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Erdös
          </surname>
          <given-names>
           EG
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1984
        </year>
        )
        <article-title>
         Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase
        </article-title>
        .
        <source>
         Peptides
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         769
        </fpage>
        –
        <lpage>
         776
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         6208535
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B307">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Solomon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rizkala
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Anand
          </surname>
          <given-names>
           IS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ge
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lam
          </surname>
          <given-names>
           CSP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maggioni
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Martinez
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Packer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial
        </article-title>
        .
        <source>
         JACC Heart Fail
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         471
        </fpage>
        –
        <lpage>
         482
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28662936
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B308">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Solomon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zile
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pieske
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Voors
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shah
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kraigher-Krainer
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bransford
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Takeuchi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          Prospective Comparison of ARNI with ARB on Management Of Heart Failure with Preserved Ejection Fraction (PARAMOUNT) Investigators
         </collab>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         380
        </volume>
        :
        <fpage>
         1387
        </fpage>
        –
        <lpage>
         1395
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22932717
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B309">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Song
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Allen
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Paxinos
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mendelsohn
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1992
        </year>
        )
        <article-title>
         Mapping of angiotensin II receptor subtype heterogeneity in rat brain
        </article-title>
        .
        <source>
         J Comp Neurol
        </source>
        <volume>
         316
        </volume>
        :
        <fpage>
         467
        </fpage>
        –
        <lpage>
         484
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1577995
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B310">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Soualmia
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Barthélemy
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Masson
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maistre
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Eurin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Carayon
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Angiotensin II-induced phosphoinositide production and atrial natriuretic peptide release in rat atrial tissue
        </article-title>
        .
        <source>
         J Cardiovasc Pharmacol
        </source>
        <volume>
         29
        </volume>
        :
        <fpage>
         605
        </fpage>
        –
        <lpage>
         611
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9213202
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B311">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Soubrier
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alhenc-Gelas
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hubert
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Allegrini
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           John
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tregear
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1988
        </year>
        )
        <article-title>
         Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         85
        </volume>
        :
        <fpage>
         9386
        </fpage>
        –
        <lpage>
         9390
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2849100
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B312">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Srivastava
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Claggett
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Solomon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McMurray
          </surname>
          <given-names>
           JJV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Packer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zile
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Desai
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rouleau
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Swedberg
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fonarow
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial
        </article-title>
        .
        <source>
         JAMA Cardiol
        </source>
        <volume>
         3
        </volume>
        :
        <fpage>
         1226
        </fpage>
        –
        <lpage>
         1231
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30484837
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B313">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Stasch
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hirth-Dietrich
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kazda
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Neuser
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1989
        </year>
        )
        <article-title>
         Endothelin stimulates release of atrial natriuretic peptides in vitro and in vivo
        </article-title>
        .
        <source>
         Life Sci
        </source>
        <volume>
         45
        </volume>
        :
        <fpage>
         869
        </fpage>
        –
        <lpage>
         875
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2552240
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B314">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Steckelings
          </surname>
          <given-names>
           UM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Artuc
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wollschläger
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wiehstutz
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Henz
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions
        </article-title>
        .
        <source>
         Acta Derm Venereol
        </source>
        <volume>
         81
        </volume>
        :
        <fpage>
         321
        </fpage>
        –
        <lpage>
         325
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11800136
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B315">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Steckelings
          </surname>
          <given-names>
           UM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kloet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sumners
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Centrally mediated cardiovascular actions of the angiotensin II type 2 receptor
        </article-title>
        .
        <source>
         Trends Endocrinol Metab
        </source>
        <volume>
         28
        </volume>
        :
        <fpage>
         684
        </fpage>
        –
        <lpage>
         693
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28733135
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B316">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Stone
          </surname>
          <given-names>
           C
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name name-style="western">
          <surname>
           Brown
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Angiotensin-converting enzyme inhibitor and other drug-associated angioedema
        </article-title>
        .
        <source>
         Immunol Allergy Clin North Am
        </source>
        <volume>
         37
        </volume>
        :
        <fpage>
         483
        </fpage>
        –
        <lpage>
         495
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28687104
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B317">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Stragier
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hristova
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sarre
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ebinger
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Michotte
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         In vivo characterization of the angiotensin-(1-7)-induced dopamine and γ-aminobutyric acid release in the striatum of the rat
        </article-title>
        .
        <source>
         Eur J Neurosci
        </source>
        <volume>
         22
        </volume>
        :
        <fpage>
         658
        </fpage>
        –
        <lpage>
         664
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16101747
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B318">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Straka
          </surname>
          <given-names>
           BT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ramirez
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Byrd
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Stone
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Woodard-Grice
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nian
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Banerji
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brown
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema
        </article-title>
        .
        <source>
         J Allergy Clin Immunol
        </source>
        <volume>
         140
        </volume>
        :
        <fpage>
         242
        </fpage>
        –
        <lpage>
         248
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27913306
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib395">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lubbe
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cozier
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwager
          </surname>
          <given-names>
           SLU
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Arowolo
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Arendse
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Belcher
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         Structural basis for the C-domain-selective angiotensin-converting enzyme inhibition by bradykinin-potentiating peptide b (BPPb)
        </article-title>
        .
        <source>
         Biochem J
        </source>
        <volume>
         476
        </volume>
        (
        <issue>
         10
        </issue>
        ):
        <fpage>
         1553
        </fpage>
        –
        <lpage>
         1570
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31072910
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B319">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sulpizio
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pullen
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Edwards
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Louttit
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           West
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brooks
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406
        </article-title>
        .
        <source>
         J Pharmacol Exp Ther
        </source>
        <volume>
         315
        </volume>
        :
        <fpage>
         1306
        </fpage>
        –
        <lpage>
         1313
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16144980
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B320">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Suwa
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Seino
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nomachi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Matsuki
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Funahashi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy
        </article-title>
        .
        <source>
         Circ J
        </source>
        <volume>
         69
        </volume>
        :
        <fpage>
         283
        </fpage>
        –
        <lpage>
         290
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15731532
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B321">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tabrizchi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Omapatrilat. Bristol-Myers Squibb
        </article-title>
        .
        <source>
         Curr Opin Investig Drugs
        </source>
        <volume>
         2
        </volume>
        :
        <fpage>
         1414
        </fpage>
        –
        <lpage>
         1422
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B322">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Takahashi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Matsushita
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iijima
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tanzawa
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         Purification and characterization of endothelin-converting enzyme from rat lung
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         268
        </volume>
        :
        <fpage>
         21394
        </fpage>
        –
        <lpage>
         21398
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8407980
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B323">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tallant
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gallagher
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor
        </article-title>
        .
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         289
        </volume>
        :
        <fpage>
         H1560
        </fpage>
        –
        <lpage>
         H1566
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15951342
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B324">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tamargo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Duarte
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ruilope
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         New antihypertensive drugs under development
        </article-title>
        .
        <source>
         Curr Med Chem
        </source>
        <volume>
         22
        </volume>
        :
        <fpage>
         305
        </fpage>
        –
        <lpage>
         342
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25386825
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B325">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tetzner
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gebolys
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Meinert
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Klein
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Uhlich
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Trebicka
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Villacañas
          </surname>
          <given-names>
           Ó
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Walther
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         G-protein-coupled receptor MrgD is a receptor for angiotensin-(1-7) involving adenylyl cyclase, cAMP, and phosphokinase A
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         68
        </volume>
        :
        <fpage>
         185
        </fpage>
        –
        <lpage>
         194
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27217404
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B326">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Than
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Leow
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         288
        </volume>
        :
        <fpage>
         15520
        </fpage>
        –
        <lpage>
         15531
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23592774
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B327">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Thomas
          </surname>
          <given-names>
           WG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sernia
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1988
        </year>
        )
        <article-title>
         Immunocytochemical localization of angiotensinogen in the rat brain
        </article-title>
        .
        <source>
         Neuroscience
        </source>
        <volume>
         25
        </volume>
        :
        <fpage>
         319
        </fpage>
        –
        <lpage>
         341
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         3393283
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B328">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Thunnissen
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nordlund
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Haeggström
          </surname>
          <given-names>
           JZ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation
        </article-title>
        .
        <source>
         Nat Struct Biol
        </source>
        <volume>
         8
        </volume>
        :
        <fpage>
         131
        </fpage>
        –
        <lpage>
         135
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11175901
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B329">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tipnis
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hyde
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Karran
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Christie
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         275
        </volume>
        :
        <fpage>
         33238
        </fpage>
        –
        <lpage>
         33243
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B330">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tirupula
          </surname>
          <given-names>
           KC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Desnoyer
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Speth
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Karnik
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Atypical signaling and functional desensitization response of MAS receptor to peptide ligands
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <volume>
         9
        </volume>
        :
        <fpage>
         e103520
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         25068582
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B331">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tom
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Vries
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Saxena
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AHJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         38
        </volume>
        :
        <fpage>
         95
        </fpage>
        –
        <lpage>
         99
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11463767
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B332">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Torrado
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cain
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mauro
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Romeo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ockaili
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chau
          </surname>
          <given-names>
           VQ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nestler
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Devarakonda
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ghosh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Das
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Sacubitril/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits
        </article-title>
        .
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         72
        </volume>
        :
        <fpage>
         2342
        </fpage>
        –
        <lpage>
         2356
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30384891
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B333">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tóth
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Turu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hunyady
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Balla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Novel mechanisms of G-protein-coupled receptors functions: AT
         <sub>
          1
         </sub>
         angiotensin receptor acts as a signaling hub and focal point of receptor cross-talk
        </article-title>
        .
        <source>
         Best Pract Res Clin Endocrinol Metab
        </source>
        <volume>
         32
        </volume>
        :
        <fpage>
         69
        </fpage>
        –
        <lpage>
         82
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29678287
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B334">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Towler
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Staker
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Prasad
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Menon
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Parsons
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ryan
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fisher
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Williams
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dales
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         279
        </volume>
        :
        <fpage>
         17996
        </fpage>
        –
        <lpage>
         18007
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14754895
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B335">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Trask
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments
        </article-title>
        .
        <source>
         Cardiovasc Drug Rev
        </source>
        <volume>
         25
        </volume>
        :
        <fpage>
         162
        </fpage>
        –
        <lpage>
         174
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17614938
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B336">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Trippodo
          </surname>
          <given-names>
           NC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Robl
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Asaad
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fox
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Panchal
          </surname>
          <given-names>
           BC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schaeffer
          </surname>
          <given-names>
           TR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1998
        </year>
        )
        <article-title>
         Effects of omapatrilat in low, normal, and high renin experimental hypertension
        </article-title>
        .
        <source>
         Am J Hypertens
        </source>
        <volume>
         11
        </volume>
        :
        <fpage>
         363
        </fpage>
        –
        <lpage>
         372
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9544878
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B337">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Turcaud
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gonzalez
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Michel
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournie-Zaluski
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Diastereoselective synthesis of mixanpril, an orally active dual inhibitor of neutral endopeptidase and angiotensin converting enzyme
        </article-title>
        .
        <source>
         Bioorg Med Chem Lett
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         1893
        </fpage>
        –
        <lpage>
         1898
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="B338">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tanzawa
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX
        </article-title>
        .
        <source>
         FASEB J
        </source>
        <volume>
         11
        </volume>
        :
        <fpage>
         355
        </fpage>
        –
        <lpage>
         364
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9141502
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B339">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Uijl
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mirabito Colafella
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sun
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ren
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Veghel
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Garrelds
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Vries
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Poglitsch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zlatev
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         73
        </volume>
        :
        <fpage>
         1249
        </fpage>
        –
        <lpage>
         1257
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31030610
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B340">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Uijl
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ren
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AHJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Angiotensin generation in the brain: a re-evaluation
        </article-title>
        .
        <source>
         Clin Sci (Lond)
        </source>
        <volume>
         132
        </volume>
        :
        <fpage>
         839
        </fpage>
        –
        <lpage>
         850
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29712882
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B341">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           van Esch
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tom
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Batenburg
          </surname>
          <given-names>
           WW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Georgiadis
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yiotakis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Gool
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Bruijn
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Vries
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         45
        </volume>
        :
        <fpage>
         120
        </fpage>
        –
        <lpage>
         125
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15583077
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B342">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           van Thiel
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Góes Martini
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Te Riet
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Severs
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Uijl
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Garrelds
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Leijten
          </surname>
          <given-names>
           FPJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van der Pluijm
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Essers
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Qadri
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Brain renin–angiotensin system: does it exist?
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         69
        </volume>
        :
        <fpage>
         1136
        </fpage>
        –
        <lpage>
         1144
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28396529
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B343">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           van Twist
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kroon
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           de Leeuw
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Angiotensin-(1-7) as a strategy in the treatment of hypertension?
        </article-title>
        <source>
         Curr Opin Nephrol Hypertens
        </source>
        <volume>
         23
        </volume>
        :
        <fpage>
         480
        </fpage>
        –
        <lpage>
         486
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25023950
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B344">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           van’t Veer
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van der Feltz
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van den Berg-Bakker
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           NC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hermens
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Oorschot
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kievits
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schrier
          </surname>
          <given-names>
           PI
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         Activation of the mas oncogene involves coupling to human alphoid sequences
        </article-title>
        .
        <source>
         Oncogene
        </source>
        <volume>
         8
        </volume>
        :
        <fpage>
         2673
        </fpage>
        –
        <lpage>
         2681
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8378079
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B345">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Vardeny
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Miller
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Solomon
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure
        </article-title>
        .
        <source>
         JACC Heart Fail
        </source>
        <volume>
         2
        </volume>
        :
        <fpage>
         663
        </fpage>
        –
        <lpage>
         670
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25306450
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B346">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Vazeux
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iturrioz
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortès
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         A tyrosine residue essential for catalytic activity in aminopeptidase A
        </article-title>
        .
        <source>
         Biochem J
        </source>
        <volume>
         327
        </volume>
        :
        <fpage>
         883
        </fpage>
        –
        <lpage>
         889
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9581570
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B347">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Vazeux
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Iturrioz
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1998
        </year>
        )
        <article-title>
         A glutamate residue contributes to the exopeptidase specificity in aminopeptidase A
        </article-title>
        .
        <source>
         Biochem J
        </source>
        <volume>
         334
        </volume>
        :
        <fpage>
         407
        </fpage>
        –
        <lpage>
         413
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9716499
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B348">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Vazeux
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortès
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         Identification of glutamate residues essential for catalytic activity and zinc coordination in aminopeptidase A
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         271
        </volume>
        :
        <fpage>
         9069
        </fpage>
        –
        <lpage>
         9074
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8621556
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B349">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Veerasingham
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Raizada
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives
        </article-title>
        .
        <source>
         Br J Pharmacol
        </source>
        <volume>
         139
        </volume>
        :
        <fpage>
         191
        </fpage>
        –
        <lpage>
         202
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12770924
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B350">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Velazquez
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Morrow
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           DeVore
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Duffy
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ambrosy
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McCague
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rocha
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Braunwald
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <collab>
          PIONEER-HF Investigators
         </collab>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         Angiotensin–neprilysin inhibition in acute decompensated heart failure
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         380
        </volume>
        :
        <fpage>
         539
        </fpage>
        –
        <lpage>
         548
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30415601
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B351">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Verdonk
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Saleh
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lankhorst
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Smilde
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van Ingen
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Garrelds
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Friesema
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Russcher
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           van den Meiracker
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Visser
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         65
        </volume>
        :
        <fpage>
         1316
        </fpage>
        –
        <lpage>
         1323
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25870197
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B352">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Vickers
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hales
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kaushik
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dick
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gavin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Godbout
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Parsons
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Baronas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hsieh
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         277
        </volume>
        :
        <fpage>
         14838
        </fpage>
        –
        <lpage>
         14843
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11815627
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B353">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Vijayaraghavan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Scicli
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Carretero
          </surname>
          <given-names>
           OA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Slaughter
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Moomaw
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hersh
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1990
        </year>
        )
        <article-title>
         The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase)
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         265
        </volume>
        :
        <fpage>
         14150
        </fpage>
        –
        <lpage>
         14155
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2201681
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B354">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Villar
          </surname>
          <given-names>
           IC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Panayiotou
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sheraz
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Madhani
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Scotland
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nobles
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kemp-Harper
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ahluwalia
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hobbs
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor
        </article-title>
        .
        <source>
         Cardiovasc Res
        </source>
        <volume>
         74
        </volume>
        :
        <fpage>
         515
        </fpage>
        –
        <lpage>
         525
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17391657
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B355">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Vodovar
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Séronde
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Laribi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gayat
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lassus
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Januzzi
          </surname>
          <given-names>
           JL
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name name-style="western">
          <surname>
           Boukef
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nouira
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Manivet
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Samuel
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <etal>
         </etal>
         <collab>
          GREAT Network
         </collab>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure
        </article-title>
        .
        <source>
         JACC Heart Fail
        </source>
        <volume>
         3
        </volume>
        :
        <fpage>
         629
        </fpage>
        –
        <lpage>
         636
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26251090
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B356">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Walters
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gaspari
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Widdop
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         45
        </volume>
        :
        <fpage>
         960
        </fpage>
        –
        <lpage>
         966
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15767466
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B357">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cooper
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         Histidine residue in the zinc-binding motif of aminopeptidase A is critical for enzymatic activity
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         90
        </volume>
        :
        <fpage>
         1222
        </fpage>
        –
        <lpage>
         1226
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8433982
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B358">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Watermeyer
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kröger
          </surname>
          <given-names>
           WL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           O’Neill
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sewell
          </surname>
          <given-names>
           BT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Probing the basis of domain-dependent inhibition using novel ketone inhibitors of angiotensin-converting enzyme
        </article-title>
        .
        <source>
         Biochemistry
        </source>
        <volume>
         47
        </volume>
        :
        <fpage>
         5942
        </fpage>
        –
        <lpage>
         5950
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18457420
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B359">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Watermeyer
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kröger
          </surname>
          <given-names>
           WL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           O’Neill
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sewell
          </surname>
          <given-names>
           BT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril
        </article-title>
        .
        <source>
         Biochem J
        </source>
        <volume>
         428
        </volume>
        :
        <fpage>
         67
        </fpage>
        –
        <lpage>
         74
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20233165
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B360">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Watts
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corey
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Silencing disease genes in the laboratory and the clinic
        </article-title>
        .
        <source>
         J Pathol
        </source>
        <volume>
         226
        </volume>
        :
        <fpage>
         365
        </fpage>
        –
        <lpage>
         379
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22069063
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B361">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Weber
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Vasopeptidase inhibitors
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         358
        </volume>
        :
        <fpage>
         1525
        </fpage>
        –
        <lpage>
         1532
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11705582
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B362">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Weber
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Messerli
          </surname>
          <given-names>
           FH
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         51
        </volume>
        :
        <fpage>
         1465
        </fpage>
        –
        <lpage>
         1467
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18413486
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B363">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wei
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Han
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials
        </article-title>
        .
        <source>
         J Am Heart Assoc
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         e003896
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         27912207
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B364">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wei
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heublein
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Perrella
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lerman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rodeheffer
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           McGregor
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Edwards
          </surname>
          <given-names>
           WD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schaff
          </surname>
          <given-names>
           HV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Burnett
          </surname>
          <given-names>
           JC
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         Natriuretic peptide system in human heart failure
        </article-title>
        .
        <source>
         Circulation
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         1004
        </fpage>
        –
        <lpage>
         1009
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8353861
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B365">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wei
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Clauser
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Alhenc-Gelas
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1992
        </year>
        )
        <article-title>
         The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         267
        </volume>
        :
        <fpage>
         13398
        </fpage>
        –
        <lpage>
         13405
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1320019
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B366">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Welches
          </surname>
          <given-names>
           WR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brosnihan
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11
        </article-title>
        .
        <source>
         Life Sci
        </source>
        <volume>
         52
        </volume>
        :
        <fpage>
         1461
        </fpage>
        –
        <lpage>
         1480
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8387132
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B367">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Whelton
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Carey
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Aronow
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Casey
          </surname>
          <given-names>
           DE
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name name-style="western">
          <surname>
           Collins
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dennison Himmelfarb
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           DePalma
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gidding
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jamerson
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jones
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in
         <italic>
          J Am Coll Cardiol
         </italic>
         (2018)
         <bold>
          71
         </bold>
         :2275–2279]
        </article-title>
        .
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         71
        </volume>
        :
        <fpage>
         e127
        </fpage>
        –
        <lpage>
         e248
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29146535
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B368">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wielbo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sernia
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gyurko
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Phillips
          </surname>
          <given-names>
           MI
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Antisense inhibition of hypertension in the spontaneously hypertensive rat
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         25
        </volume>
        :
        <fpage>
         314
        </fpage>
        –
        <lpage>
         319
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7875755
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B369">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wiemer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dobrucki
          </surname>
          <given-names>
           LW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Louka
          </surname>
          <given-names>
           FR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Malinski
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Heitsch
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium
        </article-title>
        .
        <source>
         Hypertension
        </source>
        <volume>
         40
        </volume>
        :
        <fpage>
         847
        </fpage>
        –
        <lpage>
         852
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12468568
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B370">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Williams
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Soubrier
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         Identification of two active site residues in human angiotensin I-converting enzyme
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         269
        </volume>
        :
        <fpage>
         29430
        </fpage>
        –
        <lpage>
         29434
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7961923
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B371">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Woodman
          </surname>
          <given-names>
           ZL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Oppong
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Cook
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schwager
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Brandt
          </surname>
          <given-names>
           WF
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ehlers
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites
        </article-title>
        .
        <source>
         Biochem J
        </source>
        <volume>
         347
        </volume>
        :
        <fpage>
         711
        </fpage>
        –
        <lpage>
         718
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10769174
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B372">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wright
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Musini
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gill
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         First-line drugs for hypertension
        </article-title>
        .
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         4
        </volume>
        :
        <fpage>
         CD001841
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29667175
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B373">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wright
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harding
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions
        </article-title>
        .
        <source>
         Regul Pept
        </source>
        <volume>
         59
        </volume>
        :
        <fpage>
         269
        </fpage>
        –
        <lpage>
         295
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8577933
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B374">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wright
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harding
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Important role for angiotensin III and IV in the brain renin-angiotensin system
        </article-title>
        .
        <source>
         Brain Res Brain Res Rev
        </source>
        <volume>
         25
        </volume>
        :
        <fpage>
         96
        </fpage>
        –
        <lpage>
         124
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9370053
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B375">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wright
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Miller-Wing
          </surname>
          <given-names>
           AV
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Shaffer
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Higginson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wright
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hanesworth
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harding
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory
        </article-title>
        .
        <source>
         Brain Res Bull
        </source>
        <volume>
         32
        </volume>
        :
        <fpage>
         497
        </fpage>
        –
        <lpage>
         502
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8221142
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B376">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wright
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tamura-Myers
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wilson
          </surname>
          <given-names>
           WL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Speth
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Harding
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats
        </article-title>
        .
        <source>
         Am J Physiol Regul Integr Comp Physiol
        </source>
        <volume>
         284
        </volume>
        :
        <fpage>
         R725
        </fpage>
        –
        <lpage>
         R733
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12433674
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B377">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Xu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Emoto
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Giaid
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Slaughter
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kaw
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           deWit
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yanagisawa
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1
        </article-title>
        .
        <source>
         Cell
        </source>
        <volume>
         78
        </volume>
        :
        <fpage>
         473
        </fpage>
        –
        <lpage>
         485
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8062389
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B378">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yamada
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Horiuchi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dzau
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         Angiotensin II type 2 receptor mediates programmed cell death
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         93
        </volume>
        :
        <fpage>
         156
        </fpage>
        –
        <lpage>
         160
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8552595
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B379">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yanagisawa
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Inoue
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ishikawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kasuya
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kimura
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kumagaye
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nakajima
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Watanabe
          </surname>
          <given-names>
           TX
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sakakibara
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Goto
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         1988
        </year>
        )
        <article-title>
         Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         85
        </volume>
        :
        <fpage>
         6964
        </fpage>
        –
        <lpage>
         6967
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         3045827
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B380">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yancy
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jessup
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bozkurt
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Butler
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Casey
          </surname>
          <given-names>
           DE
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name name-style="western">
          <surname>
           Colvin
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Drazner
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Filippatos
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fonarow
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Givertz
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America [published correction appears in
         <italic>
          J Am Coll Cardiol
         </italic>
         (2016)
         <bold>
          68
         </bold>
         :1495]
        </article-title>
        .
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         68
        </volume>
        :
        <fpage>
         1476
        </fpage>
        –
        <lpage>
         1488
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27216111
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B381">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yancy
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Jessup
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Bozkurt
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Butler
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Casey
          </surname>
          <given-names>
           DE
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name name-style="western">
          <surname>
           Colvin
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Drazner
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Filippatos
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fonarow
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Givertz
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
        </article-title>
        .
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         70
        </volume>
        :
        <fpage>
         776
        </fpage>
        –
        <lpage>
         803
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28461007
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B382">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yandrapalli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Khan
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rochlani
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Aronow
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy
        </article-title>
        .
        <source>
         Ther Adv Cardiovasc Dis
        </source>
        <volume>
         12
        </volume>
        :
        <fpage>
         217
        </fpage>
        –
        <lpage>
         231
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29921166
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B383">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lin
          </surname>
          <given-names>
           YL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Structural insights into central hypertension regulation by human aminopeptidase A
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         288
        </volume>
        :
        <fpage>
         25638
        </fpage>
        –
        <lpage>
         25645
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23888046
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B384">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ye
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Howatt
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Balakrishnan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Mullick
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Graham
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Danser
          </surname>
          <given-names>
           AHJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2019
        </year>
        )
        <article-title>
         Angiotensinogen and megalin interactions contribute to atherosclerosis—brief report
        </article-title>
        .
        <source>
         Arterioscler Thromb Vasc Biol
        </source>
        <volume>
         39
        </volume>
        :
        <fpage>
         150
        </fpage>
        –
        <lpage>
         155
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30567480
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B385">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Young
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Waitches
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Birchmeier
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fasano
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wigler
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1986
        </year>
        )
        <article-title>
         Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains
        </article-title>
        .
        <source>
         Cell
        </source>
        <volume>
         45
        </volume>
        :
        <fpage>
         711
        </fpage>
        –
        <lpage>
         719
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         3708691
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B386">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Yuan
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Phuong
          </surname>
          <given-names>
           HTA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Park
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Angiotensin-(1-5), an active mediator of renin-angiotensin system, stimulates ANP secretion via Mas receptor
        </article-title>
        .
        <source>
         Peptides
        </source>
        <volume>
         86
        </volume>
        :
        <fpage>
         33
        </fpage>
        –
        <lpage>
         41
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27660028
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B387">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rozanski
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zucker
          </surname>
          <given-names>
           IH
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Developmental changes in AT1 and AT2 receptor-protein expression in rats
        </article-title>
        .
        <source>
         J Renin Angiotensin Aldosterone Syst
        </source>
        <volume>
         11
        </volume>
        :
        <fpage>
         214
        </fpage>
        –
        <lpage>
         221
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20807798
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B388">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yusuf
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Teo
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Pogue
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dyal
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Copland
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Schumacher
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dagenais
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sleight
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Anderson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <collab>
          ONTARGET Investigators
         </collab>
        </person-group>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Telmisartan, ramipril, or both in patients at high risk for vascular events
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <volume>
         358
        </volume>
        :
        <fpage>
         1547
        </fpage>
        –
        <lpage>
         1559
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18378520
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B389">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zanchi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Maillard
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Burnier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Recent clinical trials with omapatrilat: new developments
        </article-title>
        .
        <source>
         Curr Hypertens Rep
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         346
        </fpage>
        –
        <lpage>
         352
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12844471
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B390">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Han
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Batyuk
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Ishchenko
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           White
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Patel
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Sadybekov
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zamlynny
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Rudd
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Hollenstein
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Structural basis for selectivity and diversity in angiotensin II receptors
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         544
        </volume>
        :
        <fpage>
         327
        </fpage>
        –
        <lpage>
         332
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28379944
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B391">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Unal
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Gati
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Han
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Zatsepin
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           James
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Nelson
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Weierstall
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Structure of the angiotensin receptor revealed by serial femtosecond crystallography
        </article-title>
        .
        <source>
         Cell
        </source>
        <volume>
         161
        </volume>
        :
        <fpage>
         833
        </fpage>
        –
        <lpage>
         844
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25913193
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B392">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Dang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Liaw
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Tran
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Boatman
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Connolly
          </surname>
          <given-names>
           DT
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Adams
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection
        </article-title>
        .
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         302
        </volume>
        :
        <fpage>
         H299
        </fpage>
        –
        <lpage>
         H311
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22003054
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B393">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zini
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournie-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Chauvel
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         93
        </volume>
        :
        <fpage>
         11968
        </fpage>
        –
        <lpage>
         11973
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8876246
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B394">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zini
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Masdehors
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Lenkei
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Fournie-Zaluski
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Roques
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name name-style="western">
          <surname>
           Llorens-Cortes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Aminopeptidase A: distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats
        </article-title>
        .
        <source>
         Neuroscience
        </source>
        <volume>
         78
        </volume>
        :
        <fpage>
         1187
        </fpage>
        –
        <lpage>
         1193
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9174084
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Gene
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Gene
      </journal-id>
      <journal-title-group>
       <journal-title>
        Gene
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0378-1119
      </issn>
      <issn pub-type="epub">
       1879-0038
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       17597310
      </article-id>
      <article-id pub-id-type="pmc">
       7127174
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0378-1119(07)00252-1
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.gene.2007.05.010
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Characterization of the first angiotensin-converting like enzyme in bacteria: Ancestor ACE is already active
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rivière
         </surname>
         <given-names>
          Guillaume
         </given-names>
        </name>
        <email>
         guillaume.riviere@dkf.unibe.ch
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ⁎
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Michaud
         </surname>
         <given-names>
          Annie
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Corradi
         </surname>
         <given-names>
          Hazel R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sturrock
         </surname>
         <given-names>
          Edward D.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ravi Acharya
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cogez
         </surname>
         <given-names>
          Virginie
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bohin
         </surname>
         <given-names>
          Jean-Pierre
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Vieau
         </surname>
         <given-names>
          Didier
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Corvol
         </surname>
         <given-names>
          Pierre
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Unité Neurosciences et Physiologie Adaptative, Université des Sciences et Technologies de Lille, 59655 Villeneuve d'Ascq Cédex, France
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       INSERM U36, Pathologie Vasculaire et Endocrinologie Rénale; Collège de France, 11, place Marcelin Berthelot, 75231, Paris cedex 05, France
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, South Africa
      </aff>
      <aff id="aff5">
       <label>
        e
       </label>
       UMR CNRS 8576, Unité de Glycobiologie structurale et fonctionnelle, Université des Sciences et Technologies de Lille, 59655 Villeneuve d'Ascq Cedex, France
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ⁎
        </label>
        Corresponding author. Department of Nephrology and Hypertension, G4-827, Inselspital, Freiburgstrasse 15, 3010 Bern, Switzerland. Tel.: +41 31 632 3013; fax: +41 31 632 9444.
        <email>
         guillaume.riviere@dkf.unibe.ch
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         1
        </label>
        <p>
         Both authors equally contributed to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        2
       </day>
       <month>
        6
       </month>
       <year>
        2007
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <day>
        1
       </day>
       <month>
        9
       </month>
       <year>
        2007
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        2
       </day>
       <month>
        6
       </month>
       <year>
        2007
       </year>
      </pub-date>
      <volume>
       399
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       81
      </fpage>
      <lpage>
       90
      </lpage>
      <history>
       <date date-type="received">
        <day>
         20
        </day>
        <month>
         3
        </month>
        <year>
         2007
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         4
        </day>
        <month>
         5
        </month>
        <year>
         2007
        </year>
       </date>
       <date date-type="accepted">
        <day>
         4
        </day>
        <month>
         5
        </month>
        <year>
         2007
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2007 Elsevier B.V. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2007
       </copyright-year>
       <copyright-holder>
        Elsevier B.V.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Angiotensin-converting enzyme (ACE) is a metallopeptidase that converts angiotensin I into angiotensin II. ACE is crucial in the control of cardiovascular and renal homeostasis and fertility in mammals. In vertebrates, both transmembrane and soluble ACE, containing one or two active sites, have been characterized. So far, only soluble, single domain ACEs from invertebrates have been cloned, and these have been implicated in reproduction in insects. Furthermore, an ACE-related carboxypeptidase was recently characterized in
        <italic>
         Leishmania
        </italic>
        , a unicellular eukaryote, suggesting the existence of ACE in more distant organisms.
       </p>
       <p>
        Interestingly,
        <italic>
         in silico
        </italic>
        databank analysis revealed that bacterial DNA sequences could encode putative ACE-like proteins, strikingly similar to vertebrates' enzymes. To gain more insight into the bacterial enzymes, we cloned the putative ACE from the phytopathogenic bacterium,
        <italic>
         Xanthomonas axonopodis
        </italic>
        pv.
        <italic>
         citri
        </italic>
        , named
        <italic>
         Xc
        </italic>
        ACE. The 2 kb open reading frame encodes a 672-amino-acid soluble protein containing a single active site.
        <italic>
         In vitro
        </italic>
        expression and biochemical characterization revealed that
        <italic>
         Xc
        </italic>
        ACE is a functional 72 kDa dipeptidyl-carboxypeptidase. As in mammals, this metalloprotease hydrolyses angiotensin I into angiotensin II.
        <italic>
         Xc
        </italic>
        ACE is sensitive to ACE inhibitors and chloride ions concentration. Variations in the active site residues, highlighted by structural modelling, can account for the different substrate selectivity and inhibition profile compared to human ACE.
        <italic>
         Xc
        </italic>
        ACE characterization demonstrates that ACE is an ancestral enzyme, provoking questions about its appearance and structure/activity specialisation during the course of evolution.
       </p>
      </abstract>
      <kwd-group>
       <title>
        Abbreviations
       </title>
       <kwd>
        Ac, acetyl
       </kwd>
       <kwd>
        ACE, Angiotensin-converting enzyme
       </kwd>
       <kwd>
        <italic>
         ACE
        </italic>
        , gene encoding ACE
       </kwd>
       <kwd>
        Ang, Angiotensin
       </kwd>
       <kwd>
        bp, base pair(s)
       </kwd>
       <kwd>
        C-, carboxy
       </kwd>
       <kwd>
        cDNA, DNA complementary to RNA
       </kwd>
       <kwd>
        CHO, chinese hamster ovary
       </kwd>
       <kwd>
        DMSO, dimethylsulfoxide
       </kwd>
       <kwd>
        DNase, desoxyribonuclease
       </kwd>
       <kwd>
        dNTP, deoxyribonucleoside triphosphate
       </kwd>
       <kwd>
        DpaOH,
        <italic>
         N
        </italic>
        <sup>
         3
        </sup>
        (2,4-dinitrophenyl)
        <sc>
         l
        </sc>
        -2,3-diaminopropionyl-OH
       </kwd>
       <kwd>
        enk, enkephalin
       </kwd>
       <kwd>
        enk-NH2, enkephalinamide
       </kwd>
       <kwd>
        FPLC, fast protein liquid chromatography
       </kwd>
       <kwd>
        HHL, Hippuryl-Histidyl-Leucine
       </kwd>
       <kwd>
        HPLC, high-performance liquid chromatography
       </kwd>
       <kwd>
        kb, kilobase(s)
       </kwd>
       <kwd>
        kDa, kilodalton
       </kwd>
       <kwd>
        Mca, 7-methoxycoumarin-4-yl)-diacetyl
       </kwd>
       <kwd>
        N-, amino
       </kwd>
       <kwd>
        ng, nanogram(s)
       </kwd>
       <kwd>
        n
        <italic>
         Xc
        </italic>
        ACE, native
        <italic>
         Xanthomonas axonopodis
        </italic>
        pv
        <italic>
         citri
        </italic>
        Angiotensin-converting enzyme
       </kwd>
       <kwd>
        ORF, open reading frame
       </kwd>
       <kwd>
        PAGE, polyacrylamide gel electrophoresis
       </kwd>
       <kwd>
        <italic>
         pv
        </italic>
        , pathovar RNase: ribonuclease
       </kwd>
       <kwd>
        r
        <italic>
         Xc
        </italic>
        ACE, recombinant
        <italic>
         Xanthomonas axonopodis
        </italic>
        pv
        <italic>
         citri
        </italic>
        Angiotensin-converting enzyme
       </kwd>
       <kwd>
        SDS, sodium dodecyl sulfate
       </kwd>
       <kwd>
        <italic>
         Xc
        </italic>
        ,
        <italic>
         Xanthomonas axonopodis pathovar citri.
        </italic>
       </kwd>
      </kwd-group>
      <kwd-group>
       <title>
        Keywords
       </title>
       <kwd>
        Evolution
       </kwd>
       <kwd>
        Cloning
       </kwd>
       <kwd>
        Biochemistry
       </kwd>
       <kwd>
        Structure
       </kwd>
       <kwd>
        Conservation
       </kwd>
       <kwd>
        Protease
       </kwd>
      </kwd-group>
     </article-meta>
     <notes>
      <p>
       Received by J.A. Engler
      </p>
     </notes>
    </front>
    <sec>
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p>
      Angiotensin-converting enzyme (ACE, dipeptidyl-peptidase A, kininase II, E.C. 3.4.15.1, DCP1) is a dipeptidyl-carboxypeptidase that belongs to the M2-metalloprotease family. In mammals, this zinc-dependent metalloprotease participates in blood pressure elevation (review in (
      <xref ref-type="bibr" rid="bib7">
       Corvol and Eyries, 2004
      </xref>
      )), generating the vasopressor angiotensin II (Ang II) from the inactive angiotensin I (Ang I), and by inactivating the vasodilator bradykinin. In vertebrates, somatic (sACE) and testicular (germinal) ACE (tACE) have been characterized. These two separate isoforms are transcribed from two alternate promoters within a single gene (
      <xref ref-type="bibr" rid="bib21">
       Howard et al., 1990
      </xref>
      ), which arose from duplication of an ancestral gene (
      <xref ref-type="bibr" rid="bib22">
       Hubert et al., 1991
      </xref>
      ). Consequently, sACE possesses two domains (termed N-domain and C-domain, respectively) bearing the highly conserved gluzincin motif HExxH, whereas tACE possesses only one, corresponding to the C-terminal domain of sACE. Crystal structures of both the human N-domain (
      <xref ref-type="bibr" rid="bib6">
       Corradi et al., 2006
      </xref>
      ) and tACE (
      <xref ref-type="bibr" rid="bib32">
       Natesh et al., 2003
      </xref>
      ) have shown them to be homologous helical ellipsoids harbouring two large cavities connected by a narrow catalytic channel containing the catalytic zinc and the HexxH motif. Somatic ACE N- and C-domain active sites have distinct enzymatic specificities with respect to
      <italic>
       in vivo
      </italic>
      and/or synthetic substrates. Indeed, the C-domain is highly selective for Hippuryl-Histidyl-Leucine (HHL) (
      <xref ref-type="bibr" rid="bib42">
       Wei et al., 1991a
      </xref>
      ) whereas the N-domain efficiently cleaves the hemoregulatory peptide Ac-Ser-Asp-Lys-Pro (AcSDKP) (
      <xref ref-type="bibr" rid="bib35">
       Rousseau et al., 1995
      </xref>
      ) and Ang 1-7 (
      <xref ref-type="bibr" rid="bib10">
       Deddish et al., 1998
      </xref>
      ). In addition, ACE inhibitors (
      <xref ref-type="bibr" rid="bib13">
       Dive et al., 1999
      </xref>
      ) and chloride ion dependence (
      <xref ref-type="bibr" rid="bib24">
       Jaspard et al., 1993
      </xref>
      ) can discriminate between the two domains. Both sACE and tACE possess a C-terminal transmembrane domain and are membrane-anchored isoforms, though a post-translational shedding releases active solubilized ACE into the extracellular milieu (
      <xref ref-type="bibr" rid="bib17">
       Eyries et al., 2001
      </xref>
      ,
      <xref ref-type="bibr" rid="bib33">
       Oppong and Hooper, 1993
      </xref>
      ). A single domain ACE homologue, ACE2, has also been characterized in the human (
      <xref ref-type="bibr" rid="bib14">
       Donoghue et al., 2000
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       Tipnis et al., 2000
      </xref>
      ) and its structure determined (
      <xref ref-type="bibr" rid="bib40">
       Towler et al., 2004
      </xref>
      ). ACE2 is an essential regulator of heart function (
      <xref ref-type="bibr" rid="bib8">
       Crackower et al., 2002
      </xref>
      ) and has also been identified as a functional receptor for the SARS coronavirus (
      <xref ref-type="bibr" rid="bib29">
       Li et al., 2003
      </xref>
      ).
     </p>
     <p>
      In invertebrates, however, functional ACE-related enzymes exist in insects and in annelids (which belong to the Ecdysozoa and Lophotrochozoa groups, respectively). Interestingly, and though
      <italic>
       in silico
      </italic>
      evidence suggest the presence of a two-domain ACE-related protein in mosquitoes (
      <xref ref-type="bibr" rid="bib3">
       Burnham et al., 2005
      </xref>
      ), all the cloned genes encode soluble, single active site enzymes (
      <xref ref-type="bibr" rid="bib37">
       Tatei et al., 1995
      </xref>
      ,
      <xref ref-type="bibr" rid="bib38">
       Taylor et al., 1996
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       Wijffels et al., 1996
      </xref>
      ). In the fruit fly
      <italic>
       Drosophila melanogaster
      </italic>
      , two homologues have been cloned and named
      <italic>
       AnCE
      </italic>
      (
      <xref ref-type="bibr" rid="bib5">
       Cornell et al., 1995
      </xref>
      ) and
      <italic>
       ACER
      </italic>
      (
      <xref ref-type="bibr" rid="bib37">
       Tatei et al. 1995
      </xref>
      ) (or
      <italic>
       Race
      </italic>
      ), of which AnCE has had its structure determined (
      <xref ref-type="bibr" rid="bib25">
       Kim et al., 2003
      </xref>
      ). AnCE and ACER show about 40% amino-acid sequence identities with vertebrate ACEs, share similar enzymatic properties (
      <xref ref-type="bibr" rid="bib4">
       Coates et al., 2000
      </xref>
      ), acting on a broad range of substrates and play a key role in development (
      <xref ref-type="bibr" rid="bib8">
       Crackower et al., 2002
      </xref>
      ) and reproduction (
      <xref ref-type="bibr" rid="bib15">
       Ekbote et al., 1999
      </xref>
      ,
      <xref ref-type="bibr" rid="bib23">
       Hurst et al., 2003
      </xref>
      ). Molecular and biochemical data from the leech ACE homologue have related it to the N-domain of mammalian ACE (
      <xref ref-type="bibr" rid="bib34">
       Riviere et al., 2004
      </xref>
      ). However, no functional ACE is present in the genome of the nematode
      <italic>
       Caenorhabditis elegans
      </italic>
      (
      <italic>
       C. elegans
      </italic>
      ), despite ACN-1, a homologue that lacks ACE-like proteolytic activity, is crucial in development (
      <xref ref-type="bibr" rid="bib2">
       Brooks et al., 2003
      </xref>
      ). Recently, a dicarboxypeptidase, LdDCP, was cloned in a pathogenic unicellular eukaryote,
      <italic>
       Leishmania donovani
      </italic>
      (
      <xref ref-type="bibr" rid="bib18">
       Goyal et al., 2005
      </xref>
      ). LdDCP, like ACE, is able to cleave a carboxyterminal dipeptide from HHL and is inhibited by captopril, suggesting that ACE may have already been present before the appearance of multicellular organisms. However, LdDCP was not reported to hydrolyse AngI and does not display sequence homology with ACE enzymes. These observations raise questions about the presence of a true ACE in more distant species.
     </p>
     <p>
      Very surprisingly,
      <italic>
       in silico
      </italic>
      databank analysis revealed that DNA sequences in bacterial genomes have been annotated as encoding potentially functional ACE-like enzymes. All these sequences display a great similarity despite phylogenetic distance (for references see
      <ext-link ext-link-type="uri" xlink:href="http://tolweb.org">
       http://tolweb.org
      </ext-link>
      and (
      <xref ref-type="bibr" rid="bib12">
       DeLong and Pace, 2001
      </xref>
      )). The striking sequence conservation in the active region of these putative ACE-like peptidases suggests that the protease activity would be conserved in these ancestral, prokaryotic species. Among them,
      <italic>
       Xanthomonas axonopodis
      </italic>
      pv.
      <italic>
       citri
      </italic>
      (
      <italic>
       X. citri
      </italic>
      ) is a phytopathogen gamma-proteobacteria in whose genome an ACE-like encoding sequence has been annotated. In order to gain more insight into stages in ACE evolution and to investigate its putative activity in unicellular organisms, we report the cloning and biochemical characterization of the expressed recombinant enzyme. We have also generated a homology-based model of
      <italic>
       Xc
      </italic>
      ACE using the structure of tACE to understand the interactions of residues in the active site. This ACE-like enzyme in
      <italic>
       X. citri
      </italic>
      is, to our knowledge, the first bacterial ACE-like enzyme ever characterized.
     </p>
    </sec>
    <sec>
     <label>
      2
     </label>
     <title>
      Materials and methods
     </title>
     <sec>
      <label>
       2.1
      </label>
      <title>
       <italic>
        In silico
       </italic>
       analysis
      </title>
      <p>
       The protein sequence of the leech ACE (
       <italic>
        Tt
       </italic>
       ACE, Genbank accession no.
       <bold>
        <underline>
         45272589
        </underline>
       </bold>
       ), the most distant known ACE characterized at the time of the present study, was submitted to similarity searches using the BLAST program suite (tblastn; default parameters) (
       <ext-link ext-link-type="uri" xlink:href="http://www.nih.nlm.ncbi.gov/blast">
        http://www.nih.nlm.ncbi.gov/blast
       </ext-link>
       ) against all bacterial genomic sequences available at the NCBI server at the time of the study. Alignments were performed using the ClustalW (default parameters) software (
       <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/clustalw/">
        http://www.ebi.ac.uk/clustalw/
       </ext-link>
       ). The distance matrix generated into the tree file of ClustalW was used in the drawtree program of the PHYLIP suite and an unrooted tree diagram was generated (
       <ext-link ext-link-type="uri" xlink:href="http://bioweb.pasteur.fr/seqanal/interfaces/drawtree-simple">
        http://bioweb.pasteur.fr/seqanal/interfaces/drawtree-simple
       </ext-link>
       ).
      </p>
     </sec>
     <sec>
      <label>
       2.2
      </label>
      <title>
       Bacterial strain
      </title>
      <p>
       <italic>
        X. citri
       </italic>
       strain N1 was from the culture collection of the Laboratory of Plant Pathology, Faculty of Agriculture, Shizuoka University, Shizuoka, Japan (
       <xref ref-type="bibr" rid="bib36">
        Talaga et al., 1996
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <label>
       2.3
      </label>
      <title>
       DNA extraction
      </title>
      <p>
       Bacterial DNA was obtained as previously described (
       <xref ref-type="bibr" rid="bib9">
        Davis et al., 1980
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec1">
      <label>
       2.4
      </label>
      <title>
       RNA extraction
      </title>
      <p>
       Total RNA was extracted using the SV total RNA isolation system (Promega).
      </p>
     </sec>
     <sec>
      <label>
       2.5
      </label>
      <title>
       Protein extraction
      </title>
      <p>
       <italic>
        X. citri
       </italic>
       was cultured in YP medium under agitation at 30 °C until an optical density of 0.3 at 620 nm and centrifuged (5000 ×
       <italic>
        g
       </italic>
       , 30 min). Cells were washed in water, centrifuged, and the pellet resuspended in water in one hundredth of the culture volume. The resulting suspension was passed twice through a French pressure cell at 15,000 lb/in.
       <sup>
        2
       </sup>
       (10
       <sup>
        8
       </sup>
       Pa) and unbroken cells and debris were removed by 5 min centrifugation at 5000 ×
       <italic>
        g
       </italic>
       .
      </p>
     </sec>
     <sec>
      <label>
       2.6
      </label>
      <title>
       RT-PCR
      </title>
      <p>
       To assess the presence of a messenger RNA correponding to the
       <italic>
        XcACE
       </italic>
       gene, total RNAs (30–40 ng) were treated with RNAse-free DNAse I and reverse transcribed with Superscript III Reverse Transcriptase (Invitrogen). The same amount of nucleic acids (170 ng) was further used in PCR reactions containing 2% DMSO using XcInt-S1 (5′-GCTGCAGCAGATCCCACAGA-3′) and XcInt-AS1 (5′-CTATTGCGTGGGCGTAGGC-3′) as primers. Water was used instead of cDNA as a negative control. PCR products were resolved on an agarose gel stained with ethidium bromide.
      </p>
     </sec>
     <sec>
      <label>
       2.7
      </label>
      <title>
       Cloning of
       <italic>
        Xc
       </italic>
       ACE, construction of the p
       <italic>
        Xc
       </italic>
       ACE vector and expression in mammalian cell cultures
      </title>
      <sec id="sec2">
       <label>
        2.7.1
       </label>
       <title>
        Cloning
       </title>
       <p>
        Full-length
        <italic>
         XcACE
        </italic>
        cDNA sequence (
        <ext-link ext-link-type="gen" xlink:href="NP641553">
         NP 641553
        </ext-link>
        ; GenBank accession no. gi:
        <bold>
         <underline>
          21241971
         </underline>
        </bold>
        ) was obtained by PCR on
        <italic>
         X. citri
        </italic>
        DNA (see
        <xref ref-type="sec" rid="sec1">
         Section 2.4
        </xref>
        ). Sense and antisense primers (
        <italic>
         XcACE
        </italic>
        FL-S1 5′-CTGACCTATTCGGATGCGCTCAAGGAT-3′ and
        <italic>
         XcACE
        </italic>
        FL-AS2 5′-CTCTAGCCTTCGGCGGACTTCACTGCAAAGGAC-3′) were used (2 pmol each) in a PCR reaction containing 400 ng DNA, 2% DMSO, 20 μM dNTPs, 5 U
        <italic>
         Pfu
        </italic>
        DNA polymerase (Promega) in 50 μL total volume. Reaction cycling parameters were 94 °C, 3 min; 94 °C, 40 s, 61 °C, 1 min, 72 °C, 4 min for 35 cycles. The expected 2.2 kb product was blunt-end subcloned into the EcoRV site of pcDNA3.1 (Invitrogen) and sequenced with
        <italic>
         XcACE
        </italic>
        and pcDNA3 specific primers.
       </p>
      </sec>
      <sec>
       <label>
        2.7.2
       </label>
       <title>
        Construct
       </title>
       <p>
        Heterologous expression of
        <italic>
         Xc
        </italic>
        ACE was carried out using mammalian CHO-K1 cells (Invitrogen). Because the start codon is GTG for
        <italic>
         XcACE
        </italic>
        , it was necessary to change it into the standard ATG, a sequence recognized as an initiation codon by CHO-K1 cells. This substitution mutation (T11A) was realised by PCR using the
        <italic>
         Xc
        </italic>
        FLAS2.2 (5′-GCT CTA GCC TTC GGC GGA CTT CAA TGC AAG-3′) antisense oligonucleotide and resulted in an in-frame ATG initiation codon. The PCR product was subcloned in pcDNA3.1 and the obtained p
        <italic>
         XcACE
        </italic>
        plasmid sequenced as described above (see
        <xref ref-type="sec" rid="sec2">
         Section 2.7.1
        </xref>
        ).
       </p>
      </sec>
      <sec>
       <label>
        2.7.3
       </label>
       <title>
        Expression
       </title>
       <p>
        CHO-K1 cells were stably transfected with p
        <italic>
         XcACE
        </italic>
        using lipofectamine 2000 reagent (Invitrogen), and were selected for resistance to Geneticin. Individual resistant colonies producing large amounts of
        <italic>
         Xc
        </italic>
        ACE were cloned by limiting dilution techniques as described (
        <xref ref-type="bibr" rid="bib43">
         Wei et al., 1991b
        </xref>
        ).
       </p>
      </sec>
     </sec>
     <sec>
      <label>
       2.8
      </label>
      <title>
       Biochemical characterization of
       <italic>
        Xc
       </italic>
       ACE
      </title>
      <sec id="sec3">
       <label>
        2.8.1
       </label>
       <title>
        Semi-purification
       </title>
       <p>
        Both native and recombinant
        <italic>
         Xc
        </italic>
        ACE were partially purified by ion exchange chromatography. Briefly, native
        <italic>
         Xc
        </italic>
        ACE was obtained from bacterial protein extract, and secreted recombinant
        <italic>
         Xc
        </italic>
        ACE from concentrated culture medium of transfected CHO cells (fraction A). The fraction A samples were first desalted on a HiPrep Fast Desalting Column (Amersham Pharmacia Biotech), then fractionated onto a FPLC MonoQ anion-exchange column system (Pharmacia). The resulting fractions showing specific ACE activity were pooled and concentrated. The resulting fractions were named native
        <italic>
         Xc
        </italic>
        ACE (n
        <italic>
         Xc
        </italic>
        ACE) and recombinant
        <italic>
         Xc
        </italic>
        ACE (r
        <italic>
         Xc
        </italic>
        ACE), respectively. For n
        <italic>
         Xc
        </italic>
        ACE purification steps, each pooled fractions containing specific ACE activity were analysed by SDS-PAGE.
       </p>
      </sec>
      <sec>
       <label>
        2.8.2
       </label>
       <title>
        Western blot
       </title>
       <p>
        Both n
        <italic>
         Xc
        </italic>
        ACE and r
        <italic>
         Xc
        </italic>
        ACE (see
        <xref ref-type="sec" rid="sec3">
         Section 2.8.1
        </xref>
        ) were submitted to western blot experiment using a polyclonal antibody (HKCE) raised against the human full-length sACE.
       </p>
      </sec>
      <sec>
       <label>
        2.8.3
       </label>
       <title>
        Enzymatic assays
       </title>
       <p>
        ACE activity was assayed using various substrates: HHL (5 mM), as a human ACE C-domain specific substrate, AcSDAcKP (Acetyl-Serine-Aspartyl-Acetyl-Lysine-Proline) (2.5 mM), as an N-domain specific substrate, Ang I (100 μM), as both an N- and a C-domain ACE substrate. Assays were performed at 37 °C for 30 or 60 min. Hydrolysis of [Leu5]-enkephalinamide ([Leu5]-enk-NH2) (0.8 mM, incubated for 330 min), as an amidated substrate and [Leu5]-enkephalin ([Leu5]-enk) (0.8 mM, incubated for 30 min), were compared to determine whether
        <italic>
         Xc
        </italic>
        ACE also exhibits endopeptidase activity. The rate of hydrolysis of all substrates used was determined and quantified using reverse phase HPLC (Waters Co, Milford, MA, USA) as previously described (
        <xref ref-type="bibr" rid="bib1">
         Azizi et al., 2000
        </xref>
        ,
        <xref ref-type="bibr" rid="bib20">
         Houard et al., 1998
        </xref>
        ,
        <xref ref-type="bibr" rid="bib43">
         Wei et al., 1991b
        </xref>
        ). The specificity of the reaction was assessed in the presence of 10 μM captopril. The effect of chloride ions (NaCl concentrations from 0 to 1.0 M) on HHL hydrolysis was determined under standard conditions.
       </p>
      </sec>
      <sec>
       <label>
        2.8.4
       </label>
       <title>
        Inhibition of
        <italic>
         Xc
        </italic>
        ACE activity by various ACE inhibitors
       </title>
       <p>
        The inhibition potentials of various tight binding ACE inhibitors (captopril, delaprilat, fosinoprilat, lisinopril, perindoprilat, RXP 407 and enalaprilat) were assessed by determining the IC
        <sub>
         50
        </sub>
        values for the fluorogenic substrate Mca-Ala-Ser-Asp-Lys-DpaOH hydrolysis in standard conditions as described previously (
        <xref ref-type="bibr" rid="bib13">
         Dive et al., 1999
        </xref>
        ). Compounds were pre-incubated with n
        <italic>
         Xc
        </italic>
        ACE (see
        <xref ref-type="sec" rid="sec3">
         Section 2.8.1
        </xref>
        ) for 1 h and reactions initiated by the addition of 12 μM substrate.
       </p>
      </sec>
     </sec>
     <sec>
      <label>
       2.9
      </label>
      <title>
       Modelling of
       <italic>
        Xc
       </italic>
       ACE
      </title>
      <p>
       A model of
       <italic>
        Xc
       </italic>
       ACE was generated by the ESyPred3D server (
       <ext-link ext-link-type="uri" xlink:href="http://www.fundp.ac.be/sciences/biologie/urbm/bioinfo/esypred/">
        http://www.fundp.ac.be/sciences/biologie/urbm/bioinfo/esypred/
       </ext-link>
       ) (
       <xref ref-type="bibr" rid="bib26">
        Lambert et al., 2002
       </xref>
       ) using testis ACE (ProteinDataBank pdb code
       <bold>
        <underline>
         1O8A
        </underline>
       </bold>
       ) as a model. This model was compared with the testis ACE structures (
       <xref ref-type="bibr" rid="bib32">
        Natesh et al., 2003
       </xref>
       ,
       <xref ref-type="bibr" rid="bib31">
        Natesh et al., 2004
       </xref>
       ) and the N-domain structure (
       <xref ref-type="bibr" rid="bib6">
        Corradi et al., 2006
       </xref>
       ) and AnCE (
       <xref ref-type="bibr" rid="bib20">
        Houard et al., 1998
       </xref>
       ) using the program Coot (
       <xref ref-type="bibr" rid="bib16">
        Emsley and Cowtan, 2004
       </xref>
       ). Figures were generated with Pymol (
       <xref ref-type="bibr" rid="bib11">
        DeLano, 2002
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <label>
       2.10
      </label>
      <title>
       <italic>
        Xc
       </italic>
       ACE activity during bacterial growth
      </title>
      <p>
       To examine
       <italic>
        Xc
       </italic>
       ACE localization, ACE activity in medium and in bacterial extracts was monitored along during bacterial growth using HHL as substrate as described above.
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <sec>
      <label>
       3.1
      </label>
      <title>
       Presence of ACE orthologues in bacterial genomes
      </title>
      <p>
       Among 465 bacterial strains genomes screened, 26 sequences produced significant similarity (
       <italic>
        E
       </italic>
       value &lt; 0.5) with leech
       <italic>
        Tt
       </italic>
       ACE. Further analysis revealed that at least 22 sequences within 19 different bacterial strains within 8 generas potentially encode putative ACE-like enzymes. These species are ecologically as well as phylogenetically distant, since they are found amongst Cyanobacteria (
       <italic>
        Gloeobacter violaceus
       </italic>
       , gi:
       <bold>
        <underline>
         37522712
        </underline>
       </bold>
       , gi:
       <bold>
        <underline>
         35213714
        </underline>
       </bold>
       ), Acidobacteria (
       <italic>
        Solibacter usitatus
       </italic>
       , gi:
       <bold>
        <underline>
         67858770
        </underline>
       </bold>
       , gi:
       <bold>
        <underline>
         66769433
        </underline>
       </bold>
       ) and Proteobacteria of the subdivision alpha (
       <italic>
        Erythrobacter litoralis
       </italic>
       , gi:
       <bold>
        <underline>
         61100845
        </underline>
       </bold>
       , gi:
       <bold>
        <underline>
         60736774
        </underline>
       </bold>
       ), delta (
       <italic>
        Anaeromyxobacter dehalogenans
       </italic>
       , gi:
       <bold>
        <underline>
         66855040
        </underline>
       </bold>
       ) and gamma (
       <italic>
        X. citri
       </italic>
       , gi:
       <bold>
        <underline>
         21241971
        </underline>
       </bold>
       , gi:
       <bold>
        <underline>
         21107345
        </underline>
       </bold>
       ;
       <italic>
        Xanthomonas oryzae
       </italic>
       , gi:
       <bold>
        <underline>
         37931607
        </underline>
       </bold>
       , gi:
       <bold>
        <underline>
         58583162
        </underline>
       </bold>
       ;
       <italic>
        Xanthomonas campestris pv campestris
       </italic>
       , gi:
       <bold>
        <underline>
         21230574
        </underline>
       </bold>
       , gi:
       <bold>
        <underline>
         21112152
        </underline>
       </bold>
       ;
       <italic>
        Shewanella oneidensis
       </italic>
       , gi:
       <bold>
        <underline>
         24374038
        </underline>
       </bold>
       , gi:
       <bold>
        <underline>
         24348510
        </underline>
       </bold>
       ) proteobacteria. All these predicted proteins share between 38 and 98% primary sequence identity between them, indicating a wide variety among the potential bacterial ACEs (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       and
       <xref ref-type="sec" rid="app1">
        Supplementary data
       </xref>
       ). Nevertheless, all these sequences exhibit key ACE features such as the presence of two highly conserved consensus VCHASAWDFY and GANPGFHEA motifs surrounding a putative M2-catalytic site HexxH (data not shown).
       <fig id="fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Homology of the bacterial ACE related to various ACEs in the phylogenetic tree. (A): Percentage of identity in amino acids between
          <italic>
           Xc
          </italic>
          ACE and various ACE-like enzymes primary sequences described or deduced from genomic sequences: Ndom, human N-domain ACE (gi:
          <bold>
           <underline>
            4732026
           </underline>
          </bold>
          , residues 1–583); Cdom, human C-domain ACE (gi:
          <bold>
           <underline>
            4732026
           </underline>
          </bold>
          , residues 641–1306); ACE2, human ACE2 (gi:
          <bold>
           <underline>
            71658783
           </underline>
          </bold>
          ); ACEr,
          <italic>
           Drosophila melanogaster
          </italic>
          ACEr (gi:
          <bold>
           <underline>
            73921650
           </underline>
          </bold>
          ); X camp,
          <italic>
           Xanthomonas campestris
          </italic>
          pv.
          <italic>
           campestris
          </italic>
          predicted dipeptidyl-carboxypeptidase (gi:
          <bold>
           <underline>
            66769433
           </underline>
          </bold>
          ); E lito,
          <italic>
           Erythrobacter litoralis
          </italic>
          predicted dipeptidyl-carboxypeptidase (gi:
          <bold>
           <underline>
            61100845
           </underline>
          </bold>
          ); G viol,
          <italic>
           Gloeobacter violaceus
          </italic>
          predicted dipeptidyl-carboxypeptidase (gi:
          <bold>
           <underline>
            37522712
           </underline>
          </bold>
          ). (B): unrooted cladogram indicating evolutionary relationships between the different ACE homologues among the living kingdom.
         </p>
        </caption>
        <graphic xlink:href="gr1">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.2
      </label>
      <title>
       Molecular characterization of
       <italic>
        Xc
       </italic>
       ACE
      </title>
      <p>
       We cloned an ACE homologue in the phytopathogenic bacterium
       <italic>
        X. citri
       </italic>
       corresponding to the sequence
       <ext-link ext-link-type="gen" xlink:href="XAC1217">
        XAC1217
       </ext-link>
       (gi:
       <bold>
        <underline>
         21107356
        </underline>
       </bold>
       , gene ID
       <bold>
        <underline>
         1155288
        </underline>
       </bold>
       ). The transcription of the
       <italic>
        XcACE
       </italic>
       gene was suggested by the sequence conservation upstream the start codon and is assessed by the presence of a specific 437-bp RT-PCR product in DNAse-treated, reverse-transcribed total RNA (
       <xref ref-type="fig" rid="fig2">
        Fig. 2
       </xref>
       ). The protein encoded by this gene, referred to as
       <italic>
        Xc
       </italic>
       ACE (
       <italic>
        Xanthomonas citri
       </italic>
       angiotensin-converting enzyme), is a 672 amino-acid protein. Hydrophobicity profile (SignalP V1.1 at
       <ext-link ext-link-type="uri" xlink:href="http://www.cbs.dtu.dk/services/SignalP">
        www.cbs.dtu.dk/services/SignalP
       </ext-link>
       ) indicates cleavage of a putative signal peptide between residues 26 and 27 of the native protein (…RDA↕AP…). There does not appear to be a motif encoding a transmembrane domain at the C-terminus or elsewhere in the mature molecule, suggesting that
       <italic>
        Xc
       </italic>
       ACE should exist only in a soluble form. Because of the mutation inserted, the recombinant proenzyme is slightly different from the native one in the N-terminal end (r
       <italic>
        Xc
       </italic>
       ACE: MQGPPVNPRLL
       <italic>
        vs
       </italic>
       n
       <italic>
        Xc
       </italic>
       ACE: MNPRLL). However, this difference does not change predictions about the signal peptide (hydrophobicity profile and cleavage site) (data not shown), indicating that the mature recombinant and native proteins have identical primary sequences. The mature enzyme has a theoretical molecular weight of 72 kDa and an isoelectric point of 5.72. Its primary structure includes all the residues implied in zinc (H
       <sup>
        429
       </sup>
       , H
       <sup>
        433
       </sup>
       and E
       <sup>
        457
       </sup>
       ), lisinopril (H
       <sup>
        391
       </sup>
       , A
       <sup>
        392
       </sup>
       , E
       <sup>
        430
       </sup>
       , K
       <sup>
        556
       </sup>
       , H
       <sup>
        558
       </sup>
       , Y
       <sup>
        565
       </sup>
       and Y
       <sup>
        568
       </sup>
       ) (
       <xref ref-type="bibr" rid="bib32">
        Natesh et al., 2003
       </xref>
       ) and captopril (Q
       <sup>
        290
       </sup>
       , K
       <sup>
        556
       </sup>
       , Y
       <sup>
        565
       </sup>
       , H
       <sup>
        391
       </sup>
       , H
       <sup>
        558
       </sup>
       and Y
       <sup>
        568
       </sup>
       ) (
       <xref ref-type="bibr" rid="bib31">
        Natesh et al., 2004
       </xref>
       ) binding. Thus the soluble, secreted enzyme should possess a single active site like the other ACEs found in invertebrates. Whereas two chloride atoms were observed bound to the human tACE,
       <italic>
        Xc
       </italic>
       ACE appears to be more similar to the N-domain in this respect, as it only has the chloride II binding site conserved (Y
       <sup>
        230
       </sup>
       and R
       <sup>
        567
       </sup>
       ), and only one amino acid among the three implicated in the binding of the first chloride atom (W
       <sup>
        530
       </sup>
       ). The
       <italic>
        Xc
       </italic>
       ACE primary sequence has between 31 and 37% identity with the other known ACEs (human,
       <italic>
        Drosophila
       </italic>
       and leech) and 26% with
       <italic>
        C. elegans
       </italic>
       ACN-1 (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       and
       <xref ref-type="sec" rid="app1">
        Supplementary data
       </xref>
       ).
       <fig id="fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          RT-PCR assay of the
          <italic>
           Xc
          </italic>
          ACE transcript. cDNA was generated and submitted to PCR (cycling parameters: 94 °C, 2 min; 94 °C, 45 s, 61 °C, 30 s, 72 °C, 1 min, for 25, 30 or 40 cycles, 72 °C, 4 min).Treatments of the different samples are indicated above the corresponding lane. The size of the expected band is indicated. L: DNA molecular weight marker, W: water control. The number of PCR cycles is indicated under each sample.
         </p>
        </caption>
        <graphic xlink:href="gr2">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.3
      </label>
      <title>
       Biochemical characterization of
       <italic>
        Xc
       </italic>
       ACE
      </title>
      <sec>
       <label>
        3.3.1
       </label>
       <title>
        Semi-purification
       </title>
       <p>
        The semi-purification of
        <italic>
         Xc
        </italic>
        ACE procedure using FPLC (
        <xref ref-type="fig" rid="fig3">
         Fig. 3
        </xref>
        A) resulted in a fraction containing a protein band at the expected size for
        <italic>
         Xc
        </italic>
        ACE (∼ 75 kDa), as revealed by SDS-PAGE analysis of the different fractions obtained after each purification step (data not shown).
        <fig id="fig3">
         <label>
          Fig. 3
         </label>
         <caption>
          <p>
           Semi-purification and Western blot of
           <italic>
            Xc
           </italic>
           ACE. (A): FPLC profile of the last purification step (see
           <xref ref-type="sec" rid="sec3">
            Section 2.8.1
           </xref>
           ), absorbance at 280 nm (full line), the gradient (dashed line) was from 0 to 50 mS/cm, arbitrary units of ACE activity (dotted line), the horizontal bar indicates the fractions pooled for further analysis. (B): Native and recombinant
           <italic>
            Xc
           </italic>
           ACE were analysed by SDS-PAGE followed by Western blot with the antiserum
           <italic>
            HKCE
           </italic>
           . Lane a, molecular-mass standards; lane b, human somatic ACE; lane c, native
           <italic>
            XcACE
           </italic>
           ; lane d, recombinant
           <italic>
            XcACE.
           </italic>
           The band corresponding to XcACE is indicated (arrow).
          </p>
         </caption>
         <graphic xlink:href="gr3">
         </graphic>
        </fig>
       </p>
      </sec>
      <sec>
       <label>
        3.3.2
       </label>
       <title>
        Immunological characterization
       </title>
       <p>
        Both native and recombinant
        <italic>
         Xc
        </italic>
        ACE were analysed by Western blotting and migrated with an apparent molecular weight of 72 kDa, matching theoretical predictions (
        <xref ref-type="fig" rid="fig3">
         Fig. 3
        </xref>
        B), and have a similar mobility on SDS-PAGE to deglycosylated human tACE (
        <xref ref-type="bibr" rid="bib47">
         Yu et al., 1997
        </xref>
        ).
       </p>
      </sec>
      <sec>
       <label>
        3.3.3
       </label>
       <title>
        Enzymatic activity
       </title>
       <p>
        <italic>
         Xc
        </italic>
        ACE shows dipeptidyl-carboxypeptidase activity, cleaving a carboxyterminal dipeptide from peptidic substrates. It generates AngII from AngI (
        <xref ref-type="fig" rid="fig4">
         Fig. 4
        </xref>
        A), hippuric acid from HHL (
        <xref ref-type="fig" rid="fig4">
         Fig. 4
        </xref>
        B), AcKP from AcSDAcKP (
        <xref ref-type="fig" rid="fig4">
         Fig. 4
        </xref>
        C), and Tyrosyl-glycyl-glycine (YGG) from Leu-enkephalin (data not shown).
        <italic>
         Xc
        </italic>
        ACE also displays an endopeptidase activity, as shown by its ability to hydrolyse the amidated substrate, Leu-enk-NH2 (
        <xref ref-type="fig" rid="fig4">
         Fig. 4
        </xref>
        D). As for AngI hydrolysis (
        <xref ref-type="fig" rid="fig4">
         Fig. 4
        </xref>
        E), the same results were obtained with recombinant
        <italic>
         Xc
        </italic>
        ACE (data not shown).
        <italic>
         Xc
        </italic>
        ACE activity depends on zinc binding. Indeed, hydrolysis of Mca-SDKP-DpaOH was abolished after zinc chelation with EDTA and dialysis but was restored by zinc addition (data not shown).
        <fig id="fig4">
         <label>
          Fig. 4
         </label>
         <caption>
          <p>
           Biochemical characterization of
           <italic>
            Xc
           </italic>
           ACE. Hydrolysis of various ACE substrates by native (n
           <italic>
            Xc
           </italic>
           ACE) (A–D) and recombinant (r
           <italic>
            Xc
           </italic>
           ACE) (E). Hydrolysis of angiotensin I (A), hydrolysis of HHL (B), AcSDAcKP (C), [Leu5]-enkephalin (D) and [Leu5]-enkephalinamide (E) by native
           <italic>
            Xc
           </italic>
           ACE. Hydrolysis of angiotensin I by recombinant XcACE (F). The specificity of the reactions was assessed in the presence of 10 μM captopril (dashed line). AngI, angiotensin I; AngII, angiotensin II; AH, hippuric acid; YGG, tyrosyl-glycyl-glycine. Chloride sensitivity of
           <italic>
            Xc
           </italic>
           ACE (F). Effect of chloride ions concentration on HHL hydrolysis by native (◇)
           <italic>
            Xc
           </italic>
           ACE, C-(ж) and N-domain (▲) of human somatic ACE.
          </p>
         </caption>
         <graphic xlink:href="gr4">
         </graphic>
        </fig>
       </p>
      </sec>
      <sec>
       <label>
        3.3.4
       </label>
       <title>
        Effect of chloride concentration
       </title>
       <p>
        Native
        <italic>
         Xc
        </italic>
        ACE is already active in the absence of chloride ions. However, its activity in the presence of increasing chloride ion concentrations increases 3-fold. In this respect,
        <italic>
         Xc
        </italic>
        ACE Cl
        <sup>
         −
        </sup>
        activation presents intermediate characteristics when compared to both N- and C-domain human ACE (
        <xref ref-type="bibr" rid="bib34">
         Riviere et al., 2004
        </xref>
        ). (
        <xref ref-type="fig" rid="fig4">
         Fig. 4
        </xref>
        F).
       </p>
      </sec>
      <sec>
       <label>
        3.3.5
       </label>
       <title>
        Effect of ACE inhibitors
       </title>
       <p>
        Fosinoprilat is the most potent inhibitor of
        <italic>
         Xc
        </italic>
        ACE activity (IC
        <sub>
         50
        </sub>
        : 3.0 · 10
        <sup>
         − 8
        </sup>
        ± 1.0 · 10
        <sup>
         − 8
        </sup>
        M), whereas captopril is less efficient (1.6 · 10
        <sup>
         − 7
        </sup>
        ± 0.1 · 10
        <sup>
         − 7
        </sup>
        M). RXP 407 (1.9 · 10
        <sup>
         − 6
        </sup>
        ± 1.5 · 10
        <sup>
         − 6
        </sup>
        M) and Enalaprilat (3.8 · 10
        <sup>
         − 6
        </sup>
        ± 2.8 · 10
        <sup>
         − 6
        </sup>
        M) displayed IC
        <sub>
         50
        </sub>
        values in the micromolar range. Perindoprilat (1.3 · 10
        <sup>
         − 4
        </sup>
        ± 1.3 · 10
        <sup>
         − 4
        </sup>
        M), delaprilat (3.7 · 10
        <sup>
         − 5
        </sup>
        ± 1.7 · 10
        <sup>
         − 5
        </sup>
        M) and lisinopril (4.7 · 10
        <sup>
         − 5
        </sup>
        ± 4.3 · 10
        <sup>
         − 5
        </sup>
        M), all containing carboxylate zinc-binding groups, were the least effective inhibitors of
        <italic>
         Xc
        </italic>
        ACE. Values are means ± standard error from three independent experiments.
       </p>
      </sec>
     </sec>
     <sec>
      <label>
       3.4
      </label>
      <title>
       Predicted structure of
       <italic>
        Xc
       </italic>
       ACE
      </title>
      <p>
       As the crystal structures of human ACE (
       <xref ref-type="bibr" rid="bib6">
        Corradi et al., 2006
       </xref>
       ,
       <xref ref-type="bibr" rid="bib32">
        Natesh et al., 2003
       </xref>
       ), ACE2 (
       <xref ref-type="bibr" rid="bib40">
        Towler et al., 2004
       </xref>
       ) and the
       <italic>
        Drosophila
       </italic>
       AnCE (
       <xref ref-type="bibr" rid="bib25">
        Kim et al., 2003
       </xref>
       ) all have the same fold, the 34% sequence identity of human tACE and bacterial
       <italic>
        Xc
       </italic>
       ACE allowed us to model with confidence the overall fold of
       <italic>
        Xc
       </italic>
       ACE based on the tACE structure (pdb code
       <bold>
        <underline>
         1O8A
        </underline>
       </bold>
       ). We identified active site residues that could account for the differences in inhibitor affinities (see
       <xref ref-type="sec" rid="sec4">
        Section 4.2
       </xref>
       ) (
       <xref ref-type="fig" rid="fig5">
        Fig. 5
       </xref>
       ).
       <fig id="fig5">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Comparison of the charge of the active site between tACE and
          <italic>
           Xc
          </italic>
          ACE. ACE is represented as a surface with the positive charge indicated in blue and the negative in red. The zinc atom is represented (green), and some of the residues are indicated. Lisinopril (in yellow) is shown to orientate the active site. A, The active site viewed as a surface from the lysyl pocket for tACE (left) and XcACE (right). B, The active site cavity viewed from the outside for tACE (left) and XcACE (right). tACE is shown to have a higher negative charge in the lysyl binding pocket.
         </p>
        </caption>
        <graphic xlink:href="gr5_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.5
      </label>
      <title>
       <italic>
        Xc
       </italic>
       ACE expression during bacterial growth and localization
      </title>
      <p>
       Only background ACE activity was detected in the culture medium, which remains constant over time. In contrast, ACE activity in bacterial extract correlates bacterial growth indicating that
       <italic>
        Xc
       </italic>
       ACE is constituvely expressed and is likely to be secreted and further localised in the periplasmic space (
       <xref ref-type="fig" rid="fig6">
        Fig. 6
       </xref>
       ).
       <fig id="fig6">
        <label>
         Fig. 6
        </label>
        <caption>
         <p>
          <italic>
           Xc
          </italic>
          ACE activity during bacterial growth. Follow-up of bacterial growth by O.D. at 600 nm (◇) and ACE activity (nmoles hippuric acid generated) in culture medium (□) and within bacteria (○). Error bars were omitted for clarity.
         </p>
        </caption>
        <graphic xlink:href="gr6">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <sec>
      <label>
       4.1
      </label>
      <title>
       ACE is an ancestral enzyme
      </title>
      <p>
       Databank analysis revealed the presence of putative ACE-encoding genomic DNA sequences in a very wide range of bacterial species, corresponding to a broad range of ecological lifestyles and terminal electron acceptor for growth (
       <xref ref-type="bibr" rid="bib12">
        DeLong and Pace, 2001
       </xref>
       ), suggesting that ACE is an ancestral enzyme. Characterization of
       <italic>
        Xc
       </italic>
       ACE constitutes the first evidence of the presence of an ACE-like enzyme in more distant organisms than cellular metazoans. Indeed, in contrast to
       <italic>
        Xc
       </italic>
       ACE, the amino-acid sequence of
       <italic>
        L. donovani
       </italic>
       dicarboxypeptidase (LdDCP) (
       <xref ref-type="bibr" rid="bib18">
        Goyal et al., 2005
       </xref>
       ) does not show any significant alignment with all other known ACEs, was not reported to hydrolyse Ang I to Ang II, and lacks conserved consensus motifs found in almost all ACE primary sequences (for references see the MEROPS database available at
       <ext-link ext-link-type="uri" xlink:href="http://merops.sanger.ac.uk/">
        http://merops.sanger.ac.uk/
       </ext-link>
       ). However, in contrast with
       <italic>
        Leishmania
       </italic>
       , none of the bacterial species putatively possessing an ACE mentioned in this study is known to be a human pathogen, whereas xanthomonadacaea are phytopathogens among which
       <italic>
        X. citri
       </italic>
       was chosen for technical reasons.
      </p>
     </sec>
     <sec id="sec4">
      <label>
       4.2
      </label>
      <title>
       Structure–activity relationship of
       <italic>
        Xc
       </italic>
       ACE, a functional angiotensin-converting enzyme
       <italic>
        in vivo
       </italic>
      </title>
      <p>
       The
       <italic>
        Xc
       </italic>
       ACE possesses a single M2 catalytic site and a signal peptide but no membrane anchor, like the ACE characterized in invertebrates. Despite the fact that the recombinant enzyme was expressed in a heterologous system, both native and recombinant forms display almost identical features, indicating a satisfactory purity of
       <italic>
        Xc
       </italic>
       ACE and strongly suggesting that the ACE in
       <italic>
        X. citri
       </italic>
       is a functional ACE enzyme
       <italic>
        in vivo
       </italic>
       .
       <italic>
        Xc
       </italic>
       ACE, like
       <italic>
        Drosophila
       </italic>
       AnCE (data not shown), is active in the absence of chloride ions and less sensitive to variations in chloride ion concentration than human C-domain ACE (
       <xref ref-type="bibr" rid="bib20">
        Houard et al., 1998
       </xref>
       ). This characteristic is likely to be due to the absence in the primary sequence of
       <italic>
        Xc
       </italic>
       ACE, as in AnCE, of two key amino acids observed to bind ClI in human tACE (
       <italic>
        Xc
       </italic>
       ACE : R186H and R489K; AnCE : R1867Y and W485F, when compared to tACE).
       <italic>
        Xc
       </italic>
       ACE hydrolyses a broad range of substrates, including human N- and C-domain ACE specific substrates (AcSDAcKP and HHL, respectively). In addition to this dicarboxypeptidase activity,
       <italic>
        Xc
       </italic>
       ACE also acts as an endopeptidase, hydrolysing the C-terminal blocked amidated substrate [Leu5]-enkephalinamide. Western blot results using polyclonal antibody raised against the full-length human sACE protein show a unique band corresponding to
       <italic>
        Xc
       </italic>
       ACE, indicating that
       <italic>
        Xc
       </italic>
       ACE shares common epitopic features with the human enzyme. Molecular modelling allowed us to visualise the structural differences in the catalytic site. Key active site residues such as the zinc-binding motif, His
       <sup>
        513
       </sup>
       and Tyr
       <sup>
        526
       </sup>
       (tACE numbering) are conserved in
       <italic>
        Xc
       </italic>
       ACE and many other ACE-like enzymes. However, in line with the assay results, the non-conserved active site residues are neither identical to the C- or N-domain of human ACE, and are the presumed cause of the different substrate selectivity and inhibition profile of
       <italic>
        Xc
       </italic>
       ACE. Comparison of the
       <italic>
        Xc
       </italic>
       ACE model with either the human tACE or N-domain shows that lisinopril fits in the
       <italic>
        Xc
       </italic>
       ACE active site and retains most of the same binding interactions. The exception is in the lysyl pocket, which has features in common with AnCE or the human N-domain including a positively charged residue, lysine (equivalent to Arg
       <sup>
        356
       </sup>
       in AnCE and Arg
       <sup>
        350
       </sup>
       in the human N-domain) that appears to affect the overall charge of the pocket (
       <xref ref-type="fig" rid="fig5">
        Fig. 5
       </xref>
       ). Indeed, similar to
       <italic>
        Xc
       </italic>
       ACE, neither AnCE nor the N-domain have as high affinity for lisinopril as tACE (
       <xref ref-type="bibr" rid="bib30">
        Michaud et al., 1997
       </xref>
       ,
       <xref ref-type="bibr" rid="bib45">
        Williams et al., 1996
       </xref>
       ). Furthermore, the difference in affinity of
       <italic>
        Xc
       </italic>
       ACE and tACE for inhibitors with hydrophobic P1 groups (
       <italic>
        i.e.
       </italic>
       lisinopril, delaprilat and perindoprilat) could be attributed to the difference in hydrophobicity of the S1 subsite.
       <italic>
        Xc
       </italic>
       ACE has a threonine and tyrosine in contrast to Phe
       <sup>
        512
       </sup>
       and Val
       <sup>
        518
       </sup>
       in tACE (
       <xref ref-type="fig" rid="fig5">
        Fig. 5
       </xref>
       ). The N-terminal aspartate,
       <italic>
        N
       </italic>
       -acetyl groups and the C-terminal amide of RXP407 are the reported determinants required for its remarkable N-domain specificity (
       <xref ref-type="bibr" rid="bib13">
        Dive et al., 1999
       </xref>
       ). Of the four possible residues suggested for N-domain selective recognition of RXP 407 (
       <xref ref-type="bibr" rid="bib6">
        Corradi et al., 2006
       </xref>
       ,
       <xref ref-type="bibr" rid="bib41">
        Tzakos and Gerothanassis, 2005
       </xref>
       ),
       <italic>
        Xc
       </italic>
       ACE only retains the threonine (T
       <sup>
        496
       </sup>
       in the N-domain) and has a lysine which replaces Arg
       <sup>
        500
       </sup>
       of the N-domain. This, combined with the hydrophobic P1 group, may be the reason that RXP407 is not a strong inhibitor for
       <italic>
        Xc
       </italic>
       ACE. The affinity of
       <italic>
        Xc
       </italic>
       ACE for fosinoprilat is harder to rationalise as it has been modelled in different conformations for the N- and C-domains of human ACE (
       <xref ref-type="bibr" rid="bib41">
        Tzakos and Gerothanassis, 2005
       </xref>
       ). However,
       <italic>
        Xc
       </italic>
       ACE retains all the residues suggested to be involved in inhibitor binding with both domains of human ACE.
      </p>
     </sec>
     <sec>
      <label>
       4.3
      </label>
      <title>
       Putative physiological roles
      </title>
      <p>
       The biological functions of
       <italic>
        Xc
       </italic>
       ACE remain unclear but could constitute the original, ancestral function of ACE.
       <italic>
        Xc
       </italic>
       ACE is soluble and its sequence exhibits a signal peptide indicating, along with the absence of ACE activity in the culture medium, that
       <italic>
        Xc
       </italic>
       ACE is a secreted enzyme which is trapped into the periplasmic space. The constitutive expression could indicate an important function for ACE in
       <italic>
        X. citri
       </italic>
       , as a possible role for the enzyme in peptidoglycan remodelling, a critical parameter in environmental adaptation. This is in line with the characterization in the periplasm of other gram negative bacteria of VanX
       <sc>
        d
       </sc>
       -alanyl-
       <sc>
        d
       </sc>
       -alanine dipeptidase, a regulated carboxypeptidase that is responsible for Vancomycin resistance (
       <xref ref-type="bibr" rid="bib28">
        Lessard and Walsh, 1999
       </xref>
       ).
       <italic>
        Xc
       </italic>
       ACE could also participate in
       <italic>
        X.citri
       </italic>
       pathogenicity within the cocktail of degradative enzymes required during plant infection. Interestingly, in this regard, ACE inhibitors are found in hydrolysates of plants sensitive to the “black rot” caused by
       <italic>
        Xanthomonas
       </italic>
       , including rice and soybean (
       <xref ref-type="bibr" rid="bib19">
        He et al., 2005
       </xref>
       ,
       <xref ref-type="bibr" rid="bib46">
        Wu and Ding, 2001
       </xref>
       ). The large number of substrates of
       <italic>
        Xc
       </italic>
       ACE does not exclude a possible function of protein degradation that might generate dipeptides for protein biosynthesis. To this extent, it is interesting to note that ACE is highly expressed in the digestive tract of all metazoan species presenting an active ACE.
      </p>
     </sec>
     <sec>
      <label>
       4.4
      </label>
      <title>
       Evolutionary and phylogenetic aspects
      </title>
      <p>
       One of the most relevant questions raised by this study deals with phylogenetic considerations and evolution of ACE. Its presence in eukarya as well as in bacteria indicates that the enzyme could have appeared before the divergence between these two groups. This strongly suggests that
       <italic>
        Xc
       </italic>
       ACE is the most ancestral present-day representative of ACE characterized to date. However, as all completely sequenced genomes of plants, algaes and mycetes lack ACE, caution should be exercised with this hypothesis. The presence of an ACE-like enzyme in bacteria could also be the result of a horizontal gene transfer from eucaryotic to bacterial species. However, conservation in sequences surrounding the
       <italic>
        ACE
       </italic>
       gene, suggestive of mobile genetic elements, is not observed within 30 kb of the gene in seven distinct bacterial strains (data not shown). Furthermore, the parasitic bacterial species with an ACE-like gene are all hosted by organisms lacking the enzyme. In addition, not all bacterial species with a putative ACE gene are parasitic. Thus, the presence of ACE in bacteria, like the situation encountered in annelids, is unlikely to be related to parasitism, suggesting that bacterial ACE, represented herein by
       <italic>
        Xc
       </italic>
       ACE, corresponds to the ancestral, original enzyme.
      </p>
     </sec>
     <sec>
      <label>
       4.5
      </label>
      <title>
       Ancestral ACE is neither related to the N- nor the C-domain of mammalian ACE
      </title>
      <p>
       <italic>
        Xc
       </italic>
       ACE exhibits a similar primary sequence identity with both N- and C-domains and, although
       <italic>
        Xc
       </italic>
       ACE cleaves the N-domain substrate AcSDAcKP, the N-domain specific inhibitor RXP407 is not a potent inhibitor of
       <italic>
        Xc
       </italic>
       ACE activity. In contrast, lisinopril, a C-domain-related inhibitor, is less efficient than captopril, related to the N-domain, though most of the residues for binding of both are conserved. Thus, from the biochemical and the structural properties of
       <italic>
        Xc
       </italic>
       ACE it is not possible to ascribe this bacterial enzyme to either the mammalian N-or C-domain of human ACE. The primitive ACE would then not be closer to either domain of the mammalian enzyme, in contrast to what was previously suggested (
       <xref ref-type="bibr" rid="bib4">
        Coates et al., 2000
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        Hubert et al., 1991
       </xref>
       ,
       <xref ref-type="bibr" rid="bib27">
        Lattion et al., 1989
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      5
     </label>
     <title>
      Conclusion
     </title>
     <p>
      This work describes the cloning, expression, purification, biochemical characterization, molecular modelling and localization of
      <italic>
       Xc
      </italic>
      ACE, the first ACE-like enzyme in a bacterium,
      <italic>
       X. citri
      </italic>
      . Taken together, our results bring the evidence of the presence of a functional ACE in prokaryotes, in contrast to the previous hypothesis about the latter appearance of ACE during phylogeny. It also appears that sequence/structure conservation of ACE enabled preservation of dipeptidase activity during evolutionary specialisation.
      <italic>
       Xc
      </italic>
      ACE is the most ancestral ACE present-day representative and has features in common to both the N- and the C-domain of mammalian somatic ACE. It is possible that this ancestral ACE was a poorly specialised protease which has acquired its present specialisation over a long evolutionary period. However, the biological function(s) as well as the endogenous substrates and/or inhibitors of bacterial ACE remain to be characterized. To clarify these issues, the use of ACE inhibitors
      <italic>
       in vivo
      </italic>
      and the generation of a mutant bacterial strain lacking ACE may be helpful. Some of these functions of ACE might also be conserved in humans, and their characterization could lead to a better understanding of the evolution of this crucial enzyme.
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="bib1">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azizi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Massien
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Michaud
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         35
        </volume>
        <year>
         2000
        </year>
        <fpage>
         1226
        </fpage>
        <lpage>
         1231
        </lpage>
        <pub-id pub-id-type="pmid">
         10856268
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brooks
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Appleford
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Isaac
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An essential role in moulting and morphogenesis of
         <italic>
          Caenorhabditis elegans
         </italic>
         for ACN-1: a novel member of the angiotensin-converting enzyme family that lacks a metallopeptidase active site
        </article-title>
        <source>
         J Biol. Chem.
        </source>
        <volume>
         278
        </volume>
        <year>
         2003
        </year>
        <fpage>
         52340
        </fpage>
        <lpage>
         52346
        </lpage>
        <pub-id pub-id-type="pmid">
         14559923
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burnham
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Isaac
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Shirras
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The angiotensin-converting enzyme (ACE) gene family of
         <italic>
          Anopheles gambiae
         </italic>
        </article-title>
        <source>
         BMC. Genomics
        </source>
        <volume>
         6
        </volume>
        <year>
         2005
        </year>
        <fpage>
         172
        </fpage>
        <pub-id pub-id-type="pmid">
         16329762
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coates
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Functional conservation of the active sites of human and
         <italic>
          Drosophila
         </italic>
         angiotensin I-converting enzyme
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         39
        </volume>
        <year>
         2000
        </year>
        <fpage>
         8963
        </fpage>
        <lpage>
         8969
        </lpage>
        <pub-id pub-id-type="pmid">
         10913309
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cornell
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cloning and expression of an evolutionary conserved single-domain angiotensin converting enzyme from
         <italic>
          Drosophila melanogaster
         </italic>
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         270
        </volume>
        <year>
         1995
        </year>
        <fpage>
         13613
        </fpage>
        <lpage>
         13619
        </lpage>
        <pub-id pub-id-type="pmid">
         7775412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corradi
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Schwager
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Nchinda
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           E.D.
          </given-names>
         </name>
         <name>
          <surname>
           Acharya
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design
        </article-title>
        <source>
         J Mol. Biol
        </source>
        <volume>
         357
        </volume>
        <year>
         2006
        </year>
        <fpage>
         964
        </fpage>
        <lpage>
         974
        </lpage>
        <pub-id pub-id-type="pmid">
         16476442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Eyries
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Peptidyl dipeptidase A: angiotensin I converting enzyme
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Rawlings
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Woessner
          </surname>
          <given-names>
           F.J.
          </given-names>
         </name>
        </person-group>
        <source>
         , Handbook of Proteolytic Enzymes
        </source>
        <year>
         2004
        </year>
        <publisher-name>
         Academic Press
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <fpage>
         332
        </fpage>
        <lpage>
         346
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib8">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is an essential regulator of heart function
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         417
        </volume>
        <year>
         2002
        </year>
        <fpage>
         822
        </fpage>
        <lpage>
         828
        </lpage>
        <pub-id pub-id-type="pmid">
         12075344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Botstein
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Advanced bacterial genetics
        </chapter-title>
        <source>
         Manual for Genetic Engineering
        </source>
        <year>
         1980
        </year>
        <publisher-name>
         Cold Spring Harbor Laboratory Press
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib10">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deddish
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Marcic
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Jackman
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Skidgel
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme : angiotensin-(1-7) and keto-ACE
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         31
        </volume>
        <year>
         1998
        </year>
        <fpage>
         912
        </fpage>
        <lpage>
         917
        </lpage>
        <pub-id pub-id-type="pmid">
         9535414
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeLano
          </surname>
          <given-names>
           W.L.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos CA USA
        </chapter-title>
        <year>
         2002
        </year>
        <comment>
         <ext-link ext-link-type="uri" xlink:href="http://www.pymol.org">
          http://www.pymol.org
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="bib12">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeLong
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Pace
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Environmental diversity of bacteria and archaea
        </article-title>
        <source>
         Syst. Biol.
        </source>
        <volume>
         50
        </volume>
        <year>
         2001
        </year>
        <fpage>
         470
        </fpage>
        <lpage>
         478
        </lpage>
        <pub-id pub-id-type="pmid">
         12116647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dive
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U.S.A
        </source>
        <volume>
         96
        </volume>
        <year>
         1999
        </year>
        <fpage>
         4330
        </fpage>
        <lpage>
         4335
        </lpage>
        <pub-id pub-id-type="pmid">
         10200262
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
        </article-title>
        <source>
         Circ. Res.
        </source>
        <volume>
         87
        </volume>
        <year>
         2000
        </year>
        <fpage>
         E1
        </fpage>
        <lpage>
         E9
        </lpage>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ekbote
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Coates
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Isaac
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A mosquito (
         <italic>
          Anopheles stephensi
         </italic>
         ) angiotensin I-converting enzyme (ACE) is induced by a blood meal and accumulates in the developing ovary
        </article-title>
        <source>
         FEBS Lett.
        </source>
        <volume>
         455
        </volume>
        <year>
         1999
        </year>
        <fpage>
         219
        </fpage>
        <lpage>
         222
        </lpage>
        <pub-id pub-id-type="pmid">
         10437776
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Emsley
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Cowtan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coot: model-building tools for molecular graphics
        </article-title>
        <source>
         Acta Crystallogr. D. Biol Crystallogr.
        </source>
        <volume>
         60
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2126
        </fpage>
        <lpage>
         2132
        </lpage>
        <pub-id pub-id-type="pmid">
         15572765
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eyries
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased shedding of angiotensin-converting enzyme by a mutation identified in the stalk region
        </article-title>
        <source>
         J Biol. Chem.
        </source>
        <volume>
         276
        </volume>
        <year>
         2001
        </year>
        <fpage>
         5525
        </fpage>
        <lpage>
         5532
        </lpage>
        <pub-id pub-id-type="pmid">
         11076943
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goyal
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Duncan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Selvapandiyan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Debrabant
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baig
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Nakhasi
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cloning and characterization of angiotensin converting enzyme related dipeptidylcarboxypeptidase from
         <italic>
          Leishmania donovani
         </italic>
        </article-title>
        <source>
         Mol. Biochem. Parasitol.
        </source>
        <year>
         2005
        </year>
       </element-citation>
      </ref>
      <ref id="bib19">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           G.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xuan
          </surname>
          <given-names>
           G.D.
          </given-names>
         </name>
         <name>
          <surname>
           Ruan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.H.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Optimization of angiotensin I-converting enzyme (ACE) inhibition by rice dregs hydrolysates using response surface methodology
        </article-title>
        <source>
         J Zhejiang. Univ Sci. B
        </source>
        <volume>
         6
        </volume>
        <year>
         2005
        </year>
        <fpage>
         508
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="pmid">
         15909335
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Houard
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The
         <italic>
          Drosophila melanogaster
         </italic>
         -related angiotensin-I-converting enzymes Acer and Ance—distinct enzymic characteristics and alternative expression during pupal development
        </article-title>
        <source>
         Eur. J. Biochem.
        </source>
        <volume>
         257
        </volume>
        <year>
         1998
        </year>
        <fpage>
         599
        </fpage>
        <lpage>
         606
        </lpage>
        <pub-id pub-id-type="pmid">
         9839949
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Howard
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
         <name>
          <surname>
           Shai
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Langford
          </surname>
          <given-names>
           K.G.
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Bernstein
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transcription of testicular angiotensin-converting enzyme (ACE) is initiated within the 12th intron of the somatic ACE gene
        </article-title>
        <source>
         Mol. Cell Biol
        </source>
        <volume>
         10
        </volume>
        <year>
         1990
        </year>
        <fpage>
         4294
        </fpage>
        <lpage>
         4302
        </lpage>
        <pub-id pub-id-type="pmid">
         2164636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hubert
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Houot
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Soubrier
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene
        </article-title>
        <source>
         J Biol. Chem.
        </source>
        <volume>
         266
        </volume>
        <year>
         1991
        </year>
        <fpage>
         15377
        </fpage>
        <lpage>
         15383
        </lpage>
        <pub-id pub-id-type="pmid">
         1651327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hurst
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rylett
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Isaac
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Shirras
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The drosophila angiotensin-converting enzyme homologue Ance is required for spermiogenesis
        </article-title>
        <source>
         Dev. Biol.
        </source>
        <volume>
         254
        </volume>
        <year>
         2003
        </year>
        <fpage>
         238
        </fpage>
        <lpage>
         247
        </lpage>
        <pub-id pub-id-type="pmid">
         12591244
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jaspard
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Alhenc-Gelas
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         268
        </volume>
        <year>
         1993
        </year>
        <fpage>
         9496
        </fpage>
        <lpage>
         9503
        </lpage>
        <pub-id pub-id-type="pmid">
         7683654
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Yoo
          </surname>
          <given-names>
           O.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of
         <italic>
          Drosophila
         </italic>
         angiotensin I-converting enzyme bound to captopril and lisinopril
        </article-title>
        <source>
         FEBS Lett.
        </source>
        <volume>
         538
        </volume>
        <year>
         2003
        </year>
        <fpage>
         65
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="pmid">
         12633854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Leonard
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           De
          </surname>
          <given-names>
           B.X.
          </given-names>
         </name>
         <name>
          <surname>
           Depiereux
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ESyPred3D: prediction of proteins 3D structures
        </article-title>
        <source>
         Bioinformatics.
        </source>
        <volume>
         18
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1250
        </fpage>
        <lpage>
         1256
        </lpage>
        <pub-id pub-id-type="pmid">
         12217917
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lattion
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Soubrier
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Allegrini
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hubert
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Alhenc-Gelas
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The testicular transcript of the angiotensin I-converting enzyme encodes for the ancestral, non-duplicated form of the enzyme
        </article-title>
        <source>
         FEBS Lett.
        </source>
        <volume>
         252
        </volume>
        <year>
         1989
        </year>
        <fpage>
         99
        </fpage>
        <lpage>
         104
        </lpage>
        <pub-id pub-id-type="pmid">
         2547653
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lessard
          </surname>
          <given-names>
           I.A.
          </given-names>
         </name>
         <name>
          <surname>
           Walsh
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         VanX, a bacterial
         <sc>
          d
         </sc>
         -alanyl-
         <sc>
          d
         </sc>
         -alanine dipeptidase: resistance, immunity, or survival function?
        </article-title>
        <source>
         Proc. Natl Acad. Sci. U.S.A
        </source>
        <volume>
         96
        </volume>
        <year>
         1999
        </year>
        <fpage>
         11028
        </fpage>
        <lpage>
         11032
        </lpage>
        <pub-id pub-id-type="pmid">
         10500118
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Michaud
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Chauvet
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of
         <italic>
          N
         </italic>
         -acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I
        </article-title>
        <source>
         Mol. Pharmacol.
        </source>
        <volume>
         51
        </volume>
        <year>
         1997
        </year>
        <fpage>
         1070
        </fpage>
        <lpage>
         1076
        </lpage>
        <pub-id pub-id-type="pmid">
         9187274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Natesh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Schwager
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Evans
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           E.D.
          </given-names>
         </name>
         <name>
          <surname>
           Acharya
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         43
        </volume>
        <year>
         2004
        </year>
        <fpage>
         8718
        </fpage>
        <lpage>
         8724
        </lpage>
        <pub-id pub-id-type="pmid">
         15236580
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Natesh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Schwager
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           E.D.
          </given-names>
         </name>
         <name>
          <surname>
           Acharya
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of the human angiotensin-converting enzyme-lisinopril complex
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         421
        </volume>
        <year>
         2003
        </year>
        <fpage>
         551
        </fpage>
        <lpage>
         554
        </lpage>
        <pub-id pub-id-type="pmid">
         12540854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oppong
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of a secretase activity which releases angiotensin-converting enzyme from the membrane
        </article-title>
        <source>
         Biochem. J.
        </source>
        <volume>
         292
        </volume>
        <issue>
         Pt 2
        </issue>
        <year>
         1993
        </year>
        <fpage>
         597
        </fpage>
        <lpage>
         603
        </lpage>
        <pub-id pub-id-type="pmid">
         8389141
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riviere
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of the first non-insect invertebrate functional angiotensin-converting enzyme (ACE): leech TtACE resembles the N-domain of mammalian ACE
        </article-title>
        <source>
         Biochem. J.
        </source>
        <volume>
         382
        </volume>
        <year>
         2004
        </year>
        <fpage>
         565
        </fpage>
        <lpage>
         573
        </lpage>
        <pub-id pub-id-type="pmid">
         15175004
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rousseau
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Michaud
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chauvet
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Lenfant
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The hemoregulatory peptide
         <italic>
          N
         </italic>
         -acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         270
        </volume>
        <year>
         1995
        </year>
        <fpage>
         3656
        </fpage>
        <lpage>
         3661
        </lpage>
        <pub-id pub-id-type="pmid">
         7876104
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Talaga
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cell-associated glucans of
         <italic>
          Burkholderia solanacearum
         </italic>
         and
         <italic>
          Xanthomonas campestris
         </italic>
         pv.
         <italic>
          citri
         </italic>
         : a new family of periplasmic glucans
        </article-title>
        <source>
         J. Bacteriol.
        </source>
        <volume>
         178
        </volume>
        <year>
         1996
        </year>
        <fpage>
         2263
        </fpage>
        <lpage>
         2271
        </lpage>
        <pub-id pub-id-type="pmid">
         8636027
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tatei
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ip
          </surname>
          <given-names>
           Y.T.
          </given-names>
         </name>
         <name>
          <surname>
           Levine
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Race: a
         <italic>
          Drosophila
         </italic>
         homologue of the angiotensin converting enzyme
        </article-title>
        <source>
         Mech. Dev.
        </source>
        <volume>
         51
        </volume>
        <year>
         1995
        </year>
        <fpage>
         157
        </fpage>
        <lpage>
         168
        </lpage>
        <pub-id pub-id-type="pmid">
         7547464
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Coates
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Shirras
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Acer gene of
         <italic>
          Drosophila
         </italic>
         codes for an angiotensin-converting enzyme homologue
        </article-title>
        <source>
         Gene
        </source>
        <volume>
         181
        </volume>
        <year>
         1996
        </year>
        <fpage>
         191
        </fpage>
        <lpage>
         197
        </lpage>
        <pub-id pub-id-type="pmid">
         8973330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Karran
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Christie
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         275
        </volume>
        <year>
         2000
        </year>
        <fpage>
         33238
        </fpage>
        <lpage>
         33243
        </lpage>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Towler
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         279
        </volume>
        <year>
         2004
        </year>
        <fpage>
         17996
        </fpage>
        <lpage>
         18007
        </lpage>
        <pub-id pub-id-type="pmid">
         14754895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tzakos
          </surname>
          <given-names>
           A.G.
          </given-names>
         </name>
         <name>
          <surname>
           Gerothanassis
          </surname>
          <given-names>
           I.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors
        </article-title>
        <source>
         Chembiochem.
        </source>
        <volume>
         6
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1089
        </fpage>
        <lpage>
         1103
        </lpage>
        <pub-id pub-id-type="pmid">
         15883972
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Alhenc-Gelas
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Clauser
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The two homologous domains of human angiotensin I-converting enzyme are both catalytically active
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         266
        </volume>
        <year>
         1991
        </year>
        <fpage>
         9002
        </fpage>
        <lpage>
         9008
        </lpage>
        <pub-id pub-id-type="pmid">
         1851160
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Alhenc-Gelas
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Soubrier
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Michaud
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Clauser
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         266
        </volume>
        <year>
         1991
        </year>
        <fpage>
         5540
        </fpage>
        <lpage>
         5546
        </lpage>
        <pub-id pub-id-type="pmid">
         1848554
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wijffels
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cloning and characterisation of angiotensin-converting enzyme from the dipteran species,
         <italic>
          Haematobia irritans exigua
         </italic>
         , and its expression in the maturing male reproductive system
        </article-title>
        <source>
         Eur. J. Biochem.
        </source>
        <volume>
         237
        </volume>
        <year>
         1996
        </year>
        <fpage>
         414
        </fpage>
        <lpage>
         423
        </lpage>
        <pub-id pub-id-type="pmid">
         8647080
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Michaud
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Houard
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chauvet
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Soubrier
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Drosophila melanogaster
         </italic>
         angiotensin I-converting enzyme expressed in
         <italic>
          Pichia pastoris
         </italic>
         resembles the C domain of the mammalian homologue and does not require glycosylation for secretion and enzymic activity
        </article-title>
        <source>
         Biochem. J.
        </source>
        <volume>
         318
        </volume>
        <issue>
         Pt 1
        </issue>
        <year>
         1996
        </year>
        <fpage>
         125
        </fpage>
        <lpage>
         131
        </lpage>
        <pub-id pub-id-type="pmid">
         8761461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hypotensive and physiological effect of angiotensin converting enzyme inhibitory peptides derived from soy protein on spontaneously hypertensive rats
        </article-title>
        <source>
         J. Agric. Food Chem.
        </source>
        <volume>
         49
        </volume>
        <year>
         2001
        </year>
        <fpage>
         501
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         11170618
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           X.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Biemann
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ehlers
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Riordan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of N-linked glycosylation sites in human testis angiotensin-converting enzyme and expression of an active deglycosylated form
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         272
        </volume>
        <year>
         1997
        </year>
        <fpage>
         3511
        </fpage>
        <lpage>
         3519
        </lpage>
        <pub-id pub-id-type="pmid">
         9013598
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="app1" sec-type="supplementary-material">
      <label>
       Appendix A
      </label>
      <title>
       Supplementary data
      </title>
      <p>
       <supplementary-material content-type="local-data" id="d32e2307">
        <media xlink:href="mmc1.doc">
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       This work was supported by grants from INSERM (Institut National pour la Santé et la Recherche Médicale), Region Nord Pas de Calais and CNRS (Centre National pour la Recherche Scientifique) and Wellcome Trust (U.K.) grants 070060 (K.R.A.) and 071047 (E.D.S.).
      </p>
     </ack>
     <fn-group>
      <fn fn-type="supplementary-material" id="d32e2310">
       <label>
        Appendix A
       </label>
       <p>
        Supplementary data associated with this article can be found, in the online version, at
        <ext-link ext-link-type="doi" xlink:href="10.1016/j.gene.2007.05.010">
         doi:10.1016/j.gene.2007.05.010
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-title-group>
       <journal-title>
        Chinese Journal of Biotechnology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1872-2075
      </issn>
      <issn pub-type="epub">
       1872-2075
      </issn>
      <publisher>
       <publisher-name>
        Institute of Microbiology, Chinese Academy of Sciences and Chinese Society for Microbiology. Published by Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       18464595
      </article-id>
      <article-id pub-id-type="pmc">
       7148949
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1872-2075(08)60007-2
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/S1872-2075(08)60007-2
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Structure and Function of Angiotensin Converting Enzyme and Its Inhibitors
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          Yulan
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          Chuanlian
         </given-names>
        </name>
        <email>
         chuanlianxu@163.com
        </email>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff>
       College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Corresponding author: Chuanlian Xu. Tel: +86-571-86843566; Fax: +86-571-86843335
        <email>
         chuanlianxu@163.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        8
       </day>
       <month>
        3
       </month>
       <year>
        2008
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        2
       </month>
       <year>
        2008
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        8
       </day>
       <month>
        3
       </month>
       <year>
        2008
       </year>
      </pub-date>
      <volume>
       24
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       171
      </fpage>
      <lpage>
       176
      </lpage>
      <history>
       <date date-type="received">
        <day>
         21
        </day>
        <month>
         5
        </month>
        <year>
         2007
        </year>
       </date>
       <date date-type="accepted">
        <day>
         10
        </day>
        <month>
         7
        </month>
        <year>
         2007
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2008 Institute of Microbiology, Chinese Academy of Sciences and Chinese Society for Microbiology. Published by Elsevier B.V. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2008
       </copyright-year>
       <copyright-holder>
        Institute of Microbiology, Chinese Academy of Sciences and Chinese Society for Microbiology
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Angiotensin converting enzyme (ACE, EC 3.4.15.1) is a membrane-bound, zinc dependent dipeptidase that catalyzes the conversion of the decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II by removing the two C-terminal amino acids. ACE is well known to be a key part of the rennin-angiotensin system that regulates blood pressure. The inhibitors of ACE have the potency of treating hypertension. This article reviews the structure-function relationship of ACE as well as its gene polymorphism and inhibitor development. In particular, it has been found that the catalytic mechanisms of the two active sites of somatic ACE in the cleavage of angiotensin I and bradykin are different. Therefore, by specifically targeting the individual active sites of somatic ACE, it will likely offer a new way to develop novel ACE inhibitors with fewer side effects.
       </p>
      </abstract>
      <kwd-group>
       <title>
        Keywords
       </title>
       <kwd>
        angiotensin converting enzyme
       </kwd>
       <kwd>
        structure and function
       </kwd>
       <kwd>
        gene polymorphism
       </kwd>
       <kwd>
        inhibitor
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Mello
          </surname>
          <given-names>
           WC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme and the arrhythmogenic action of angiotensin?: cardiac cell membrane as a site of angiotensin?conversion
        </article-title>
        <source>
         Regul Pept
        </source>
        <volume>
         121
        </volume>
        <year>
         2004
        </year>
        <fpage>
         83
        </fpage>
        <lpage>
         88
        </lpage>
        <pub-id pub-id-type="pmid">
         15256277
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coates
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         The angiotensin converting enzyme (ACE)
        </article-title>
        <source>
         Int J Biochem Cell Biol
        </source>
        <volume>
         35
        </volume>
        <year>
         2003
        </year>
        <fpage>
         769
        </fpage>
        <lpage>
         773
        </lpage>
        <pub-id pub-id-type="pmid">
         12676162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hubert
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Houot
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sructure of the angiotensin-converting enzyme gene: two alternate promoters correspond to evolutionary steps of a duplicated gene
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         266
        </volume>
        <year>
         1991
        </year>
        <fpage>
         15377
        </fpage>
        <lpage>
         15383
        </lpage>
        <pub-id pub-id-type="pmid">
         1651327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thekkumkara
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <name>
          <surname>
           Livingston?
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of alternative polyadenylation sites for tissue-specific transcription of two angiotensin-converting enzyme mRNAs
        </article-title>
        <source>
         Nucl Acids Res
        </source>
        <volume>
         20
        </volume>
        <year>
         1992
        </year>
        <fpage>
         683
        </fpage>
        <lpage>
         687
        </lpage>
        <pub-id pub-id-type="pmid">
         1311831
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ehlers
          </surname>
          <given-names>
           MRW
          </given-names>
         </name>
         <name>
          <surname>
           Fox
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Strydom
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme
        </article-title>
        <source>
         Proce Natl Acad Sci USA
        </source>
        <volume>
         86
        </volume>
        <year>
         1989
        </year>
        <fpage>
         7741
        </fpage>
        <lpage>
         7745
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Kusari
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           RoyQII
          </surname>
          <given-names>
           SN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of testicular angiotensin-converting enzyme
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         264
        </volume>
        <year>
         1989
        </year>
        <fpage>
         16754
        </fpage>
        <lpage>
         16758
        </lpage>
        <pub-id pub-id-type="pmid">
         2550457
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riordan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-?-converting enzyme and its relatives
        </article-title>
        <source>
         Genome Biol
        </source>
        <volume>
         4
        </volume>
        <year>
         2003
        </year>
        <fpage>
         225
        </fpage>
        <pub-id pub-id-type="pmid">
         12914653
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Igarashi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Kamata
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nakagawa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme degrades Alzheimer Amyloid β-Peptide (Aβ); rerards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         276
        </volume>
        <year>
         2001
        </year>
        <fpage>
         47863
        </fpage>
        <lpage>
         47868
        </lpage>
        <pub-id pub-id-type="pmid">
         11604391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kondoh
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Tojo
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Nakatani
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization
        </article-title>
        <source>
         Nature Medicine
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         160
        </fpage>
        <lpage>
         166
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morshed
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Akhteruzzaman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Association between Angiotensin?-converting enzyme gene polymorphism and hypertension in selected individuals of the Bangladeshi population
        </article-title>
        <source>
         J Biochem and Mol Biol
        </source>
        <volume>
         35
        </volume>
        <year>
         2002
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         12297007
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agachan
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Isbir
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Yilmaz
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme
         <italic>
          I/D
         </italic>
         , Angiotensinogen T174M-M235T and angiotensin II type 1 receptor A1166C gene polymorphisms in Turkish hypertensive patients
        </article-title>
        <source>
         Exp Mol Med
        </source>
        <volume>
         35
        </volume>
        <year>
         2003
        </year>
        <fpage>
         545
        </fpage>
        <lpage>
         549
        </lpage>
        <pub-id pub-id-type="pmid">
         14749533
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohira
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Matsumoto
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Tamaki
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme insertion/deletion polymorphism modulates coronary release of tissue plasminogen activator in response to bradykinin
        </article-title>
        <source>
         Hypertens Res
        </source>
        <volume>
         27
        </volume>
        <year>
         2004
        </year>
        <fpage>
         39
        </fpage>
        <lpage>
         45
        </lpage>
        <pub-id pub-id-type="pmid">
         15055254
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iwai
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Tamaki
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Ohmichi
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         The II genotype of the angiotensin-converting enzyme gene delays the onset of acute coronary syndromes
        </article-title>
        <source>
         Arterioscler Thromb Basc Biol
        </source>
        <volume>
         17
        </volume>
        <year>
         1997
        </year>
        <fpage>
         1730
        </fpage>
        <lpage>
         1733
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homolog of angiotensin-converting enzyme
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         275
        </volume>
        <year>
         2000
        </year>
        <fpage>
         33238
        </fpage>
        <lpage>
         33243
        </lpage>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           XQ
          </given-names>
         </name>
         <name>
          <surname>
           Mit
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Okano
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and expression of the ecdysteroid-inducible angiotensin-converting enzyme -related gene in wing discs of
         <italic>
          Bombyx mori
         </italic>
        </article-title>
        <source>
         Insect Biochem Mol Biol
        </source>
        <volume>
         31
        </volume>
        <year>
         2001
        </year>
        <fpage>
         97
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="pmid">
         11102839
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel angiotenin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin?to angiotensin1–9
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         87
        </volume>
        <year>
         2000
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         10884362
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rice
          </surname>
          <given-names>
           GI
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism
        </article-title>
        <source>
         Biochem J
        </source>
        <volume>
         383
        </volume>
        <year>
         2004
        </year>
        <fpage>
         45
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="pmid">
         15283675
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lang
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Osterhqus
          </surname>
          <given-names>
           ADME
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interferon-γ and interlwukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         6
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           TY
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction
        </article-title>
        <source>
         Antiviral Res
        </source>
        <volume>
         2103
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         10
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bicket
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Using ACE inhibitors appropriately
        </article-title>
        <source>
         Am Fam Physician
        </source>
        <volume>
         66
        </volume>
        <year>
         2002
        </year>
        <fpage>
         461
        </fpage>
        <lpage>
         468
        </lpage>
        <pub-id pub-id-type="pmid">
         12182524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pagliaro
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Penna
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rethinking the rennin-angiotensin system and its role in cardiovascular regulation
        </article-title>
        <source>
         Cardiovasc Drugs Ther
        </source>
        <volume>
         19
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1977
        </fpage>
        <lpage>
         1987
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pitt
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE inhibitors in heart failure: prospects and limitations
        </article-title>
        <source>
         Cardiovasc Drugs Ther
        </source>
        <volume>
         11
        </volume>
        <year>
         1997
        </year>
        <fpage>
         285
        </fpage>
        <lpage>
         290
        </lpage>
        <pub-id pub-id-type="pmid">
         9211022
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Gusmao
          </surname>
          <given-names>
           FB
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Carvalho
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II inhibition during myocardial ischemia-reperfusion in dogs: effects on leukocyte infiltration, nitric oxide synthase isoenzymes activity
        </article-title>
        <source>
         Int J Cardiol
        </source>
        <volume>
         100
        </volume>
        <year>
         2005
        </year>
        <fpage>
         363
        </fpage>
        <lpage>
         370
        </lpage>
        <pub-id pub-id-type="pmid">
         15837077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Francis
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Shun
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Brain angiotensin-converting enzyme activity and autonomic regulation in heart failure
        </article-title>
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         287
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2138
        </fpage>
        <lpage>
         2146
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Georgiadis
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Beau
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Czarny
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Roles of two sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin?and bradykinin: insight from selective inhibitors
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         93
        </volume>
        <year>
         2003
        </year>
        <fpage>
         148
        </fpage>
        <lpage>
         154
        </lpage>
        <pub-id pub-id-type="pmid">
         12805239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Van Esch
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Tom
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <article-title>
         Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin?-induced vasoconstriction
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         45
        </volume>
        <year>
         2005
        </year>
        <fpage>
         120
        </fpage>
        <lpage>
         125
        </lpage>
        <pub-id pub-id-type="pmid">
         15583077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Junot
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gonzales
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Ezan
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         A selective inhibitor of the N-domain of angiotensin?-converting enzyme, blocks
         <italic>
          in vivo
         </italic>
         the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin?hydrolysis
        </article-title>
        <source>
         J Pharmacol Exp Ther
        </source>
        <volume>
         297
        </volume>
        <year>
         2001
        </year>
        <fpage>
         606
        </fpage>
        <lpage>
         611
        </lpage>
        <pub-id pub-id-type="pmid">
         11303049
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dive
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Cotton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Yiotakis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         RXP407, a phpsphinic peptide, is a potent inhibitor of angiotensin?converting enzyme able to differentiate between its two active sites
        </article-title>
        <source>
         Proce Natl Acad Sci USA
        </source>
        <volume>
         96
        </volume>
        <year>
         1999
        </year>
        <fpage>
         4330
        </fpage>
        <lpage>
         4335
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Nat Rev Cardiol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Nat Rev Cardiol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Nature Reviews. Cardiology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1759-5002
      </issn>
      <issn pub-type="epub">
       1759-5010
      </issn>
      <publisher>
       <publisher-name>
        Nature Publishing Group UK
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       24776703
      </article-id>
      <article-id pub-id-type="pmc">
       7097196
      </article-id>
      <article-id pub-id-type="publisher-id">
       BFnrcardio201459
      </article-id>
      <article-id pub-id-type="doi">
       10.1038/nrcardio.2014.59
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          Fan
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
        <bio>
         <p id="Par1">
          Fan Jiang obtained his PhD degree in pharmacology in 1999, then received his postdoctoral research training in Melbourne, Australia. Jiang is a basic research scientist in the field of cardiovascular pharmacology and vascular biology. Currently Fan Jiang is a Professor at the Key Laboratory of Cardiovascular Remodeling and Function Research at Shandong University, Shandong, China. His current research primarily focuses on the role of cell stress responses in cardiovascular disease.
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Jianmin
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
        <bio>
         <p id="Par2">
          Jianmin Yang obtained his PhD degree in cardiology in 2010. He is now a cardiologist at the Department of Cardiology, Qilu Hospital, Shandong University, Shandong, China. His current research interests include mechanisms of atherosclerosis and discovery of novel treatment strategies.
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Yongtao
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
        <bio>
         <p id="Par3">
          Yongtao Zhang is a PhD student at the Key Laboratory of Cardiovascular Remodeling and Function Research, Shandong University, Shandong, China.
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Dong
         </surname>
         <given-names>
          Mei
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
        <bio>
         <p id="Par4">
          Mei Dong obtained her PhD degree in cardiology in 2013. She is now a cardiologist at the Department of Cardiology, Qilu Hospital, Shandong University, Shandong, China. Her current research interests include mechanisms of atherosclerosis and discovery of novel treatment strategies.
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Shuangxi
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
        <bio>
         <p id="Par5">
          Shuangxi Wang obtained his PhD degree in Xiangya Medicine College, Central South University, Changsha, China in 2005; he received his postdoctoral training in University of Oklahoma. Currently, he is a full professor at Shandong University, Jinan, China. Wang's research focuses on molecular medicine in cardiovascular diseases.
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Qunye
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
        <bio>
         <p id="Par6">
          Qunye Zhang obtained his PhD degree in genetics in 2004, and then worked in Ruijin hospital affiliated to Shanghai Jiaotong University medical School. Zhang is a researcher in the field of proteomics, systems biology and genetics of cardiovascular biology and cancer. Currently, he is a Professor at the Key Laboratory of Cardiovascular Remodeling and Function Research at Shandong University, Shandong, China.
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Fang Fang
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
        <bio>
         <p id="Par7">
          Fang Fang Liu is a PhD student at the Key Laboratory of Cardiovascular Remodeling and Function Research, Shandong University, Shandong, China.
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Kai
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
        <bio>
         <p id="Par8">
          Kai Zhang is a PhD student at the Key Laboratory of Cardiovascular Remodeling and Function Research, Shandong University, Shandong, China.
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Cheng
         </given-names>
        </name>
        <address>
         <email>
          zhangc@sdu.edu.cn
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
        <bio>
         <p id="Par9">
          Cheng Zhang obtained his MD and PhD degrees in 2004 and 2009, respectively, at Shandong University. Currently, he is a Professor at the Key Laboratory of Cardiovascular Remodeling and Function Research of Shandong University. Cheng Zhang's major research interest is to investigate the molecular mechanisms and therapeutic targets of atherosclerosis. His research mainly focuses on new approaches to the treatment by targeting ACE2/angiotensin 1–7/Mas in the renin–aldosterone system, mechanisms of inflammation and immune modulation in atherosclerotic plaques, and novel molecular mechanisms of plaque instability induced by disorganized collagen metabolism.
         </p>
        </bio>
       </contrib>
       <aff id="Aff1">
        Key Laboratory of Cardiovascular Remodelling and Function Research, Qilu Hospital, Shandong University, 107 Wen Hua Xi Road, Jinan 250012, Shandong Province, China., ,
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        29
       </day>
       <month>
        4
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       11
      </volume>
      <issue>
       7
      </issue>
      <fpage>
       413
      </fpage>
      <lpage>
       426
      </lpage>
      <permissions>
       <copyright-statement>
        © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2014
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="KeyPoints" id="Abs1">
       <title>
        Key Points
       </title>
       <p id="Par10">
        <list list-type="bullet">
         <list-item>
          <p id="Par11">
           Angiotensin-converting enzyme (ACE) 2 and its product angiotensin 1–7 are thought to have effects that counteract the adverse actions of other, better-known renin–angiotensin system (RAS) components
          </p>
         </list-item>
         <list-item>
          <p id="Par12">
           Numerous experimental studies have suggested that ACE2 and angiotensin 1–7 have notable protective effects in the heart and blood vessels
          </p>
         </list-item>
         <list-item>
          <p id="Par13">
           ACE2-mediated catabolism of angiotensin II is likely to have a major role in cardiovascular protection, whereas the functional importance and signalling mechanisms of angiotensin-1–7-induced actions remain unclear
          </p>
         </list-item>
         <list-item>
          <p id="Par14">
           New pharmacological interventions targeting ACE2 are expected to be useful in clinical treatment of cardiovascular disease, especially those associated with overactivation of the conventional RAS
          </p>
         </list-item>
         <list-item>
          <p id="Par15">
           More studies, especially randomized controlled clinical trials, are needed to clearly delineate the benefits of therapies targeting angiotensin 1–7 actions
          </p>
         </list-item>
        </list>
       </p>
       <sec>
        <title>
         Supplementary information
        </title>
        <p>
         The online version of this article (doi:10.1038/nrcardio.2014.59) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <abstract abstract-type="web-summary" id="Abs2">
       <p id="Par16">
        Angiotensin-converting enzyme 2, and its product angiotensin 1–7, are thought to have counteracting effects against the adverse actions of the better-known members of the renin–angiotensin system and might, therefore, be useful therapeutic targets in patients with cardiovascular disease. Professor Jiang and colleagues review the evidence for the potential roles of these proteins in various cardiovascular conditions, including hypertension, atherosclerosis, myocardial remodelling, heart failure, ischaemic stroke, and diabetes.
       </p>
       <sec>
        <title>
         Supplementary information
        </title>
        <p>
         The online version of this article (doi:10.1038/nrcardio.2014.59) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <abstract id="Abs3">
       <p id="Par17">
        The renin–angiotensin system (RAS) has pivotal roles in the regulation of normal physiology and the pathogenesis of cardiovascular disease. Angiotensin-converting enzyme (ACE) 2, and its product angiotensin 1–7, are thought to have counteracting effects against the adverse actions of other, better known and understood, members of the RAS. The physiological and pathological importance of ACE2 and angiotensin 1–7 in the cardiovascular system are not completely understood, but numerous experimental studies have indicated that these components have protective effects in the heart and blood vessels. Here, we provide an overview on the basic properties of ACE2 and angiotensin 1–7 and a summary of the evidence from experimental and clinical studies of various pathological conditions, such as hypertension, atherosclerosis, myocardial remodelling, heart failure, ischaemic stroke, and diabetes mellitus. ACE2-mediated catabolism of angiotensin II is likely to have a major role in cardiovascular protection, whereas the relevant functions and signalling mechanisms of actions induced by angiotensin 1–7 have not been conclusively determined. The ACE2–angiotensin 1–7 pathway, however, might provide a useful therapeutic target for the treatment of cardiovascular disease, especially in patients with overactive RAS.
       </p>
       <sec>
        <title>
         Supplementary information
        </title>
        <p>
         The online version of this article (doi:10.1038/nrcardio.2014.59) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
       <title>
        Subject terms
       </title>
       <kwd>
        Hypertension
       </kwd>
       <kwd>
        Heart failure
       </kwd>
       <kwd>
        Myocardial infarction
       </kwd>
       <kwd>
        Pathogenesis
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer Nature Limited 2014
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Introduction
     </title>
     <p id="Par18">
      The importance of the renin–angiotensin system (RAS) in the regulation of normal physiology and pathogenesis of cardiovascular disease is well established.
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
      </sup>
      The best-known components of the RAS include angiotensinogen, angiotensin I and II, and the peptidases renin and angiotensin-converting enzyme (ACE). Renin is the rate-limiting enzyme in the RAS, whereas angiotensin II is the major effector molecule, which exerts its biological actions via the type-1 angiotensin II (AT1) and type-2 angiotensin II (AT2) receptors. Angiotensin II is generated in the circulation and within tissues (local RAS).
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
      </sup>
      RAS is implicated in the pathogenesis of various cardiovascular disorders, including hypertension, atherosclerosis, myocardial infarction, pathological cardiac remodelling, heart failure, and metabolic syndrome.
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
      </sup>
      ACE2 and its product angiotensin 1–7 were identified more recently than the aforementioned components of this system, and are thought to have counteracting effects against the adverse actions of these other RAS components (
      <xref ref-type="fig" rid="Fig1">
       Figure 1
      </xref>
      ),
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      although their physiological and pathophysiological roles are incompletely understood. Findings from numerous experimental studies have suggested notable protective effects in the heart, blood vessels, kidney, and central nervous system. ACE2 and angiotensin 1–7 might, therefore, represent new therapeutic targets for cardiovascular disease.
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      In this Review, we summarize the evidence from experimental and clinical studies of the effects of ACE2 and angiotensin 1–7 in various pathological cardiovascular conditions.
      <fig id="Fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <title>
         Overview of the ACE2–Ang 1–7 pathway.
        </title>
        <p>
         ACE2 converts Ang II to Ang 1–7. ACE2 can also convert Ang I to Ang 1–9, which is then cleaved by either NEP or ACE to yield Ang 1-7. The membrane-bound ACE2 can be cleaved by the metalloproteinase ADAM17, forming a soluble form of ACE2. The physiological relevance of soluble ACE2 is not fully understood. Abbreviations: ACE, angiotensin-converting enzyme; Ang, angiotensin; NEP, neutral endopeptidase; PCP, prolyl carboxypeptidase.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM4">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e371" xlink:href="41569_2014_Article_BFnrcardio201459_Fig1_HTML">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Properties of ACE2
     </title>
     <sec id="Sec3">
      <title>
       Biochemical characteristics
      </title>
      <p id="Par19">
       ACE2 (also known as ACE-related carboxypeptidase, angiotensin-converting enzyme homologue, or ACEH) is a monocarboxypeptidase that is mainly expressed in vascular endothelial cells and the renal tubular epithelium.
       <sup>
        <xref ref-type="bibr" rid="CR8">
         8
        </xref>
       </sup>
       The gene for ACE2 was cloned in 2000 by two independent groups as a homologue of human ACE.
       <sup>
        <xref ref-type="bibr" rid="CR8">
         8
        </xref>
        ,
        <xref ref-type="bibr" rid="CR9">
         9
        </xref>
       </sup>
       The ACE2 protein is an 805 amino-acid type-I transmembrane protein that contains an extracellular (ecto) domain (amino acids 18–739), a transmembrane region (amino acids 740–768), and an intracellular tail. The extracellular part of ACE2 (
       <xref ref-type="fig" rid="Fig2">
        Figure 2
       </xref>
       ) contains the catalytic domain (amino acids 147–555), which has a substrate binding region (amino acids 273–345) and a typical HEMGH metalloproteinase zinc-binding site (amino acids 374–378).
       <sup>
        <xref ref-type="bibr" rid="CR8">
         8
        </xref>
        ,
        <xref ref-type="bibr" rid="CR10">
         10
        </xref>
        ,
        <xref ref-type="bibr" rid="CR11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="CR12">
         12
        </xref>
        ,
        <xref ref-type="bibr" rid="CR13">
         13
        </xref>
       </sup>
       The C-terminal part of ACE2 (614–805) is homologous (48% identity) to a transporter protein known as collectrin.
       <sup>
        <xref ref-type="bibr" rid="CR11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
       </sup>
       The catalytic domain of ACE2 is 42% identical to that of ACE.
       <sup>
        <xref ref-type="bibr" rid="CR8">
         8
        </xref>
       </sup>
       <fig id="Fig2">
        <label>
         Figure 2
        </label>
        <caption>
         <title>
          Structure of the extracellular domain (from Ser19 to Asp615) of human ACE2.
         </title>
         <p>
          In this image, the extracellular domain is arbitrarily divided into two subdomains (shown in green and purple), forming a deep cleft that is proposed to be the active site for substrate binding and catalysis. The catalytic domain (amino acids 147–555) has a substrate binding region (amino acids 273–345) and a typical HEMGH metalloproteinase zinc-binding site (amino acids 374–378). The regions shown in ball-and-stick figuration are proposed binding sites for the ACE2 inhibitor MLN-4760. Abbreviation: ACE2, angiotensin-converting enzyme 2. Amino acid sequence annotations are derived from Towler, P.
          <italic>
           et al
          </italic>
          .
          <italic>
           J. Biol. Chem.
          </italic>
          <bold>
           279
          </bold>
          , 17996–18007 (2004).
          <sup>
           <xref ref-type="bibr" rid="CR28">
            28
           </xref>
          </sup>
         </p>
         <p>
          <xref ref-type="media" rid="MOESM5">
           PowerPoint slide
          </xref>
         </p>
        </caption>
        <graphic id="d29e448" xlink:href="41569_2014_Article_BFnrcardio201459_Fig2_HTML">
        </graphic>
       </fig>
      </p>
      <p id="Par20">
       The peptidase activity of ACE2 is dependent on the C-terminus sequence of the substrate (sequence specificity). ACE2 substrates generally have a hydrophobic or basic residue at the C-terminal end, preceded by a Pro-X-Pro motif, where either one of the two proline residues is sufficient to allow ACE2-dependent hydrolysis.
       <sup>
        <xref ref-type="bibr" rid="CR15">
         15
        </xref>
       </sup>
       In this circumstance, ACE2 displays potent peptidase activity to angiotensin II (Pro-Phe), angiotensin I (Pro-Phe-His-Leu), and des-Arg
       <sup>
        <xref ref-type="bibr" rid="CR9">
         9
        </xref>
       </sup>
       bradykinin (Ser-Pro-Phe), but shows no activity towards angiotensin 1–9, angiotensin 1–7, or bradykinin.
       <sup>
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
       </sup>
       ACE2 can also hydrolyse other bioactive peptides, such as apelin-13, β-casomorphin, dynorphin A 1–13, and ghrelin.
       <sup>
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
       </sup>
       The most-important active product of ACE2 is angiotensin 1–7, which can be primarily generated via two routes. First, ACE2 can directly hydrolyse angiotensin II to yield angiotensin 1–7; second, ACE2 can convert angiotensin I to angiotensin 1–9, which is then cleaved by either neutral endopeptidase (NEP) or ACE to yield angiotensin 1–7.
       <sup>
        <xref ref-type="bibr" rid="CR12">
         12
        </xref>
        ,
        <xref ref-type="bibr" rid="CR17">
         17
        </xref>
        ,
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
       </sup>
       In addition, angiotensin 1–7 can be produced by prolyl carboxypeptidase from angiotensin II or by NEP directly from angiotensin I.
       <sup>
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
       </sup>
       The biological functions of angiotensin 1–9 are poorly understood, although important effects in the cardiovascular system have been purported.
       <sup>
        <xref ref-type="bibr" rid="CR19">
         19
        </xref>
        ,
        <xref ref-type="bibr" rid="CR20">
         20
        </xref>
       </sup>
       The affinity of ACE2 to angiotensin II (K
       <sub>
        m
       </sub>
       = 2.0 μmol/l, which represents the concentration of substrate required for the enzyme to achieve half maximum catalytic velocity; that is, the higher the K
       <sub>
        m
       </sub>
       value, the lower the affinity) is higher than to angiotensin I (K
       <sub>
        m
       </sub>
       = 6.9 μmol/l). The ACE2 catalytic efficiency for angiotensin II is &gt;300 times that for angiotensin I.
       <sup>
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
       </sup>
       The angiotensin I–ACE–angiotensin II–ACE2–angiotensin 1–7 pathway (
       <xref ref-type="fig" rid="Fig1">
        Figure 1
       </xref>
       ) ought, therefore, to have a predominant role in the production of angiotensin 1–7
       <italic>
        in vivo
       </italic>
       .
      </p>
      <p id="Par21">
       The membrane-bound ectodomain of ACE2 can be cleaved by the metalloproteinase ADAM17, which releases a soluble form of ACE2 (
       <xref ref-type="fig" rid="Fig1">
        Figure 1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="CR21">
         21
        </xref>
        ,
        <xref ref-type="bibr" rid="CR22">
         22
        </xref>
       </sup>
       By use of serial deletion constructs of ACE2, Iwata and colleagues identified a juxtamembrane region (amino acids 720–729) that is essential for ADAM17-mediated ectodomain shedding.
       <sup>
        <xref ref-type="bibr" rid="CR23">
         23
        </xref>
       </sup>
       The physiological relevance of soluble ACE2 is not fully understood. Its activity in plasma is raised in patients with chronic heart failure
       <sup>
        <xref ref-type="bibr" rid="CR23">
         23
        </xref>
       </sup>
       and is associated with increased cardiac dysfunction and poor clinical outcomes.
       <sup>
        <xref ref-type="bibr" rid="CR24">
         24
        </xref>
       </sup>
       Moreover, soluble ACE2 activity is raised after myocardial infarction, which has been associated with an increased incidence of subsequent adverse left ventricular remodelling.
       <sup>
        <xref ref-type="bibr" rid="CR25">
         25
        </xref>
       </sup>
       Findings from one study suggested that angiotensin II promotes ACE2 shedding by increasing ADAM17 activity in the myocardium. This action represents a positive feedback mechanism by which angiotensin II facilitates myocardial injury.
       <sup>
        <xref ref-type="bibr" rid="CR26">
         26
        </xref>
       </sup>
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Pharmacological activators and inhibitors
      </title>
      <p id="Par22">
       Several compounds are known to affect ACE2 activity. MLN-4760 is a specific and potent ACE2 inhibitor with a half maximum inhibitory concentration (IC
       <sub>
        50
       </sub>
       ) of 0.4 nmol/l.
       <sup>
        <xref ref-type="bibr" rid="CR27">
         27
        </xref>
       </sup>
       X-ray diffraction studies have revealed that the catalytic domain of ACE2 contains two subdomains linked by an α-helix hinge region, which forms a long and deep cleft. MLN-4760 binds to both of the subdomains (
       <xref ref-type="fig" rid="Fig2">
        Figure 2
       </xref>
       ) and causes the hinge to flex, which shrinks the cleft and prevents substrate binding.
       <sup>
        <xref ref-type="bibr" rid="CR28">
         28
        </xref>
       </sup>
       ACE2 inhibition
       <italic>
        in vivo
       </italic>
       by MLN-4760 aggravated glomerular injury in a model of type 1 diabetes mellitus,
       <sup>
        <xref ref-type="bibr" rid="CR29">
         29
        </xref>
       </sup>
       and exacerbated cardiac hypertrophy and fibrosis in transgenic hypertensive rats.
       <sup>
        <xref ref-type="bibr" rid="CR30">
         30
        </xref>
       </sup>
      </p>
      <p id="Par23">
       DX600 is a peptide inhibitor of ACE2 with a high affinity (K
       <sub>
        <italic>
         d
        </italic>
       </sub>
       = 10.8 nmol/l; this value is the equilibrated concentration required to achieve 50% occupancy of the receptors in radioligand binding assays; that is, the higher the K
       <sub>
        <italic>
         d
        </italic>
       </sub>
       value, the lower the affinity) and high efficacy (IC
       <sub>
        50
       </sub>
       = 10.1 nmol/l), but has no obvious inhibitory effect toward ACE.
       <sup>
        <xref ref-type="bibr" rid="CR31">
         31
        </xref>
       </sup>
       In
       <italic>
        in vitro
       </italic>
       and
       <italic>
        in vivo
       </italic>
       experiments, DX600 has shown antagonistic effects on ACE2-mediated actions.
       <sup>
        <xref ref-type="bibr" rid="CR32">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="CR33">
         33
        </xref>
       </sup>
       Kinetic analyses have revealed that DX600 exhibits a mixed competitive and noncompetitive type of inhibition, which indicates that this peptide might act as a partial allosteric modulator of ACE2; this mode of action is analogous to that of some ACE inhibitors, such as captopril.
       <sup>
        <xref ref-type="bibr" rid="CR31">
         31
        </xref>
       </sup>
       Several studies reported that DX600 displayed different efficacy of inhibition for human and rodent ACE2.
       <sup>
        <xref ref-type="bibr" rid="CR34">
         34
        </xref>
        ,
        <xref ref-type="bibr" rid="CR35">
         35
        </xref>
       </sup>
      </p>
      <p id="Par24">
       Given the potential protective roles of ACE2 in the cardiovascular system, identification of novel ACE2 activators is an important avenue for drug discovery. Two small-molecule ACE2 enhancers, xanthenone and resorcinolnaphthalein, have been discovered.
       <sup>
        <xref ref-type="bibr" rid="CR36">
         36
        </xref>
       </sup>
       <italic>
        In vitro
       </italic>
       , these compounds enhanced ACE2 activity by around twofold at concentrations of 100 μmol/l, but showed no effects on ACE activity. The pharmacological effects of xanthenone were further explored
       <italic>
        in vivo
       </italic>
       in healthy, normal rats and spontaneously hypertensive rats (SHRs), and showed remarkable hypotensive and cardiac protective actions.
       <sup>
        <xref ref-type="bibr" rid="CR36">
         36
        </xref>
        ,
        <xref ref-type="bibr" rid="CR37">
         37
        </xref>
       </sup>
       Potent antithrombotic actions were reported for xanthenone in a rat model of venous thrombosis, whereas DX600 led to opposite effects.
       <sup>
        <xref ref-type="bibr" rid="CR33">
         33
        </xref>
       </sup>
       These beneficial effects should, however, be interpreted with caution, because xanthenone can increase ACE2 expression.
       <sup>
        <xref ref-type="bibr" rid="CR37">
         37
        </xref>
       </sup>
       Indeed, the specificity of xanthenone for ACE2 has been questioned.
       <sup>
        <xref ref-type="bibr" rid="CR38">
         38
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec id="Sec5">
     <title>
      Properties of angiotensin 1–7
     </title>
     <sec id="Sec6">
      <title>
       Biochemical characteristics
      </title>
      <p id="Par25">
       In addition to ACE2-dependent routes, angiotensin 1–7 can be generated directly from angiotensin I by prolyl endopeptidase and NEP.
       <sup>
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
       </sup>
       The heart, brain, and kidney are major sources of angiotensin 1–7 production.
       <sup>
        <xref ref-type="bibr" rid="CR17">
         17
        </xref>
       </sup>
       In the human coronary circulation, NEP seems to have a more-prominent role in angiotensin 1–7 production than ACE2.
       <sup>
        <xref ref-type="bibr" rid="CR39">
         39
        </xref>
       </sup>
       Pharmacokinetic experiments have determined that, in humans, angiotensin 1–7 has a short half-life of ∼0.5 h.
       <sup>
        <xref ref-type="bibr" rid="CR40">
         40
        </xref>
       </sup>
       Following subcutaneous injection, the peptide is quickly available in the blood and reaches its peak plasma concentration at ∼1 h.
       <sup>
        <xref ref-type="bibr" rid="CR40">
         40
        </xref>
       </sup>
       In rats, the plasma half-life of angiotensin 1–7 is only 9 s.
       <sup>
        <xref ref-type="bibr" rid="CR41">
         41
        </xref>
       </sup>
       Angiotensin 1–7 is metabolized mainly by ACE in the lungs.
       <sup>
        <xref ref-type="bibr" rid="CR42">
         42
        </xref>
       </sup>
       In addition, aminopeptidase and NEP can degrade angiotensin 1–7 into peptide segments.
       <sup>
        <xref ref-type="bibr" rid="CR42">
         42
        </xref>
       </sup>
      </p>
      <p id="Par26">
       Angiotensin 1–7 has broad effects in the cardiovascular system, including vasodilatation; myocardial protection; antiarrhythmic, antihypertensive, and positive inotropic effects; and inhibition of pathological cardiac remodelling.
       <sup>
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ,
        <xref ref-type="bibr" rid="CR43">
         43
        </xref>
        ,
        <xref ref-type="bibr" rid="CR44">
         44
        </xref>
       </sup>
       In addition, angiotensin 1–7 is thought to have favourable effects on metabolism by lessening insulin resistance.
       <sup>
        <xref ref-type="bibr" rid="CR45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="CR46">
         46
        </xref>
        ,
        <xref ref-type="bibr" rid="CR47">
         47
        </xref>
       </sup>
       Although most effects are protective, some seem to be variable. For example, effects on arrhythmia might be biphasic, with high concentrations of angiotensin 1–7 promoting cardiac arrhythmias and low concentrations having protective effects.
       <sup>
        <xref ref-type="bibr" rid="CR48">
         48
        </xref>
        ,
        <xref ref-type="bibr" rid="CR49">
         49
        </xref>
        ,
        <xref ref-type="bibr" rid="CR50">
         50
        </xref>
       </sup>
       Similarly, some experimental findings suggest that the biological functions of angiotensin 1–7 in the kidney might be beneficial (diuretic or natriuretic, antifibrotic, and antiproliferative), whereas other findings suggest they are detrimental (antidiuretic, proinflammatory, and profibrotic).
       <sup>
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ,
        <xref ref-type="bibr" rid="CR44">
         44
        </xref>
       </sup>
      </p>
      <p id="Par27">
       Although the biological actions of angiotensin 1–7 are well described, the signalling mechanisms are still poorly understood. Treatment with angiotensin 1–7 activates the phosphatidylinositol-3-kinase–Akt pathway
       <italic>
        in vitro
       </italic>
       <sup>
        <xref ref-type="bibr" rid="CR51">
         51
        </xref>
        ,
        <xref ref-type="bibr" rid="CR52">
         52
        </xref>
        ,
        <xref ref-type="bibr" rid="CR53">
         53
        </xref>
        ,
        <xref ref-type="bibr" rid="CR54">
         54
        </xref>
       </sup>
       and
       <italic>
        in vivo
       </italic>
       .
       <sup>
        <xref ref-type="bibr" rid="CR45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="CR55">
         55
        </xref>
       </sup>
       This action could at least partly explain the beneficial effects of angiotensin 1–7 on blood vessel functions and metabolism, given the pivotal roles of Akt in promoting endothelial nitric oxide synthase function and insulin signalling.
       <sup>
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
       </sup>
       By contrast, angiotensin 1–7 has inhibitory effects on activated mitogen-activated protein kinase (MAPK) pathways in endothelial cells,
       <sup>
        <xref ref-type="bibr" rid="CR56">
         56
        </xref>
       </sup>
       smooth-muscle cells,
       <sup>
        <xref ref-type="bibr" rid="CR57">
         57
        </xref>
        ,
        <xref ref-type="bibr" rid="CR58">
         58
        </xref>
       </sup>
       cardiac myocytes,
       <sup>
        <xref ref-type="bibr" rid="CR59">
         59
        </xref>
       </sup>
       and renal proximal tubular cells.
       <sup>
        <xref ref-type="bibr" rid="CR60">
         60
        </xref>
       </sup>
       In these cells, angiotensin II induces oxidative, hypertrophic, and proliferative responses by activating MAPKs and, therefore, angiotensin 1–7 might counter-regulate these effects. The effects of angiotensin 1–7 on MAPKs, however, are highly cell specific; in some types of cells, angiotensin 1–7 augments basal or angiotensin-II-induced MAPK activation.
       <sup>
        <xref ref-type="bibr" rid="CR61">
         61
        </xref>
        ,
        <xref ref-type="bibr" rid="CR62">
         62
        </xref>
        ,
        <xref ref-type="bibr" rid="CR63">
         63
        </xref>
       </sup>
       Smooth-muscle depolarization via angiotensin 1–7-induced opening of potassium channels has been demonstrated, and seems to be dependent on activation of the cAMP–cAMP-dependent protein kinase (PKA) pathway.
       <sup>
        <xref ref-type="bibr" rid="CR64">
         64
        </xref>
       </sup>
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       Receptors and their agonists and antagonists
      </title>
      <p id="Par28">
       Early radioligand-binding studies indicated that angiotensin 1–7 could bind to the AT1 receptor in the brain and kidney,
       <sup>
        <xref ref-type="bibr" rid="CR65">
         65
        </xref>
        ,
        <xref ref-type="bibr" rid="CR66">
         66
        </xref>
       </sup>
       although in a study that used a more-homogenous assay system, virtually no binding was observed in HEK293 cells stably expressing AT1 receptors.
       <sup>
        <xref ref-type="bibr" rid="CR67">
         67
        </xref>
       </sup>
       Angiotensin 1–7 binds to the AT2 receptor with a moderate affinity (five times lower than that for angiotensin II).
       <sup>
        <xref ref-type="bibr" rid="CR67">
         67
        </xref>
       </sup>
       <italic>
        In vitro
       </italic>
       <sup>
        <xref ref-type="bibr" rid="CR68">
         68
        </xref>
       </sup>
       and
       <italic>
        in vivo
       </italic>
       <sup>
        <xref ref-type="bibr" rid="CR69">
         69
        </xref>
       </sup>
       studies have demonstrated that certain biological effects of angiotensin 1–7 can be attenuated by use of the AT2 receptor antagonist PD123319 and, therefore, angiotensin 1–7 binding to AT2 receptors is functionally relevant.
      </p>
      <p id="Par29">
       The Mas protein, which was originally cloned as an oncogene product,
       <sup>
        <xref ref-type="bibr" rid="CR70">
         70
        </xref>
       </sup>
       is a seven-transmembrane G-protein-coupled receptor with a high affinity for angiotensin 1–7 (K
       <sub>
        <italic>
         d
        </italic>
       </sub>
       = 0.83 nmol/l).
       <sup>
        <xref ref-type="bibr" rid="CR71">
         71
        </xref>
       </sup>
       The gene for this protein,
       <italic>
        MAS1
       </italic>
       , is mainly expressed in the brain, testis, kidney, and heart.
       <sup>
        <xref ref-type="bibr" rid="CR72">
         72
        </xref>
        ,
        <xref ref-type="bibr" rid="CR73">
         73
        </xref>
        ,
        <xref ref-type="bibr" rid="CR74">
         74
        </xref>
        ,
        <xref ref-type="bibr" rid="CR75">
         75
        </xref>
        ,
        <xref ref-type="bibr" rid="CR76">
         76
        </xref>
       </sup>
       The expression level of Mas is dynamically regulated by physiological and pathological stimuli in the heart.
       <sup>
        <xref ref-type="bibr" rid="CR77">
         77
        </xref>
       </sup>
       Mas expression is also observed in vascular endothelial cells.
       <sup>
        <xref ref-type="bibr" rid="CR53">
         53
        </xref>
        ,
        <xref ref-type="bibr" rid="CR73">
         73
        </xref>
        ,
        <xref ref-type="bibr" rid="CR78">
         78
        </xref>
       </sup>
       Expression of Mas remains to be confirmed in vascular smooth-muscle cells, although angiotensin 1–7-induced effects have been readily observed in these cells in various functional experiments.
       <sup>
        <xref ref-type="bibr" rid="CR58">
         58
        </xref>
        ,
        <xref ref-type="bibr" rid="CR79">
         79
        </xref>
        ,
        <xref ref-type="bibr" rid="CR80">
         80
        </xref>
       </sup>
       <italic>
        Mas1
       </italic>
       -knockout animals show cardiovascular-related phenotypes, including myocardial contractile dysfunction, cardiac fibrosis, hypertension, endothelial dysfunction, renal fibrosis, glomerular dysfunction, insulin resistance, and dyslipidaemia.
       <sup>
        <xref ref-type="bibr" rid="CR75">
         75
        </xref>
        ,
        <xref ref-type="bibr" rid="CR81">
         81
        </xref>
        ,
        <xref ref-type="bibr" rid="CR82">
         82
        </xref>
        ,
        <xref ref-type="bibr" rid="CR83">
         83
        </xref>
       </sup>
       However, in two studies in which different models of hypertension (the two-kidney, one-clip model and hypertension induced in response to high salt ingestion) were assessed, Mas deficiency had opposite effects on blood pressure.
       <sup>
        <xref ref-type="bibr" rid="CR84">
         84
        </xref>
        ,
        <xref ref-type="bibr" rid="CR85">
         85
        </xref>
       </sup>
      </p>
      <p id="Par30">
       Functional studies have suggested that most cardiovascular effects of angiotensin 1–7 are likely to be mediated by Mas.
       <sup>
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ,
        <xref ref-type="bibr" rid="CR86">
         86
        </xref>
        ,
        <xref ref-type="bibr" rid="CR87">
         87
        </xref>
        ,
        <xref ref-type="bibr" rid="CR88">
         88
        </xref>
       </sup>
       The precise angiotensin 1–7–Mas signalling mechanisms in the context of cardiovascular physiology have not, however, been firmly established. First,
       <italic>
        MAS1
       </italic>
       is an oncogene, and activation of Mas signalling induces cell transformation via the small GTPase p21-Rac1.
       <sup>
        <xref ref-type="bibr" rid="CR89">
         89
        </xref>
       </sup>
       This effect is not reproduced by angiotensin 1–7. Rather, it has some antitumorigenic effects.
       <sup>
        <xref ref-type="bibr" rid="CR90">
         90
        </xref>
        ,
        <xref ref-type="bibr" rid="CR91">
         91
        </xref>
       </sup>
       Second, Mas is constitutively coupled to Gα
       <sub>
        q/11
       </sub>
       and downstream phospholipase C–protein kinase C signalling.
       <sup>
        <xref ref-type="bibr" rid="CR92">
         92
        </xref>
        ,
        <xref ref-type="bibr" rid="CR93">
         93
        </xref>
       </sup>
       Evidence indicates, however, that angiotensin 1–7 does not stimulate Gα
       <sub>
        q
       </sub>
       signalling in Mas-expressing cells.
       <sup>
        <xref ref-type="bibr" rid="CR93">
         93
        </xref>
       </sup>
       Moreover, ectopic expression of Mas induces an increase in the intracellular concentration of Ca
       <sup>
        2+
       </sup>
       , whereas angiotensin 1–7 treatment does not raise intracellular concentrations of Ca
       <sup>
        2+
       </sup>
       .
       <sup>
        <xref ref-type="bibr" rid="CR93">
         93
        </xref>
        ,
        <xref ref-type="bibr" rid="CR94">
         94
        </xref>
        ,
        <xref ref-type="bibr" rid="CR95">
         95
        </xref>
       </sup>
       Third, the mechanistic link between Mas and the Akt pathway, which has been implicated in the cardioprotective actions of angiotensin 1–7, is still missing.
      </p>
      <p id="Par31">
       In many circumstances, the effects of angiotensin 1–7 are antagonistic to those induced by angiotensin II in the cardiovascular system,
       <sup>
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ,
        <xref ref-type="bibr" rid="CR56">
         56
        </xref>
        ,
        <xref ref-type="bibr" rid="CR58">
         58
        </xref>
        ,
        <xref ref-type="bibr" rid="CR96">
         96
        </xref>
       </sup>
       but the underlying signalling mechanisms remain to be defined. Mas binds directly to the AT1 receptor, but the interaction is unlikely to have a role in mediating angiotensin 1–7 effects, since administration of angiotensin 1–7 has no effects on this complex.
       <sup>
        <xref ref-type="bibr" rid="CR97">
         97
        </xref>
       </sup>
       Despite the discovery of binding, Mas is still classified as a class A orphan receptor under the latest International Union of Basic and Clinical Pharmacology classification.
       <sup>
        <xref ref-type="bibr" rid="CR98">
         98
        </xref>
       </sup>
      </p>
      <p id="Par32">
       The widely used Mas antagonist (
       <sc>
        D
       </sc>
       -Ala
       <sup>
        <xref ref-type="bibr" rid="CR7">
         7
        </xref>
       </sup>
       )-angiotensin-(1–7) is an angiotensin 1–7 analogue with the last proline residue substituted with
       <sc>
        D
       </sc>
       -Ala.
       <sup>
        <xref ref-type="bibr" rid="CR99">
         99
        </xref>
       </sup>
       This agent is water soluble. Radioligand-binding experiments show that (
       <sc>
        D
       </sc>
       -Ala
       <sup>
        <xref ref-type="bibr" rid="CR7">
         7
        </xref>
       </sup>
       )-angiotensin-(1–7) has a high efficacy in Mas inhibition (IC
       <sub>
        50
       </sub>
       for angiotensin 1–7 binding = 0.3 nmol/l).
       <sup>
        <xref ref-type="bibr" rid="CR71">
         71
        </xref>
       </sup>
       By contrast, the binding affinity of (
       <sc>
        D
       </sc>
       -Ala
       <sup>
        <xref ref-type="bibr" rid="CR7">
         7
        </xref>
       </sup>
       )-angiotensin-(1–7) to the AT1 and AT2 receptors is negligible.
       <sup>
        <xref ref-type="bibr" rid="CR67">
         67
        </xref>
        ,
        <xref ref-type="bibr" rid="CR99">
         99
        </xref>
       </sup>
       A similar peptide Mas antagonist is (
       <sc>
        D
       </sc>
       -Pro
       <sup>
        <xref ref-type="bibr" rid="CR7">
         7
        </xref>
       </sup>
       )-angiotensin-(1–7). The pharmacological properties of this agent have not been fully characterized, but at 10 μmol/l it exhibits similar effects to (
       <sc>
        D
       </sc>
       -Ala
       <sup>
        <xref ref-type="bibr" rid="CR7">
         7
        </xref>
       </sup>
       )-angiotensin-(1–7) in competing for angiotensin 1–7 binding, and showed weak affinities for the AT1 and AT2 receptors.
       <sup>
        <xref ref-type="bibr" rid="CR100">
         100
        </xref>
       </sup>
       Currently, no specific nonpeptide Mas antagonist is available.
      </p>
      <p id="Par33">
       AVE 0991 is a small-molecule agonist with high affinity and selectivity for Mas that competes for specific binding of angiotensin 1–7. It has an IC
       <sub>
        50
       </sub>
       of ∼10
       <sup>
        −8
       </sup>
       mol/l, and virtually no affinity to the AT1 or AT2 receptors.
       <sup>
        <xref ref-type="bibr" rid="CR67">
         67
        </xref>
        ,
        <xref ref-type="bibr" rid="CR101">
         101
        </xref>
        ,
        <xref ref-type="bibr" rid="CR102">
         102
        </xref>
       </sup>
       The maximum stimulating effect of AVE 0991 on release of endothelial nitric oxide is equivalent to that of angiotensin 1–7.
       <sup>
        <xref ref-type="bibr" rid="CR101">
         101
        </xref>
       </sup>
      </p>
      <p id="Par34">
       CGEN-856S is a 24 amino acid peptide with no obvious homology to angiotensin fragments or other known endogenous GPCR ligands.
       <sup>
        <xref ref-type="bibr" rid="CR103">
         103
        </xref>
       </sup>
       CGEN-856S at 0.1 μmol/l and 1.0 μmol/l is equally as potent as angiotensin 1–7 for Mas receptor binding. This agent has no binding activity for the AT1 receptor, but it shows a moderate binding affinity for the AT2 receptor (IC
       <sub>
        50
       </sub>
       ∼5 μmol/l).
       <sup>
        <xref ref-type="bibr" rid="CR103">
         103
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec id="Sec8">
     <title>
      Blood-pressure regulation
     </title>
     <p id="Par35">
      ACE2 seems to have beneficial effects on the regulation of blood pressure (
      <xref ref-type="table" rid="Tab1">
       Table 1
      </xref>
      ;
      <xref ref-type="fig" rid="Fig3">
       Figure 3
      </xref>
      ). ACE2-deficient C57BL/6 mice have raised basal blood pressure, with notable amplifications of angiotensin-II-induced hypertension, and have increased accumulation of angiotensin II in plasma and the kidney after angiotensin II infusion.
      <sup>
       <xref ref-type="bibr" rid="CR104">
        104
       </xref>
      </sup>
      Gain-of-function experiments in SHRs indicated that ACE2 expression in the central nervous system is associated with substantially decreased blood pressure. For example, overexpression of human ACE2 in the rostral ventrolateral medulla produced long-term hypotensive effects in SHRs.
      <sup>
       <xref ref-type="bibr" rid="CR105">
        105
       </xref>
      </sup>
      Similarly, overexpression of ACE2 in the paraventricular nucleus ameliorated hypertension induced by angiotensin II in healthy, normal rats.
      <sup>
       <xref ref-type="bibr" rid="CR106">
        106
       </xref>
      </sup>
      Moreover, pan-neuronal expression of ACE2 in the brain and delivery of ACE2-expressing adenoviruses into the cerebral ventricle have attenuated high blood pressure and improved baroreflex dysfunction induced by angiotensin II.
      <sup>
       <xref ref-type="bibr" rid="CR107">
        107
       </xref>
       ,
       <xref ref-type="bibr" rid="CR108">
        108
       </xref>
      </sup>
      In addition to these central actions, targeted expression of human ACE2 in vascular smooth muscle cells decreases blood pressure in stroke-prone SHRs.
      <sup>
       <xref ref-type="bibr" rid="CR109">
        109
       </xref>
      </sup>
      <table-wrap id="Tab1">
       <label>
        Table 1
       </label>
       <caption>
        <title>
         Experimental findings for the effects of ACE2 and Ang 1–7 on BP
        </title>
        <p>
         <xref ref-type="media" rid="MOESM10">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Animal models
          </th>
          <th>
           Interventions
          </th>
          <th>
           BP effect
          </th>
          <th>
           References
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="4">
           <bold>
            <italic>
             Effects of ACE2
            </italic>
           </bold>
          </td>
         </tr>
         <tr>
          <td>
           Hypertension induced by Ang II in mice
          </td>
          <td>
           <italic>
            Ace2
           </italic>
           gene deletion
          </td>
          <td>
           ↑
          </td>
          <td>
           <xref ref-type="bibr" rid="CR104">
            104
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           SHR and hypertension induced by Ang II in rats
          </td>
          <td>
           <italic>
            Ace2
           </italic>
           gene transfer in CNS
          </td>
          <td>
           ↓
          </td>
          <td>
           <xref ref-type="bibr" rid="CR105">
            105
           </xref>
           ,
           <xref ref-type="bibr" rid="CR106">
            106
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Hypertension induced by Ang II in mice
          </td>
          <td>
           <italic>
            Ace2
           </italic>
           neuron-specific gene transfer in CNS
          </td>
          <td>
           ↓
          </td>
          <td>
           <xref ref-type="bibr" rid="CR107">
            107
           </xref>
           ,
           <xref ref-type="bibr" rid="CR108">
            108
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Stroke-prone SHRs
          </td>
          <td>
           Vascular smooth-muscle-cell-specific
           <italic>
            Ace2
           </italic>
           gene transfer
          </td>
          <td>
           ↓
          </td>
          <td>
           <xref ref-type="bibr" rid="CR109">
            109
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Hypertension induced by Ang II in mice, SHRs
          </td>
          <td>
           Systemic infusion of human or murine recombinant ACE2
          </td>
          <td>
           ↓
          </td>
          <td>
           <xref ref-type="bibr" rid="CR35">
            35
           </xref>
           ,
           <xref ref-type="bibr" rid="CR110">
            110
           </xref>
           ,
           <xref ref-type="bibr" rid="CR111">
            111
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           SHRs
          </td>
          <td>
           Systemic infusion of an ACE2 activator
          </td>
          <td>
           ↓
          </td>
          <td>
           <xref ref-type="bibr" rid="CR36">
            36
           </xref>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="4">
           <bold>
            <italic>
             Effects of angiotensin 1–7
            </italic>
           </bold>
          </td>
         </tr>
         <tr>
          <td>
           Healthy, normal rats
          </td>
          <td>
           Ang 1–7 infusion in CNS
          </td>
          <td>
           Null
          </td>
          <td>
           <xref ref-type="bibr" rid="CR113">
            113
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Rats with normal blood pressure and SHRs
          </td>
          <td>
           Ang 1–7 infusion in CNS
          </td>
          <td>
           ↑
          </td>
          <td>
           <xref ref-type="bibr" rid="CR99">
            99
           </xref>
           ,
           <xref ref-type="bibr" rid="CR100">
            100
           </xref>
           ,
           <xref ref-type="bibr" rid="CR126">
            126
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Hypertension induced by Ang II in mice
          </td>
          <td>
           Systemic infusion with Ang 1–7
          </td>
          <td>
           Null
          </td>
          <td>
           <xref ref-type="bibr" rid="CR110">
            110
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Healthy, normal rats. SHR, RHRs
          </td>
          <td>
           Systemic infusion with Ang 1–7
          </td>
          <td>
           Null
          </td>
          <td>
           <xref ref-type="bibr" rid="CR112">
            112
           </xref>
           ,
           <xref ref-type="bibr" rid="CR113">
            113
           </xref>
           ,
           <xref ref-type="bibr" rid="CR114">
            114
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Healthy, normal rats, SHRs, RHRs
          </td>
          <td>
           Systemic infusion with Ang 1–7
          </td>
          <td>
           ↓
           <sup>
            *
           </sup>
          </td>
          <td>
           <xref ref-type="bibr" rid="CR112">
            112
           </xref>
           ,
           <xref ref-type="bibr" rid="CR116">
            116
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Dahl salt-sensitive rats, SHRs
          </td>
          <td>
           Systemic infusion with Ang 1–7
          </td>
          <td>
           ↓
          </td>
          <td>
           <xref ref-type="bibr" rid="CR115">
            115
           </xref>
           ,
           <xref ref-type="bibr" rid="CR117">
            117
           </xref>
           ,
           <xref ref-type="bibr" rid="CR118">
            118
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           DOCA-salt hypertensive rats
          </td>
          <td>
           Systemic infusion with Ang 1–7
          </td>
          <td>
           Null
          </td>
          <td>
           <xref ref-type="bibr" rid="CR119">
            119
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           DOCA and aldosterone salt-hypertensive rats
          </td>
          <td>
           Ang 1–7 infusion in CNS
          </td>
          <td>
           ↓
          </td>
          <td>
           <xref ref-type="bibr" rid="CR124">
            124
           </xref>
           ,
           <xref ref-type="bibr" rid="CR125">
            125
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           2K1C hypertensive rats
          </td>
          <td>
           Systemic infusion with Ang 1–7
          </td>
          <td>
           Null
           <sup>
            ‡
           </sup>
          </td>
          <td>
           <xref ref-type="bibr" rid="CR120">
            120
           </xref>
           ,
           <xref ref-type="bibr" rid="CR121">
            121
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Subtotal-nephrectomy-induced hypertension in rats
          </td>
          <td>
           Systemic infusion with Ang 1–7
          </td>
          <td>
           ↑
          </td>
          <td>
           <xref ref-type="bibr" rid="CR122">
            122
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           SHRs
          </td>
          <td>
           Infusion of monoclonal antibody to Ang 1–7
          </td>
          <td>
           ↑
          </td>
          <td>
           <xref ref-type="bibr" rid="CR130">
            130
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Rats with normal blood pressure and SHRs
          </td>
          <td>
           Systemic infusion with (
           <sc>
            D
           </sc>
           -Ala
           <sup>
            7
           </sup>
           )-Ang-(1–7)
          </td>
          <td>
           Null
          </td>
          <td>
           <xref ref-type="bibr" rid="CR128">
            128
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           2K1C hypertensive rats
          </td>
          <td>
           Systemic infusion with (
           <sc>
            D
           </sc>
           -Ala
           <sup>
            7
           </sup>
           )-Ang-(1–7)
          </td>
          <td>
           ↑
          </td>
          <td>
           <xref ref-type="bibr" rid="CR113">
            113
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Aldosterone salt-hypertensive rats
          </td>
          <td>
           (
           <sc>
            D
           </sc>
           -Ala
           <sup>
            7
           </sup>
           )-Ang-(1–7) infusion in CNS
          </td>
          <td>
           ↑
          </td>
          <td>
           <xref ref-type="bibr" rid="CR125">
            125
           </xref>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         <sup>
          *
         </sup>
         Effects observed only in the presence of bradykinin.
        </p>
        <p>
         <sup>
          ‡
         </sup>
         Some beneficial effects observed in exercise-trained animals and for endogenous Ang 1–7.
        </p>
        <p>
         Abbreviations: 2K1C, two-kidney one clip; ACE2, angiotensin-converting enzyme 2; Ang, angiotensin; BP, blood pressure; CNS, central nervous system; DOCA, deoxycorticosterone-acetate; RHR, renal hypertensive rat; SHR, spontaneously hypertensive rat.
        </p>
       </table-wrap-foot>
      </table-wrap>
      <fig id="Fig3">
       <label>
        Figure 3
       </label>
       <caption>
        <title>
         Potential effects of ACE2 and Ang 1–7 on blood-pressure regulation.
        </title>
        <p>
         ACE2 is known to cause reductions in blood pressure, whereas various experimental evidence has indicated no effects, hypotensive effects, and hypertensive effects of Ang 1–7. Abbreviations: ACE2, angiotensin-converting enzyme 2; Ang, angiotensin; CNS, central nervous system; PVN, paraventricular nucleus, RVLM, rostral ventrolateral medulla.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM6">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e1559" xlink:href="41569_2014_Article_BFnrcardio201459_Fig3_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par36">
      Pharmacological intervention studies have revealed similar beneficial effects of ACE2 on high blood pressure. Systemic administration of human recombinant ACE2 counteracted pressor effects induced by angiotensin II, which was associated with accelerated clearance of circulating angiotensin II.
      <sup>
       <xref ref-type="bibr" rid="CR110">
        110
       </xref>
       ,
       <xref ref-type="bibr" rid="CR111">
        111
       </xref>
      </sup>
      Moreover, in SHRs, chronic ACE2 treatment resulted in a sustained decrease in blood pressure.
      <sup>
       <xref ref-type="bibr" rid="CR111">
        111
       </xref>
      </sup>
      Murine recombinant ACE2 has similar antihypertensive effects to human ACE2 in hypertension induced by angiotensin II.
      <sup>
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
      </sup>
      Likewise, chronic infusion of the ACE2-activating compound xanthenone slightly decreases blood pressure in SHRs.
      <sup>
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
      </sup>
     </p>
     <p id="Par37">
      In contrast to the reported protective effects of ACE2 in experimental hypertension, studies with angiotensin 1–7 have yielded rather heterogeneous results (
      <xref ref-type="table" rid="Tab1">
       Table 1
      </xref>
      ). Most of the studies have shown that acute systemic infusion of angiotensin 1–7, in either rats with normal blood pressure or those with hypertension due to various aetiologies, does not change blood pressure.
      <sup>
       <xref ref-type="bibr" rid="CR112">
        112
       </xref>
       ,
       <xref ref-type="bibr" rid="CR113">
        113
       </xref>
       ,
       <xref ref-type="bibr" rid="CR114">
        114
       </xref>
      </sup>
      Decreases in mean blood pressure in Dahl salt-sensitive rats, however, have been reported.
      <sup>
       <xref ref-type="bibr" rid="CR115">
        115
       </xref>
      </sup>
      In anaesthetized mice, bolus administration of angiotensin 1–7 showed no effect on angiotensin-II-induced elevation in blood pressure or on blood-pressure recovery after injected angiotensin II was stopped.
      <sup>
       <xref ref-type="bibr" rid="CR110">
        110
       </xref>
      </sup>
      In healthy, normal rats, acute infusion of angiotensin 1–7 led to an enhancement of the hypotensive effects of bradykinin.
      <sup>
       <xref ref-type="bibr" rid="CR112">
        112
       </xref>
       ,
       <xref ref-type="bibr" rid="CR116">
        116
       </xref>
      </sup>
      Chronic treatment with angiotensin 1–7 was associated with transient or sustained reductions in blood pressure in various hypertensive models, including SHRs and Dahl salt-sensitive rats,
      <sup>
       <xref ref-type="bibr" rid="CR117">
        117
       </xref>
       ,
       <xref ref-type="bibr" rid="CR118">
        118
       </xref>
      </sup>
      but not in deoxycorticosterone-acetate (DOCA) salt-treated rats.
      <sup>
       <xref ref-type="bibr" rid="CR119">
        119
       </xref>
      </sup>
      Results in the two-kidney one-clip model of hypertension in rats have been inconsistent.
      <sup>
       <xref ref-type="bibr" rid="CR120">
        120
       </xref>
       ,
       <xref ref-type="bibr" rid="CR121">
        121
       </xref>
      </sup>
      Moreover, chronic angiotensin 1–7 treatment has been observed to further increase blood pressure in rats with hypertension induced by subtotal nephrectomy.
      <sup>
       <xref ref-type="bibr" rid="CR122">
        122
       </xref>
      </sup>
     </p>
     <p id="Par38">
      Administration of angiotensin 1–7 into the central nervous system of rats has induced null, hypertensive, and hypotensive effects. Intracerebroventricular infusion of angiotensin 1–7 showed no effects in rats with normal blood pressure,
      <sup>
       <xref ref-type="bibr" rid="CR113">
        113
       </xref>
       ,
       <xref ref-type="bibr" rid="CR123">
        123
       </xref>
      </sup>
      and lowered blood pressure in DOCA and aldosterone salt-hypertensive rats.
      <sup>
       <xref ref-type="bibr" rid="CR124">
        124
       </xref>
       ,
       <xref ref-type="bibr" rid="CR125">
        125
       </xref>
      </sup>
      Conversely, injection of angiotensin 1–7 into the rostral ventrolateral medulla triggered an increase in blood pressure in rats with normal blood pressure and in SHRs.
      <sup>
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
       ,
       <xref ref-type="bibr" rid="CR100">
        100
       </xref>
       ,
       <xref ref-type="bibr" rid="CR126">
        126
       </xref>
      </sup>
     </p>
     <p id="Par39">
      In anaesthetized mice, acute treatment with (
      <sc>
       D
      </sc>
      -Ala
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      )-angiotensin-(1–7) showed no effect on basal or angiotensin-II-induced systolic hypertension.
      <sup>
       <xref ref-type="bibr" rid="CR110">
        110
       </xref>
      </sup>
      Acute central administration of (
      <sc>
       D
      </sc>
      -Ala
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      )-angiotensin-(1–7) does not change mean arterial blood pressure
      <sup>
       <xref ref-type="bibr" rid="CR127">
        127
       </xref>
      </sup>
      and chronic treatment does not modify the blood pressure
      <sup>
       <xref ref-type="bibr" rid="CR128">
        128
       </xref>
      </sup>
      in rats with normal blood pressure or SHRs. (
      <sc>
       D
      </sc>
      -Ala
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      )-angiotensin-(1–7) given centrally or systemically, however, antagonizes the hypotensive actions of ACE2 in transgenic mice
      <sup>
       <xref ref-type="bibr" rid="CR108">
        108
       </xref>
      </sup>
      and worsens hypertension, baroreflex dysfunction, or both in various models.
      <sup>
       <xref ref-type="bibr" rid="CR120">
        120
       </xref>
       ,
       <xref ref-type="bibr" rid="CR125">
        125
       </xref>
       ,
       <xref ref-type="bibr" rid="CR129">
        129
       </xref>
      </sup>
      Acute infusion of a monoclonal antibody to angiotensin 1–7 in SHRs notably raised blood pressure.
      <sup>
       <xref ref-type="bibr" rid="CR130">
        130
       </xref>
      </sup>
     </p>
     <p id="Par40">
      In humans, infusion of angiotensin 1–7 induced notable vasodilator effects in control individuals with normal blood pressure and in patients with hypertension.
      <sup>
       <xref ref-type="bibr" rid="CR131">
        131
       </xref>
      </sup>
      Yet, in another study, acute infusion of angiotensin 1–7 did not change the blood pressure in individuals with normal blood pressure.
      <sup>
       <xref ref-type="bibr" rid="CR132">
        132
       </xref>
      </sup>
     </p>
     <p id="Par41">
      Taken together, these results suggest that ACE2 has potential blood-pressure-lowering effects via multiple mechanisms, among which catabolism of angiotensin II is likely to be essential (
      <xref ref-type="fig" rid="Fig3">
       Figure 3
      </xref>
      ). By contrast, the functional importance of ACE2-dependent angiotensin 1–7 production remains to be confirmed.
     </p>
    </sec>
    <sec id="Sec9">
     <title>
      Atherosclerosis
     </title>
     <p id="Par42">
      ACE2 is expressed in atherosclerotic lesions in animal and human vessels.
      <sup>
       <xref ref-type="bibr" rid="CR133">
        133
       </xref>
       ,
       <xref ref-type="bibr" rid="CR134">
        134
       </xref>
       ,
       <xref ref-type="bibr" rid="CR135">
        135
       </xref>
      </sup>
      The role of ACE2 in atherogenesis (
      <xref ref-type="fig" rid="Fig4">
       Figure 4
      </xref>
      ) has been investigated with use of various
      <italic>
       in vivo
      </italic>
      models.
      <sup>
       <xref ref-type="bibr" rid="CR136">
        136
       </xref>
      </sup>
      Systemic overexpression of ACE2 suppressed atherogenesis in apolipoprotein-E-knockout mice.
      <sup>
       <xref ref-type="bibr" rid="CR137">
        137
       </xref>
      </sup>
      A similar antiatherosclerotic effect of ACE2 was seen in rabbits fed with a high-cholesterol diet.
      <sup>
       <xref ref-type="bibr" rid="CR138">
        138
       </xref>
      </sup>
      ACE2 overexpression also stabilized the atherosclerotic plaques via inhibition of inflammation and production of matrix metalloproteinases; this effect was reversed by (
      <sc>
       D
      </sc>
      -Ala
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      )-angiotensin-(1–7).
      <sup>
       <xref ref-type="bibr" rid="CR139">
        139
       </xref>
      </sup>
      Conversely, loss-of-function mutations in
      <italic>
       Ace2
      </italic>
      promoted plaque accumulation with increased expression of inflammatory adhesion molecules and cytokines.
      <sup>
       <xref ref-type="bibr" rid="CR140">
        140
       </xref>
       ,
       <xref ref-type="bibr" rid="CR141">
        141
       </xref>
       ,
       <xref ref-type="bibr" rid="CR142">
        142
       </xref>
      </sup>
      <fig id="Fig4">
       <label>
        Figure 4
       </label>
       <caption>
        <title>
         Protective effects of ACE2 and Ang 1–7 on atherosclerosis and resultant myocardial infarction and stroke.
        </title>
        <p>
         Abbreviations: ACE2, angiotensin-converting enzyme 2; Ang, angiotensin; VSMC, vascular smooth muscle cell.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM7">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e1798" xlink:href="41569_2014_Article_BFnrcardio201459_Fig4_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par43">
      Similar to ACE2, angiotensin 1–7 has beneficial effects in experimental atherosclerosis (
      <xref ref-type="fig" rid="Fig4">
       Figure 4
      </xref>
      ). Long-term treatment with angiotensin 1–7 in apolipoprotein-E-knockout mice prevented progression of atherosclerotic lesions and improved endothelial function of nitric oxide.
      <sup>
       <xref ref-type="bibr" rid="CR143">
        143
       </xref>
      </sup>
      These effects seemed to involve both Mas and the AT2 receptor. Systemic administration of angiotensin 1–7 inhibited atherosclerotic lesion formation and enhanced plaque stability in mice in a dose-dependent manner. These effects were associated with decreased proliferation and migration of vascular smooth muscle cells, and decreased macrophage release of inflammatory cytokines.
      <sup>
       <xref ref-type="bibr" rid="CR144">
        144
       </xref>
      </sup>
      Activation of the angiotensin 1–7 receptor with AVE 0991 also inhibited atherogenesis in apolipoprotein-E-knockout mice.
      <sup>
       <xref ref-type="bibr" rid="CR145">
        145
       </xref>
       ,
       <xref ref-type="bibr" rid="CR146">
        146
       </xref>
      </sup>
      The atheroprotective actions of angiotensin 1–7 could be related to its inhibitory effects on vascular inflammation and smooth-muscle-cell proliferation and migration, probably via Mas-mediated suppression of the nuclear factor κB or MAPK pathways, or both.
      <sup>
       <xref ref-type="bibr" rid="CR58">
        58
       </xref>
       ,
       <xref ref-type="bibr" rid="CR144">
        144
       </xref>
       ,
       <xref ref-type="bibr" rid="CR147">
        147
       </xref>
      </sup>
      Although (
      <sc>
       D
      </sc>
      -Ala
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      )-angiotensin-(1–7) alone does not modulate early atherogenesis, it seems to aggravate destabilization of atherosclerotic plaques.
      <sup>
       <xref ref-type="bibr" rid="CR143">
        143
       </xref>
       ,
       <xref ref-type="bibr" rid="CR144">
        144
       </xref>
      </sup>
     </p>
    </sec>
    <sec id="Sec10">
     <title>
      Cardiac remodelling and heart failure
     </title>
     <p id="Par44">
      <italic>
       ACE2
      </italic>
      was originally cloned as a heart-failure-associated gene from the heart tissue of a patient with idiopathic dilated cardiomyopathy,
      <sup>
       <xref ref-type="bibr" rid="CR8">
        8
       </xref>
      </sup>
      but studies have not unequivocally confirmed that cardiac expression is changed in human heart failure.
      <sup>
       <xref ref-type="bibr" rid="CR148">
        148
       </xref>
       ,
       <xref ref-type="bibr" rid="CR149">
        149
       </xref>
       ,
       <xref ref-type="bibr" rid="CR150">
        150
       </xref>
       ,
       <xref ref-type="bibr" rid="CR151">
        151
       </xref>
      </sup>
      The level and activity of soluble ACE2 in plasma seem to be increased in patients with heart failure.
      <sup>
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="CR152">
        152
       </xref>
      </sup>
      Associations between
      <italic>
       ACE2
      </italic>
      polymorphisms and hypertrophic cardiomyopathy have also been reported.
      <sup>
       <xref ref-type="bibr" rid="CR153">
        153
       </xref>
       ,
       <xref ref-type="bibr" rid="CR154">
        154
       </xref>
      </sup>
     </p>
     <p id="Par45">
      ACE2 shows multiple beneficial effects in left ventricular remodelling and dysfunction in rat models of cardiac hypertrophy induced by angiotensin II, diabetic cardiomyopathy induced by streptozotocin, and myocardial infarction induced by coronary artery occlusion.
      <sup>
       <xref ref-type="bibr" rid="CR155">
        155
       </xref>
       ,
       <xref ref-type="bibr" rid="CR156">
        156
       </xref>
       ,
       <xref ref-type="bibr" rid="CR157">
        157
       </xref>
      </sup>
      In mice with right ventricular dysfunction induced by pressure overload, treatment with recombinant human ACE2 reduces ventricular hypertrophy and improves systolic and diastolic functions.
      <sup>
       <xref ref-type="bibr" rid="CR158">
        158
       </xref>
      </sup>
      By contrast,
      <italic>
       Ace2
      </italic>
      knockout augments angiotensin-II-induced myocardial hypertrophy and interstitial fibrosis and accelerates the transition from hypertrophy to heart failure.
      <sup>
       <xref ref-type="bibr" rid="CR159">
        159
       </xref>
       ,
       <xref ref-type="bibr" rid="CR160">
        160
       </xref>
       ,
       <xref ref-type="bibr" rid="CR161">
        161
       </xref>
       ,
       <xref ref-type="bibr" rid="CR162">
        162
       </xref>
      </sup>
      <italic>
       Ace2
      </italic>
      knockout also aggravates cardiac dysfunction induced by diabetes in mice.
      <sup>
       <xref ref-type="bibr" rid="CR163">
        163
       </xref>
      </sup>
      Although the cardioprotective mechanisms of ACE2 are not completely clear, mediation of angiotensin II catabolism and subsequent inhibition of angiotensin-II-induced oxidative stress, inflammation, and interstitial fibrosis are thought to have important roles (
      <xref ref-type="fig" rid="Fig5">
       Figure 5
      </xref>
      ).
      <sup>
       <xref ref-type="bibr" rid="CR156">
        156
       </xref>
       ,
       <xref ref-type="bibr" rid="CR160">
        160
       </xref>
       ,
       <xref ref-type="bibr" rid="CR163">
        163
       </xref>
      </sup>
      In addition, reductions in sympathetic nerve activity might be attributable to
      <italic>
       ACE2
      </italic>
      -induced cardioprotection, as demonstrated in studies with central ACE2 overexpression (
      <xref ref-type="fig" rid="Fig5">
       Figure 5
      </xref>
      ).
      <sup>
       <xref ref-type="bibr" rid="CR164">
        164
       </xref>
      </sup>
      <fig id="Fig5">
       <label>
        Figure 5
       </label>
       <caption>
        <title>
         Potential protective effects of ACE2 and Ang 1–7 on pathological cardiac remodelling and heart failure.
        </title>
        <p>
         Abbreviations: ACE2, angiotensin-converting enzyme 2; Ang, angiotensin.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM8">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e1964" xlink:href="41569_2014_Article_BFnrcardio201459_Fig5_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par46">
      Production of angiotensin 1–7 is substantially increased in heart failure induced by myocardial infarction.
      <sup>
       <xref ref-type="bibr" rid="CR165">
        165
       </xref>
      </sup>
      To date, most studies support that angiotensin 1–7 has protective effects on pathological cardiac remodelling and heart failure (
      <xref ref-type="fig" rid="Fig5">
       Figure 5
      </xref>
      ). For instance, systemic infusion of angiotensin 1–7 prevents the development of heart failure following myocardial infarction in rats.
      <sup>
       <xref ref-type="bibr" rid="CR166">
        166
       </xref>
      </sup>
      The angiotensin 1–7 receptor agonist AVE 0991 shows similar beneficial effects.
      <sup>
       <xref ref-type="bibr" rid="CR167">
        167
       </xref>
      </sup>
      Infusion of angiotensin 1–7 also prevents cardiac remodelling induced by angiotensin II in rats,
      <sup>
       <xref ref-type="bibr" rid="CR168">
        168
       </xref>
      </sup>
      and diabetes-induced diastolic dysfunction (with a preserved ejection fraction) in db/db mice.
      <sup>
       <xref ref-type="bibr" rid="CR169">
        169
       </xref>
      </sup>
      Testis-specific angiotensin 1–7 in transgenic rats, which doubles the concentration of circulating angiotensin 1–7, has notable protective effects on myocardial hypertrophy and fibrosis induced by β-adrenoceptor agonists.
      <sup>
       <xref ref-type="bibr" rid="CR170">
        170
       </xref>
       ,
       <xref ref-type="bibr" rid="CR171">
        171
       </xref>
      </sup>
      Treatment with angiotensin 1–7 also produces equivalent protective actions on pressure-overload-induced cardiac hypertrophy and remodelling as AT1-receptor blockade in ACE2-null mice.
      <sup>
       <xref ref-type="bibr" rid="CR172">
        172
       </xref>
      </sup>
     </p>
     <p id="Par47">
      The cardiac protective actions of angiotensin 1–7 are unlikely to be primarily mediated by a local mechanism in the myocardium, since the effects of cardiomyocyte-restricted overexpression on pathological cardiac remodelling seem to be inconsistent.
      <sup>
       <xref ref-type="bibr" rid="CR173">
        173
       </xref>
       ,
       <xref ref-type="bibr" rid="CR174">
        174
       </xref>
       ,
       <xref ref-type="bibr" rid="CR175">
        175
       </xref>
      </sup>
      Additionally, the effects of angiotensin 1–7 on arrhythmia are biphasic; the beneficial effects on the myocardium associated with low concentrations arise through induction of hyperpolarization and increased the conduction velocity and refractoriness, whereas high concentrations have arrhythmogenic actions.
      <sup>
       <xref ref-type="bibr" rid="CR50">
        50
       </xref>
      </sup>
      Whether angiotensin 1–7 leads to cardiac dysfunction and remodelling in rodent models of renal disease is controversial.
      <sup>
       <xref ref-type="bibr" rid="CR122">
        122
       </xref>
       ,
       <xref ref-type="bibr" rid="CR176">
        176
       </xref>
      </sup>
     </p>
    </sec>
    <sec id="Sec11">
     <title>
      Cerebral vessels and ischaemic stroke
     </title>
     <p id="Par48">
      Involvement of angiotensin 1–7 in modulation of cerebral vascular functions and the process of ischaemic stroke (
      <xref ref-type="fig" rid="Fig4">
       Figure 4
      </xref>
      ) is supported by several studies. In
      <italic>
       ex vivo
      </italic>
      preparations of canine middle cerebral arteries, Feterik
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="CR177">
        177
       </xref>
      </sup>
      demonstrated that angiotensin 1–7 induced endothelium-dependent relaxation sensitive to blockade of nitric oxide synthase and soluble guanylyl cyclase. Relaxation induced by angiotensin 1–7 is not affected by (
      <sc>
       D
      </sc>
      -Ala
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      )-angiotensin-(1–7) or the AT2 receptor antagonist PD123319, but is partially blocked by a bradykinin B2 receptor antagonist.
      <sup>
       <xref ref-type="bibr" rid="CR177">
        177
       </xref>
      </sup>
      Similar vasodilatory effects have been observed in rat middle cerebral arteries.
      <sup>
       <xref ref-type="bibr" rid="CR178">
        178
       </xref>
      </sup>
      Moreover, chronic intravenous infusion of angiotensin 1–7 reversed endothelial dysfunction in the middle cerebral artery in rats maintained on a high-salt diet.
      <sup>
       <xref ref-type="bibr" rid="CR178">
        178
       </xref>
      </sup>
     </p>
     <p id="Par49">
      In rats with acute ischaemic stroke, expression of ACE2 and Mas are upregulated, and concentrations of local and circulating angiotensin 1–7 are substantially increased.
      <sup>
       <xref ref-type="bibr" rid="CR179">
        179
       </xref>
      </sup>
      In a rat model of stroke, induced by occlusion of middle cerebral arteries, pretreatment with angiotensin 1–7 by intracerebroventricular infusion was associated with reductions in infarct size and severity of neurological deficits; these effects were blocked by administration of (
      <sc>
       D
      </sc>
      -Ala
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      )-angiotensin-(1–7).
      <sup>
       <xref ref-type="bibr" rid="CR180">
        180
       </xref>
       ,
       <xref ref-type="bibr" rid="CR181">
        181
       </xref>
      </sup>
      The neural protective actions of angiotensin 1–7 in brain ischaemia, however, are unlikely to be related to alterations in cerebral blood flow. Rather, they seem to be mediated by an anti-inflammatory effect of angiotensin 1–7, as evidenced by reductions in the expression of inducible nitric oxide synthase and cyclo-oxygenase-2, activation of nuclear factor κB, oxidative stress, and release of proinflammatory cytokines in the injured brain tissue.
      <sup>
       <xref ref-type="bibr" rid="CR180">
        180
       </xref>
       ,
       <xref ref-type="bibr" rid="CR181">
        181
       </xref>
       ,
       <xref ref-type="bibr" rid="CR182">
        182
       </xref>
      </sup>
     </p>
    </sec>
    <sec id="Sec12">
     <title>
      Diabetes
     </title>
     <p id="Par50">
      Accumulating evidence has suggested that the functions of ACE2 and angiotensin 1–7 are affected by diabetes. Additionally, however, ACE2 and angiotensin 1–7 substantially affect glucose metabolism, which suggests they could have potential beneficial effects in patients with diabetes (
      <xref ref-type="fig" rid="Fig6">
       Figure 6
      </xref>
      ). Circulating ACE2 activity was increased in streptozotocin-treated rats with diabetes and in nonobese mice with diabetes.
      <sup>
       <xref ref-type="bibr" rid="CR183">
        183
       </xref>
       ,
       <xref ref-type="bibr" rid="CR184">
        184
       </xref>
      </sup>
      Likewise, ACE2 activity in serum was increased in humans with type 1 diabetes.
      <sup>
       <xref ref-type="bibr" rid="CR185">
        185
       </xref>
      </sup>
      Ectopic expression of human ACE2 in the pancreas of young db/db mice was associated with significantly decreased hyperglycaemia, improved islet function, and reduced β-cell apoptosis.
      <sup>
       <xref ref-type="bibr" rid="CR186">
        186
       </xref>
      </sup>
      These effects were prevented by administration of (
      <sc>
       D
      </sc>
      -Ala
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      )-angiotensin-(1–7).
      <sup>
       <xref ref-type="bibr" rid="CR186">
        186
       </xref>
      </sup>
      Conversely, ACE2 deficiency aggravated impaired glucose tolerance and insulin sensitivity induced by diet.
      <sup>
       <xref ref-type="bibr" rid="CR187">
        187
       </xref>
      </sup>
      Increased circulating concentrations of angiotensin 1–7, as a result of chronic infusion or transgenic expression, ameliorated hyperinsulinaemia, insulin resistance, and inflammatory responses in adipose tissue in overnourished rats,
      <sup>
       <xref ref-type="bibr" rid="CR45">
        45
       </xref>
       ,
       <xref ref-type="bibr" rid="CR188">
        188
       </xref>
       ,
       <xref ref-type="bibr" rid="CR189">
        189
       </xref>
      </sup>
      and increased insulin sensitivity and glucose tolerance in normoglycaemic rats.
      <sup>
       <xref ref-type="bibr" rid="CR47">
        47
       </xref>
      </sup>
      Moreover, in a rat model of type 2 diabetes, chronic oral treatment with an angiotensin 1–7 formula induced a substantial hypoglycaemic effect, improved insulin sensitivity, and prevented hyperinsulinaemia.
      <sup>
       <xref ref-type="bibr" rid="CR190">
        190
       </xref>
      </sup>
      <fig id="Fig6">
       <label>
        Figure 6
       </label>
       <caption>
        <title>
         Beneficial effects of ACE2 and Ang 1-7 on insulin resistance and diabetes.
        </title>
        <p>
         The conversion of Ang II to Ang 1-7 by ACE2 is increased in type 1 and in type 2 diabetes. Ang 1-7 increases insulin sensitivity and glucose uptake through activation of PI3K–Akt signalling and reduction of pancreatic β-cell apoptosis. Blockade of the effects of ACE2 by MLN-4760, or Ang 1-7 by A-779, might reverse the metabolic effects of ACE2 and Ang 1-7 and thereby worsen vascular complications. Abbreviations: ACE, angiotensin-converting enzyme; Ang, angiotensin; PI3K, phosphatidylinositol 3-kinase.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM9">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e2161" xlink:href="41569_2014_Article_BFnrcardio201459_Fig6_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par51">
      The mechanisms underlying the beneficial actions of ACE2 and angiotensin 1–7 in glucose metabolism could be multifaceted. First, activation of the RAS, especially the local RAS, for instance in skeletal muscle, adipose tissue, and the pancreas, contributes notably to the development of insulin resistance and diabetes.
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="CR191">
        191
       </xref>
      </sup>
      Hence, increased degradation of angiotensin II by ACE2 might be important in glucose metabolism. Second, angiotensin 1–7 can activate the phosphatidylinositol-3-kinase–Akt pathway
      <sup>
       <xref ref-type="bibr" rid="CR45">
        45
       </xref>
       ,
       <xref ref-type="bibr" rid="CR51">
        51
       </xref>
       ,
       <xref ref-type="bibr" rid="CR52">
        52
       </xref>
       ,
       <xref ref-type="bibr" rid="CR53">
        53
       </xref>
       ,
       <xref ref-type="bibr" rid="CR54">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
      </sup>
      and thereby facilitate insulin-induced signalling and glucose uptake. Angiotensin 1–7 might also antagonize dysfunction in insulin signalling induced by angiotensin II by preventing serine phosphorylation of insulin receptor substrate 1,
      <sup>
       <xref ref-type="bibr" rid="CR96">
        96
       </xref>
      </sup>
      probably via inhibition of activation of MAPK pathways induced by angiotensin II.
      <sup>
       <xref ref-type="bibr" rid="CR58">
        58
       </xref>
       ,
       <xref ref-type="bibr" rid="CR60">
        60
       </xref>
       ,
       <xref ref-type="bibr" rid="CR192">
        192
       </xref>
      </sup>
      Moreover, evidence suggests that angiotensin 1–7 facilitates glucose uptake by upregulation of glucose transporter type 4 expression, which is the major glucose transporter in humans.
      <sup>
       <xref ref-type="bibr" rid="CR187">
        187
       </xref>
      </sup>
     </p>
     <p id="Par52">
      ACE2 and angiotensin 1–7 have shown remarkable protective actions against diabetic nephropathy in several studies. Clinical and experimental studies have revealed reduced ACE2 expression in the kidney in the setting of diabetes and associated kidney disease.
      <sup>
       <xref ref-type="bibr" rid="CR183">
        183
       </xref>
       ,
       <xref ref-type="bibr" rid="CR193">
        193
       </xref>
       ,
       <xref ref-type="bibr" rid="CR194">
        194
       </xref>
       ,
       <xref ref-type="bibr" rid="CR195">
        195
       </xref>
      </sup>
      ACE2 inhibition with MLN-4760 worsened glomerular injury in mice with streptozotocin-induced diabetes,
      <sup>
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
      </sup>
      and
      <italic>
       Ace2
      </italic>
      knockout accelerated diabetes-induced kidney injuries.
      <sup>
       <xref ref-type="bibr" rid="CR196">
        196
       </xref>
       ,
       <xref ref-type="bibr" rid="CR197">
        197
       </xref>
      </sup>
      Increasing the ACE2 function in Akita mice with diabetes by systemic treatment with recombinant ACE2, however, ameliorated albuminuria and prevents glomerular proliferation, fibrosis, and oxidative stress.
      <sup>
       <xref ref-type="bibr" rid="CR198">
        198
       </xref>
      </sup>
      In rats with diabetes, global overexpression of ACE2 has produced remarkable renal protection similar to that induced by the ACE inhibitor benazepril, but no synergistic actions between ACE inhibition and ACE2 have been observed.
      <sup>
       <xref ref-type="bibr" rid="CR199">
        199
       </xref>
      </sup>
      Local overexpression of ACE2 in renal podocytes also seems to prevent kidney injuries in mice with diabetes.
      <sup>
       <xref ref-type="bibr" rid="CR200">
        200
       </xref>
      </sup>
      Additionally, chronic systemic treatment with angiotensin 1–7 reduced the risk of renal fibrosis, oxidative stress, and inflammation in the Zucker obese rat model of type 2 diabetes.
      <sup>
       <xref ref-type="bibr" rid="CR201">
        201
       </xref>
      </sup>
     </p>
    </sec>
    <sec id="Sec13">
     <title>
      The gut
     </title>
     <p id="Par53">
      ACE2 is highly expressed in gut tissues, at least in rodents.
      <sup>
       <xref ref-type="bibr" rid="CR202">
        202
       </xref>
      </sup>
      ACE2 in the gut has been shown to have a critical role in the regulation of intestinal innate immunity, amino acid homeostasis, and the ecology of the gut microbiota.
      <sup>
       <xref ref-type="bibr" rid="CR203">
        203
       </xref>
      </sup>
      ACE2 deficiency results in increased susceptibility to intestinal inflammation induced by epithelial damage.
      <sup>
       <xref ref-type="bibr" rid="CR203">
        203
       </xref>
      </sup>
      Of note, some evidence suggests that metabolism of dietary components by the intestinal microbiota might also have effects on the cardiovascular health,
      <sup>
       <xref ref-type="bibr" rid="CR204">
        204
       </xref>
      </sup>
      which raises the possibility that ACE2 expressed in the gut contributes to vascular protection indirectly by modulating the interactions between gut microbiota and the intestinal epithelium.
     </p>
    </sec>
    <sec id="Sec14">
     <title>
      Targeted clinical therapies
     </title>
     <p id="Par54">
      The success of chemical ACE inhibitors and AT1-receptor blockers in clinical management of various cardiovascular diseases underscores the possibility that searching for chemical modulators that target other active components of RAS could be fruitful. In a first-in-human study, human recombinant ACE2 was administered intravenously to healthy volunteers to assess the pharmacokinetic, pharmacodynamic, and safety profiles of native ACE2.
      <sup>
       <xref ref-type="bibr" rid="CR205">
        205
       </xref>
      </sup>
      Bioavailability of recombinant ACE2 in the human body showed a linear dose-dependent increase and had a terminal elimination half-life of ∼10 h. Strikingly, within 30 min of administration of ACE2 at 400 μg/kg and 1,200 μg/kg, the plasma concentration of angiotensin II dropped and remained suppressed for more than 24 h. The level of angiotensin 1–7 varied in response to different doses of ACE2. Recombinant ACE2 was well tolerated, with no obvious effects on haemodynamic parameters.
      <sup>
       <xref ref-type="bibr" rid="CR205">
        205
       </xref>
      </sup>
      These results also highlight the possibility that, in humans, the potential cardiovascular protective actions of raised ACE2 concentrations might largely be mediated by the accelerated catabolism of angiotensin II.
     </p>
     <p id="Par55">
      The basic pharmacokinetic and safety profiles of native angiotensin 1–7 were mainly obtained from several studies in patients with cancer.
      <sup>
       <xref ref-type="bibr" rid="CR40">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="CR206">
        206
       </xref>
      </sup>
      Native angiotensin 1–7 causes vasodilatation in healthy individuals and patients with hypertension,
      <sup>
       <xref ref-type="bibr" rid="CR131">
        131
       </xref>
      </sup>
      but it shows no effect in patients with heart failure.
      <sup>
       <xref ref-type="bibr" rid="CR207">
        207
       </xref>
      </sup>
      Angiotensin 1–7 is continuously catabolized by ACE, NEP, and aminopeptidases; therefore, decreased degradation seems to be a plausible contributor to the beneficial effects of ACE inhibitors.
      <sup>
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
      </sup>
      The value of angiotensin 1–7 as a therapeutic agent could be limited by the very short half-life of this peptide in the body. An ACE-resistant, cyclic angiotensin 1–7 analogue, in which a thioether bridge is introduced to the modified residues 4 and 7 of angiotensin 1–7, has been described.
      <sup>
       <xref ref-type="bibr" rid="CR208">
        208
       </xref>
      </sup>
      The bridged peptide was highly resistant to ACE activity, and showed a substantial (34-fold) reduction in plasma clearance in rats. Moreover, this agent induced a Mas-dependent vasodilator effect in isolated rat aorta.
      <sup>
       <xref ref-type="bibr" rid="CR208">
        208
       </xref>
      </sup>
      Thioether-bridged angiotensin 1–7 is stable at low (2.0) pH and is bioavailable after oral administration in rats.
      <sup>
       <xref ref-type="bibr" rid="CR209">
        209
       </xref>
      </sup>
      In a rat model of myocardial infarction, chronic infusion of thioether-bridged angiotensin 1–7 started 2 weeks after the infarction suppressed myocyte hypertrophy and improved cardiac and vascular functions.
      <sup>
       <xref ref-type="bibr" rid="CR210">
        210
       </xref>
      </sup>
     </p>
     <p id="Par56">
      A hydroxypropyl β-cyclodextrin-incorporated angiotensin 1–7 formulation (HPβCD/Ang1–7) designed to overcome the instability of native angiotensin 1–7 in the gastrointestinal tract has been created.
      <sup>
       <xref ref-type="bibr" rid="CR211">
        211
       </xref>
      </sup>
      Oral treatment with HPβCD/Ang1–7 has shown remarkable cardioprotective effects in rats with myocardial infarction and pathological remodelling after coronary artery occlusion.
      <sup>
       <xref ref-type="bibr" rid="CR211">
        211
       </xref>
       ,
       <xref ref-type="bibr" rid="CR212">
        212
       </xref>
      </sup>
      Moreover, orally administered HPβCD/Ang1–7 was associated with improved lipid metabolism and prevention of hepatic steatosis in mice fed a high-fat diet.
      <sup>
       <xref ref-type="bibr" rid="CR213">
        213
       </xref>
      </sup>
      Similarly, long-term oral HPβCD/Ang1–7 treatment was found to reverse established hyperglycaemia, improve insulin sensitivity, and prevent diabetic nephropathy in a transgenic rat model of insulin resistance and type 2 diabetes.
      <sup>
       <xref ref-type="bibr" rid="CR190">
        190
       </xref>
      </sup>
     </p>
     <p id="Par57">
      Our understanding of the roles of ACE2 and angiotensin 1–7 is mainly derived from studies of experimental models.
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
       ,
       <xref ref-type="bibr" rid="CR214">
        214
       </xref>
       ,
       <xref ref-type="bibr" rid="CR215">
        215
       </xref>
       ,
       <xref ref-type="bibr" rid="CR216">
        216
       </xref>
       ,
       <xref ref-type="bibr" rid="CR217">
        217
       </xref>
      </sup>
      and evidence for biological actions in humans is sparse. Nevertheless, new drugs or pharmaceutical formulations targeting ACE2 and angiotensin 1–7 are expected to have strong clinical potential to treat cardiovascular diseases, especially those associated with increased activation of the conventional RAS. Research taking various directions,
      <sup>
       <xref ref-type="bibr" rid="CR218">
        218
       </xref>
      </sup>
      including modifications of native ACE2 and angiotensin 1–7 and identification of compounds that can specifically modulate the functions of ACE2, is underway. The latter might include small-molecule ACE2 activators and angiotensin 1–7 mimetics. Clearly, randomized, controlled clinical trials are required to assess the therapeutic efficacy and safety of targeted interventions.
     </p>
    </sec>
    <sec id="Sec15">
     <title>
      Conclusions
     </title>
     <p id="Par58">
      Numerous experimental studies have suggested that ACE2 has protective effects in the heart and blood vessels, primarily by modulating the homeostasis of systemic neurohumoral factors and by improving cardiovascular risk factors. ACE2-mediated catabolism of angiotensin II is likely to have a major role in cardiovascular protection, especially in patients with overactive RAS. Interventions targeting ACE2, therefore, might represent a promising direction in the discovery of novel therapies for cardiovascular disease.
     </p>
     <p id="Par59">
      By contrast, the physiological and pharmacological actions of angiotensin 1–7 are complex and even paradoxical in certain circumstances, such as in the kidney. Similarly, the effects of angiotensin 1–7 on blood-pressure regulation are variable. Infusion of angiotensin 1–7 induces either vasodilatation or a null effect in normotensive humans. The effects of angiotensin 1–7 on cardiac dysfunction and remodelling caused by renal disease in rodents are contradictory in different studies. Moreover, angiotensin 1–7 shows biphasic actions on cardiac arrhythmia following myocardial injury. Therefore, more studies, especially controlled clinical trials, are needed to clearly delineate the benefits of angiotensin-1–7-based therapies.
     </p>
    </sec>
    <sec id="Sec16">
     <title>
      Review criteria
     </title>
     <p id="Par60">
      The articles reviewed in this paper were selected from the PubMed database using the search terms: “angiotensin-converting enzyme 2 OR ACE2”, or “angiotensin 1-7” or “Mas”, plus other identifiers, including (but not limited to) “hypertension OR blood pressure”, “atherosclerosis”, “heart OR cardiac remodeling”, “diabetes OR insulin resistance OR hyperinsulinaemia”, and “stroke OR cerebral vascular”. Review articles were filtered by using the search term “review [pt]”. Articles relating to the biochemistry and pharmacology of ACE2/angiotensin 1-7/Mas were searched using terms including “biochemistry”, “inhibitor OR antagonist”, “agonist OR activator”, “binding affinity”, “ligand binding”, or “pharmacokinetics OR pharmacodynamics”. On some occasions, terms including “domain structure”, “domains”, or “crystallography” were also used for a general search in the internet. We applied no restrictions on date of publication or origin of the work, but only articles published in English were included. Most of the papers cited were full-text articles. Selected reference lists from retrieved papers were used to identify further relevant citations. During the revision stage we searched again to update the reference list with the latest published articles.
     </p>
    </sec>
    <back>
     <app-group>
      <app id="App1">
       <sec id="Sec17">
        <title>
         PowerPoint slides
        </title>
        <p id="Par62">
         <media id="MOESM4" position="anchor" xlink:href="41569_2014_BFnrcardio201459_MOESM4_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 1
           </p>
          </caption>
         </media>
         <media id="MOESM5" position="anchor" xlink:href="41569_2014_BFnrcardio201459_MOESM5_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 2
           </p>
          </caption>
         </media>
         <media id="MOESM6" position="anchor" xlink:href="41569_2014_BFnrcardio201459_MOESM6_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 3
           </p>
          </caption>
         </media>
         <media id="MOESM7" position="anchor" xlink:href="41569_2014_BFnrcardio201459_MOESM7_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 4
           </p>
          </caption>
         </media>
         <media id="MOESM8" position="anchor" xlink:href="41569_2014_BFnrcardio201459_MOESM8_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 5
           </p>
          </caption>
         </media>
         <media id="MOESM9" position="anchor" xlink:href="41569_2014_BFnrcardio201459_MOESM9_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 6
           </p>
          </caption>
         </media>
        </p>
        <p id="Par63">
         <media id="MOESM10" position="anchor" xlink:href="41569_2014_BFnrcardio201459_MOESM10_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Table 1
           </p>
          </caption>
         </media>
        </p>
       </sec>
      </app>
     </app-group>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       The authors are supported by research grants from National 973 Basic Research Program (No. 2010CB732605, 2011CB503906, 2012CB518603, 2013CB530703), National High-tech Research and Development Program of China (No. 2012AA02A510), Program of Introducing Talents of Discipline to Universities (No. B07035), the State Program of National Natural Science Foundation of China for Innovative Research Group (No. 81321061), International Collaboration and Exchange Program of China (No. 81320108004) and the State Key Program of National Natural Science of China (No. 61331001).
      </p>
     </ack>
     <notes notes-type="author-contribution">
      <title>
       Author Contributions
      </title>
      <p>
       All authors participated in literature research and data classification. F.J., J.Y., and C.Z. wrote the manuscript. F.J. and C.Z. reviewed and/or edited the manuscript before submission. F.J., M.D, S.W., Q.Z. and F.F.L. contributed to the creation of artworks.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Competing interests
      </title>
      <p id="Par61">
       The authors declare no competing financial interests.
      </p>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Putnam
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Shoemaker
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Yiannikouris
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Cassis
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
        </person-group>
        <article-title>
         The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2012
        </year>
        <volume>
         302
        </volume>
        <fpage>
         H1219
        </fpage>
        <lpage>
         H1230
        </lpage>
        <pub-id pub-id-type="pmid">
         22227126
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lang
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Struthers
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Targeting the renin-angiotensin-aldosterone system in heart failure
        </article-title>
        <source>
         Nat. Rev. Cardiol.
        </source>
        <year>
         2013
        </year>
        <volume>
         10
        </volume>
        <fpage>
         125
        </fpage>
        <lpage>
         134
        </lpage>
        <pub-id pub-id-type="pmid">
         23319100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nguyen Dinh Cat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Touyz
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new look at the renin-angiotensin system—focusing on the vascular system
        </article-title>
        <source>
         Peptides
        </source>
        <year>
         2011
        </year>
        <volume>
         32
        </volume>
        <fpage>
         2141
        </fpage>
        <lpage>
         2150
        </lpage>
        <pub-id pub-id-type="pmid">
         21945916
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoogwerf
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Renin-angiotensin system blockade and cardiovascular and renal protection
        </article-title>
        <source>
         Am. J. Cardiol.
        </source>
        <year>
         2010
        </year>
        <volume>
         105
        </volume>
        <fpage>
         30A
        </fpage>
        <lpage>
         35A
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Herichova
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Szantoova
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Renin-angiotensin system: upgrade of recent knowledge and perspectives
        </article-title>
        <source>
         Endocr. Regul.
        </source>
        <year>
         2013
        </year>
        <volume>
         47
        </volume>
        <fpage>
         39
        </fpage>
        <lpage>
         52
        </lpage>
        <pub-id pub-id-type="pmid">
         23363256
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Mello
          </surname>
          <given-names>
           WC
          </given-names>
         </name>
         <name>
          <surname>
           Frohlich
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        <article-title>
         On the local cardiac renin angiotensin system. Basic and clinical implications
        </article-title>
        <source>
         Peptides
        </source>
        <year>
         2011
        </year>
        <volume>
         32
        </volume>
        <fpage>
         1774
        </fpage>
        <lpage>
         1779
        </lpage>
        <pub-id pub-id-type="pmid">
         21729730
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2, angiotensin-(1–7), and Mas: the other side of the coin
        </article-title>
        <source>
         Pflugers Arch.
        </source>
        <year>
         2013
        </year>
        <volume>
         465
        </volume>
        <fpage>
         79
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         23463883
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2000
        </year>
        <volume>
         87
        </volume>
        <fpage>
         E1
        </fpage>
        <lpage>
         E9
        </lpage>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2000
        </year>
        <volume>
         275
        </volume>
        <fpage>
         33238
        </fpage>
        <lpage>
         33243
        </lpage>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Phillips
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Milani
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Three key proteases—angiotensin-I-converting enzyme (ACE), ACE2 and renin—within and beyond the renin-angiotensin system
        </article-title>
        <source>
         Arch. Cardiovasc. Dis.
        </source>
        <year>
         2012
        </year>
        <volume>
         105
        </volume>
        <fpage>
         373
        </fpage>
        <lpage>
         385
        </lpage>
        <pub-id pub-id-type="pmid">
         22800722
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases
        </article-title>
        <source>
         Circ. J.
        </source>
        <year>
         2013
        </year>
        <volume>
         77
        </volume>
        <fpage>
         301
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         23328447
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Clarke
          </surname>
          <given-names>
           NE
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2: the first decade
        </article-title>
        <source>
         Int. J. Hypertens.
        </source>
        <year>
         2012
        </year>
        <volume>
         2012
        </volume>
        <fpage>
         307315
        </fpage>
        <pub-id pub-id-type="pmid">
         22121476
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guy
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Jensen
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis
        </article-title>
        <source>
         FEBS J.
        </source>
        <year>
         2005
        </year>
        <volume>
         272
        </volume>
        <fpage>
         3512
        </fpage>
        <lpage>
         3520
        </lpage>
        <pub-id pub-id-type="pmid">
         16008552
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2001
        </year>
        <volume>
         276
        </volume>
        <fpage>
         17132
        </fpage>
        <lpage>
         17139
        </lpage>
        <pub-id pub-id-type="pmid">
         11278314
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guy
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence
        </article-title>
        <source>
         Biochemistry
        </source>
        <year>
         2003
        </year>
        <volume>
         42
        </volume>
        <fpage>
         13185
        </fpage>
        <lpage>
         13192
        </lpage>
        <pub-id pub-id-type="pmid">
         14609329
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vickers
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2002
        </year>
        <volume>
         277
        </volume>
        <fpage>
         14838
        </fpage>
        <lpage>
         14843
        </lpage>
        <pub-id pub-id-type="pmid">
         11815627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Trask
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Jessup
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular function
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2005
        </year>
        <volume>
         289
        </volume>
        <fpage>
         H2281
        </fpage>
        <lpage>
         H2290
        </lpage>
        <pub-id pub-id-type="pmid">
         16055515
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Verano-Braga
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2, angiotensin-(1–7) and Mas: new players of the renin-angiotensin system
        </article-title>
        <source>
         J. Endocrinol.
        </source>
        <year>
         2013
        </year>
        <volume>
         216
        </volume>
        <fpage>
         R1
        </fpage>
        <lpage>
         R17
        </lpage>
        <pub-id pub-id-type="pmid">
         23092879
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Flores-Munoz
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Godinho
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Almalik
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Nicklin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adenoviral delivery of angiotensin-(1–7) or angiotensin-(1–9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2012
        </year>
        <volume>
         7
        </volume>
        <fpage>
         e45564
        </fpage>
        <pub-id pub-id-type="pmid">
         23029101
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Flores-Munoz
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2012
        </year>
        <volume>
         59
        </volume>
        <fpage>
         300
        </fpage>
        <lpage>
         307
        </lpage>
        <pub-id pub-id-type="pmid">
         22184331
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Tumor
         </italic>
         necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2005
        </year>
        <volume>
         280
        </volume>
        <fpage>
         30113
        </fpage>
        <lpage>
         30119
        </lpage>
        <pub-id pub-id-type="pmid">
         15983030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iwata
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Silva Enciso
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Greenberg
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor α-converting enzyme
        </article-title>
        <source>
         Am. J. Physiol. Cell Physiol.
        </source>
        <year>
         2009
        </year>
        <volume>
         297
        </volume>
        <fpage>
         C1318
        </fpage>
        <lpage>
         C1329
        </lpage>
        <pub-id pub-id-type="pmid">
         19759332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Epelman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system
        </article-title>
        <source>
         J. Am. Coll. Cardiol.
        </source>
        <year>
         2008
        </year>
        <volume>
         52
        </volume>
        <fpage>
         750
        </fpage>
        <lpage>
         754
        </lpage>
        <pub-id pub-id-type="pmid">
         18718423
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Epelman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes
        </article-title>
        <source>
         J. Card Fail
        </source>
        <year>
         2009
        </year>
        <volume>
         15
        </volume>
        <fpage>
         565
        </fpage>
        <lpage>
         571
        </lpage>
        <pub-id pub-id-type="pmid">
         19700132
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ortiz-Perez
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2013
        </year>
        <volume>
         8
        </volume>
        <fpage>
         e61695
        </fpage>
        <pub-id pub-id-type="pmid">
         23630610
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           VB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS
        </article-title>
        <source>
         J. Mol. Cell Cardiol.
        </source>
        <year>
         2014
        </year>
        <volume>
         66
        </volume>
        <fpage>
         167
        </fpage>
        <lpage>
         176
        </lpage>
        <pub-id pub-id-type="pmid">
         24332999
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dales
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors
        </article-title>
        <source>
         J. Am. Chem. Soc.
        </source>
        <year>
         2002
        </year>
        <volume>
         124
        </volume>
        <fpage>
         11852
        </fpage>
        <lpage>
         11853
        </lpage>
        <pub-id pub-id-type="pmid">
         12358520
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Towler
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2004
        </year>
        <volume>
         279
        </volume>
        <fpage>
         17996
        </fpage>
        <lpage>
         18007
        </lpage>
        <pub-id pub-id-type="pmid">
         14754895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soler
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice
        </article-title>
        <source>
         Kidney Int.
        </source>
        <year>
         2007
        </year>
        <volume>
         72
        </volume>
        <fpage>
         614
        </fpage>
        <lpage>
         623
        </lpage>
        <pub-id pub-id-type="pmid">
         17579661
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Trask
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats
        </article-title>
        <source>
         Am. J. Hypertens.
        </source>
        <year>
         2010
        </year>
        <volume>
         23
        </volume>
        <fpage>
         687
        </fpage>
        <lpage>
         693
        </lpage>
        <pub-id pub-id-type="pmid">
         20300067
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel peptide inhibitors of angiotensin-converting enzyme 2
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2003
        </year>
        <volume>
         278
        </volume>
        <fpage>
         15532
        </fpage>
        <lpage>
         15540
        </lpage>
        <pub-id pub-id-type="pmid">
         12606557
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Uhal
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Abdul-Hafez
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1–7/Mas axis
        </article-title>
        <source>
         Am. J. Physiol. Lung Cell. Mol. Physiol.
        </source>
        <year>
         2011
        </year>
        <volume>
         301
        </volume>
        <fpage>
         L269
        </fpage>
        <lpage>
         L274
        </lpage>
        <pub-id pub-id-type="pmid">
         21665960
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fraga-Silva
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 activation promotes antithrombotic activity
        </article-title>
        <source>
         Mol. Med.
        </source>
        <year>
         2010
        </year>
        <volume>
         16
        </volume>
        <fpage>
         210
        </fpage>
        <lpage>
         215
        </lpage>
        <pub-id pub-id-type="pmid">
         20111697
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pedersen
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name>
          <surname>
           Sriramula
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Chhabra
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays
        </article-title>
        <source>
         Am. J. Physiol. Regul. Integr. Comp. Physiol.
        </source>
        <year>
         2011
        </year>
        <volume>
         301
        </volume>
        <fpage>
         R1293
        </fpage>
        <lpage>
         R1299
        </lpage>
        <pub-id pub-id-type="pmid">
         21880865
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2012
        </year>
        <volume>
         60
        </volume>
        <fpage>
         730
        </fpage>
        <lpage>
         740
        </lpage>
        <pub-id pub-id-type="pmid">
         22777933
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hernández Prada
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2008
        </year>
        <volume>
         51
        </volume>
        <fpage>
         1312
        </fpage>
        <lpage>
         1317
        </lpage>
        <pub-id pub-id-type="pmid">
         18391097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases
        </article-title>
        <source>
         Exp. Physiol.
        </source>
        <year>
         2011
        </year>
        <volume>
         96
        </volume>
        <fpage>
         287
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="pmid">
         21148624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haber
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies
         <italic>
          in vivo
         </italic>
         ,
         <italic>
          ex vivo
         </italic>
         , and
         <italic>
          in vitro
         </italic>
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2014
        </year>
        <volume>
         63
        </volume>
        <fpage>
         774
        </fpage>
        <lpage>
         782
        </lpage>
        <pub-id pub-id-type="pmid">
         24446061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Zeitz
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Esler
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Horowitz
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation
        </article-title>
        <source>
         J. Hypertens.
        </source>
        <year>
         2004
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1971
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="pmid">
         15361769
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Petty
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phase I and pharmacokinetic study of angiotensin-(1–7), an endogenous antiangiogenic hormone
        </article-title>
        <source>
         Clin. Cancer Res.
        </source>
        <year>
         2009
        </year>
        <volume>
         15
        </volume>
        <fpage>
         7398
        </fpage>
        <lpage>
         7404
        </lpage>
        <pub-id pub-id-type="pmid">
         19920106
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Iyer
          </surname>
          <given-names>
           SN
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Ganten
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Converting enzyme determines plasma clearance of angiotensin-(1–7)
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1998
        </year>
        <volume>
         32
        </volume>
        <fpage>
         496
        </fpage>
        <lpage>
         502
        </lpage>
        <pub-id pub-id-type="pmid">
         9740616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Allred
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Diz
          </surname>
          <given-names>
           DI
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathways for angiotensin-(1–7) metabolism in pulmonary and renal tissues
        </article-title>
        <source>
         Am. J. Physiol. Renal Physiol.
        </source>
        <year>
         2000
        </year>
        <volume>
         279
        </volume>
        <fpage>
         F841
        </fpage>
        <lpage>
         F850
        </lpage>
        <pub-id pub-id-type="pmid">
         11053044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iusuf
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Henning
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
         <name>
          <surname>
           van Gilst
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Roks
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7): pharmacological properties and pharmacotherapeutic perspectives
        </article-title>
        <source>
         Eur. J. Pharmacol.
        </source>
        <year>
         2008
        </year>
        <volume>
         585
        </volume>
        <fpage>
         303
        </fpage>
        <lpage>
         312
        </lpage>
        <pub-id pub-id-type="pmid">
         18417117
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zimmerman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Burns
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) in kidney disease: a review of the controversies
        </article-title>
        <source>
         Clin. Sci. (Lond.)
        </source>
        <year>
         2012
        </year>
        <volume>
         123
        </volume>
        <fpage>
         333
        </fpage>
        <lpage>
         346
        </lpage>
        <pub-id pub-id-type="pmid">
         22639821
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giani
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chronic infusion of angiotensin-(1–7) improves insulin resistance and hypertension induced by a high-fructose diet in rats
        </article-title>
        <source>
         Am. J. Physiol. Endocrinol. Metab.
        </source>
        <year>
         2009
        </year>
        <volume>
         296
        </volume>
        <fpage>
         E262
        </fpage>
        <lpage>
         E271
        </lpage>
        <pub-id pub-id-type="pmid">
         19001546
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Echeverria-Rodriguez
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Del Valle-Mondragon
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin 1–7 improves insulin sensitivity by increasing skeletal muscle glucose uptake
         <italic>
          in vivo
         </italic>
        </article-title>
        <source>
         Peptides
        </source>
        <year>
         2014
        </year>
        <volume>
         51
        </volume>
        <fpage>
         26
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         24184594
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1–7)
        </article-title>
        <source>
         Arterioscler. Thromb. Vasc. Biol.
        </source>
        <year>
         2010
        </year>
        <volume>
         30
        </volume>
        <fpage>
         953
        </fpage>
        <lpage>
         961
        </lpage>
        <pub-id pub-id-type="pmid">
         20203301
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins
        </article-title>
        <source>
         J. Mol. Cell Cardiol.
        </source>
        <year>
         2003
        </year>
        <volume>
         35
        </volume>
        <fpage>
         1043
        </fpage>
        <lpage>
         1053
        </lpage>
        <pub-id pub-id-type="pmid">
         12967627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Neves
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Almeida
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Khosla
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Campagnole-Santos
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of angiotensin-(1–7) on reperfusion arrhythmias in isolated rat hearts
        </article-title>
        <source>
         Braz. J. Med. Biol. Res.
        </source>
        <year>
         1997
        </year>
        <volume>
         30
        </volume>
        <fpage>
         801
        </fpage>
        <lpage>
         809
        </lpage>
        <pub-id pub-id-type="pmid">
         9292120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Mello
          </surname>
          <given-names>
           WC
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Jessup
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Beneficial versus harmful effects of angiotensin (1–7) on impulse propagation and cardiac arrhythmias in the failing heart
        </article-title>
        <source>
         J. Renin Angiotensin Aldosterone Syst.
        </source>
        <year>
         2007
        </year>
        <volume>
         8
        </volume>
        <fpage>
         74
        </fpage>
        <lpage>
         80
        </lpage>
        <pub-id pub-id-type="pmid">
         17703433
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dias-Peixoto
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular mechanisms involved in the angiotensin-(1–7)/Mas signaling pathway in cardiomyocytes
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2008
        </year>
        <volume>
         52
        </volume>
        <fpage>
         542
        </fpage>
        <lpage>
         548
        </lpage>
        <pub-id pub-id-type="pmid">
         18695148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giani
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart
         <italic>
          in vivo
         </italic>
         : role of the AT1 and Mas receptors
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2007
        </year>
        <volume>
         293
        </volume>
        <fpage>
         H1154
        </fpage>
        <lpage>
         H1163
        </lpage>
        <pub-id pub-id-type="pmid">
         17496209
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sampaio
          </surname>
          <given-names>
           WO
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2007
        </year>
        <volume>
         49
        </volume>
        <fpage>
         185
        </fpage>
        <lpage>
         192
        </lpage>
        <pub-id pub-id-type="pmid">
         17116756
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Than
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Leow
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Control of adipogenesis by the autocrine interplays between angiotensin 1–7/Mas receptor and angiotensin II/AT1 receptor signaling pathways
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2013
        </year>
        <volume>
         288
        </volume>
        <fpage>
         15520
        </fpage>
        <lpage>
         15531
        </lpage>
        <pub-id pub-id-type="pmid">
         23592774
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munoz
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Giani
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Dominici
          </surname>
          <given-names>
           FP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) stimulates the phosphorylation of Akt in rat extracardiac tissues
         <italic>
          in vivo
         </italic>
         via receptor Mas
        </article-title>
        <source>
         Regul. Pept.
        </source>
        <year>
         2010
        </year>
        <volume>
         161
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         20188769
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sampaio
          </surname>
          <given-names>
           WO
          </given-names>
         </name>
         <name>
          <surname>
           Henrique de Castro
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Schiffrin
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Touyz
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) counterregulates angiotensin II signaling in human endothelial cells
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2007
        </year>
        <volume>
         50
        </volume>
        <fpage>
         1093
        </fpage>
        <lpage>
         1098
        </lpage>
        <pub-id pub-id-type="pmid">
         17984366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tallant
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular mechanisms of inhibition of vascular growth by angiotensin-(1–7)
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2003
        </year>
        <volume>
         42
        </volume>
        <fpage>
         574
        </fpage>
        <lpage>
         579
        </lpage>
        <pub-id pub-id-type="pmid">
         12953014
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Different effects of angiotensin II and angiotensin-(1–7) on vascular smooth muscle cell proliferation and migration
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2010
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e12323
        </fpage>
        <pub-id pub-id-type="pmid">
         20808802
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tallant
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptor
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2005
        </year>
        <volume>
         289
        </volume>
        <fpage>
         H1560
        </fpage>
        <lpage>
         H1566
        </lpage>
        <pub-id pub-id-type="pmid">
         15951342
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zimpelmann
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Burns
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells
        </article-title>
        <source>
         Kidney Int.
        </source>
        <year>
         2006
        </year>
        <volume>
         69
        </volume>
        <fpage>
         2212
        </fpage>
        <lpage>
         2218
        </lpage>
        <pub-id pub-id-type="pmid">
         16672906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) enhances angiotensin II induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells
        </article-title>
        <source>
         Mol. Immunol.
        </source>
        <year>
         2009
        </year>
        <volume>
         46
        </volume>
        <fpage>
         355
        </fpage>
        <lpage>
         361
        </lpage>
        <pub-id pub-id-type="pmid">
         19041135
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zimpelmann
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Burns
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) activates growth-stimulatory pathways in human mesangial cells
        </article-title>
        <source>
         Am. J. Physiol. Renal Physiol.
        </source>
        <year>
         2009
        </year>
        <volume>
         296
        </volume>
        <fpage>
         F337
        </fpage>
        <lpage>
         F346
        </lpage>
        <pub-id pub-id-type="pmid">
         19052102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Scholey
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells
        </article-title>
        <source>
         Am. J. Physiol. Renal Physiol.
        </source>
        <year>
         2012
        </year>
        <volume>
         302
        </volume>
        <fpage>
         F784
        </fpage>
        <lpage>
         F790
        </lpage>
        <pub-id pub-id-type="pmid">
         22189944
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Mello
          </surname>
          <given-names>
           WC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin (1–7) increases the potassium current and the resting potential of arterial myocytes from vascular resistance vessels of normal adult rats: pathophysiological implications
        </article-title>
        <source>
         J. Am. Soc. Hypertens.
        </source>
        <year>
         2014
        </year>
        <volume>
         8
        </volume>
        <fpage>
         14
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         24220548
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name>
          <surname>
           Saylor
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Speth
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Absher
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) binding at angiotensin II receptors in the rat brain
        </article-title>
        <source>
         Regul. Pept.
        </source>
        <year>
         1995
        </year>
        <volume>
         56
        </volume>
        <fpage>
         139
        </fpage>
        <lpage>
         146
        </lpage>
        <pub-id pub-id-type="pmid">
         7652190
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gironacci
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Coba
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name>
          <surname>
           Pena
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) binds at the type 1 angiotensin II receptors in rat renal cortex
        </article-title>
        <source>
         Regul. Pept.
        </source>
        <year>
         1999
        </year>
        <volume>
         84
        </volume>
        <fpage>
         51
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         10535408
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosnyak
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors
        </article-title>
        <source>
         Clin. Sci. (Lond.)
        </source>
        <year>
         2011
        </year>
        <volume>
         121
        </volume>
        <fpage>
         297
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="pmid">
         21542804
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR68">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lara Lda
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Involvement of the G
         <sub>
          i/o
         </sub>
         /cGMP/PKG pathway in the AT
         <sub>
          2
         </sub>
         -mediated inhibition of outer cortex proximal tubule Na
         <sup>
          +
         </sup>
         -ATPase by Ang-(1–7)
        </article-title>
        <source>
         Biochem. J.
        </source>
        <year>
         2006
        </year>
        <volume>
         395
        </volume>
        <fpage>
         183
        </fpage>
        <lpage>
         190
        </lpage>
        <pub-id pub-id-type="pmid">
         16390332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walters
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Gaspari
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Widdop
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2005
        </year>
        <volume>
         45
        </volume>
        <fpage>
         960
        </fpage>
        <lpage>
         966
        </lpage>
        <pub-id pub-id-type="pmid">
         15767466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR70">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Young
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Waitches
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Birchmeier
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Fasano
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Wigler
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains
        </article-title>
        <source>
         Cell
        </source>
        <year>
         1986
        </year>
        <volume>
         45
        </volume>
        <fpage>
         711
        </fpage>
        <lpage>
         719
        </lpage>
        <pub-id pub-id-type="pmid">
         3708691
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR71">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2003
        </year>
        <volume>
         100
        </volume>
        <fpage>
         8258
        </fpage>
        <lpage>
         8263
        </lpage>
        <pub-id pub-id-type="pmid">
         12829792
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR72">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Metzger
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues
        </article-title>
        <source>
         FEBS Lett.
        </source>
        <year>
         1995
        </year>
        <volume>
         357
        </volume>
        <fpage>
         27
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="pmid">
         8001672
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR73">
       <label>
        73
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alenina
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Rentzsch
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Patkin
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetically altered animal models for Mas and angiotensin-(1–7)
        </article-title>
        <source>
         Exp. Physiol.
        </source>
        <year>
         2008
        </year>
        <volume>
         93
        </volume>
        <fpage>
         528
        </fpage>
        <lpage>
         537
        </lpage>
        <pub-id pub-id-type="pmid">
         18156169
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR74">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Young
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           O'Neill
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Jessell
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Wigler
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         1988
        </year>
        <volume>
         85
        </volume>
        <fpage>
         5339
        </fpage>
        <lpage>
         5342
        </lpage>
        <pub-id pub-id-type="pmid">
         2455902
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR75">
       <label>
        75
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impairment of
         <italic>
          in vitro
         </italic>
         and
         <italic>
          in vivo
         </italic>
         heart function in angiotensin-(1–7) receptor MAS knockout mice
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2006
        </year>
        <volume>
         47
        </volume>
        <fpage>
         996
        </fpage>
        <lpage>
         1002
        </lpage>
        <pub-id pub-id-type="pmid">
         16567589
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR76">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Regulation of angiotensin-converting enzyme 2 and Mas receptor by Ang-(1–7) in heart and kidney of spontaneously hypertensive rats
        </article-title>
        <source>
         J. Renin Angiotensin Aldosterone Syst.
        </source>
        <year>
         2011
        </year>
        <volume>
         12
        </volume>
        <fpage>
         413
        </fpage>
        <lpage>
         419
        </lpage>
        <pub-id pub-id-type="pmid">
         21436210
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR77">
       <label>
        77
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dias-Peixoto
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
        </person-group>
        <article-title>
         The cardiac expression of Mas receptor is responsive to different physiological and pathological stimuli
        </article-title>
        <source>
         Peptides
        </source>
        <year>
         2012
        </year>
        <volume>
         35
        </volume>
        <fpage>
         196
        </fpage>
        <lpage>
         201
        </lpage>
        <pub-id pub-id-type="pmid">
         22504011
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR78">
       <label>
        78
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Grammas
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Giacomelli
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Wiener
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Selective expression of c-mas proto-oncogene in rat cerebral endothelial cells
        </article-title>
        <source>
         Neuroreport
        </source>
        <year>
         1996
        </year>
        <volume>
         8
        </volume>
        <fpage>
         93
        </fpage>
        <lpage>
         96
        </lpage>
        <pub-id pub-id-type="pmid">
         9051759
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR79">
       <label>
        79
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muthalif
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Benter
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         <name>
          <surname>
           Uddin
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Harper
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           KU
          </given-names>
         </name>
        </person-group>
        <article-title>
         Signal transduction mechanisms involved in angiotensin-(1–7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells
        </article-title>
        <source>
         J. Pharmacol. Exp. Ther.
        </source>
        <year>
         1998
        </year>
        <volume>
         284
        </volume>
        <fpage>
         388
        </fpage>
        <lpage>
         398
        </lpage>
        <pub-id pub-id-type="pmid">
         9435202
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR80">
       <label>
        80
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Freeman
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Chisolm
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Tallant
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) inhibits vascular smooth muscle cell growth
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1996
        </year>
        <volume>
         28
        </volume>
        <fpage>
         104
        </fpage>
        <lpage>
         108
        </lpage>
        <pub-id pub-id-type="pmid">
         8675248
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR81">
       <label>
        81
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabelo
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ablation of angiotensin (1–7) receptor Mas in C57Bl/6 mice causes endothelial dysfunction
        </article-title>
        <source>
         J. Am. Soc. Hypertens.
        </source>
        <year>
         2008
        </year>
        <volume>
         2
        </volume>
        <fpage>
         418
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="pmid">
         20409925
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR82">
       <label>
        82
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiró
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function
        </article-title>
        <source>
         J. Hypertens.
        </source>
        <year>
         2007
        </year>
        <volume>
         25
        </volume>
        <fpage>
         2421
        </fpage>
        <lpage>
         2425
        </lpage>
        <pub-id pub-id-type="pmid">
         17984663
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR83">
       <label>
        83
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pinheiro
          </surname>
          <given-names>
           SV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic deletion of the angiotensin-(1–7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria
        </article-title>
        <source>
         Kidney Int.
        </source>
        <year>
         2009
        </year>
        <volume>
         75
        </volume>
        <fpage>
         1184
        </fpage>
        <lpage>
         1193
        </lpage>
        <pub-id pub-id-type="pmid">
         19262461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR84">
       <label>
        84
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rakusan
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Knockout of angiotensin 1–7 receptor Mas worsens the course of two-kidney, one-clip Goldblatt hypertension: roles of nitric oxide deficiency and enhanced vascular responsiveness to angiotensin II
        </article-title>
        <source>
         Kidney Blood Press Res.
        </source>
        <year>
         2010
        </year>
        <volume>
         33
        </volume>
        <fpage>
         476
        </fpage>
        <lpage>
         488
        </lpage>
        <pub-id pub-id-type="pmid">
         21071955
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR85">
       <label>
        85
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Heringer-Walther
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         The genetic deletion of Mas abolishes salt induced hypertension in mice
        </article-title>
        <source>
         Eur. J. Pharmacol.
        </source>
        <year>
         2012
        </year>
        <volume>
         689
        </volume>
        <fpage>
         147
        </fpage>
        <lpage>
         153
        </lpage>
        <pub-id pub-id-type="pmid">
         22652430
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR86">
       <label>
        86
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Sriramula
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2/ANG-(1–7)/Mas pathway in the brain: the axis of good
        </article-title>
        <source>
         Am. J. Physiol. Regul. Integr. Comp. Physiol.
        </source>
        <year>
         2011
        </year>
        <volume>
         300
        </volume>
        <fpage>
         R804
        </fpage>
        <lpage>
         R817
        </lpage>
        <pub-id pub-id-type="pmid">
         21178125
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR87">
       <label>
        87
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Varagic
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         The ANG-(1–7)/ACE2/mas axis in the regulation of nephron function
        </article-title>
        <source>
         Am. J. Physiol. Renal Physiol.
        </source>
        <year>
         2010
        </year>
        <volume>
         298
        </volume>
        <fpage>
         F1297
        </fpage>
        <lpage>
         F1305
        </lpage>
        <pub-id pub-id-type="pmid">
         20375118
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR88">
       <label>
        88
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iwai
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Horiuchi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1–7)-Mas receptor axis
        </article-title>
        <source>
         Hypertens. Res.
        </source>
        <year>
         2009
        </year>
        <volume>
         32
        </volume>
        <fpage>
         533
        </fpage>
        <lpage>
         536
        </lpage>
        <pub-id pub-id-type="pmid">
         19461648
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR89">
       <label>
        89
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zohn
          </surname>
          <given-names>
           IE
          </given-names>
         </name>
         <name>
          <surname>
           Symons
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Chrzanowska-Wodnicka
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Westwick
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Der
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mas oncogene signaling and transformation require the small GTP-binding protein Rac
        </article-title>
        <source>
         Mol. Cell Biol.
        </source>
        <year>
         1998
        </year>
        <volume>
         18
        </volume>
        <fpage>
         1225
        </fpage>
        <lpage>
         1235
        </lpage>
        <pub-id pub-id-type="pmid">
         9488437
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR90">
       <label>
        90
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Tallant
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of human lung cancer cell growth by angiotensin-(1–7)
        </article-title>
        <source>
         Carcinogenesis
        </source>
        <year>
         2004
        </year>
        <volume>
         25
        </volume>
        <fpage>
         2045
        </fpage>
        <lpage>
         2052
        </lpage>
        <pub-id pub-id-type="pmid">
         15284177
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR91">
       <label>
        91
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Krishnan
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Torti
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Tallant
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1
        </article-title>
        <source>
         Prostate
        </source>
        <year>
         2013
        </year>
        <volume>
         73
        </volume>
        <fpage>
         60
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="pmid">
         22644934
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR92">
       <label>
        92
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Canals
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Jenkins
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Kellett
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Milligan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Up-regulation of the angiotensin II type 1 receptor by the MAS proto-oncogene is due to constitutive activation of Gq/G11 by MAS
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2006
        </year>
        <volume>
         281
        </volume>
        <fpage>
         16757
        </fpage>
        <lpage>
         16767
        </lpage>
        <pub-id pub-id-type="pmid">
         16611642
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR93">
       <label>
        93
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2012
        </year>
        <volume>
         302
        </volume>
        <fpage>
         H299
        </fpage>
        <lpage>
         H311
        </lpage>
        <pub-id pub-id-type="pmid">
         22003054
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR94">
       <label>
        94
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chansel
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Vandermeersch
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Oko
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Curat
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ardaillou
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of angiotensin IV and angiotensin-(1–7) on basal and angiotensin II-stimulated cytosolic Ca2
         <sup>
          +
         </sup>
         in mesangial cells
        </article-title>
        <source>
         Eur. J. Pharmacol.
        </source>
        <year>
         2001
        </year>
        <volume>
         414
        </volume>
        <fpage>
         165
        </fpage>
        <lpage>
         175
        </lpage>
        <pub-id pub-id-type="pmid">
         11239916
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR95">
       <label>
        95
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7): a new hormone of the angiotensin system
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1991
        </year>
        <volume>
         18
        </volume>
        <fpage>
         III126
        </fpage>
        <lpage>
         III133
        </lpage>
        <pub-id pub-id-type="pmid">
         1937675
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR96">
       <label>
        96
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tassone
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin (1–7) counteracts the negative effect of angiotensin II on insulin signalling in HUVECs
        </article-title>
        <source>
         Cardiovasc. Res.
        </source>
        <year>
         2013
        </year>
        <volume>
         99
        </volume>
        <fpage>
         129
        </fpage>
        <lpage>
         136
        </lpage>
        <pub-id pub-id-type="pmid">
         23524303
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR97">
       <label>
        97
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kostenis
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          G.
         </italic>
         -protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         2005
        </year>
        <volume>
         111
        </volume>
        <fpage>
         1806
        </fpage>
        <lpage>
         1813
        </lpage>
        <pub-id pub-id-type="pmid">
         15809376
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR98">
       <label>
        98
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davenport
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
        </person-group>
        <article-title>
         International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands
        </article-title>
        <source>
         Pharmacol. Rev.
        </source>
        <year>
         2013
        </year>
        <volume>
         65
        </volume>
        <fpage>
         967
        </fpage>
        <lpage>
         986
        </lpage>
        <pub-id pub-id-type="pmid">
         23686350
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR99">
       <label>
        99
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of a new angiotensin antagonist selective for angiotensin-(1–7): evidence that the actions of angiotensin-(1–7) are mediated by specific angiotensin receptors
        </article-title>
        <source>
         Brain Res. Bull.
        </source>
        <year>
         1994
        </year>
        <volume>
         35
        </volume>
        <fpage>
         293
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="pmid">
         7850477
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR100">
       <label>
        100
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of a new selective antagonist for angiotensin-(1–7),
         <sc>
          D
         </sc>
         -pro
         <sup>
          7
         </sup>
         -angiotensin-(1–7)
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2003
        </year>
        <volume>
         41
        </volume>
        <fpage>
         737
        </fpage>
        <lpage>
         743
        </lpage>
        <pub-id pub-id-type="pmid">
         12623989
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR101">
       <label>
        101
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wiemer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Dobrucki
          </surname>
          <given-names>
           LW
          </given-names>
         </name>
         <name>
          <surname>
           Louka
          </surname>
          <given-names>
           FR
          </given-names>
         </name>
         <name>
          <surname>
           Malinski
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Heitsch
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1–7) on the endothelium
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2002
        </year>
        <volume>
         40
        </volume>
        <fpage>
         847
        </fpage>
        <lpage>
         852
        </lpage>
        <pub-id pub-id-type="pmid">
         12468568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR102">
       <label>
        102
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pinheiro
          </surname>
          <given-names>
           SV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nonpeptide AVE 0991 is an angiotensin-(1–7) receptor Mas agonist in the mouse kidney
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2004
        </year>
        <volume>
         44
        </volume>
        <fpage>
         490
        </fpage>
        <lpage>
         496
        </lpage>
        <pub-id pub-id-type="pmid">
         15326087
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR103">
       <label>
        103
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savergnini
          </surname>
          <given-names>
           SQ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2010
        </year>
        <volume>
         56
        </volume>
        <fpage>
         112
        </fpage>
        <lpage>
         120
        </lpage>
        <pub-id pub-id-type="pmid">
         20479330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR104">
       <label>
        104
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gurley
          </surname>
          <given-names>
           SB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice
        </article-title>
        <source>
         J. Clin. Invest.
        </source>
        <year>
         2006
        </year>
        <volume>
         116
        </volume>
        <fpage>
         2218
        </fpage>
        <lpage>
         2225
        </lpage>
        <pub-id pub-id-type="pmid">
         16878172
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR105">
       <label>
        105
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamazato
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yamazato
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Diez-Freire
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Raizada
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2007
        </year>
        <volume>
         49
        </volume>
        <fpage>
         926
        </fpage>
        <lpage>
         931
        </lpage>
        <pub-id pub-id-type="pmid">
         17325232
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR106">
       <label>
        106
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sriramula
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Cardinale
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Francis
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension
        </article-title>
        <source>
         Cardiovasc. Res.
        </source>
        <year>
         2011
        </year>
        <volume>
         92
        </volume>
        <fpage>
         401
        </fpage>
        <lpage>
         408
        </lpage>
        <pub-id pub-id-type="pmid">
         21952934
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR107">
       <label>
        107
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2008
        </year>
        <volume>
         102
        </volume>
        <fpage>
         729
        </fpage>
        <lpage>
         736
        </lpage>
        <pub-id pub-id-type="pmid">
         18258853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR108">
       <label>
        108
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2010
        </year>
        <volume>
         106
        </volume>
        <fpage>
         373
        </fpage>
        <lpage>
         382
        </lpage>
        <pub-id pub-id-type="pmid">
         19926873
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR109">
       <label>
        109
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rentzsch
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2008
        </year>
        <volume>
         52
        </volume>
        <fpage>
         967
        </fpage>
        <lpage>
         973
        </lpage>
        <pub-id pub-id-type="pmid">
         18809792
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR110">
       <label>
        110
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wysocki
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2010
        </year>
        <volume>
         55
        </volume>
        <fpage>
         90
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="pmid">
         19948988
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR111">
       <label>
        111
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats
        </article-title>
        <source>
         Exp. Physiol.
        </source>
        <year>
         2013
        </year>
        <volume>
         98
        </volume>
        <fpage>
         109
        </fpage>
        <lpage>
         122
        </lpage>
        <pub-id pub-id-type="pmid">
         22750422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR112">
       <label>
        112
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lima
          </surname>
          <given-names>
           CV
          </given-names>
         </name>
         <name>
          <surname>
           Paula
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
         <name>
          <surname>
           Resende
          </surname>
          <given-names>
           FL
          </given-names>
         </name>
         <name>
          <surname>
           Khosla
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1–7) in normotensive and hypertensive rats
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1997
        </year>
        <volume>
         30
        </volume>
        <fpage>
         542
        </fpage>
        <lpage>
         548
        </lpage>
        <pub-id pub-id-type="pmid">
         9322979
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR113">
       <label>
        113
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Campagnole-Santos
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Heringer
          </surname>
          <given-names>
           SB
          </given-names>
         </name>
         <name>
          <surname>
           Batista
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
         <name>
          <surname>
           Khosla
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differential baroreceptor reflex modulation by centrally infused angiotensin peptides
        </article-title>
        <source>
         Am. J. Physiol.
        </source>
        <year>
         1992
        </year>
        <volume>
         263
        </volume>
        <fpage>
         R89
        </fpage>
        <lpage>
         R94
        </lpage>
        <pub-id pub-id-type="pmid">
         1636797
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR114">
       <label>
        114
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sampaio
          </surname>
          <given-names>
           WO
          </given-names>
         </name>
         <name>
          <surname>
           Nascimento
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Systemic and regional hemodynamic effects of angiotensin-(1–7) in rats
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2003
        </year>
        <volume>
         284
        </volume>
        <fpage>
         H1985
        </fpage>
        <lpage>
         H1994
        </lpage>
        <pub-id pub-id-type="pmid">
         12573992
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR115">
       <label>
        115
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bayorh
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         1A-779 attenuates angiotensin-(1–7) depressor response in salt-induced hypertensive rats
        </article-title>
        <source>
         Peptides
        </source>
        <year>
         2002
        </year>
        <volume>
         23
        </volume>
        <fpage>
         57
        </fpage>
        <lpage>
         64
        </lpage>
        <pub-id pub-id-type="pmid">
         11814618
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR116">
       <label>
        116
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abbas
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gorelik
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Carbini
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Scicli
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) induces bradykinin-mediated hypotensive responses in anesthetized rats
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1997
        </year>
        <volume>
         30
        </volume>
        <fpage>
         217
        </fpage>
        <lpage>
         221
        </lpage>
        <pub-id pub-id-type="pmid">
         9260983
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR117">
       <label>
        117
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benter
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Diz
          </surname>
          <given-names>
           DI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antihypertensive actions of angiotensin-(1–7) in spontaneously hypertensive rats
        </article-title>
        <source>
         Am. J. Physiol.
        </source>
        <year>
         1995
        </year>
        <volume>
         269
        </volume>
        <fpage>
         H313
        </fpage>
        <lpage>
         H319
        </lpage>
        <pub-id pub-id-type="pmid">
         7631863
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR118">
       <label>
        118
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eatman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gender differences in the attenuation of salt-induced hypertension by angiotensin (1–7)
        </article-title>
        <source>
         Peptides
        </source>
        <year>
         2001
        </year>
        <volume>
         22
        </volume>
        <fpage>
         927
        </fpage>
        <lpage>
         933
        </lpage>
        <pub-id pub-id-type="pmid">
         11390023
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR119">
       <label>
        119
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grobe
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Mecca
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Mao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Katovich
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2006
        </year>
        <volume>
         290
        </volume>
        <fpage>
         H2417
        </fpage>
        <lpage>
         H2423
        </lpage>
        <pub-id pub-id-type="pmid">
         16415071
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR120">
       <label>
        120
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burgelova
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impairment of the angiotensin-converting enzyme 2-angiotensin-(1–7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension
        </article-title>
        <source>
         J. Hypertens.
        </source>
        <year>
         2009
        </year>
        <volume>
         27
        </volume>
        <fpage>
         1988
        </fpage>
        <lpage>
         2000
        </lpage>
        <pub-id pub-id-type="pmid">
         19593210
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR121">
       <label>
        121
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shah
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           YB
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) attenuates hypertension in exercise-trained renal hypertensive rats
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2012
        </year>
        <volume>
         302
        </volume>
        <fpage>
         H2372
        </fpage>
        <lpage>
         H2380
        </lpage>
        <pub-id pub-id-type="pmid">
         22467306
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR122">
       <label>
        122
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Velkoska
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Dean
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <name>
          <surname>
           Griggs
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Burchill
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Burrell
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy
        </article-title>
        <source>
         Clin. Sci. (Lond.)
        </source>
        <year>
         2011
        </year>
        <volume>
         120
        </volume>
        <fpage>
         335
        </fpage>
        <lpage>
         345
        </lpage>
        <pub-id pub-id-type="pmid">
         21091432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR123">
       <label>
        123
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moriguchi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Brosnihan
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name>
          <surname>
           Ganten
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differential regulation of central vasopressin in transgenic rats harboring the mouse Ren-2 gene
        </article-title>
        <source>
         Am. J. Physiol.
        </source>
        <year>
         1994
        </year>
        <volume>
         267
        </volume>
        <fpage>
         R786
        </fpage>
        <lpage>
         R791
        </lpage>
        <pub-id pub-id-type="pmid">
         8092324
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR124">
       <label>
        124
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guimaraes
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chronic infusion of angiotensin-(1–7) into the lateral ventricle of the brain attenuates hypertension in DOCA-salt rats
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2012
        </year>
        <volume>
         303
        </volume>
        <fpage>
         H393
        </fpage>
        <lpage>
         H400
        </lpage>
        <pub-id pub-id-type="pmid">
         22661512
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR125">
       <label>
        125
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Central endogenous angiotensin-(1–7) protects against aldosterone/NaCl-induced hypertension in female rats
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2013
        </year>
        <volume>
         305
        </volume>
        <fpage>
         H699
        </fpage>
        <lpage>
         H705
        </lpage>
        <pub-id pub-id-type="pmid">
         23812385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR126">
       <label>
        126
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nakagaki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of angiotensin-(1–7) in rostral ventrolateral medulla in blood pressure regulation via sympathetic nerve activity in Wistar-Kyoto and spontaneous hypertensive rats
        </article-title>
        <source>
         Clin. Exp. Hypertens.
        </source>
        <year>
         2011
        </year>
        <volume>
         33
        </volume>
        <fpage>
         223
        </fpage>
        <lpage>
         230
        </lpage>
        <pub-id pub-id-type="pmid">
         21699448
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR127">
       <label>
        127
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oliveira
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
         <name>
          <surname>
           Khosla
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Campagnole-Santos
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1996
        </year>
        <volume>
         27
        </volume>
        <fpage>
         1284
        </fpage>
        <lpage>
         1290
        </lpage>
        <pub-id pub-id-type="pmid">
         8641737
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR128">
       <label>
        128
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simoes e Silva
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Bello
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Baracho
          </surname>
          <given-names>
           NC
          </given-names>
         </name>
         <name>
          <surname>
           Khosla
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diuresis and natriuresis produced by long term administration of a selective angiotensin-(1–7) antagonist in normotensive and hypertensive rats
        </article-title>
        <source>
         Regul. Pept.
        </source>
        <year>
         1998
        </year>
        <volume>
         74
        </volume>
        <fpage>
         177
        </fpage>
        <lpage>
         184
        </lpage>
        <pub-id pub-id-type="pmid">
         9712179
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR129">
       <label>
        129
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Britto
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Fagundes-Moura
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <name>
          <surname>
           Khosla
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Campagnole-Santos
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of angiotensin-(1–7) in the modulation of the baroreflex in renovascular hypertensive rats
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1997
        </year>
        <volume>
         30
        </volume>
        <fpage>
         549
        </fpage>
        <lpage>
         556
        </lpage>
        <pub-id pub-id-type="pmid">
         9322980
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR130">
       <label>
        130
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iyer
          </surname>
          <given-names>
           SN
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Averill
          </surname>
          <given-names>
           DB
          </given-names>
         </name>
         <name>
          <surname>
           Diz
          </surname>
          <given-names>
           DI
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vasodepressor actions of angiotensin-(1–7) unmasked during combined treatment with lisinopril and losartan
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1998
        </year>
        <volume>
         31
        </volume>
        <fpage>
         699
        </fpage>
        <lpage>
         705
        </lpage>
        <pub-id pub-id-type="pmid">
         9461243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR131">
       <label>
        131
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sasaki
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of angiotensin-(1–7) on forearm circulation in normotensive subjects and patients with essential hypertension
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2001
        </year>
        <volume>
         38
        </volume>
        <fpage>
         90
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         11463766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR132">
       <label>
        132
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plovsing
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of truncated angiotensins in humans after double blockade of the renin system
        </article-title>
        <source>
         Am. J. Physiol. Regul. Integr. Comp. Physiol.
        </source>
        <year>
         2003
        </year>
        <volume>
         285
        </volume>
        <fpage>
         R981
        </fpage>
        <lpage>
         R991
        </lpage>
        <pub-id pub-id-type="pmid">
         12869368
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR133">
       <label>
        133
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zulli
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Rai
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Buxton
          </surname>
          <given-names>
           BF
          </given-names>
         </name>
         <name>
          <surname>
           Burrell
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Hare
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-localization of angiotensin-converting enzyme 2-, octomer-4- and CD34-positive cells in rabbit atherosclerotic plaques
        </article-title>
        <source>
         Exp. Physiol.
        </source>
        <year>
         2008
        </year>
        <volume>
         93
        </volume>
        <fpage>
         564
        </fpage>
        <lpage>
         569
        </lpage>
        <pub-id pub-id-type="pmid">
         18192339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR134">
       <label>
        134
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Purushothaman
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression of angiotensin-converting enzyme 2 and its end product angiotensin 1–7 is increased in diabetic atheroma: implications for inflammation and neovascularization
        </article-title>
        <source>
         Cardiovasc. Pathol.
        </source>
        <year>
         2013
        </year>
        <volume>
         22
        </volume>
        <fpage>
         42
        </fpage>
        <lpage>
         48
        </lpage>
        <pub-id pub-id-type="pmid">
         22749485
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR135">
       <label>
        135
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sluimer
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions
        </article-title>
        <source>
         J. Pathol.
        </source>
        <year>
         2008
        </year>
        <volume>
         215
        </volume>
        <fpage>
         273
        </fpage>
        <lpage>
         279
        </lpage>
        <pub-id pub-id-type="pmid">
         18498093
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR136">
       <label>
        136
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Tikellis
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Golledge
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme 2 and atherosclerosis
        </article-title>
        <source>
         Atherosclerosis
        </source>
        <year>
         2013
        </year>
        <volume>
         226
        </volume>
        <fpage>
         3
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         22947420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR137">
       <label>
        137
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lovren
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2008
        </year>
        <volume>
         295
        </volume>
        <fpage>
         H1377
        </fpage>
        <lpage>
         H1384
        </lpage>
        <pub-id pub-id-type="pmid">
         18660448
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR138">
       <label>
        138
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2010
        </year>
        <volume>
         107
        </volume>
        <fpage>
         15886
        </fpage>
        <lpage>
         15891
        </lpage>
        <pub-id pub-id-type="pmid">
         20798044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR139">
       <label>
        139
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis
        </article-title>
        <source>
         Arterioscler. Thromb. Vasc. Biol.
        </source>
        <year>
         2008
        </year>
        <volume>
         28
        </volume>
        <fpage>
         1270
        </fpage>
        <lpage>
         1276
        </lpage>
        <pub-id pub-id-type="pmid">
         18403726
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR140">
       <label>
        140
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic
         <italic>
          Ace2
         </italic>
         deficiency accentuates vascular inflammation and atherosclerosis in the
         <italic>
          ApoE
         </italic>
         knockout mouse
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2010
        </year>
        <volume>
         107
        </volume>
        <fpage>
         888
        </fpage>
        <lpage>
         897
        </lpage>
        <pub-id pub-id-type="pmid">
         20671240
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR141">
       <label>
        141
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thatcher
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor
         <sup>
          −/−
         </sup>
         mice
        </article-title>
        <source>
         Arterioscler. Thromb. Vasc. Biol.
        </source>
        <year>
         2011
        </year>
        <volume>
         31
        </volume>
        <fpage>
         758
        </fpage>
        <lpage>
         765
        </lpage>
        <pub-id pub-id-type="pmid">
         21252069
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR142">
       <label>
        142
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sahara
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation
        </article-title>
        <source>
         Cardiovasc. Res.
        </source>
        <year>
         2014
        </year>
        <volume>
         101
        </volume>
        <fpage>
         236
        </fpage>
        <lpage>
         246
        </lpage>
        <pub-id pub-id-type="pmid">
         24193738
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR143">
       <label>
        143
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tesanovic
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vinh
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gaspari
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Casley
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Widdop
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vasoprotective and atheroprotective effects of angiotensin (1–7) in apolipoprotein E-deficient mice
        </article-title>
        <source>
         Arterioscler. Thromb. Vasc. Biol.
        </source>
        <year>
         2010
        </year>
        <volume>
         30
        </volume>
        <fpage>
         1606
        </fpage>
        <lpage>
         1613
        </lpage>
        <pub-id pub-id-type="pmid">
         20448208
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR144">
       <label>
        144
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells
        </article-title>
        <source>
         Arterioscler. Thromb. Vasc. Biol.
        </source>
        <year>
         2013
        </year>
        <volume>
         33
        </volume>
        <fpage>
         1978
        </fpage>
        <lpage>
         1985
        </lpage>
        <pub-id pub-id-type="pmid">
         23723368
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR145">
       <label>
        145
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Toton-Zuranska
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         AVE 0991-angiotensin-(1–7) receptor agonist, inhibits atherogenesis in apoE-knockout mice
        </article-title>
        <source>
         J. Physiol. Pharmacol.
        </source>
        <year>
         2010
        </year>
        <volume>
         61
        </volume>
        <fpage>
         181
        </fpage>
        <lpage>
         183
        </lpage>
        <pub-id pub-id-type="pmid">
         20436218
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR146">
       <label>
        146
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jawien
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice
        </article-title>
        <source>
         J. Physiol. Pharmacol.
        </source>
        <year>
         2012
        </year>
        <volume>
         63
        </volume>
        <fpage>
         77
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         22460464
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR147">
       <label>
        147
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) regulates angiotensin II-induced VCAM-1 expression on vascular endothelial cells
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2013
        </year>
        <volume>
         430
        </volume>
        <fpage>
         642
        </fpage>
        <lpage>
         646
        </lpage>
        <pub-id pub-id-type="pmid">
         23219836
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR148">
       <label>
        148
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goulter
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
         <name>
          <surname>
           Goddard
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 gene expression is up-regulated in the human failing heart
        </article-title>
        <source>
         BMC Med.
        </source>
        <year>
         2004
        </year>
        <volume>
         2
        </volume>
        <fpage>
         19
        </fpage>
        <pub-id pub-id-type="pmid">
         15151696
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR149">
       <label>
        149
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohtsuki
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure
        </article-title>
        <source>
         Int. J. Cardiol.
        </source>
        <year>
         2010
        </year>
        <volume>
         145
        </volume>
        <fpage>
         333
        </fpage>
        <lpage>
         334
        </lpage>
        <pub-id pub-id-type="pmid">
         20060185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR150">
       <label>
        150
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kittleson
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure
        </article-title>
        <source>
         Physiol. Genomics
        </source>
        <year>
         2005
        </year>
        <volume>
         21
        </volume>
        <fpage>
         299
        </fpage>
        <lpage>
         307
        </lpage>
        <pub-id pub-id-type="pmid">
         15769906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR151">
       <label>
        151
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Batlle
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure
        </article-title>
        <source>
         J. Heart Lung Transplant
        </source>
        <year>
         2006
        </year>
        <volume>
         25
        </volume>
        <fpage>
         1117
        </fpage>
        <lpage>
         1125
        </lpage>
        <pub-id pub-id-type="pmid">
         16962475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR152">
       <label>
        152
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP
        </article-title>
        <source>
         J. Card. Fail.
        </source>
        <year>
         2010
        </year>
        <volume>
         16
        </volume>
        <fpage>
         157
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="pmid">
         20142028
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR153">
       <label>
        153
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lieb
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy
        </article-title>
        <source>
         J. Mol. Med. (Berl.)
        </source>
        <year>
         2006
        </year>
        <volume>
         84
        </volume>
        <fpage>
         88
        </fpage>
        <lpage>
         96
        </lpage>
        <pub-id pub-id-type="pmid">
         16283142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR154">
       <label>
        154
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Merwe
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic variation in angiotensin-converting enzyme 2 gene is associated with extent of left ventricular hypertrophy in hypertrophic cardiomyopathy
        </article-title>
        <source>
         Hum. Genet.
        </source>
        <year>
         2008
        </year>
        <volume>
         124
        </volume>
        <fpage>
         57
        </fpage>
        <lpage>
         61
        </lpage>
        <pub-id pub-id-type="pmid">
         18560893
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR155">
       <label>
        155
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huentelman
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats
        </article-title>
        <source>
         Exp. Physiol.
        </source>
        <year>
         2005
        </year>
        <volume>
         90
        </volume>
        <fpage>
         783
        </fpage>
        <lpage>
         790
        </lpage>
        <pub-id pub-id-type="pmid">
         16049057
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR156">
       <label>
        156
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy
        </article-title>
        <source>
         J. Am. Coll. Cardiol.
        </source>
        <year>
         2012
        </year>
        <volume>
         59
        </volume>
        <fpage>
         739
        </fpage>
        <lpage>
         747
        </lpage>
        <pub-id pub-id-type="pmid">
         22340266
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR157">
       <label>
        157
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           YX
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction
        </article-title>
        <source>
         Hum. Gene Ther.
        </source>
        <year>
         2010
        </year>
        <volume>
         21
        </volume>
        <fpage>
         1545
        </fpage>
        <lpage>
         1554
        </lpage>
        <pub-id pub-id-type="pmid">
         20507236
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR158">
       <label>
        158
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           West
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Maynard
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name>
          <surname>
           Hemnes
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 improves right ventricular function in a pressure overload model
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e20828
        </fpage>
        <pub-id pub-id-type="pmid">
         21695173
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR159">
       <label>
        159
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice
        </article-title>
        <source>
         Cardiovasc. Res.
        </source>
        <year>
         2007
        </year>
        <volume>
         75
        </volume>
        <fpage>
         29
        </fpage>
        <lpage>
         39
        </lpage>
        <pub-id pub-id-type="pmid">
         17499227
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR160">
       <label>
        160
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         2010
        </year>
        <volume>
         122
        </volume>
        <fpage>
         717
        </fpage>
        <lpage>
         728
        </lpage>
        <pub-id pub-id-type="pmid">
         20679547
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR161">
       <label>
        161
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bodiga
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit
        </article-title>
        <source>
         Cardiovasc. Res.
        </source>
        <year>
         2011
        </year>
        <volume>
         91
        </volume>
        <fpage>
         151
        </fpage>
        <lpage>
         161
        </lpage>
        <pub-id pub-id-type="pmid">
         21285291
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR162">
       <label>
        162
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2006
        </year>
        <volume>
         47
        </volume>
        <fpage>
         718
        </fpage>
        <lpage>
         726
        </lpage>
        <pub-id pub-id-type="pmid">
         16505206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR163">
       <label>
        163
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           VB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2012
        </year>
        <volume>
         110
        </volume>
        <fpage>
         1322
        </fpage>
        <lpage>
         1335
        </lpage>
        <pub-id pub-id-type="pmid">
         22474255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR164">
       <label>
        164
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Hans
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           McIlwain
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Varner
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2012
        </year>
        <volume>
         7
        </volume>
        <fpage>
         e48910
        </fpage>
        <pub-id pub-id-type="pmid">
         23155428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR165">
       <label>
        165
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Averill
          </surname>
          <given-names>
           DB
          </given-names>
         </name>
         <name>
          <surname>
           Ishiyama
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cardiac angiotensin-(1–7) in ischemic cardiomyopathy
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         2003
        </year>
        <volume>
         108
        </volume>
        <fpage>
         2141
        </fpage>
        <lpage>
         2146
        </lpage>
        <pub-id pub-id-type="pmid">
         14517166
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR166">
       <label>
        166
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loot
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) attenuates the development of heart failure after myocardial infarction in rats
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         2002
        </year>
        <volume>
         105
        </volume>
        <fpage>
         1548
        </fpage>
        <lpage>
         1550
        </lpage>
        <pub-id pub-id-type="pmid">
         11927520
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR167">
       <label>
        167
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The nonpeptide angiotensin-(1–7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2007
        </year>
        <volume>
         292
        </volume>
        <fpage>
         H1113
        </fpage>
        <lpage>
         H1119
        </lpage>
        <pub-id pub-id-type="pmid">
         17056670
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR168">
       <label>
        168
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mori
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin 1–7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation
        </article-title>
        <source>
         Circ. Heart Fail.
        </source>
        <year>
         2014
        </year>
        <volume>
         7
        </volume>
        <fpage>
         327
        </fpage>
        <lpage>
         339
        </lpage>
        <pub-id pub-id-type="pmid">
         24389129
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR169">
       <label>
        169
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grobe
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7)
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2007
        </year>
        <volume>
         292
        </volume>
        <fpage>
         H736
        </fpage>
        <lpage>
         H742
        </lpage>
        <pub-id pub-id-type="pmid">
         17098828
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR170">
       <label>
        170
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression of an angiotensin-(1–7)-producing fusion protein produces cardioprotective effects in rats
        </article-title>
        <source>
         Physiol. Genomics
        </source>
        <year>
         2004
        </year>
        <volume>
         17
        </volume>
        <fpage>
         292
        </fpage>
        <lpage>
         299
        </lpage>
        <pub-id pub-id-type="pmid">
         15039487
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR171">
       <label>
        171
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nadu
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Reudelhuber
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <name>
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1–7)3292 rats
        </article-title>
        <source>
         J. Am. Soc. Hypertens.
        </source>
        <year>
         2008
        </year>
        <volume>
         2
        </volume>
        <fpage>
         341
        </fpage>
        <lpage>
         348
        </lpage>
        <pub-id pub-id-type="pmid">
         20409916
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR172">
       <label>
        172
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           VB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1–7 in experimental heart failure in angiotensin-converting enzyme 2-null mice
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2012
        </year>
        <volume>
         59
        </volume>
        <fpage>
         1195
        </fpage>
        <lpage>
         1203
        </lpage>
        <pub-id pub-id-type="pmid">
         22508831
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR173">
       <label>
        173
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Circulating rather than cardiac angiotensin-(1–7) stimulates cardioprotection after myocardial infarction
        </article-title>
        <source>
         Circ. Heart Fail.
        </source>
        <year>
         2010
        </year>
        <volume>
         3
        </volume>
        <fpage>
         286
        </fpage>
        <lpage>
         293
        </lpage>
        <pub-id pub-id-type="pmid">
         20103774
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR174">
       <label>
        174
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mercure
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin(1–7) blunts hypertensive cardiac remodeling by a direct effect on the heart
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2008
        </year>
        <volume>
         103
        </volume>
        <fpage>
         1319
        </fpage>
        <lpage>
         1326
        </lpage>
        <pub-id pub-id-type="pmid">
         18845809
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR175">
       <label>
        175
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1–7)-producing fusion protein in the heart
        </article-title>
        <source>
         Ther. Adv. Cardiovasc. Dis.
        </source>
        <year>
         2010
        </year>
        <volume>
         4
        </volume>
        <fpage>
         83
        </fpage>
        <lpage>
         96
        </lpage>
        <pub-id pub-id-type="pmid">
         20051448
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR176">
       <label>
        176
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin (1–7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice
        </article-title>
        <source>
         Hypertens. Res.
        </source>
        <year>
         2009
        </year>
        <volume>
         32
        </volume>
        <fpage>
         369
        </fpage>
        <lpage>
         374
        </lpage>
        <pub-id pub-id-type="pmid">
         19325560
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR177">
       <label>
        177
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feterik
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Katusic
          </surname>
          <given-names>
           ZS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) causes endothelium-dependent relaxation in canine middle cerebral artery
        </article-title>
        <source>
         Brain Res.
        </source>
        <year>
         2000
        </year>
        <volume>
         873
        </volume>
        <fpage>
         75
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         10915812
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR178">
       <label>
        178
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Durand
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Raffai
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Weinberg
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         <name>
          <surname>
           Lombard
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2010
        </year>
        <volume>
         299
        </volume>
        <fpage>
         H1024
        </fpage>
        <lpage>
         H1033
        </lpage>
        <pub-id pub-id-type="pmid">
         20656887
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR179">
       <label>
        179
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         The expression of angiotensin-converting enzyme 2-angiotensin-(1–7)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats
        </article-title>
        <source>
         Neuropeptides
        </source>
        <year>
         2013
        </year>
        <volume>
         47
        </volume>
        <fpage>
         289
        </fpage>
        <lpage>
         295
        </lpage>
        <pub-id pub-id-type="pmid">
         24090950
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR180">
       <label>
        180
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mecca
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cerebroprotection by angiotensin-(1–7) in endothelin-1-induced ischaemic stroke
        </article-title>
        <source>
         Exp. Physiol.
        </source>
        <year>
         2011
        </year>
        <volume>
         96
        </volume>
        <fpage>
         1084
        </fpage>
        <lpage>
         1096
        </lpage>
        <pub-id pub-id-type="pmid">
         21685445
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR181">
       <label>
        181
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Suppressing inflammation by inhibiting the NF-kappaB pathway contributes to the neuroprotective effect of angiotensin-(1–7) in rats with permanent cerebral ischaemia
        </article-title>
        <source>
         Br. J. Pharmacol.
        </source>
        <year>
         2012
        </year>
        <volume>
         167
        </volume>
        <fpage>
         1520
        </fpage>
        <lpage>
         1532
        </lpage>
        <pub-id pub-id-type="pmid">
         22817481
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR182">
       <label>
        182
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Regenhardt
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-inflammatory effects of angiotensin-(1–7) in ischemic stroke
        </article-title>
        <source>
         Neuropharmacology
        </source>
        <year>
         2013
        </year>
        <volume>
         71
        </volume>
        <fpage>
         154
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="pmid">
         23583926
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR183">
       <label>
        183
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamaleyeva
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes
        </article-title>
        <source>
         Am. J. Physiol. Renal Physiol.
        </source>
        <year>
         2010
        </year>
        <volume>
         302
        </volume>
        <fpage>
         F1374
        </fpage>
        <lpage>
         F1384
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR184">
       <label>
        184
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riera
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2014
        </year>
        <volume>
         9
        </volume>
        <fpage>
         e84683
        </fpage>
        <pub-id pub-id-type="pmid">
         24400109
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR185">
       <label>
        185
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soro-Paavonen
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications
        </article-title>
        <source>
         J. Hypertens.
        </source>
        <year>
         2012
        </year>
        <volume>
         30
        </volume>
        <fpage>
         375
        </fpage>
        <lpage>
         383
        </lpage>
        <pub-id pub-id-type="pmid">
         22179088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR186">
       <label>
        186
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bindom
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Hans
          </surname>
          <given-names>
           CP
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Boulares
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice
        </article-title>
        <source>
         Diabetes
        </source>
        <year>
         2010
        </year>
        <volume>
         59
        </volume>
        <fpage>
         2540
        </fpage>
        <lpage>
         2548
        </lpage>
        <pub-id pub-id-type="pmid">
         20660625
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR187">
       <label>
        187
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takeda
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice
        </article-title>
        <source>
         Diabetes
        </source>
        <year>
         2013
        </year>
        <volume>
         62
        </volume>
        <fpage>
         223
        </fpage>
        <lpage>
         233
        </lpage>
        <pub-id pub-id-type="pmid">
         22933108
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR188">
       <label>
        188
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marcus
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin 1–7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model
        </article-title>
        <source>
         Diabetes
        </source>
        <year>
         2013
        </year>
        <volume>
         62
        </volume>
        <fpage>
         1121
        </fpage>
        <lpage>
         1130
        </lpage>
        <pub-id pub-id-type="pmid">
         23250359
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR189">
       <label>
        189
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased circulating angiotensin-(1–7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet
        </article-title>
        <source>
         Regul. Pept.
        </source>
        <year>
         2012
        </year>
        <volume>
         178
        </volume>
        <fpage>
         64
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="pmid">
         22749992
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR190">
       <label>
        190
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Oral administration of angiotensin-(1–7) ameliorates type 2 diabetes in rats
        </article-title>
        <source>
         J. Mol. Med. (Berl.)
        </source>
        <year>
         2014
        </year>
        <volume>
         92
        </volume>
        <fpage>
         255
        </fpage>
        <lpage>
         265
        </lpage>
        <pub-id pub-id-type="pmid">
         24162089
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR191">
       <label>
        191
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Underwood
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Adler
          </surname>
          <given-names>
           GK
          </given-names>
         </name>
        </person-group>
        <article-title>
         The renin angiotensin aldosterone system and insulin resistance in humans
        </article-title>
        <source>
         Curr. Hypertens. Rep.
        </source>
        <year>
         2013
        </year>
        <volume>
         15
        </volume>
        <fpage>
         59
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="pmid">
         23242734
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR192">
       <label>
        192
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Andreozzi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Laratta
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Sciacqua
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Perticone
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Sesti
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2004
        </year>
        <volume>
         94
        </volume>
        <fpage>
         1211
        </fpage>
        <lpage>
         1218
        </lpage>
        <pub-id pub-id-type="pmid">
         15044323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR193">
       <label>
        193
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reich
          </surname>
          <given-names>
           HN
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Scholey
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Herzenberg
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease
        </article-title>
        <source>
         Kidney Int.
        </source>
        <year>
         2008
        </year>
        <volume>
         74
        </volume>
        <fpage>
         1610
        </fpage>
        <lpage>
         1616
        </lpage>
        <pub-id pub-id-type="pmid">
         19034303
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR194">
       <label>
        194
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes
        </article-title>
        <source>
         J. Am. Soc. Nephrol.
        </source>
        <year>
         2006
        </year>
        <volume>
         17
        </volume>
        <fpage>
         3067
        </fpage>
        <lpage>
         3075
        </lpage>
        <pub-id pub-id-type="pmid">
         17021266
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR195">
       <label>
        195
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mizuiri
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls
        </article-title>
        <source>
         Am. J. Kidney Dis.
        </source>
        <year>
         2008
        </year>
        <volume>
         51
        </volume>
        <fpage>
         613
        </fpage>
        <lpage>
         623
        </lpage>
        <pub-id pub-id-type="pmid">
         18371537
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR196">
       <label>
        196
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2007
        </year>
        <volume>
         171
        </volume>
        <fpage>
         438
        </fpage>
        <lpage>
         451
        </lpage>
        <pub-id pub-id-type="pmid">
         17600118
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR197">
       <label>
        197
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shiota
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice
        </article-title>
        <source>
         Hypertens. Res.
        </source>
        <year>
         2010
        </year>
        <volume>
         33
        </volume>
        <fpage>
         298
        </fpage>
        <lpage>
         307
        </lpage>
        <pub-id pub-id-type="pmid">
         20186149
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR198">
       <label>
        198
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human recombinant ACE2 reduces the progression of diabetic nephropathy
        </article-title>
        <source>
         Diabetes
        </source>
        <year>
         2010
        </year>
        <volume>
         59
        </volume>
        <fpage>
         529
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="pmid">
         19934006
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR199">
       <label>
        199
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           CX
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition
        </article-title>
        <source>
         Mol. Med.
        </source>
        <year>
         2011
        </year>
        <volume>
         17
        </volume>
        <fpage>
         59
        </fpage>
        <lpage>
         69
        </lpage>
        <pub-id pub-id-type="pmid">
         20844835
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR200">
       <label>
        200
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nadarajah
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice
        </article-title>
        <source>
         Kidney Int.
        </source>
        <year>
         2012
        </year>
        <volume>
         82
        </volume>
        <fpage>
         292
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="pmid">
         22475818
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR201">
       <label>
        201
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giani
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) attenuates diabetic nephropathy in Zucker diabetic fatty rats
        </article-title>
        <source>
         Am. J. Physiol. Renal Physiol.
        </source>
        <year>
         2012
        </year>
        <volume>
         302
        </volume>
        <fpage>
         F1606
        </fpage>
        <lpage>
         F1615
        </lpage>
        <pub-id pub-id-type="pmid">
         22492942
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR202">
       <label>
        202
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gembardt
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents
        </article-title>
        <source>
         Peptides
        </source>
        <year>
         2005
        </year>
        <volume>
         26
        </volume>
        <fpage>
         1270
        </fpage>
        <lpage>
         1277
        </lpage>
        <pub-id pub-id-type="pmid">
         15949646
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR203">
       <label>
        203
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hashimoto
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2012
        </year>
        <volume>
         487
        </volume>
        <fpage>
         477
        </fpage>
        <lpage>
         481
        </lpage>
        <pub-id pub-id-type="pmid">
         22837003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR204">
       <label>
        204
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2011
        </year>
        <volume>
         472
        </volume>
        <fpage>
         57
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="pmid">
         21475195
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR205">
       <label>
        205
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haschke
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects
        </article-title>
        <source>
         Clin. Pharmacokinet
        </source>
        <year>
         2013
        </year>
        <volume>
         52
        </volume>
        <fpage>
         783
        </fpage>
        <lpage>
         792
        </lpage>
        <pub-id pub-id-type="pmid">
         23681967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR206">
       <label>
        206
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rodgers
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name>
          <surname>
           Oliver
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           diZerega
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phase I/II dose escalation study of angiotensin 1–7 [A(1–7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer
        </article-title>
        <source>
         Cancer Chemother. Pharmacol.
        </source>
        <year>
         2006
        </year>
        <volume>
         57
        </volume>
        <fpage>
         559
        </fpage>
        <lpage>
         568
        </lpage>
        <pub-id pub-id-type="pmid">
         16096787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR207">
       <label>
        207
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davie
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           McMurray
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of angiotensin-(1–7) and bradykinin in patients with heart failure treated with an ACE inhibitor
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1999
        </year>
        <volume>
         34
        </volume>
        <fpage>
         457
        </fpage>
        <lpage>
         460
        </lpage>
        <pub-id pub-id-type="pmid">
         10489393
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR208">
       <label>
        208
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kluskens
          </surname>
          <given-names>
           LD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1–7) analog
        </article-title>
        <source>
         J. Pharmacol. Exp. Ther.
        </source>
        <year>
         2009
        </year>
        <volume>
         328
        </volume>
        <fpage>
         849
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="pmid">
         19038778
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR209">
       <label>
        209
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Vries
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Oral and pulmonary delivery of thioether-bridged angiotensin-(1–7)
        </article-title>
        <source>
         Peptides
        </source>
        <year>
         2010
        </year>
        <volume>
         31
        </volume>
        <fpage>
         893
        </fpage>
        <lpage>
         898
        </lpage>
        <pub-id pub-id-type="pmid">
         20206220
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR210">
       <label>
        210
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Durik
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of the thioether-bridged, stabilized angiotensin-(1–7) analogue cyclic ang-(1–7) on cardiac remodeling and endothelial function in rats with myocardial infarction
        </article-title>
        <source>
         Int. J. Hypertens.
        </source>
        <year>
         2012
        </year>
        <volume>
         2012
        </volume>
        <fpage>
         536426
        </fpage>
        <pub-id pub-id-type="pmid">
         22121478
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR211">
       <label>
        211
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marques
          </surname>
          <given-names>
           FD
          </given-names>
         </name>
        </person-group>
        <article-title>
         An oral formulation of angiotensin-(1–7) produces cardioprotective effects in infarcted and isoproterenol-treated rats
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2011
        </year>
        <volume>
         57
        </volume>
        <fpage>
         477
        </fpage>
        <lpage>
         483
        </lpage>
        <pub-id pub-id-type="pmid">
         21282558
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR212">
       <label>
        212
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marques
          </surname>
          <given-names>
           FD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Beneficial effects of long-term administration of an oral formulation of angiotensin-(1–7) in infarcted rats
        </article-title>
        <source>
         Int. J. Hypertens.
        </source>
        <year>
         2012
        </year>
        <volume>
         2012
        </volume>
        <fpage>
         795452
        </fpage>
        <pub-id pub-id-type="pmid">
         22482038
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR213">
       <label>
        213
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feltenberger
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Oral formulation of angiotensin-(1–7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2013
        </year>
        <volume>
         62
        </volume>
        <fpage>
         324
        </fpage>
        <lpage>
         330
        </lpage>
        <pub-id pub-id-type="pmid">
         23753417
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR214">
       <label>
        214
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Passos-Silva
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Verano-Braga
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7): beyond the cardio-renal actions
        </article-title>
        <source>
         Clin. Sci. (Lond.)
        </source>
        <year>
         2013
        </year>
        <volume>
         124
        </volume>
        <fpage>
         443
        </fpage>
        <lpage>
         456
        </lpage>
        <pub-id pub-id-type="pmid">
         23249272
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR215">
       <label>
        215
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabelo
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Alenina
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2-angiotensin-(1–7)-Mas axis and oxidative stress in cardiovascular disease
        </article-title>
        <source>
         Hypertens. Res.
        </source>
        <year>
         2011
        </year>
        <volume>
         34
        </volume>
        <fpage>
         154
        </fpage>
        <lpage>
         160
        </lpage>
        <pub-id pub-id-type="pmid">
         21124322
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR216">
       <label>
        216
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simoes e Silva
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Silveira
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Teixeira
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2, angiotensin-(1–7) and Mas receptor axis in inflammation and fibrosis
        </article-title>
        <source>
         Br. J. Pharmacol.
        </source>
        <year>
         2013
        </year>
        <volume>
         169
        </volume>
        <fpage>
         477
        </fpage>
        <lpage>
         492
        </lpage>
        <pub-id pub-id-type="pmid">
         23488800
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR217">
       <label>
        217
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2: central regulator for cardiovascular function
        </article-title>
        <source>
         Curr. Hypertens. Rep.
        </source>
        <year>
         2010
        </year>
        <volume>
         12
        </volume>
        <fpage>
         170
        </fpage>
        <lpage>
         175
        </lpage>
        <pub-id pub-id-type="pmid">
         20424953
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR218">
       <label>
        218
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Therapeutic targeting of the angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas cascade in the renin-angiotensin system: a patent review
        </article-title>
        <source>
         Expert Opin. Ther. Pat.
        </source>
        <year>
         2012
        </year>
        <volume>
         22
        </volume>
        <fpage>
         567
        </fpage>
        <lpage>
         574
        </lpage>
        <pub-id pub-id-type="pmid">
         22510001
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <?properties manuscript?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">
       9604391
      </journal-id>
      <journal-id journal-id-type="pubmed-jr-id">
       21634
      </journal-id>
      <journal-id journal-id-type="nlm-ta">
       Drug Discov Today
      </journal-id>
      <journal-title>
       Drug discovery today
      </journal-title>
      <issn pub-type="ppub">
       1359-6446
      </issn>
      <issn pub-type="epub">
       1878-5832
      </issn>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       20170743
      </article-id>
      <article-id pub-id-type="pmc">
       3005694
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.drudis.2010.02.003
      </article-id>
      <article-id pub-id-type="manuscript">
       NIHMS186889
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Angiotensin-converting enzymes and drug discovery in cardiovascular diseases
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Shi
         </surname>
         <given-names>
          Lijun
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
        <xref ref-type="author-notes" rid="FN1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mao
         </surname>
         <given-names>
          Caiping
         </given-names>
        </name>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
        <xref ref-type="author-notes" rid="FN1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          Zhice
         </given-names>
        </name>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
        <xref ref-type="aff" rid="A3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Lubo
         </given-names>
        </name>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
        <xref ref-type="aff" rid="A3">
         3
        </xref>
       </contrib>
      </contrib-group>
      <aff id="A1">
       <label>
        1
       </label>
       Department of Human Sport Science, Beijing Sport University, Beijing 100084, China
      </aff>
      <aff id="A2">
       <label>
        2
       </label>
       First Hospital of Soochow University &amp; Perinatal Biology Center of Soochow University, Suzhou, 215000, China
      </aff>
      <aff id="A3">
       <label>
        3
       </label>
       Center for Perinatal Biology, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA
      </aff>
      <author-notes>
       <corresp id="cor1">
        <italic>
         Corresponding author:
        </italic>
        Xu, Z. (
        <email>
         xuzhice@suda.edu.cn
        </email>
        )
       </corresp>
       <fn fn-type="equal" id="FN1">
        <label>
         *
        </label>
        <p id="P1">
         These authors and institution 1 and 2 contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
       <day>
        8
       </day>
       <month>
        12
       </month>
       <year>
        2010
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        17
       </day>
       <month>
        2
       </month>
       <year>
        2010
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        5
       </month>
       <year>
        2010
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        1
       </day>
       <month>
        5
       </month>
       <year>
        2011
       </year>
      </pub-date>
      <volume>
       15
      </volume>
      <issue>
       9-10
      </issue>
      <fpage>
       332
      </fpage>
      <lpage>
       341
      </lpage>
      <permissions>
       <copyright-statement>
        © 2010 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2010
       </copyright-year>
      </permissions>
      <abstract>
       <p id="P2">
        Angiotensin-converting enzyme (ACE) is a major target in the treatment of cardiovascular diseases (CVDs). In addition to ACE, ACE2 – which is a homolog of ACE and promotes the degradation of angiotensin II (AngII) to Ang (1–7) – has been recognized recently as a potential therapeutic target in the management of CVDs. This article reviews different metabolic pathways of ACE and ACE2 (AngI-AngII-AT1 receptors and AngI-Ang (1–7)-Mas receptors) in the regulation of cardiovascular function and their potential in new drug development in the therapy of CVDs. In addition, recent progress in the study of angiotensin and ACE in fetal origins of cardiovascular disease, which might present an interesting field in perinatal medicine and preventive medicine, is briefly summarized.
       </p>
      </abstract>
      <contract-num rid="HL1">
       R01 HL089012-03
				||HL
      </contract-num>
      <contract-num rid="HL1">
       R01 HL083966-04
				||HL
      </contract-num>
      <contract-num rid="HL1">
       R01 HL082779-04
				||HL
      </contract-num>
      <contract-sponsor id="HL1">
       National Heart, Lung, and Blood Institute : NHLBI
      </contract-sponsor>
     </article-meta>
    </front>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Curr Opin Pharmacol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Curr Opin Pharmacol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Current Opinion in Pharmacology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1471-4892
      </issn>
      <issn pub-type="epub">
       1471-4973
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       16581295
      </article-id>
      <article-id pub-id-type="pmc">
       7106490
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1471-4892(06)00057-9
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.coph.2006.03.001
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Angiotensin-converting enzyme 2 in lung diseases
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kuba
         </surname>
         <given-names>
          Keiji
         </given-names>
        </name>
        <email>
         Keiji.kuba@imba.oeaw.ac.at
        </email>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Imai
         </surname>
         <given-names>
          Yumiko
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Penninger
         </surname>
         <given-names>
          Josef M
         </given-names>
        </name>
        <email>
         Josef.penninger@imba.oeaw.ac.at
        </email>
       </contrib>
      </contrib-group>
      <aff>
       IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Dr. Bohr-gasse 3, A-1030 Vienna, Austria
      </aff>
      <pub-date pub-type="pmc-release">
       <day>
        3
       </day>
       <month>
        4
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        6
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        3
       </day>
       <month>
        4
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <volume>
       6
      </volume>
      <issue>
       3
      </issue>
      <fpage>
       271
      </fpage>
      <lpage>
       276
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2006 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2006
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        The renin-angiotensin system (RAS) plays a key role in maintaining blood pressure homeostasis, as well as fluid and salt balance. Angiotensin II, a key effector peptide of the system, causes vasoconstriction and exerts multiple biological functions. Angiotensin-converting enzyme (ACE) plays a central role in generating angiotensin II from angiotensin I, and capillary blood vessels in the lung are one of the major sites of ACE expression and angiotensin II production in the human body. The RAS has been implicated in the pathogenesis of pulmonary hypertension and pulmonary fibrosis, both commonly seen in chronic lung diseases such as chronic obstructive lung disease. Recent studies indicate that the RAS also plays a critical role in acute lung diseases, especially acute respiratory distress syndrome (ARDS). ACE2, a close homologue of ACE, functions as a negative regulator of the angiotensin system and was identified as a key receptor for SARS (severe acute respiratory syndrome) coronavirus infections. In the lung, ACE2 protects against acute lung injury in several animal models of ARDS. Thus, the RAS appears to play a critical role in the pathogenesis of acute lung injury. Indeed, increasing ACE2 activity might be a novel approach for the treatment of acute lung failure in several diseases.
       </p>
      </abstract>
     </article-meta>
    </front>
    <sec>
     <title>
      Introduction
     </title>
     <p>
      For many decades, the roles of the renin-angiotensin system (RAS) have been studied in physiology and multiple disorders, in particular cardiovascular diseases [
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib2">
       2
      </xref>
      ]. Angiotensin II (ANG II), a key effector peptide of the RAS, exerts multiple biological functions including the vasoconstriction and sodium balance involved in blood pressure homeostasis. Angiotensin-converting enzyme (ACE) plays a central role in generating ANG II from angiotensin I (ANG I) [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib4">
       4
      </xref>
      ] (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ), and ACE inhibitors or ANG II receptor blockers exhibit beneficial effects in cardiovascular diseases. Capillary blood vessels in the lung are a major site of high-level expression of ACE [
      <xref ref-type="bibr" rid="bib5">
       5
      </xref>
      ]. Thus, the lung is an important organ in generating circulating ANG II, acting as a classical circulation-borne endocrine system. In contrast to this endocrine RAS model, numerous studies have highlighted the importance of local RASs [
      <xref ref-type="bibr" rid="bib6">
       6
      </xref>
      ]. For example, an increase in endothelial ACE expression in the muscularized intra-acinar arteries of lungs was shown both in patients with pulmonary hypertension [
      <xref ref-type="bibr" rid="bib7">
       7
      </xref>
      ] and in rats with hypoxia-induced pulmonary hypertension [
      <xref ref-type="bibr" rid="bib8">
       8
      </xref>
      ]. In addition to ACE, other components of the RAS are expressed in lungs, including renin [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ], angiotensinogen [
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      ] and ANG II receptors [
      <xref ref-type="bibr" rid="bib11">
       11
      </xref>
      ].
      <fig id="fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Current view of the RAS in pulmonary hypertension and pulmonary fibrosis. ANG I serves as a substrate for both ACE and ACE2. ANG II is known to act as vasoconstrictor as well as a mitogen for smooth muscle cells or fibroblasts, mainly through the AT
         <sub>
          1
         </sub>
         receptor. The function of angiotensin-(1–9) is not well understood. Both ACE and ACE2 are involved in the production of the vasodilator peptide angiotensin-(1–7).
        </p>
       </caption>
       <graphic xlink:href="gr1">
       </graphic>
      </fig>
     </p>
     <p>
      In 2000, ACE2, a homologue of ACE, was identified; its discovery instantaneously added a new complexity to the RAS [
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib13">
       13
      </xref>
      ]. Although ACE2 functions similarly to ACE as a carboxypeptidase, ACE2 has a different substrate specificity [
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib13">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="bib14">
       14
      </xref>
      ], shown by
      <italic>
       in vitro
      </italic>
      analyses using recombinant ACE2 protein. Whereas ACE removes dipeptides from the C-terminus of peptide substrates, generating the octapeptide ANG II from the decapeptide ANG I [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib15">
       15
      </xref>
      ], ACE2 cleaves a single residue from ANG II, generating angiotensin-(1–9) [
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib13">
       13
      </xref>
      ], and a single residue from ANG II to generate angiotensin-(1–7) [
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ]. Genetic inactivation of ACE using homologous recombination results in a phenotype characterized by spontaneous hypotension, reduced male fertility and kidney malformation [
      <xref ref-type="bibr" rid="bib16">
       16
      </xref>
      ]. By contrast, targeted disruption of murine ACE2 resulted in increased systemic ANG II levels and impaired cardiac contractility in aged mice [
      <xref ref-type="bibr" rid="bib17">
       17
      </xref>
      ]. Loss of ACE on an ACE2 background reversed this cardiac phenotype [
      <xref ref-type="bibr" rid="bib17">
       17
      </xref>
      ]. Thus, ACE2 appears to be a negative regulator of the RAS and counterbalances the function of ACE (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ).
     </p>
     <p>
      The importance of the RAS in lung diseases has recently re-emerged since the identification of ACE2 as a severe acute respiratory syndrome (SARS) coronavirus receptor. During several months of 2003, SARS — a newly identified illness — spread rapidly from China throughout the world, causing more than 800 deaths [
      <xref ref-type="bibr" rid="bib18">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="bib19">
       19
      </xref>
      ]. A novel coronavirus was identified as the SARS pathogen, which triggered atypical pneumonia characterized by high fever and severe dyspnea [
      <xref ref-type="bibr" rid="bib18">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="bib19">
       19
      </xref>
      ]. The death rate following SARS coronavirus exposure approached almost 10% of infected people owing to the development of acute respiratory distress syndrome (ARDS). ARDS is the most severe form of acute lung injury and is characterized by pulmonary oedema, accumulation of inflammatory cells and severe hypoxia [
      <xref ref-type="bibr" rid="bib20">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="bib21">
       21
      </xref>
      ]. Clinical as well as experimental animal studies have implicated ACE in the pathogenesis of ARDS [
      <xref ref-type="bibr" rid="bib22">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="bib23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       24
      </xref>
      ]. ACE2 is expressed in the lungs of healthy and diseased humans [
      <xref ref-type="bibr" rid="bib25">
       25
      </xref>
      ], and recent ARDS and SARS studies have shown that ACE2 protects murine lungs from severe acute injury [
      <xref ref-type="bibr" rid="bib26">
       26••
      </xref>
      ,
      <xref ref-type="bibr" rid="bib27">
       27••
      </xref>
      ]. Importantly, these experiments also revealed that ACE2 is an essential receptor for SARS infections
      <italic>
       in vitro
      </italic>
      and
      <italic>
       in vivo
      </italic>
      [
      <xref ref-type="bibr" rid="bib27">
       27••
      </xref>
      ,
      <xref ref-type="bibr" rid="bib28">
       28
      </xref>
      ]. In this review, we review the role of the RAS, in particular of the SARS receptor ACE2, in lung diseases, focusing on pulmonary hypertension, pulmonary fibrosis and acute lung injury. The possible applications of blocking the RAS and/or modulating ACE2 for the treatment of lung diseases are discussed.
     </p>
    </sec>
    <sec>
     <title>
      Pulmonary hypertension
     </title>
     <p>
      Pulmonary hypertension is characterized by elevations in pulmonary artery pressure and pulmonary vascular resistance caused by multiple etiologies, including primary pulmonary hypertension, chronic obstructive pulmonary disease (COPD), high altitude or pulmonary embolism. Abnormal pulmonary vasoconstriction and pulmonary vascular remodeling are major pathological features seen in most forms of pulmonary hypertension [
      <xref ref-type="bibr" rid="bib29">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="bib30">
       30
      </xref>
      ]. Although ANG II is well known as a potent vasopressor peptide, in the pathogenesis of pulmonary hypertension ANG II seems to play a role in pulmonary vascular remodeling rather than pulmonary vasoconstriction. In
      <italic>
       in vitro
      </italic>
      cell culture models, ANG II has been shown to directly cause growth/proliferation of pulmonary artery smooth muscle cells largely through ANG II type I (AT
      <sub>
       1
      </sub>
      ), rather than through type II (AT
      <sub>
       2
      </sub>
      ), receptors [
      <xref ref-type="bibr" rid="bib31">
       31
      </xref>
      ] (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ). In pulmonary hypertension
      <italic>
       in vivo
      </italic>
      , the expression of ACE is increased in the endothelial layer of small, as well as elastic, pulmonary arteries [
      <xref ref-type="bibr" rid="bib7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="bib32">
       32
      </xref>
      ]. In addition, in hypoxic, but not monocrotaline-treated [
      <xref ref-type="bibr" rid="bib33">
       33
      </xref>
      ], pulmonary hypertensive rats, both ANG II binding and the number of AT
      <sub>
       1
      </sub>
      receptors are increased [
      <xref ref-type="bibr" rid="bib34">
       34
      </xref>
      ,
      <xref ref-type="bibr" rid="bib35">
       35
      </xref>
      ].
     </p>
     <p>
      In human patients, an association between an ACE insertion/deletion polymorphism (the D allele of the human ACE gene confers increased ACE activity in plasma) and pulmonary hypertension has been reported; this association is, however, controversial. For instance, one study showed that the ACE D/D genotype is associated with less right ventricular hypertrophy [
      <xref ref-type="bibr" rid="bib36">
       36
      </xref>
      ], whereas another reported a correlation between the ACE D/D genotype and the severity of symptoms [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ]. Pharmacologic treatment of animals with either an ACE blocker or an ANG II receptor antagonist inhibited pulmonary vascular remodeling associated with the development of pulmonary hypertension in chronically hypoxic rats or mice [
      <xref ref-type="bibr" rid="bib38">
       38
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       39
      </xref>
      ] or in monocrotaline-treated rats [
      <xref ref-type="bibr" rid="bib40">
       40
      </xref>
      ]. By contrast, tissue ACE-deficient mice, which exhibit undetectable lung ACE activity but retain ∼34% of the ACE activity in plasma, show the same remodeling of pulmonary arterioles as do wild-type mice [
      <xref ref-type="bibr" rid="bib41">
       41
      </xref>
      ]. In addition, despite earlier studies of acute ACE inhibition [
      <xref ref-type="bibr" rid="bib42">
       42
      </xref>
      ,
      <xref ref-type="bibr" rid="bib43">
       43
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       44
      </xref>
      ], a recent pilot study on patients with pulmonary hypertension secondary to COPD showed that treatment with the AT
      <sub>
       1
      </sub>
      receptor blocker losartan (50 mg) showed no statistically significant beneficial effect in terms of pulmonary artery pressure, exercise capacity or breathlessness score [
      <xref ref-type="bibr" rid="bib45">
       45
      </xref>
      ]. The discrepancy between hypoxic rat studies and this human trial might be caused by differences in the pathogenesis of hypoxic rats versus patients with COPD-related pulmonary hypertension. Further studies are required to solve these important issues.
     </p>
    </sec>
    <sec>
     <title>
      Pulmonary fibrosis
     </title>
     <p>
      Pulmonary fibrosis is a frequent response to insults or injuries to the lung. Etiologies include idiopathic pulmonary fibrosis, sarcoidosis, irradiation-induced pneumonitis or ARDS. Excess deposition of extracellular matrix proteins is a key feature of interstitial fibrosis in the lung. The pathogenesis of pulmonary fibrosis includes endothelial and epithelial cell injury, influx of inflammatory cells and the production of chemical mediators leading to the proliferation and activation of fibroblasts [
      <xref ref-type="bibr" rid="bib46">
       46
      </xref>
      ,
      <xref ref-type="bibr" rid="bib47">
       47
      </xref>
      ]. Although there are various initiating mechanisms and etiologies, the terminal phases of fibrosis are commonly characterized by the proliferation and progressive accumulation of connective tissue replacing normal functional parenchyma.
     </p>
     <p>
      ANG II immunoreactivity is also significantly increased within lung fibroblasts, macrophages and bronchiolar and alveolar epithelium after irradiation [
      <xref ref-type="bibr" rid="bib48">
       48
      </xref>
      ]. In addition, angiotensinogen is produced by fibroblasts from fibrotic but not normal human lung. ANG II upregulates the expression of the profibrotic cytokine transforming growth factor-β1, which is involved in both the conversion of fibroblasts to myofibroblasts and the accumulation of collagen [
      <xref ref-type="bibr" rid="bib49">
       49
      </xref>
      ] (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ). An
      <italic>
       in vivo
      </italic>
      role for ANG II in pulmonary fibrosis has been implied from animal models with bleomycin- or irradiation-mediated lung injury. In bleomycin-induced pulmonary fibrosis in rats or mice, ACE inhibitors or AT
      <sub>
       1
      </sub>
      receptor blockers can attenuate epithelial apoptosis, interstitial fibrosis and collagen deposition [
      <xref ref-type="bibr" rid="bib50">
       50
      </xref>
      ,
      <xref ref-type="bibr" rid="bib51">
       51
      </xref>
      ,
      <xref ref-type="bibr" rid="bib52">
       52
      </xref>
      ]. In irradiation-induced lung fibrosis, ACE inhibitors attenuate endothelial dysfunction and fibrosis in rats [
      <xref ref-type="bibr" rid="bib53">
       53
      </xref>
      ]. Conversely, retrospective comparison of the incidence of irradiation-induced lung injury between subjects who took ACE inhibitors and those who did not, failed to reveal a protective effect [
      <xref ref-type="bibr" rid="bib54">
       54
      </xref>
      ]. However, serum concentrations of ACE inhibitors used by subjects in the human study would be expected to be considerably less than those achieved in the animal models cited above. As there are no published prospective or retrospective studies regarding the use of other ACE inhibitors or AT
      <sub>
       1
      </sub>
      receptor blockers in human pulmonary fibrosis induced by factors other than irradiation, it is therefore still unclear if inhibition of the RAS would indeed have beneficial effects on lung fibrosis.
     </p>
    </sec>
    <sec>
     <title>
      Acute respiratory distress syndrome/acute lung injury
     </title>
     <p>
      ARDS is the most severe form of acute lung injury, and affects approximately one million individuals worldwide/year with a mortality rate of at least 30–50% [
      <xref ref-type="bibr" rid="bib20">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="bib21">
       21
      </xref>
      ]. ARDS can be triggered by multiple diseases such as sepsis, aspiration, trauma, acute pancreatitis, or pneumonias following infections with SARS coronavirus or avian and human influenza viruses. Recent cohort studies of ARDS showed a significant association between an ACE insertion/deletion polymorphism and the susceptibility and outcome of ARDS [
      <xref ref-type="bibr" rid="bib23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       24
      </xref>
      ]. The D/D genotype frequency was increased in patients with ARDS compared with a control cohort [
      <xref ref-type="bibr" rid="bib23">
       23
      </xref>
      ]. In addition, the ACE D/D allele was significantly associated with mortality in the ARDS group [
      <xref ref-type="bibr" rid="bib23">
       23
      </xref>
      ]. Another study showed that patients carrying the ACE I/I genotype have a significantly increased survival rate [
      <xref ref-type="bibr" rid="bib24">
       24
      </xref>
      ]. Thus, from the results of inhibitor experiments in rodents [
      <xref ref-type="bibr" rid="bib22">
       22
      </xref>
      ] and ACE allelic correlation studies in humans [
      <xref ref-type="bibr" rid="bib23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       24
      </xref>
      ], it has been suggested that the RAS could play a role in acute lung failure.
     </p>
     <p>
      Our group has investigated the role of ACE2 in ARDS by using
      <italic>
       ace2
      </italic>
      knockout mice. In acid-aspiration-induced ARDS, endotoxin-induced ARDS and peritoneal sepsis-induced ARDS,
      <italic>
       ace2
      </italic>
      knockout mice exhibited severe disease compared with control mice that express ACE2 [
      <xref ref-type="bibr" rid="bib26">
       26
       <sup>
        ••
       </sup>
      </xref>
      ]. Loss of ACE2 expression in mutant mice resulted in enhanced vascular permeability, increased lung edema, neutrophil accumulation and worsened lung function. Importantly, treatment with catalytically active, but not enzymatically inactive, recombinant ACE2 protein improved the symptoms of acute lung injury in wild-type mice, as well as in
      <italic>
       ace2
      </italic>
      knockout mice [
      <xref ref-type="bibr" rid="bib26">
       26
       <sup>
        ••
       </sup>
      </xref>
      ]. Thus, ACE2 plays a protective role in acute lung injury. Mechanistically, the negative regulation of ANG II levels by ACE2 accounts, in part, for the protective function of ACE2 in ARDS. For example, AT
      <sub>
       1
      </sub>
      receptor inhibitor treatment or additional
      <italic>
       ace
      </italic>
      gene deficiency on an
      <italic>
       ace2
      </italic>
      knockout background rescues the severe phenotype of
      <italic>
       ace2
      </italic>
      single mutant mice in acute lung injury [
      <xref ref-type="bibr" rid="bib26">
       26
       <sup>
        ••
       </sup>
      </xref>
      ]. In addition,
      <italic>
       ace
      </italic>
      knockout mice and AT
      <sub>
       1a
      </sub>
      receptor knockout mice showed improved symptoms of acute lung injury [
      <xref ref-type="bibr" rid="bib26">
       26
       <sup>
        ••
       </sup>
      </xref>
      ]. Therefore, in acute lung injury, ACE, ANG II and AT
      <sub>
       1
      </sub>
      receptors function as lung injury-promoting factors [
      <xref ref-type="bibr" rid="bib26">
       26••
      </xref>
      ,
      <xref ref-type="bibr" rid="bib55">
       55
      </xref>
      ], whereas ACE2 protects against lung injury [
      <xref ref-type="bibr" rid="bib26">
       26
       <sup>
        ••
       </sup>
      </xref>
      ] (
      <xref ref-type="fig" rid="fig2">
       Figure 2
      </xref>
      ). These findings suggest that the beneficial effects of ACE inhibitors or AT
      <sub>
       1
      </sub>
      receptor blockers in lung injury models induced by bleomycin or irradiation, observed in the earlier studies, derive largely from their effects on the acute phase of those injuries.
      <fig id="fig2">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Schematic diagram of the proposed role of the RAS in development of severe ARDS. In acute lung injury such as SARS-CoV infections, acid aspiration, pneumonias or sepsis, the generation of ANG II from ANG I is enhanced by ACE. ANG II contributes to acute lung failure through stimulation of the AT
         <sub>
          1
         </sub>
         receptor, whereas ACE2 and the AT
         <sub>
          2
         </sub>
         receptor negatively regulate this pathway and protect from acute lung failure. However, additional ACE2-regulated, but ANG II-independent, pathways seem to also contribute to ARDS.
        </p>
       </caption>
       <graphic xlink:href="gr2">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec>
     <title>
      ACE2 in SARS-mediated lung injury
     </title>
     <p>
      Within a few months following the publication of the SARS-CoV genome [
      <xref ref-type="bibr" rid="bib56">
       56
      </xref>
      ,
      <xref ref-type="bibr" rid="bib57">
       57
      </xref>
      ], ACE2 was identified as a potential receptor in cell line studies
      <italic>
       in vitro
      </italic>
      [
      <xref ref-type="bibr" rid="bib28">
       28
      </xref>
      ]. ACE2 has been demonstrated to bind SARS-CoV spike and to support ‘syncytia formation’, the fusion of spike-protein-expressing cells into large multinucleated cells that can also be seen in ‘real’ SARS infections. Using a mouse SARS infection model with
      <italic>
       ace2
      </italic>
      knockout mice, our group provided evidence that ACE2 is indeed essential for SARS infections
      <italic>
       in vivo
      </italic>
      [
      <xref ref-type="bibr" rid="bib27">
       27
       <sup>
        ••
       </sup>
      </xref>
      ]. When
      <italic>
       ace2
      </italic>
      knockout mice are infected with the SARS coronavirus, they become resistant to virus infection [
      <xref ref-type="bibr" rid="bib27">
       27
       <sup>
        ••
       </sup>
      </xref>
      ]. Virus titers from the lung tissues of infected
      <italic>
       ace2
      </italic>
      knockout mice were 10
      <sup>
       5
      </sup>
      -fold lower than those isolated from the lung of SARS-CoV-infected wild-type mice [
      <xref ref-type="bibr" rid="bib27">
       27
       <sup>
        ••
       </sup>
      </xref>
      ]. The lung histology from
      <italic>
       ace2
      </italic>
      knockout mice challenged with SARS coronavirus showed no signs of inflammation [
      <xref ref-type="bibr" rid="bib27">
       27
       <sup>
        ••
       </sup>
      </xref>
      ], whereas some (but not all) SARS-infected wild-type mice displayed mild inflammation with leukocyte infiltration [
      <xref ref-type="bibr" rid="bib27">
       27••
      </xref>
      ,
      <xref ref-type="bibr" rid="bib58">
       58
      </xref>
      ]. Thus, ACE2 is an essential receptor for SARS infections
      <italic>
       in vivo
      </italic>
      .
     </p>
     <p>
      Despite many studies on SARS-CoV, the reasons why SARS-CoV infections trigger severe lung disease with such a high mortality, in contrast to other coronaviruses, remain a mystery. Accumulating evidence indicates that severe SARS infections are dependent upon the burden of viral replication as well as on the immunopathologic consequences of the host response (for review, see [
      <xref ref-type="bibr" rid="bib59">
       59
      </xref>
      ,
      <xref ref-type="bibr" rid="bib60">
       60
      </xref>
      ]). In addition to the aberrant activation of immune systems, our own studies have implicated the involvement of the RAS in SARS pathogenesis: firstly, ACE2 is a critical SARS receptor
      <italic>
       in vivo
      </italic>
      ; and secondly, ACE2 and other components of the RAS play a central role in controlling the severity of acute lung failure once the disease process has been initiated [
      <xref ref-type="bibr" rid="bib27">
       27
       <sup>
        ••
       </sup>
      </xref>
      ] (
      <xref ref-type="fig" rid="fig2">
       Figure 2
      </xref>
      ). Intriguingly, wild-type mice infected with SARS-CoV showed markedly downregulated ACE2 expression in lungs [
      <xref ref-type="bibr" rid="bib27">
       27
       <sup>
        ••
       </sup>
      </xref>
      ]. Similarly, treatment with recombinant SARS-spike protein, in the absence of any other virus components, downregulates ACE2 expression
      <italic>
       in vitro
      </italic>
      and
      <italic>
       in vivo
      </italic>
      [
      <xref ref-type="bibr" rid="bib27">
       27
       <sup>
        ••
       </sup>
      </xref>
      ]. Thus, SARS-CoV-infected or spike protein-treated wild-type mice resemble
      <italic>
       ace2
      </italic>
      knockout mice, and, similar to
      <italic>
       ace2
      </italic>
      mutant mice, spike-treated wild-type mice show markedly more severe pathology of acute lung injury. Additionally, in spike-treated mice, ANG II peptide levels were increased and the worsened ARDS symptoms could be partially reversed by AT
      <sub>
       1
      </sub>
      receptor blocker treatment [
      <xref ref-type="bibr" rid="bib27">
       27
       <sup>
        ••
       </sup>
      </xref>
      ]. By contrast, spike does not affect the ARDS symptoms in
      <italic>
       ace2
      </italic>
      knockout mice [
      <xref ref-type="bibr" rid="bib27">
       27
       <sup>
        ••
       </sup>
      </xref>
      ]. Thus, the downregulation of ACE2 expression in SARS-CoV infections might play a causal role in SARS pathogenesis, especially in disease progression to ARDS.
     </p>
    </sec>
    <sec>
     <title>
      Conclusions and perspectives
     </title>
     <p>
      ANG II plays roles in tissue remodeling and fibrotic changes through acting on fibroblasts or smooth muscle cells, thereby contributing to the pathogenesis or progression of pulmonary fibrosis or pulmonary hypertension. This notion is strongly supported by the successful treatment of these disease conditions using ACE inhibitors or AT
      <sub>
       1
      </sub>
      receptor blockers in animal models. However, pilot clinical trials have failed to observe significant beneficial effects of ACE inhibitors on radiation-induced pulmonary fibrosis or positive effects of AT
      <sub>
       1
      </sub>
      receptor blockers on COPD-related pulmonary hypertension. Recently, the critical importance of the RAS in the pathogenesis of acute lung disease (i.e
      <italic>
       .
      </italic>
      ARDS/acute lung injury) has emerged. Hypothetically, the RAS appears to contribute to the initial severity of lung diseases rather than to later stages that define chronic fibrosis and tissue remodeling. In line with this notion, the D/D polymorphism of the ACE gene has been associated with the incidence of pneumonias in Japanese elderly patients [
      <xref ref-type="bibr" rid="bib61">
       61
      </xref>
      ] and mortality of ARDS patients [
      <xref ref-type="bibr" rid="bib23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       24
      </xref>
      ]. Importantly, ACE2 has been identified as a key SARS receptor, and ACE2 protects murine lungs from acute lung injury induced by acid aspiration, endotoxin shock, peritoneal sepsis or SARS spike challenge. These findings might provide the opportunity to develop ACE2 as a novel drug for ARDS that develops in emerging lung infectious diseases such as avian influenza A (H5N1) [
      <xref ref-type="bibr" rid="bib62">
       62
      </xref>
      ] or other diseases that affect lung function [
      <xref ref-type="bibr" rid="bib63">
       63
      </xref>
      ]. Because ACE2 is an non-specific protease, it would also be interesting to investigate the role of ACE2 and its metabolites, including angiotensin-(1–7), des-Arg(9)-bradykinin, apelin and dynorphin, in ARDS [
      <xref ref-type="bibr" rid="bib14">
       14
      </xref>
      ]. We look forward to the use of angiotensin system-modulating agents/molecules, in particular ACE2, as novel therapeutic agents to treat severe acute lung failure, a syndrome that currently affects millions of people without any effective drug treatment.
     </p>
    </sec>
    <sec>
     <title>
      References and recommended reading
     </title>
     <p>
      Papers of particular interest, published within the annual period of review, have been highlighted as:
      <list list-type="simple">
       <list-item>
        <p>
         • of special interest
        </p>
       </list-item>
       <list-item>
        <p>
         •• of outstanding interest
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The renin-angiotensin system: importance in physiology and pathology
        </article-title>
        <source>
         J Cardiovasc Pharmacol
        </source>
        <volume>
         15
        </volume>
        <issue>
         Suppl 3
        </issue>
        <year>
         1990
        </year>
        <fpage>
         S1
        </fpage>
        <lpage>
         S5
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Richards
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Agarwal
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The importance of the renin-angiotensin system in cardiovascular disease
        </article-title>
        <source>
         J Hum Hypertens
        </source>
        <volume>
         12
        </volume>
        <year>
         1998
        </year>
        <fpage>
         295
        </fpage>
        <lpage>
         299
        </lpage>
        <pub-id pub-id-type="pmid">
         9655650
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skeggs
          </surname>
          <given-names>
           L.T.
          </given-names>
         </name>
         <name>
          <surname>
           Dorer
          </surname>
          <given-names>
           F.E.
          </given-names>
         </name>
         <name>
          <surname>
           Levine
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lentz
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kahn
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The biochemistry of the renin-angiotensin system
        </article-title>
        <source>
         Adv Exp Med Biol
        </source>
        <volume>
         130
        </volume>
        <year>
         1980
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         27
        </lpage>
        <pub-id pub-id-type="pmid">
         6250339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The angiotensin-converting enzyme gene family: genomics and pharmacology
        </article-title>
        <source>
         Trends Pharmacol Sci
        </source>
        <volume>
         23
        </volume>
        <year>
         2002
        </year>
        <fpage>
         177
        </fpage>
        <lpage>
         183
        </lpage>
        <pub-id pub-id-type="pmid">
         11931993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Studdy
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
         <name>
          <surname>
           Lapworth
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Bird
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme and its clinical significance — a review
        </article-title>
        <source>
         J Clin Pathol
        </source>
        <volume>
         36
        </volume>
        <year>
         1983
        </year>
        <fpage>
         938
        </fpage>
        <lpage>
         947
        </lpage>
        <pub-id pub-id-type="pmid">
         6308066
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lavoie
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sigmund
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Minireview: overview of the renin-angiotensin system–an endocrine and paracrine system
        </article-title>
        <source>
         Endocrinology
        </source>
        <volume>
         144
        </volume>
        <year>
         2003
        </year>
        <fpage>
         2179
        </fpage>
        <lpage>
         2183
        </lpage>
        <pub-id pub-id-type="pmid">
         12746271
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Orte
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Polak
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Haworth
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Yacoub
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Morrell
          </surname>
          <given-names>
           N.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension
        </article-title>
        <source>
         J Pathol
        </source>
        <volume>
         192
        </volume>
        <year>
         2000
        </year>
        <fpage>
         379
        </fpage>
        <lpage>
         384
        </lpage>
        <pub-id pub-id-type="pmid">
         11054722
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morrell
          </surname>
          <given-names>
           N.W.
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           K.G.
          </given-names>
         </name>
         <name>
          <surname>
           Stenmark
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension
        </article-title>
        <source>
         Am J Physiol
        </source>
        <volume>
         269
        </volume>
        <year>
         1995
        </year>
        <fpage>
         H1186
        </fpage>
        <lpage>
         H1194
        </lpage>
        <pub-id pub-id-type="pmid">
         7485548
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dezso
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Nielsen
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Poulsen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of renin in resident alveolar macrophages and monocytes: HPLC and immunohistochemical study
        </article-title>
        <source>
         J Cell Sci
        </source>
        <volume>
         91
        </volume>
        <year>
         1988
        </year>
        <fpage>
         155
        </fpage>
        <lpage>
         159
        </lpage>
        <pub-id pub-id-type="pmid">
         3075624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohkubo
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Nakayama
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Nakanishi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue distribution of rat angiotensinogen mRNA and structural analysis of its heterogeneity
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         261
        </volume>
        <year>
         1986
        </year>
        <fpage>
         319
        </fpage>
        <lpage>
         323
        </lpage>
        <pub-id pub-id-type="pmid">
         3753601
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kakar
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Sellers
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Devor
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Musgrove
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Neill
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <volume>
         183
        </volume>
        <year>
         1992
        </year>
        <fpage>
         1090
        </fpage>
        <lpage>
         1096
        </lpage>
        <pub-id pub-id-type="pmid">
         1567388
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Godbout
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gosselin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stagliano
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Donovan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Woolf
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Robison
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Jeyaseelan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         87
        </volume>
        <year>
         2000
        </year>
        <fpage>
         E1
        </fpage>
        <lpage>
         E9
        </lpage>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Karran
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Christie
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         275
        </volume>
        <year>
         2000
        </year>
        <fpage>
         33238
        </fpage>
        <lpage>
         33243
        </lpage>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vickers
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hales
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kaushik
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Dick
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gavin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Godbout
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Parsons
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         277
        </volume>
        <year>
         2002
        </year>
        <fpage>
         14838
        </fpage>
        <lpage>
         14843
        </lpage>
        <pub-id pub-id-type="pmid">
         11815627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Soubrier
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Peptidyl dipeptidase A: angiotensin I-converting enzyme
        </article-title>
        <source>
         Methods Enzymol
        </source>
        <volume>
         248
        </volume>
        <year>
         1995
        </year>
        <fpage>
         283
        </fpage>
        <lpage>
         305
        </lpage>
        <pub-id pub-id-type="pmid">
         7674927
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Krege
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           John
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Langenbach
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Hodgin
          </surname>
          <given-names>
           J.B.
          </given-names>
         </name>
         <name>
          <surname>
           Hagaman
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bachman
          </surname>
          <given-names>
           E.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jennette
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           O’Brien
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Smithies
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Male-female differences in fertility and blood pressure in ACE-deficient mice
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         375
        </volume>
        <year>
         1995
        </year>
        <fpage>
         146
        </fpage>
        <lpage>
         148
        </lpage>
        <pub-id pub-id-type="pmid">
         7753170
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kozieradzki
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Scanga
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Oliveira-dos-Santos
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           da Costa
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is an essential regulator of heart function
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         417
        </volume>
        <year>
         2002
        </year>
        <fpage>
         822
        </fpage>
        <lpage>
         828
        </lpage>
        <pub-id pub-id-type="pmid">
         12075344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Stohr
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The severe acute respiratory syndrome
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         349
        </volume>
        <year>
         2003
        </year>
        <fpage>
         2431
        </fpage>
        <lpage>
         2441
        </lpage>
        <pub-id pub-id-type="pmid">
         14681510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         S88
        </fpage>
        <lpage>
         S97
        </lpage>
        <pub-id pub-id-type="pmid">
         15577937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hudson
          </surname>
          <given-names>
           L.D.
          </given-names>
         </name>
         <name>
          <surname>
           Milberg
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Anardi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Maunder
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical risks for development of the acute respiratory distress syndrome
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         151
        </volume>
        <year>
         1995
        </year>
        <fpage>
         293
        </fpage>
        <lpage>
         301
        </lpage>
        <pub-id pub-id-type="pmid">
         7842182
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ware
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Matthay
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The acute respiratory distress syndrome
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         342
        </volume>
        <year>
         2000
        </year>
        <fpage>
         1334
        </fpage>
        <lpage>
         1349
        </lpage>
        <pub-id pub-id-type="pmid">
         10793167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raiden
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nahmod
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Nahmod
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Semeniuk
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Pereira
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Giordano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Geffner
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome
        </article-title>
        <source>
         J Pharmacol Exp Ther
        </source>
        <volume>
         303
        </volume>
        <year>
         2002
        </year>
        <fpage>
         45
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="pmid">
         12235231
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marshall
          </surname>
          <given-names>
           R.P.
          </given-names>
         </name>
         <name>
          <surname>
           Webb
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bellingan
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Montgomery
          </surname>
          <given-names>
           H.E.
          </given-names>
         </name>
         <name>
          <surname>
           Chaudhari
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           McAnulty
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Humphries
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Laurent
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         166
        </volume>
        <year>
         2002
        </year>
        <fpage>
         646
        </fpage>
        <lpage>
         650
        </lpage>
        <pub-id pub-id-type="pmid">
         12204859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <mixed-citation publication-type="other">
        Jerng JS, Yu CJ, Wang HC, Chen KY, Cheng SL, Yang PC:
        <bold>
         Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome
        </bold>
        .
        <italic>
         Crit Care Med
        </italic>
        2006, in press.
       </mixed-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamming
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Timens
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bulthuis
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lely
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Navis
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           van Goor
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
        </article-title>
        <source>
         J Pathol
        </source>
        <volume>
         203
        </volume>
        <year>
         2004
        </year>
        <fpage>
         631
        </fpage>
        <lpage>
         637
        </lpage>
        <pub-id pub-id-type="pmid">
         15141377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26••
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wada
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Leong-Poi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 protects from severe acute lung failure
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         436
        </volume>
        <year>
         2005
        </year>
        <fpage>
         112
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="pmid">
         16001071
        </pub-id>
       </element-citation>
       <note>
        <p>
         The first genetic demonstration of the critical involvement of the angiotensin system and ACE2 in early phase of pathogenesis of ARDS by using murine models of acute lung injury, mimicking ARDS patients in intensive care unit settings.
        </p>
       </note>
      </ref>
      <ref id="bib27">
       <label>
        27••
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
       <note>
        <p>
         The first demonstration of ACE2 as a SARS-CoV receptor
         <italic>
          in vivo
         </italic>
         , and SARS-CoV spike-protein-mediated ACE2 downregulation followed by enhanced severity in acute lung injury.
        </p>
       </note>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jeffery
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wanstall
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension
        </article-title>
        <source>
         Pharmacol Ther
        </source>
        <volume>
         92
        </volume>
        <year>
         2001
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         11750034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mandegar
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Remillard
          </surname>
          <given-names>
           C.V.
          </given-names>
         </name>
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           J.X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension
        </article-title>
        <source>
         Microvasc Res
        </source>
        <volume>
         68
        </volume>
        <year>
         2004
        </year>
        <fpage>
         75
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="pmid">
         15313118
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morrell
          </surname>
          <given-names>
           N.W.
          </given-names>
         </name>
         <name>
          <surname>
           Upton
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Kotecha
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huntley
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yacoub
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Polak
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wharton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II activates MAPK and stimulates growth of human pulmonary artery smooth muscle via AT1 receptors
        </article-title>
        <source>
         Am J Physiol
        </source>
        <volume>
         277
        </volume>
        <year>
         1999
        </year>
        <fpage>
         L440
        </fpage>
        <lpage>
         L448
        </lpage>
        <pub-id pub-id-type="pmid">
         10484450
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schuster
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Crouch
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
         <name>
          <surname>
           Parks
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Botney
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme expression in primary pulmonary hypertension
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         154
        </volume>
        <year>
         1996
        </year>
        <fpage>
         1087
        </fpage>
        <lpage>
         1091
        </lpage>
        <pub-id pub-id-type="pmid">
         8887612
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cassis
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shenoy
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Lipke
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Baughn
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Fettinger
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gillespie
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lung angiotensin receptor binding characteristics during the development of monocrotaline-induced pulmonary hypertension
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <volume>
         54
        </volume>
        <year>
         1997
        </year>
        <fpage>
         27
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="pmid">
         9296348
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           al-Tubuly
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Sebkhi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Owji
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nunez
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wilkins
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung
        </article-title>
        <source>
         Br J Pharmacol
        </source>
        <volume>
         119
        </volume>
        <year>
         1996
        </year>
        <fpage>
         1217
        </fpage>
        <lpage>
         1222
        </lpage>
        <pub-id pub-id-type="pmid">
         8937726
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chassagne
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Eddahibi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Adamy
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Rideau
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Marotte
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Dubois-Rande
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Adnot
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Samuel
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Teiger
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension
        </article-title>
        <source>
         Am J Respir Cell Mol Biol
        </source>
        <volume>
         22
        </volume>
        <year>
         2000
        </year>
        <fpage>
         323
        </fpage>
        <lpage>
         332
        </lpage>
        <pub-id pub-id-type="pmid">
         10696069
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Suylen
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wouters
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Pennings
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Cheriex
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
         <name>
          <surname>
           van Pol
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ambergen
          </surname>
          <given-names>
           A.W.
          </given-names>
         </name>
         <name>
          <surname>
           Vermelis
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Daemen
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         159
        </volume>
        <year>
         1999
        </year>
        <fpage>
         1791
        </fpage>
        <lpage>
         1795
        </lpage>
        <pub-id pub-id-type="pmid">
         10351920
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kanazawa
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Okamoto
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Hirata
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yoshikawa
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         162
        </volume>
        <year>
         2000
        </year>
        <fpage>
         1235
        </fpage>
        <lpage>
         1238
        </lpage>
        <pub-id pub-id-type="pmid">
         11029323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zakheim
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Mattioli
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Molteni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Mullis
          </surname>
          <given-names>
           K.B.
          </given-names>
         </name>
         <name>
          <surname>
           Bartley
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I-converting enzyme in the rat
        </article-title>
        <source>
         Lab Invest
        </source>
        <volume>
         33
        </volume>
        <year>
         1975
        </year>
        <fpage>
         57
        </fpage>
        <lpage>
         61
        </lpage>
        <pub-id pub-id-type="pmid">
         167232
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Stassen
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Moons
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Collen
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Janssens
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         94
        </volume>
        <year>
         1996
        </year>
        <fpage>
         1941
        </fpage>
        <lpage>
         1947
        </lpage>
        <pub-id pub-id-type="pmid">
         8873672
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Molteni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           W.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ts’ao
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Solliday
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <name>
          <surname>
           Dunne
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine
        </article-title>
        <source>
         Proc Soc Exp Biol Med
        </source>
        <volume>
         180
        </volume>
        <year>
         1985
        </year>
        <fpage>
         112
        </fpage>
        <lpage>
         120
        </lpage>
        <pub-id pub-id-type="pmid">
         2994075
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Suylen
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Aartsen
          </surname>
          <given-names>
           W.M.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Daemen
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dissociation of pulmonary vascular remodeling and right ventricular pressure in tissue angiotensin-converting enzyme-deficient mice under conditions of chronic alveolar hypoxia
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         163
        </volume>
        <year>
         2001
        </year>
        <fpage>
         1241
        </fpage>
        <lpage>
         1245
        </lpage>
        <pub-id pub-id-type="pmid">
         11316665
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pison
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wolf
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dubois
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Brambilla
          </surname>
          <given-names>
           C.G.
          </given-names>
         </name>
         <name>
          <surname>
           Paramelle
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of captopril combined with oxygen therapy at rest and on exercise in patients with chronic bronchitis and pulmonary hypertension
        </article-title>
        <source>
         Respiration
        </source>
        <volume>
         58
        </volume>
        <year>
         1991
        </year>
        <fpage>
         9
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         1649486
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peacock
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transpulmonary angiotensin II formation and pulmonary haemodynamics in stable hypoxic lung disease: the effect of captopril
        </article-title>
        <source>
         Respir Med
        </source>
        <volume>
         86
        </volume>
        <year>
         1992
        </year>
        <fpage>
         21
        </fpage>
        <lpage>
         26
        </lpage>
        <pub-id pub-id-type="pmid">
         1565813
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kiely
          </surname>
          <given-names>
           D.G.
          </given-names>
         </name>
         <name>
          <surname>
           Cargill
          </surname>
          <given-names>
           R.I.
          </given-names>
         </name>
         <name>
          <surname>
           Wheeldon
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Coutie
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lipworth
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale
        </article-title>
        <source>
         Cardiovasc Res
        </source>
        <volume>
         33
        </volume>
        <year>
         1997
        </year>
        <fpage>
         201
        </fpage>
        <lpage>
         208
        </lpage>
        <pub-id pub-id-type="pmid">
         9059545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morrell
          </surname>
          <given-names>
           N.W.
          </given-names>
         </name>
         <name>
          <surname>
           Higham
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Phillips
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Shakur
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Robinson
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Beddoes
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease
        </article-title>
        <source>
         Respir Res
        </source>
        <volume>
         6
        </volume>
        <year>
         2005
        </year>
        <fpage>
         88
        </fpage>
        <pub-id pub-id-type="pmid">
         16060962
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marshall
          </surname>
          <given-names>
           R.P.
          </given-names>
         </name>
         <name>
          <surname>
           McAnulty
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Laurent
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The pathogenesis of pulmonary fibrosis: is there a fibrosis gene?
        </article-title>
        <source>
         Int J Biochem Cell Biol
        </source>
        <volume>
         29
        </volume>
        <year>
         1997
        </year>
        <fpage>
         107
        </fpage>
        <lpage>
         120
        </lpage>
        <pub-id pub-id-type="pmid">
         9076945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuwano
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Hagimoto
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hara
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular mechanisms of pulmonary fibrosis and current treatment
        </article-title>
        <source>
         Curr Mol Med
        </source>
        <volume>
         1
        </volume>
        <year>
         2001
        </year>
        <fpage>
         551
        </fpage>
        <lpage>
         573
        </lpage>
        <pub-id pub-id-type="pmid">
         11899231
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kinetic alterations of angiotensin-II and nitric oxide in radiation pulmonary fibrosis
        </article-title>
        <source>
         J Environ Pathol Toxicol Oncol
        </source>
        <volume>
         17
        </volume>
        <year>
         1998
        </year>
        <fpage>
         141
        </fpage>
        <lpage>
         150
        </lpage>
        <pub-id pub-id-type="pmid">
         9546751
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair
        </article-title>
        <source>
         Semin Nephrol
        </source>
        <volume>
         17
        </volume>
        <year>
         1997
        </year>
        <fpage>
         467
        </fpage>
        <lpage>
         491
        </lpage>
        <pub-id pub-id-type="pmid">
         9316215
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ibarra-Sunga
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Verlinski
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pick
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Uhal
          </surname>
          <given-names>
           B.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor
        </article-title>
        <source>
         Am J Physiol Lung Cell Mol Physiol
        </source>
        <volume>
         279
        </volume>
        <year>
         2000
        </year>
        <fpage>
         L143
        </fpage>
        <lpage>
         L151
        </lpage>
        <pub-id pub-id-type="pmid">
         10893213
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Rayford
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Uhal
          </surname>
          <given-names>
           B.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice
        </article-title>
        <source>
         Am J Pathol
        </source>
        <volume>
         163
        </volume>
        <year>
         2003
        </year>
        <fpage>
         2523
        </fpage>
        <lpage>
         2530
        </lpage>
        <pub-id pub-id-type="pmid">
         14633624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Otsuka
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Shiratori
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chiba
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Abe
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist
        </article-title>
        <source>
         Thorax
        </source>
        <volume>
         59
        </volume>
        <year>
         2004
        </year>
        <fpage>
         31
        </fpage>
        <lpage>
         38
        </lpage>
        <pub-id pub-id-type="pmid">
         14694243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           W.F.
          </given-names>
         </name>
         <name>
          <surname>
           Sharplin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Franko
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hinz
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Radiation-induced pulmonary endothelial dysfunction and hydroxyproline accumulation in four strains of mice
        </article-title>
        <source>
         Radiat Res
        </source>
        <volume>
         120
        </volume>
        <year>
         1989
        </year>
        <fpage>
         113
        </fpage>
        <lpage>
         120
        </lpage>
        <pub-id pub-id-type="pmid">
         2552496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.W.
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Clough
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Sibley
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bentel
          </surname>
          <given-names>
           G.C.
          </given-names>
         </name>
         <name>
          <surname>
           Marks
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Anscher
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis?
        </article-title>
        <source>
         Radiat Res
        </source>
        <volume>
         153
        </volume>
        <year>
         2000
        </year>
        <fpage>
         405
        </fpage>
        <lpage>
         410
        </lpage>
        <pub-id pub-id-type="pmid">
         10761000
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mancini
          </surname>
          <given-names>
           G.B.
          </given-names>
         </name>
         <name>
          <surname>
           Khalil
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II type 1 receptor blocker inhibits pulmonary injury
        </article-title>
        <source>
         Clin Invest Med
        </source>
        <volume>
         28
        </volume>
        <year>
         2005
        </year>
        <fpage>
         118
        </fpage>
        <lpage>
         126
        </lpage>
        <pub-id pub-id-type="pmid">
         16021985
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Oberste
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Monroe
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Nix
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Campagnoli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Icenogle
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Penaranda
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bankamp
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Maher
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of a novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         Science
        </source>
        <volume>
         300
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1394
        </fpage>
        <lpage>
         1399
        </lpage>
        <pub-id pub-id-type="pmid">
         12730500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marra
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Astell
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Holt
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brooks-Wilson
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Butterfield
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Khattra
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Asano
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Barber
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The genome sequence of the SARS-associated coronavirus
        </article-title>
        <source>
         Science
        </source>
        <volume>
         300
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1399
        </fpage>
        <lpage>
         1404
        </lpage>
        <pub-id pub-id-type="pmid">
         12730501
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hogan
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Flieder
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Paragas
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kobinger
          </surname>
          <given-names>
           G.P.
          </given-names>
         </name>
         <name>
          <surname>
           Wivel
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Crystal
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Boyer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         78
        </volume>
        <year>
         2004
        </year>
        <fpage>
         11416
        </fpage>
        <lpage>
         11421
        </lpage>
        <pub-id pub-id-type="pmid">
         15452265
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dandekar
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunopathogenesis of coronavirus infections: implications for SARS
        </article-title>
        <source>
         Nat Rev Immunol
        </source>
        <volume>
         5
        </volume>
        <year>
         2005
        </year>
        <fpage>
         917
        </fpage>
        <lpage>
         927
        </lpage>
        <pub-id pub-id-type="pmid">
         16322745
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of severe acute respiratory syndrome
        </article-title>
        <source>
         Curr Opin Immunol
        </source>
        <volume>
         17
        </volume>
        <year>
         2005
        </year>
        <fpage>
         404
        </fpage>
        <lpage>
         410
        </lpage>
        <pub-id pub-id-type="pmid">
         15950449
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morimoto
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Okaishi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Onishi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Katsuya
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Okuro
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sakurai
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Onishi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ogihara
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deletion allele of the angiotensin-converting enzyme gene as a risk factor for pneumonia in elderly patients
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         112
        </volume>
        <year>
         2002
        </year>
        <fpage>
         89
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         11835945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ungchusak
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Auewarakul
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Kitphati
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Auwanit
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Puthavathana
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Uiprasertkul
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Boonnak
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Pittayawonganon
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Probable person-to-person transmission of avian influenza A (H5N1)
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         352
        </volume>
        <year>
         2005
        </year>
        <fpage>
         333
        </fpage>
        <lpage>
         340
        </lpage>
        <pub-id pub-id-type="pmid">
         15668219
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Geisbert
          </surname>
          <given-names>
           T.W.
          </given-names>
         </name>
         <name>
          <surname>
           Jahrling
          </surname>
          <given-names>
           P.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Exotic emerging viral diseases: progress and challenges
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         S110
        </fpage>
        <lpage>
         S121
        </lpage>
        <pub-id pub-id-type="pmid">
         15577929
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       We thank Chengyu Jiang, Shuan Rao and many others for their contributions. Supported by grants from The National Bank of Austria, The Austrian Ministry of Science and Education, IMBA, and EUGeneHeart to JMP. KK is supported by a Marie Curie Fellowship from the EU.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <?properties manuscript?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">
       100888706
      </journal-id>
      <journal-id journal-id-type="pubmed-jr-id">
       21614
      </journal-id>
      <journal-id journal-id-type="nlm-ta">
       IUBMB Life
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       IUBMB Life
      </journal-id>
      <journal-title-group>
       <journal-title>
        IUBMB life
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1521-6543
      </issn>
      <issn pub-type="epub">
       1521-6551
      </issn>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       23893738
      </article-id>
      <article-id pub-id-type="pmc">
       4557790
      </article-id>
      <article-id pub-id-type="doi">
       10.1002/iub.1190
      </article-id>
      <article-id pub-id-type="manuscript">
       NIHMS491335
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Angiotensin converting enzyme 2: A new important player in the regulation of glycemia
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chhabra
         </surname>
         <given-names>
          Kavaljit H.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chodavarapu
         </surname>
         <given-names>
          Harshita
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lazartigues
         </surname>
         <given-names>
          Eric
         </given-names>
        </name>
        <xref ref-type="author-notes" rid="FN1">
         *
        </xref>
       </contrib>
       <aff id="A1">
        Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA, USA
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="FN1">
        <label>
         *
        </label>
        Address correspondence to: Eric Lazartigues, Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA, USA. Tel: +5045683210. Fax: +5045682361.
        <email>
         elazar@lsuhsc.edu
        </email>
       </corresp>
       <fn fn-type="other" id="FN2">
        <p>
         Anthony Kanai (
         <email>
          ajk5@pitt.edu
         </email>
         )
        </p>
       </fn>
       <fn fn-type="conflict" id="FN3">
        <p>
         <bold>
          Conflict of Interest
         </bold>
        </p>
        <p>
         The authors declare no potential conflicts of interest pertaining to this article.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
       <day>
        27
       </day>
       <month>
        8
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        29
       </day>
       <month>
        7
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        9
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        02
       </day>
       <month>
        9
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       65
      </volume>
      <issue>
       9
      </issue>
      <fpage>
       731
      </fpage>
      <lpage>
       738
      </lpage>
      <!--elocation-id from pubmed: 10.1002/iub.1190-->
      <abstract>
       <p id="P1">
        In spite of the novel anti-diabetic drugs available on the market, type 2 diabetes mellitus (T2DM) affects nearly 25 million people in the USA and causes about 5% of all deaths globally each year. Given the rate and proportion by which T2DM is affecting human beings, it is indispensable to identify new therapeutic targets that can control the disease. Recent pre-clinical and clinical studies suggest that attenuating the activity of the renin-angiotensin system (RAS) could improve glycemia in diabetic patients. Angiotensin converting enzyme 2 (ACE2) counteracts RAS over-activity by degrading Ang-II, a vasoconstrictor, to Ang-(1-7) which is a vasodilator. A decrease in ACE2 and an increase in ADAM17-mediated shedding activity have been observed with the progression of T2DM suggesting the importance of this mechanism in the disease. Indeed, restoration of ACE2 improves glycemia in db/db and Ang-II-infused mice. The beneficial effects of ACE2 can be attributed to reduced oxidative stress and ADAM17 expression in the islets of Langerhans in addition to the improvement of blood flow to the β-cells. The advantage of ACE2 over other RAS blockers is that ACE2 not only counteracts the negative effects of Ang-II but also increases Ang-(1-7)/MasR [a receptor through which Ang-(1-7) produces its actions] signaling in the cells. Increased Ang-(1-7)/MasR signaling has been reported to improve insulin sensitivity and glycemia in diabetic animals. Altogether, ACE2/Ang-(1-7)/MasR axis of the RAS appears to be protective in T2DM and strategies to restore ACE2 levels in the disease seem to be a promising therapy for Ang-II-mediated T2DM.
       </p>
      </abstract>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Cardiovasc Drugs Ther
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Cardiovasc Drugs Ther
      </journal-id>
      <journal-title-group>
       <journal-title>
        Cardiovascular Drugs and Therapy
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0920-3206
      </issn>
      <issn pub-type="epub">
       1573-7241
      </issn>
      <publisher>
       <publisher-name>
        Kluwer Academic Publishers
       </publisher-name>
       <publisher-loc>
        Boston
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       15883759
      </article-id>
      <article-id pub-id-type="pmc">
       7087601
      </article-id>
      <article-id pub-id-type="publisher-id">
       6900
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/s10557-005-6900-8
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Rethinking the Renin-Angiotensin System and Its Role in Cardiovascular Regulation
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Pagliaro
         </surname>
         <given-names>
          Pasquale
         </given-names>
        </name>
        <degrees>
         MD PhD
        </degrees>
        <address>
         <phone>
          39-11 6705430/7710
         </phone>
         <fax>
          39-11 9038639
         </fax>
         <email>
          pasquale.pagliaro@unito.it
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Penna
         </surname>
         <given-names>
          Claudia
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.7605.4
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000123366580
         </institution-id>
         <institution>
          Dipartimento di Scienze Cliniche e Biologiche,
         </institution>
         <institution>
          Università degli Studi di Torino,
         </institution>
        </institution-wrap>
        Italy
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.7605.4
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2336 6580
         </institution-id>
         <institution>
          Dipartimento di Scienze Cliniche e, Biologiche,
         </institution>
         <institution>
          Università di Torino Ospedale S. Luigi,
         </institution>
        </institution-wrap>
        Regione Gonzole, 10043 Orbassano (TO), Italy
       </aff>
      </contrib-group>
      <pub-date pub-type="ppub">
       <year>
        2005
       </year>
      </pub-date>
      <volume>
       19
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       77
      </fpage>
      <lpage>
       87
      </lpage>
      <permissions>
       <copyright-statement>
        © Springer Science + Business Media, Inc. 2005
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p>
        Angiotensin-converting enzyme (ACE) plays a pivotal role in the renin-angiotensin system (RAS) and ACE-inhibitors are widely used in several clinical conditions, including hypertension and heart failure. Recently, a homologue of ACE, ACE
        <sub>
         2
        </sub>
        has been discovered. Both ACE and ACE
        <sub>
         2
        </sub>
        are emerging as key enzymes of the RAS, where ACE
        <sub>
         2
        </sub>
        may play a role as negative regulator of ACE. Moreover, ACE
        <sub>
         2
        </sub>
        appears to be an important enzyme outside the classical RAS, as it hydrolyzes apelins, dynorphin A 1-13, des-Arg-bradykinin and other peptide substrates. The precise interplay between tissue ACE, ACE
        <sub>
         2
        </sub>
        , and their substrates and by-products are presently still unclear.
       </p>
       <p>
        ACE-inhibitors reduce angiotensin II formation and bradykinin degradation, but do not inhibit ACE
        <sub>
         2
        </sub>
        activity. Moreover, ACE-inhibitors differ in their affinity for tissue ACE, and it has been suggested that tissue ACE affinity might be responsible for some of the beneficial properties of these drugs. ACE-inhibitors also increase nitric oxide availability, and activate several kinases that may regulate protein synthesis by interacting with the nucleus of the cells (
        <italic>
         outside-in signaling
        </italic>
        ). The
        <italic>
         outside-in signaling
        </italic>
        may also be activated by bradykinin itself. Although, the precise significance of the
        <italic>
         outside-in signaling
        </italic>
        is still unclear, this new role of ACE-inhibitors may represent a discriminant factor versus angiotensin II receptors antagonists.
       </p>
       <p>
        This mini review will summarize some new aspects concerning the recently discovered biological functions of RAS and in particular of ACE, ACE
        <sub>
         2
        </sub>
        and ACE-inhibitors in cardiovascular system.
       </p>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Key Words
       </title>
       <kwd>
        angiotensin-converting enzyme (ACE)
       </kwd>
       <kwd>
        ACE-associated kinases
       </kwd>
       <kwd>
        ACE-inhibitors
       </kwd>
       <kwd>
        Bradykinin
       </kwd>
       <kwd>
        renin-angiotensin system
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer Science + Business Media, Inc. 2005
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <back>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Karran
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Christie
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2000
        </year>
        <volume>
         275
        </volume>
        <fpage>
         33238
        </fpage>
        <lpage>
         33243
        </lpage>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rastaldo
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Paolocci
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Chiribiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Penna
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gattullo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Pagliaro
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cytochrome P-450 metabolite of arachidonic acid mediates bradykinin-induced negative inotropic effect
        </article-title>
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <year>
         2001
        </year>
        <volume>
         280
        </volume>
        <fpage>
         H2823
        </fpage>
        <lpage>
         2832
        </lpage>
        <pub-id pub-id-type="pmid">
         11356641
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kohlstedt
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Shoghi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Muller-Esterl
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Busse
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fleming
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         2002
        </year>
        <volume>
         91
        </volume>
        <fpage>
         749
        </fpage>
        <lpage>
         756
        </lpage>
        <pub-id pub-id-type="pmid">
         12386153
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kohlstedt
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Busse
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fleming
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Signaling via the Angiotensin-Converting Enzyme Enhances the Expression of Cyclooxygenase-2 in Endothelial Cells
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2005
        </year>
        <volume>
         45
        </volume>
        <fpage>
         126
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         15569856
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kohlstedt
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Brandes
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
         <name>
          <surname>
           Muller-Esterl
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Busse
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fleming
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         2004
        </year>
        <volume>
         94
        </volume>
        <fpage>
         60
        </fpage>
        <lpage>
         67
        </lpage>
        <pub-id pub-id-type="pmid">
         14615289
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Vane
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fate of angiotensin I in the circulation
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1968
        </year>
        <volume>
         218
        </volume>
        <fpage>
         144
        </fpage>
        <lpage>
         150
        </lpage>
        <pub-id pub-id-type="pmid">
         4296306
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Vane
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
        </person-group>
        <article-title>
         The conversion of angiotensin I to angiotensin II
         <italic>
          in vivo
         </italic>
        </article-title>
        <source>
         Naunyn Schmiedebergs Arch Exp Pathol Pharmakol
        </source>
        <year>
         1968
        </year>
        <volume>
         259
        </volume>
        <fpage>
         188
        </fpage>
        <lpage>
         189
        </lpage>
        <pub-id pub-id-type="pmid">
         4298591
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Fabris
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
         <name>
          <surname>
           Mendelsohn
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
        </person-group>
        <article-title>
         Localization of angiotensin converting enzyme in rat heart
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         1991
        </year>
        <volume>
         68
        </volume>
        <fpage>
         141
        </fpage>
        <lpage>
         149
        </lpage>
        <pub-id pub-id-type="pmid">
         1845851
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falkenhahn
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Franke
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Bohle
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cellular distribution of angiotensin-converting enzyme after myocardial infarction
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1995
        </year>
        <volume>
         25
        </volume>
        <fpage>
         219
        </fpage>
        <lpage>
         226
        </lpage>
        <pub-id pub-id-type="pmid">
         7531176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hirsch
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name>
          <surname>
           Talsness
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
         <name>
          <surname>
           Schunkert
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Paul
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dzau
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         1991
        </year>
        <volume>
         69
        </volume>
        <fpage>
         475
        </fpage>
        <lpage>
         482
        </lpage>
        <pub-id pub-id-type="pmid">
         1650297
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schunkert
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Ingelfinger
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Hirsch
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         1992
        </year>
        <volume>
         90
        </volume>
        <fpage>
         1523
        </fpage>
        <lpage>
         1529
        </lpage>
        <pub-id pub-id-type="pmid">
         1401084
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Claudio
          </surname>
          <given-names>
           PP
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         1998
        </year>
        <volume>
         101
        </volume>
        <fpage>
         1326
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="pmid">
         9525975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rajagopalan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kurz
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Munzel
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         1996
        </year>
        <volume>
         97
        </volume>
        <fpage>
         1916
        </fpage>
        <lpage>
         1923
        </lpage>
        <pub-id pub-id-type="pmid">
         8621776
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gattullo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Pagliaro
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Marsh
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
         <name>
          <surname>
           Losano
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         New insights into nitric oxide and coronary circulation
        </article-title>
        <source>
         Life Sci
        </source>
        <year>
         1999
        </year>
        <volume>
         65
        </volume>
        <fpage>
         2167
        </fpage>
        <lpage>
         2174
        </lpage>
        <pub-id pub-id-type="pmid">
         10576588
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hokimoto
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Yasue
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Fujimoto
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         1996
        </year>
        <volume>
         94
        </volume>
        <fpage>
         1513
        </fpage>
        <lpage>
         1518
        </lpage>
        <pub-id pub-id-type="pmid">
         8840838
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Lannoy
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Danser
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Bouhuizen
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Saxena
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name>
          <surname>
           Schalekamp
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Localization and production of angiotensin II in the isolated perfused rat heart
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1998
        </year>
        <volume>
         31
        </volume>
        <fpage>
         1111
        </fpage>
        <lpage>
         1117
        </lpage>
        <pub-id pub-id-type="pmid">
         9576122
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Urata
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Kinoshita
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Misono
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Bumpus
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
         <name>
          <surname>
           Husain
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         1990
        </year>
        <volume>
         265
        </volume>
        <fpage>
         22348
        </fpage>
        <lpage>
         22357
        </lpage>
        <pub-id pub-id-type="pmid">
         2266130
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruzicka
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Skarda
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Leenen
          </surname>
          <given-names>
           FH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         1995
        </year>
        <volume>
         92
        </volume>
        <fpage>
         3568
        </fpage>
        <lpage>
         3573
        </lpage>
        <pub-id pub-id-type="pmid">
         8521580
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           YA
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Lindpaintner
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system
         <italic>
          in vivo
         </italic>
         : A comprehensive study of all its components in the dog
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         1996
        </year>
        <volume>
         93
        </volume>
        <fpage>
         11035
        </fpage>
        <lpage>
         11040
        </lpage>
        <pub-id pub-id-type="pmid">
         8855304
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sadoshima
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Slayter
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Izumo
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes
         <italic>
          in vitro
         </italic>
        </article-title>
        <source>
         Cell
        </source>
        <year>
         1993
        </year>
        <volume>
         75
        </volume>
        <fpage>
         977
        </fpage>
        <lpage>
         984
        </lpage>
        <pub-id pub-id-type="pmid">
         8252633
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pfeifer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Bruckschlegel
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Holmer
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Paul
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Riegger
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Schunkert
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reciprocal regulation of pulmonary and cardiac angiotensin-converting enzyme in rats with severe left ventricular hypertrophy
        </article-title>
        <source>
         Cardiovasc Res
        </source>
        <year>
         1998
        </year>
        <volume>
         38
        </volume>
        <fpage>
         125
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         9683914
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lowes
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         <name>
          <surname>
           Minobe
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Abraham
          </surname>
          <given-names>
           WT
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         1997
        </year>
        <volume>
         100
        </volume>
        <fpage>
         2315
        </fpage>
        <lpage>
         2324
        </lpage>
        <pub-id pub-id-type="pmid">
         9410910
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pinto
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           van Gilst
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Kingma
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Schunkert
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators
        </article-title>
        <source>
         J Am Coll Cardiol
        </source>
        <year>
         1995
        </year>
        <volume>
         25
        </volume>
        <fpage>
         1622
        </fpage>
        <lpage>
         1626
        </lpage>
        <pub-id pub-id-type="pmid">
         7759715
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohmichi
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Iwai
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Maeda
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genetic basis of left ventricular remodeling after myocardial infarction
        </article-title>
        <source>
         Int J Cardiol
        </source>
        <year>
         1996
        </year>
        <volume>
         53
        </volume>
        <fpage>
         265
        </fpage>
        <lpage>
         272
        </lpage>
        <pub-id pub-id-type="pmid">
         8793580
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           ST
          </given-names>
         </name>
         <name>
          <surname>
           Boerwinkle
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Sing
          </surname>
          <given-names>
           CF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Context-dependent associations of the ACE I/D polymorphism with blood pressure
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1999
        </year>
        <volume>
         34
        </volume>
        <fpage>
         773
        </fpage>
        <lpage>
         778
        </lpage>
        <pub-id pub-id-type="pmid">
         10523359
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pfohl
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Koch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Prescod
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Haase
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Haring
          </surname>
          <given-names>
           HU
          </given-names>
         </name>
         <name>
          <surname>
           Karsch
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study
        </article-title>
        <source>
         Eur Heart J
        </source>
        <year>
         1999
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1318
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="pmid">
         10462466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Davia
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Bennett
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Pepper
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Poole-Wilson
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         <name>
          <surname>
           Harding
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         1995
        </year>
        <volume>
         92
        </volume>
        <fpage>
         2540
        </fpage>
        <lpage>
         2549
        </lpage>
        <pub-id pub-id-type="pmid">
         7586355
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frey
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Olson
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cardiac hypertrophy: The good, the bad, and the ugly
        </article-title>
        <source>
         Annu Rev Physiol
        </source>
        <year>
         2003
        </year>
        <volume>
         65
        </volume>
        <fpage>
         45
        </fpage>
        <lpage>
         79
        </lpage>
        <pub-id pub-id-type="pmid">
         12524460
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schluter
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
         <name>
          <surname>
           Wollert
          </surname>
          <given-names>
           KC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Synchronization and integration of multiple hypertrophic pathways in the heart
        </article-title>
        <source>
         Cardiovasc Res
        </source>
        <year>
         2004
        </year>
        <volume>
         63
        </volume>
        <fpage>
         367
        </fpage>
        <lpage>
         372
        </lpage>
        <pub-id pub-id-type="pmid">
         15276461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           WG
          </given-names>
         </name>
         <name>
          <surname>
           Brandenburger
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Autelitano
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Pham
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Hannan
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         2002
        </year>
        <volume>
         90
        </volume>
        <fpage>
         135
        </fpage>
        <lpage>
         142
        </lpage>
        <pub-id pub-id-type="pmid">
         11834705
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rocic
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Govindarajan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Sabri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lucchesi
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <article-title>
         A role for PYK2 in regulation of ERK1/2 MAP kinases and PI 3-kinase by ANG II in vascular smooth muscle
        </article-title>
        <source>
         Am J Physiol Cell Physiol
        </source>
        <year>
         2001
        </year>
        <volume>
         280
        </volume>
        <fpage>
         C90
        </fpage>
        <lpage>
         C99
        </lpage>
        <pub-id pub-id-type="pmid">
         11121380
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Daub
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           FU
          </given-names>
         </name>
         <name>
          <surname>
           Wallasch
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ullrich
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1996
        </year>
        <volume>
         379
        </volume>
        <fpage>
         557
        </fpage>
        <lpage>
         560
        </lpage>
        <pub-id pub-id-type="pmid">
         8596637
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seta
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Nanamori
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Modrall
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Neubig
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
         <name>
          <surname>
           Sadoshima
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2002
        </year>
        <volume>
         277
        </volume>
        <fpage>
         9268
        </fpage>
        <lpage>
         9277
        </lpage>
        <pub-id pub-id-type="pmid">
         11777928
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Karmazyn
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Obligatory role for endogenous endothelin in mediating the hypertrophic effects of phenylephrine and angiotensin II in neonatal rat ventricular myocytes: Evidence for two distinct mechanisms for endothelin regulation
        </article-title>
        <source>
         J Pharmacol Exp Ther
        </source>
        <year>
         2004
        </year>
        <volume>
         310
        </volume>
        <fpage>
         43
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="pmid">
         15007106
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pellieux
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Foletti
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Peduto
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         2001
        </year>
        <volume>
         108
        </volume>
        <fpage>
         1843
        </fpage>
        <lpage>
         1851
        </lpage>
        <pub-id pub-id-type="pmid">
         11748268
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Packer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impossible task of developing a new treatment for heart failure
        </article-title>
        <source>
         J Card Fail
        </source>
        <year>
         2002
        </year>
        <volume>
         8
        </volume>
        <fpage>
         193
        </fpage>
        <lpage>
         196
        </lpage>
        <pub-id pub-id-type="pmid">
         12397564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Remme
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pharmacological modulation of cardiovascular remodeling: A guide to heart failure therapy
        </article-title>
        <source>
         Cardiovasc Drugs Ther
        </source>
        <year>
         2003
        </year>
        <volume>
         17
        </volume>
        <fpage>
         349
        </fpage>
        <lpage>
         360
        </lpage>
        <pub-id pub-id-type="pmid">
         14618097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Flather
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Yusuf
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kober
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2000
        </year>
        <volume>
         355
        </volume>
        <fpage>
         1575
        </fpage>
        <lpage>
         1581
        </lpage>
        <pub-id pub-id-type="pmid">
         10821360
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohta
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hasebe
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Tsuji
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol
        </article-title>
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <year>
         2004
        </year>
        <volume>
         287
        </volume>
        <fpage>
         H2914
        </fpage>
        <lpage>
         H2921
        </lpage>
        <pub-id pub-id-type="pmid">
         15297251
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fox
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         362
        </volume>
        <fpage>
         782
        </fpage>
        <lpage>
         788
        </lpage>
        <pub-id pub-id-type="pmid">
         13678872
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yusuf
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Sleight
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Pogue
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Dagenais
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2000
        </year>
        <volume>
         342
        </volume>
        <fpage>
         145
        </fpage>
        <lpage>
         153
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJM200001203420301
        </pub-id>
        <pub-id pub-id-type="pmid">
         10639539
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Remme
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Should ACE inhibition always be first-line therapy in heart failure? Lessons from the CARMEN Study
        </article-title>
        <source>
         Cardiovasc Drugs Ther
        </source>
        <year>
         2003
        </year>
        <volume>
         17
        </volume>
        <fpage>
         107
        </fpage>
        <lpage>
         109
        </lpage>
        <pub-id pub-id-type="pmid">
         14562822
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pfeffer
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Pfeffer
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Mirsky
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Braunwald
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         1982
        </year>
        <volume>
         79
        </volume>
        <fpage>
         3310
        </fpage>
        <lpage>
         3314
        </lpage>
        <pub-id pub-id-type="pmid">
         6212929
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fleischmann
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
         <name>
          <surname>
           Schmieder
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?
        </article-title>
        <source>
         Curr Cardiol Rep
        </source>
        <year>
         2002
        </year>
        <volume>
         4
        </volume>
        <fpage>
         474
        </fpage>
        <lpage>
         478
        </lpage>
        <pub-id pub-id-type="pmid">
         12379166
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eichhorn
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Bristow
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         1996
        </year>
        <volume>
         94
        </volume>
        <fpage>
         2285
        </fpage>
        <lpage>
         2296
        </lpage>
        <pub-id pub-id-type="pmid">
         8901684
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dzau
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Bernstein
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Celermajer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data
        </article-title>
        <source>
         Am J Cardiol
        </source>
        <year>
         2001
        </year>
        <volume>
         88
        </volume>
        <fpage>
         1L
        </fpage>
        <lpage>
         20L
        </lpage>
        <pub-id pub-id-type="pmid">
         11423049
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dzau
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Bernstein
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Celermajer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pathophysiologic and therapeutic importance of tissue ACE: A consensus report
        </article-title>
        <source>
         Cardiovasc Drugs Ther
        </source>
        <year>
         2002
        </year>
        <volume>
         16
        </volume>
        <fpage>
         149
        </fpage>
        <lpage>
         160
        </lpage>
        <pub-id pub-id-type="pmid">
         12090908
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sauer
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Baer
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Berlin
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Kimmel
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction
        </article-title>
        <source>
         Am J Cardiol
        </source>
        <year>
         2004
        </year>
        <volume>
         94
        </volume>
        <fpage>
         1171
        </fpage>
        <lpage>
         1173
        </lpage>
        <pub-id pub-id-type="pmid">
         15518614
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fabris
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           BZ
          </given-names>
         </name>
         <name>
          <surname>
           Pupic
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Perich
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue
        </article-title>
        <source>
         J Cardiovasc Pharmacol
        </source>
        <year>
         1990
        </year>
        <volume>
         15
        </volume>
        <issue>
         Suppl 2
        </issue>
        <fpage>
         S6
        </fpage>
        <lpage>
         S13
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kinoshita
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Urata
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Bumpus
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
         <name>
          <surname>
           Husain
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Measurement of angiotensin I converting enzyme inhibition in the heart
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         1993
        </year>
        <volume>
         73
        </volume>
        <fpage>
         51
        </fpage>
        <lpage>
         60
        </lpage>
        <pub-id pub-id-type="pmid">
         8389676
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Sapojnikov
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kreutz
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zurcher
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Ganten
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of chromosome X in the Sabra rat model of salt-sensitive hypertension
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         1999
        </year>
        <volume>
         33
        </volume>
        <fpage>
         261
        </fpage>
        <lpage>
         265
        </lpage>
        <pub-id pub-id-type="pmid">
         9931114
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is an essential regulator of heart function
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2002
        </year>
        <volume>
         417
        </volume>
        <fpage>
         822
        </fpage>
        <lpage>
         828
        </lpage>
        <pub-id pub-id-type="pmid">
         12075344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         2000
        </year>
        <volume>
         87
        </volume>
        <fpage>
         E1
        </fpage>
        <lpage>
         E9
        </lpage>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harmer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Gilbert
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Borman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme
        </article-title>
        <source>
         FEBS Lett
        </source>
        <year>
         2002
        </year>
        <volume>
         532
        </volume>
        <fpage>
         107
        </fpage>
        <lpage>
         110
        </lpage>
        <pub-id pub-id-type="pmid">
         12459472
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Komatsu
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular cloning, mRNA expression and chromosomal localization of mouse angiotensin-converting enzyme-related carboxypeptidase (mACE2)
        </article-title>
        <source>
         DNA Seq
        </source>
        <year>
         2002
        </year>
        <volume>
         13
        </volume>
        <fpage>
         217
        </fpage>
        <lpage>
         220
        </lpage>
        <pub-id pub-id-type="pmid">
         12487024
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warner
          </surname>
          <given-names>
           FJ
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme-2: A molecular and cellular perspective
        </article-title>
        <source>
         Cell Mol Life Sci
        </source>
        <year>
         2004
        </year>
        <volume>
         61
        </volume>
        <fpage>
         2704
        </fpage>
        <lpage>
         2713
        </lpage>
        <pub-id pub-id-type="pmid">
         15549171
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Barnes
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Foti
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Nolin
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lewitzsky
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Metivier
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Two single nucleotide polymorphisms in theACE2 locus are associated with cardiovascular disease
        </article-title>
        <source>
         Gen Epidem
        </source>
        <year>
         2002
        </year>
        <volume>
         23
        </volume>
        <fpage>
         272
        </fpage>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iyer
          </surname>
          <given-names>
           SN
          </given-names>
         </name>
         <name>
          <surname>
           Averill
          </surname>
          <given-names>
           DB
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Allred
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2000
        </year>
        <volume>
         36
        </volume>
        <fpage>
         417
        </fpage>
        <lpage>
         422
        </lpage>
        <pub-id pub-id-type="pmid">
         10988275
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Garvin
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Carretero
          </surname>
          <given-names>
           OA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2002
        </year>
        <volume>
         39
        </volume>
        <fpage>
         799
        </fpage>
        <lpage>
         802
        </lpage>
        <pub-id pub-id-type="pmid">
         11897767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Sexton
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Skogerson
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Novel peptide inhibitors of angiotensin-converting enzyme 2
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2003
        </year>
        <volume>
         278
        </volume>
        <fpage>
         15532
        </fpage>
        <lpage>
         15540
        </lpage>
        <pub-id pub-id-type="pmid">
         12606557
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
        </person-group>
        <article-title>
         The angiotensin-converting enzyme gene family: Genomics and pharmacology
        </article-title>
        <source>
         Trends Pharmacol Sci
        </source>
        <year>
         2002
        </year>
        <volume>
         23
        </volume>
        <fpage>
         177
        </fpage>
        <lpage>
         183
        </lpage>
        <pub-id pub-id-type="pmid">
         11931993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Krege
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           John
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Langenbach
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Male-female differences in fertility and blood pressure in ACE-deficient mice
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1995
        </year>
        <volume>
         375
        </volume>
        <fpage>
         146
        </fpage>
        <lpage>
         148
        </lpage>
        <pub-id pub-id-type="pmid">
         7753170
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Backx
          </surname>
          <given-names>
           PH
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of ACE2 in cardiovascular physiology
        </article-title>
        <source>
         Trends Cardiovasc Med
        </source>
        <year>
         2003
        </year>
        <volume>
         13
        </volume>
        <fpage>
         93
        </fpage>
        <lpage>
         101
        </lpage>
        <pub-id pub-id-type="pmid">
         12691672
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Allred
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Acton
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Coffman
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Regulation of blood pressure by the angiotensin converting en-zyme homologue ACE2
        </article-title>
        <source>
         Am J Nephrol
        </source>
        <year>
         2002
        </year>
        <volume>
         13
        </volume>
        <fpage>
         52A
        </fpage>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hypothesis: ACE2 modulates blood pressure in the mammalian organism
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2003
        </year>
        <volume>
         41
        </volume>
        <fpage>
         871
        </fpage>
        <lpage>
         873
        </lpage>
        <pub-id pub-id-type="pmid">
         12654716
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Kogler
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Georgakopoulos
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transgenic mouse model of stunned myocardium
        </article-title>
        <source>
         Science
        </source>
        <year>
         2000
        </year>
        <volume>
         287
        </volume>
        <fpage>
         488
        </fpage>
        <lpage>
         491
        </lpage>
        <pub-id pub-id-type="pmid">
         10642551
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guy
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Acharya
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme-2 (ACE2): Comparative modeling of the active site, specificity requirements, and chloride dependence
        </article-title>
        <source>
         Biochemistry
        </source>
        <year>
         2003
        </year>
        <volume>
         42
        </volume>
        <fpage>
         13185
        </fpage>
        <lpage>
         13192
        </lpage>
        <pub-id pub-id-type="pmid">
         14609329
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR68">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vickers
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Hales
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Kaushik
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2002
        </year>
        <volume>
         277
        </volume>
        <fpage>
         14838
        </fpage>
        <lpage>
         14843
        </lpage>
        <pub-id pub-id-type="pmid">
         11815627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bedendi
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Alloatti
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Marcantoni
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin
        </article-title>
        <source>
         Eur J Pharmacol
        </source>
        <year>
         2003
        </year>
        <volume>
         476
        </volume>
        <fpage>
         87
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="pmid">
         12969753
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR70">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tatemoto
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Takayama
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           MX
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism
        </article-title>
        <source>
         Regul Pept
        </source>
        <year>
         2001
        </year>
        <volume>
         99
        </volume>
        <fpage>
         87
        </fpage>
        <lpage>
         92
        </lpage>
        <pub-id pub-id-type="pmid">
         11384769
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR71">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Mota
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Reaux-Le Goazigo
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           El Messari
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         10464
        </fpage>
        <lpage>
         10469
        </lpage>
        <pub-id pub-id-type="pmid">
         15231996
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR72">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Szokodi
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Tavi
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Foldes
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         2002
        </year>
        <volume>
         91
        </volume>
        <fpage>
         434
        </fpage>
        <lpage>
         440
        </lpage>
        <pub-id pub-id-type="pmid">
         12215493
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR73">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Berry
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Pirolli
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <name>
          <surname>
           Jayasankar
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Apelin has
         <italic>
          in vivo
         </italic>
         inotropic effects on normal and failing hearts
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         2004
        </year>
        <volume>
         110
        </volume>
        <issue>
         11 Suppl 1
        </issue>
        <fpage>
         II187
        </fpage>
        <lpage>
         II193
        </lpage>
        <pub-id pub-id-type="pmid">
         15364861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR74">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hosoya
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kawamata
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Fukusumi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2000
        </year>
        <volume>
         275
        </volume>
        <fpage>
         21061
        </fpage>
        <lpage>
         21067
        </lpage>
        <pub-id pub-id-type="pmid">
         10777510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR75">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ishida
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Hashimoto
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hashimoto
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure
         <italic>
          in vivo
         </italic>
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2004
        </year>
        <volume>
         279
        </volume>
        <fpage>
         26274
        </fpage>
        <lpage>
         26279
        </lpage>
        <pub-id pub-id-type="pmid">
         15087458
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR76">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ashley
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Powers
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading
         <italic>
          in vivo
         </italic>
        </article-title>
        <source>
         Cardiovasc Res
        </source>
        <year>
         2005
        </year>
        <volume>
         65
        </volume>
        <fpage>
         73
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         15621035
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR77">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamming
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Timens
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Bulthuis
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Lely
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name>
          <surname>
           Navis
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           van Goor
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
        </article-title>
        <source>
         J Pathol
        </source>
        <year>
         2004
        </year>
        <volume>
         203
        </volume>
        <fpage>
         631
        </fpage>
        <lpage>
         637
        </lpage>
        <pub-id pub-id-type="pmid">
         15141377
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Arch Cardiovasc Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Arch Cardiovasc Dis
      </journal-id>
      <journal-title-group>
       <journal-title>
        Archives of Cardiovascular Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1875-2136
      </issn>
      <issn pub-type="epub">
       1875-2128
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Masson SAS.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       22800722
      </article-id>
      <article-id pub-id-type="pmc">
       7102827
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1875-2136(12)00095-2
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.acvd.2012.02.010
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Three key proteases – angiotensin-I-converting enzyme (ACE), ACE2 and renin – within and beyond the renin-angiotensin system
       </article-title>
       <trans-title-group xml:lang="fr">
        <trans-title>
         Protéases clés du système rénine-angiotensine : enzyme de conversion de l’angiotensine 1 et 2 et rénine
        </trans-title>
       </trans-title-group>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Guang
         </surname>
         <given-names>
          Cuie
         </given-names>
        </name>
        <email>
         guang1226@hotmail.com
        </email>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
        <xref ref-type="aff" rid="aff0010">
         b
        </xref>
        <xref ref-type="corresp" rid="cor0005">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Phillips
         </surname>
         <given-names>
          Robert D.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0010">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          Bo
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Milani
         </surname>
         <given-names>
          Franco
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0015">
         c
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0005">
       <label>
        a
       </label>
       State Key Lab of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, China
      </aff>
      <aff id="aff0010">
       <label>
        b
       </label>
       Department of Food Science and Technology, University of Georgia, Griffin, GA, USA
      </aff>
      <aff id="aff0015">
       <label>
        c
       </label>
       Department of Food Science, University of Wisconsin-Madison, Madison, WI, USA
      </aff>
      <author-notes>
       <corresp id="cor0005">
        <label>
         ⁎
        </label>
        Corresponding author. Fax: +86 510 8519 7883.
        <email>
         guang1226@hotmail.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        15
       </day>
       <month>
        6
       </month>
       <year>
        2012
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date iso-8601-date="2012-07-01" pub-type="ppub">
       <season>
        June-July
       </season>
       <year>
        2012
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        15
       </day>
       <month>
        6
       </month>
       <year>
        2012
       </year>
      </pub-date>
      <volume>
       105
      </volume>
      <issue>
       6
      </issue>
      <fpage>
       373
      </fpage>
      <lpage>
       385
      </lpage>
      <history>
       <date date-type="received">
        <day>
         23
        </day>
        <month>
         12
        </month>
        <year>
         2011
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         6
        </day>
        <month>
         2
        </month>
        <year>
         2012
        </year>
       </date>
       <date date-type="accepted">
        <day>
         7
        </day>
        <month>
         2
        </month>
        <year>
         2012
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2012 Elsevier Masson SAS. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2012
       </copyright-year>
       <copyright-holder>
        Elsevier Masson SAS
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <title>
        Summary
       </title>
       <p>
        The discovery of angiotensin-I-converting enzyme 2 (ACE2) and a (pro)renin receptor has renewed interest in the physiology of the renin-angiotensin system (RAS). Through the ACE2/angiotensin-(1–7)/Mas counter-regulatory axis, ACE2 balances the vasoconstrictive, proliferative, fibrotic and proinflammatory effects of the ACE/angiotensin II/AT1 axis. The (pro)renin receptor system shows an angiotensin-dependent function related to increased generation of angiotensin I, and an angiotensin-independent aspect related to intracellular signalling. Activation of ACE2 and inhibition of ACE and renin have been at the core of the RAS regulation. The aim of this review is to discuss the biochemistry and biological functions of ACE, ACE2 and renin within and beyond the RAS, and thus provide a perspective for future bioactives from natural plant and/or food resources related to the three proteases.
       </p>
      </abstract>
      <trans-abstract xml:lang="fr">
       <title>
        Résumé
       </title>
       <p>
        La découverte de l’enzyme de conversion de l’angiotensine 2 (AC2) et un récepteur à la prorénine est une avancée récente dans la compréhension de la physiologie du système rénine-angiotensine. Au sein de l’axe inhibiteur de l’enzyme de conversion de l’angiotensine 2/angiotensine 1/MAS, l’AC2 contrebalance l’effet vasoconstricteur, prolifératif, fibrosant et pro-inflammatoire de l’axe ACE/angiotensine 2/AT1. Le récepteur à la prorénine a une fonction angiotensine dépendante, liée à l’augmentation de la production d’angiotensine 1, et un aspect indépendant de l’angiotensine, lié aux signaux intracellulaires. L’activation de l’AC2 et l’inhibition de l’ACE de la rénine ont été considérées comme au centre de la régulation du système rénine-angiotensine. L’objet de cette revue générale est de discuter les fonctions biochimiques et biologiques de l’ACE, de l’AC2 et de la rénine au sein et au-delà du système rénine-angiotensine et ainsi de proposer une perspective de développement d’agents actifs extraits de plantes naturelles ou d’alimentation, produits liés à ces trois protéases.
       </p>
      </trans-abstract>
      <kwd-group>
       <title>
        Keywords
       </title>
       <kwd>
        Angiotensin
       </kwd>
       <kwd>
        ACE
       </kwd>
       <kwd>
        ACE2
       </kwd>
       <kwd>
        Renin
       </kwd>
       <kwd>
        (Pro)renin receptor
       </kwd>
      </kwd-group>
      <kwd-group xml:lang="fr">
       <title>
        Mots clés
       </title>
       <kwd>
        Angiotensine
       </kwd>
       <kwd>
        Inhibiteurs de l’enzyme de conversion
       </kwd>
       <kwd>
        Inhibiteur de l’enzyme de conversion II
       </kwd>
       <kwd>
        Rénine
       </kwd>
       <kwd>
        Récepteur de la prorénine
       </kwd>
      </kwd-group>
      <kwd-group>
       <title>
        Abbreviations
       </title>
       <kwd>
        Aβ, Alzheimer amyloid β-peptide
       </kwd>
       <kwd>
        ACE, angiotensin-I-converting enzyme
       </kwd>
       <kwd>
        ACE2, angiotensin-I-converting enzyme 2
       </kwd>
       <kwd>
        AcSDKP, N-acetyl-Ser-Asp-Lys-Pro
       </kwd>
       <kwd>
        AGT, angiotensinogen
       </kwd>
       <kwd>
        Ang I, angiotensin I
       </kwd>
       <kwd>
        Ang II, angiotensin II
       </kwd>
       <kwd>
        ARB, AT1 receptor blocker
       </kwd>
       <kwd>
        AT1 receptor, angiotensin II receptor, type 1
       </kwd>
       <kwd>
        cAMP, cyclic adenosine monophosphate
       </kwd>
       <kwd>
        CoV, coronavirus
       </kwd>
       <kwd>
        gACE, germinal ACE
       </kwd>
       <kwd>
        HEXXH, His-Glu-X-X-His
       </kwd>
       <kwd>
        HRP, hand region peptide
       </kwd>
       <kwd>
        LH-RH, luteinizing hormone-releasing hormone
       </kwd>
       <kwd>
        (P)RR, (pro)renin receptor
       </kwd>
       <kwd>
        RAS, renin-angiotensin system
       </kwd>
       <kwd>
        sACE, somatic ACE
       </kwd>
       <kwd>
        SARS, severe acute respiratory syndrome
       </kwd>
       <kwd>
        SHR, spontaneously hypertensive rat
       </kwd>
       <kwd>
        TACE, tumour necrosis factor-alpha cleavage enzyme
       </kwd>
       <kwd>
        XNT, 1-[(2-diethylamino)ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl)sulphonyloxy]-9H-xanthene-9-one
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec0005">
     <title>
      Background
     </title>
     <p id="par0005">
      The renin-angiotensin system (RAS) is not only an endocrine but also a paracrine and an intracrine system
      <xref ref-type="bibr" rid="bib0005">
       [1]
      </xref>
      . In mammals, the intravascular RAS plays a key role in maintaining blood pressure homeostasis and fluid and salt balance, and the tissue or local RAS is involved in physiological and pathological processes, such as tissue growth and remodelling, development and inflammation
      <xref ref-type="bibr" rid="bib0010">
       [2]
      </xref>
      . In a classical RAS, the substrate angiotensinogen (AGT), which is released into the circulation from the liver, is degraded by the enzyme renin that originates in the kidney, generating the inactive angiotensin I (Ang I). When this decapeptide comes into contact with angiotensin-I-converting enzyme (ACE) at the endothelial surface of blood vessels, the C-terminal dipeptide is cleaved, giving rise to angiotensin II (Ang II), the main effector molecule of the RAS. Through interactions with specific receptors, particularly its type 1 or AT1 receptor, Ang II stimulates a wide variety of signalling pathways in the heart, blood vessels, kidneys, adipose tissue, pancreas and brain, initiating most of the physiological and pathophysiological effects that have been attributed to the RAS
      <xref ref-type="bibr" rid="bib0015">
       [3]
      </xref>
      . Due to the function of directly generating the main effector Ang II, ACE – together with the classical axis ACE/Ang II/AT1 – has been at the core of RAS studies since its discovery.
     </p>
     <p id="par0010">
      In 2000, a homologue of ACE, known as angiotensin-I-converting enzyme 2 (ACE2), was cloned by two independent research groups
      <xref ref-type="bibr" rid="bib0020">
       [4]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0025">
       [5]
      </xref>
      . Evidence indicates that ACE2 negatively regulates the activated RAS by degrading Ang II to the heptapeptide Ang-(1–7). Moreover, through the Mas receptor (a G protein-coupled receptor), the resulting Ang-(1–7) counterbalances the cardiovascular effects of Ang II by opposing many AT1 receptor-mediated actions
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      . ACE2 and the axis ACE2/Ang-(1–7)/Mas are becoming the focus of intense research regarding the RAS
      <xref ref-type="bibr" rid="bib0005">
       [1]
      </xref>
      . The discovery of a (pro)renin receptor ([P]RR) and the introduction of renin inhibitors have also brought (pro)renin back into the spotlight
      <xref ref-type="bibr" rid="bib0035">
       [7]
      </xref>
      . Far from being a straightforward cascade containing one substrate (AGT), two proteases (renin and ACE), two peptides (Ang I and Ang II) and one receptor (AT1), the RAS currently consists of several axes upstream and downstream of the classical cascade, which include more than two dozen peptidases, nearly a dozen Ang fragments and at least six different receptors
      <xref ref-type="bibr" rid="bib0040">
       [8]
      </xref>
      . Here, we review three critical proteases (ACE, ACE2 and renin) within and beyond the RAS and thus intend to find new connections between natural plant and/or food resources and the RAS.
     </p>
    </sec>
    <sec id="sec0010">
     <title>
      Occurrence, gene encoding and structure of ACE
     </title>
     <p id="par0015">
      ACE (EC 3.4.15.1) is a monomeric glycoprotein that is distributed in many tissues and biological fluids. There are two isoforms of ACE in humans: somatic ACE (sACE) and germinal ACE (gACE). Somatic ACE is found in many types of endothelial and epithelial cells
      <xref ref-type="bibr" rid="bib0045">
       [9]
      </xref>
      . Germinal ACE or testicular ACE is present exclusively in germinal cells in the male testis. Although ACE is a type I integral membrane protein, it can also be released as a soluble enzyme into extracellular fluids, such as plasma and seminal and cerebrospinal fluids, following post-translational proteolytic cleavage by a membrane protein sheddase or secretase
      <xref ref-type="bibr" rid="bib0050">
       [10]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0055">
       [11]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0060">
       [12]
      </xref>
      .
     </p>
     <p id="par0020">
      Somatic ACE and gACE are encoded by a single gene containing 26 exons. The promoter for sACE is situated in the 5′ flanking region of the first exon, whereas that for gACE is within intron 12, which results in different lengths for the two isoforms. The longer sACE (150–180 kDa) is transcribed from exon 1 to exon 26, excluding exon 13, whereas the shorter gACE (90–110 kDa) is transcribed from exon 13 to exon 26. Exon 13 encodes a unique sequence for the N-terminus of gACE, whereas downstream exons encode a common sequence for both isozymes
      <xref ref-type="bibr" rid="bib0065">
       [13]
      </xref>
      .
     </p>
     <p id="par0025">
      Somatic ACE and gACE both consist of a 28-residue hydrophilic C-terminal cytoplasmic domain, a 22-residue hydrophobic transmembrane domain that anchors the protein in the membrane and an N-terminal ectodomain (
      <xref ref-type="fig" rid="fig0005">
       Fig. 1
      </xref>
      ) that is heavily glycosylated with mannose, galactose, fructose, N-acetylneuraminic acid and N-acetylglucosamine
      <xref ref-type="bibr" rid="bib0070">
       [14]
      </xref>
      . The ectodomain of sACE is further divided into two similar domains (N domain and C domain) encoded by the homologous exons 4–11 and 17–24, respectively, and each domain contains an active His-Glu-X-X-His (HEXXH) sequence
      <xref ref-type="bibr" rid="bib0045">
       [9]
      </xref>
      . Somatic ACE is the only known metallopeptidase with two homologous active sites
      <xref ref-type="bibr" rid="bib0075">
       [15]
      </xref>
      , which implies that there has been a gene duplication event during evolution
      <xref ref-type="bibr" rid="bib0080">
       [16]
      </xref>
      . Except for a unique sequence constituting its N-terminus, gACE is identical to the C-terminal half of sACE
      <xref ref-type="bibr" rid="bib0085">
       [17]
      </xref>
      . Due to cleavage of the membrane-bound residues by ACE secretase, soluble circulating ACE lacks a transmembrane portion and a cytosolic domain
      <xref ref-type="bibr" rid="bib0090">
       [18]
      </xref>
      .
      <fig id="fig0005">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Schematic representation of the primary structures of sACE, gACE, ACE2 and collectrin
         <xref ref-type="bibr" rid="bib0030">
          [6]
         </xref>
         . ACE: angiotensin-I-converting enzyme; gACE: germinal ACE; HEXXH: His-Glu-X-X-His; sACE: somatic ACE.
        </p>
       </caption>
       <graphic xlink:href="gr1">
       </graphic>
      </fig>
     </p>
     <p id="par0030">
      The three-dimensional X-ray crystallographic structure of a deglycosylated truncated version of gACE (C domain of sACE), reveals a preponderance of α-helices with a zinc ion and two chloride ions incorporated. A deep narrow channel separates the molecule into two subdomains and the active site is located toward the bottom of this channel. An N-terminal ‘lid’ on the top of molecule appears to allow only small peptide substrates access to the active site cleft. In fact, the structure bears little similarity to that of carboxypeptidase A (M14 family) on which the initial drug development of ACE inhibitors was based. Instead, it resembles rat neurolysin (M3 family) and
      <italic>
       Pyrococcus furiosus
      </italic>
      carboxypeptidase (M32 family), despite sharing little sequence similarity with these two proteins
      <xref ref-type="bibr" rid="bib0085">
       [17]
      </xref>
      . Corradi et al.
      <xref ref-type="bibr" rid="bib0090">
       [18]
      </xref>
      reported the crystal structure of the N domain of sACE. Similarly, it has an ellipsoid shape with a central groove dividing it into two subdomains, one of which contains the N-terminal region that covers the central binding cavity. But the structure reveals differences in the active site and it contains only one chloride ion, equivalent to chloride II of gACE. The three-dimensional structures of C domains (based on gACE) and N domains provide an opportunity to design domain-selective ACE inhibitors that may exhibit new pharmacological profiles
      <xref ref-type="bibr" rid="bib0085">
       [17]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0090">
       [18]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0015">
     <title>
      Catalytic mechanism of ACE
     </title>
     <p id="par0035">
      According to the catalytic mechanism and the critical amino acid residue involved, peptidases are classified into four major types: serine, cysteine, aspartic and metallo
      <xref ref-type="bibr" rid="bib0075">
       [15]
      </xref>
      . ACE is an M2 family metallopeptidase: MA(E), the gluzincins
      <xref ref-type="bibr" rid="bib0095">
       [19]
      </xref>
      . Two histidine residues of the functional motif HEXXH and a third distant glutamate positioned 23–24 residues further towards the C-terminus are the ligands for the zinc cofactor
      <xref ref-type="bibr" rid="bib0100">
       [20]
      </xref>
      . An activated water molecule complexed to Zn
      <sup>
       2+
      </sup>
      serves as the nucleophile to attack the carbonyl group of the targeted peptide bond
      <xref ref-type="bibr" rid="bib0075">
       [15]
      </xref>
      .
     </p>
     <p id="par0040">
      The activity of ACE is also chloride dependent. Chloride primarily activates the active sites of ACE and enhances the binding of substrates
      <xref ref-type="bibr" rid="bib0045">
       [9]
      </xref>
      . Each active domain of ACE displays differences in sensitivity to chloride activation
      <xref ref-type="bibr" rid="bib0105">
       [21]
      </xref>
      . The activity of the C domain of sACE depends highly on chloride ion concentration and is inactive in its absence, whereas the N domain can be completely activated at relatively low concentrations of this anion and is still active in the absence of chloride
      <xref ref-type="bibr" rid="bib0110">
       [22]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0115">
       [23]
      </xref>
      . Germinal ACE depends on chloride to a lesser extent compared with the C domain of sACE
      <xref ref-type="bibr" rid="bib0045">
       [9]
      </xref>
      . Cushman and Cheung
      <xref ref-type="bibr" rid="bib0120">
       [24]
      </xref>
      reported an optimal in vitro ACE activity of rabbit rung acetone extract in the presence of 300 mM NaCl at pH 8.1–8.3.
     </p>
     <p id="par0045">
      The two active domains of sACE are also subtly different in substrate specificity. They hydrolyze bradykinin almost equally but the C domain active site can hydrolyze Ang I, substrate P
      <xref ref-type="bibr" rid="bib0115">
       [23]
      </xref>
      and Hippuryl-His-Leu
      <xref ref-type="bibr" rid="bib0125">
       [25]
      </xref>
      more efficiently, while the N domain active site preferentially hydrolyzes Ang-(1–7)
      <xref ref-type="bibr" rid="bib0130">
       [26]
      </xref>
      , luteinizing hormone-releasing hormone (LH-RH)
      <xref ref-type="bibr" rid="bib0115">
       [23]
      </xref>
      , the haemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP)
      <xref ref-type="bibr" rid="bib0135">
       [27]
      </xref>
      and Alzheimer amyloid β-peptide (Aβ)
      <xref ref-type="bibr" rid="bib0140">
       [28]
      </xref>
      . Fuchs et al.
      <xref ref-type="bibr" rid="bib0145">
       [29]
      </xref>
      proved that the C-terminal catalytic domain was the main site of Ang I cleavage in mice. The differentiation of catalytic specificity might be due to very subtle variation in substrate-specific amino acids
      <xref ref-type="bibr" rid="bib0110">
       [22]
      </xref>
      and chloride-induced conformational alteration of active sites
      <xref ref-type="bibr" rid="bib0115">
       [23]
      </xref>
      .
     </p>
     <p id="par0050">
      ACE acts as an exopeptidase to cleave dipeptides from the free C-termini of two typical substrates, Ang I and bradykinin. For certain substrates such as cholecystokinin
      <xref ref-type="bibr" rid="bib0150">
       [30]
      </xref>
      , substrate P
      <xref ref-type="bibr" rid="bib0155">
       [31]
      </xref>
      and LH-RH
      <xref ref-type="bibr" rid="bib0160">
       [32]
      </xref>
      , which have amidated C-termini, ACE not only displays exopeptidase activity but also acts as an endopeptidase
      <xref ref-type="bibr" rid="bib0165">
       [33]
      </xref>
      . The most prominent example of endopeptidase activity is ACE hydrolyzing the synthetic Aβ-(1–40) peptide into four fragments: an Aβ-(8–40) peptide and the others corresponding to products of Aβ-(1–7) hydrolysis
      <xref ref-type="bibr" rid="bib0170">
       [34]
      </xref>
      . Thus, ACE might have a more general impact on the metabolism of biologically active peptides than previously recognized
      <xref ref-type="bibr" rid="bib0080">
       [16]
      </xref>
      . The two substrates used most often for measuring ACE activity and inhibition in vitro – Hippuryl-His-Leu and N-[3-(2-furyl)acryloyl]-L-phenylalanylglycylglycine (FAPGG) – only have the N-termini blocked and substrates with two termini blocked have been developed
      <xref ref-type="bibr" rid="bib0110">
       [22]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0020">
     <title>
      Biological impact of ACE
     </title>
     <p id="par0055">
      ACE was originally isolated in 1956 as a ‘hypertensin-converting enzyme’
      <xref ref-type="bibr" rid="bib0175">
       [35]
      </xref>
      . In the RAS, ACE cleaves the decapeptide Ang I-(1–10) (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) into the octapeptide Ang II-(1–8) by removing the C-terminal dipeptide His-Leu. When the RAS is overactive, Ang II exerts its harmful effects primarily via the AT1 receptor, whereas the AT2 receptor may oppose and counterbalance those effects mediated by AT1 receptor to exert protective actions
      <xref ref-type="bibr" rid="bib0005">
       [1]
      </xref>
      . Ang II is a potent vasoconstrictor, stimulates the release of aldosterone and antidiuretic hormone or vasopressin and increases the retention of sodium and water. These effects act directly in concert to raise blood pressure. A nonapeptide derivative of Ang I, des-Asp1-Ang I-(2–10), prevents infarction-related and non-infarction-related cardiac injuries and disorders. His-Leu can be cleaved from the peptide by ACE to produce Ang III-(2–8)
      <xref ref-type="bibr" rid="bib0070">
       [14]
      </xref>
      , which has 40% of the vasoconstriction activity of Ang II. Ang III exerts its effects, in principle, in a similar manner to Ang II, and may be equally or even more important in mediating the release of vasopressin
      <xref ref-type="bibr" rid="bib0005">
       [1]
      </xref>
      . ACE also degrades Ang-(1–9) to Ang-(1–7) then further degrades this peptide to the inactive Ang-(1–5) (
      <xref ref-type="fig" rid="fig0010">
       Fig. 2
      </xref>
      ). In addition, ACE (also termed kininase II) inactivates the vasodilators bradykinin-(1–9) (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) and kallidin (Lys-bradykinin) in the kallikrein-kinin system, by cleaving the C-terminal dipeptide Phe-Arg. ACE eventually cleaves its primary metabolite bradykinin-(1–7) into the shorter fragment bradykinin-(1–5)
      <xref ref-type="bibr" rid="bib0180">
       [36]
      </xref>
      .
      <fig id="fig0010">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Multiple effector systems of the renin-angiotensin system. ACE: angiotensin-I-converting enzyme; ACE2: angiotensin-I-converting enzyme 2; AGT: angiotensinogen; AMPA: aminopeptidase A; AMPM: aminopeptidase A; Ang I: angiotensin I; Ang II: angiotensin II; AT1R: angiotensin II receptor, type 1; AT2R: angiotensin II receptor, type 2; IRAP: insulin-regulated aminopeptidase; NEP: neutral endopeptidase; PEP: prolyl endopeptidase.
        </p>
       </caption>
       <graphic xlink:href="gr2">
       </graphic>
      </fig>
     </p>
     <p id="par0060">
      Through Ang II and aldosterone, ACE may also be implicated in the impairment of nitric oxide bioavailability and cell oxidative stress, augmenting the generation of reactive oxygen species and peroxynitrite
      <xref ref-type="bibr" rid="bib0185">
       [37]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0190">
       [38]
      </xref>
      . With the ability to hydrolyze neuropeptides such as enkephalin
      <xref ref-type="bibr" rid="bib0195">
       [39]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0200">
       [40]
      </xref>
      , substrate P, neurotensin
      <xref ref-type="bibr" rid="bib0155">
       [31]
      </xref>
      and LH-RH, ACE may be involved in the functioning of the brain and nervous system. ACE may affect the digestive system by hydrolyzing the peptide hormone cholecystokinin and gastrin
      <xref ref-type="bibr" rid="bib0150">
       [30]
      </xref>
      . The in vivo experiment conducted by Azizi et al.
      <xref ref-type="bibr" rid="bib0205">
       [41]
      </xref>
      proved that acute ACE inhibition could increase the level of the natural stem cell regulator AcSDKP in plasma. AcSDKP substantially inhibits cell cycle entry of normal haematopoietic stem cells and protects haemopoiesis against damage caused by cycle-active cytotoxic agents
      <xref ref-type="bibr" rid="bib0210">
       [42]
      </xref>
      . AcSDKP can also inhibit the proliferation of hepatocytes
      <xref ref-type="bibr" rid="bib0215">
       [43]
      </xref>
      and lymphocytes
      <xref ref-type="bibr" rid="bib0220">
       [44]
      </xref>
      and stimulate angiogenesis
      <xref ref-type="bibr" rid="bib0225">
       [45]
      </xref>
      in vivo. The in vivo antifibrotic effect of ACE inhibition is partially mediated by AcSDKP
      <xref ref-type="bibr" rid="bib0230">
       [46]
      </xref>
      . ACE may also affect susceptibility to Alzheimer's disease by degrading Aβ and preventing the accumulation of amyloid plaques in vivo
      <xref ref-type="bibr" rid="bib0235">
       [47]
      </xref>
      . In the brains of amyloid precursor protein Swedish mutation transgenic mice, ACE converts Aβ
      <sub>
       1–42
      </sub>
      to Aβ
      <sub>
       1–40
      </sub>
      and degrades Aβ, and chronic inhibition of ACE with captopril enhances predominant Aβ
      <sub>
       1–42
      </sub>
      deposition
      <xref ref-type="bibr" rid="bib0240">
       [48]
      </xref>
      . However, through the inhibition of brain ACE activity in the Aβ
      <sub>
       25–35
      </sub>
      -injected mice, perindopril ameliorates cognitive impairment and may therefore have a beneficial effect on Alzheimer's disease as well as hypertension
      <xref ref-type="bibr" rid="bib0245">
       [49]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0025">
     <title>
      ACE inhibitors
     </title>
     <p id="par0065">
      Using the assumed mechanistic analogy to other zinc metallopeptidases, plus the knowledge that several snake-venom peptides potentiate the action of bradykinin by inhibiting ACE, efforts were undertaken to develop orally-active peptide analogues for potential use in the treatment of hypertension
      <xref ref-type="bibr" rid="bib0045">
       [9]
      </xref>
      . The first such compound, captopril or D-3-mercapto-2-methylpropanoyl-L-proline, is an analogue of the Ala-Pro sequence, with sulphydryl as a strong chelating group for the zinc ion. Its adverse effects, which were the same as those caused by mercapto-containing penicillamine, prompted the design of non-sulphydryl ACE inhibitors
      <xref ref-type="bibr" rid="bib0250">
       [50]
      </xref>
      . The results were two active inhibitors: enalaprilat and lisinopril. They are both essentially tripeptide analogues with a zinc-co-ordinating carboxyl group and a phenylalanine that occupies the S1 groove in the enzyme. Lisinopril is a lysine analogue of enalaprilat but it is hydrophilic, with greater affinity than enalaprilat. The later compounds are all variations of the first three inhibitors, with most of the differences residing in the functionalities that bind the active site zinc and the S2′ pocket. In addition to phosphonates, ketones are also useful as chelators
      <xref ref-type="bibr" rid="bib0255">
       [51]
      </xref>
      .
     </p>
     <p id="par0070">
      Currently, there are more than 10 ACE inhibitors marketed that are widely used as first-line therapy for cardiovascular diseases, including hypertension, heart failure, heart attack and left ventricular dysfunction. According to the functional moiety, they are divided into three types: thiol (captopril), carboxylate (benazepril, enalapril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril) or phosphate (fosinopril). Some ACE inhibitors are now administrated clinically as ethyl-ester prodrugs, which have good bioavailability but are inactive in their own right. They are then converted to the active diacid molecules in vivo by esterases.
     </p>
     <p id="par0075">
      As a drug class, ACE inhibitors are very effective, have a relatively low incidence of side effects and are well tolerated. A common side effect of ACE inhibitors is a dry cough, which appears in 5–20% of patients and may result in the discontinuation of treatment. Another serious problem is angioedema, which affects 0.1–0.5% of patients and can be life-threatening. The two side effects have generally been attributed to altered concentrations of bradykinin
      <xref ref-type="bibr" rid="bib0255">
       [51]
      </xref>
      . Use of ACE inhibitors during the second and third trimesters of pregnancy is contraindicated because of their association with an increased risk of foetopathy, a group of conditions that includes oligohydramnios, intrauterine growth retardation, hypocalvaria, renal dysplasia, anuria, renal failure and death. Exposure to ACE inhibitors during the first trimester of pregnancy may place the infant at increased risk for major congenital malformations
      <xref ref-type="bibr" rid="bib0260">
       [52]
      </xref>
      .
     </p>
     <p id="par0080">
      The initial drug development of clinical ACE inhibitors was based on the assumption of an active site related to that of carboxypeptidase A but organized to remove a dipeptide rather than a single amino acid from the C-terminus of its substrate. It is now known that sACE has two active sites, neither of which resembles that of carboxypeptidase A, and that these sites are not identical. Clinical ACE inhibitors, however, show little discrimination between these two active sites
      <xref ref-type="bibr" rid="bib0045">
       [9]
      </xref>
      . Ang I is hydrolyzed predominantly by the C domain of sACE in vivo
      <xref ref-type="bibr" rid="bib0145">
       [29]
      </xref>
      but bradykinin is hydrolyzed by both active sites
      <xref ref-type="bibr" rid="bib0265">
       [53]
      </xref>
      ; therefore a C domain-selective inhibitor would allow some degradation of bradykinin by the N domain and this degradation could be enough to prevent the accumulation of excess bradykinin that has been observed during attacks of angioedema. That is, the C domain-selective inhibition could possibly result in specialized control of blood pressure with fewer vasodilator-related adverse effects
      <xref ref-type="bibr" rid="bib0255">
       [51]
      </xref>
      . A structure-activity study has proved that the group substitution involving the phenyl ring and carbon chain at the sulphonyl and propionyl moieties of captopril is essential for better activity towards the C domain of ACE
      <xref ref-type="bibr" rid="bib0270">
       [54]
      </xref>
      . There is increasing evidence that the N domain of sACE is responsible for the in vivo degradation of the natural haemoregulatory hormone AcSDKP
      <xref ref-type="bibr" rid="bib0135">
       [27]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0205">
       [41]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0275">
       [55]
      </xref>
      . So, N domain-selective inhibition might open up novel therapeutic areas. Two phosphinic tetrapeptides, RXPA380 and RXP407, have been found to be highly selective inhibitors of the C and N domains of sACE, respectively
      <xref ref-type="bibr" rid="bib0255">
       [51]
      </xref>
      . The availability of the three-dimensional structures of the C and N domains of sACE makes the structure-based design of active site-specific inhibitors possible
      <xref ref-type="bibr" rid="bib0085">
       [17]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0090">
       [18]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0030">
     <title>
      ACE2
     </title>
     <p id="par0085">
      ACE2 (EC 3.4.17.-) is also a type I transmembrane glycoprotein and its expression has now been recognized as being ubiquitous. It appears to be susceptible to cleavage that releases the catalytical active ectodomain. A disintegrin and metalloprotease 17 (ADAM17; also known as tumour necrosis factor-alpha cleavage enzyme [TACE]) is a major protease for soluble ACE2 shedding, while phorbol ester, ionomycin, endotoxin and the proinflammatory cytokines interleukin-1β and tumour necrosis factor-alpha can also acutely induce ectodomain release
      <xref ref-type="bibr" rid="bib0280">
       [56]
      </xref>
      . Calmodulin binding sites have been identified in the cytoplasmic tail of ACE2 and calmodulin inhibitors are proved to increase ACE2 shedding
      <xref ref-type="bibr" rid="bib0285">
       [57]
      </xref>
      . The cleavage site resides between amino acids 716 and 741 near the predicted transmembrane domain and residue Lys
      <sup>
       548
      </sup>
      in the ectodomain plays an important role in dictating ACE2 ectodomain shedding
      <xref ref-type="bibr" rid="bib0290">
       [58]
      </xref>
      . ACE2 has 805 amino acids encoded from 18 exons and shares about 42% sequence identity with the N and C domains of sACE
      <xref ref-type="bibr" rid="bib0080">
       [16]
      </xref>
      . ACE2 also belongs to the M2 family of metalloproteases but consists of a single active site domain that, by sequence comparison, more closely resembles the N domain than the C domain of sACE (
      <xref ref-type="fig" rid="fig0005">
       Fig. 1
      </xref>
      )
      <xref ref-type="bibr" rid="bib0055">
       [11]
      </xref>
      . In addition to the conserved zinc metallopeptidase consensus sequence HEXXH (amino acids 374–378), there is a conserved glutamate residue 24 residues C-terminal to the second histidine of the zinc motif, which serves as the third zinc ligand
      <xref ref-type="bibr" rid="bib0080">
       [16]
      </xref>
      . The three-dimensional structure of a truncated extracellular region of human ACE2 shows that the active site domain (residues 19–611) can be further divided into two subdomains I and II, which form two sides of a long deep cleft and are connected only at the floor of the active site cleft by a prominent α-helix. The deeply recessed and shielded proteolytic active site of ACE2 is a common structural feature of proteases and can avoid hydrolysis of correctly folded and functional proteins. The zinc is co-ordinated by His
      <sup>
       374
      </sup>
      , His
      <sup>
       378
      </sup>
      , Glu
      <sup>
       402
      </sup>
      and one water molecule in the subdomain I near the bottom, whereas a chloride ion is co-ordinated by Arg
      <sup>
       169
      </sup>
      , Trp
      <sup>
       477
      </sup>
      and Lys
      <sup>
       481
      </sup>
      in the subdomain II
      <xref ref-type="bibr" rid="bib0290">
       [58]
      </xref>
      . The ACE2 transmembrane C-terminal domain shares 48% sequence identity with collectrin (
      <xref ref-type="fig" rid="fig0005">
       Fig. 1
      </xref>
      ), a non-catalytic protein shown to have a critical role in amino acid reabsorption in the kidney
      <xref ref-type="bibr" rid="bib0295">
       [59]
      </xref>
      , pancreatic beta cell proliferation and possibly insulin exocytosis
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      .
     </p>
     <p id="par0090">
      Unlike sACE and gACE, which are primarily dipeptidylcarboxypeptidases, ACE2 functions predominantly as a monocarboxypeptidase, with a substrate preference for hydrolysis between proline and a hydrophobic or basic C-terminal residue
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      . It is like carboxypeptidase A in its action model but is different in active structure because the latter has an HXXE zinc-binding motif with the third ligand (histidine) positioned 108–135 residues further towards the C-terminus
      <xref ref-type="bibr" rid="bib0080">
       [16]
      </xref>
      . ACE2 efficiently cleaves a single residue phenylalanine from Ang II to generate Ang-(1–7), with about 400-fold higher catalytic efficiency than the conversion of Ang I to Ang-(1–9) by removing the C-terminal leucine residue (
      <xref ref-type="fig" rid="fig0010">
       Fig. 2
      </xref>
      ). Other substrates with high catalytic efficiency are apelin-13, dynorphin A-(1–13) and des-Arg9-bradykinin
      <xref ref-type="bibr" rid="bib0300">
       [60]
      </xref>
      . Arg
      <sup>
       514
      </sup>
      of ACE2 has been identified as a residue critical to substrate selectivity
      <xref ref-type="bibr" rid="bib0305">
       [61]
      </xref>
      . ACE2 activity is also regulated by chloride ions; it has been proposed that chloride binding induces subtle changes in the conformation of the active site, which either facilitate or hinder substrate binding
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      . For the substrate Ang I, ACE2 activity increases with increased [Cl
      <sup>
       −
      </sup>
      ] and a plateau is reached at approximately 500 mM Cl
      <sup>
       −
      </sup>
      . For the substrate Ang II, an increase in ACE2 activity is observed as [Cl
      <sup>
       −
      </sup>
      ] increases from 0–100 mM but any further increase in [Cl
      <sup>
       −
      </sup>
      ] decreases ACE2 activity until a plateau is reached at 500 mM Cl
      <sup>
       −
      </sup>
      ; ACE2 activity at 500 mM Cl
      <sup>
       −
      </sup>
      is even lower than that in the absence of Cl
      <sup>
       −
      </sup>
      (0 mM). Consequently, an increase in [Cl
      <sup>
       −
      </sup>
      ] above 100 mM, which is the physiological concentration in human plasma, increases Ang I and decreases Ang II cleavage by ACE2. This has an effect on the localized concentration of Ang II in the kidney, where ACE2 has a high level of expression and extracellular chloride ion levels fluctuate. Thus, in vivo Cl
      <sup>
       −
      </sup>
      sensitivity may serve as a homeostatic regulatory mechanism
      <xref ref-type="bibr" rid="bib0305">
       [61]
      </xref>
      . ACE2 activity is unaffected by inhibitors of ACE (captopril, lisinopril and enalaprilat) or carboxypeptidase A (benzylsuccinate and potato carboxypeptidase inhibitor)
      <xref ref-type="bibr" rid="bib0080">
       [16]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0035">
     <title>
      Biological actions of ACE2
     </title>
     <p id="par0095">
      The major function of ACE2 is to counter-regulate ACE activity by reducing Ang II bioavailability and increasing Ang-(1–7) formation. As a result, ACE2 plays a crucial role in maintaining the balance between the two axes ACE2/Ang-(1–7)/Mas and ACE/Ang II/AT1 of the RAS; a chronic and sustained imbalance may lead to pathophysiology of the cardiovascular, renal, pulmonary and central nervous systems
      <xref ref-type="bibr" rid="bib0310">
       [62]
      </xref>
      . Studies have shown that ACE2 overexpression and recombinant ACE2 treatment can attenuate hypertension in animal models
      <xref ref-type="bibr" rid="bib0315">
       [63]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0320">
       [64]
      </xref>
      , while in humans, there is a strong association between ACE2 polymorphisms and hypertension in Han Chinese
      <xref ref-type="bibr" rid="bib0325">
       [65]
      </xref>
      . In addition to the Ang II system, ACE2 may regulate blood pressure through other peptide systems, such as bradykinin and/or apelin
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      . ACE2 gene delivery
      <xref ref-type="bibr" rid="bib0330">
       [66]
      </xref>
      and ACE-(1–7) infusion
      <xref ref-type="bibr" rid="bib0335">
       [67]
      </xref>
      also have beneficial effects on atherosclerosis, whereas ACE2 deficiency accentuates vascular atherosclerosis and inflammation
      <xref ref-type="bibr" rid="bib0335">
       [67]
      </xref>
      in animal models. Regarding heart function, ACE2 null mice display impaired cardiac contractility
      <xref ref-type="bibr" rid="bib0340">
       [68]
      </xref>
      and the loss of ACE2 in wild-type mice accelerates adverse ventricular remodelling by potentiation of Ang II effects by means of the AT1 receptors
      <xref ref-type="bibr" rid="bib0345">
       [69]
      </xref>
      . Ang-(1–7), through interaction with the Mas receptor, can improve atrial tachyarrhythmias
      <xref ref-type="bibr" rid="bib0350">
       [70]
      </xref>
      , myocardial performance, cardiac modelling and survival
      <xref ref-type="bibr" rid="bib0015">
       [3]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      in rodent heart failure models. In humans, ACE2 gene variants might be involved in modulation of left ventricular mass in men
      <xref ref-type="bibr" rid="bib0355">
       [71]
      </xref>
      and soluble ACE2 activity is increased in patients with heart failure and correlates with disease severity to exert cardioprotective actions
      <xref ref-type="bibr" rid="bib0360">
       [72]
      </xref>
      . Deletion of the ACE2 gene in mice leads to the development of glomerulosclerosis and increased albuminuria
      <xref ref-type="bibr" rid="bib0365">
       [73]
      </xref>
      , while treatment with the ACE2 inhibitor MLN4760 can worsen renal damage in streptozotocin-induced diabetic mice
      <xref ref-type="bibr" rid="bib0370">
       [74]
      </xref>
      . Chronic treatment with Ang-(1–7) improves renal endothelial dysfunction via the Mas receptor in apolipoprotein E-deficient mice, by increasing levels of endogenous nitric oxide
      <xref ref-type="bibr" rid="bib0375">
       [75]
      </xref>
      , whereas genetic deletion of the Mas receptor in mice leads to a reduction in urine volume, sodium retention, microalbuminuria and reduced renal blood flow, which are associated with upregulation of the AT1 receptor and transforming growth factor-beta messenger ribonucleic acid
      <xref ref-type="bibr" rid="bib0380">
       [76]
      </xref>
      . This evidence indicates the protective role of ACE2/Ang-(1–7)/Mas in renal function. ACE2 has also been shown to regulate cardiovascular functions in brain regions. Overexpression of ACE2 in the rostral ventrolateral medulla reduces high blood pressure and heart rate in spontaneously hypertensive rats (SHRs)
      <xref ref-type="bibr" rid="bib0385">
       [77]
      </xref>
      . In the nucleus tractus solitarius of SHRs, ACE2 gene transfer improves baroreceptor heart rate reflex
      <xref ref-type="bibr" rid="bib0390">
       [78]
      </xref>
      . In the mouse subfornical organ, ACE2 overexpression inhibits AT1 receptor expression and prevents Ang II-mediated pressor and drinking responses
      <xref ref-type="bibr" rid="bib0395">
       [79]
      </xref>
      . In addition, ACE2/Ang-(1–7)/Mas can exert cerebroprotective functions in endothelin-1-induced ischaemic stroke in rodent models
      <xref ref-type="bibr" rid="bib0400">
       [80]
      </xref>
      . ACE2 exerts a host of actions on the cardiopulmonary system, which include prevention of endothelial dysfunction, reduction in pulmonary oxidative stress, attenuation of vascular impairment, anti-inflammatory effects and anticardiac remodelling effects. All these properties are responsible for the protective role of ACE2 against pulmonary arterial hypertension
      <xref ref-type="bibr" rid="bib0405">
       [81]
      </xref>
      .
     </p>
     <p id="par0100">
      Structure-based drug screening has identified two ACE2 activators: a xanthenone (1-[(2-diethylamino)ethyl-amino]-4-(hydroxymethyl)-7-[(4-methylphenyl)sulphonyloxy]-9H-xanthene-9-one; XNT) and resorcinolnaphthalein. XNT hydrogen bonds with ACE2 residues Lys
      <sup>
       94
      </sup>
      , Tyr
      <sup>
       196
      </sup>
      , Gly
      <sup>
       205
      </sup>
      and His
      <sup>
       195
      </sup>
      , and resorcinolnaphthalein is involved in three hydrogen bonds with residues Gln
      <sup>
       98
      </sup>
      , Gln
      <sup>
       101
      </sup>
      and Gly
      <sup>
       205
      </sup>
      . XNT and resorcinolnaphthalein modulate ACE2 activity possibly by two mechanisms. Logically, the closed conformation of the enzyme cannot allow the substrate into its active site. In the presence of compound, the free enzyme may be shifted to the open form, effectively increasing the activity coefficient of the enzyme. Alternatively, product release is a rate-limiting step in ACE2 turnover. ACE2 activity may be enhanced in the presence of compound, as the enzyme-product complex empties more quickly and ACE2 becomes available to start another cycle. XNT and resorcinolnaphthalein enhance in vitro ACE2 activity in a dose-dependent manner and show no significant effects on ACE activity. Administration of XNT to SHRs can result in a decrease in blood pressure, improvements in cardiac function and reversal of myocardial, perivascular and renal fibrosis
      <xref ref-type="bibr" rid="bib0410">
       [82]
      </xref>
      . The protective role of XNT against hypertension-induced cardiac fibrosis is associated with activation of ACE2, increases in Ang-(1–7) and inhibition of extracellular signal-regulated kinases
      <xref ref-type="bibr" rid="bib0415">
       [83]
      </xref>
      . Furthermore, ACE2 activation by XNT attenuates thrombus formation and reduces platelet attachment to vessels
      <xref ref-type="bibr" rid="bib0420">
       [84]
      </xref>
      . XNT also prevents pulmonary vascular remodelling and right ventricular hypertrophy and fibrosis in a rat model of monocrotaline-induced pulmonary hypertension
      <xref ref-type="bibr" rid="bib0425">
       [85]
      </xref>
      . Development of XNT is being pursued to translate the vasoprotective concept of ACE2 into an effective cardiovascular therapy
      <xref ref-type="bibr" rid="bib0310">
       [62]
      </xref>
      . Diminazine aceturate, a small molecule antiprotozoal agent that shares structural similarity with XNT, has recently been demonstrated to be a potent activator of ACE2 and to decrease mean arterial pressure and myocardial fibrosis in SHRs
      <xref ref-type="bibr" rid="bib0430">
       [86]
      </xref>
      . Intracerebroventricular infusion of diminazine aceturate, prior to and following endothelin-1-induced middle cerebral artery occlusion, significantly attenuates cerebral infarct size and neurological deficits in a rat model
      <xref ref-type="bibr" rid="bib0400">
       [80]
      </xref>
      . These data suggest that diminazine aceturate may serve as a lead compound for the discovery of the next generation of drugs for the treatment of cardiovascular disease and hypertension
      <xref ref-type="bibr" rid="bib0430">
       [86]
      </xref>
      .
     </p>
     <p id="par0105">
      Interestingly, peptidase-independent actions of ACE2 have also been elucidated. ACE2 has been identified as an essential receptor for the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). The spike protein of SARS-CoV attaches the virus to its cellular receptor ACE2 with a binding domain on the spike protein mediating the interaction
      <xref ref-type="bibr" rid="bib0435">
       [87]
      </xref>
      . This ACE2-spike interaction leads to endocytosis of virus particles through internalization with ACE2, induces the fusion of virus with host cells and establishes SARS-CoV infection with the release of viral RNAs into cytoplasm
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      . The spike protein of SARS-CoV also induces TACE-dependent shedding of the ACE2 ectodomain, with the involvement of the ACE2 cytoplasmic domain. Cellular TACE and the ACE2 cytoplasmic tail promote viral entry and infection. These observations indicate that ACE2 shedding and its causative cellular signals may be attributable to SARS-CoV-induced tissue damage
      <xref ref-type="bibr" rid="bib0440">
       [88]
      </xref>
      . An ACE2 inhibitor, N-(2-aminoethyl)-1 aziridine-ethanamine, has been identified as being effective in blocking SARS-CoV spike protein-mediated cell fusion
      <xref ref-type="bibr" rid="bib0445">
       [89]
      </xref>
      . The SARS-CoV receptor function of ACE2 is independent of its catalytic activities for Ang II degradation but ACE2-mediated Ang II degradation is still important for lung protection from SARS pathogenesis
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0450">
       [90]
      </xref>
      . So, the consequence of long-term activation of ACE2 must be determined and the effects of ACE2 activators on the immune competence of animals and their vulnerability to SARS-CoV infection must be tested before these molecules are ready for preclinical trials
      <xref ref-type="bibr" rid="bib0320">
       [64]
      </xref>
      . ACE2 is also the receptor for the human coronavirus NL63 that was discovered in 2004 in the Netherlands and was shown to be globally distributed
      <xref ref-type="bibr" rid="bib0455">
       [91]
      </xref>
      . Additionally, due to the high homology with collectrin at its transmembrane, ACE2 binds to B
      <sup>
       0
      </sup>
      AT1-family amino acid transporters and contributes to the absorption of neutral amino acids in animal intestines
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0460">
       [92]
      </xref>
      . Thus, ACE2 may be involved in multiple biological functions.
     </p>
    </sec>
    <sec id="sec0040">
     <title>
      Renin, prorenin and the (pro)renin receptor
     </title>
     <p id="par0110">
      Renin (EC 3.4.23.15) is a key enzyme of the RAS. Since its discovery 100 years ago, an impressive quantity of information about renin has been compiled. It is generally accepted that the active renin found in the circulation of mammals almost exclusively originates from the kidney. In addition to systemic renin, there are a number of extrarenal tissues that express renin as part of the local or tissue-specific RASs. Within the kidney, renin is predominantly produced by the juxtaglomerular cells. (Pro)renin gene transcription in these cells is controlled through several mechanisms, among which cyclic adenosine monophosphate (cAMP)/protein kinase A/cAMP response element binding protein (stimulatory) and calcium/protein kinase C (inhibitory) cascades are employed by physiological cues, whereas signal transducers, activators of transcription and nuclear factor κB transcription factors (inhibitory) and members of the nuclear receptor superfamily probably become relevant in pathological situations. Prorenin is stored in vesicles, activated to renin and then released upon demand. The release of renin is under the control of the intracellular cAMP (stimulatory), Ca
      <sup>
       2+
      </sup>
      (inhibitory) and cyclic guanosine monophosphate signalling pathways. Meanwhile, a great number of intrarenally generated or systemically acting factors have been identified that control renin secretion directly at the level of renin-producing cells, by activating the cAMP or Ca
      <sup>
       2+
      </sup>
      signalling pathways
      <xref ref-type="bibr" rid="bib0465">
       [93]
      </xref>
      . Renin is an aspartyl protease with a typical structure made of two lobes. The cleft between the lobes contains the active site, characterized by two catalytic aspartic residues. Renin is a highly specific enzyme and has only one known substrate (AGT)
      <xref ref-type="bibr" rid="bib0470">
       [94]
      </xref>
      .
     </p>
     <p id="par0115">
      Prorenin is the ‘inactive’ precursor of renin. In addition to the main organ, the kidney, other tissues, such as the brain, the adrenal gland, the submandibular gland, the glands of the reproductive system and adipose tissue, are also able to secrete prorenin in the surrounding milieu and in plasma. In contrast to renin, prorenin is released constitutively; renin and prorenin levels are usually well correlated. Under some physiopathological circumstances, such as pregnancy and diabetes, prorenin levels exceed by far those of renin
      <xref ref-type="bibr" rid="bib0470">
       [94]
      </xref>
      . Prorenin has a prosegment of 43 amino acid residues attached to the N-terminus of mature renin; the prosegment folds into an active site cleft of mature renin to prevent catalytic interaction with AGT
      <xref ref-type="bibr" rid="bib0475">
       [95]
      </xref>
      . Prorenin-renin conversion occurs in the kidney before renin is released from the juxtaglomerular cells. Several enzymes, including proconvertase 1 and cathepsin B, have been proposed to be responsible for this irreversible cleavage of the prosegment from prorenin to form mature renin. A (reversible) non-proteolytic activation of prorenin may also occur. At acidic pH and/or low temperature, prorenin is capable of undergoing a conformational change, involving the unfolding of the prosegment from the enzymatic cleft. This non-proteolytically-activated prorenin is fully enzymatically active
      <xref ref-type="bibr" rid="bib0480">
       [96]
      </xref>
      . Under physiological conditions, approximately 2% of plasma prorenin is in the open form and can also display enzymatic activity
      <xref ref-type="bibr" rid="bib0470">
       [94]
      </xref>
      .
     </p>
     <p id="par0120">
      The traditional assumptions of renin being just an enzyme responsible for the cleavage of AGT and prorenin being just an ‘inactive’ proenzyme were challenged by the cloning of a human (P)RR in 2002
      <xref ref-type="bibr" rid="bib0470">
       [94]
      </xref>
      . The (P)RR is a single transmembrane-domain protein of 350 amino acids, with a large unglycosylated and highly hydrophobic N-terminal domain responsible for renin and prorenin binding and a short cytoplasmic tail of about 20 amino acids involved in intracellular signalling
      <xref ref-type="bibr" rid="bib0485">
       [97]
      </xref>
      . The (P)RR was first identified on cultured human mesangial cells and bound well to renin and prorenin with a
      <italic>
       K
      </italic>
      <sub>
       D
      </sub>
      in the nanomolar range
      <xref ref-type="bibr" rid="bib0480">
       [96]
      </xref>
      . Binding of prorenin induced a conformational change in the molecule, increasing its enzymatic activity from virtually zero to values similar to those of active renin in solution without proteolytic removal of the prosegment
      <xref ref-type="bibr" rid="bib0465">
       [93]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0490">
       [98]
      </xref>
      . Two regions in the human prorenin segment, namely T
      <sup>
       7P
      </sup>
      FKR
      <sup>
       10P
      </sup>
      (a gate that is not accessible by its specific antibodies until it is loosened from the active site cleft) and I
      <sup>
       11P
      </sup>
      FLKR
      <sup>
       15P
      </sup>
      (a handle, a protruding pentameric segment), have been identified as being crucial for the non-proteolytic activation
      <xref ref-type="bibr" rid="bib0495">
       [99]
      </xref>
      . Renin bound to the (P)RR displays a 3- to 5-fold increase in the catalytic efficiency of AGT conversion to Ang I compared with free renin
      <xref ref-type="bibr" rid="bib0485">
       [97]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0500">
       [100]
      </xref>
      . In addition to the Ang-dependent function on the cell surface related to the increased catalytic activity of receptor-bound (pro)renin (renin activity of activated prorenin and increased activity of renin) that leads to the formation of Ang I from AGT, the (P)RR system also has Ang-independent intracellular effects that are not necessarily related to the RAS
      <xref ref-type="bibr" rid="bib0035">
       [7]
      </xref>
      . Pathological conditions like high blood pressure upregulate the receptor, whereas elevated (pro)renin concentrations downregulate the receptor via translocation of the transcription factor promyelotic zinc finger protein to the nucleus
      <xref ref-type="bibr" rid="bib0490">
       [98]
      </xref>
      . In the Ang-independent signalling pathways, prorenin-induced activation of mitogen-activated protein kinase p38 and subsequent phosphorylation of heat shock protein 27 result in actin polymerization, while (pro)renin-induced activation of the extracellular signal-regulated kinase 1/2 (p44/p42) signalling cascade leads to the intracellular expression of profibrotic genes, giving rise to the synthesis of transforming growth factor-β, plasminogen activator inhibitor-1, collagen 1 and fibronectin. These effects potentially increase cardiac and renal hypertrophy and fibrosis
      <xref ref-type="bibr" rid="bib0485">
       [97]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0505">
       [101]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0510">
       [102]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0515">
       [103]
      </xref>
      . The discovery of the (P)RR has confirmed the hypothesis that renin is also a hormone. It has been suggested that blocking the (P)RR may be a new target for renal and cardiac end-organ protection
      <xref ref-type="bibr" rid="bib0005">
       [1]
      </xref>
      . Additionally, the mannose-6-phosphate/insulin-like growth factor II receptor can bind both renin and prorenin with high affinity and is believed to serve as a clearance receptor for renin/prorenin. An intracellular renin-binding protein has been also cloned and found to be an inhibitor of renin activity but its deletion affected neither blood pressure nor plasma renin
      <xref ref-type="bibr" rid="bib0470">
       [94]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0045">
     <title>
      (Pro)renin receptor antagonist and renin inhibitors
     </title>
     <p id="par0125">
      After the discovery of the receptor, a (P)RR antagonist was designed, based on the idea that the prosegment contains a handle region that binds to the receptor, allowing prorenin to become catalytically active in a non-proteolytic manner
      <xref ref-type="bibr" rid="bib0480">
       [96]
      </xref>
      . The antagonist (also known as hand region peptide, HRP), consisting of 10 amino acids (NH
      <sub>
       2
      </sub>
      -RILLKKMPSV-COOH), resembles the handle region (I
      <sup>
       11P
      </sup>
      LLKK
      <sup>
       15P
      </sup>
      ) of rat prorenin prosegment and will thus competitively bind to the (P)RR as a decoy peptide and inhibit the receptor-mediated activation of prorenin
      <xref ref-type="bibr" rid="bib0475">
       [95]
      </xref>
      . Treatment with the HRP in diabetic mice and rats decreased the renal content of Ang I and II and inhibited the development of nephropathy without affecting hyperglycaemia
      <xref ref-type="bibr" rid="bib0520">
       [104]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0525">
       [105]
      </xref>
      . In stroke-prone SHRs, continuous subcutaneous administration of the HRP inhibited activation of the tissue RAS without affecting the circulating RAS or arterial pressure and significantly attenuated the development and progression of proteinuria, glomerulosclerosis and cardiac fibrosis
      <xref ref-type="bibr" rid="bib0530">
       [106]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0535">
       [107]
      </xref>
      . Infusion of the HRP in human (P)RR transgenic rats significantly inhibited the development of glomerulosclerosis, proteinuria, mitogen-activated protein kinase activation and transforming growth factor-β expression in the kidneys
      <xref ref-type="bibr" rid="bib0540">
       [108]
      </xref>
      . Future research should be able to determine to what degree the beneficial in vivo effects of HRP are due to prorenin blockade
      <xref ref-type="bibr" rid="bib0490">
       [98]
      </xref>
      and are related to interference with renin binding and the RAS
      <xref ref-type="bibr" rid="bib0020">
       [4]
      </xref>
      . Decoy effects of the HRP, however, were not confirmed by other research groups
      <xref ref-type="bibr" rid="bib0545">
       [109]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0550">
       [110]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0555">
       [111]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0560">
       [112]
      </xref>
      .
     </p>
     <p id="par0130">
      ACE inhibitors and AT1 receptor blockers (ARBs) are proven to be effective therapeutic agents in the treatment of CVD. However, both ACE inhibitors and ARBs lead to a substantial compensatory rise in circulating active renin and Ang peptides that may eventually limit their therapeutic potential
      <xref ref-type="bibr" rid="bib0565">
       [113]
      </xref>
      . Moreover, the increased Ang I seen with ACE inhibitors can subsequently be converted to Ang II by non-ACE pathways, mediated by chymase and chymotrypsin-like Ang-generating enzyme
      <xref ref-type="bibr" rid="bib0570">
       [114]
      </xref>
      . In addition to the side effects of ACE inhibitors, such as cough and angioedema, a meta-analysis of randomized controlled trials in 2010 suggested that ARBs are associated with a modestly increased risk of new cancer diagnosis, although conclusions about the exact risk of cancer associated with each particular drug have not been drawn
      <xref ref-type="bibr" rid="bib0575">
       [115]
      </xref>
      . Based on this study, the United States Food and Drug Administration is conducting a review to assess the possible link between the use of ARBs and cancer. Therefore, direct renin inhibition may be an alternative pharmacological approach to RAS inhibition.
     </p>
     <p id="par0135">
      Renin is the rate-limiting step of the RAS and the concept of blocking the RAS at its origin by inhibiting renin has existed for at least 50 years
      <xref ref-type="bibr" rid="bib0565">
       [113]
      </xref>
      . The first-generation renin inhibitors were peptide analogues of AGT and the second-generation compounds were peptidomimetic agents that are dipeptide transition-state analogue inhibitors of the active site. But these renin inhibitors had limited clinical use due to poor metabolic stability and oral bioavailability, short duration of action, weak antihypertensive activity and high cost of synthesis
      <xref ref-type="bibr" rid="bib0570">
       [114]
      </xref>
      . A combination of molecular modelling and X-ray crystallographic analysis of the active site of renin led to the development of aliskiren, a new non-peptide low-molecular-weight orally-active renin inhibitor. Aliskiren has a high binding affinity for renin and appears to bind to both the hydrophobic S1-/S3-binding pocket and a large, distinct subpocket that extends from the S3-binding site toward the hydrophobic core of the enzyme. Aliskiren is a potent competitive inhibitor of renin but very poorly inhibits related aspartic peptidases. It shows no effects on cytochrome P450 isoenzyme activities and is not bound extensively to blood proteins, therefore having a low potential for drug interactions
      <xref ref-type="bibr" rid="bib0565">
       [113]
      </xref>
      . Compared with the earlier renin inhibitors, aliskiren is more resistant to intestinal degradation and possesses significantly improved oral bioavailability. The terminal half-life ranges from 23 to 40 hours, which makes it suitable for once-daily dosing. Aliskiren monotherapy displays an antihypertensive efficacy similar if not superior to that of other first-line antihypertensive drugs, with a safety and tolerability profile similar to that of ARBs. Combined with various antihypertensive agents, aliskiren exhibits synergistic effects
      <xref ref-type="bibr" rid="bib0570">
       [114]
      </xref>
      . From 2007, aliskiren was approved by regulatory bodies in both Europe and the United States, for use alone and with other agents in the treatment of hypertension
      <xref ref-type="bibr" rid="bib0565">
       [113]
      </xref>
      . Recent studies showed that aliskiren treatment also markedly increased the plasma concentration of (pro)renin in patients and failed to inhibit the non-catalytic effects of (pro)renin
      <xref ref-type="bibr" rid="bib0550">
       [110]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0580">
       [116]
      </xref>
      . The pharmaceutical company Novartis reported that the addition of aliskiren to standard therapy for patients recovering from a heart attack did not provide the anticipated effect of limiting adverse changes to the heart's left ventricle. In December 2011, Novartis announced the early termination of the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) and advised that aliskiren should not be used in combination with ACE inhibitors or ARBs in patients with diabetes. The study was conducted in type 2 diabetic patients at high risk of fatal and non-fatal cardiovascular and renal events; aliskiren 300 mg was given in addition to an ACE inhibitor or an ARB. The overseeing Data Monitoring Committee concluded that study patients were unlikely to benefit from aliskiren and that there was a higher incidence of adverse events related to non-fatal stroke, renal complications, hyperkalaemia and hypotension in this high-risk population after 18–24 months of combined therapy (
      <ext-link ext-link-type="uri" xlink:href="http://www.novartis.com/">
       www.novartis.com
      </ext-link>
      ). Aliskiren has been shown to be a very safe antihypertensive after more than 20,000 patient-years of data. However, as we have seen in Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) that the combination of telmisartan (an ARB) and ramipril (an ACE inhibitor) is associated with more adverse events without an increase in benefit in patients with vascular disease or high-risk diabetes without heart failure
      <xref ref-type="bibr" rid="bib0585">
       [117]
      </xref>
      , the combination of multiple safe drugs in this class may no longer be a promising strategy.
     </p>
    </sec>
    <sec id="sec0050">
     <title>
      Future directions of bioactives from natural plant and/or food resources for RAS regulation
     </title>
     <p id="par0140">
      Over the last decade, a number of food-derived compounds have been shown to have in vitro ACE inhibitory activity. Some of them display significant antihypertensive activity in rats and humans. Among these compounds, food-derived ACE inhibitory peptides have been most widely studied
      <xref ref-type="bibr" rid="bib0070">
       [14]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0590">
       [118]
      </xref>
      . A quantitative structure-activity relationship study indicated that a potent ACE inhibitory dipeptide should have a large and hydrophobic amino acid at the C-terminus and a non-polar amino acid or possibly a positively charged amino acid at the N-terminus. For tripeptides, the most favourable residues for the C-terminus are aromatic amino acids, while hydrophobic amino acids are preferred for the N-terminus and positively charged amino acids are preferred for the middle position
      <xref ref-type="bibr" rid="bib0595">
       [119]
      </xref>
      . The in vitro half-maximal inhibitory concentration (IC
      <sub>
       50
      </sub>
      ) values of food-derived ACE inhibitory peptides are about 1000-fold higher than that of synthetic captopril but they have higher in vivo activities than would be expected from their in vitro activities. It has been suggested that food-derived peptides might act via different antihypertensive mechanisms, possess higher affinities for tissues and be more slowly eliminated than synthetic captopril
      <xref ref-type="bibr" rid="bib0590">
       [118]
      </xref>
      . Until now, only two lactotripeptides (VPP and IPP) have been successfully commercialized. Data from van Mierlo et al., however, did not support a blood pressure-lowering effect of the two tripeptides in Caucasians
      <xref ref-type="bibr" rid="bib0600">
       [120]
      </xref>
      . Given the discrepancy between in vivo and in vitro results, further investigation into the in vivo and clinical antihypertensive effects and mechanisms of food-derived ACE inhibitors is necessary. Three dipeptides (IR, KF and EF) in pea protein hydrolate have been identified as inhibiting renin activity in vitro
      <xref ref-type="bibr" rid="bib0640">
       [121]
      </xref>
      . Oleic acid and linoleic acid isolated from rice and some cereals also have in vitro renin inhibitory activity
      <xref ref-type="bibr" rid="bib0610">
       [122]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0615">
       [123]
      </xref>
      . A series of studies have shown that saponins from different food/plant sources, primarily from soybean, can inhibit in vitro renin activity
      <xref ref-type="bibr" rid="bib0620">
       [124]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0625">
       [125]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0630">
       [126]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0635">
       [127]
      </xref>
      ; among them, orally administered soybean saponin can lead to a reduction of blood pressure in SHRs but the direct evidence for saponin suppressing plasma renin activity in vivo is still lacking
      <xref ref-type="bibr" rid="bib0620">
       [124]
      </xref>
      . Experiments are required to further investigate the biochemical and biological properties of these plant/food-derived non-peptides that are related to renin inhibition. Significant conceptual progress made in the last few years leads us to conclude that ACE2 could serve as a new direction for improved therapeutics for cardiovascular disease. Compared with ACE inhibitor therapy, ACE2 is an endogenous regulator of the RAS. Targeting ACE2 would not only produce the vasoprotective/antiproliferative peptide Ang-(1–7) but would also influence the vasoconstrictive/proliferative effects of the ACE/Ang II/AT1 axis. As a part of the vasoprotective/antiproliferative axis, ACE2 can effectively control fibrosis and structural remodelling and is extremely beneficial for pulmonary hypertension. ACE2 activation may provide improved protection and reversal of ischaemia-induced neural damage. Thus, direct activation of ACE2 could result in better outcomes in cardiovascular disease. Additionally, ACE2 is a multifunctional enzyme with many biologically active substrates. The effects of ACE2 on substrates other than Ang I and Ang II may hold relevance for the treatment of cardiovascular disease
      <xref ref-type="bibr" rid="bib0310">
       [62]
      </xref>
      . XNT analogues exist in many natural plant resources and have shown various physiological functions. Using these resources to search for in vitro ACE2 activators would be a good starting point for developing plant food-derived ACE2 activating agents. Ongoing experiments would characterize these ACE2 activators. Compared with RAS regulatory drugs, these plant/food-derived bioactives appear more natural and safer to the consumer. As part of a daily diet, bioactives from food sources may result in a much lower healthcare cost. Plant/food-derived RAS regulators could be applied in the prevention of hypertension and as initial treatment in mildly hypertensive individuals
      <xref ref-type="bibr" rid="bib0590">
       [118]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0055">
     <title>
      Disclosure of interest
     </title>
     <p id="par0145">
      The authors declare that they have no conflicts of interest concerning this article.
     </p>
    </sec>
    <back>
     <ref-list id="bibl0005">
      <title>
       References
      </title>
      <ref id="bib0005">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fyhrquist
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Saijonmaa
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Renin-angiotensin system revisited
        </article-title>
        <source>
         J Intern Med
        </source>
        <volume>
         264
        </volume>
        <year>
         2008
        </year>
        <fpage>
         224
        </fpage>
        <lpage>
         236
        </lpage>
        <pub-id pub-id-type="pmid">
         18793332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Contrepas
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Physiology and pharmacology of the (pro)renin receptor
        </article-title>
        <source>
         Curr Opin Pharmacol
        </source>
        <volume>
         8
        </volume>
        <year>
         2008
        </year>
        <fpage>
         127
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         18243793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenberg
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An ACE in the hole alternative pathways of the renin angiotensin system and their potential role in cardiac remodeling
        </article-title>
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         52
        </volume>
        <year>
         2008
        </year>
        <fpage>
         755
        </fpage>
        <lpage>
         757
        </lpage>
        <pub-id pub-id-type="pmid">
         18718424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         87
        </volume>
        <year>
         2000
        </year>
        <fpage>
         E1
        </fpage>
        <lpage>
         E9
        </lpage>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         275
        </volume>
        <year>
         2000
        </year>
        <fpage>
         33238
        </fpage>
        <lpage>
         33243
        </lpage>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ohto-Nakanishi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters
        </article-title>
        <source>
         Pharmacol Ther
        </source>
        <volume>
         128
        </volume>
        <year>
         2010
        </year>
        <fpage>
         119
        </fpage>
        <lpage>
         128
        </lpage>
        <pub-id pub-id-type="pmid">
         20599443
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Danser
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents
        </article-title>
        <source>
         Exp Physiol
        </source>
        <volume>
         93
        </volume>
        <year>
         2008
        </year>
        <fpage>
         557
        </fpage>
        <lpage>
         563
        </lpage>
        <pub-id pub-id-type="pmid">
         18376005
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A map and new directions for the (pro)renin receptor in the brain: focus on “A role of the (pro)renin receptor in neuronal cell differentiation”
        </article-title>
        <source>
         Am J Physiol Regul Integr Comp Physiol
        </source>
        <volume>
         297
        </volume>
        <year>
         2009
        </year>
        <fpage>
         R248
        </fpage>
        <lpage>
         R249
        </lpage>
        <pub-id pub-id-type="pmid">
         19494175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riordan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-I-converting enzyme and its relatives
        </article-title>
        <source>
         Genome Biol
        </source>
        <volume>
         4
        </volume>
        <year>
         2003
        </year>
        <fpage>
         225
        </fpage>
        <pub-id pub-id-type="pmid">
         12914653
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balyasnikova
          </surname>
          <given-names>
           I.V.
          </given-names>
         </name>
         <name>
          <surname>
           Karran
          </surname>
          <given-names>
           E.H.
          </given-names>
         </name>
         <name>
          <surname>
           Albrecht
          </surname>
          <given-names>
           R.F.
          </given-names>
          <suffix>
           2nd.
          </suffix>
         </name>
        </person-group>
        <article-title>
         Epitope-specific antibody-induced cleavage of angiotensin-converting enzyme from the cell surface
        </article-title>
        <source>
         Biochem J
        </source>
        <volume>
         362
        </volume>
        <year>
         2002
        </year>
        <fpage>
         585
        </fpage>
        <lpage>
         595
        </lpage>
        <pub-id pub-id-type="pmid">
         11879185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An ACE structure
        </article-title>
        <source>
         Nat Struct Biol
        </source>
        <volume>
         10
        </volume>
        <year>
         2003
        </year>
        <fpage>
         155
        </fpage>
        <lpage>
         157
        </lpage>
        <pub-id pub-id-type="pmid">
         12605218
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parkin
          </surname>
          <given-names>
           E.T.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Secretase-mediated cell surface shedding of the angiotensin-converting enzyme
        </article-title>
        <source>
         Protein Pept Lett
        </source>
        <volume>
         11
        </volume>
        <year>
         2004
        </year>
        <fpage>
         423
        </fpage>
        <lpage>
         432
        </lpage>
        <pub-id pub-id-type="pmid">
         15544563
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hubert
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Houot
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         266
        </volume>
        <year>
         1991
        </year>
        <fpage>
         15377
        </fpage>
        <lpage>
         15383
        </lpage>
        <pub-id pub-id-type="pmid">
         1651327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
         <name>
          <surname>
           FitzGerald
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production
        </article-title>
        <source>
         Curr Pharm Des
        </source>
        <volume>
         13
        </volume>
        <year>
         2007
        </year>
        <fpage>
         773
        </fpage>
        <lpage>
         791
        </lpage>
        <pub-id pub-id-type="pmid">
         17430180
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lew
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The zinc metallopeptidase family: new faces, new functions
        </article-title>
        <source>
         Protein Pept Lett
        </source>
        <volume>
         11
        </volume>
        <year>
         2004
        </year>
        <fpage>
         407
        </fpage>
        <lpage>
         414
        </lpage>
        <pub-id pub-id-type="pmid">
         15544561
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The angiotensin-converting enzyme gene family: genomics and pharmacology
        </article-title>
        <source>
         Trends Pharmacol Sci
        </source>
        <volume>
         23
        </volume>
        <year>
         2002
        </year>
        <fpage>
         177
        </fpage>
        <lpage>
         183
        </lpage>
        <pub-id pub-id-type="pmid">
         11931993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Natesh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Schwager
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           E.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of the human angiotensin-converting enzyme-lisinopril complex
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         421
        </volume>
        <year>
         2003
        </year>
        <fpage>
         551
        </fpage>
        <lpage>
         554
        </lpage>
        <pub-id pub-id-type="pmid">
         12540854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0090">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corradi
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Schwager
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Nchinda
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design
        </article-title>
        <source>
         J Mol Biol
        </source>
        <volume>
         357
        </volume>
        <year>
         2006
        </year>
        <fpage>
         964
        </fpage>
        <lpage>
         974
        </lpage>
        <pub-id pub-id-type="pmid">
         16476442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0095">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rawlings
          </surname>
          <given-names>
           N.D.
          </given-names>
         </name>
         <name>
          <surname>
           Barrett
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evolutionary families of peptidases
        </article-title>
        <source>
         Biochem J
        </source>
        <volume>
         290
        </volume>
        <issue>
         Pt 1
        </issue>
        <year>
         1993
        </year>
        <fpage>
         205
        </fpage>
        <lpage>
         218
        </lpage>
        <pub-id pub-id-type="pmid">
         8439290
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0100">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coates
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The angiotensin converting enzyme (ACE)
        </article-title>
        <source>
         Int J Biochem Cell Biol
        </source>
        <volume>
         35
        </volume>
        <year>
         2003
        </year>
        <fpage>
         769
        </fpage>
        <lpage>
         773
        </lpage>
        <pub-id pub-id-type="pmid">
         12676162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0105">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Alhenc-Gelas
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The two homologous domains of human angiotensin I-converting enzyme are both catalytically active
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         266
        </volume>
        <year>
         1991
        </year>
        <fpage>
         9002
        </fpage>
        <lpage>
         9008
        </lpage>
        <pub-id pub-id-type="pmid">
         1851160
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0110">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Araujo
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Melo
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Cesari
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         39
        </volume>
        <year>
         2000
        </year>
        <fpage>
         8519
        </fpage>
        <lpage>
         8525
        </lpage>
        <pub-id pub-id-type="pmid">
         10913258
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0115">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jaspard
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Alhenc-Gelas
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         268
        </volume>
        <year>
         1993
        </year>
        <fpage>
         9496
        </fpage>
        <lpage>
         9503
        </lpage>
        <pub-id pub-id-type="pmid">
         7683654
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0120">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cushman
          </surname>
          <given-names>
           D.W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           H.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <volume>
         20
        </volume>
        <year>
         1971
        </year>
        <fpage>
         1637
        </fpage>
        <lpage>
         1648
        </lpage>
        <pub-id pub-id-type="pmid">
         4355305
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0125">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corradi
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Chitapi
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Sewell
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         46
        </volume>
        <year>
         2007
        </year>
        <fpage>
         5473
        </fpage>
        <lpage>
         5478
        </lpage>
        <pub-id pub-id-type="pmid">
         17439247
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0130">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deddish
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Marcic
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Jackman
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         31
        </volume>
        <year>
         1998
        </year>
        <fpage>
         912
        </fpage>
        <lpage>
         917
        </lpage>
        <pub-id pub-id-type="pmid">
         9535414
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0135">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rousseau
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Michaud
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chauvet
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         270
        </volume>
        <year>
         1995
        </year>
        <fpage>
         3656
        </fpage>
        <lpage>
         3661
        </lpage>
        <pub-id pub-id-type="pmid">
         7876104
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0140">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oba
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Igarashi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kamata
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide
        </article-title>
        <source>
         Eur J Neurosci
        </source>
        <volume>
         21
        </volume>
        <year>
         2005
        </year>
        <fpage>
         733
        </fpage>
        <lpage>
         740
        </lpage>
        <pub-id pub-id-type="pmid">
         15733091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0145">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fuchs
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Hubert
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         51
        </volume>
        <year>
         2008
        </year>
        <fpage>
         267
        </fpage>
        <lpage>
         274
        </lpage>
        <pub-id pub-id-type="pmid">
         18158355
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0150">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dubreuil
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Fulcrand
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide
        </article-title>
        <source>
         Biochem J
        </source>
        <volume>
         262
        </volume>
        <year>
         1989
        </year>
        <fpage>
         125
        </fpage>
        <lpage>
         130
        </lpage>
        <pub-id pub-id-type="pmid">
         2554881
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0155">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skidgel
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Engelbrecht
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         5
        </volume>
        <year>
         1984
        </year>
        <fpage>
         769
        </fpage>
        <lpage>
         776
        </lpage>
        <pub-id pub-id-type="pmid">
         6208535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0160">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skidgel
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel activity of human angiotensin I converting enzyme: release of the NH2- and COOH-terminal tripeptides from the luteinizing hormone-releasing hormone
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         82
        </volume>
        <year>
         1985
        </year>
        <fpage>
         1025
        </fpage>
        <lpage>
         1029
        </lpage>
        <pub-id pub-id-type="pmid">
         2983326
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0165">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Naqvi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular basis of exopeptidase activity in the C-terminal domain of human angiotensin I-converting enzyme: insights into the origins of its exopeptidase activity
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         280
        </volume>
        <year>
         2005
        </year>
        <fpage>
         6669
        </fpage>
        <lpage>
         6675
        </lpage>
        <pub-id pub-id-type="pmid">
         15615692
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0170">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Toropygin
          </surname>
          <given-names>
           I.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kugaevskaya
          </surname>
          <given-names>
           E.V.
          </given-names>
         </name>
         <name>
          <surname>
           Mirgorodskaya
          </surname>
          <given-names>
           O.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
        </article-title>
        <source>
         Rapid Commun Mass Spectrom
        </source>
        <volume>
         22
        </volume>
        <year>
         2008
        </year>
        <fpage>
         231
        </fpage>
        <lpage>
         239
        </lpage>
        <pub-id pub-id-type="pmid">
         18085519
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0175">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skeggs
          </surname>
          <given-names>
           L.T.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Kahn
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Shumway
          </surname>
          <given-names>
           N.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The preparation and function of the hypertensin-converting enzyme
        </article-title>
        <source>
         J Exp Med
        </source>
        <volume>
         103
        </volume>
        <year>
         1956
        </year>
        <fpage>
         295
        </fpage>
        <lpage>
         299
        </lpage>
        <pub-id pub-id-type="pmid">
         13295487
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0180">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sivieri
          </surname>
          <given-names>
           D.O.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Bispo-da-Silva
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Oliveira
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         50
        </volume>
        <year>
         2007
        </year>
        <fpage>
         110
        </fpage>
        <lpage>
         115
        </lpage>
        <pub-id pub-id-type="pmid">
         17470724
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0185">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imanishi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ikejima
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsujioka
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         51
        </volume>
        <year>
         2008
        </year>
        <fpage>
         734
        </fpage>
        <lpage>
         741
        </lpage>
        <pub-id pub-id-type="pmid">
         18227404
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0190">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hyun
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme I inhibitory activity of phlorotannins from Ecklonia stolonifera
        </article-title>
        <source>
         Fisheries Sci
        </source>
        <volume>
         72
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1292
        </fpage>
        <lpage>
         1299
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0195">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Le
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Houston
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Degradation of Met-enkephalin by hemolymph peptidases in Mytilus edulis
        </article-title>
        <source>
         Cell Mol Neurobiol
        </source>
        <volume>
         12
        </volume>
        <year>
         1992
        </year>
        <fpage>
         367
        </fpage>
        <lpage>
         378
        </lpage>
        <pub-id pub-id-type="pmid">
         1334805
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0200">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lund
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bak
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Friis
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The enzymatic degradation and transport of leucine-enkephalin and 4-imidazolidinone enkephalin prodrugs at the blood-brain barrier
        </article-title>
        <source>
         Int J Pharm
        </source>
        <volume>
         172
        </volume>
        <year>
         1998
        </year>
        <fpage>
         97
        </fpage>
        <lpage>
         101
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0205">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azizi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rousseau
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ezan
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline
        </article-title>
        <source>
         J Clin Invest
        </source>
        <volume>
         97
        </volume>
        <year>
         1996
        </year>
        <fpage>
         839
        </fpage>
        <lpage>
         844
        </lpage>
        <pub-id pub-id-type="pmid">
         8609242
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0210">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Genevay
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Mormont
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654)
        </article-title>
        <source>
         Exp Hematol
        </source>
        <volume>
         24
        </volume>
        <year>
         1996
        </year>
        <fpage>
         77
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="pmid">
         8536796
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0215">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lombard
          </surname>
          <given-names>
           M.N.
          </given-names>
         </name>
         <name>
          <surname>
           Sotty
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wdzieczak-Bakala
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vivo effect of the tetrapeptide, N-acetyl-Ser-Asp-Lys-Pro, on the G1-S transition of rat hepatocytes
        </article-title>
        <source>
         Cell Tissue Kinet
        </source>
        <volume>
         23
        </volume>
        <year>
         1990
        </year>
        <fpage>
         99
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="pmid">
         2317837
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0220">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Volkov
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Quere
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Coudert
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The tetrapeptide AcSDKP, a negative regulator of cell cycle entry, inhibits the proliferation of human and chicken lymphocytes
        </article-title>
        <source>
         Cell Immunol
        </source>
        <volume>
         168
        </volume>
        <year>
         1996
        </year>
        <fpage>
         302
        </fpage>
        <lpage>
         306
        </lpage>
        <pub-id pub-id-type="pmid">
         8640879
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0225">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lawrence
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Kovacevic
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo
        </article-title>
        <source>
         Blood
        </source>
        <volume>
         101
        </volume>
        <year>
         2003
        </year>
        <fpage>
         3014
        </fpage>
        <lpage>
         3020
        </lpage>
        <pub-id pub-id-type="pmid">
         12480715
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0230">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Castoldi
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           di Gioia
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bombardi
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats
        </article-title>
        <source>
         Clin Sci (Lond)
        </source>
        <volume>
         118
        </volume>
        <year>
         2010
        </year>
        <fpage>
         211
        </fpage>
        <lpage>
         220
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0235">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Igarashi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kamata
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         276
        </volume>
        <year>
         2001
        </year>
        <fpage>
         47863
        </fpage>
        <lpage>
         54788
        </lpage>
        <pub-id pub-id-type="pmid">
         11604391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0240">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yamaguchi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Akatsu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition
        </article-title>
        <source>
         J Neurosci
        </source>
        <volume>
         27
        </volume>
        <year>
         2007
        </year>
        <fpage>
         8628
        </fpage>
        <lpage>
         8635
        </lpage>
        <pub-id pub-id-type="pmid">
         17687040
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0245">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Uchida
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease
        </article-title>
        <source>
         Brain Res
        </source>
        <volume>
         1352
        </volume>
        <year>
         2010
        </year>
        <fpage>
         176
        </fpage>
        <lpage>
         186
        </lpage>
        <pub-id pub-id-type="pmid">
         20627092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0250">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patchett
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Tristram
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new class of angiotensin-converting enzyme inhibitors
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         288
        </volume>
        <year>
         1980
        </year>
        <fpage>
         280
        </fpage>
        <lpage>
         283
        </lpage>
        <pub-id pub-id-type="pmid">
         6253826
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0255">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Acharya
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           E.D.
          </given-names>
         </name>
         <name>
          <surname>
           Riordan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ace revisited: a new target for structure-based drug design
        </article-title>
        <source>
         Nat Rev Drug Discov
        </source>
        <volume>
         2
        </volume>
        <year>
         2003
        </year>
        <fpage>
         891
        </fpage>
        <lpage>
         902
        </lpage>
        <pub-id pub-id-type="pmid">
         14668810
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0260">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           W.O.
          </given-names>
         </name>
         <name>
          <surname>
           Hernandez-Diaz
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Arbogast
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Major congenital malformations after first-trimester exposure to ACE inhibitors
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         354
        </volume>
        <year>
         2006
        </year>
        <fpage>
         2443
        </fpage>
        <lpage>
         2451
        </lpage>
        <pub-id pub-id-type="pmid">
         16760444
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0265">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Georgiadis
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Beau
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Czarny
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         93
        </volume>
        <year>
         2003
        </year>
        <fpage>
         148
        </fpage>
        <lpage>
         154
        </lpage>
        <pub-id pub-id-type="pmid">
         12805239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0270">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           San Juan
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         3D-QSAR studies on angiotensin-converting enzyme (ACE) inhibitors: a molecular design in hypertensive agents
        </article-title>
        <source>
         Bull Korean Chem Soc
        </source>
        <volume>
         26
        </volume>
        <year>
         2005
        </year>
        <fpage>
         952
        </fpage>
        <lpage>
         958
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0275">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Junot
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gonzales
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ezan
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis
        </article-title>
        <source>
         J Pharmacol Exp Ther
        </source>
        <volume>
         297
        </volume>
        <year>
         2001
        </year>
        <fpage>
         606
        </fpage>
        <lpage>
         611
        </lpage>
        <pub-id pub-id-type="pmid">
         11303049
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0280">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           H.P.
          </given-names>
         </name>
         <name>
          <surname>
           Look
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia
        </article-title>
        <source>
         Am J Physiol Lung Cell Mol Physiol
        </source>
        <volume>
         297
        </volume>
        <year>
         2009
        </year>
        <fpage>
         L84
        </fpage>
        <lpage>
         L96
        </lpage>
        <pub-id pub-id-type="pmid">
         19411314
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0285">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           D.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yarski
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Warner
          </surname>
          <given-names>
           F.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         280
        </volume>
        <year>
         2005
        </year>
        <fpage>
         30113
        </fpage>
        <lpage>
         33019
        </lpage>
        <pub-id pub-id-type="pmid">
         15983030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0290">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Towler
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Staker
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Prasad
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         279
        </volume>
        <year>
         2004
        </year>
        <fpage>
         17996
        </fpage>
        <lpage>
         18007
        </lpage>
        <pub-id pub-id-type="pmid">
         14754895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0295">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Verrey
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Singer
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ramadan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kidney amino acid transport
        </article-title>
        <source>
         Pflugers Arch
        </source>
        <volume>
         458
        </volume>
        <year>
         2009
        </year>
        <fpage>
         53
        </fpage>
        <lpage>
         60
        </lpage>
        <pub-id pub-id-type="pmid">
         19184091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0300">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vickers
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hales
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kaushik
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         277
        </volume>
        <year>
         2002
        </year>
        <fpage>
         14838
        </fpage>
        <lpage>
         14843
        </lpage>
        <pub-id pub-id-type="pmid">
         11815627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0305">
       <label>
        61
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rushworth
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Guy
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis
        </article-title>
        <source>
         FEBS J
        </source>
        <volume>
         275
        </volume>
        <year>
         2008
        </year>
        <fpage>
         6033
        </fpage>
        <lpage>
         6042
        </lpage>
        <pub-id pub-id-type="pmid">
         19021774
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0310">
       <label>
        62
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bradford
          </surname>
          <given-names>
           C.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         55
        </volume>
        <year>
         2010
        </year>
        <fpage>
         207
        </fpage>
        <lpage>
         213
        </lpage>
        <pub-id pub-id-type="pmid">
         20038757
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0315">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rentzsch
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Todiras
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Iliescu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         52
        </volume>
        <year>
         2008
        </year>
        <fpage>
         967
        </fpage>
        <lpage>
         973
        </lpage>
        <pub-id pub-id-type="pmid">
         18809792
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0320">
       <label>
        64
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wysocki
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         55
        </volume>
        <year>
         2010
        </year>
        <fpage>
         90
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="pmid">
         19948988
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0325">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation of angiotensin-converting enzyme 2 gene polymorphisms with stage 2 hypertension in Han Chinese
        </article-title>
        <source>
         Transl Res
        </source>
        <volume>
         150
        </volume>
        <year>
         2007
        </year>
        <fpage>
         374
        </fpage>
        <lpage>
         380
        </lpage>
        <pub-id pub-id-type="pmid">
         18022600
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0330">
       <label>
        66
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lovren
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Quan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis
        </article-title>
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         295
        </volume>
        <year>
         2008
        </year>
        <fpage>
         H1377
        </fpage>
        <lpage>
         H1384
        </lpage>
        <pub-id pub-id-type="pmid">
         18660448
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0335">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Pickering
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tsorotes
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         107
        </volume>
        <year>
         2010
        </year>
        <fpage>
         888
        </fpage>
        <lpage>
         897
        </lpage>
        <pub-id pub-id-type="pmid">
         20671240
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0340">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nakamura
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Koibuchi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Nishimatsu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice
        </article-title>
        <source>
         Hypertens Res
        </source>
        <volume>
         31
        </volume>
        <year>
         2008
        </year>
        <fpage>
         1953
        </fpage>
        <lpage>
         1961
        </lpage>
        <pub-id pub-id-type="pmid">
         19015603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0345">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kassiri
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction
        </article-title>
        <source>
         Circ Heart Fail
        </source>
        <volume>
         2
        </volume>
        <year>
         2009
        </year>
        <fpage>
         446
        </fpage>
        <lpage>
         455
        </lpage>
        <pub-id pub-id-type="pmid">
         19808375
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0350">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Moraes
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Foureaux
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The angiotensin-(1-7)/Mas receptor axis is expressed in sinoatrial node cells of rats
        </article-title>
        <source>
         J Histochem Cytochem
        </source>
        <volume>
         59
        </volume>
        <year>
         2011
        </year>
        <fpage>
         761
        </fpage>
        <lpage>
         768
        </lpage>
        <pub-id pub-id-type="pmid">
         21606202
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0355">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lieb
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Graf
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gotz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy
        </article-title>
        <source>
         J Mol Med
        </source>
        <volume>
         84
        </volume>
        <year>
         2006
        </year>
        <fpage>
         88
        </fpage>
        <lpage>
         96
        </lpage>
        <pub-id pub-id-type="pmid">
         16283142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0360">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Epelman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system
        </article-title>
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         52
        </volume>
        <year>
         2008
        </year>
        <fpage>
         750
        </fpage>
        <lpage>
         754
        </lpage>
        <pub-id pub-id-type="pmid">
         18718423
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0365">
       <label>
        73
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Herzenberg
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kassiri
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis
        </article-title>
        <source>
         Am J Pathol
        </source>
        <volume>
         168
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1808
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         16723697
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0370">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soler
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wysocki
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice
        </article-title>
        <source>
         Kidney Int
        </source>
        <volume>
         72
        </volume>
        <year>
         2007
        </year>
        <fpage>
         614
        </fpage>
        <lpage>
         623
        </lpage>
        <pub-id pub-id-type="pmid">
         17579661
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0375">
       <label>
        75
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stegbauer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Potthoff
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Quack
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chronic treatment with angiotensin-(1-7) improves renal endothelial dysfunction in apolipoproteinE-deficient mice
        </article-title>
        <source>
         Br J Pharmacol
        </source>
        <volume>
         163
        </volume>
        <year>
         2011
        </year>
        <fpage>
         974
        </fpage>
        <lpage>
         983
        </lpage>
        <pub-id pub-id-type="pmid">
         21371005
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0380">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pinheiro
          </surname>
          <given-names>
           S.V.
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kitten
          </surname>
          <given-names>
           G.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria
        </article-title>
        <source>
         Kidney Int
        </source>
        <volume>
         75
        </volume>
        <year>
         2009
        </year>
        <fpage>
         1184
        </fpage>
        <lpage>
         1193
        </lpage>
        <pub-id pub-id-type="pmid">
         19262461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0385">
       <label>
        77
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamazato
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yamazato
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         49
        </volume>
        <year>
         2007
        </year>
        <fpage>
         926
        </fpage>
        <lpage>
         931
        </lpage>
        <pub-id pub-id-type="pmid">
         17325232
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0390">
       <label>
        78
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamazato
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Yamazato
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gene transfer of angiotensin-converting enzyme 2 in the nucleus tractus solitarius improves baroreceptor heart rate reflex in spontaneously hypertensive rats
        </article-title>
        <source>
         J Renin Angiotensin Aldosterone Syst
        </source>
        <volume>
         12
        </volume>
        <year>
         2011
        </year>
        <fpage>
         456
        </fpage>
        <lpage>
         461
        </lpage>
        <pub-id pub-id-type="pmid">
         21719524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0395">
       <label>
        79
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yue
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         102
        </volume>
        <year>
         2008
        </year>
        <fpage>
         729
        </fpage>
        <lpage>
         736
        </lpage>
        <pub-id pub-id-type="pmid">
         18258853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0400">
       <label>
        80
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mecca
          </surname>
          <given-names>
           A.P.
          </given-names>
         </name>
         <name>
          <surname>
           Regenhardt
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           O’Connor
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke
        </article-title>
        <source>
         Exp Physiol
        </source>
        <volume>
         96
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1084
        </fpage>
        <lpage>
         1096
        </lpage>
        <pub-id pub-id-type="pmid">
         21685445
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0405">
       <label>
        81
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shenoy
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Katovich
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2, a promising therapeutic target for pulmonary hypertension
        </article-title>
        <source>
         Curr Opin Pharmacol
        </source>
        <volume>
         11
        </volume>
        <year>
         2011
        </year>
        <fpage>
         150
        </fpage>
        <lpage>
         155
        </lpage>
        <pub-id pub-id-type="pmid">
         21215698
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0410">
       <label>
        82
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hernandez Prada
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Katovich
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         51
        </volume>
        <year>
         2008
        </year>
        <fpage>
         1312
        </fpage>
        <lpage>
         1317
        </lpage>
        <pub-id pub-id-type="pmid">
         18391097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0415">
       <label>
        83
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Shenoy
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases
        </article-title>
        <source>
         Exp Physiol
        </source>
        <volume>
         96
        </volume>
        <year>
         2011
        </year>
        <fpage>
         287
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="pmid">
         21148624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0420">
       <label>
        84
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fraga-Silva
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sorg
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
         <name>
          <surname>
           Wankhede
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 activation promotes antithrombotic activity
        </article-title>
        <source>
         Mol Med
        </source>
        <volume>
         16
        </volume>
        <year>
         2010
        </year>
        <fpage>
         210
        </fpage>
        <lpage>
         215
        </lpage>
        <pub-id pub-id-type="pmid">
         20111697
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0425">
       <label>
        85
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Shenoy
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Yamazato
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         179
        </volume>
        <year>
         2009
        </year>
        <fpage>
         1048
        </fpage>
        <lpage>
         1054
        </lpage>
        <pub-id pub-id-type="pmid">
         19246717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0430">
       <label>
        86
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gjymishka
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kulemina
          </surname>
          <given-names>
           L.V.
          </given-names>
         </name>
         <name>
          <surname>
           Shenoy
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diminazene aceturate is an ACE2 activator and a novel antihypertensive drug
        </article-title>
        <source>
         FASEB J
        </source>
        <volume>
         24
        </volume>
        <year>
         2010
        </year>
        <comment>
         1032.3 [abstract]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0435">
       <label>
        87
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
        </article-title>
        <source>
         Science
        </source>
        <volume>
         309
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1864
        </fpage>
        <lpage>
         1868
        </lpage>
        <pub-id pub-id-type="pmid">
         16166518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0440">
       <label>
        88
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Nakai-Murakami
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         105
        </volume>
        <year>
         2008
        </year>
        <fpage>
         7809
        </fpage>
        <lpage>
         7814
        </lpage>
        <pub-id pub-id-type="pmid">
         18490652
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0445">
       <label>
        89
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huentelman
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zubcevic
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hernandez Prada
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         44
        </volume>
        <year>
         2004
        </year>
        <fpage>
         903
        </fpage>
        <lpage>
         906
        </lpage>
        <pub-id pub-id-type="pmid">
         15492138
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0450">
       <label>
        90
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0455">
       <label>
        91
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glowacka
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Herzog
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         84
        </volume>
        <year>
         2010
        </year>
        <fpage>
         1198
        </fpage>
        <lpage>
         1205
        </lpage>
        <pub-id pub-id-type="pmid">
         19864379
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0460">
       <label>
        92
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Camargo
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Singer
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Makrides
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations
        </article-title>
        <source>
         Gastroenterology
        </source>
        <volume>
         136
        </volume>
        <year>
         2009
        </year>
        <fpage>
         872
        </fpage>
        <lpage>
         882
        </lpage>
        <pub-id pub-id-type="pmid">
         19185582
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0465">
       <label>
        93
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Castrop
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hocherl
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kurtz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Physiology of kidney renin
        </article-title>
        <source>
         Physiol Rev
        </source>
        <volume>
         90
        </volume>
        <year>
         2010
        </year>
        <fpage>
         607
        </fpage>
        <lpage>
         673
        </lpage>
        <pub-id pub-id-type="pmid">
         20393195
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0470">
       <label>
        94
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Danser
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Deinum
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Renin, prorenin and the putative (pro)renin receptor
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         46
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1069
        </fpage>
        <lpage>
         1076
        </lpage>
        <pub-id pub-id-type="pmid">
         16186442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0475">
       <label>
        95
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ichihara
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hayashi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kaneshiro
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin
        </article-title>
        <source>
         J Clin Invest
        </source>
        <volume>
         114
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1128
        </fpage>
        <lpage>
         1135
        </lpage>
        <pub-id pub-id-type="pmid">
         15489960
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0480">
       <label>
        96
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jan Danser
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Batenburg
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           van Esch
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prorenin and the (pro)renin receptor--an update
        </article-title>
        <source>
         Nephrol Dial Transplant
        </source>
        <volume>
         22
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1288
        </fpage>
        <lpage>
         1292
        </lpage>
        <pub-id pub-id-type="pmid">
         17259648
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0485">
       <label>
        97
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Delarue
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Burckle
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin
        </article-title>
        <source>
         J Clin Invest
        </source>
        <volume>
         109
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1417
        </fpage>
        <lpage>
         1427
        </lpage>
        <pub-id pub-id-type="pmid">
         12045255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0490">
       <label>
        98
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Batenburg
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Jan Danser
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The (pro)renin receptor: a new addition to the renin-angiotensin system?
        </article-title>
        <source>
         Eur J Pharmacol
        </source>
        <volume>
         585
        </volume>
        <year>
         2008
        </year>
        <fpage>
         320
        </fpage>
        <lpage>
         324
        </lpage>
        <pub-id pub-id-type="pmid">
         18417113
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0495">
       <label>
        99
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Hayakawa
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nakagawa
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human prorenin has “gate and handle” regions for its non-proteolytic activation
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         278
        </volume>
        <year>
         2003
        </year>
        <fpage>
         22217
        </fpage>
        <lpage>
         22222
        </lpage>
        <pub-id pub-id-type="pmid">
         12684512
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0500">
       <label>
        100
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nabi
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kageshima
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Uddin
          </surname>
          <given-names>
           M.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system
        </article-title>
        <source>
         Int J Mol Med
        </source>
        <volume>
         18
        </volume>
        <year>
         2006
        </year>
        <fpage>
         483
        </fpage>
        <lpage>
         488
        </lpage>
        <pub-id pub-id-type="pmid">
         16865234
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0505">
       <label>
        101
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Noble
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells
        </article-title>
        <source>
         Kidney Int
        </source>
        <volume>
         72
        </volume>
        <year>
         2007
        </year>
        <fpage>
         45
        </fpage>
        <lpage>
         52
        </lpage>
        <pub-id pub-id-type="pmid">
         17396111
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0510">
       <label>
        102
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wongamorntham
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kasting
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms
        </article-title>
        <source>
         Kidney Int
        </source>
        <volume>
         69
        </volume>
        <year>
         2006
        </year>
        <fpage>
         105
        </fpage>
        <lpage>
         113
        </lpage>
        <pub-id pub-id-type="pmid">
         16374430
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0515">
       <label>
        103
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saris
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hoen
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Garrelds
          </surname>
          <given-names>
           I.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         48
        </volume>
        <year>
         2006
        </year>
        <fpage>
         564
        </fpage>
        <lpage>
         571
        </lpage>
        <pub-id pub-id-type="pmid">
         16940215
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0520">
       <label>
        104
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ichihara
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Nakagawa
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice
        </article-title>
        <source>
         J Am Soc Nephrol
        </source>
        <volume>
         17
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1950
        </fpage>
        <lpage>
         1961
        </lpage>
        <pub-id pub-id-type="pmid">
         16738017
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0525">
       <label>
        105
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ichihara
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kaneshiro
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade
        </article-title>
        <source>
         J Am Soc Nephrol
        </source>
        <volume>
         18
        </volume>
        <year>
         2007
        </year>
        <fpage>
         2054
        </fpage>
        <lpage>
         2061
        </lpage>
        <pub-id pub-id-type="pmid">
         17538189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0530">
       <label>
        106
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ichihara
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kaneshiro
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Takemitsu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage
        </article-title>
        <source>
         J Am Soc Nephrol
        </source>
        <volume>
         17
        </volume>
        <year>
         2006
        </year>
        <fpage>
         2495
        </fpage>
        <lpage>
         2503
        </lpage>
        <pub-id pub-id-type="pmid">
         16885412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0535">
       <label>
        107
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ichihara
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kaneshiro
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Takemitsu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         47
        </volume>
        <year>
         2006
        </year>
        <fpage>
         894
        </fpage>
        <lpage>
         900
        </lpage>
        <pub-id pub-id-type="pmid">
         16585419
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0540">
       <label>
        108
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaneshiro
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ichihara
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sakoda
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats
        </article-title>
        <source>
         J Am Soc Nephrol
        </source>
        <volume>
         18
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1789
        </fpage>
        <lpage>
         1795
        </lpage>
        <pub-id pub-id-type="pmid">
         17494887
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0545">
       <label>
        109
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Batenburg
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Krop
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Garrelds
          </surname>
          <given-names>
           I.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor
        </article-title>
        <source>
         J Hypertens
        </source>
        <volume>
         25
        </volume>
        <year>
         2007
        </year>
        <fpage>
         2441
        </fpage>
        <lpage>
         2453
        </lpage>
        <pub-id pub-id-type="pmid">
         17984666
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0550">
       <label>
        110
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feldt
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Batenburg
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Mazak
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         51
        </volume>
        <year>
         2008
        </year>
        <fpage>
         682
        </fpage>
        <lpage>
         688
        </lpage>
        <pub-id pub-id-type="pmid">
         18212269
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0555">
       <label>
        111
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feldt
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Maschke
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Dechend
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling
        </article-title>
        <source>
         J Am Soc Nephrol
        </source>
        <volume>
         19
        </volume>
        <year>
         2008
        </year>
        <fpage>
         743
        </fpage>
        <lpage>
         748
        </lpage>
        <pub-id pub-id-type="pmid">
         18235083
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0560">
       <label>
        112
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           D.N.
          </given-names>
         </name>
         <name>
          <surname>
           Klanke
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Feldt
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         (Pro)renin receptor peptide inhibitor “handle-region” peptide does not affect hypertensive nephrosclerosis in Goldblatt rats
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         51
        </volume>
        <year>
         2008
        </year>
        <fpage>
         676
        </fpage>
        <lpage>
         681
        </lpage>
        <pub-id pub-id-type="pmid">
         18212268
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0565">
       <label>
        113
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tabassum
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aliskiren: a new renin inhibitor as anti-hypertensive
        </article-title>
        <source>
         J Appl Pharm Sci
        </source>
        <volume>
         1
        </volume>
        <year>
         2011
        </year>
        <fpage>
         30
        </fpage>
        <lpage>
         33
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0570">
       <label>
        114
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fogari
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zoppi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         New class of agents for treatment of hypertension: focus on direct renin inhibition
        </article-title>
        <source>
         Vasc Health Risk Manag
        </source>
        <volume>
         6
        </volume>
        <year>
         2010
        </year>
        <fpage>
         869
        </fpage>
        <lpage>
         882
        </lpage>
        <pub-id pub-id-type="pmid">
         20957132
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0575">
       <label>
        115
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sipahi
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Debanne
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Rowland
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
        </article-title>
        <source>
         Lancet Oncol
        </source>
        <volume>
         11
        </volume>
        <year>
         2010
        </year>
        <fpage>
         627
        </fpage>
        <lpage>
         636
        </lpage>
        <pub-id pub-id-type="pmid">
         20542468
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0580">
       <label>
        116
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schefe
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Neumann
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Goebel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren
        </article-title>
        <source>
         J Hypertens
        </source>
        <volume>
         26
        </volume>
        <year>
         2008
        </year>
        <fpage>
         1787
        </fpage>
        <lpage>
         1794
        </lpage>
        <pub-id pub-id-type="pmid">
         18698213
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0585">
       <label>
        117
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yusuf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Teo
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Pogue
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Telmisartan, ramipril, or both in patients at high risk for vascular events
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         358
        </volume>
        <year>
         2008
        </year>
        <fpage>
         1547
        </fpage>
        <lpage>
         1559
        </lpage>
        <pub-id pub-id-type="pmid">
         18378520
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0590">
       <label>
        118
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Phillips
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Plant food-derived Angiotensin I converting enzyme inhibitory peptides
        </article-title>
        <source>
         J Agric Food Chem
        </source>
        <volume>
         57
        </volume>
        <year>
         2009
        </year>
        <fpage>
         5113
        </fpage>
        <lpage>
         5120
        </lpage>
        <pub-id pub-id-type="pmid">
         19449887
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0595">
       <label>
        119
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Aluko
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Nakai
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural requirements of Angiotensin I-converting enzyme inhibitory peptides: quantitative structure-activity relationship study of di- and tripeptides
        </article-title>
        <source>
         J Agric Food Chem
        </source>
        <volume>
         54
        </volume>
        <year>
         2006
        </year>
        <fpage>
         732
        </fpage>
        <lpage>
         738
        </lpage>
        <pub-id pub-id-type="pmid">
         16448176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0600">
       <label>
        120
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Mierlo
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Koning
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           van der Zander
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lactotripeptides do not lower ambulatory blood pressure in untreated whites: results from 2 controlled multicenter crossover studies
        </article-title>
        <source>
         Am J Clin Nutr
        </source>
        <volume>
         89
        </volume>
        <year>
         2009
        </year>
        <fpage>
         617
        </fpage>
        <lpage>
         623
        </lpage>
        <pub-id pub-id-type="pmid">
         19106238
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0640">
       <label>
        121
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Aluko
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification and inhibitory properties of multifunctional peptides from PEA protein hydrolysate
        </article-title>
        <source>
         J Agric Food Chem
        </source>
        <volume>
         58
        </volume>
        <year>
         2010
        </year>
        <fpage>
         11471
        </fpage>
        <lpage>
         11476
        </lpage>
        <pub-id pub-id-type="pmid">
         20929253
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0610">
       <label>
        122
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tokiwano
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Hata
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The occurrence of renin inhibitor in rice: isolation, identification, and structure-function relationship
        </article-title>
        <source>
         Biosci Biotechnol Biochem
        </source>
        <volume>
         74
        </volume>
        <year>
         2010
        </year>
        <fpage>
         1713
        </fpage>
        <lpage>
         1715
        </lpage>
        <pub-id pub-id-type="pmid">
         20699562
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0615">
       <label>
        123
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tokiwano
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Renin inhibitory activity in rice and cereals
        </article-title>
        <source>
         J Biol Macromol
        </source>
        <volume>
         10
        </volume>
        <year>
         2010
        </year>
        <fpage>
         83
        </fpage>
        <lpage>
         91
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0620">
       <label>
        124
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hiwatashi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Shirakawa
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hori
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduction of blood pressure by soybean saponins, renin inhibitors from soybean, in spontaneously hypertensive rats
        </article-title>
        <source>
         Biosci Biotechnol Biochem
        </source>
        <volume>
         74
        </volume>
        <year>
         2010
        </year>
        <fpage>
         2310
        </fpage>
        <lpage>
         2312
        </lpage>
        <pub-id pub-id-type="pmid">
         21071835
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0625">
       <label>
        125
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hori
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Hokari
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of human renin activity by saponins
        </article-title>
        <source>
         Biomed Res
        </source>
        <volume>
         31
        </volume>
        <year>
         2010
        </year>
        <fpage>
         155
        </fpage>
        <lpage>
         159
        </lpage>
        <pub-id pub-id-type="pmid">
         20460744
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0630">
       <label>
        126
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hori
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kumagai
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human renin inhibitory activity in legumes
        </article-title>
        <source>
         J Biol Macromol
        </source>
        <volume>
         7
        </volume>
        <year>
         2007
        </year>
        <fpage>
         49
        </fpage>
        <lpage>
         54
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0635">
       <label>
        127
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hori
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Shinbo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of human renin inhibitor from soybean: soyasaponin I is the novel human renin inhibitor in soybean
        </article-title>
        <source>
         Biosci Biotechnol Biochem
        </source>
        <volume>
         72
        </volume>
        <year>
         2008
        </year>
        <fpage>
         3232
        </fpage>
        <lpage>
         3236
        </lpage>
        <pub-id pub-id-type="pmid">
         19060406
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       This work was supported partly by Fundamental Research Funds for the Central Universities (JUSRP211A06) and the Self-Determined Research Program of Jiangnan University (No. 5815210232110800 &amp; No. 5815210372100530).
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Diabetes Metab Syndr
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Diabetes Metab Syndr
      </journal-id>
      <journal-title-group>
       <journal-title>
        Diabetes &amp; Metabolic Syndrome
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1871-4021
      </issn>
      <issn pub-type="epub">
       1878-0334
      </issn>
      <publisher>
       <publisher-name>
        Diabetes India. Published by Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32283499
      </article-id>
      <article-id pub-id-type="pmc">
       7144598
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1871-4021(20)30056-4
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.dsx.2020.03.016
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Singh
         </surname>
         <given-names>
          Awadhesh Kumar
         </given-names>
        </name>
        <email>
         draksingh_2001@yahoo.com
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Gupta
         </surname>
         <given-names>
          Ritesh
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Misra
         </surname>
         <given-names>
          Anoop
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       G. D Hospital &amp; Diabetes Institute, Kolkata, India
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Fortis CDOC Hospital for Diabetes and Allied Sciences, New Delhi, India
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       Diabetes Foundation (India), New Delhi, India
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding author.
        <email>
         draksingh_2001@yahoo.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        9
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date iso-8601-date="2020-08-01" pub-type="ppub">
       <season>
        July-August
       </season>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        9
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       14
      </volume>
      <issue>
       4
      </issue>
      <fpage>
       283
      </fpage>
      <lpage>
       287
      </lpage>
      <history>
       <date date-type="received">
        <day>
         28
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         28
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Diabetes India
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <sec>
        <title>
         Background and aims
        </title>
        <p>
         COVID-19 is already a pandemic. Emerging data suggest an increased association and a heightened mortality in patients of COVID-19 with comorbidities. We aimed to evaluate the outcome in hypertensive patients with COVID-19 and its relation to the use of renin-angiotensin system blockers (RASB).
        </p>
       </sec>
       <sec>
        <title>
         Methods
        </title>
        <p>
         We have systematically searched the medical database up to March 27, 2020 and retrieved all the published articles in English language related to our topic using MeSH key words.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         From the pooled data of all ten available Chinese studies (n = 2209) that have reported the characteristics of comorbidities in patients with COVID-19, hypertension was present in nearly 21%, followed by diabetes in nearly 11%, and established cardiovascular disease (CVD) in approximately 7% of patients. Although the emerging data hints to an increase in mortality in COVID-19 patients with known hypertension, diabetes and CVD, it should be noted that it was not adjusted for multiple confounding factors. Harm or benefit in COVID-19 patients receiving RASB has not been typically assessed in these studies yet, although mechanistically and plausibly both, benefit and harm is possible with these agents, given that COVID-19 expresses to tissues through the receptor of angiotensin converting enzyme-2.
        </p>
       </sec>
       <sec>
        <title>
         Conclusion
        </title>
        <p>
         Special attention is definitely required in patients with COVID-19 with associated comorbidities including hypertension, diabetes and established CVD. Although the role of RASB has a mechanistic equipoise, patients with COVID-19 should not stop these drugs at this point of time, as recommended by various world organizations and without the advice of health care provider.
        </p>
       </sec>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0015">
       <title>
        Highlights
       </title>
       <p>
        <list id="ulist0010" list-type="simple">
         <list-item id="u0010">
          <label>
           •
          </label>
          <p id="p0010">
           There is a high prevalence of hypertension, diabetes and cardiovascular disease in patients with COVID-19.
          </p>
         </list-item>
         <list-item id="u0015">
          <label>
           •
          </label>
          <p id="p0015">
           There is an evidence of increased mortality with these comorbidities in patients with COVID-19, in an unadjusted analyses.
          </p>
         </list-item>
         <list-item id="u0020">
          <label>
           •
          </label>
          <p id="p0020">
           Although theoretically, there is a clinical equipoise on harm or benefit with renin angiotensin system blocker (RASB) in patients with COVID-19, there is not enough evidence to stop RASB in patients with COVID-19 at this moment.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Comorbidities
       </kwd>
       <kwd>
        Hypertension
       </kwd>
       <kwd>
        Angiotensin-converting enzyme inhibitors
       </kwd>
       <kwd>
        Angiotensin-receptor blockers
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0025">
      Coronavirus disease 2019 (COVID-19) has been declared as a pandemic by Word Health Organization on March 11, 2020, as soon as it satisfied the epidemiological criteria (infection in more than 100,000 people in 100 countries) [
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ]. As of March 27, 2020, world has witnessed more than half a million cases of COVID-19 with more than 24,000 deaths [
      <xref ref-type="bibr" rid="bib2">
       2
      </xref>
      ]. This suggests the magnitude of its spread across the world, since it was first reported on December 31, 2019 from Wuhan, Hubei province in China. Emerging data suggests that older COVID-19 patients with other comorbid conditions such as diabetes, hypertension, cardiac and pulmonary disease are in particular more susceptible, compared to general populations and have higher mortality. Therefore, it is necessary to re-look into these subgroups of COVID-19 patients with associated co-morbidities.
     </p>
     <p id="p0030">
      In this review article, we have collated all the available evidence that has emerged so far on outcomes and comorbidities in patients with COVID-19. Here, we have focused on outcomes in patients of COVID-19 with hypertension and analyzed the controversies surrounding the use of renin-angiotensin system blockers (RASB).
     </p>
    </sec>
    <sec id="sec2">
     <label>
      2
     </label>
     <title>
      Methods
     </title>
     <p id="p0035">
      We have systematically searched the PubMed medical database up till March 27, 2020 using MeSH key words that include Covid-19, coronavirus, hypertension, diabetes, cardiovascular disease, angiotensin receptor blockers, angiotensin converting enzyme inhibitors. We have retrieved all the available literature published in English language on COVID-19, that reported the outcomes in different co-morbidities.
     </p>
    </sec>
    <sec id="sec3">
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <sec id="sec3.1">
      <label>
       3.1
      </label>
      <title>
       Hypertension as a significant comorbidity with COVID-19
      </title>
      <p id="p0040">
       The association of hypertension and diabetes in patients with COVID-19 is not unexpected, given the rising prevalence of both of these chronic diseases, globally. Interestingly, in the pooled data from the ten Chinese studies (n = 2209) that have reported the characteristics of comorbidities in patients with COVID-19; associations of hypertension, diabetes and presence of established cardiovascular disease (CVD) are larger, varying from 15 to 30% (average 21%), 5–20% (average 11%) and 2–40% (average 7%) respectively (
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ). Established CVD was also present in nearly 43% in Italian study of 355 patients with COVID-19. Table summarizes the prevalence of these comorbidities in all available studies to-date in patients with COVID-19 [
       <xref ref-type="bibr" rid="bib3">
        [3]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib4">
        [4]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib5">
        [5]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib6">
        [6]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib7">
        [7]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib8">
        [8]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib9">
        [9]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib10">
        [10]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib11">
        [11]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib12">
        [12]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib13">
        [13]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib14">
        [14]
       </xref>
       ].
       <table-wrap id="tbl1" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Hypertension, diabetes and other co-morbidities in COVID-19, world-wide data.
         </p>
        </caption>
        <alt-text id="alttext0010">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            First author
           </th>
           <th>
            n
           </th>
           <th>
            Smokers,
            <break>
            </break>
            %
           </th>
           <th>
            HTN, %
           </th>
           <th>
            Diabetes, %
           </th>
           <th>
            CVD, %
           </th>
           <th>
            COPD, %
           </th>
           <th>
            CKD, %
           </th>
           <th>
            CLD,
            <break>
            </break>
            %
           </th>
           <th>
            Ref.
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left" colspan="10">
            COVID-19 in China
           </td>
          </tr>
          <tr>
           <td align="left">
            Liu et al.
           </td>
           <td align="left">
            61
           </td>
           <td align="left">
            6.6
           </td>
           <td align="left">
            19.7
           </td>
           <td align="left">
            8.2
           </td>
           <td align="left">
            1.6
           </td>
           <td align="left">
            8.2
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            <italic>
             3
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left">
            Guan et al.
           </td>
           <td align="left">
            1099
           </td>
           <td align="left">
            12.6
           </td>
           <td align="left">
            15.0
           </td>
           <td align="left">
            7.4
           </td>
           <td align="left">
            3.8
           </td>
           <td align="left">
            1.1
           </td>
           <td align="left">
            0.7
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            <italic>
             4
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left">
            Huang et al.
           </td>
           <td align="left">
            41
           </td>
           <td align="left">
            7.3
           </td>
           <td align="left">
            14.6
           </td>
           <td align="left">
            19.5
           </td>
           <td align="left">
            15.0
           </td>
           <td align="left">
            2.4
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            2.4
           </td>
           <td align="left">
            <italic>
             5
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left">
            Chen et al.
           </td>
           <td align="left">
            99
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            12.1
           </td>
           <td align="left">
            40.0
           </td>
           <td align="left">
            1.0
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            <italic>
             6
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left">
            Wang et al.
           </td>
           <td align="left">
            138
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            31.2
           </td>
           <td align="left">
            10.1
           </td>
           <td align="left">
            19.6
           </td>
           <td align="left">
            2.9
           </td>
           <td align="left">
            2.9
           </td>
           <td align="left">
            2.9
           </td>
           <td align="left">
            <italic>
             7
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left">
            Zhou et al.
           </td>
           <td align="left">
            191
           </td>
           <td align="left">
            6.0
           </td>
           <td align="left">
            30
           </td>
           <td align="left">
            19
           </td>
           <td align="left">
            8.0
            <sup>
             #
            </sup>
           </td>
           <td align="left">
            3.0
           </td>
           <td align="left">
            1.0
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            <italic>
             8
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left">
            Zhang et al.
           </td>
           <td align="left">
            140
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            30
           </td>
           <td align="left">
            12.1
           </td>
           <td align="left">
            8.6
           </td>
           <td align="left">
            1.4
           </td>
           <td align="left">
            1.4
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            <italic>
             9
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left">
            Yang et al.
           </td>
           <td align="left">
            52
           </td>
           <td align="left">
            4.0
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            17.0
           </td>
           <td align="left">
            23.0
           </td>
           <td align="left">
            8.0
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            <italic>
             10
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left">
            Wu et al.
           </td>
           <td align="left">
            201
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            19.4
           </td>
           <td align="left">
            10.9
           </td>
           <td align="left">
            4.0
           </td>
           <td align="left">
            2.5
           </td>
           <td align="left">
            1.0
           </td>
           <td align="left">
            3.5
           </td>
           <td align="left">
            <italic>
             11
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left">
            Guo et al.
           </td>
           <td align="left">
            187
           </td>
           <td align="left">
            9.6
           </td>
           <td align="left">
            32.6
           </td>
           <td align="left">
            15.0
           </td>
           <td align="left">
            11.2
            <sup>
             #
            </sup>
           </td>
           <td align="left">
            2.1
           </td>
           <td align="left">
            3.2
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            <italic>
             14
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left" colspan="2">
            <bold>
             <italic>
              Overall, China,
             </italic>
            </bold>
            <break>
            </break>
            <bold>
             N
            </bold>
            =
            <bold>
             2209
            </bold>
           </td>
           <td align="left">
            <bold>
             10.7%
            </bold>
           </td>
           <td align="left">
            <bold>
             20.7%
            </bold>
           </td>
           <td align="left">
            <bold>
             10.5%
            </bold>
           </td>
           <td align="left">
            <bold>
             7.4%
            </bold>
           </td>
           <td align="left">
            <bold>
             2.0%
            </bold>
           </td>
           <td align="left">
            <bold>
             1.2%
            </bold>
           </td>
           <td align="left" colspan="2">
            <bold>
             3.2%
            </bold>
           </td>
          </tr>
          <tr>
           <td align="left" colspan="10">
            <bold>
             <italic>
              COVID-19 in Italy
             </italic>
            </bold>
           </td>
          </tr>
          <tr>
           <td align="left">
            Onder et al.
           </td>
           <td align="left">
            355
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            35.5
           </td>
           <td align="left">
            42.5
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            <italic>
             12
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left" colspan="10">
            <bold>
             <italic>
              COVID-19 in Singapore
             </italic>
            </bold>
           </td>
          </tr>
          <tr>
           <td align="left">
            Young et al.
           </td>
           <td align="left">
            18
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            <italic>
             13
            </italic>
           </td>
          </tr>
          <tr>
           <td align="left" colspan="10">
            # reported coronary heart disease only, HTN- hypertension, CVD- cardiovascular disease, COPD- chronic obstructive pulmonary disease, CKD- chronic kidney disease, CLD- chronic liver disease, NR- not reported, Ref.- references
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec3.2">
      <label>
       3.2
      </label>
      <title>
       Hypertension as a prognostic indicator for severity and mortality in COVID-19
      </title>
      <p id="p0050">
       While consistent association of hypertension in patients with COVID-19 across all these studies is unique, the concern which needs a serious attention is the increase in mortality. Two Chinese studies have worked in this direction to-date. In 191 patients with COVID-19, Zhou et al. found hypertension to have an odds ratio (OR) of 3.05 (95% CI, 1.57 to 5.92; p &lt; 0.006), diabetes with OR of 2.85 (95% CI, 1.35 to 6.05; p &lt; 0.001), whereas presence of coronary artery disease had an OR of 21.40 (95% CI, 4.64 to 98.76; p &lt; 0.0001) for in-hospital mortality, in an univariate analysis [
       <xref ref-type="bibr" rid="bib8">
        8
       </xref>
       ]. However, the association between these disorders and COVID-19 mortality were no longer significant after a multivariate regression analysis. Similarly, in an analysis of 201 patients with COVID-19, Wu et al. found hypertension to have a hazard ratio (HR) of 1.82 (95% CI, 1.13 to 2.95; p = 0.01) for acute respiratory distress syndrome (ARDS) and 1.70 (95% CI, 0.92 to 3.14, p = 0.09) for death. The diabetic patients had a HR of 2.34 (95% CI, 1.35 to 4.05; p = 0.002) for ARDS and HR of 1.58 (95% CI, 0.80 to 3.13, p = 0.19) for death, in a bivariate cox regression analysis [
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ]. It should be noted however, that neither of these studies were adjusted for all confounding variables. Nevertheless, a study of 187 patients with COVID-19, Guo et al. reported nearly a twice increase in mortality in patients with established CVD and raised troponin T (TnT), compared to patients without CVD and raised TnT (69.4% vs. 37.5% respectively) [
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ].
      </p>
      <p id="p0055">
       The Chinese Center for Disease Control and Prevention in a summary report of COVID-19, reported a case fatality rate (CFR) of 2.3% (1023 deaths among 44,672 confirmed cases). However, CFR was elevated to 6.0% for hypertension, 7.3% for diabetes, and 10.5% for presence of CVD [
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       ]. Unsurprisingly, based on the above findings, researchers have recently proposed that the course of treatment and prognosis of COVID-19 should be stratified based on the absence or presence of co-morbidities in to type A, B and C. Type A denotes COVID-19 patients with pneumonia but without comorbidities, Type B denotes COVID-19 pneumonia and comorbidities, whereas, Type C denotes COVID-19 patients with multi-organ dysfunction [
       <xref ref-type="bibr" rid="bib16">
        16
       </xref>
       ].
      </p>
      <p id="p0060">
       Nonetheless, it still remains unclear whether these increased association of hypertension with COVID-19 and heightened risk of mortality is directly related to hypertension or other associated comorbidities, or, anti-hypertensive treatment. There has been a growing concern that this association with hypertension and or CVD may be confounded by the treatment with certain antihypertensive medications such as RASB. Although a recent paper has proposed to stop RASB and suggested to replace it with the calcium channel blocker, while treating hypertension in patients with COVID-19 [
       <xref ref-type="bibr" rid="bib17">
        17
       </xref>
       ], this hypothesis has been questioned by several other colleagues [
       <xref ref-type="bibr" rid="bib18">
        [18]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib19">
        [19]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib20">
        [20]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib21">
        [21]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        [22]
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec3.3">
      <label>
       3.3
      </label>
      <title>
       Role of renin angiotensin system and its inhibitors in SARS CoV2 infection
      </title>
      <p id="p0065">
       The entry of coronavirus into the cell is facilitated by the spike (S) protein. Before attachment to the receptor on host cell, the S protein needs to be primed by a serine protease named TMPRSS2. The S proteins of different coronaviruses may utilise different receptors; MERS utilises CD26 while SARS CoV and SARS CoV2 utilise Angiotensin Converting Enzyme-2 (ACE-2) [
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
       ]. The efficiency of the interaction between S-protein and ACE-2 may be a key determinant of the transmissibility of the virus, viral replication and the severity of disease. In theory, this efficiency could be influenced by changes or amino acid substitutions in either the viral S-protein or the ACE-2 receptor on host cell.
       <list id="olist0010" list-type="simple">
        <list-item id="o0010">
         <label>
          a)
         </label>
         <p id="p0070">
          <italic>
           Changes in S-protein
          </italic>
          : Molecular studies and the elucidation of the atomic and crystal structure of ACE-2/S protein interface of SARS CoV have provided important insights [
          <xref ref-type="bibr" rid="bib24">
           24
          </xref>
          ]. The major outbreak of SARS CoV occurred in 2002–2003 with a minor localised outbreak with mild symptoms in 2003–2004. It was observed that the S-protein of SARS CoV in the 2002–2003 outbreak bound to ACE-2 receptor much more efficiently than that of SARS CoV in the 2003–2004 outbreak, consistent with the absence of human-to-human transmission during the latter outbreak. Several molecular changes in the S-protein influence the binding with human ACE-2; for example, the substitution of threonine by serine at position 487 in S protein reduces the binding [
          <xref ref-type="bibr" rid="bib25">
           25
          </xref>
          ]. Similarly, asparagine at position 479 increased the binding affinity [
          <xref ref-type="bibr" rid="bib26">
           26
          </xref>
          ]. Methylation at position 487 has also been shown to influence binding. Recently, S-protein of SARS CoV2 has been shown to be similar to that of SARS CoV, barring a few gains of function mutations. The most important of these is a glutamine at position 493 at the receptor binding domain, which explains its increased transmissibility compared to SARS CoV [
          <xref ref-type="bibr" rid="bib27">
           27
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0015">
         <label>
          b)
         </label>
         <p id="p0075">
          <italic>
           Changes in ACE-2 Receptor
          </italic>
          : With regard to MERS-CoV, which employs CD26 (DPP-4) as its receptor for cellular entry, there are naturally-occurring polymorphisms in DPP4 that impact cellular entry of MERS-CoV and might thus modulate MERS development in infected patients [
          <xref ref-type="bibr" rid="bib28">
           28
          </xref>
          ]. There is a possibility that similar variations or polymorphisms in ACE-2 could affect the viral entry and disease course. Polymorphisms of ACE-2 gene have been identified; however, there is no evidence that they affect susceptibility to or severity of SARS CoV2 infection [
          <xref ref-type="bibr" rid="bib29">
           29
          </xref>
          ]. A recent study found differential ACE-2 gene expression in human lung tissue with no racial/gender differences, but a higher gene expression in lungs of smokers compared to non-smokers, which could explain the higher risk of infection in smokers [
          <xref ref-type="bibr" rid="bib30">
           30
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="sec3.4">
      <label>
       3.4
      </label>
      <title>
       Physiological role of ACE-2 and its relationship with coronavirus infection
      </title>
      <p id="p0080">
       The role of ACE-2 on vascular bed is opposite to that of angiotensin converting enzyme (ACE). ACE converts angiotensin I to angiotensin II, which is a vasoconstrictor. ACE-2 converts angiotensin II to angiotensin (1–7) which causes vasodilatation after binding to the Mas receptor in the vascular bed [
       <xref ref-type="bibr" rid="bib31">
        31
       </xref>
       ]. Downregulation of ACE-2 was observed in animal models of lung injury induced by SARS CoV [
       <xref ref-type="bibr" rid="bib32">
        32
       </xref>
       ]. Recombinant ACE-2 improved pulmonary blood flow and oxygenation in animals with lung injury, indicating that ACE-2 may be the main determinant of lung injury caused by SARS CoV [
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
       ]. However, there is lack of human data except a small study in 10 patients with acute respiratory distress syndrome which showed that recombinant ACE-2 was well tolerated and led to an increase in angiotensin (1–7) [
       <xref ref-type="bibr" rid="bib34">
        34
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec3.5">
      <label>
       3.5
      </label>
      <title>
       Effects of ACE inhibitors and angiotensin receptor blockers
      </title>
      <p id="p0085">
       There has been considerable interest regarding the role of RAS blockers in COVID-19 infection. Both benefit and harm have been postulated. Figure 1 illustrates the interactions between the effect of RASB and COVID-19.
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       <list id="olist0015" list-type="simple">
        <list-item id="o0020">
         <label>
          a)
         </label>
         <p id="p0090">
          <italic>
           Rationale and Evidence for Harm
          </italic>
          : There is evidence that ACE-2 expression increases with the use of ACE inhibitors and ARB, especially in heart and kidney [
          <xref ref-type="bibr" rid="bib35">
           35
          </xref>
          ,
          <xref ref-type="bibr" rid="bib36">
           36
          </xref>
          ]. This has raised a theoretical concern that by increasing ACE-2 expression, ACEIs and ARBs could facilitate the entry of virus into the host cell and increase the chances of infection or its severity [
          <xref ref-type="bibr" rid="bib17">
           17
          </xref>
          ]. Also, there is increased ACE-2 expression in elderly [
          <xref ref-type="bibr" rid="bib37">
           37
          </xref>
          ]. To what extent this predisposes the elderly to infection with SARSCoV2 is not known. In a study of 187 patients with COVID-19, Guo et al. reported an increased trend in mortality with those receiving RASB, compared to those not receiving. Mortality was 36.8% (6 of 19) and 25.6% (43 of 168) in patients with or without RASB, respectively [
          <xref ref-type="bibr" rid="bib14">
           14
          </xref>
          ]. Indeed, increased association and heightened mortality with COVID-19 have been observed consistently across the studies in elderly, hypertensive, diabetics and known CVD; however, it is not exactly known whether it has any causal relation with the use of RASB or these subgroups are more on RASB due to these illness, compared to the rest of population. Moreover, there is no solid evidence to back this concern either in COVID-19 or in infection by other coronaviruses.
         </p>
        </list-item>
        <list-item id="o0025">
         <label>
          b)
         </label>
         <p id="p0095">
          <italic>
           Rationale and Evidence for Benefit
          </italic>
          : As discussed above, increasing ACE-2 levels in coronavirus infection could reduce lung injury. In an experimental study with mice, Kuba et al. found that losartan showed significantly diminished lung injury and pulmonary edema after acid aspiration-induced acute lung injury (with addition of SARS-CoV spike protein) compared to placebo [
          <xref ref-type="bibr" rid="bib32">
           32
          </xref>
          ]. Similarly, severe lung injury and pulmonary edema were prevented by both recombinant human ACE-2 infusions or losartan in ACE2-knockout mice [
          <xref ref-type="bibr" rid="bib38">
           38
          </xref>
          ]. Mice with coronavirus induced lung injury showed improvement when treated with losartan [
          <xref ref-type="bibr" rid="bib39">
           39
          </xref>
          ]. Moreover, a retrospective analysis found reduced rates of death and endotracheal intubation in patients with viral pneumonia who were continued on ACE inhibitors [
          <xref ref-type="bibr" rid="bib40">
           40
          </xref>
          ]. Treatment with ARBs was reported to reduce mortality in Ebola virus infection [
          <xref ref-type="bibr" rid="bib41">
           41
          </xref>
          ]. The exact mechanism of apparent benefit of these drugs in coronavirus infection is not yet clear. However, there could be several explanations [
          <xref ref-type="bibr" rid="bib42">
           42
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0030">
         <label>
          i.
         </label>
         <p id="p0100">
          Increased ACE-2 expression may not result in more viral entry into the cell because of the limited availability of the serine protease TMPRSS2. Camostat mesylate, which is a TMPRSS2 inhibitor, has been shown to inhibit cellular entry of SARS CoV2 and could be a potential therapeutic option [
          <xref ref-type="bibr" rid="bib43">
           43
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0035">
         <label>
          ii.
         </label>
         <p id="p0105">
          Increased ACE-2 expression on the cell membrane may also lead to increased soluble ACE-2 in blood, which may actually bind to most of SARS CoV2 and prevent its interaction with the membrane bound receptor.
         </p>
        </list-item>
        <list-item id="o0040">
         <label>
          iii.
         </label>
         <p id="p0110">
          RAS blockers increase angiotensin II, which is a substrate for ACE-2. The interaction of ACE-2 with angiotensin II could induce a conformational change in the receptor binding domain of ACE-2, limiting its ability to bind with SARS CoV2 [
          <xref ref-type="bibr" rid="bib44">
           44
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0045">
         <label>
          iv.
         </label>
         <p id="p0115">
          ACE-2 receptors are present at a much higher density in lung tissue of children and young adults, compared to older individuals. Thus, the upregulation of ACE-2 receptors by the use of RASB over time in older people may emulate ACE expression in young people. It is also possible that having more ACE-2 receptors and increased ACE-2 functions will likely produce more angiotensin (1–7) that might provide resilience against target-mediated destruction and development of pulmonary failure in patients with COVID-19 [
          <xref ref-type="bibr" rid="bib22">
           22
          </xref>
          ]. This postulated positive effects on lung can be also protective during overwhelming infection with COVID-19.
         </p>
        </list-item>
        <list-item id="o0050">
         <label>
          v.
         </label>
         <p id="p0120">
          Indiscriminate discontinuation of RASB in patients with heart failure may also lead to readmission to hospital and increase in mortality [
          <xref ref-type="bibr" rid="bib45">
           45
          </xref>
          ].
         </p>
        </list-item>
       </list>
       <fig id="fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Components of Renin-Angiotensin System pathway and possible interaction of Angiotensin Converting Enzyme inhibitors (ACE-I), Angiotensin-Receptor Blockers (ARB) and COVID-19.
         </p>
        </caption>
        <alt-text id="alttext0010a">
         Fig. 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0125">
       Collectively, relationship between RAS activity and use of RASB in SARS CoV2 infection is very scarce. The only indirect evidence of RAS activation in COVID-19 is high incidence of hypokalaemia [
       <xref ref-type="bibr" rid="bib46">
        46
       </xref>
       ]. With regards to the use of RASB, a retrospective analysis of 112 COVID-19 hospitalised patients with cardiovascular disease in Wuhan, there was no significant difference in the proportion of ACEI/ARB medication between non-survivors and survivors [
       <xref ref-type="bibr" rid="bib47">
        47
       </xref>
       ]. However, a study of 187 patient reported by Guo et al., there was a trend of increase in mortality in patients with COVID-19 receiving RASB (36.8%), compared to those not receiving (25.6%) [
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec4">
     <label>
      4
     </label>
     <title>
      Conclusion
     </title>
     <p id="p0130">
      COVID-19 is increasingly associated with comorbidities that include hypertension and diabetes. Special care is required in patients with COVID-19 with associated comorbidities, given the heightened risk of in-hospital death.
     </p>
     <p id="p0135">
      In view of lack of robust evidence for either benefit or harm, and with bulk of the experimental evidence in favour of benefit, it is reasonable for patients to continue using ACE inhibitors and ARB, as recommended by the European Society of Cardiology, Hypertension Canada, The Canadian Cardiovascular Society, UK Renal Association, the International Society of Hypertension, and European Society of Hypertension and American Heart Association [
      <xref ref-type="bibr" rid="bib48">
       [48]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib49">
       [49]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib50">
       [50]
      </xref>
      ]. Future studies reporting the outcome stratified on the basis of different anti-hypertensive agents in COVID-19 may further enlighten us in this regard.
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of competing interest
     </title>
     <p id="p0140">
      We hereby declare that we have no conflict of interest related to this article.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Callaway
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Time to use the p-word? Coronavirus enter dangerous new phase
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         579
        </volume>
        <year>
         2020
        </year>
        <fpage>
         12
        </fpage>
        <pub-id pub-id-type="pmid">
         32132700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="other">
        <article-title>
         WHO
        </article-title>
        <ext-link ext-link-type="uri" id="intref0010" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200326-sitrep-66-covid-19.pdf?sfvrsn=81b94e61_2">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200326-sitrep-66-covid-19.pdf?sfvrsn=81b94e61_2
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Pu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage
        </article-title>
        <ext-link ext-link-type="uri" id="intref0015" xlink:href="https://www.medrxiv.org/content/10.1101/2020.02.10.20021584v1">
         https://www.medrxiv.org/content/10.1101/2020.02.10.20021584v1
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of coronavirus disease 2019 in China
        </article-title>
        <ext-link ext-link-type="uri" id="intref0020" xlink:href="https://www.nejm.org/doi/full/10.1056/NEJMoa2002032">
         https://www.nejm.org/doi/full/10.1056/NEJMoa2002032
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in wuhan, China
        </article-title>
        <source>
         J Am Med Assoc
        </source>
        <volume>
         323
        </volume>
        <issue>
         11
        </issue>
        <year>
         2020
        </year>
        <fpage>
         1061
        </fpage>
        <lpage>
         1069
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
        </article-title>
        <source>
         Published Online March
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.D.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.B.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           Y.Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China
        </article-title>
        <source>
         Allergy
        </source>
        <year>
         2020 Feb 19
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <comment>
         Published Online February 21, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <mixed-citation id="sref11" publication-type="other">
        Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994 (Accessed on March 27, 2020).
       </mixed-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Onder
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Rezza
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Brusaferro
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
        </article-title>
        <source>
         J Am Med Assoc
        </source>
        <year>
         2020 Mar 23
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <mixed-citation id="sref13" publication-type="other">
        Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. J Am Med Assoc. doi:10.1001/jama.2020.3204. Published online March 3, 2020.
       </mixed-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <mixed-citation id="sref14" publication-type="other">
        Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. doi:10.1001/jamacardio.2020.1017. Published online March 27, 2020.
       </mixed-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease Control and prevention
        </article-title>
        <source>
         J Am Med Assoc
        </source>
        <year>
         2020 Feb 24
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <mixed-citation id="sref16" publication-type="other">
        Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B. Comorbidities and multi-organ injuries in the treatment of COVID-19. Published Online March 9, 2020. HYPERLINK "
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30558-4
        </pub-id>
        " (Accessed on March 27, 2020).
       </mixed-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Karakiulakis
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 11
        </comment>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
         <name>
          <surname>
           Verma
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. What is the evidence?
        </article-title>
        <source>
         JAMA. Published online March
        </source>
        <volume>
         24
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tiganelli
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ingraham
          </surname>
          <given-names>
           N.E.
          </given-names>
         </name>
         <name>
          <surname>
           Sparks
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Benson
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Schacker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chipman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Puskarich
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antihypertensive drugs and risk of COVID-19?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <comment>
         Published Online March 26, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antihypertensive drugs and risk of COVID-19?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <comment>
         Published Online March 26, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sref21" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lo
          </surname>
          <given-names>
           K.B.
          </given-names>
         </name>
         <name>
          <surname>
           Mc Cullogh
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rangaswami
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antihypertensive drugs and risk of COVID-19?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <comment>
         Published Online March 26, 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gurwitz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics
        </article-title>
        <source>
         Drug Dev Res
        </source>
        <year>
         2020
        </year>
        <comment>
         published online March 4
        </comment>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kleine-Weber
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Krüger
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
        </article-title>
        <source>
         bioRxiv
        </source>
        <year>
         2020
        </year>
        <fpage>
         2020
        </fpage>
        <comment>
         01.31.929042
        </comment>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
        </article-title>
        <source>
         Science
        </source>
        <volume>
         309
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1864
        </fpage>
        <lpage>
         1868
        </lpage>
        <pub-id pub-id-type="pmid">
         16166518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2
        </article-title>
        <source>
         EMBO J
        </source>
        <volume>
         24
        </volume>
        <issue>
         8
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1634
        </fpage>
        <lpage>
         1643
        </lpage>
        <pub-id pub-id-type="pmid">
         15791205
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Nan
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Pei
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reconstruction of the most recent common ancestor sequences of SARS-Cov S gene and detection of adaptive evolution in the spike protein
        </article-title>
        <source>
         Chin Sci Bull
        </source>
        <volume>
         49
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1311
        </fpage>
        <lpage>
         1313
        </lpage>
        <pub-id pub-id-type="pmid">
         32214711
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         94
        </volume>
        <issue>
         7
        </issue>
        <year>
         2020 Mar 17
        </year>
        <comment>
         e00127-20
        </comment>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kleine-Weber
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Schroeder
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Krüger
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg Microb Infect
        </source>
        <volume>
         9
        </volume>
        <issue>
         1
        </issue>
        <year>
         2020 Jan 21
        </year>
        <fpage>
         155
        </fpage>
        <lpage>
         168
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China
        </article-title>
        <source>
         Lipids Health Dis
        </source>
        <volume>
         17
        </volume>
        <issue>
         1
        </issue>
        <year>
         2018 Oct 20
        </year>
        <fpage>
         241
        </fpage>
        <pub-id pub-id-type="pmid">
         30342552
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov
        </article-title>
        <source>
         Preprints
        </source>
        <year>
         2020
        </year>
        <comment>
         2020020051
        </comment>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lessons from SARS: a new potential therapy for acute respiratory distress syndrome (ARDS) with angiotensin converting enzyme 2 (ACE2)
        </article-title>
        <source>
         Masui
        </source>
        <volume>
         57
        </volume>
        <issue>
         3
        </issue>
        <year>
         2008
        </year>
        <fpage>
         302
        </fpage>
        <lpage>
         310
        </lpage>
        <pub-id pub-id-type="pmid">
         18340998
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         11
        </volume>
        <issue>
         8
        </issue>
        <year>
         2005
        </year>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reml
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Neu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Kleinsasser
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         38
        </volume>
        <issue>
         2
        </issue>
        <year>
         2010 Feb
        </year>
        <fpage>
         596
        </fpage>
        <lpage>
         601
        </lpage>
        <pub-id pub-id-type="pmid">
         19851091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Benthin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zeno
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pilot clinical trial of recombinant human angiotensin converting enzyme 2 in acute respiratory distress syndrome
        </article-title>
        <source>
         Crit Care
        </source>
        <volume>
         21
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <fpage>
         234
        </fpage>
        <pub-id pub-id-type="pmid">
         28877748
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhuo
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The vasoprotective axes of the renin-angiotensin system:physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases
        </article-title>
        <source>
         Pharmacol Res
        </source>
        <volume>
         125
        </volume>
        <year>
         2017
        </year>
        <fpage>
         21
        </fpage>
        <lpage>
         38
        </lpage>
        <pub-id pub-id-type="pmid">
         28619367
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Jessup
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         111
        </volume>
        <issue>
         20
        </issue>
        <year>
         2005 May
        </year>
        <fpage>
         2605
        </fpage>
        <lpage>
         2610
        </lpage>
        <pub-id pub-id-type="pmid">
         15897343
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sref37" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bukowska
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Spiller
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wolke
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men
        </article-title>
        <source>
         Exp Biol Med
        </source>
        <volume>
         242
        </volume>
        <issue>
         14
        </issue>
        <year>
         2017
        </year>
        <fpage>
         1412
        </fpage>
        <lpage>
         1423
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 protects from severe acute lung failure
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         436
        </volume>
        <year>
         2005
        </year>
        <fpage>
         112
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="pmid">
         16001071
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sref39" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury
        </article-title>
        <source>
         Sci Rep
        </source>
        <volume>
         4
        </volume>
        <year>
         2014
        </year>
        <fpage>
         7027
        </fpage>
        <pub-id pub-id-type="pmid">
         25391767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Henry
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zaizafoun
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Ghamande
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Arroliga
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           White
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia
        </article-title>
        <source>
         SAVE Proc
        </source>
        <volume>
         31
        </volume>
        <issue>
         4
        </issue>
        <year>
         2018
        </year>
        <fpage>
         419
        </fpage>
        <lpage>
         423
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fedson
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jacobson
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rordam
          </surname>
          <given-names>
           O.M.
          </given-names>
         </name>
         <name>
          <surname>
           Opal
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers
        </article-title>
        <source>
         mBio
        </source>
        <volume>
         6
        </volume>
        <issue>
         3
        </issue>
        <year>
         2015 Jun 23
        </year>
        <object-id pub-id-type="publisher-id">
         e00716
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sref42" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perico
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Benigni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Remuzzi
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade
        </article-title>
        <source>
         Nephron
        </source>
        <year>
         2020 Mar 23
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         9
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kleine-Weber
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Schroeder
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
        </article-title>
        <source>
         Cell
        </source>
        <year>
         2020 Mar 4
        </year>
        <comment>
         S0092-8674(20)30229-4
        </comment>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Towler
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Staker
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Prasad
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         279
        </volume>
        <issue>
         17
        </issue>
        <year>
         2004 Apr
        </year>
        <fpage>
         17996
        </fpage>
        <lpage>
         18007
        </lpage>
        <pub-id pub-id-type="pmid">
         14754895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oliveros
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Oni
          </surname>
          <given-names>
           E.T.
          </given-names>
         </name>
         <name>
          <surname>
           Shahzad
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Benefits and risks of continuing angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and mineralocorticoid receptor antagonists during hospitalizations for acute heart failure
        </article-title>
        <source>
         Cardiorenal Med
        </source>
        <volume>
         10
        </volume>
        <year>
         2020
        </year>
        <fpage>
         69
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         32062648
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <mixed-citation id="sref46" publication-type="other">
        Chen D, Li X, Song Q, Hu C, Su F, DaiJ, Ye Y, HuangJ, Zhang X. Hypokalemia and Clinical Implications in Patients with CoronavirusDisease 2019 (COVID-19). medRxiv preprint doi:
        <pub-id pub-id-type="doi">
         10.1101/2020.02.27.20028530
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation id="sref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           Y.D.
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           H.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Leng
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           R.R.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           B.Y.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           L.X.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           Q.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV
        </article-title>
        <source>
         Zhonghua Xinxueguanbing Zazhi
        </source>
        <volume>
         48
        </volume>
        <year>
         2020 Mar 2
        </year>
        <fpage>
         E004
        </fpage>
        <comment>
         0
        </comment>
        <pub-id pub-id-type="pmid">
         32120458
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation id="sref48" publication-type="other">
        <article-title>
         Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers
        </article-title>
        <comment>
         Mar 11 2020
        </comment>
        <ext-link ext-link-type="uri" id="intref0035" xlink:href="https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang">
         https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation id="sref49" publication-type="other">
        <article-title>
         ESH statement on COVID-19
        </article-title>
        <comment>
         March 12
        </comment>
        <ext-link ext-link-type="uri" id="intref0040" xlink:href="https://www.eshonline.org/spotlights/esh-statement-on-covid-19/">
         https://www.eshonline.org/spotlights/esh-statement-on-covid-19/
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation id="sref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Y.P.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           G.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibitors of RAS might Be a good choice for the therapy of COVID-19 pneumonia
        </article-title>
        <source>
         Zhonghua Jiehe He Huxi Zazhi
        </source>
        <volume>
         43
        </volume>
        <issue>
         3
        </issue>
        <year>
         2020 Mar 12
        </year>
        <fpage>
         219
        </fpage>
        <lpage>
         222
        </lpage>
        <pub-id pub-id-type="pmid">
         32164092
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Cancers (Basel)
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Cancers (Basel)
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       cancers
      </journal-id>
      <journal-title-group>
       <journal-title>
        Cancers
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2072-6694
      </issn>
      <publisher>
       <publisher-name>
        MDPI
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32245239
      </article-id>
      <article-id pub-id-type="pmc">
       7140054
      </article-id>
      <article-id pub-id-type="doi">
       10.3390/cancers12030747
      </article-id>
      <article-id pub-id-type="publisher-id">
       cancers-12-00747
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer—A Nationwide, Population-Based, Propensity Score-Matched Cohort Study
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Shih-Yi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-cancers-12-00747">
         1
        </xref>
        <xref ref-type="aff" rid="af2-cancers-12-00747">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0001-9926-3668
        </contrib-id>
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Cheng-Li
         </given-names>
        </name>
        <xref ref-type="aff" rid="af3-cancers-12-00747">
         3
        </xref>
        <xref ref-type="aff" rid="af4-cancers-12-00747">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Cheng-Chieh
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-cancers-12-00747">
         1
        </xref>
        <xref ref-type="aff" rid="af5-cancers-12-00747">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hsu
         </surname>
         <given-names>
          Wu-Huei
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-cancers-12-00747">
         1
        </xref>
        <xref ref-type="aff" rid="af6-cancers-12-00747">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Chia-Der
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-cancers-12-00747">
         1
        </xref>
        <xref ref-type="aff" rid="af7-cancers-12-00747">
         7
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          I.-Kuan
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-cancers-12-00747">
         1
        </xref>
        <xref ref-type="aff" rid="af2-cancers-12-00747">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hsu
         </surname>
         <given-names>
          Chung-Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-cancers-12-00747">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0002-6368-3676
        </contrib-id>
        <name>
         <surname>
          Kao
         </surname>
         <given-names>
          Chia-Hung
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-cancers-12-00747">
         1
        </xref>
        <xref ref-type="aff" rid="af8-cancers-12-00747">
         8
        </xref>
        <xref ref-type="aff" rid="af9-cancers-12-00747">
         9
        </xref>
        <xref ref-type="aff" rid="af10-cancers-12-00747">
         10
        </xref>
        <xref ref-type="corresp" rid="c1-cancers-12-00747">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1-cancers-12-00747">
       <label>
        1
       </label>
       Graduate Institute of Biomedical Sciences and School of Medicine, College of Medicine, China Medical University, Taichung 40447, Taiwan;
       <email>
        oasisbestonly@yahoo.com.tw
       </email>
       (S.-Y.L.);
       <email>
        cclin@mail.cmuh.org.tw
       </email>
       (C.-C.L.);
       <email>
        hsuwh@mail.cmuh.org.tw
       </email>
       (W.-H.H.);
       <email>
        d6355@mail.cmuh.org.tw
       </email>
       (C.-D.L.);
       <email>
        ikwang@mail.cmuh.org.tw
       </email>
       (I.-K.W.);
       <email>
        hsucy63141@gmail.com
       </email>
       (C.-Y.H.)
      </aff>
      <aff id="af2-cancers-12-00747">
       <label>
        2
       </label>
       Division of Nephrology and Kidney Institute, China Medical University Hospital, Taichung, Taiwan
      </aff>
      <aff id="af3-cancers-12-00747">
       <label>
        3
       </label>
       Management Office for Health Data, China Medical University Hospital, Taichung 40447, Taiwan;
       <email>
        orangechengli@gmail.com
       </email>
      </aff>
      <aff id="af4-cancers-12-00747">
       <label>
        4
       </label>
       College of Medicine, China Medical University, Taichung 40447, Taiwan
      </aff>
      <aff id="af5-cancers-12-00747">
       <label>
        5
       </label>
       Department of Family Medicine, China Medical University Hospital, Taichung 40447, Taiwan
      </aff>
      <aff id="af6-cancers-12-00747">
       <label>
        6
       </label>
       Department of Chest Medicine, China Medical University Hospital, Taichung 40447, Taiwan
      </aff>
      <aff id="af7-cancers-12-00747">
       <label>
        7
       </label>
       Department of Otolaryngology, China Medical University Hospital, Taichung 40447, Taiwan
      </aff>
      <aff id="af8-cancers-12-00747">
       <label>
        8
       </label>
       Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung 40447, Taiwan
      </aff>
      <aff id="af9-cancers-12-00747">
       <label>
        9
       </label>
       Department of Bioinformatics and Medical Engineering, Asia University, Taichung 40447, Taiwan
      </aff>
      <aff id="af10-cancers-12-00747">
       <label>
        10
       </label>
       Center of Augmented Intelligence in Healthcare, China Medical University Hospital, Taichung 40447, Taiwan
      </aff>
      <author-notes>
       <corresp id="c1-cancers-12-00747">
        <label>
         *
        </label>
        Correspondence:
        <email>
         d10040@mail.cmuh.org.tw
        </email>
        ; Tel.: +886-4-22052121 (ext. 7412); Fax: +886-4-22336174
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        21
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       12
      </volume>
      <issue>
       3
      </issue>
      <elocation-id>
       747
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         10
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         20
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 by the authors.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Background: Direct evidence of lung cancer risk in Asian users of angiotensin-converting enzyme inhibitors (ACEIs) is lacking. Methods: The ACEI cohort comprised 22,384 patients aged ≥ 18 years with a first prescription of ACEI. The comparison angiotensin receptor blocker (ARB) cohort consisted of age-, sex- and comorbidity-matched patients at a ratio of 1:1. The primary outcome was the incidence of lung cancer, which was evaluated using a proportional hazard model. Results: The overall incidence rates of lung cancer in the ACEI and ARB cohorts were 16.6 and 12.2 per 10,000 person-years, respectively. The ACEI cohort had a significantly higher risk of lung cancer than the ARB cohort (adjusted hazard ratio [aHR]. = 1.36; 95% confidence interval [CI]. = 1.11–1.67). Duration–response and dose–response analyses revealed that compared with patients who did not receive ACEIs, patients who received ACEIs for more than 45 days per year (aHR = 1.87; 95% CI = 1.48–2.36) and patients who received more than 540 defined daily doses of ACEIs per year (aHR =1.80; 95% CI = 1.43–-2.27) had a significantly higher risk of lung cancer. The cumulative incidence of lung cancer was also significantly higher in the ACEI cohort than in the ARB cohort (log-rank test,
        <italic>
         p
        </italic>
        = 0.002). Conclusions: ACEI use is associated with an increased risk of lung cancer compared with ARB use. Patients using ARBs have a significantly lower risk of lung cancer than non-ARB users.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        angiotensin-converting enzyme inhibitors (ACEIs)
       </kwd>
       <kwd>
        lung cancer
       </kwd>
       <kwd>
        air pollutant
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1-cancers-12-00747" sec-type="intro">
     <title>
      1. Introduction
     </title>
     <p>
      Angiotensin-converting enzyme inhibitors (ACEIs) cause vasodilation by inhibiting the formation of angiotensin II and ACEIs comprise a critical class of antihypertensive medication indicated for heart failure, asymptomatic left ventricular dysfunction, proteinuria, diabetic nephropathy and postmyocardial infarction [
      <xref ref-type="bibr" rid="B1-cancers-12-00747">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="B2-cancers-12-00747">
       2
      </xref>
      ]. Safety concerns regarding the use of ACEIs have been raised, especially their cancer risk [
      <xref ref-type="bibr" rid="B3-cancers-12-00747">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="B4-cancers-12-00747">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B5-cancers-12-00747">
       5
      </xref>
      ]. Hicks et al. reported that the use of ACEIs is associated with a 1.14-fold higher risk of lung cancer compared with the use of angiotensin receptor blockers (ARBs) [
      <xref ref-type="bibr" rid="B6-cancers-12-00747">
       6
      </xref>
      ]. However, the latest meta-analysis conducted by Bahaj et al. concluded that no significant association exists between ACEI use and the development of lung cancer [
      <xref ref-type="bibr" rid="B7-cancers-12-00747">
       7
      </xref>
      ]. Therefore, the association between ACEIs and lung cancer remains unclear [
      <xref ref-type="bibr" rid="B4-cancers-12-00747">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B6-cancers-12-00747">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="B7-cancers-12-00747">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B8-cancers-12-00747">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="B9-cancers-12-00747">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="B10-cancers-12-00747">
       10
      </xref>
      ]. Possible reasons for the discrepancies among these studies might be the baseline bias of other comorbidities, insufficient follow-up, confounding effects of other antihypertensive medications and inadequate selection of the control cohort [
      <xref ref-type="bibr" rid="B4-cancers-12-00747">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B6-cancers-12-00747">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="B9-cancers-12-00747">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="B10-cancers-12-00747">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="B11-cancers-12-00747">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="B12-cancers-12-00747">
       12
      </xref>
      ].
     </p>
     <p>
      A nationwide propensity score-matched cohort study to reduce baseline bias from comorbidities and other antihypertensive medications is required.
     </p>
     <p>
      In addition, air pollution has gradually become a global concern and is associated with an increased risk of lung cancer [
      <xref ref-type="bibr" rid="B13-cancers-12-00747">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="B14-cancers-12-00747">
       14
      </xref>
      ]. When determining the hazardous effects of drugs on lung cancer risk in the real-world setting, exposure to air pollutants should be considered a confounding factor. Furthermore, the variant of insertion or deletion in the ACE gene is significantly different between Asian and Caucasian populations [
      <xref ref-type="bibr" rid="B15-cancers-12-00747">
       15
      </xref>
      ]. Hicks et al. reported an association between ACEI use and lung cancer but their study participants were mostly Caucasian. Chiang et al. indicated that ACEI and ARB use is not associated with all-cancer risk in the Taiwanese population [
      <xref ref-type="bibr" rid="B16-cancers-12-00747">
       16
      </xref>
      ]. However, the results of Chiang et al. cannot be used to establish whether Asian ACEI users have a higher lung cancer risk because that study had a relatively short follow-up period for cancer latency, did not consider other antihypertensive medications and did not specify lung cancer as a study outcome [
      <xref ref-type="bibr" rid="B16-cancers-12-00747">
       16
      </xref>
      ]. Direct evidence of lung cancer risk in Asian ACEI users is lacking. Therefore, we combined data from the National Health Insurance Research Database (NHIRD) and Taiwan Air Quality Monitoring Database (TAQMD) to conduct a propensity score-matched cohort study to determine lung cancer risk in Asian ACEI users.
     </p>
    </sec>
    <sec id="sec2-cancers-12-00747" sec-type="methods">
     <title>
      2. Methods
     </title>
     <sec id="sec2dot1-cancers-12-00747">
      <title>
       2.1. Data Source
      </title>
      <p>
       The National Health Insurance (NHI) program of Taiwan was established in 1995 and provides universal coverage to over 99% of the residents of Taiwan. The NHIRD is a comprehensive database that includes information on hospitalization, emergency care and medical visits. We conducted this population-based retrospective cohort study using data from the Longitudinal Health Insurance Database (LHID), a subset constructed from original registration files and original claims data in the NHIRD. The LHID contains the data of one million enrollees randomly sampled individuals from the NHIRD. Diagnoses were coded with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes. The NHIRD ensures the encryption of patient information; therefore, informed consent is not required. This study was approved by the Institutional Review Board of China Medical University (CMUH104-REC2-115[CR-4]). We also used the TAQMD for obtaining information on the air pollutants PM2.5, PM10 and SO
       <sub>
        2
       </sub>
       . We combined and stratified the LHID and the TAQMD data by linking the residential areas of enrollees with nearby air quality monitoring stations.
      </p>
     </sec>
     <sec id="sec2dot2-cancers-12-00747">
      <title>
       2.2. Study Population
      </title>
      <p>
       We enrolled patients aged older than 20 years from 1 January 2000 to 31 December 2012 and divided them into two cohorts: the ACEI cohort and the ARB cohort. The ACEI cohort consisted of patients prescribed ACEIs for at least 28 days, whereas the ARB cohort consisted of patients prescribed ARB for at least 28 days. The date of first ACEI or ARB use during the study period was defined as the index date. Patients who had cancer (ICD-9-CM codes 140–208) during the study period or who had a history of lung cancer before the index date were excluded from this study. To control for confounding effects, we performed 1:1 propensity score matching between the ACEI and ARB cohorts by the following covariates: age, sex, monthly income, urbanization level; diagnosis of hypertension, diabetes, tuberculosis, alcohol-related disease, chronic obstructive pulmonary disease (COPD), chronic liver disease, hyperlipidemia, asthma, stroke, coronary artery disease and rheumatologic disease; use of medication, including α-blockers, β-blockers, potassium-sparing diuretics, thiazides, loop diuretics and calcium channel blockers; and air pollutants. Air pollutant concentrations refer to the daily average concentrations of PM2.5, PM10 and SO
       <sub>
        2
       </sub>
       .
      </p>
      <p>
       Lung cancer (ICD-9-CM code 162) was defined as the endpoint of this study. All participants were followed-up from the index date until the date of lung cancer diagnosis, withdrawal from the NHI program or December 31, 2013, whichever occurred first.
      </p>
     </sec>
     <sec id="sec2dot3-cancers-12-00747">
      <title>
       2.3. Statistical Analysis
      </title>
      <p>
       To estimate the propensity score, a logistic regression model was used, in which ACEI and ARB use status was regressed on the baseline characteristics listed in
       <xref ref-type="table" rid="cancers-12-00747-t001">
        Table 1
       </xref>
       . The distributions of demographic characteristics and clinical comorbidity status were compared between the ACEI and ARB cohorts. Differences were examined using Student’s t-test for continuous variables and the chi-square test for categorical variables. The age, PM2.5 μg/m3 daily average, PM10 μg/m
       <sup>
        3
       </sup>
       daily average and SO
       <sub>
        2
       </sub>
       ppb daily average distribution is not Gaussian/normal distribution. Therefore, we used nonparametric statistics (Mann-Whitney U test) to test age, PM2.5 μg/m
       <sup>
        3
       </sup>
       daily average, PM10 μg/m
       <sup>
        3
       </sup>
       daily average and SO
       <sub>
        2
       </sub>
       ppb daily average differences between both cohorts. We classified monthly income and urbanization into three and four levels, respectively. Cox proportional hazard regression was used to estimate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) of lung cancer occurrence and the results were further analyzed according to the various dose–response categories. Covariables listed in the
       <xref ref-type="table" rid="cancers-12-00747-t001">
        Table 1
       </xref>
       were included in a multivariable Cox proportional hazards regression model. We further analyzed the dose–response effect among patients using ACEI or ARB. We calculated the average days, average dose and average DDD (defined daily dosages) of ACEI and ARB per year by dividing the total used days or total prescribed dose by the follow-up period. We classified the patients into two subgroups by median. We measured the cumulative incidence of lung cancer in the ACEI and ARB cohorts using the Kaplan–Meier method and we assessed the curve difference using the log-rank test. SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) was used for all data analyses. The two-sided significance level was set at
       <italic>
        p
       </italic>
       &lt; 0.05.
      </p>
     </sec>
    </sec>
    <sec id="sec3-cancers-12-00747" sec-type="results">
     <title>
      3. Results
     </title>
     <p>
      We selected 22,384 patients who received ACEI treatment and 22,384 patients who received ARB treatment. Sex and age distributions were similar between the two cohorts. The mean age in both cohorts was approximately 59 years. Significant differences were observed in monthly income and urbanization level between the two cohorts (
      <italic>
       p
      </italic>
      &lt; 0.05). The ARB cohort was more likely to have coronary artery disease (
      <italic>
       p
      </italic>
      &lt; 0.05). Regarding the distribution of air pollutants, the daily average concentrations of PM2.5, PM10 and SO
      <sub>
       2
      </sub>
      were significantly higher in the ACEI cohort than in the ARB cohort (
      <italic>
       p
      </italic>
      &lt; 0.05) (
      <xref ref-type="table" rid="cancers-12-00747-t001">
       Table 1
      </xref>
      ).
     </p>
     <p>
      The mean follow-up times were 6.33 ± 3.52 years and 6.12 ± 3.47 years in the ARB and ACEI cohorts, respectively. At the end of the study period, the overall incidence rates of lung cancer in the ARB and ACEI cohorts were 12.2 and 16.6 per 10,000 person-years, respectively. After multivariable Cox proportional hazards regression model adjusting for age, sex, comorbidities, medication and air pollutants, a significantly higher risk of lung cancer was observed in the ACEI cohort than in the ARB cohort (aHR = 1.36; 95% CI = 1.11–1.67) (
      <xref ref-type="table" rid="cancers-12-00747-t002">
       Table 2
      </xref>
      ).
     </p>
     <p>
      Duration–response and dose–response analyses revealed that compared with patients who did not receive ACEI treatment, patients who received ACEI treatment for more than 45 days per year (aHR = 1.87; 95% CI = 1.48–2.36), patients who received more than 540 mg of ACEIs per year (aHR =1.80; 95% CI = 1.43–2.27) and patients who received more than 50 defined daily doses (DDDs) of ACEIs per year (aHR =1.85; 95% CI = 1.46–2.34) had a significantly higher risk of lung cancer. Compared with patients who did not receive ARB treatment, patients who received ARB treatment for fewer than 200 days per year (aHR = 0.61; 95% CI = 0.47–0.80), patients who received more than 11200 mg of ARB per year (aHR =0.62; 95% CI = 0.50–0.79) and patients who received fewer than 200 DDDs of ARB per year (aHR = 0.63; 95% CI = 0.48–0.81) had a significantly lower risk of lung cancer (
      <xref ref-type="table" rid="cancers-12-00747-t003">
       Table 3
      </xref>
      ).
     </p>
     <p>
      In Kaplan–Meier analysis, the cumulative incidence of lung cancer was significantly higher in the ACEI cohort than in the ARB cohort (log-rank test,
      <italic>
       p
      </italic>
      = 0.002) (
      <xref ref-type="fig" rid="cancers-12-00747-f001">
       Figure 1
      </xref>
      ).
     </p>
    </sec>
    <sec id="sec4-cancers-12-00747" sec-type="discussion">
     <title>
      4. Discussion
     </title>
     <p>
      Similar to the findings of Hick et al. [
      <xref ref-type="bibr" rid="B6-cancers-12-00747">
       6
      </xref>
      ] our study revealed that ACEI users were at a 1.36-fold higher risk of lung cancer compared with ARB users. Further analysis revealed that ACEI users were at a 1.87-fold and 1.8-fold higher risks of lung cancer when the medication was used for &gt; 45 days or the accumulated dosage of ACEI was &gt; 540 mg, respectively. Patients receiving ARB at an accumulated dosage of &gt; 11,200 mg were at a 0.62-fold lower risk of lung cancer.
     </p>
     <p>
      In addition to causing vasodilatation in the circulation system, ACEIs are also active in the lungs, where ACEs are abundant [
      <xref ref-type="bibr" rid="B17-cancers-12-00747">
       17
      </xref>
      ]. Use of ACEIs could result in increased levels of bradykinin in the lungs, which are normally degraded by ACEIs. This may mediate the sensitization of the airway and enhance the cough reflex [
      <xref ref-type="bibr" rid="B18-cancers-12-00747">
       18
      </xref>
      ]. Furthermore, bradykinin is associated with the regulation of neointimal formation and mitogenesis through the mitogen-activated protein kinase pathway [
      <xref ref-type="bibr" rid="B19-cancers-12-00747">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="B20-cancers-12-00747">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="B21-cancers-12-00747">
       21
      </xref>
      ]. Chee et al. indicated that bradykinin receptors are highly expressed in the cytoplasm of all types of lung tumors, [
      <xref ref-type="bibr" rid="B22-cancers-12-00747">
       22
      </xref>
      ]. which would mediate proangiogenic properties and cancer migration, invasion and metastasis [
      <xref ref-type="bibr" rid="B23-cancers-12-00747">
       23
      </xref>
      ]. In addition, ACEI use could cause the accumulation of substance P in the lung. Esteban et al. reported that the activation of neurokinin-1 receptors through substance P is one mechanism linking mitogenesis and cancer promotion and progression [
      <xref ref-type="bibr" rid="B24-cancers-12-00747">
       24
      </xref>
      ]. Munoz et al. indicated that substance P may induce the proliferation of both tumor cells and endothelial cells, thus stimulating angiogenesis [
      <xref ref-type="bibr" rid="B25-cancers-12-00747">
       25
      </xref>
      ]. Therefore, increased levels of substance P and bradykinin in the lungs may be the mechanism through which ACEI users are at a higher risk of lung cancer. The duration–response and dose–response relationships between ACEI use and lung cancer further strengthen our clinical findings.
     </p>
     <p>
      In the present study, we observed that ARB users had a significantly lower risk of lung cancer than non-ARB users. The meta-analysis of Zhang et al. also demonstrated that ARBs are associated with significantly lower lung cancer risk [
      <xref ref-type="bibr" rid="B26-cancers-12-00747">
       26
      </xref>
      ]. Cohort studies conducted by Chang et al. and Huang et al. have also revealed that ARB use is associated with a decreased risk of lung cancer [
      <xref ref-type="bibr" rid="B11-cancers-12-00747">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="B27-cancers-12-00747">
       27
      </xref>
      ]. Bhaskaran et al. observed a 0.84-fold decreased risk of lung cancer in ARB users [
      <xref ref-type="bibr" rid="B28-cancers-12-00747">
       28
      </xref>
      ]. Studies have reported that angiotensin II receptors, AT1 receptors and AT2 receptors are involved in enhancing tissue vascular endothelial growth factor protein levels, angiogenesis and tumor growth [
      <xref ref-type="bibr" rid="B29-cancers-12-00747">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="B30-cancers-12-00747">
       30
      </xref>
      ]. In addition, AT1 receptors are abundantly expressed in malignant neoplasms, including various types of lung cancer [
      <xref ref-type="bibr" rid="B31-cancers-12-00747">
       31
      </xref>
      ,
      <xref ref-type="bibr" rid="B32-cancers-12-00747">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="B33-cancers-12-00747">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="B34-cancers-12-00747">
       34
      </xref>
      ]. Fujita et al. revealed that blocking angiotensin II receptors could reduce tumor growth and metastasis [
      <xref ref-type="bibr" rid="B35-cancers-12-00747">
       35
      </xref>
      ]. Suganuma et al. and Fujimoto et al. have reported that blockade therapy for angiotensin II receptors could suppress the metastasis of human ovarian cancer and pancreatic cancer in vitro [
      <xref ref-type="bibr" rid="B36-cancers-12-00747">
       36
      </xref>
      ,
      <xref ref-type="bibr" rid="B37-cancers-12-00747">
       37
      </xref>
      ]. Gong et al. indicated that blocking angiotensin II type 1 receptors could induce apoptotic cell death in human pancreatic cancer cells in vitro [
      <xref ref-type="bibr" rid="B38-cancers-12-00747">
       38
      </xref>
      ]. The aforementioned findings indicate the potential biological mechanisms for the finding that ARB users have a lower risk of lung cancer.
     </p>
     <p>
      Blockade of the renin–angiotensin system (RAS) is well-known to be beneficial in preserving heart and kidney function in those with heart failure, postmyocardial infarction and kidney disease [
      <xref ref-type="bibr" rid="B39-cancers-12-00747">
       39
      </xref>
      ]. Therefore, it would be impossible to completely omit all RAS-blocking medications in patients with heart or kidney diseases. Therefore, we employed a study design similar to that of Hicks et al. [
      <xref ref-type="bibr" rid="B6-cancers-12-00747">
       6
      </xref>
      ] to compare lung cancer risk in the ACEI and ARB cohorts. We compared lung cancer risk in ACEI and non-ACEI users as well as in ARB users and non-ARB users. Our results directly answer real-world clinical questions and provide sufficient information for decision-making in the selection of RAS blockers.
     </p>
     <p>
      Several limitations of the current study should be noted. First, information on smoking habits, including intensity and duration; physical exercise; personal exposure to secondhand smoke, asbestos, beryllium, cadmium, silica and other inhaled carcinogens; and body mass index is unavailable in the NHIRD. Since lung cancer was end point of this paper, lack information about smoking habits and exposure to carcinogens of lung cancer should raise concern for baseline bias. However, we have attempted to use COPD as proxy for smoking habitats and we also considered and analyzed asthma, tuberculosis and levels of air pollutants PM2.5, the possible baseline bias might be minimized. Second, we did not adjust for medical visits and chest examination frequency, including chest X-ray, computed tomography, magnetic resonance imaging and ultrasonography; therefore, surveillance bias might be present, because ACEI users have more symptoms of dry cough and undergo more chest examinations. Third, detailed pathological reports such as small cell or non-small cell lung cancer and staging of lung cancer are unavailable in the NHIRD; therefore, further analysis of the association between ACEI use and subgroups of lung cancer could not be performed in this study. Fourth, the mobility of each participant could not be certain. Therefore, select PM2.5 in residential area as a feature would not so representative of real PM2.5 exposure conditions of each participant. Finally, medication adherence could not be fully ascertained in this study.
     </p>
     <p>
      This study has several strengths. First, we used propensity score matching to mitigate baseline bias between the ACEI and ARB cohorts. Because diverse populations have different reasons for ACEI use, propensity score matching could minimize baseline bias of underlying diseases between the ACEI and ARB cohorts. In addition to matching comorbidities, we also matched each type of antihypertensive medication between the ACEI and ARB cohorts; thereby, baseline bias of antihypertensive medications was minimized. Second, we considered air pollutants (PM2.5, PM10 and SO
      <sub>
       2
      </sub>
      ), which have been recognized as significant risk factors for lung cancer [
      <xref ref-type="bibr" rid="B14-cancers-12-00747">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B40-cancers-12-00747">
       40
      </xref>
      ,
      <xref ref-type="bibr" rid="B41-cancers-12-00747">
       41
      </xref>
      ]. According to our literature review, this is the first study considering air pollutants as covariables in the investigation of the association between ACEIs and lung cancer. Third, this study only enrolled those who started using ACEI or ARB from the index date. Those who used ACEIs or ARBs before the index date or those who switched between ACEIs and ARBs were all excluded from our study. Thereby, the bias was considerably minimized. Fourth, NHI covers over 99.7% of the population of Taiwan and contains decades of data. Thus, to the best of our knowledge, the mean follow-up duration of this nationwide population-based study is the longest among similar studies of ACEIs and lung cancer [
      <xref ref-type="bibr" rid="B3-cancers-12-00747">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="B6-cancers-12-00747">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="B42-cancers-12-00747">
       42
      </xref>
      ]. This long follow-up enabled a more representative analysis of the relationship between ACEI dosage and duration and lung cancer risk. Furthermore, Hicks et al. speculated that the increased lung cancer risk observed in ACEI users might be due to the protective effect of ARBs against lung cancers [
      <xref ref-type="bibr" rid="B6-cancers-12-00747">
       6
      </xref>
      ]. Our study clearly demonstrated the protective effects of ARBs against lung cancer and the potential of ACEIs to cause lung cancer because we separately compared ACEI users and non-ACEI users and ARB users and non-ARB users.
     </p>
    </sec>
    <sec id="sec5-cancers-12-00747" sec-type="conclusions">
     <title>
      5. Conclusions
     </title>
     <p>
      In conclusion, ACEI users are at a higher risk of lung cancer than ARB users in Taiwan. Dosage–response and duration–response relationships exist between ACEI use and lung cancer risk.
     </p>
    </sec>
    <back>
     <notes>
      <title>
       Author Contributions
      </title>
      <p>
       Conception/Design: S.-Y.L. and C.-H.K.; Provision of study materials: C.-H.K.; Collection and/or assembly of data: S.-Y.L., C.-L.L. and C.-H.K.; Data analysis and interpretation: S.-Y.L., C.-L.L., W.-H.H., C.-C.L., C.-D.L., I.-K.W., C.-Y.H. and C.-H.K.; Manuscript writing: S.-Y.L., C.-L.L., W.-H.H., C.-C.L., I.-K.W. and C.-H.K.; Final approval of manuscript: S.-Y.L., C.-L.L., W.-H.H., C.-C.L., C.-D.L., I.-K.W., C.-Y.H. and C.-H.K. All authors have read and agreed to the published version of the manuscript.
      </p>
     </notes>
     <notes>
      <title>
       Funding
      </title>
      <p>
       This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW108-TDU-B-212-133004); China Medical University Hospital (DMR-107-192, CMU107-ASIA-19); MOST Clinical Trial Consortium for Stroke (MOHW109-TDU-B-212-114004); Tseng-Lien Lin Foundation, Taichung, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no role in the study design, data collection and analysis, the decision to publish or preparation of the manuscript. No additional external funding was received for this study.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Conflicts of Interest
      </title>
      <p>
       The authors declare no financial or other conflicts of interest.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1-cancers-12-00747">
       <label>
        1.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Herman
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Bashir
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin Converting Enzyme Inhibitors (ACEI) [Updated 2019 Oct 22]
        </article-title>
        <source>
         StatPearls [Internet]
        </source>
        <publisher-name>
         StatPearls Publishing
        </publisher-name>
        <publisher-loc>
         Treasure Island, FL, USA
        </publisher-loc>
        <year>
         2019
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK431051/">
          https://www.ncbi.nlm.nih.gov/books/NBK431051/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-25">
         (accessed on 25 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B2-cancers-12-00747">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amann
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Tinzmann
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Angelkort
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1
        </article-title>
        <source>
         Diabetes Care
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <fpage>
         2421
        </fpage>
        <lpage>
         2425
        </lpage>
        <pub-id pub-id-type="doi">
         10.2337/diacare.26.8.2421
        </pub-id>
        <pub-id pub-id-type="pmid">
         12882873
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3-cancers-12-00747">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Opelz
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Döhler
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: A collaborative transplant study report
        </article-title>
        <source>
         Am. J. Transplant.
        </source>
        <year>
         2011
        </year>
        <volume>
         11
        </volume>
        <fpage>
         2483
        </fpage>
        <lpage>
         2489
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1600-6143.2011.03681.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         21929646
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4-cancers-12-00747">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hallas
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Christensen
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Andersen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Friis
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bjerrum
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: A population-based case-control study
        </article-title>
        <source>
         Br. J. Clin. Pharmacol.
        </source>
        <year>
         2012
        </year>
        <volume>
         74
        </volume>
        <fpage>
         180
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-2125.2012.04170.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         22243442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5-cancers-12-00747">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bangalore
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kjeldsen
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Makani
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Grossman
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Wetterslev
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gupta
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sever
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
         <name>
          <surname>
           Gluud
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Messerli
          </surname>
          <given-names>
           F.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antihypertensive drugs and risk of cancer: Network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials
        </article-title>
        <source>
         Lancet Oncol.
        </source>
        <year>
         2011
        </year>
        <volume>
         12
        </volume>
        <fpage>
         65
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1470-2045(10)70260-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         21123111
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6-cancers-12-00747">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hicks
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Filion
          </surname>
          <given-names>
           K.B.
          </given-names>
         </name>
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Sakr
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Udell
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Azoulay
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme inhibitors and risk of lung cancer: Population based cohort study
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2018
        </year>
        <volume>
         363
        </volume>
        <fpage>
         k4209
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.k4209
        </pub-id>
        <pub-id pub-id-type="pmid">
         30355745
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7-cancers-12-00747">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bahaj
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Albawaliz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Qureini
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Abughanimeh
          </surname>
          <given-names>
           O.K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Younis
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tahboub
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Noman
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Abdulhak
          </surname>
          <given-names>
           A.A.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme inhibitors use and development of lung cancer: A systematic review and meta-analysis
        </article-title>
        <source>
         J. Clin. Oncol.
        </source>
        <year>
         2019
        </year>
        <volume>
         37
        </volume>
        <fpage>
         e13093
        </fpage>
        <pub-id pub-id-type="doi">
         10.1200/JCO.2019.37.15_suppl.e13093
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8-cancers-12-00747">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pasternak
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Svanström
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Callréus
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Melbye
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hviid
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of angiotensin receptor blockers and the risk of cancer
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         2011
        </year>
        <volume>
         123
        </volume>
        <fpage>
         1729
        </fpage>
        <lpage>
         1736
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/CIRCULATIONAHA.110.007336
        </pub-id>
        <pub-id pub-id-type="pmid">
         21482967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9-cancers-12-00747">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lever
          </surname>
          <given-names>
           A.F.
          </given-names>
         </name>
         <name>
          <surname>
           Hole
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gillis
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           McCallum
          </surname>
          <given-names>
           I.R.
          </given-names>
         </name>
         <name>
          <surname>
           McInnes
          </surname>
          <given-names>
           G.T.
          </given-names>
         </name>
         <name>
          <surname>
           MacKinnon
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Meredith
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Reid
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           J.W.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         1998
        </year>
        <volume>
         352
        </volume>
        <fpage>
         179
        </fpage>
        <lpage>
         184
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(98)03228-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         9683206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B10-cancers-12-00747">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Friis
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sørensen
          </surname>
          <given-names>
           H.T.
          </given-names>
         </name>
         <name>
          <surname>
           Mellemkjaer
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           McLaughlin
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Nielsen
          </surname>
          <given-names>
           G.L.
          </given-names>
         </name>
         <name>
          <surname>
           Blot
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Olsen
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme inhibitors and the risk of cancer: A population-based cohort study in Denmark
        </article-title>
        <source>
         Cancer
        </source>
        <year>
         2001
        </year>
        <volume>
         92
        </volume>
        <fpage>
         2462
        </fpage>
        <lpage>
         2470
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/1097-0142(20011101)92:9&lt;2462::AID-CNCR1596&gt;3.0.CO;2-L
        </pub-id>
        <pub-id pub-id-type="pmid">
         11745304
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11-cancers-12-00747">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: A nationwide case-control study
        </article-title>
        <source>
         J. Clin. Oncol.
        </source>
        <year>
         2011
        </year>
        <volume>
         29
        </volume>
        <fpage>
         3001
        </fpage>
        <lpage>
         3007
        </lpage>
        <pub-id pub-id-type="doi">
         10.1200/JCO.2011.35.1908
        </pub-id>
        <pub-id pub-id-type="pmid">
         21690476
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B12-cancers-12-00747">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gokhale
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Girman
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pate
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Funk
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Stürmer
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers
        </article-title>
        <source>
         Pharmacoepidemiol. Drug Saf.
        </source>
        <year>
         2016
        </year>
        <volume>
         25
        </volume>
        <fpage>
         512
        </fpage>
        <lpage>
         520
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/pds.3977
        </pub-id>
        <pub-id pub-id-type="pmid">
         26860956
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13-cancers-12-00747">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pope
          </surname>
          <given-names>
           C.A.
          </given-names>
          <suffix>
           III
          </suffix>
         </name>
         <name>
          <surname>
           Burnett
          </surname>
          <given-names>
           R.T.
          </given-names>
         </name>
         <name>
          <surname>
           Thun
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Calle
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Krewski
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ito
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Thurston
          </surname>
          <given-names>
           G.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2002
        </year>
        <volume>
         287
        </volume>
        <fpage>
         1132
        </fpage>
        <lpage>
         1141
        </lpage>
        <pub-id pub-id-type="doi">
         10.1001/jama.287.9.1132
        </pub-id>
        <pub-id pub-id-type="pmid">
         11879110
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14-cancers-12-00747">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raaschou-Nielsen
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Andersen
          </surname>
          <given-names>
           Z.J.
          </given-names>
         </name>
         <name>
          <surname>
           Beelen
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Samoli
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Stafoggia
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Weinmayr
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Nieuwenhuijsen
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Brunekreef
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Air pollution and lung cancer incidence in 17 European cohorts: Prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE)
        </article-title>
        <source>
         Lancet Oncol.
        </source>
        <year>
         2013
        </year>
        <volume>
         14
        </volume>
        <fpage>
         813
        </fpage>
        <lpage>
         822
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1470-2045(13)70279-1
        </pub-id>
        <pub-id pub-id-type="pmid">
         23849838
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15-cancers-12-00747">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           X.M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Bian
          </surname>
          <given-names>
           Y.F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           R.-S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.-C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism and ACE inhibitor-related cough: A meta-analysis
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2012
        </year>
        <volume>
         7
        </volume>
        <elocation-id>
         e37396
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0037396
        </pub-id>
        <pub-id pub-id-type="pmid">
         22723835
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B16-cancers-12-00747">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           K.B.
          </given-names>
         </name>
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lowered cancer risk with ACE inhibitors/ARBs: A population-based cohort study
        </article-title>
        <source>
         J. Clin. Hypertens. Greenwich.
        </source>
        <year>
         2014
        </year>
        <volume>
         16
        </volume>
        <fpage>
         27
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/jch.12228
        </pub-id>
        <pub-id pub-id-type="pmid">
         24304931
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B17-cancers-12-00747">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1267
        </pub-id>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18-cancers-12-00747">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fox
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lalloo
          </surname>
          <given-names>
           U.G.
          </given-names>
         </name>
         <name>
          <surname>
           Belvisi
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Bernareggi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Barnes
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin-evoked sensitization of airway sensory nerves: A mechanism for ACE-inhibitor cough
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         1996
        </year>
        <volume>
         2
        </volume>
        <fpage>
         814
        </fpage>
        <lpage>
         817
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm0796-814
        </pub-id>
        <pub-id pub-id-type="pmid">
         8673930
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19-cancers-12-00747">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chien
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Hsiao
          </surname>
          <given-names>
           L.D.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin B2 receptor-mediated proliferation via activation of the Ras/Raf/MEK/MAPK pathway in rat vascular smooth muscle cells
        </article-title>
        <source>
         J. Biomed. Sci.
        </source>
        <year>
         2003
        </year>
        <volume>
         10
        </volume>
        <fpage>
         208
        </fpage>
        <lpage>
         218
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/BF02256056
        </pub-id>
        <pub-id pub-id-type="pmid">
         12595757
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20-cancers-12-00747">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gutkind
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors
        </article-title>
        <source>
         Sci. STKE
        </source>
        <year>
         2000
        </year>
        <volume>
         2000
        </volume>
        <fpage>
         re1
        </fpage>
        <pub-id pub-id-type="doi">
         10.1126/stke.2000.40.re1
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21-cancers-12-00747">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Golias
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Charalabopoulos
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Stagikas
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Charalabopoulos
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Batistatou
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The kinin system—Bradykinin: Biological effects and clinical implications. Multiple role of the kinin system—Bradykinin
        </article-title>
        <source>
         Hippokratia
        </source>
        <year>
         2007
        </year>
        <volume>
         11
        </volume>
        <fpage>
         124
        </fpage>
        <lpage>
         128
        </lpage>
        <pub-id pub-id-type="pmid">
         19582206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22-cancers-12-00747">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chee
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Naran
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Misso
          </surname>
          <given-names>
           N.L.
          </given-names>
         </name>
         <name>
          <surname>
           Thompson
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bhoola
          </surname>
          <given-names>
           K.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer
        </article-title>
        <source>
         Biol. Chem.
        </source>
        <year>
         2008
        </year>
        <volume>
         389
        </volume>
        <fpage>
         1225
        </fpage>
        <lpage>
         1233
        </lpage>
        <pub-id pub-id-type="doi">
         10.1515/BC.2008.139
        </pub-id>
        <pub-id pub-id-type="pmid">
         18713009
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23-cancers-12-00747">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Da Costa
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sirois
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Tannock
          </surname>
          <given-names>
           I.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chammas
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of kinin receptors in cancer and therapeutic opportunities
        </article-title>
        <source>
         Cancer Lett.
        </source>
        <year>
         2014
        </year>
        <volume>
         345
        </volume>
        <fpage>
         27
        </fpage>
        <lpage>
         38
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.canlet.2013.12.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         24333733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24-cancers-12-00747">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Esteban
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Muñoz
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           González-Moles
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rosso
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A role for substance P in cancer promotion and progression: A mechanism to counteract intracellular death signals following oncogene activation or DNA damage
        </article-title>
        <source>
         Cancer Metastasis Rev.
        </source>
        <year>
         2006
        </year>
        <volume>
         25
        </volume>
        <fpage>
         137
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s10555-006-8161-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         16680578
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25-cancers-12-00747">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muñoz
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Coveñas
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Involvement of substance P and the NK-1 receptor in cancer progression
        </article-title>
        <source>
         Peptides
        </source>
        <year>
         2013
        </year>
        <volume>
         48
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.peptides.2013.07.024
        </pub-id>
        <pub-id pub-id-type="pmid">
         23933301
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26-cancers-12-00747">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: A systematic review and meta-analysis
        </article-title>
        <source>
         Int. J. Clin. Exp. Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         8
        </volume>
        <fpage>
         12656
        </fpage>
        <lpage>
         12660
        </lpage>
        <pub-id pub-id-type="pmid">
         26550179
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27-cancers-12-00747">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           W.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           T.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Leu
          </surname>
          <given-names>
           H.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension
        </article-title>
        <source>
         Am. J. Cardiol.
        </source>
        <year>
         2011
        </year>
        <volume>
         107
        </volume>
        <fpage>
         1028
        </fpage>
        <lpage>
         1033
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.amjcard.2010.11.026
        </pub-id>
        <pub-id pub-id-type="pmid">
         21256465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28-cancers-12-00747">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bhaskaran
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Douglas
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Evans
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           van Staa
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Smeeth
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin receptor blockers and risk of cancer: Cohort study among people receiving antihypertensive drugs in UK General Practice Research Database
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2012
        </year>
        <volume>
         344
        </volume>
        <fpage>
         e2697
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.e2697
        </pub-id>
        <pub-id pub-id-type="pmid">
         22531797
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29-cancers-12-00747">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Egami
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Murohara
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Shimada
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Sasaki
          </surname>
          <given-names>
           K.I.
          </given-names>
         </name>
         <name>
          <surname>
           Shintani
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sugaya
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ishii
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Akagi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ikeda
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuishi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth
        </article-title>
        <source>
         J. Clin. Invest.
        </source>
        <year>
         2003
        </year>
        <volume>
         112
        </volume>
        <fpage>
         67
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="doi">
         10.1172/JCI16645
        </pub-id>
        <pub-id pub-id-type="pmid">
         12840060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30-cancers-12-00747">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fujiyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Matsubara
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Nozawa
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Maruyama
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Mori
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tsutsumi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Masaki
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Uchiyama
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Koyama
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Nose
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2001
        </year>
        <volume>
         88
        </volume>
        <fpage>
         22
        </fpage>
        <lpage>
         29
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/01.RES.88.1.22
        </pub-id>
        <pub-id pub-id-type="pmid">
         11139469
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31-cancers-12-00747">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ino
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Shibata
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kajiyama
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Nagasaka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Nawa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Nomura
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kikkawa
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival
        </article-title>
        <source>
         Br. J. Cancer
        </source>
        <year>
         2006
        </year>
        <volume>
         94
        </volume>
        <fpage>
         552
        </fpage>
        <lpage>
         560
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/sj.bjc.6602961
        </pub-id>
        <pub-id pub-id-type="pmid">
         16434990
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32-cancers-12-00747">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Batra
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Gopalakrishnan
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           McNeill
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hickie
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II elevates cytosolic free calcium in human lung adenocarcinoma cells via activation of AT1 receptors
        </article-title>
        <source>
         Cancer Lett.
        </source>
        <year>
         1994
        </year>
        <volume>
         76
        </volume>
        <fpage>
         19
        </fpage>
        <lpage>
         24
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0304-3835(94)90129-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         8124662
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33-cancers-12-00747">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arrieta
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Villarreal-Garza
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Vizcaíno
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Pineda
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Hernández-Pedro
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Guevara-Salazar
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wegman-Ostrosky
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Villanueva-Rodriguez
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Gamboa-Dominguez
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer
        </article-title>
        <source>
         Tumour Biol.
        </source>
        <year>
         2015
        </year>
        <volume>
         36
        </volume>
        <fpage>
         5627
        </fpage>
        <lpage>
         5634
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s13277-015-3235-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         25682288
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34-cancers-12-00747">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Fei
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer
        </article-title>
        <source>
         Oncol. Rep.
        </source>
        <year>
         2010
        </year>
        <volume>
         23
        </volume>
        <fpage>
         941
        </fpage>
        <lpage>
         948
        </lpage>
        <pub-id pub-id-type="pmid">
         20204277
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35-cancers-12-00747">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fujita
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hayashi
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Yamashina
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Itoman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Majima
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2002
        </year>
        <volume>
         294
        </volume>
        <fpage>
         441
        </fpage>
        <lpage>
         447
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0006-291X(02)00496-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         12051731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36-cancers-12-00747">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Suganuma
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ino
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Shibata
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kajiyama
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Nagasaka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Mizutani
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kikkawa
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination
        </article-title>
        <source>
         Clin. Cancer Res.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         2686
        </fpage>
        <lpage>
         2694
        </lpage>
        <pub-id pub-id-type="doi">
         10.1158/1078-0432.CCR-04-1946
        </pub-id>
        <pub-id pub-id-type="pmid">
         15814650
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B37-cancers-12-00747">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fujimoto
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sasaki
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tsuchida
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chayama
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist
        </article-title>
        <source>
         FEBS Lett.
        </source>
        <year>
         2001
        </year>
        <volume>
         495
        </volume>
        <fpage>
         197
        </fpage>
        <lpage>
         200
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0014-5793(01)02377-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         11334891
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B38-cancers-12-00747">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chipitsyna
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Yeo
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Arafat
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells
        </article-title>
        <source>
         Pancreas
        </source>
        <year>
         2010
        </year>
        <volume>
         39
        </volume>
        <fpage>
         581
        </fpage>
        <lpage>
         594
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/MPA.0b013e3181c314cd
        </pub-id>
        <pub-id pub-id-type="pmid">
         20118823
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B39-cancers-12-00747">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Makani
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Bangalore
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Desouza
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Shah
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Messerli
          </surname>
          <given-names>
           F.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2013
        </year>
        <volume>
         346
        </volume>
        <fpage>
         f360
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.f360
        </pub-id>
        <pub-id pub-id-type="pmid">
         23358488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B40-cancers-12-00747">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xing
          </surname>
          <given-names>
           Y.F.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lian
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of PM2.5 on the human respiratory system
        </article-title>
        <source>
         J. Thorac. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         8
        </volume>
        <fpage>
         E69
        </fpage>
        <lpage>
         E74
        </lpage>
        <pub-id pub-id-type="pmid">
         26904255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B41-cancers-12-00747">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Teschke
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kauppinen
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Andersen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jäppinen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Szadkowska-Stanczyk
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Pearce
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Persson
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Bergeret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Facchini
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mortality from lung cancer in workers exposed to sulfur dioxide in the pulp and paper industry
        </article-title>
        <source>
         Environ. Health Perspect.
        </source>
        <year>
         2002
        </year>
        <volume>
         110
        </volume>
        <fpage>
         991
        </fpage>
        <lpage>
         995
        </lpage>
        <pub-id pub-id-type="doi">
         10.1289/ehp.02110991
        </pub-id>
        <pub-id pub-id-type="pmid">
         12361923
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B42-cancers-12-00747">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilop
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           von Hobe
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Crysandt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Esser
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Osieka
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Jost
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy
        </article-title>
        <source>
         J. Cancer Res. Clin. Oncol.
        </source>
        <year>
         2009
        </year>
        <volume>
         135
        </volume>
        <fpage>
         1429
        </fpage>
        <lpage>
         1435
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00432-009-0587-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         19399518
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="cancers-12-00747-f001" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Cumulative incidence of lung cancer between ACEI and ARB users.
       </p>
      </caption>
      <graphic xlink:href="cancers-12-00747-g001">
      </graphic>
     </fig>
     <table-wrap id="cancers-12-00747-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       cancers-12-00747-t001_Table 1
      </object-id>
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Demographic characteristics and clinical comorbidity status in study cohorts by propensity score matching.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
          Covariate
         </th>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          ARB
          <break>
          </break>
          N = 22384
         </th>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          ACEI
          <break>
          </break>
          N = 22384
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <italic>
           n
          </italic>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          %
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <italic>
           n
          </italic>
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          %
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <italic>
           p
          </italic>
          -Value
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Age, years
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Mean ± SD
          <sup>
           a
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          58.9
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.9
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          58.8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          14.0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.39
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Sex
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.98
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Women
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          10225
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          45.7
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          10223
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          45.7
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Men
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12159
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          54.3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12161
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          54.3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Monthly income (NTD)
          <sup>
           †
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.001
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          &lt;15,000
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6222
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          27.8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6010
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          26.9
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          15,000−19,999
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11791
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          52.7
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12271
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          54.8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          ≥ 20,000
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4371
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          19.5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4103
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          18.3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Urbanization level
          <sup>
           ‡
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.001
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1 (highest)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6666
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          29.8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6072
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          27.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6166
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          27.6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          7005
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          31.3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3812
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          17.0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3791
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          16.9
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4 (lowest)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5740
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          25.6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5516
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          24.6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Comorbidity
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Hypertension
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          19772
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          88.3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          19776
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          88.4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.95
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Diabetes
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3347
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          15.0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3320
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          14.8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.72
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Tuberculosis
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          434
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.94
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          450
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.01
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.59
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Alcohol-related disease
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1199
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5.36
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1195
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5.34
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.93
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          COPD
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3459
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          15.5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3474
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          15.5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.84
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Chronic liver disease
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5838
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          26.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5782
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          25.8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.55
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Hyperlipidemia
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          8819
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          39.4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          8631
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          38.6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.07
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Asthma
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3044
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2993
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.48
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Stroke
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3148
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          14.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3268
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          14.6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.11
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          CAD
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          8158
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          36.5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          7900
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          35.3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.01
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Rheumatologic disease
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          748
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.34
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          742
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.31
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.87
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Medications
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          α-Blockers
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3359
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          15.0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3365
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          15.0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.94
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          β-Blockers
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13300
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          59.4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13310
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          59.5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.92
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Potassium sparing diuretics
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3076
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.7
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3087
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.88
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Thiazides
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          10450
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          46.7
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          10436
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          46.6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.89
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Loop diuretics
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5783
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          25.8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5767
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          25.8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.86
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          CCB (non-DHP or DHP)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          15484
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          69.2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          15603
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          69.7
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.22
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Others
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4173
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          18.6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4245
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          19.0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.38
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Air pollutants
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          PM2.5 μg/m
          <sup>
           3
          </sup>
          <break>
          </break>
          daily average (SD)
          <sup>
           a
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          34.8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          8.33
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          36.0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          8.47
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          &lt; 0.001
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          PM10 μg/m
          <sup>
           3
          </sup>
          <break>
          </break>
          daily average (SD)
          <sup>
           a
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          59.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          61.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          &lt; 0.001
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SO
          <sub>
           2
          </sub>
          ppb
          <break>
          </break>
          daily average (SD)
          <sup>
           a
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4.72
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1.93
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4.82
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1.99
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          &lt; 0.001
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         Chi-square test,
         <sup>
          a
         </sup>
         Mann-Whitney U test.
         <sup>
          †
         </sup>
         New Taiwan Dollar (NTD), 1 NTD is equal to 0.03 USD.
         <sup>
          ‡
         </sup>
         Urbanization level was divided into four levels according to the population density of the residential area, with level 1 being the most urbanized and level 4 being the least. Abbreviations: CAD, coronary artery disease.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="cancers-12-00747-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       cancers-12-00747-t002_Table 2
      </object-id>
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Cox analysis of overall incidence of lung cancer (per 10,000 person-years) and estimated hazard ratios according to medication status.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          ARB
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          ACEI
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Variables
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (N = 22384)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (N = 22384)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Person-years
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          141645
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          136981
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Follow-up time (y), Mean ± SD
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6.33 ± 3.52
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6.12 ± 3.47
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Event, n
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          173
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          228
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Rate
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12.2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          16.6
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          cHR (95% CI)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1(Reference)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.36(1.11, 1.65) **
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          aHR (95% CI)
          <sup>
           a
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1(Reference)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.36(1.11, 1.67) **
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         <sup>
          a
         </sup>
         Adjusting for sex, monthly income (in NTD), urbanization level and comorbidities including hypertension, diabetes, tuberculosis, alcohol-related disease, COPD, chronic liver disease, hyperlipidemia, asthma, stroke, CAD and rheumatologic disease, medication use including α-Blockers, β-Blockers, potassium-sparing diuretics, thiazides, loop diuretics, CCB (non-DHP or DHP), others and air pollutants including PM2.5, PM10 and SO2. Abbreviations: ACEI, angiotensin II converting enzyme inhibitor; ARB, angiotensin receptor blocker; cHR, crude hazard ratio; aHR, adjusted hazard ratio; **
         <italic>
          p
         </italic>
         &lt; 0.01.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="cancers-12-00747-t003" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       cancers-12-00747-t003_Table 3
      </object-id>
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Incidence and adjusted hazard ratios of lung cancer stratified by average days used per year, average dose per year and average DDD (defined daily dosages) per year of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Medication Exposed
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          N
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Event
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Person-Year
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Rate
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          aHR (95% CI)
          <sup>
           a
          </sup>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          ACEI
          <sup>
           #
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          Non-ACEI
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          22384
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          173
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          141645
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          12.2
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          1.00
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          ≤45 days
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11159
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          89
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          77982
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11.4
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          0.97(0.75, 1.26)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          &gt;45 days
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11225
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          139
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          58998
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          23.6
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          1.87(1.48, 2.36) ***
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          Non-ACEI
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          1.00
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          ≤540 mg
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11183
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          85
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          75254
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11.3
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          0.98(0.75, 1.28)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          &gt;540 mg
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11201
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          143
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          61726
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          23.2
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          1.80(1.43, 2.27) ***
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          Non-ACEI
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          1.00
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          ≤50 DDD
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11215
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          91
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          77329
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11.8
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          0.99(0.76, 1.28)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          &gt;50 DDD
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11169
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          137
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          59651
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          23.0
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          1.85(1.46, 2.34) ***
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          ARB
          <sup>
           #
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          Non-ARB
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          22384
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          228
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          136981
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          16.6
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          1.00
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          ≤200 days
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11175
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          78
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          73104
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          10.7
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          0.61(0.47, 0.80) ***
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          &gt;200 days
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11209
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          95
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          68541
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          13.9
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          0.88(0.69, 1.13)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          Non-ARB
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          1.00
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          ≤11200 mg
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          5394
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          56
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          27325
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          20.5
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          1.17(0.86, 1.59)
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          &gt;11200 mg
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          16990
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          117
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          114320
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          10.2
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          0.62(0.50, 0.79) ***
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          Non-ARB
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          1.00
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          ≤200 DDD
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11363
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          81
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          73414
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          11.0
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          0.63(0.48, 0.81) ***
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          &gt;200 DDD
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          11021
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          92
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          68231
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          13.5
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          0.87(0.67, 1.11)
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         <sup>
          #
         </sup>
         Average days used per year and average DDD dose per year are partitioned into two segments by median.
         <sup>
          a
         </sup>
         Adjusting for sex, monthly income (NTD), urbanization level and comorbidities including hypertension, diabetes, tuberculosis, alcohol-related disease, COPD, chronic liver disease, hyperlipidemia, asthma, stroke, CAD and rheumatologic disease and medication use including α-Blockers, β-Blockers, potassium-sparing diuretics, thiazides, loop diuretics, CCB (non-DHP or DHP), others and air pollutants including PM2.5, PM10 and SO2. Abbreviations: ACEI, angiotensin II converting enzyme inhibitor; ARB, angiotensin receptor blocker; aHR, adjusted hazard ratio; ***
         <italic>
          p
         </italic>
         &lt; 0.001.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Alzheimers Res Ther
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Alzheimers Res Ther
      </journal-id>
      <journal-title-group>
       <journal-title>
        Alzheimer's Research &amp; Therapy
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1758-9193
      </issn>
      <publisher>
       <publisher-name>
        BioMed Central
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       27884212
      </article-id>
      <article-id pub-id-type="pmc">
       5123239
      </article-id>
      <article-id pub-id-type="publisher-id">
       217
      </article-id>
      <article-id pub-id-type="doi">
       10.1186/s13195-016-0217-7
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Kehoe
         </surname>
         <given-names>
          Patrick Gavin
         </given-names>
        </name>
        <address>
         <phone>
          +44 (0) 117 4147821
         </phone>
         <email>
          Patrick.Kehoe@bristol.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wong
         </surname>
         <given-names>
          Steffenny
         </given-names>
        </name>
        <address>
         <email>
          sw0485@bristol.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          AL Mulhim
         </surname>
         <given-names>
          Noura
         </given-names>
        </name>
        <address>
         <email>
          na15725@bristol.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Palmer
         </surname>
         <given-names>
          Laura Elyse
         </given-names>
        </name>
        <address>
         <email>
          laura.e.palmer@bristol.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Miners
         </surname>
         <given-names>
          J. Scott
         </given-names>
        </name>
        <address>
         <phone>
          +44 (0) 117 4147818
         </phone>
         <email>
          Scot.Miners@bristol.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <aff id="Aff1">
        Dementia Research Group, University of Bristol, Level 1, Learning and Research, Southmead Hospital, Bristol, BS10 5NB UK
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        25
       </day>
       <month>
        11
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        25
       </day>
       <month>
        11
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2016
       </year>
      </pub-date>
      <volume>
       8
      </volume>
      <elocation-id>
       50
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         23
        </day>
        <month>
         9
        </month>
        <year>
         2016
        </year>
       </date>
       <date date-type="accepted">
        <day>
         20
        </day>
        <month>
         10
        </month>
        <year>
         2016
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s). 2016
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         <bold>
          Open Access
         </bold>
         This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">
          http://creativecommons.org/publicdomain/zero/1.0/
         </ext-link>
         ) applies to the data made available in this article, unless otherwise stated.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <sec>
        <title>
         Background
        </title>
        <p>
         Hyperactivity of the classical axis of the renin-angiotensin system (RAS), mediated by angiotensin II (Ang II) activation of the angiotensin II type 1 receptor (AT1R), is implicated in the pathogenesis of Alzheimer’s disease (AD). Angiotensin-converting enzyme-2 (ACE-2) degrades Ang II to angiotensin 1–7 (Ang ﻿﻿(1-7)) and counter-regulates the classical axis of RAS. We have investigated the expression and distribution of ACE-2 in post-mortem human brain tissue in relation to AD pathology and classical RAS axis activity.
        </p>
       </sec>
       <sec>
        <title>
         Methods
        </title>
        <p>
         We measured ACE-2 activity by fluorogenic peptide substrate assay in mid-frontal cortex (Brodmann area 9) in a cohort of AD (
         <italic>
          n
         </italic>
         = 90) and age-matched non-demented controls (
         <italic>
          n
         </italic>
         = 59) for which we have previous data on ACE-1 activity, amyloid β (Aβ) level and tau pathology, as well as known
         <italic>
          ACE1
         </italic>
         (rs1799752) indel polymorphism, apolipoprotein E (
         <italic>
          APOE
         </italic>
         ) genotype, and cerebral amyloid angiopathy severity scores.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         ACE-2 activity was significantly reduced in AD compared with age-matched controls (
         <italic>
          P
         </italic>
         &lt; 0.0001) and correlated inversely with levels of Aβ (
         <italic>
          r
         </italic>
         = −0.267,
         <italic>
          P
         </italic>
         &lt; 0.001) and phosphorylated tau (p-tau) pathology (
         <italic>
          r
         </italic>
         = −0.327,
         <italic>
          P
         </italic>
         &lt; 0.01). ACE-2 was reduced in individuals possessing an
         <italic>
          APOE
         </italic>
         ε4 allele (
         <italic>
          P
         </italic>
         &lt; 0.05) and was associated with
         <italic>
          ACE1
         </italic>
         indel polymorphism (
         <italic>
          P
         </italic>
         &lt; 0.05), with lower ACE-2 activity in individuals homozygous for the
         <italic>
          ACE1
         </italic>
         insertion AD risk allele. ACE-2 activity correlated inversely with ACE-1 activity (
         <italic>
          r
         </italic>
         = −0.453,
         <italic>
          P
         </italic>
         &lt; 0.0001), and the ratio of ACE-1 to ACE-2 was significantly elevated in AD (
         <italic>
          P
         </italic>
         &lt; 0.0001). Finally, we show that the ratio of Ang II to Ang (1–7) (a proxy measure of ACE-2 activity indicating  conversion of Ang II to Ang (1–7)) is reduced in AD.
        </p>
       </sec>
       <sec>
        <title>
         Conclusions
        </title>
        <p>
         Together, our findings indicate that ACE-2 activity is reduced in AD and is an important regulator of the central classical ACE-1/Ang II/AT1R axis of RAS, and also that dysregulation of this pathway likely plays a significant role in the pathogenesis of AD.
        </p>
       </sec>
       <sec>
        <title>
         Electronic supplementary material
        </title>
        <p>
         The online version of this article (doi:10.1186/s13195-016-0217-7) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Angiotensin-converting enzyme-2
       </kwd>
       <kwd>
        Renin-angiotensin system
       </kwd>
       <kwd>
        Angiotensin-converting enzyme-1
       </kwd>
       <kwd>
        Angiotensin II
       </kwd>
       <kwd>
        Alzheimer’s disease
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2016
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Background
     </title>
     <p>
      Genetic, clinical and epidemiological data as well as experimental cell and animal studies all support a role for the renin-angiotensin system (RAS) in the pathogenesis of Alzheimer’s disease (AD) [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]. Many of the pro-inflammatory, anti-cholinergic and vasopressor actions of RAS associated with the pathogenesis of AD are mediated by angiotensin II (Ang II) signalling through the angiotensin II type 1 receptor (AT1R), commonly referred to as the
      <italic>
       classical axis
      </italic>
      (reviewed in [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]). Intracerebroventricular infusion of Ang II increased both amyloid-β (Aβ) (via increased amyloidogenic processing of amyloid precursor protein [APP]) [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ] and tau pathology, and also reduced cognitive performance [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ], in aged normal rats. We have previously reported that angiotensin-converting enzyme-1 (ACE-1), the rate-limiting enzyme in the production of angiotensin II (Ang II), is increased in AD in human brain tissue [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ]. Angiotensin II type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) reduce the amount of AD-like pathology and improve cognitive performance in most but not all mouse models of AD [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      –
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ]. Translation of these treatments in AD is also supported in secondary outcomes of clinical trials of various ARBs and ACEIs, as well as in epidemiological studies where the prevalence of AD was reduced [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      –
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ]. Last, the
      <italic>
       ACE-1
      </italic>
      indel polymorphism (rs1799752) is a genetic risk factor for sporadic AD [
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ]. This finding has previously been supported by several meta-analyses [
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
      –
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
      ] but not by recent genome-wide association studies.
     </p>
     <p>
      ACE-2 is a zinc metallopeptidase which shares 42% sequence homology within the ACE-1 catalytic region [
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ]. The ACE-2 metalloprotease is expressed mostly as a transmembrane protein, but it also exists in an active soluble truncated form [
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ]. It is expressed predominantly in endothelial and arterial smooth muscle cells throughout the body [
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ], but it is also expressed in non-vascular cells within the brain, including neuronal cell bodies [
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      ] and astroglial cells [
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      ]. Upon its discovery, ACE-2 was shown to generate angiotensin 1–7 (Ang (1-7)) from Ang II, and, to a lesser extent, angiotensin 1–9 (Ang (1-9)) from Ang I [
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ]. Emerging data suggest that ACE-2-mediated conversion of Ang II to Ang (1–7) and subsequent activation of the Mas receptor by Ang (1–7) (comprising the ACE-2/Ang (1-7) /Mas axis) oppose the local actions of the classical RAS pathway in both the periphery (reviewed in [
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      ]) and brain (reviewed in [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      –
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ]). In experimental animal studies, ACE-2 regulates blood pressure by counteracting the effects of the classical axis. A reduction in ACE-2 expression has been implicated in cardiac and renal pathologies (reviewed in [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ]) associated with chronic hypertension. Activation of brain ACE-2 has been shown to be neuroprotective in animal models of ischaemic stroke [
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ,
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
      ].
     </p>
     <p>
      Previous studies have suggested a link between reduced activity of the ACE-2/Ang (1–7)/Mas axis and neurodegenerative conditions, including multiple sclerosis [
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
      ]. A recent study provided the first clues of an association with AD and reported reduced serum ACE-2 activity in patients with AD compared with control subjects [
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ]. Notably, this study also identified that ACE-2 converts Aβ
      <sub>
       43
      </sub>
      (an early deposited and highly amyloidogenic form of Aβ that seeds plaque formation [
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      ]) to Aβ
      <sub>
       42
      </sub>
      , which in turn is cleaved by ACE-1 to less toxic Aβ
      <sub>
       40
      </sub>
      and Aβ
      <sub>
       41
      </sub>
      species [
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ]. Ang (1–7) levels were also reduced in a mouse model of sporadic AD in association with hyperphosphorylation of tau [
      <xref ref-type="bibr" rid="CR39">
       39
      </xref>
      ].
     </p>
     <p>
      In the present study, we investigated the expression and distribution of ACE-2 in relation to AD pathology and the classical RAS axis in human post-mortem brain tissue. We show, for the first time to our knowledge, that ACE-2 activity is reduced in human post-mortem brain tissue in AD in relation to Aβ and tau pathology, and also that ACE-2 correlates inversely with ACE-1 activity. We also show that the ratio of Ang II to Ang (1–7) (a proxy measure of ACE-2 activity) was increased in AD, indicating reduced conversion of Ang II to Ang (1–7). Together, these data indicate that the ACE-2/Ang (1–7)/Mas axis is dysregulated in AD and that loss of function of this regulatory arm of RAS may contribute, at least in part, to overactivation of the classical RAS axis associated with AD pathogenesis.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Methods
     </title>
     <sec id="Sec3">
      <title>
       Case selection
      </title>
      <p>
       Brain tissue was obtained from the South West Dementia Brain Bank, University of Bristol, UK, with local research ethics committee approval (National Research Ethics Service 08/H0106/28 + 5). Tissue was dissected from the mid-frontal cortex (Brodmann area 9) in 90 cases of AD and 59 age-matched controls. Brains had been subjected to detailed neuropathological assessment according to the National Institute on Aging-Alzheimer’s Association guidelines [
       <xref ref-type="bibr" rid="CR40">
        40
       </xref>
       ], and AD pathology was a sufficient explanation for the dementia in these cases. Control brains were from people who had no history of dementia, had been extensively assessed neuropathologically, and had few or absent neuritic plaques, Braak tangle stage III or less, and no other neuropathological abnormalities. The demographic data for these cases are presented in Table
       <xref ref-type="table" rid="Tab1">
        1
       </xref>
       , and the Medical Research Council UK Brain Banks Network (MRC UK-BBN) database identifiers are shown in Additional file
       <xref ref-type="media" rid="MOESM1">
        1
       </xref>
       : Table S1.
       <table-wrap id="Tab1">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Demographics of the study cohort
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
           </th>
           <th>
            Control (
            <italic>
             n
            </italic>
            = 59)
           </th>
           <th>
            AD (
            <italic>
             n
            </italic>
            = 90)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Age, years, mean ± SD
           </td>
           <td>
            78.5 ± 10.1
           </td>
           <td>
            78.5 ± 9.7
           </td>
          </tr>
          <tr>
           <td>
            Sex, F/M
           </td>
           <td>
            22/37
           </td>
           <td>
            55/35
           </td>
          </tr>
          <tr>
           <td>
            PM delay, h, mean ± SD)
           </td>
           <td>
            43.8 ± 36.4
           </td>
           <td>
            45.2 ± 25.1
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          <italic>
           AD
          </italic>
          Alzheimer’s disease,
          <italic>
           PM
          </italic>
          Post-mortem
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p>
       Previous measurements of ACE-1 activity, measured by fluorogenic activity assay, were available for all cases [
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="CR41">
        41
       </xref>
       ]. Total soluble (Nonidet P-40-extracted) and insoluble (6 M guanidine hydrochloride-extracted) Aβ levels were measured previously by sandwich enzyme-linked immunosorbent assay (ELISA) [
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
       ], and cerebral amyloid angiopathy (CAA) severity, which was graded semi-quantitatively on a 4-point scale by a method adapted from that of Olichney et al. [
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
       ], had previously been reported [
       <xref ref-type="bibr" rid="CR44">
        44
       </xref>
       ]. Phosphorylated tau (p-tau) load (area fraction of cerebral cortex immunopositive for p-tau) had been measured for all cases, as previously reported [
       <xref ref-type="bibr" rid="CR45">
        45
       </xref>
       ,
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
       ].
       <italic>
        ACE1
       </italic>
       genotype data for the Alu 237-bp insertion(I)/deletion(D) (indel) polymorphism (rs1799752) in intron 16 of the ACE1 gene were previously reported [
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="CR41">
        41
       </xref>
       ]. Last, all cases had previously been apolipoprotein E (
       <italic>
        APOE
       </italic>
       )-genotyped [
       <xref ref-type="bibr" rid="CR44">
        44
       </xref>
       ,
       <xref ref-type="bibr" rid="CR47">
        47
       </xref>
       ] by a polymerase chain reaction method [
       <xref ref-type="bibr" rid="CR48">
        48
       </xref>
       ].
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Brain tissue
      </title>
      <p>
       The right cerebral cortex had been fixed in 10% formalin for a minimum of 3 weeks before the tissue was processed and paraffin blocks were taken for pathological assessment. The left cerebral hemisphere had been sliced and frozen at −80 °C until used for biochemical assessment. For each case, 200 mg of dissected frozen brain tissue was homogenised in a Precellys homogeniser (Stretton Scientific, Stretton, UK) as previously described [
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
       ]. The samples were centrifuged at 13,000 rpm, and the clarified supernatants were aliquoted and stored at −80 °C until required. Total protein was measured using the Total Protein kit (Sigma-Aldrich, Poole, UK) following the manufacturer’s guidelines. All brain tissue was obtained within 72 h after death.
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       ACE-2 activity assay
      </title>
      <p>
       ACE-2 activity was measured in brain tissue using the SensoLyte® 390 ACE2 activity assay kit (catalogue number AS-72086; AnaSpec, Fremont, CA, USA). The assay was performed in black, flat-bottomed, non-binding, 96-well Nunc FluoroNunc plates (Fisher Scientific, Loughborough, UK) following the manufacturer’s guidelines with minor modifications. Brain tissue homogenates were prepared in assay buffer provided in the kit, to which 0.05% Triton X-100 was added. Samples were centrifuged at 13,000 rpm for 15 minutes at 4 °C, and supernatants were removed and stored at −80 °C until used. Supernatants were diluted 1:100 in the proprietary ACE-2 assay buffer and incubated for 10 minutes at room temperature prior to addition of the ACE-2-specific fluorescence resonance energy transfer (FRET) peptide and then incubated for 30 minutes in the dark. Cleavage of the ACE-2 FRET peptide was measured using a BMG FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) at an excitation/emission wavelength of 330/390 nm. ACE-2 activity was interpolated from a serial dilution of 7-methoxycoumarin-4-yl-acetyl (Mca) fluorescence reference standard, and measurements for each case were repeated in duplicate.
      </p>
      <p>
       To confirm the specificity of the commercial ACE-2 assay kit, we measured ACE-2 activity in a subset of samples (ten controls and ten AD) for which we had previously measured ACE-2 activity as outlined above. The assay was performed in black, flat-bottomed, non-binding, 96-well Nunc FluoroNunc plates. Recombinant human ACE-2 (440-6 ng/ml) (R&amp;D Systems, Cambridge, UK) and brain tissue supernatants (diluted 1:20) were diluted in assay buffer (75 mM Tris, 1 M NaCl, pH 7.5) and pre-incubated with an ACE-2 specific inhibitor, MLN4760 (10 μM) (Calbiochem, Nottingham, UK) or assay buffer alone for 10 minutes at 37 °C. An ACE-2 fluorogenic peptide Mca-APK(Dnp) (Enzo Life Sciences, Exeter, UK) was then added, and the reaction was incubated at 37 °C for 30 minutes in the dark. Fluorescence was read at an excitation/emission wavelength of 330/405 nm using a BMG FLUOstar OPTIMA microplate reader. ACE-2-specific activity was calculated after subtracting fluorescence in the presence of MLN-4760 from the uninhibited sample. We observed a very strong correlation between the independent measurements of ACE-2 in the presence of MLN4760 (10 μM) and with the kit, indicating the specificity of the ACE-2 assay kit (Additional file
       <xref ref-type="media" rid="MOESM2">
        2
       </xref>
       : Figure S1).
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       Angiotensin II sandwich ELISA
      </title>
      <p>
       Ang II levels were measured in brain tissue homogenates extracted in 1% SDS lysis buffer (100 μM NaCl, 10 mM Tris, pH 6, 1 μM phenylmethylsulphonylfluoride, 1 μg/ml aprotinin [Sigma-Aldrich] and 1% SDS in distilled water) using a commercially available sandwich ELISA kit (Abcam, Cambridge, UK) following the manufacturer’s guidelines. In brief, recombinant human Ang II or brain tissue supernatants (diluted 1:2 in PBS) were added in duplicate to wells that had been pre-coated with an Ang II-specific capture antibody and incubated for 2 h at room temperature. After a wash step, the wells were incubated for 2 h with biotinylated anti-Ang II antibody at room temperature. The plate was again washed, followed by a 30-minute incubation with streptavidin/HRP. After a final wash, 3,3′,5,5′-tetramethylbenzidine (TMB) substrate was added for 20 minutes, and the absorbance at 450 nm was read using a FLUOstar OPTIMA plate reader. The concentration of Ang II was interpolated from a serial dilution of recombinant Ang II (1000–62.5 pg/ml) and measured in duplicate for each case.
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       Angiotensin (1–7) direct ELISA
      </title>
      <p>
       Ang (1–7) levels were measured in human brain tissue homogenates in 1% SDS lysis buffer (see above) using an in-house direct ELISA kit. Recombinant human Ang (1–7) (Enzo Life Sciences) or human brain tissue homogenates (diluted 1:40 In PBS) were incubated for 2 h in a clear, high binding capacity Nunc MaxiSorp plate (Thermo Fisher Scientific, Waltham, MA, USA) at 26 °C with shaking. The wells were washed five times in PBS with 0.05% Tween-20 and blocked for 1 h in PBS:1% bovine serum albumin (Sigma-Aldrich). After another five washes, the wells were incubated with biotinylated anti-human Ang 1–7 (2 μg/ml in PBS) (Cloud-Clone, Wuhan, China) for 2 h at 26 °C with shaking, followed by a further wash step. Streptavidin/HRP (1:200) in PBS/0.01% Tween-20 was added to each well, which was incubated at room temperature for 20 minutes in the dark. TMB substrate (R&amp;D Systems) was added after a further wash and left to develop in the dark for 20 minutes. Absorbance at 450 nm was read following the addition of 2 N sulphuric acid (‘stop’ solution) using a FLUOstar OPTIMA plate reader. Ang (1–7) concentration was interpolated from a standard curve generated by serially diluting recombinant human Ang (1–7) (5000–78.125 pg/ml). The assay showed minimal cross-reactivity with a number of closely related peptides, including Ang I, Ang II and Ang III.
      </p>
     </sec>
     <sec id="Sec8">
      <title>
       ACE-2 immunoperoxidase labelling
      </title>
      <p>
       Formalin-fixed, paraffin-embedded tissue sections (7 μm) were cut and de-waxed prior to immunohistochemistry. Sections were pre-treated in trisodium citrate buffer (9 mM), pH 6, and microwaved for 5 minutes, left to stand for 5 minutes, and boiled for a further 5 minutes before being left to stand for 15 minutes at room temperature. Sections were then rinsed thoroughly and covered in horse serum blocking solution, rinsed again, and incubated overnight at room temperature with anti-ACE-2 antibody (0.05 μg/ml, ab15348; Abcam). Bound antibody was visualised using a biotinylated universal antibody followed by VECTASTAIN Elite ABC avidin-biotin complex kit (Vector Laboratories, Peterborough, UK) and a reaction with 0.01% H
       <sub>
        2
       </sub>
       O
       <sub>
        2
       </sub>
       . Specificity of the antibody was assessed by pre-adsorption of the ACE-2 antibody with a 250-fold molar excess of recombinant human ACE-2 protein (R&amp;D Systems).
      </p>
     </sec>
     <sec id="Sec9">
      <title>
       Statistical analysis
      </title>
      <p>
       Unpaired two-tailed
       <italic>
        t
       </italic>
       tests or analysis of variance (ANOVA) with Bonferroni’s post hoc analysis was used for comparisons between groups, and Pearson’s test was used to assess linear correlation with SPSS version 16 (SPSS, Chicago, IL, USA) and GraphPad Prism version 6 (GraphPad Software, La Jolla, CA, USA) software.
       <italic>
        P
       </italic>
       values &lt;0.05 were considered statistically significant.
      </p>
     </sec>
    </sec>
    <sec id="Sec10">
     <title>
      Results
     </title>
     <sec id="Sec11">
      <title>
       ACE-2 enzyme activity is reduced in Alzheimer’s disease in association with increasing Aβ load and tau pathology
      </title>
      <p>
       ACE-2 activity was significantly reduced by approximately 50% in the mid-frontal cortex in AD compared with age-matched controls (
       <italic>
        P
       </italic>
       &lt; 0.0001) (Fig.
       <xref ref-type="fig" rid="Fig1">
        1a
       </xref>
       ). ACE-2 varied according to disease severity when the controls and AD cases were grouped and stratified into the following Braak tangle stage groups: 0–II, III–IV, and V-VI (
       <italic>
        P
       </italic>
       &lt; 0.0001 by ANOVA). Post hoc analysis using the Bonferroni correction for multiple comparisons revealed that ACE-2 activity was significantly reduced in Braak tangle stages V–VI compared with stages 0–II (
       <italic>
        P
       </italic>
       &lt; 0.0001) and stages III–IV (
       <italic>
        P
       </italic>
       &lt; 0.05) (Fig.
       <xref ref-type="fig" rid="Fig1">
        1b
       </xref>
       ). No difference was observed between Braak stages 0–II and stages III–IV.
       <fig id="Fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Angiotensin-converting enzyme 2 (ACE-2) activity is reduced in Alzheimer’s disease (AD).
          <bold>
           a
          </bold>
          Bar chart showing reduced ACE-2 activity in the mid-frontal cortex in AD (
          <italic>
           n
          </italic>
          = 90) compared with age-matched controls (
          <italic>
           n
          </italic>
          = 59) (
          <italic>
           P
          </italic>
          &lt; 0.0001).
          <bold>
           b
          </bold>
          Bar chart showing reduced ACE-2 activity in relation to disease severity when all cases were combined and grouped according to Braak stage (0–II, II–IV, and V–VI) (
          <italic>
           P
          </italic>
          &lt; 0.0001). Post hoc analysis revealed that ACE-2 activity was reduced in Braak tangle stages V–VI compared with stages 0–II and III-IV (﻿
          <italic>
           P
          </italic>
          &lt; 0.0001 and
          <italic>
           P &lt;
          </italic>
          0.05 respectively) and in Braak tangle stages III–IV compared with stages 0–II, but the difference was not statistically different. The bars indicate the mean value and SEM.
          <bold>
           c
          </bold>
          and
          <bold>
           d
          </bold>
          Scatterplots showing that ACE-2 activity was inversely correlated with insoluble amyloid-β (Aβ) load (measured by enzyme-linked immunosorbent assay) (
          <italic>
           r
          </italic>
          = −0.267,
          <italic>
           P
          </italic>
          &lt; 0.01) and phosphorylated tau (p-tau) load (measured by field fraction analysis) (
          <italic>
           r
          </italic>
          = −0.327,
          <italic>
           P
          </italic>
          &lt; 0.001). The
          <italic>
           solid inner line
          </italic>
          indicates the best-fit linear regression and the
          <italic>
           outer lines
          </italic>
          the 95% confidence intervals. *
          <italic>
           P
          </italic>
          &lt; 0.05, **
          <italic>
           P
          </italic>
          &lt; 0.01, ***
          <italic>
           P
          </italic>
          &lt; 0.001, ****
          <italic>
           P
          </italic>
          &lt; 0.0001.
          <italic>
           rfu
          </italic>
          Relative fluorescence units
         </p>
        </caption>
        <graphic id="MO1" xlink:href="13195_2016_217_Fig1_HTML">
        </graphic>
       </fig>
      </p>
      <p>
       In a combined AD and control cohort, ACE-2 activity correlated inversely with total insoluble Aβ levels (
       <italic>
        r
       </italic>
       = −0.267,
       <italic>
        P
       </italic>
       &lt; 0.01) (Fig.
       <xref ref-type="fig" rid="Fig1">
        1c
       </xref>
       ) but not with soluble Aβ (data not shown). ACE-2 correlated inversely with β-secretase activity (
       <italic>
        r
       </italic>
       = −0.277
       <italic>
        P
       </italic>
       &lt; 0.001) (Additional file
       <xref ref-type="media" rid="MOESM3">
        3
       </xref>
       : Figure S2). ACE-2 correlated inversely with p-tau load (
       <italic>
        r
       </italic>
       = 0.327,
       <italic>
        P
       </italic>
       &lt; 0.01) (Fig.
       <xref ref-type="fig" rid="Fig1">
        1d
       </xref>
       ).
      </p>
     </sec>
     <sec id="Sec12">
      <title>
       ACE-2 activity is reduced in relation to
       <italic>
        APOE
       </italic>
       and
       <italic>
        ACE1
       </italic>
       polymorphisms and CAA severity
      </title>
      <p>
       ACE-2 activity was significantly lower in individuals possessing an
       <italic>
        APOE
       </italic>
       ε4 allele, an established genetic risk factor for sporadic AD [
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
       ], than in those without (
       <italic>
        P
       </italic>
       &lt; 0.05) (Fig.
       <xref ref-type="fig" rid="Fig2">
        2a
       </xref>
       ). ACE-2 activity also differed significantly between
       <italic>
        ACE1
       </italic>
       (rs1799752) indel genotypes (
       <italic>
        P
       </italic>
       &lt; 0.05), with individuals who were homozygous II for
       <italic>
        ﻿ACE-1
       </italic>
       (previously associated with increased risk for AD [
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ]) having the lowest ACE-2 activity, although post hoc analysis revealed that this did not reach statistical significance (Fig.
       <xref ref-type="fig" rid="Fig2">
        2b
       </xref>
       ).
       <fig id="Fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Angiotensin-converting enzyme 2 (ACE-2) activity is reduced in association with apolipoprotein E (
          <italic>
           APOE
          </italic>
          ) ε4 and
          <italic>
           ACE1
          </italic>
          (rs1799752) indel polymorphism and increased in cerebral amyloid angiopathy (CAA).
          <bold>
           a
          </bold>
          Bar chart showing reduced ACE-2 activity in individuals with an
          <italic>
           APOE
          </italic>
          ε4 allele (
          <italic>
           P
          </italic>
          &lt; 0.05).
          <bold>
           b
          </bold>
          Bar chart showing that ACE-2 activity varied according to
          <italic>
           ACE1
          </italic>
          ﻿indel polymorphism (
          <italic>
           P
          </italic>
          &lt; 0.05), with a trend towards reduced ACE-2 activity in
          <italic>
           ACE-1
          </italic>
          II homozygotes.
          <bold>
           c
          </bold>
          Bar chart showing elevated ACE-2 activity in moderate to severe CAA compared with absent to mild CAA, approaching significance (
          <italic>
           P
          </italic>
          = 0.08). The bars indicate the mean value and SEM. *
          <italic>
           P
          </italic>
          &lt; 0.05.
          <italic>
           rfu
          </italic>
          Relative fluorescence units
         </p>
        </caption>
        <graphic id="MO2" xlink:href="13195_2016_217_Fig2_HTML">
        </graphic>
       </fig>
      </p>
      <p>
       We assessed ACE-2 activity in relation to CAA severity and found, as for ACE-1 activity [
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
       ], a tendency, although not significant, towards increased ACE-2 activity in cases with moderate to severe CAA compared with absent to mild CAA (
       <italic>
        P
       </italic>
       = 0.08) (Fig.
       <xref ref-type="fig" rid="Fig2">
        2c
       </xref>
       ).
      </p>
     </sec>
     <sec id="Sec13">
      <title>
       ACE-2 is inversely correlated with ACE-1, and the ratio of ACE-1 to ACE-2 is increased in Alzheimer’s disease
      </title>
      <p>
       ACE-2 activity correlated inversely with ACE-1 activity in a combined AD and control cohort (
       <italic>
        r
       </italic>
       = −0.453,
       <italic>
        P
       </italic>
       &gt; 0.0001) (Fig.
       <xref ref-type="fig" rid="Fig3">
        3a
       </xref>
       ). The same pattern was observed and remained statistically significant when the control (
       <italic>
        r
       </italic>
       = −0.390,
       <italic>
        P
       </italic>
       &lt; 0.05) and AD (
       <italic>
        r
       </italic>
       = −0.257,
       <italic>
        P
       </italic>
       &lt; 0.05) groups were analysed separately.
       <fig id="Fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Angiotensin-converting enzyme 2 (ACE-2) activity is inversely correlated with ACE-1 activity, and the ACE-1/ACE-2 ratio is increased, in Alzheimer’s disease (AD).
          <bold>
           a
          </bold>
          Scatterplot showing a strong inverse relationship between ACE-1 and ACE-2 activity in mid-frontal cortex (
          <italic>
           r
          </italic>
          = −.453,
          <italic>
           P
          </italic>
          &lt; 0.0001). The
          <italic>
           inner solid line
          </italic>
          indicates the best-fit linear regression and the
          <italic>
           outer lines
          </italic>
          the 95% confidence intervals. Each dot represents an individual brain.
          <bold>
           b
          </bold>
          Bar chart showing elevated ACE-1/ACE-2 ratio in AD (
          <italic>
           P
          </italic>
          &lt; 0.0001).
          <bold>
           c
          </bold>
          and
          <bold>
           d
          </bold>
          Scatterplots showing positive correlation between the ACE-1/ACE-2 ratio and insoluble amyloid-β (Aβ) load (
          <italic>
           r
          </italic>
          = 0.199,
          <italic>
           P
          </italic>
          = 0.059) and p-tau load (
          <italic>
           r
          </italic>
          = 0.252,
          <italic>
           P
          </italic>
          &lt; 0.05).
          <bold>
           e
          </bold>
          Bar chart showing a trend towards increased ACE-1/ACE-2 ratio in individuals who possessed an apolipoprotein E (
          <italic>
           APOE
          </italic>
          ) ε4 allele.
          <bold>
           f
          </bold>
          Bar chart showing lower ACE:ACE-2 ratio in individuals who were homozygous DD for the
          <italic>
           ACE1
          </italic>
          (rs1799752) indel polymorphism compared with II (
          <italic>
           P
          </italic>
          &lt; 0.01) and ID (
          <italic>
           P
          </italic>
          &lt; 0.05). The bars indicate the mean value and SEM. *
          <italic>
           P
          </italic>
          &lt; 0.05, **
          <italic>
           P
          </italic>
          &lt; 0.01, ****
          <italic>
           P
          </italic>
          &lt; 0.0001.
          <italic>
           rfu
          </italic>
          Relative fluorescence units
         </p>
        </caption>
        <graphic id="MO3" xlink:href="13195_2016_217_Fig3_HTML">
        </graphic>
       </fig>
      </p>
      <p>
       Previous reports have suggested the ratio of ACE-1 to ACE-2 is a good proxy measure for the activation status of classical and regulatory RAS pathways [
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
       ]. With this in mind, we calculated the ACE-1/ACE-2 ratio for all cases and found that it was significantly increased in AD compared with controls (
       <italic>
        P
       </italic>
       &gt; 0.0001) (Fig.
       <xref ref-type="fig" rid="Fig3">
        3b
       </xref>
       ). The ACE-1/ACE-2 ratio also correlated positively with insoluble Aβ level, approaching significance (
       <italic>
        r
       </italic>
       = 0.199,
       <italic>
        P
       </italic>
       = 0.059) (Fig.
       <xref ref-type="fig" rid="Fig3">
        3c
       </xref>
       ), and significantly with p-tau (
       <italic>
        r
       </italic>
       = 0.252,
       <italic>
        P
       </italic>
       &lt; 0.05) (Fig.
       <xref ref-type="fig" rid="Fig3">
        3d
       </xref>
       ). The ACE-1/ACE-2 ratio was increased in individuals possessing an
       <italic>
        APOE
       </italic>
       ε4 allele, approaching significance (
       <italic>
        P
       </italic>
       = 0.093) (Fig.
       <xref ref-type="fig" rid="Fig3">
        3e
       </xref>
       ), and differed significantly according to
       <italic>
        ACE1
       </italic>
       (rs1799752) indel polymorphism (
       <italic>
        P
       </italic>
       &lt; 0.01). Post hoc analysis revealed that the ratio was significantly higher in individuals with
       <italic>
        ACE1
       </italic>
       II (AD risk factor) than in DD (
       <italic>
        P
       </italic>
       &lt; 0.01) and in ID than in DD (
       <italic>
        P
       </italic>
       &lt; 0.05) (Fig.
       <xref ref-type="fig" rid="Fig3">
        3f
       </xref>
       ).
      </p>
     </sec>
     <sec id="Sec14">
      <title>
       Ang II/Ang (1-7) ratio is increased in AD
      </title>
      <p>
       Ang II levels were significantly increased in mid-frontal cortex in AD compared with age-matched controls (
       <italic>
        P
       </italic>
       &lt; 0.0001) (Fig.
       <xref ref-type="fig" rid="Fig4">
        4a
       </xref>
       ), whereas Ang (1–7) levels were unchanged (Fig.
       <xref ref-type="fig" rid="Fig4">
        4b
       </xref>
       ). We calculated the Ang II/Ang (1–7) ratio (as a proxy indicator of ACE-2 activity) and found that the Ang II/Ang (1–7) ratio was significantly increased in AD (
       <italic>
        P
       </italic>
       &gt; 0.001) (Fig.
       <xref ref-type="fig" rid="Fig4">
        4c
       </xref>
       ). These data indicate that the conversion of Ang II to Ang (1–7) is likely to be reduced in AD because of lower ACE-2 activity.
       <fig id="Fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          The ratio of angiotensin II (Ang II) to angiotensin (1–7) ﻿﻿(Ang ﻿(1-7)) (a proxy measure of ACE-2 activity) is increased, indicating reduced conversion of Ang II to Ang (1–7) in Alzheimer’s disease (AD). Bar charts showing
          <bold>
           a
          </bold>
          elevated Ang II levels in AD and
          <bold>
           b
          </bold>
          unchanged Ang (1–7) levels in AD compared with age-matched controls in mid-fontal cortex.
          <bold>
           c
          </bold>
          Bar chart showing the Ang II/Ang (1–7) ratio was significantly increased in AD (
          <italic>
           P
          </italic>
          &lt; 0.001). The bars indicate the mean value and SEM. ***
          <italic>
           P
          </italic>
          &lt; 0.001, ****
          <italic>
           P
          </italic>
          &lt; 0.0001
         </p>
        </caption>
        <graphic id="MO4" xlink:href="13195_2016_217_Fig4_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec15">
      <title>
       ACE-2 expression in human brain tissue
      </title>
      <p>
       ACE-2 was localised primarily to capillaries but also had a perivascular distribution around larger arterioles (Fig.
       <xref ref-type="fig" rid="Fig5">
        5a
       </xref>
       ). ACE-2 labelled non-vascular cells that strongly resembled astrocytes (Fig.
       <xref ref-type="fig" rid="Fig5">
        5b and c
       </xref>
       ). Labelling was not observed with pre-adsorption of the ACE-2 antibody with recombinant human ACE-2, demonstrating specificity of the antibody (Fig.
       <xref ref-type="fig" rid="Fig5">
        5d
       </xref>
       ).
       <fig id="Fig5">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Angiotensin-converting enzyme 2 (ACE-2) expression in mid-frontal cortex in Alzheimer’s disease.
          <bold>
           a
          </bold>
          and
          <bold>
           b
          </bold>
          ACE-2 displayed strong capillary labelling (
          <italic>
           black arrows
          </italic>
          ) and abundant perivascular labelling of larger arterioles (scale bar = 100 μm). Shown in
          <bold>
           b
          </bold>
          at higher magnification (scale bar = 50 μm).
          <bold>
           b
          </bold>
          and
          <bold>
           c
          </bold>
          ACE-2 was present in astrocytes (scale bar = 50 μm).
          <bold>
           d
          </bold>
          Pre-adsorption of ACE-2 antibody with recombinant human ACE-2 abolished labelling, confirming antibody specificity (scale bar = 100 μm)
         </p>
        </caption>
        <graphic id="MO5" xlink:href="13195_2016_217_Fig5_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="Sec16">
     <title>
      Discussion
     </title>
     <p>
      In the present study, we show that ACE-2 activity is reduced in post-mortem brain tissue in AD in association with increased Aβ and tau pathology. The reduction in ACE-2 was more pronounced in individuals carrying an
      <italic>
       APOE
      </italic>
      ε4 allele and in those who were homozygous II for the
      <italic>
       ACE1
      </italic>
      (rs1799752)﻿ indel polymorphism (both of which are suggested genetic risk factors for AD [
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ]). ACE-2 activity correlated inversely with ACE-1 activity (which we have previously shown to be increased in AD [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ]), and the ACE-1/ACE-2 ratio was higher in AD. Together, these data strongly suggest that reduced ACE-2 activity within the brain contributes to AD pathogenesis and is associated with increased activation of the central classical RAS axis.
     </p>
     <p>
      The brain has its own intrinsic RAS [
      <xref ref-type="bibr" rid="CR50">
       50
      </xref>
      –
      <xref ref-type="bibr" rid="CR52">
       52
      </xref>
      ], and we have shown in our previous studies that ACE-1, the rate-limiting enzyme in the production of Ang II, is overactive in AD [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ]. It is widely accepted that Ang II-mediated signalling via AT1R (commonly termed the
      <italic>
       classical axis
      </italic>
      ) is overactive in AD and is associated with AD pathogenesis (reviewed in [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]). This view has been supported in various animal studies in which infusion of Ang II resulted in elevated plaque and tau pathology and significant cognitive impairment [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. Secondary observations in clinical trials and epidemiological studies have provided further evidence that RAS-targeting drugs that either block the production of Ang II or prevent AT1R-mediated signalling reduce the prevalence of AD [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      –
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ], while cognitive performance is improved and pathology reduced, in animal models of AD [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      –
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ]. Until recently, the prevailing view of the RAS in AD has been oversimplified because it has failed to consider the contribution of the other downstream RAS regulatory pathways within the brain.
     </p>
     <p>
      In this study, we found reduced brain ACE-2 activity in AD, which supports a recent study showing lower peripheral serum ACE-2 levels in AD [
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ]. ACE-2 activity correlated inversely with parenchymal Aβ load and increased p-tau levels. We also observed a strong inverse relationship between ACE-2 and β-secretase activity, suggesting that ACE-2 may contribute in some way to regulating the amyloidogenic processing of APP. There are several possible mechanisms that link reduced ACE-2 activity to the pathogenesis of AD. Firstly, lower ACE-2 activity will, via a lower conversion of Ang II to Ang (1–7), result in elevated Ang II levels (as we have shown in this study). An increase in Ang II/Ang (1–7) ratio has commonly been reported in other chronic conditions associated with overactivation of the central axis [
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
      ]. Secondly, ACE-2 is primarily responsible for generating Ang (1–7) from Ang II [
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="CR54">
       54
      </xref>
      ,
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
      ], and subsequent Ang (1–7) activation of the Mas receptor counter-regulates the detrimental effects of the classical (ACE-1/Ang II/AT1R) axis [
      <xref ref-type="bibr" rid="CR56">
       56
      </xref>
      –
      <xref ref-type="bibr" rid="CR58">
       58
      </xref>
      ] and has been linked with enhancing learning and memory processing [
      <xref ref-type="bibr" rid="CR59">
       59
      </xref>
      ,
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
      ]. Lastly, ACE-2 has recently been shown to convert Aβ
      <sub>
       43
      </sub>
      , a highly amyloidogenic form of Aβ that seeds plaque formation [
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      ], to Aβ
      <sub>
       42
      </sub>
      , which in turn is cleaved by ACE-1 to Aβ
      <sub>
       40
      </sub>
      or, to a lesser extent, Aβ
      <sub>
       41
      </sub>
      , which have reduced toxicity [
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ]. Lower ACE-2 activity in AD may therefore promote the early deposition of Aβ
      <sub>
       43
      </sub>
      and prevent downstream cleavage of Aβ
      <sub>
       42
      </sub>
      by ACE-1.Together, these data suggest a putative protective role of the ACE-2/Ang (1–7)/Mas pathway, not only against the development of pathology but also against the decline in cognitive function, that is lost in AD.
     </p>
     <p>
      Our findings indicate that the balance between the classical (ACE-1/Ang II/AT1R) axis and regulatory (ACE-2/Ang (1–7)/Mas) axis of RAS is disturbed in AD, as previously shown in various mouse models of cardiovascular disease [
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ] and diabetic nephropathy [
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
      ]. ACE-2 activity is reduced in AD and is inversely correlated with increasing ACE-1 activity, and the ACE-1/ACE-2 ratio is increased in AD in association with disease pathology. These findings support commonly observed traits in cardiac and renal pathologies showing that dysregulation of the ACE-2/Ang (1–7)/Mas pathway, including reduced ACE-2 activity, is associated with sustained hypertension mediated by overactivation of the classical axis (reviewed in [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ]). Despite the ratio of Ang II to Ang (1–7) (a proxy measure of ACE-2 activity) being increased in AD (i.e., reduced conversion of Ang II to Ang (1-7)), we did not observe an overall reduction in total Ang (1–7) in AD. This is inconsistent with a recent report showing reduced serum Ang (1–7) levels, rather than reduced ACE-2 activity, in senescence-accelerated mouse prone 8, a mouse model of sporadic AD (involving overexpression of APP). The authors observed that Ang (1–7) levels correlated inversely with Ang II and p-tau levels [
      <xref ref-type="bibr" rid="CR39">
       39
      </xref>
      ]. The reason for the discrepant findings between human and mouse brain tissue is unclear; however, both studies indicate that the ACE-2/Ang (1–7)/Mas pathway is dysregulated in AD and that further work is required to determine the exact contribution of each component of the pathway in AD.
     </p>
     <p>
      Activation of the ACE-2/Ang (1–7)/Mas pathway, by inducing ACE-2 activity, or infusion of Ang (1–7) or a Mas receptor agonist, is protective in various experimental animal models of cardiovascular disease and is associated with a reduction of the classical RAS pathway (reviewed in [
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ]). Neuronal overexpression of brain ACE-2 is also neuroprotective in a chronic hypertension mouse model (transgenic for renin and angiotensinogen that overproduces Ang II) following experimental induction of ischaemic stroke [
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ,
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
      ,
      <xref ref-type="bibr" rid="CR62">
       62
      </xref>
      ]. These protective effects were partially reversed in the presence of a Mas receptor antagonist, demonstrating the specificity of the ACE-2/Ang (1–7)/Mas pathway, and they have been shown to be mediated by counter-regulating the effects of Ang II-mediated reactive oxygen species production [
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      ]. In AD, there is growing recognition that re-positioning of brain-penetrating ARBs and ACEIs may have clinical benefits in AD [
      <xref ref-type="bibr" rid="CR64">
       64
      </xref>
      ]. In addition to reducing the central pool of Ang II, ARBs and ACEIs might also exert their protective effects by preventing AT1R-mediated reduction in ACE-2 activity [
      <xref ref-type="bibr" rid="CR65">
       65
      </xref>
      ] that can be reversed by ARBs [
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="CR66">
       66
      </xref>
      –
      <xref ref-type="bibr" rid="CR69">
       69
      </xref>
      ]. ACE-2 activation is also associated with reduced ACE-1 activity [
      <xref ref-type="bibr" rid="CR70">
       70
      </xref>
      ] and with down-regulation of Ang II levels and AT1R expression [
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="CR65">
       65
      </xref>
      ,
      <xref ref-type="bibr" rid="CR71">
       71
      </xref>
      –
      <xref ref-type="bibr" rid="CR73">
       73
      </xref>
      ]. These studies suggest that activation of ACE-2 may exert protective effects in AD above and beyond dampening RAS activation that the use of ACEIs and ARBs currently allow.
     </p>
     <p>
      Lastly, we explored the distribution of ACE-2 within the mid-frontal and temporal cortices and found it to be localised predominantly within endothelial cells and smooth muscle cells of cerebral arteries, as previously reported [
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ]. Interestingly, as for ACE-1, we also observed extensive perivascular ACE-2 expression and found that ACE-2 activity was increased in individuals with moderate to severe CAA, as has previously been shown for ACE-1 [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. We speculate that the sequential cleavage of Aβ
      <sub>
       43
      </sub>
      , first by ACE-2, and the subsequent cleavage of Aβ
      <sub>
       42
      </sub>
      to Aβ
      <sub>
       40
      </sub>
      (the predominant species in CAA [
      <xref ref-type="bibr" rid="CR74">
       74
      </xref>
      ]) by ACE-1, provides a potential mechanistic link with CAA. Further studies are required to determine the relationship between ACE-2 and CAA severity.
     </p>
    </sec>
    <sec id="Sec17">
     <title>
      Conclusions
     </title>
     <p>
      These data indicate that reduced activity of the ACE-2/Ang (1–7)/Mas axis is strongly linked to overactivity of the classical RAS pathway and with AD-related pathology.
     </p>
    </sec>
    <back>
     <app-group>
      <app id="App1">
       <sec id="Sec18">
        <title>
         Additional files
        </title>
        <p>
         <media id="MOESM1" position="anchor" xlink:href="13195_2016_217_MOESM1_ESM.doc">
          <label>
           Additional file 1: Table S1.
          </label>
          <caption>
           <p>
            MRC identifiers for all cases. (DOC 80 kb)
           </p>
          </caption>
         </media>
         <media id="MOESM2" position="anchor" xlink:href="13195_2016_217_MOESM2_ESM.tif">
          <label>
           Additional file 2: Figure S1.
          </label>
          <caption>
           <p>
            Scatterplot showing a strong positive correlation between two independent measures of ACE-2 activity in brain tissue samples. ACE-2 was measured using either a commercially available ACE-2 activity assay kit (SensoLyte® 390) or an ACE-2 fluorogenic peptide substrate (Mca-APK[Dnp]) in the presence of a selective ACE-2 inhibitor, MLN4760 (10 μM). The
            <italic>
             solid inner line
            </italic>
            indicates the best-fit linear regression, and the
            <italic>
             outer lines
            </italic>
            the 95% confidence intervals. Each point represents a separate brain. ****
            <italic>
             P
            </italic>
            &lt; 0.0001. (TIF 26 kb)
           </p>
          </caption>
         </media>
         <media id="MOESM3" position="anchor" xlink:href="13195_2016_217_MOESM3_ESM.tif">
          <label>
           Additional file 3: Figure S2.
          </label>
          <caption>
           <p>
            Scatterplot showing an inverse relationship between ACE-2 activity and BACE-1 activity in a combined Alzheimer’s disease and age-matched control cohort. ACE-2 activity was measured using the SensoLyte® 390 ACE-2 activity assay kit, and BACE-1 activity was measured using the β-secretase specific fluorogenic substrate (Mca-SEVNLDAEFRK[Dnp]RR-NH2). The
            <italic>
             inner solid line
            </italic>
            indicates the best-fit linear regression, and the
            <italic>
             outer lines
            </italic>
            the 95% confidence intervals. Each point represents a separate brain. ***
            <italic>
             P
            </italic>
            &lt; 0.001. (TIF 25 kb)
           </p>
          </caption>
         </media>
        </p>
       </sec>
      </app>
     </app-group>
     <glossary>
      <title>
       Abbreviations
      </title>
      <def-list>
       <def-item>
        <term>
         ACE
        </term>
        <def>
         <p>
          Angiotensin-converting enzyme
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ACEI
        </term>
        <def>
         <p>
          Angiotensin-converting enzyme inhibitors
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         AD
        </term>
        <def>
         <p>
          Alzheimer’s disease
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         Ang (1–7)
        </term>
        <def>
         <p>
          Angiotensin (1–7) peptide
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         Ang (1–9)
        </term>
        <def>
         <p>
          Angiotensin (1–9) peptide
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         Ang II
        </term>
        <def>
         <p>
          Angiotensin II peptide
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ANOVA
        </term>
        <def>
         <p>
          Analysis of variance
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         APOE
        </term>
        <def>
         <p>
          Apolipoprotein E
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         APP
        </term>
        <def>
         <p>
          Amyloid precursor protein
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ARB
        </term>
        <def>
         <p>
          Angiotensin II type 1 receptor blocker
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         AT1R
        </term>
        <def>
         <p>
          Angiotensin II type 1 receptor
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         Aβ
        </term>
        <def>
         <p>
          Amyloid-β
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         CAA
        </term>
        <def>
         <p>
          Cerebral amyloid angiopathy
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         D/D
         <italic>
          ACE-1
         </italic>
         (rs1799752)
        </term>
        <def>
         <p>
          Deletion/deletion polymorphism
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ELISA
        </term>
        <def>
         <p>
          Enzyme-linked immunosorbent assay
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         FRET
        </term>
        <def>
         <p>
          Fluorescence resonance energy transfer
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         I/D
         <italic>
          ACE-1
         </italic>
         (rs1799752)
        </term>
        <def>
         <p>
          Insertion/deletion polymorphism
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         I/I
         <italic>
          ACE-1
         </italic>
         (rs1799752)
        </term>
        <def>
         <p>
          Insertion/insertion polymorphism
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         Mca
        </term>
        <def>
         <p>
          7-Methoxycoumarin-4-yl-acetyl
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MRC
        </term>
        <def>
         <p>
          Medical Research Council
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MRC UK-BBN
        </term>
        <def>
         <p>
          Medical Research Council UK Brain Banks Network
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         p-tau
        </term>
        <def>
         <p>
          Phosphorylated tau
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PM
        </term>
        <def>
         <p>
          Post-mortem
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         RAS
        </term>
        <def>
         <p>
          Renin-angiotensin system
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         rfu
        </term>
        <def>
         <p>
          Relative fluorescence units
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         TMB
        </term>
        <def>
         <p>
          3,3′,5,5′-Tetramethylbenzidine
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       We acknowledge Professor Seth Love, University of Bristol, for his academic input and neuropathological assessment.
      </p>
      <sec id="FPar1">
       <title>
        Funding
       </title>
       <p>
        This work was supported by Alzheimer’s Research UK (ART-PG2011-1). The South West Dementia Brain Bank is part of the Brains for Dementia Research program, jointly funded by Alzheimer’s Research UK and the Alzheimer’s Society, and is supported by Bristol Research into Alzheimer’s and Care of the Elderly (BRACE) and the Medical Research Council.
       </p>
      </sec>
      <sec id="FPar2">
       <title>
        Availability of data and material
       </title>
       <p>
        All data within the article is linked to the MRC UK-BBN by a unique numeric MRC UK-BBN identifier (Additional file
        <xref ref-type="media" rid="MOESM2">
         2
        </xref>
        : Figure S1). There is no risk of disclosure of personal information, because all of the information held within the database has been anonymised.
       </p>
      </sec>
      <sec id="FPar3">
       <title>
        Authors’ contributions
       </title>
       <p>
        JSM carried out the angiotensin-II measurements and validated the ACE-2 activity measurements, performed the statistical analysis and was primarily responsible for drafting and finalizing the manuscript. SW carried out the ACE-2 activity measurements, performed statistical analysis and helped to draft the manuscript. NAM carried out the angiotensin (1–7) measurements, performed statistical analysis and helped draft the manuscript. LEP carried out the ACE-2 immunolabelling and analysis and revised the manuscript. PGK conceived and was responsible for overall planning and design of the study, and helped to revise and finalize the manuscript. All authors read and approved the final manuscript.
       </p>
      </sec>
      <sec id="FPar4">
       <title>
        Authors’ information
       </title>
       <p>
        All authors are members of the Dementia Research Group, Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, UK.
       </p>
      </sec>
      <sec id="FPar5">
       <title>
        Competing interests
       </title>
       <p>
        The authors declare that they have no competing interests.
       </p>
      </sec>
      <sec id="FPar6">
       <title>
        Ethics approval and consent to participate
       </title>
       <p>
        The use of human brain tissue for this study was approved by the management committee of the South West Dementia Brain Bank (Human Tissue Authority licence number 12273) under the terms of Bristol Research Ethics Committee approval of the brain bank (reference 08/H0106/28 + 5). All participants provided consent to post-mortem removal of whole brain and CSF and the retention of these for use in research. Consent included access to the donor’s medical records to collect information on past medical history relevant to the donation, but that in all publications this information would be anonymised.
       </p>
      </sec>
     </ack>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kehoe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Miners
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Love
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensins in Alzheimer’s disease - friend or foe?
        </article-title>
        <source>
         Trends Neurosci
        </source>
        <year>
         2009
        </year>
        <volume>
         32
        </volume>
        <fpage>
         619
        </fpage>
        <lpage>
         28
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tins.2009.07.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         19796831
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e16037
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0016037
        </pub-id>
        <pub-id pub-id-type="pmid">
         21297982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains
        </article-title>
        <source>
         FEBS Lett
        </source>
        <year>
         2012
        </year>
        <volume>
         586
        </volume>
        <fpage>
         3737
        </fpage>
        <lpage>
         45
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.febslet.2012.09.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         22982863
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miners
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Ashby
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Van Helmond
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Chalmers
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Palmer
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name>
          <surname>
           Love
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer’s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy
        </article-title>
        <source>
         Neuropathol Appl Neurobiol
        </source>
        <year>
         2008
        </year>
        <volume>
         34
        </volume>
        <fpage>
         181
        </fpage>
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-2990.2007.00885.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         17973905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miners
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Ashby
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Baig
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Tayler
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Speedy
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme levels and activity in Alzheimer’s disease: differences in brain and CSF ACE and association with ACE1 genotypes
        </article-title>
        <source>
         Am J Transl Res
        </source>
        <year>
         2009
        </year>
        <volume>
         1
        </volume>
        <fpage>
         163
        </fpage>
        <lpage>
         77
        </lpage>
        <pub-id pub-id-type="pmid">
         19956428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Danielyan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Klein
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Hanson
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
         <name>
          <surname>
           Buadze
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Schwab
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Gleiter
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease
        </article-title>
        <source>
         Rejuvenation Res
        </source>
        <year>
         2010
        </year>
        <volume>
         13
        </volume>
        <fpage>
         195
        </fpage>
        <lpage>
         201
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/rej.2009.0944
        </pub-id>
        <pub-id pub-id-type="pmid">
         20370487
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           YF
          </given-names>
         </name>
         <name>
          <surname>
           Kataoka
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Tokutomi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Nako
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Nakamura
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Toyama
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease
        </article-title>
        <source>
         FASEB J
        </source>
        <year>
         2011
        </year>
        <volume>
         25
        </volume>
        <fpage>
         2911
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="doi">
         10.1096/fj.11-182873
        </pub-id>
        <pub-id pub-id-type="pmid">
         21593435
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ongali
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Nicolakakis
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           XK
          </given-names>
         </name>
         <name>
          <surname>
           Aboulkassim
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Papadopoulos
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Rosa-Neto
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model
        </article-title>
        <source>
         Neurobiol Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         68
        </volume>
        <fpage>
         126
        </fpage>
        <lpage>
         36
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.nbd.2014.04.018
        </pub-id>
        <pub-id pub-id-type="pmid">
         24807206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsukuda
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Mogi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Iwanami
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Min
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Sakata
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jing
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2009
        </year>
        <volume>
         54
        </volume>
        <fpage>
         782
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/HYPERTENSIONAHA.109.136879
        </pub-id>
        <pub-id pub-id-type="pmid">
         19635982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         2007
        </year>
        <volume>
         117
        </volume>
        <fpage>
         3393
        </fpage>
        <lpage>
         402
        </lpage>
        <pub-id pub-id-type="doi">
         10.1172/JCI31547
        </pub-id>
        <pub-id pub-id-type="pmid">
         17965777
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Uchida
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Takayama
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease
        </article-title>
        <source>
         Brain Res
        </source>
        <year>
         2010
        </year>
        <volume>
         1352
        </volume>
        <fpage>
         176
        </fpage>
        <lpage>
         86
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.brainres.2010.07.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         20627092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Kehoe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Ben-Shlomo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias
        </article-title>
        <source>
         J Alzheimers Dis
        </source>
        <year>
         2011
        </year>
        <volume>
         26
        </volume>
        <fpage>
         699
        </fpage>
        <lpage>
         708
        </lpage>
        <pub-id pub-id-type="pmid">
         21709373
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Forette
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Seux
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Staessen
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Thijs
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Birkenhager
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Babarskiene
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         1998
        </year>
        <volume>
         352
        </volume>
        <fpage>
         1347
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(98)03086-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         9802273
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           NC
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Whitmer
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Kivipelto
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Lawler
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Kazis
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2010
        </year>
        <volume>
         340
        </volume>
        <fpage>
         b5465
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.b5465
        </pub-id>
        <pub-id pub-id-type="pmid">
         20068258
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tzourio
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Chapman
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Woodward
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Neal
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           MacMahon
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <year>
         2003
        </year>
        <volume>
         163
        </volume>
        <fpage>
         1069
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="doi">
         10.1001/archinte.163.9.1069
        </pub-id>
        <pub-id pub-id-type="pmid">
         12742805
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kume
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hanyu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Sakurai
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Takada
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Onuma
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Iwamoto
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease
        </article-title>
        <source>
         Geriatr Gerontol Int
        </source>
        <year>
         2012
        </year>
        <volume>
         12
        </volume>
        <fpage>
         207
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1447-0594.2011.00746.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         21929736
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kehoe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Russ
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           McIlory
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Holmans
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease
        </article-title>
        <source>
         Nat Genet
        </source>
        <year>
         1999
        </year>
        <volume>
         21
        </volume>
        <fpage>
         71
        </fpage>
        <lpage>
         2
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/5009
        </pub-id>
        <pub-id pub-id-type="pmid">
         9916793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           McQueen
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Mullin
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Blacker
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Tanzi
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
        </article-title>
        <source>
         Nat Genet
        </source>
        <year>
         2007
        </year>
        <volume>
         39
        </volume>
        <fpage>
         17
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/ng1934
        </pub-id>
        <pub-id pub-id-type="pmid">
         17192785
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elkins
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Douglas
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alzheimer disease risk and genetic variation in ACE: a meta-analysis
        </article-title>
        <source>
         Neurology
        </source>
        <year>
         2004
        </year>
        <volume>
         62
        </volume>
        <fpage>
         363
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1212/01.WNL.0000106823.72493.FF
        </pub-id>
        <pub-id pub-id-type="pmid">
         14872014
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kehoe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Katzov
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Feuk
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Bennet
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Johansson
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Wiman
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Haplotypes extending across ACE are associated with Alzheimer’s disease
        </article-title>
        <source>
         Hum Mol Genet
        </source>
        <year>
         2003
        </year>
        <volume>
         12
        </volume>
        <fpage>
         859
        </fpage>
        <lpage>
         67
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/hmg/ddg094
        </pub-id>
        <pub-id pub-id-type="pmid">
         12668609
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lehmann
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Cortina-Borja
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Warden
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Sleegers
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Prince
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer’s disease
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        <year>
         2005
        </year>
        <volume>
         162
        </volume>
        <fpage>
         305
        </fpage>
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/aje/kwi202
        </pub-id>
        <pub-id pub-id-type="pmid">
         16033878
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wetten
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           St Jean
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
         <name>
          <surname>
           Upmanyu
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Surh
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
        </article-title>
        <source>
         Arch Neurol
        </source>
        <year>
         2008
        </year>
        <volume>
         65
        </volume>
        <fpage>
         45
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="doi">
         10.1001/archneurol.2007.3
        </pub-id>
        <pub-id pub-id-type="pmid">
         17998437
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Godbout
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Gosselin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Stagliano
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         2000
        </year>
        <volume>
         87
        </volume>
        <fpage>
         E1
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/01.RES.87.5.e1
        </pub-id>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Karran
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Christie
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2000
        </year>
        <volume>
         275
        </volume>
        <fpage>
         33238
        </fpage>
        <lpage>
         43
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M002615200
        </pub-id>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamming
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Timens
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Bulthuis
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Lely
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name>
          <surname>
           Navis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           van Goor
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis
        </article-title>
        <source>
         J Pathol
        </source>
        <year>
         2004
        </year>
        <volume>
         203
        </volume>
        <fpage>
         631
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/path.1570
        </pub-id>
        <pub-id pub-id-type="pmid">
         15141377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Doobay
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Talman
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <name>
          <surname>
           Obr
          </surname>
          <given-names>
           TD
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Davisson
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system
        </article-title>
        <source>
         Am J Physiol Regul Integr Comp Physiol
        </source>
        <year>
         2007
        </year>
        <volume>
         292
        </volume>
        <fpage>
         R373
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="doi">
         10.1152/ajpregu.00292.2006
        </pub-id>
        <pub-id pub-id-type="pmid">
         16946085
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Tallant
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Distinct roles for ANG II and ANG-(1–7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes
        </article-title>
        <source>
         Am J Physiol Cell Physiol
        </source>
        <year>
         2006
        </year>
        <volume>
         290
        </volume>
        <fpage>
         C420
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="doi">
         10.1152/ajpcell.00409.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         16176966
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Kozieradzki
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Scanga
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is an essential regulator of heart function
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2002
        </year>
        <volume>
         417
        </volume>
        <fpage>
         822
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature00786
        </pub-id>
        <pub-id pub-id-type="pmid">
         12075344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2: central regulator for cardiovascular function
        </article-title>
        <source>
         Curr Hypertens Rep
        </source>
        <year>
         2010
        </year>
        <volume>
         12
        </volume>
        <fpage>
         170
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s11906-010-0105-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         20424953
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 in the brain: properties and future directions
        </article-title>
        <source>
         J Neurochem
        </source>
        <year>
         2008
        </year>
        <volume>
         107
        </volume>
        <fpage>
         1482
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1471-4159.2008.05723.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         19014390
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Sriramula
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2/ANG-(1–7)/Mas pathway in the brain: the axis of good
        </article-title>
        <source>
         Am J Physiol Regul Integr Comp Physiol
        </source>
        <year>
         2011
        </year>
        <volume>
         300
        </volume>
        <fpage>
         R804
        </fpage>
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="doi">
         10.1152/ajpregu.00222.2010
        </pub-id>
        <pub-id pub-id-type="pmid">
         21178125
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           YD
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2-Ang-(1–7)-Mas axis in brain: a potential target for prevention and treatment of ischemic stroke
        </article-title>
        <source>
         Curr Neuropharmacol
        </source>
        <year>
         2013
        </year>
        <volume>
         11
        </volume>
        <fpage>
         209
        </fpage>
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="doi">
         10.2174/1570159X11311020007
        </pub-id>
        <pub-id pub-id-type="pmid">
         23997755
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RAS
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Silva AC
          </surname>
          <given-names>
           S e
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent advances in the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axis
        </article-title>
        <source>
         Exp Physiol
        </source>
        <year>
         2008
        </year>
        <volume>
         93
        </volume>
        <fpage>
         519
        </fpage>
        <lpage>
         27
        </lpage>
        <pub-id pub-id-type="doi">
         10.1113/expphysiol.2008.042002
        </pub-id>
        <pub-id pub-id-type="pmid">
         18310257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mecca
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Regenhardt
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name>
          <surname>
           O’Connor
          </surname>
          <given-names>
           TE
          </given-names>
         </name>
         <name>
          <surname>
           Joseph
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Raizada
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <name>
          <surname>
           Katovich
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cerebroprotection by angiotensin-(1–7) in endothelin-1-induced ischaemic stroke
        </article-title>
        <source>
         Exp Physiol
        </source>
        <year>
         2011
        </year>
        <volume>
         96
        </volume>
        <fpage>
         1084
        </fpage>
        <lpage>
         96
        </lpage>
        <pub-id pub-id-type="doi">
         10.1113/expphysiol.2011.058578
        </pub-id>
        <pub-id pub-id-type="pmid">
         21685445
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Suppressing inflammation by inhibiting the NF-κB pathway contributes to the neuroprotective effect of angiotensin-(1–7) in rats with permanent cerebral ischaemia
        </article-title>
        <source>
         Br J Pharmacol
        </source>
        <year>
         2012
        </year>
        <volume>
         167
        </volume>
        <fpage>
         1520
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1476-5381.2012.02105.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         22817481
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kawajiri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mogi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Higaki
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Matsuoka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Ohyagi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Tsukuda
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis
        </article-title>
        <source>
         Mult Scler
        </source>
        <year>
         2009
        </year>
        <volume>
         15
        </volume>
        <fpage>
         262
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/1352458508097923
        </pub-id>
        <pub-id pub-id-type="pmid">
         19136547
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Miura
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Tanabe
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Maeda
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Terayama
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Conversion of Aβ43 to Aβ40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme
        </article-title>
        <source>
         J Neurosci Res
        </source>
        <year>
         2014
        </year>
        <volume>
         92
        </volume>
        <fpage>
         1178
        </fpage>
        <lpage>
         86
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jnr.23404
        </pub-id>
        <pub-id pub-id-type="pmid">
         24823497
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hiraga
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Tanabe
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Aβ43 is the earliest-depositing Aβ species in APP transgenic mouse brain and is converted to Aβ41 by two active domains of ACE
        </article-title>
        <source>
         Am J Pathol
        </source>
        <year>
         2013
        </year>
        <volume>
         182
        </volume>
        <fpage>
         2322
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ajpath.2013.01.053
        </pub-id>
        <pub-id pub-id-type="pmid">
         23562443
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           YD
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           XC
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           YY
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-(1–7) is reduced and inversely correlates with tau hyperphosphorylation in animal models of Alzheimer’s disease
        </article-title>
        <source>
         Mol Neurobiol
        </source>
        <year>
         2016
        </year>
        <volume>
         53
        </volume>
        <fpage>
         2489
        </fpage>
        <lpage>
         97
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s12035-015-9260-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         26044748
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Montine
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <name>
          <surname>
           Phelps
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Beach
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <name>
          <surname>
           Bigio
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
         <name>
          <surname>
           Cairns
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
         <name>
          <surname>
           Dickson
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach
        </article-title>
        <source>
         Acta Neuropathol
        </source>
        <year>
         2012
        </year>
        <volume>
         123
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00401-011-0910-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         22101365
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miners
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           van Helmond
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Raiker
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Love
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kehoe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE variants and association with brain Aβ levels in Alzheimer’s disease
        </article-title>
        <source>
         Am J Transl Res
        </source>
        <year>
         2010
        </year>
        <volume>
         3
        </volume>
        <fpage>
         73
        </fpage>
        <lpage>
         80
        </lpage>
        <pub-id pub-id-type="pmid">
         21139807
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Helmond
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Miners
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Kehoe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Love
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Higher soluble amyloid β concentration in frontal cortex of young adults than in normal elderly or Alzheimer’s disease
        </article-title>
        <source>
         Brain Pathol
        </source>
        <year>
         2010
        </year>
        <volume>
         20
        </volume>
        <fpage>
         787
        </fpage>
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1750-3639.2010.00374.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         20175777
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Olichney
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Hansen
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Galasko
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Saitoh
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hofstetter
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
         <name>
          <surname>
           Katzman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The apolipoprotein E ε4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer’s disease and Lewy body variant
        </article-title>
        <source>
         Neurology
        </source>
        <year>
         1996
        </year>
        <volume>
         47
        </volume>
        <fpage>
         190
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="doi">
         10.1212/WNL.47.1.190
        </pub-id>
        <pub-id pub-id-type="pmid">
         8710076
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chalmers
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wilcock
          </surname>
          <given-names>
           GK
          </given-names>
         </name>
         <name>
          <surname>
           Love
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          APOE
         </italic>
         ε4 influences the pathological phenotype of Alzheimer’s disease by favouring cerebrovascular over parenchymal accumulation of A β protein
        </article-title>
        <source>
         Neuropathol Appl Neurobiol
        </source>
        <year>
         2003
        </year>
        <volume>
         29
        </volume>
        <fpage>
         231
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1046/j.1365-2990.2003.00457.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         12787320
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ballard
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
         <name>
          <surname>
           Chalmers
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Todd
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           McKeith
          </surname>
          <given-names>
           IG
          </given-names>
         </name>
         <name>
          <surname>
           O’Brien
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Wilcock
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cholinesterase inhibitors reduce cortical Aβ in dementia with Lewy bodies
        </article-title>
        <source>
         Neurology
        </source>
        <year>
         2007
        </year>
        <volume>
         68
        </volume>
        <fpage>
         1726
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1212/01.wnl.0000261920.03297.64
        </pub-id>
        <pub-id pub-id-type="pmid">
         17502555
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chalmers
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Wilcock
          </surname>
          <given-names>
           GK
          </given-names>
         </name>
         <name>
          <surname>
           Vinters
          </surname>
          <given-names>
           HV
          </given-names>
         </name>
         <name>
          <surname>
           Perry
          </surname>
          <given-names>
           EK
          </given-names>
         </name>
         <name>
          <surname>
           Perry
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Ballard
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer’s disease
        </article-title>
        <source>
         J Neurol
        </source>
        <year>
         2009
        </year>
        <volume>
         256
        </volume>
        <fpage>
         717
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00415-009-5000-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         19240967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Love
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Nicoll
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wilcock
          </surname>
          <given-names>
           GK
          </given-names>
         </name>
        </person-group>
        <article-title>
         APOE and cerebral amyloid angiopathy in the elderly
        </article-title>
        <source>
         Neuroreport
        </source>
        <year>
         2003
        </year>
        <volume>
         14
        </volume>
        <fpage>
         1535
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/00001756-200308060-00027
        </pub-id>
        <pub-id pub-id-type="pmid">
         12960780
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wenham
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name>
          <surname>
           Price
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Blandell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Apolipoprotein E genotyping by one-stage PCR
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         1991
        </year>
        <volume>
         337
        </volume>
        <fpage>
         1158
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0140-6736(91)92823-K
        </pub-id>
        <pub-id pub-id-type="pmid">
         1674030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenberg
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Rebeck
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name>
          <surname>
           Vonsattel
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Gomez-Isla
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hyman
          </surname>
          <given-names>
           BT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy
        </article-title>
        <source>
         Ann Neurol
        </source>
        <year>
         1995
        </year>
        <volume>
         38
        </volume>
        <fpage>
         254
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/ana.410380219
        </pub-id>
        <pub-id pub-id-type="pmid">
         7654074
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wright
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Harding
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Brain renin-angiotensin—a new look at an old system
        </article-title>
        <source>
         Prog Neurobiol
        </source>
        <year>
         2011
        </year>
        <volume>
         95
        </volume>
        <fpage>
         49
        </fpage>
        <lpage>
         67
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.pneurobio.2011.07.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         21777652
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wright
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Harding
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        <article-title>
         The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases
        </article-title>
        <source>
         Pflugers Arch
        </source>
        <year>
         2013
        </year>
        <volume>
         465
        </volume>
        <fpage>
         133
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00424-012-1102-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         22535332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Phillips
          </surname>
          <given-names>
           MI
          </given-names>
         </name>
         <name>
          <surname>
           de Oliveira
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Brain renin angiotensin in disease
        </article-title>
        <source>
         J Mol Med
        </source>
        <year>
         2008
        </year>
        <volume>
         86
        </volume>
        <fpage>
         715
        </fpage>
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00109-008-0331-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         18385968
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Padda
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Lo
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7): a novel peptide to treat hypertension and nephropathy in diabetes?
        </article-title>
        <source>
         J Diabetes Metab
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <fpage>
         615
        </fpage>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elased
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Cunha
          </surname>
          <given-names>
           TS
          </given-names>
         </name>
         <name>
          <surname>
           Marcondes
          </surname>
          <given-names>
           FK
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Brain angiotensin-converting enzymes: role of angiotensin-converting enzyme 2 in processing angiotensin II in mice
        </article-title>
        <source>
         Exp Physiol
        </source>
        <year>
         2008
        </year>
        <volume>
         93
        </volume>
        <fpage>
         665
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="doi">
         10.1113/expphysiol.2007.040311
        </pub-id>
        <pub-id pub-id-type="pmid">
         18263657
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vickers
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Hales
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Kaushik
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Dick
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Gavin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2002
        </year>
        <volume>
         277
        </volume>
        <fpage>
         14838
        </fpage>
        <lpage>
         43
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M200581200
        </pub-id>
        <pub-id pub-id-type="pmid">
         11815627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Trask
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Jessup
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular function
        </article-title>
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <year>
         2005
        </year>
        <volume>
         289
        </volume>
        <fpage>
         H2281
        </fpage>
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="doi">
         10.1152/ajpheart.00618.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         16055515
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Campagnole-Santos
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Andrade
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7): an update
        </article-title>
        <source>
         Regul Pept
        </source>
        <year>
         2000
        </year>
        <volume>
         91
        </volume>
        <fpage>
         45
        </fpage>
        <lpage>
         62
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0167-0115(00)00138-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         10967201
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RAS
          </given-names>
         </name>
         <name>
          <surname>
           Silva AC
          </surname>
          <given-names>
           S e
          </given-names>
         </name>
         <name>
          <surname>
           Maric
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           DMR
          </given-names>
         </name>
         <name>
          <surname>
           Machado
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
         <name>
          <surname>
           de Buhr
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2003
        </year>
        <volume>
         100
        </volume>
        <fpage>
         8258
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1432869100
        </pub-id>
        <pub-id pub-id-type="pmid">
         12829792
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hellner
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Walther
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Schubert
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Albrecht
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas
        </article-title>
        <source>
         Mol Cell Neurosci
        </source>
        <year>
         2005
        </year>
        <volume>
         29
        </volume>
        <fpage>
         427
        </fpage>
        <lpage>
         35
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.mcn.2005.03.012
        </pub-id>
        <pub-id pub-id-type="pmid">
         15950155
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lazaroni
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <name>
          <surname>
           Raslan
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Fontes
          </surname>
          <given-names>
           WR
          </given-names>
         </name>
         <name>
          <surname>
           de Oliveira
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Bader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alenina
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-(1–7)/Mas axis integrity is required for the expression of object recognition memory
        </article-title>
        <source>
         Neurobiol Learn Mem
        </source>
        <year>
         2012
        </year>
        <volume>
         97
        </volume>
        <fpage>
         113
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.nlm.2011.10.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         22067210
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Speth
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2: a new target for neurogenic hypertension
        </article-title>
        <source>
         Exp Physiol
        </source>
        <year>
         2010
        </year>
        <volume>
         95
        </volume>
        <fpage>
         601
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="doi">
         10.1113/expphysiol.2009.047407
        </pub-id>
        <pub-id pub-id-type="pmid">
         19923158
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Neuronal over-expression of ACE2 protects brain from ischemia-induced damage
        </article-title>
        <source>
         Neuropharmacology
        </source>
        <year>
         2014
        </year>
        <volume>
         79
        </volume>
        <fpage>
         550
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.neuropharm.2014.01.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         24440367
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bihl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Buck
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Activation of the ACE2/Ang-(1–7)/Mas pathway reduces oxygen-glucose deprivation-induced tissue swelling, ROS production, and cell death in mouse brain with angiotensin II overproduction
        </article-title>
        <source>
         Neuroscience
        </source>
        <year>
         2014
        </year>
        <volume>
         273
        </volume>
        <fpage>
         39
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.neuroscience.2014.04.060
        </pub-id>
        <pub-id pub-id-type="pmid">
         24814023
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ashby
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Kehoe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer’s disease
        </article-title>
        <source>
         Expert Opin Investig Drugs
        </source>
        <year>
         2013
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1229
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="doi">
         10.1517/13543784.2013.812631
        </pub-id>
        <pub-id pub-id-type="pmid">
         23800077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Obr
          </surname>
          <given-names>
           TD
          </given-names>
         </name>
         <name>
          <surname>
           Hickman
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2009
        </year>
        <volume>
         53
        </volume>
        <fpage>
         210
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/HYPERTENSIONAHA.108.123844
        </pub-id>
        <pub-id pub-id-type="pmid">
         19124678
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chappel
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1–7)
        </article-title>
        <source>
         Kidney Int
        </source>
        <year>
         2006
        </year>
        <volume>
         70
        </volume>
        <fpage>
         8
        </fpage>
        <lpage>
         10
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/sj.ki.5000321
        </pub-id>
        <pub-id pub-id-type="pmid">
         16810285
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Varagic
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         The ANG-(1–7)/ACE2/Mas axis in the regulation of nephron function. Am J Physiol Renal Physiol. 2010;298:F1297–305
        </article-title>
        <source>
         A published erratum appears in Am J Physiol Renal Physiol
        </source>
        <year>
         2010
        </year>
        <volume>
         299
        </volume>
        <fpage>
         F1515
        </fpage>
        <pub-id pub-id-type="doi">
         10.1152/ajprenal.zh2-6109-corr.2010
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR68">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Igase
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kohara
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Nagai
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Miki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade
        </article-title>
        <source>
         Hypertens Res
        </source>
        <year>
         2008
        </year>
        <volume>
         31
        </volume>
        <fpage>
         553
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1291/hypres.31.553
        </pub-id>
        <pub-id pub-id-type="pmid">
         18497476
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iwanami
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Mogi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tsukuda
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           XL
          </given-names>
         </name>
         <name>
          <surname>
           Nakaoka
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Ohshima
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Role of angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis in the hypotensive effect of azilsartan
        </article-title>
        <source>
         Hypertens Res
        </source>
        <year>
         2014
        </year>
        <volume>
         37
        </volume>
        <fpage>
         616
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/hr.2014.49
        </pub-id>
        <pub-id pub-id-type="pmid">
         24599018
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR70">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sriramula
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Cardinale
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Francis
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension
        </article-title>
        <source>
         Cardiovasc Res
        </source>
        <year>
         2011
        </year>
        <volume>
         92
        </volume>
        <fpage>
         401
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cvr/cvr242
        </pub-id>
        <pub-id pub-id-type="pmid">
         21952934
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR71">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kar
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zucker
          </surname>
          <given-names>
           IH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing-induced heart failure
        </article-title>
        <source>
         J Appl Physiol
        </source>
        <year>
         2010
        </year>
        <volume>
         108
        </volume>
        <fpage>
         923
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="doi">
         10.1152/japplphysiol.00840.2009
        </pub-id>
        <pub-id pub-id-type="pmid">
         20093667
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR72">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lazartigues
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Zucker
          </surname>
          <given-names>
           IH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Brain-selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances baroreflex function in chronic heart failure
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2011
        </year>
        <volume>
         58
        </volume>
        <fpage>
         1057
        </fpage>
        <lpage>
         65
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/HYPERTENSIONAHA.111.176636
        </pub-id>
        <pub-id pub-id-type="pmid">
         22025374
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR73">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yue
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Bindom
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Hickman
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Filipeanu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         2008
        </year>
        <volume>
         102
        </volume>
        <fpage>
         729
        </fpage>
        <lpage>
         36
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/CIRCRESAHA.107.169110
        </pub-id>
        <pub-id pub-id-type="pmid">
         18258853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR74">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gravina
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Eckman
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name>
          <surname>
           Otvos
          </surname>
          <given-names>
           L
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Younkin
          </surname>
          <given-names>
           LH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Amyloid β protein (Aβ) in Alzheimer’s disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42(43)
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         1995
        </year>
        <volume>
         270
        </volume>
        <fpage>
         7013
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.270.13.7013
        </pub-id>
        <pub-id pub-id-type="pmid">
         7706234
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Biochim Biophys Acta Proteins Proteom
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Biochim Biophys Acta Proteins Proteom
      </journal-id>
      <journal-title-group>
       <journal-title>
        Biochimica et Biophysica Acta. Proteins and Proteomics
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1570-9639
      </issn>
      <issn pub-type="epub">
       1878-1454
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       16054014
      </article-id>
      <article-id pub-id-type="pmc">
       7105243
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1570-9639(04)00292-4
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.bbapap.2004.10.010
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Membrane-associated zinc peptidase families: comparing ACE and ACE2
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Guy
         </surname>
         <given-names>
          J.L.
         </given-names>
        </name>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lambert
         </surname>
         <given-names>
          D.W.
         </given-names>
        </name>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Warner
         </surname>
         <given-names>
          F.J.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hooper
         </surname>
         <given-names>
          N.M.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Turner
         </surname>
         <given-names>
          A.J.
         </given-names>
        </name>
        <email>
         a.j.turner@leeds.ac.uk
        </email>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff>
       Proteolysis Research Group, School of Biochemistry and Microbiology, University of Leeds, Leeds, LS2 9JT, UK
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Corresponding author. Tel.: +44 113 343 3131; fax: +44 113 242 3187.
        <email>
         a.j.turner@leeds.ac.uk
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         1
        </label>
        <p>
         These authors contributed equally to the preparation of this manuscript.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        6
       </day>
       <month>
        11
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <day>
        1
       </day>
       <month>
        8
       </month>
       <year>
        2005
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        6
       </day>
       <month>
        11
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <volume>
       1751
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       2
      </fpage>
      <lpage>
       8
      </lpage>
      <history>
       <date date-type="received">
        <day>
         25
        </day>
        <month>
         5
        </month>
        <year>
         2004
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         14
        </day>
        <month>
         10
        </month>
        <year>
         2004
        </year>
       </date>
       <date date-type="accepted">
        <day>
         26
        </day>
        <month>
         10
        </month>
        <year>
         2004
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2004 Elsevier B.V. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2004
       </copyright-year>
       <copyright-holder>
        Elsevier B.V.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        In contrast to the relatively ubiquitous angiotensin-converting enzyme (ACE), expression of the mammalian ACE homologue, ACE2, was initially described in the heart, kidney and testis. ACE2 is a type I integral membrane protein with its active site domain exposed to the extracellular surface of endothelial cells and the renal tubular epithelium. Here ACE2 is poised to metabolise circulating peptides which may include angiotensin II, a potent vasoconstrictor and the product of angiotensin I cleavage by ACE. To this end, ACE2 may counterbalance the effects of ACE within the renin–angiotensin system (RAS). Indeed, ACE2 has been implicated in the regulation of heart and renal function where it is proposed to control the levels of angiotensin II relative to its hypotensive metabolite, angiotensin-(1–7). The recent solution of the structure of ACE2, and ACE, has provided new insight into the substrate and inhibitor profiles of these two key regulators of the RAS. As the complexity of this crucial pathway is unravelled, there is a growing interest in the therapeutic potential of agents that modulate the activity of ACE2.
       </p>
      </abstract>
      <kwd-group>
       <title>
        Abbreviations
       </title>
       <kwd>
        ACE, angiotensin-converting enzyme
       </kwd>
       <kwd>
        CP-A, carboxypeptidase-A
       </kwd>
       <kwd>
        CoV, coronavirus
       </kwd>
       <kwd>
        NEP, neutral endopeptidase/neprilysin
       </kwd>
       <kwd>
        QTL, quantitative trait locus
       </kwd>
       <kwd>
        RAS, renin–angiotensin system
       </kwd>
       <kwd>
        SARS, severe acute respiratory syndrome
       </kwd>
       <kwd>
        SNP, single nucleotide polymorphism
       </kwd>
       <kwd>
        SHR, spontaneous hypertensive rat
       </kwd>
      </kwd-group>
      <kwd-group>
       <title>
        Keywords
       </title>
       <kwd>
        Metallopeptidase
       </kwd>
       <kwd>
        Angiotensin
       </kwd>
       <kwd>
        SARS
       </kwd>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        Structure
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec>
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p>
      The cell surface, particularly of some cell types, is endowed with proteolytic activity able to modulate the activity of membrane proteins or circulating regulatory peptides. These proteases or peptidases, mostly metalloenzymes using zinc as cofactor, are structurally organised as ectoenzymes with their catalytic sites facing into the extracellular space. Examples include neutral endopeptidase (neprilysin, NEP), aminopeptidases and carboxypeptidases of various specificities and the subjects of this article, the angiotensin-converting enzymes (ACE and ACE2). These ectopeptidases mainly exist as single membrane-spanning proteins of type I (C-terminus intracellular), type II (N-terminus intracellular) topology, or glycosyl-phosphatidylinositol-linked proteins. Undoubtedly the best studied of these ectopeptidases by far is ACE, largely because of its physiological and pathological roles. For almost 50 years, ACE was a unique mammalian enzyme distinct from other growing peptidase families. The discovery of a human homologue of ACE (ACEH or ACE2) has led to the resurgence of studies on ACE biology coupled with detailed structural information on the enzyme itself. The pace of knowledge concerning ACE2 has been breathtaking in comparison to the relatively leisurely developments in understanding ACE structure and function over several decades
      <xref ref-type="bibr" rid="bib1">
       [1]
      </xref>
      . In a period of 4 years, ACE2 has been cloned, purified, knocked-out, knocked-in, inhibitors have been developed, its 3D structure determined and new functions have emerged. ACE2 is implicated in cardiovascular and renal biology, diabetes, and obesity, and most remarkably, ACE2 may serve as a receptor for the severe acute respiratory syndrome (SARS) virus.
     </p>
    </sec>
    <sec>
     <label>
      2
     </label>
     <title>
      ACE, the renin–angiotensin system (RAS) and the kallikrein–kinin system
     </title>
     <p>
      Cardiovascular diseases continue to be one of the leading causes of death in developed countries, most commonly resulting from hypertension and congestive heart failure. A major revolution in the treatment of hypertension came with the development of inhibitors of ACE. ACE inhibitors (e.g., captopril and lisinopril) have proved to be highly effective and safe drugs, which are used clinically to treat not only hypertension, but also congestive heart failure and renal disorders. Inhibition of ACE imposes its effects primarily via the RAS. The RAS mediates numerous effects in the cardiovascular system including blood pressure homeostasis and maintenance of fluid and salt balance
      <xref ref-type="bibr" rid="bib2">
       [2]
      </xref>
      . ACE is a crucial regulator of the RAS, converting the inactive decapeptide angiotensin I to the potent vasoconstrictor angiotensin II
      <xref ref-type="bibr" rid="bib3">
       [3]
      </xref>
      whilst also metabolising the hypotensive peptide, bradykinin
      <xref ref-type="bibr" rid="bib4">
       [4]
      </xref>
      .
     </p>
    </sec>
    <sec>
     <label>
      3
     </label>
     <title>
      The discovery of ACE2: a type I transmembrane glycoprotein
     </title>
     <p>
      In 2000, a novel mammalian homologue of ACE, originally termed ACEH and subsequently ACE2, was identified by two distinct molecular strategies
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib6">
       [6]
      </xref>
      . The
      <italic>
       ace2
      </italic>
      gene maps to the human X chromosome and encodes an 805-amino-acid, type I membrane-bound glycoprotein with an apparent molecular weight of approximately 120 kDa. The amino-terminal domain of ACE2 shares around 40% sequence identity with the corresponding domain of somatic ACE and contains a single HEXXH zinc-binding motif
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      . Intriguingly, the carboxy-terminal domain displays 48% sequence homology with collectrin, an enzymically inactive glycoprotein of unknown function expressed exclusively in the kidney
      <xref ref-type="bibr" rid="bib7">
       [7]
      </xref>
      . ACE2 initially appeared to be more limited in its tissue distribution than ACE, with significant levels only detected in the heart, kidneys, testes and gastrointestinal tract
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib8">
       [8]
      </xref>
      . A recent study, however, detected significant levels of ACE2 expression in a wide variety of tissues
      <xref ref-type="bibr" rid="bib9">
       [9]
      </xref>
      .
     </p>
    </sec>
    <sec>
     <label>
      4
     </label>
     <title>
      Comparing the specificities of ACE and ACE2
     </title>
     <p>
      On first inspection, owing to the high degree of sequence similarity that exists between ACE2 and ACE, it could be assumed that ACE2 might function, like ACE, as a dipeptidyl carboxypeptidase. Indeed, the only previously characterised ACE-like proteins, the
      <italic>
       Drosophila
      </italic>
      ACE orthologues AnCE and Acer, do display such an activity
      <xref ref-type="bibr" rid="bib10">
       [10]
      </xref>
      . Surprisingly, however, ACE2 functions as a carboxypeptidase, cleaving only a single C-terminal residue from its peptide substrate (
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ). Indeed, ACE2 is unable to cleave the archetypal ACE substrates, bradykinin and Hip-His-Leu, and is insensitive to the potent ACE inhibitors lisinopril and captopril
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      . Further characterisation using a panel of biologically active peptides has provided a consensus sequence of Pro-X-Pro-hydrophobic/basic for the protease specificity of ACE2
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      . This consensus sequence is supported by the ACE2 active site model proposed by Guy et al.
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      . It has also been ascertained that the chain length of hydrolysed peptides is not limiting although the cleavage of dipeptides is very slow. The catalytic activity of ACE2, like ACE, is pH- and anion-dependent
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       [12]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib13">
       [13]
      </xref>
      .
      <table-wrap id="tbl1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Hydrolysis of biologically active peptides by ACE2
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th valign="top">
          </th>
          <th valign="top">
           Peptide sequence
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td valign="top">
           Apelin-13
          </td>
          <td valign="top">
           QRPRLSHKGPM P⇑ F
          </td>
         </tr>
         <tr>
          <td valign="top">
           Angiotensin I
          </td>
          <td valign="top">
           DRVYIHPFH ⇑ L
          </td>
         </tr>
         <tr>
          <td valign="top">
           Angiotensin II
          </td>
          <td valign="top">
           DRVYIHP ⇑ F
          </td>
         </tr>
         <tr>
          <td valign="top">
           des-Arg
           <sup>
            9
           </sup>
           -Bradykinin
          </td>
          <td valign="top">
           RPPGFS ⇑ F
          </td>
         </tr>
         <tr>
          <td valign="top">
           β-Casomorphin-(1–7)
          </td>
          <td valign="top">
           YPFVEP ⇑ I
          </td>
         </tr>
         <tr>
          <td valign="top">
           Dynorphin A-(1–13)
          </td>
          <td valign="top">
           YGGFLRRIRPKL ⇑ K
          </td>
         </tr>
         <tr>
          <td valign="top">
           Ghrelin (C terminus shown)
          </td>
          <td valign="top">
           …ESKKPPAKLQP ⇑ R
          </td>
         </tr>
         <tr>
          <td valign="top">
           Neurotensin-(1–8)
          </td>
          <td valign="top">
           pELYENKP ⇑ R
          </td>
         </tr>
         <tr>
          <td valign="top">
           Neurotensin-(1–11)
          </td>
          <td valign="top">
           pELYENKPRRP ⇑ Y
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          The major peptides that are hydrolysed by ACE2 are shown with their amino acid sequence. An arrow indicates the site of cleavage. pE is pyroglutamyl.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
    </sec>
    <sec>
     <label>
      5
     </label>
     <title>
      Comparing the active sites of ACE and ACE2
     </title>
     <p>
      The structures of tACE
      <xref ref-type="bibr" rid="bib14">
       [14]
      </xref>
      and the
      <italic>
       Drosophila
      </italic>
      homologue AnCE
      <xref ref-type="bibr" rid="bib15">
       [15]
      </xref>
      have recently been elucidated. The minimum glycosylation requirement for expression and processing of enzymically active tACE was investigated by progressive deglycosylation
      <xref ref-type="bibr" rid="bib16">
       [16]
      </xref>
      . A truncated, soluble form of tACE, lacking the first 36 residues at the N-terminus, expressed in CHO cells in the presence of the glycosidase-I inhibitor (
      <italic>
       N
      </italic>
      -butyldeoxynojirimycin) retained the activity of the native enzyme and yielded crystals that diffracted to 2.0-Å resolution. Natesh et al.
      <xref ref-type="bibr" rid="bib14">
       [14]
      </xref>
      described the structure of tACE alone and in complex with the inhibitor lisinopril and thereby provided a detailed picture of the active site. The tACE molecule has an overall ellipsoid shape with a central groove that extends approximately 30 Å into the protein dividing it into two subdomains with the active site located towards the bottom of this groove. Simultaneously, the crystal structure of
      <italic>
       Drosophila
      </italic>
      AnCE was determined
      <xref ref-type="bibr" rid="bib15">
       [15]
      </xref>
      . It is not clear from the information presented if a minimally glycosylated form of AnCE was expressed and purified for the crystallisation studies. However, a previous report by a separate group has shown that AnCE does not require glycosylation for secretion or activity
      <xref ref-type="bibr" rid="bib17">
       [17]
      </xref>
      . Data from the AnCE crystals revealed that, like ACE, a large internal channel encompasses the entire protein molecule and the active site is located at the bottleneck connecting two chambers of unequal size within this cavity.
     </p>
     <p>
      Most recently, the crystal structures of the extracellular domain, lacking the transmembrane and cytosolic regions, of native and inhibitor-bound ACE2 have been determined to 2.2- and 3.0-Å resolution, respectively
      <xref ref-type="bibr" rid="bib18">
       [18]
      </xref>
      . These data confirm the integrity of the active site model of ACE2 proposed by Guy et al.
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      . This model, based on the crystal structure of tACE, indicated that the catalytic mechanism of ACE2 resembles that of ACE. The predicted structural differences between the active site of ACE (dipeptidyl carboxypeptidase) and ACE2 (carboxypeptidase), responsible for the differences in specificity, were also verified by the ACE2 structure. In essence, the main differences occur in the ligand-binding pockets, particularly at the S2′ subsite of ACE and in the binding of the peptide carboxy-terminus. The cavity in tACE is larger than that of ACE2, allowing an extra amino acid to bind in the specificity pocket. Most importantly, the R273 to Q substitution between ACE2 and ACE appears to be largely responsible for the elimination of the S2′ pocket in ACE2. These structural differences offer an explanation as to why the classical ACE inhibitor lisinopril is unable to bind to ACE2.
     </p>
     <p>
      The ACE2 crystals, grown in the presence of MLN-4760
      <xref ref-type="bibr" rid="bib19">
       [19]
      </xref>
      , revealed an unanticipated inverse binding orientation of the inhibitor in the active site (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ). This can be rationalised by the Y510 to V substitution between ACE2 and ACE whereby the size of the S1 pocket, in ACE2, is considerably reduced and can no longer accommodate the bulky dichlorobenzyl group. Moreover, this explains why substrates like bradykinin, angiotensin-(1–9) and Leu-enkephalin are poor substrates for ACE2, but good substrates for ACE. Another surprising observation is the absence of a bound chloride in ACE2 in an identical position to the second binding site (CL2) of tACE
      <xref ref-type="bibr" rid="bib14">
       [14]
      </xref>
      , as an occupied CL2 site is largely responsible for the chloride activation of ACE
      <xref ref-type="bibr" rid="bib20">
       [20]
      </xref>
      . ACE2 is clearly different from ACE and displays unique enzyme function despite the sequence similarity that exists between the two proteins and the common features of their activity profiles.
      <fig id="fig1">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Interaction of the catalytic sites of ACE2 and tACE with inhibitors. Schematic view of the binding interactions of (A) the inhibitor MLN-4760 at the active site of ACE2 (adapted from Ref.
         <xref ref-type="bibr" rid="bib18">
          [18]
         </xref>
         ) and (B) lisinopril at the active site of tACE (adapted from Ref.
         <xref ref-type="bibr" rid="bib11">
          [11]
         </xref>
         ). Hydrogen bonds to the ligand are shown (dotted lines). The different binding subsites are labelled.
        </p>
       </caption>
       <graphic xlink:href="gr1">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec>
     <label>
      6
     </label>
     <title>
      Developing inhibitors of ACE2
     </title>
     <p>
      The first class of selective inhibitors for ACE2 includes a series of non-peptide compounds whose design was based upon the substrate specificity of ACE2 and the requirement of a centrally located carboxylate to coordinate the inhibitor
      <xref ref-type="bibr" rid="bib19">
       [19]
      </xref>
      . The lead compound possesses sub-nanomolar affinity (IC
      <sub>
       50
      </sub>
      0.44 nM) for ACE2 and 220 000- and 22 000-fold less affinity for human tACE and bovine carboxypeptidase-A (CP-A), respectively. Using an alternative strategy, potent ACE2 peptide inhibitors have been identified through screening of constrained peptide libraries
      <xref ref-type="bibr" rid="bib13">
       [13]
      </xref>
      . A stable peptide inhibitor of ACE2, DX600, displays a
      <italic>
       K
      </italic>
      <sub>
       i
      </sub>
      of 2.8 nM with angiotensin I as substrate. DX600 is a 26-amino-acid N-terminal acetylated and C-terminal amidated peptide. In addition, the dipeptide Pro–Phe has been identified as an inhibitor of ACE2 activity
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      . This finding would allow for a peptide-based approach to inhibitor design by comparison of the inhibitory effect of Pro–Phe and Pro–Leu (not a substrate for ACE2 and a weaker inhibitor than Pro–Phe) with other dipeptides. These ACE2 inhibitor compounds are fundamental tools for exploring ACE2 biology and enzymology.
     </p>
     <p>
      In comparison with ACE2, the way in which the very first inhibitors of ACE were discovered was quite different. Teprotide is a nonapeptide that owes its potency and selectivity to natural selection, being a component of the venom of a Brazilian pit-viper. Captopril, on the other hand, owes its potency and selectivity to chemical design and this was guided not only by the hypothetical active site model but also by data on the substrate specificity of ACE and comparison with CP-A. For example, the study carried out by Cheung et al.
      <xref ref-type="bibr" rid="bib21">
       [21]
      </xref>
      was a major contributing factor in the design of second-generation inhibitors of ACE. Here, the active site binding and other properties of substrates and competitive inhibitors of ACE were investigated. Using a series of simple tri- and dipeptides, it was determined that the binding of a substrate or inhibitor to ACE is wholly dependent upon the C-terminal residues and their subsite interactions. In this vein, the importance of an exhaustive study to determine structure–activity correlations for ACE2 is critical for the systematic development of inhibitor compounds. Although ACE inhibitors were designed in part on the basis of similarities between the enzymic properties of ACE and those of CP-A, no significant segmental homology was found with carboxypeptidases (M14 family) upon solution of the crystal structure of tACE
      <xref ref-type="bibr" rid="bib14">
       [14]
      </xref>
      .
     </p>
    </sec>
    <sec>
     <label>
      7
     </label>
     <title>
      The cell biology of ACE2
     </title>
     <p>
      In contrast to the growing availability of data on the enzyme kinetics and possible physiological roles of ACE2, comparatively little is known about ACE2 at the cellular level. In keeping with predictions made from its peptide sequence and its interactions as a viral receptor, recombinant ACE2 expressed in CHO and HEK293 cells is localised predominantly in the plasma membrane. Analysis of media taken from cells expressing ACE2 has revealed the presence of a soluble form of ACE2, most likely a product of a proteolytic cleavage event. Indeed, proteolytic release of ACE2 has been observed from cardiomyocytes in which ACE2 is overexpressed
      <xref ref-type="bibr" rid="bib22">
       [22]
      </xref>
      , and a soluble form of ACE2 has been detected in urine (D.W. Lambert, G.I. Rice, N.M. Hooper and A.J. Turner, unpublished data). Preliminary evidence indicates that the secretase responsible for the shedding of ACE2 is distinct from that of ACE (D.W. Lambert, N.M. Hooper and A.J. Turner, unpublished data). In light of the ability of soluble ACE2 to prevent SARS CoV infection
      <xref ref-type="bibr" rid="bib23">
       [23]
      </xref>
      , further study of ACE2 secretion is of prime significance.
     </p>
     <p>
      Analysis of the ACE2 sequence reveals the presence of seven potential
      <italic>
       N
      </italic>
      -glycosylation sequons
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      . The recently resolved crystal structure of ACE2 provided evidence that six of these sites (N53, N90, N103, N322, N432 and N546) are glycosylated; it is not clear from this data whether the most C-terminal site is also occupied
      <xref ref-type="bibr" rid="bib18">
       [18]
      </xref>
      . This study reported that soluble ACE2 expressed in insect cells has a molecular weight of 90 kDa, compared to the predicted 83.5 kDa, a difference accounted for by the presence of the carbohydrate groups. This molecular weight of 90 kDa has also been reported for ACE2 in rat and mouse tissue
      <xref ref-type="bibr" rid="bib22">
       [22]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       [24]
      </xref>
      . It should be noted, however, that other studies have reported a molecular weight of 120–130 kDa in the same species
      <xref ref-type="bibr" rid="bib25">
       [25]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib26">
       [26]
      </xref>
      . Indeed, ACE2 overexpressed in mammalian cells has an apparent molecular weight of 120 kDa, which is reduced to approximately 85 kDa following enzymic deglycosylation
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      . Whilst the difference between the reported molecular weights of ACE2 in insect and mammalian cells can be assigned to species differences in posttranslational modification, the reasons for the remaining discrepancies are unclear. Disruption of normal glycosylation of ACE2 expressed in CHO cells, by treatment with the glycosidase inhibitor tunicamycin, prevented correct cellular sorting of full-length ACE2 and abolished secretion of a truncated mutant lacking the transmembrane and cytosolic domains (D.W. Lambert, K. Pogson and A.J. Turner, unpublished observations). The resulting unglycosylated protein was also catalytically inactive, indicating a requirement for glycosylation for membrane targeting and activity.
     </p>
     <p>
      In vivo, ACE2 expression is confined to endothelial cells and renal tubular epithelium; it has also been identified in vascular smooth muscle cells and the Leydig and Sertoli cells of the testes
      <xref ref-type="bibr" rid="bib6">
       [6]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib25">
       [25]
      </xref>
      . The very low expression level of ACE2 in a wide variety of cell lines (F.J. Warner, D.W. Lambert, N.M. Hooper and A.J. Turner, unpublished data) has impeded further studies of the intracellular processing of ACE2. Furthermore, identification of a suitable in vitro model is vital in order to gain insight into events regulating the expression of ACE2 and to elucidate further its role(s) in vivo
      <italic>
       .
      </italic>
     </p>
    </sec>
    <sec>
     <label>
      8
     </label>
     <title>
      The physiology and pathology of ACE2
     </title>
     <p>
      The first direct evidence concerning the physiological role of ACE2 was provided by studies on transgenic ACE2 knockout mice (
      <italic>
       ace2
      </italic>
      <sup>
       −/−
      </sup>
      ) carried out by Crackower et al.
      <xref ref-type="bibr" rid="bib27">
       [27]
      </xref>
      . These mice show no gross abnormalities, are fertile, and have normal blood pressure and renal function despite moderately elevated angiotensin II levels. Closer examination, however, revealed the mice suffered from severe cardiac dysfunction manifest in a profound decrease in cardiac contractility resulting from the thinning of the left ventricle wall and an increase in ventricle chamber dimensions. This disruption of heart function was associated with an up-regulation of genes induced by hypoxia and bore a remarkable resemblance to a condition resulting from cardiac surgery referred to as ‘cardiac stunning’. Significantly, ablation of the ACE gene against an ACE2 knockout background rescues the cardiac phenotype, suggesting that ACE2 serves as a regulator of the effects of ACE in the RAS. In a separate study, targeted disruption of the
      <italic>
       ace2
      </italic>
      gene resulted in viable, fertile progeny lacking gross anatomical/structural abnormalities
      <xref ref-type="bibr" rid="bib28">
       [28]
      </xref>
      and displaying only moderately elevated systolic blood pressure. After chronic infusion of angiotensin II (at a level that does not induce hypertension), increased blood pressure and decreased heart rate were evident in ACE2 null mice compared with wild-type littermates. Thus, it appears that in the absence of ACE2 the mice are more susceptible to angiotensin II-induced hypertension.
     </p>
     <p>
      Transgenic mice in which ACE2 was overexpressed exclusively in cardiac myocytes exhibited complete atrioventricular block from 3 weeks of age
      <xref ref-type="bibr" rid="bib22">
       [22]
      </xref>
      . The transgenic mice appeared healthy with a grossly normal heart structure and only slightly lowered blood pressure. However, the mice suffered from an increased susceptibility to sudden cardiac death, which directly correlated with the transgene dose. Detailed electrophysiological analysis revealed severe, progressive conduction and rhythm disturbances along with sustained ventricular tachycardia and terminal ventricular fibrillation. In light of the observation that the gap junction proteins connexin40 and connexin43 were down-regulated in the hearts of these transgenic mice, it was suggested that the electrical remodelling was a result of gap junction dysregulation. In surviving older mice the expression of human ACE2 in cardiac myocytes was progressively down-regulated (the down-regulation of proteins under the control of the heart-specific αMHC promoter is a phenomenon reported for other models). This coincided with the reciprocal up-regulation of connexin43 resulting in partial restoration of the cardiac phenotype. However, it is important to note that ACE2 is not normally expressed in cardiac myocytes but rather in cardiac endothelium.
     </p>
     <p>
      The ability of ACE2 to cleave vasoactive peptides such as angiotensin II indicates a possible role in blood pressure regulation. This theory was given increased credence by the observation that the
      <italic>
       ace2
      </italic>
      gene maps to a candidate quantitative trait locus (QTL) in a salt-sensitive rat model of hypertension. Furthermore, these rats display reduced ACE2 mRNA and protein expression compared to healthy littermates
      <xref ref-type="bibr" rid="bib29">
       [29]
      </xref>
      . Overlapping QTLs have also been identified in other rat models of hypertension. In addition, two single nucleotide polymorphisms (SNPs) were identified in the ACE2 locus, which have been associated with the risk of cardiovascular disease in a Caucasian population
      <xref ref-type="bibr" rid="bib30">
       [30]
      </xref>
      .
     </p>
     <p>
      Chronic administration of omapatrilat, a dual inhibitor of the vasopeptidases ACE and neprilysin (NEP), in spontaneous hypertensive rats (SHRs) results in a significant reduction in blood pressure, marked diuresis and augmented renal excretion of the vasodilatory peptide angiotensin-(1–7)
      <xref ref-type="bibr" rid="bib31">
       [31]
      </xref>
      . ACE2 is capable of producing angiotensin-(1–7) from angiotensin II in vitro and is abundantly expressed in the kidney
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      . Upon treatment of SHRs with omapatrilat, increased staining of both angiotensin-(1–7) and ACE2 is observed in the renal proximal tubules, with a simultaneous increase of ACE2 mRNA expression in the cortex. The authors suggest that omapatrilat exerts this effect by inducing ACE2 expression, resulting in a concomitant increase in angiotensin-(1–7) production from angiotensin II and an associated decrease in blood pressure, rather than via the inhibition of ACE and NEP, both of which are known to cleave angiotensin-(1–7). It has been demonstrated that the concentrations of angiotensin-(1–7) in kidney and urine are increased during normal pregnancy in rats
      <xref ref-type="bibr" rid="bib32">
       [32]
      </xref>
      . In light of the evidence of renal ACE2 expression, Brosnihan et al.
      <xref ref-type="bibr" rid="bib33">
       [33]
      </xref>
      investigated the possibility that changes in ACE2 expression may be associated with the previous finding that the levels of angiotensin-(1–7) increase during pregnancy. It was found that the renal distribution of angiotensin-(1–7) and ACE2 is similar and does not change during gestation; however, the intensity of staining for both was elevated (56% and 117%, respectively) in pregnant rats. These findings suggest that ACE2 is the primary candidate for the local production and increased angiotensin-(1–7) generation during pregnancy.
     </p>
     <p>
      Further evidence of the role ACE2 may play in the RAS came from a study by Zisman et al.
      <xref ref-type="bibr" rid="bib34">
       [34]
      </xref>
      in which they report up-regulation of ACE2 expression in failing human heart ventricles. In a parallel paper, the same group presented evidence of the involvement of a novel angiotensin-(1–7) activity in the intact failing heart
      <xref ref-type="bibr" rid="bib35">
       [35]
      </xref>
      . The later study demonstrated that formation of angiotensin-(1–7) was correlated with the level of ACE2 expression and could be completely abolished by administration of an ACE2-specific inhibitor. These data indicated that in failing hearts the major route for the increased production of angiotensin-(1–7) is from angiotensin II via ACE2 rather than from angiotensin I via neprilysin, as had previously been suggested.
     </p>
     <p>
      A separate study has implicated renal ACE2 in the pathogenesis of diabetic nephropathy
      <xref ref-type="bibr" rid="bib26">
       [26]
      </xref>
      . In this study it was shown that ACE2 mRNA and protein expression levels were significantly reduced in the kidneys of 24-week-old streptozocin-induced diabetic rats. The reduction in ACE2 mRNA expression was not influenced by ACE inhibitor treatment. However, the decrease in ACE2 protein expression was prevented under the same conditions, thereby suggesting that ACE2 protein expression is associated with ACE activity. In contrast, renal ACE2 protein was found to be higher, with the absence of a concomitant increase in ACE2 mRNA levels, in young diabetic mice (db/db) before the onset of diabetic nephropathy
      <xref ref-type="bibr" rid="bib36">
       [36]
      </xref>
      . The balance between ACE and ACE2 (low versus high protein levels, respectively) may be renoprotective in the early stages of diabetes with this balance being lost upon progression to renal damage. Hence, it is postulated that ACE2 is involved in the aetiology of diabetes via the RAS, a role for which has been previously characterised in this disease state (for a review, see Ref.
      <xref ref-type="bibr" rid="bib37">
       [37]
      </xref>
      ).
     </p>
     <p>
      Collectively, these studies in vivo provide strong evidence of a role for ACE2 in the RAS through localised production of angiotensin-(1–7) from angiotensin II, perhaps serving as a negative regulator of the vasoconstrictive effects of ACE to maintain blood pressure homeostasis and maintain cardiac and renal function (
      <xref ref-type="fig" rid="fig2">
       Fig. 2
      </xref>
      ).
      <fig id="fig2">
       <label>
        Fig. 2
       </label>
       <caption>
        <p>
         Schematic representation of the renin–angiotensin system (RAS). ACE, angiotensin-converting enzyme; NEP, neprilysin; AT
         <sub>
          1
         </sub>
         , angiotensin II type I receptor; and AT
         <sub>
          2
         </sub>
         , angiotensin type II receptor. The conversion of angiotensin I to angiotensin-(1–9) by ACE2 is kinetically much less favourable than the conversion of angiotensin II to angiotensin-(1–7).
        </p>
       </caption>
       <graphic xlink:href="gr2">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec>
     <label>
      9
     </label>
     <title>
      A secret life
     </title>
     <p>
      A surprising discovery is that ACE2 is a functional receptor for the SARS coronavirus, the causative agent of SARS. In a series of elegant experiments, Li et al.
      <xref ref-type="bibr" rid="bib23">
       [23]
      </xref>
      co-immunoprecipitated the virus attachment glycoprotein (S1) with lysates from an African green monkey kidney cell line (Vero E6) and subjected the precipitated proteins to mass spectrometry. Among the sequences, a number were obtained corresponding to ACE2. Subsequently, it was demonstrated that recombinant soluble ACE2, but not ACE, was able to block the association between Vero E6 cells and the SARS CoV S protein. Expression of recombinant ACE2 and of S1 protein resulted in cell fusion and the formation of syncytia in 293T cells, a cell line normally resistant to SARS CoV infection. Furthermore, 293T cells expressing ACE2 permitted efficient replication of the coronavirus, with viral genome copies increased 100 000-fold over a 48-h period, compared to 10-fold in untransfected cells. An ACE2-specific antibody inhibited the cytopathicity of SARS-CoV in a dose-dependent manner.
     </p>
     <p>
      The expression profiling of mRNA, performed by Harmer et al.
      <xref ref-type="bibr" rid="bib8">
       [8]
      </xref>
      , demonstrates the expression of low levels of ACE2 in the bronchus and lung parenchyma. This, taken together with evidence that the primary sites of murine ACE2 expression are in the lung and the kidney
      <xref ref-type="bibr" rid="bib38">
       [38]
      </xref>
      , led Li et al.
      <xref ref-type="bibr" rid="bib23">
       [23]
      </xref>
      to suggest that the tissue distribution of ACE2 is consistent with the pathology of SARS-CoV. Furthermore, Hamming et al.
      <xref ref-type="bibr" rid="bib9">
       [9]
      </xref>
      recently provided evidence that ACE2 is abundantly expressed in the epithelia of the lung and the small intestine, possible entry sites for the SARS virus.
     </p>
     <p>
      Whilst research determining the receptor binding properties of the SARS CoV S protein has progressed at a rapid rate, little is known about the residues of ACE2 involved in binding. Preliminary experiments performed by Li et al.
      <xref ref-type="bibr" rid="bib23">
       [23]
      </xref>
      indicate that disrupting the active site of ACE2 has no effect on S1 binding; further studies are required to understand the nature of the protein:protein interactions.
     </p>
    </sec>
    <sec>
     <label>
      10
     </label>
     <title>
      Future perspectives
     </title>
     <p>
      Until recently, it was widely assumed that the intricacies of the RAS had largely been elucidated. Recent studies examining the properties of ACE2, however, have provided evidence that this crucial pathway may be significantly more complicated than previously thought. Whilst, as yet, the precise physiological role of ACE2 remains to be determined, it is becoming increasingly apparent that ACE2 may act as a counterbalance to the effects of ACE in the RAS. Given the significance of ACE inhibitors in the treatment of a number of pathophysiological disorders, the contribution of ACE2 to the regulation of the RAS cannot be ignored. Indeed, modulation of ACE2 activity may provide a significant new therapeutic opportunity in the treatment of cardiovascular disease, either in isolation or in conjunction with existing ACE inhibitors. This exciting possibility highlights the need for continuing efforts to elucidate the in vivo roles and biochemical properties of this emerging player in the RAS.
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The angiotensin-converting enzyme gene family: genomics and pharmacology
        </article-title>
        <source>
         Trends Pharmacol. Sci.
        </source>
        <volume>
         23
        </volume>
        <year>
         2002
        </year>
        <fpage>
         177
        </fpage>
        <pub-id pub-id-type="pmid">
         11931993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue renin–angiotensin system: sites of angiotensin formation
        </article-title>
        <source>
         J. Cardiovasc. Pharmacol.
        </source>
        <volume>
         10
        </volume>
        <year>
         1987
        </year>
        <fpage>
         S1
        </fpage>
        <lpage>
         S8
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skeggs
          </surname>
          <given-names>
           L.T.
          </given-names>
         </name>
         <name>
          <surname>
           Kahn
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Shumway
          </surname>
          <given-names>
           N.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The preparation and function of the hypertensin-converting enzyme
        </article-title>
        <source>
         J. Exp. Biol.
        </source>
        <volume>
         103
        </volume>
        <year>
         1956
        </year>
        <fpage>
         295
        </fpage>
        <lpage>
         299
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           H.Y.T.
          </given-names>
         </name>
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           Levin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin
        </article-title>
        <source>
         Biochim. Biophys. Acta
        </source>
        <volume>
         214
        </volume>
        <year>
         1970
        </year>
        <fpage>
         374
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="pmid">
         4322742
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Karran
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Christie
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homologue of angiotensin-converting enzyme
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         275
        </volume>
        <year>
         2000
        </year>
        <fpage>
         33238
        </fpage>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Godbout
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gosselin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stagliano
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Donovan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Woolf
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Robison
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Jeyaseelan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Breitbart
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Acton
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9
        </article-title>
        <source>
         Circ. Res.
        </source>
        <volume>
         87
        </volume>
        <year>
         2000
        </year>
        <fpage>
         e1
        </fpage>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wada
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hida
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsuchiyama
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hiragushi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Shikata
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kanwar
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homologue of ACE2 and is developmentally regulated in embryonic kidneys
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         276
        </volume>
        <year>
         2001
        </year>
        <fpage>
         17132
        </fpage>
        <pub-id pub-id-type="pmid">
         11278314
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harmer
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Gilbert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Borman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme
        </article-title>
        <source>
         FEBS Lett.
        </source>
        <volume>
         532
        </volume>
        <year>
         2002
        </year>
        <fpage>
         107
        </fpage>
        <pub-id pub-id-type="pmid">
         12459472
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamming
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Timens
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bulthuis
          </surname>
          <given-names>
           M.L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lely
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Navis
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           van Goor
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue distribution of ACE2 protein, the functional receptor for SARS cornavirus. A first step in understanding SARS pathogenesis
        </article-title>
        <source>
         J. Pathol.
        </source>
        <volume>
         203
        </volume>
        <year>
         2004
        </year>
        <fpage>
         631
        </fpage>
        <pub-id pub-id-type="pmid">
         15141377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <mixed-citation publication-type="other">
        X. Houard, T.A. Williams, A. Michaud, P. Dani, R.E. Isaac, A.D. Shirras, D. Coates, P. Corvol, The Drosophila melanogaster-related angiotensin-I-converting enzymes Acer and Ance-distinct enzymic characteristics and alternative expression during pupal development 257 (1998) 599–606.
       </mixed-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guy
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Acharya
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           E.D.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme-2 (ACE2): comparative modelling of the active site, substrate specificity and chloride sensitivity
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         42
        </volume>
        <year>
         2003
        </year>
        <fpage>
         13185
        </fpage>
        <pub-id pub-id-type="pmid">
         14609329
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vickers
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hales
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kaushik
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Dick
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gavin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Godbout
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Parsons
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Acton
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Patane
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nichols
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tummino
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         277
        </volume>
        <year>
         2002
        </year>
        <fpage>
         14838
        </fpage>
        <pub-id pub-id-type="pmid">
         11815627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Sexton
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Skogerson
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Devlin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Sanyal
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Parry
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kent
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Enright
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Conley
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           DeOliveira
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Morganelli
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ducar
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wescott
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Ladner
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel peptide inhibitors of angiotensin-converting enzyme 2
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         278
        </volume>
        <year>
         2003
        </year>
        <fpage>
         15532
        </fpage>
        <pub-id pub-id-type="pmid">
         12606557
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Natesh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Schwager
          </surname>
          <given-names>
           S.L.U.
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           E.D.
          </given-names>
         </name>
         <name>
          <surname>
           Acharya
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of the human angiotensin-converting enzyme–lisinopril complex
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         421
        </volume>
        <year>
         2003
        </year>
        <fpage>
         551
        </fpage>
        <pub-id pub-id-type="pmid">
         12540854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Yoo
          </surname>
          <given-names>
           O.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of
         <italic>
          Drosophila
         </italic>
         angiotensin I-converting enzyme bound to captopril and lisinopril
        </article-title>
        <source>
         FEBS Lett.
        </source>
        <volume>
         538
        </volume>
        <year>
         2003
        </year>
        <fpage>
         65
        </fpage>
        <pub-id pub-id-type="pmid">
         12633854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gordon
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Redelinghuys
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Schwager
          </surname>
          <given-names>
           S.L.U.
          </given-names>
         </name>
         <name>
          <surname>
           Ehlers
          </surname>
          <given-names>
           M.R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Papageorgiou
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Natesh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Acharya
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           E.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deglycosylation, processing and crystallisation of human testis angiotensin-converting enzyme
        </article-title>
        <source>
         Biochem. J.
        </source>
        <volume>
         371
        </volume>
        <year>
         2003
        </year>
        <fpage>
         437
        </fpage>
        <pub-id pub-id-type="pmid">
         12542396
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Michaud
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Houard
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chauvet
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Soubrier
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Drosophila melanogaster
         </italic>
         angiotensin I-converting enzyme expressed in
         <italic>
          Pichia pastoris
         </italic>
         resembles the C domain of the mammalian homologue and does not require glycosylation for secretion and enzymic activity
        </article-title>
        <source>
         Biochem. J.
        </source>
        <volume>
         318
        </volume>
        <year>
         1996
        </year>
        <fpage>
         125
        </fpage>
        <pub-id pub-id-type="pmid">
         8761461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Towler
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Staker
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Prasad
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Menon
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Parsons
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ryan
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Fisher
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Dales
          </surname>
          <given-names>
           N.A
          </given-names>
         </name>
         <name>
          <surname>
           Patane
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Pantoliano
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         279
        </volume>
        <year>
         2004
        </year>
        <fpage>
         17996
        </fpage>
        <pub-id pub-id-type="pmid">
         14754895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dales
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gould
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Calderwood
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Minor
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gavin
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hales
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kaushik
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Stewart
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tummino
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vickers
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ocain
          </surname>
          <given-names>
           T.D.
          </given-names>
         </name>
         <name>
          <surname>
           Patane
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors
        </article-title>
        <source>
         J. Am. Chem. Soc.
        </source>
        <volume>
         124
        </volume>
        <year>
         2002
        </year>
        <fpage>
         11852
        </fpage>
        <pub-id pub-id-type="pmid">
         12358520
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wouters
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Heyberger
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Husain
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Arg
         <sup>
          1098
         </sup>
         is critical for the chloride dependence of human angiotensin I-converting enzyme C-domain catalytic activity
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         36
        </volume>
        <year>
         2001
        </year>
        <fpage>
         33518
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           H.S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           F.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ondetti
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sabo
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Cushman
          </surname>
          <given-names>
           D.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Binding of peptide substrates and inhibitors of angiotensin-converting enzyme
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         255
        </volume>
        <year>
         1980
        </year>
        <fpage>
         401
        </fpage>
        <pub-id pub-id-type="pmid">
         6243277
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wakimoto
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Maguire
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Acton
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hales
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Stagliano
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fairchild-Huntress
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lorenz
          </surname>
          <given-names>
           J.N.
          </given-names>
         </name>
         <name>
          <surname>
           Kadambi
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Berul
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Breitbart
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with down-regulated connexins
        </article-title>
        <source>
         J. Mol. Cell. Cardiol.
        </source>
        <volume>
         35
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1043
        </fpage>
        <pub-id pub-id-type="pmid">
         12967627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zimplemann
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wilkins
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Burns
          </surname>
          <given-names>
           K.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of angiotensin converting enzyme 2 in the generation of angiotensin 1–7 by rat proximal tubules
        </article-title>
        <source>
         Am. J. Physiol., Renal Physiol.
        </source>
        <year>
         2004
        </year>
        <comment>
         (Online prepublication)
        </comment>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Douglas
          </surname>
          <given-names>
           G.C.
          </given-names>
         </name>
         <name>
          <surname>
           O'Brian
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hedger
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           D.K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yarski
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           A.I.
          </given-names>
         </name>
         <name>
          <surname>
           Lew
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The novel angiotensin-converting enzyme (ACE) homologue, ACE2, is selectively expressed by adult leydig cells of the testis
        </article-title>
        <source>
         Endocrinology
        </source>
        <volume>
         145
        </volume>
        <year>
         2004
        </year>
        <fpage>
         4703
        </fpage>
        <lpage>
         4711
        </lpage>
        <pub-id pub-id-type="pmid">
         15231706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tikellis
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Forbes
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Burns
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Burrell
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Risvanis
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterisation of renal angiotensin-converting enzyme 2 in diabetic nephropathy
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         41
        </volume>
        <year>
         2003
        </year>
        <fpage>
         392
        </fpage>
        <pub-id pub-id-type="pmid">
         12623933
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kozieradzki
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Scanga
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Oliveira-dos-Santos
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           da Costa
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Scholey
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Manoukian
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Backx
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is an essential regulator of heart function
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         417
        </volume>
        <year>
         2002
        </year>
        <fpage>
         822
        </fpage>
        <pub-id pub-id-type="pmid">
         12075344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Allred
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Acton
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Coffman
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Regulation of blood pressure by the angiotensin converting enzyme homologue ACE2
        </article-title>
        <source>
         Am. J. Nephrol.
        </source>
        <volume>
         13
        </volume>
        <year>
         2002
        </year>
        <fpage>
         52A
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2—A novel candidate gene for hypertension
        </article-title>
        <source>
         Am. J. Hypertens.
        </source>
        <volume>
         14
        </volume>
        <year>
         2001
        </year>
        <fpage>
         A78
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Barnes
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Foti
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Nolin
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Lewitzsky
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Metivier
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Parker
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Topol
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Two single nucleotide polymorphisms in the ACE2 locus are associated with cardiovascular disease
        </article-title>
        <source>
         Genet. Epidemiol.
        </source>
        <volume>
         23
        </volume>
        <year>
         2002
        </year>
        <fpage>
         272
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Averill
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Omapatrilat treatment is associated with increased ACE2 and angiotensin (1–7) in spontaneously hypertensive rats
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         40
        </volume>
        <year>
         2002
        </year>
        <fpage>
         409
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Neves
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           A.F.
          </given-names>
         </name>
         <name>
          <surname>
           Averill
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Walkup
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Brosnihan
          </surname>
          <given-names>
           K.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pregnancy enhances the angiotensin (Ang)-(1–7) vasodilator response in mesenteric arteries and increases the renal concentration and urinary excretion of Ang-(1–7)
        </article-title>
        <source>
         Endocrinology
        </source>
        <volume>
         144
        </volume>
        <year>
         2003
        </year>
        <fpage>
         3338
        </fpage>
        <pub-id pub-id-type="pmid">
         12865311
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brosnihan
          </surname>
          <given-names>
           K.B.
          </given-names>
         </name>
         <name>
          <surname>
           Neves
          </surname>
          <given-names>
           L.A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Joyner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Averill
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhanced renal immunocytochemical expression of Ang-(1–7) and ACE2 during pregnancy
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         42
        </volume>
        <year>
         2003
        </year>
        <fpage>
         749
        </fpage>
        <pub-id pub-id-type="pmid">
         12874086
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zisman
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Keller
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Weaver
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Speth
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Bristow
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Canver
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased angiotensin-(1–7)-forming activity in failing human heart ventricles. Evidence for up-regulation of the angiotensin-converting enzyme homologue ACE2
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         108
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1707
        </fpage>
        <pub-id pub-id-type="pmid">
         14504186
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zisman
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Meixell
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Bristow
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Canver
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) formation in the intact human heart. In vivo dependence on angiotensin II as substrate
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         108
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1679
        </fpage>
        <pub-id pub-id-type="pmid">
         14504185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wysocki
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Naaz
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Salabat
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           LaPointe
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Batlle
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice. A renoprotective combination?
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         43
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1120
        </fpage>
        <pub-id pub-id-type="pmid">
         15078862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gilbert
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Krum
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wilkinson-Berka
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kelly
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The renin–angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations
        </article-title>
        <source>
         Diabet. Med.
        </source>
        <volume>
         20
        </volume>
        <year>
         2003
        </year>
        <fpage>
         607
        </fpage>
        <pub-id pub-id-type="pmid">
         12873287
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Komatsu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sugano
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hida
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tanigami
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Muroi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hanaoka
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular cloning, mRNA expression and chromosomal localisation of mouse angiotensin-converting enzyme-related carboxypeptidase (mACE2)
        </article-title>
        <source>
         DNA Sequence
        </source>
        <volume>
         13
        </volume>
        <year>
         2002
        </year>
        <fpage>
         217
        </fpage>
        <pub-id pub-id-type="pmid">
         12487024
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       We thank the UK Medical Research Council, the Wellcome Trust, the British Heart Foundation and the National Heart Research Foundation for their support of this work. FJW is the recipient of a C.J. Martin Research Fellowship awarded by the National Health and Medical Research Council (Australia).
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Peptides
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Peptides
      </journal-id>
      <journal-title-group>
       <journal-title>
        Peptides
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0196-9781
      </issn>
      <issn pub-type="epub">
       1873-5169
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       15949642
      </article-id>
      <article-id pub-id-type="pmc">
       7115577
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0196-9781(05)00168-3
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.peptides.2005.03.046
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Potentiation of bradykinin actions by analogues of the bradykinin potentiating nonapeptide BPP
        <sub>
         9α
        </sub>
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mueller
         </surname>
         <given-names>
          Sylvia
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gothe
         </surname>
         <given-names>
          Rita
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Siems
         </surname>
         <given-names>
          Wolf-Dieter
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Vietinghoff
         </surname>
         <given-names>
          Gabriele
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Paegelow
         </surname>
         <given-names>
          Inge
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Reissmann
         </surname>
         <given-names>
          Siegmund
         </given-names>
        </name>
        <email>
         siegmund.reissmann@uni-jena.de
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Institute of Biochemistry and Biophysics, Biological and Pharmaceutical Faculty, Friedrich-Schiller-University, Jena, 07743 Jena, Germany
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Institute of Molecular Pharmacology (FMP), Campus Berlin-Buch, 13125 Berlin, Germany
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Department of Experimental and Clinical Pharmacology and Toxicology, University of Rostock, 18057 Rostock, Germany
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Corresponding author. Tel.: +49 3641 350; fax: +49 3641 352.
        <email>
         siegmund.reissmann@uni-jena.de
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        25
       </day>
       <month>
        4
       </month>
       <year>
        2005
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        7
       </month>
       <year>
        2005
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        25
       </day>
       <month>
        4
       </month>
       <year>
        2005
       </year>
      </pub-date>
      <volume>
       26
      </volume>
      <issue>
       7
      </issue>
      <fpage>
       1235
      </fpage>
      <lpage>
       1247
      </lpage>
      <history>
       <date date-type="received">
        <day>
         20
        </day>
        <month>
         8
        </month>
        <year>
         2004
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         10
        </day>
        <month>
         12
        </month>
        <year>
         2004
        </year>
       </date>
       <date date-type="accepted">
        <day>
         21
        </day>
        <month>
         3
        </month>
        <year>
         2005
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2005 Elsevier Inc. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2005
       </copyright-year>
       <copyright-holder>
        Elsevier Inc.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Synthetic analogues of the bradykinin potentiating nonapeptide BPP
        <sub>
         9α
        </sub>
        indicate significantly different structural requirements for potentiation of the bradykinin (BK)-induced smooth muscle contraction (GPI) and the inhibition of isolated somatic angiotensin I-converting enzyme (ACE). The results disprove the ACE inhibition as the only single mechanism and also the direct interaction of potentiating peptides with the bradykinin receptors in transfected COS-7 cells as molecular mechanism of potentiation. Our results indicate a stimulation of inositol phosphates (IP
        <sub>
         <italic>
          n
         </italic>
        </sub>
        ) formation independently from the B
        <sub>
         2
        </sub>
        receptor. Furthermore, the results with La
        <sup>
         3+
        </sup>
        support the role of extracellular Ca
        <sup>
         2+
        </sup>
        and its influx through corresponding channels. The missing effect of calyculin on the GPI disproves the role of phosphatases in the potentiating action. These experimental studies should not only contribute to a better understanding of the potentiating mechanisms but also incorporate a shift in the research towards the immune system, in particular towards the immunocompetent polymorphonuclear leukocytes. The chemotaxis of these cells can be potentiated most likely by exclusive inhibition of the enzymatic degradation of bradykinin. Thus the obtained results give evidence that the potentiation of the bradykinin action can occur by different mechanisms, depending on the system and on the applied potentiating factor.
       </p>
      </abstract>
      <kwd-group>
       <title>
        Abbreviations
       </title>
       <kwd>
        AA, arachidonic acid
       </kwd>
       <kwd>
        ABA, 4-azidobenzoic acid
       </kwd>
       <kwd>
        ACE, angiotensin I-converting enzyme
       </kwd>
       <kwd>
        Aloc, allyl oxycarbonyl
       </kwd>
       <kwd>
        ASA, 4-azidosalicylic acid
       </kwd>
       <kwd>
        BK, bradykinin
       </kwd>
       <kwd>
        BKR, bradykinin receptor
       </kwd>
       <kwd>
        BKR-B
        <sub>
         1
        </sub>
        , bradykinin B1 receptor
       </kwd>
       <kwd>
        BKR-B
        <sub>
         2
        </sub>
        , bradykinin B2 receptor
       </kwd>
       <kwd>
        Boc,
        <italic>
         tert
        </italic>
        -butyloxycarbonyl
       </kwd>
       <kwd>
        BPA,
        <italic>
         p
        </italic>
        -benzoylphenylalanine
       </kwd>
       <kwd>
        BPP, bradykinin potentiating peptide
       </kwd>
       <kwd>
        BPP
        <sub>
         9α
        </sub>
        , bradykinin potentiating peptide 9α (Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro)
       </kwd>
       <kwd>
        BOP, benzotriazole-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate
       </kwd>
       <kwd>
        DCM, dichloromethane
       </kwd>
       <kwd>
        Dde,
        <italic>
         N
        </italic>
        -(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl
       </kwd>
       <kwd>
        Ddz, α,α-dimethyl-3,5-dimethoxy-benzyloxycarbonyl
       </kwd>
       <kwd>
        DEAE, diethylaminoethyl
       </kwd>
       <kwd>
        DIEA, diisopropylethylamine
       </kwd>
       <kwd>
        DIC, diisopropylcarbodiimide
       </kwd>
       <kwd>
        DMEM, Dulbecco's modified Eagle's medium
       </kwd>
       <kwd>
        DMF,
        <italic>
         N
        </italic>
        ,
        <italic>
         N
        </italic>
        -dimethylformamide
       </kwd>
       <kwd>
        DMSO, dimethylsulfoxide
       </kwd>
       <kwd>
        DTE, dithioerithritol
       </kwd>
       <kwd>
        ED, effective dose
       </kwd>
       <kwd>
        Fmoc, 9-fluorenylmethyl oxycarbonyl
       </kwd>
       <kwd>
        ɛAbu(ßPhe), erythro-α-amino-ß-phenyl-butyric acid
       </kwd>
       <kwd>
        FR190997, 8-[2,6-dichloro-3-[
        <italic>
         N
        </italic>
        -(
        <italic>
         E
        </italic>
        )-4-(
        <italic>
         N
        </italic>
        -methylcarbamoyl)cinnamidoacetyl]-
        <italic>
         N
        </italic>
        -methylamino]benzyloxy]-2-methyl-4-(2-pyridyl-methoxy)quinoline
       </kwd>
       <kwd>
        GPI, guinea pig ileum
       </kwd>
       <kwd>
        HOAt, 1-hydroxy-7-azabenzotriazole
       </kwd>
       <kwd>
        HBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylguanidinium hexafluorophosphate
       </kwd>
       <kwd>
        HOBt, 1-hydroxybenzotriazole
       </kwd>
       <kwd>
        HOCr, hydroxycrotonic acid
       </kwd>
       <kwd>
        HYCRAM, hydroxycrotonyl amidomethyl linker
       </kwd>
       <kwd>
        IP
        <sub>
         3
        </sub>
        , inositol 1,4,5-trisphosphate
       </kwd>
       <kwd>
        IP
        <sub>
         <italic>
          n
         </italic>
        </sub>
        , inositol phosphates
       </kwd>
       <kwd>
        J526, Pyr-Trp-Pro-Lys(ASA)-Pro-Gln-Ile-Pro-Pro
       </kwd>
       <kwd>
        J527, Pro-Trp-Pro-Lys-Pro-Gln-Ile-Pro-Pro
       </kwd>
       <kwd>
        J725, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-Pro-ɛAbu(ßPh)-Arg
       </kwd>
       <kwd>
        MEM, Eagle's minimal essential medium
       </kwd>
       <kwd>
        Mtr, methoxytrimethylbenzene sulphonyl
       </kwd>
       <kwd>
        Pd
        <sup>
         0
        </sup>
        , palladium
        <italic>
         tetrakis
        </italic>
        triphenylphosphine
       </kwd>
       <kwd>
        PMN, polymorphonuclear leukocytes (neutrophils)
       </kwd>
       <kwd>
        Ram, ramiprilat
       </kwd>
       <kwd>
        TBTU, 2-(1H-benzotriazol-1-yl)1,1,3,3-tetramethylguanidinium tetrafluoroborate
       </kwd>
       <kwd>
        TFA, trifluoroacetic acid
       </kwd>
       <kwd>
        Trt, triphenylmethyl
       </kwd>
      </kwd-group>
      <kwd-group>
       <title>
        Keywords
       </title>
       <kwd>
        Potentiation
       </kwd>
       <kwd>
        Bradykinin
       </kwd>
       <kwd>
        Bradykinin potentiating peptide
       </kwd>
       <kwd>
        Angiotensin I-converting enzyme
       </kwd>
       <kwd>
        Inositol phosphate
       </kwd>
       <kwd>
        Arachidonic acid
       </kwd>
       <kwd>
        Ca
        <sup>
         2+
        </sup>
        -influx
       </kwd>
       <kwd>
        Protein phosphatases
       </kwd>
       <kwd>
        Polymorphonuclear leukocytes
       </kwd>
       <kwd>
        Chemotaxis
       </kwd>
       <kwd>
        Smooth muscle contraction
       </kwd>
       <kwd>
        Radioligand binding
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec>
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p>
      Hormone actions can be potentiated by different factors interacting with the receptor, by enzymatic degradation or by signal pathways. However the entire overall process has been studied in detail for only very few hormones
      <xref ref-type="bibr" rid="bib30">
       [30]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib69">
       [69]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib45">
       [45]
      </xref>
      .
     </p>
     <p>
      At least 40 years ago a potentiating action was observed for the nonapeptide hormone bradykinin (BK). Indeed the history of BK isolation and characterization has long been closely related to the use of potentiating factors. Werle and coworkers
      <xref ref-type="bibr" rid="bib74">
       [74]
      </xref>
      used snake venoms to trigger the formation of BK from plasma and to describe this tissue hormone functionally. Immediately after the isolation, chemical characterization, synthesis and functional characterization, certain snake venoms were described as bradykinin potentiating compounds. Kato and Suzuki
      <xref ref-type="bibr" rid="bib39">
       [39]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib40">
       [40]
      </xref>
      , Ferreira et al.
      <xref ref-type="bibr" rid="bib26">
       [26]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib27">
       [27]
      </xref>
      , and Ondetti et al.
      <xref ref-type="bibr" rid="bib13">
       [13]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib59">
       [59]
      </xref>
      isolated different oligopeptides with bradykinin potentiating activity from the venoms of the two snakes
      <italic>
       Agkistrodon halys blomhoffii
      </italic>
      and
      <italic>
       Bothrops jararaca
      </italic>
      , including the bradykinin potentiating nonapeptide BPP
      <sub>
       9α
      </sub>
      (trade name TEPROTIDE).
     </p>
     <p>
      Bradykinin potentiating peptides have also been isolated from other snakes
      <xref ref-type="bibr" rid="bib8">
       [8]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib9">
       [9]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib23">
       [23]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       [24]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib25">
       [25]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib35">
       [35]
      </xref>
      or other toxins
      <xref ref-type="bibr" rid="bib3">
       [3]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib21">
       [21]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib22">
       [22]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       [44]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib52">
       [52]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib73">
       [73]
      </xref>
      as well. Very recently new potentiating peptides have been isolated from the venom of
      <italic>
       B. jararaca
      </italic>
      <xref ref-type="bibr" rid="bib36">
       [36]
      </xref>
      . Surprisingly peptides with potentiating activity have also been formed by the partial hydrolysis of proteins taken from serum
      <xref ref-type="bibr" rid="bib80">
       [80]
      </xref>
      , hemoglobin
      <xref ref-type="bibr" rid="bib38">
       [38]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib66">
       [66]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib81">
       [81]
      </xref>
      , milk
      <xref ref-type="bibr" rid="bib34">
       [34]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib46">
       [46]
      </xref>
      , or wheat germ
      <xref ref-type="bibr" rid="bib51">
       [51]
      </xref>
      . Also degradation fragments of angiotensin such as the heptapeptide 1–7 were found to potentiate the BK action
      <xref ref-type="bibr" rid="bib64">
       [64]
      </xref>
      . In addition linear BK analogues, partial sequences
      <xref ref-type="bibr" rid="bib7">
       [7]
      </xref>
      , certain active and inactive side chain and backbone cyclic agonists are able to potentiate the BK action on GPI
      <xref ref-type="bibr" rid="bib68">
       [68]
      </xref>
      .
     </p>
     <p>
      The angiotensin I-converting enzyme (ACE) cleaves dipeptides from the C-terminus of angiotensin I and bradykinin resulting on the one hand in the formation of the highly hypertensive hormone angiotensin II and on the other hand in the inactivation of the hypotensive BK. This enzyme has been extensively studied because of these important functions in the blood pressure regulation. ACE contains a N-terminal as well as a C-terminal catalytic domain, described in most publications as having only slight differences in their structural requirements
      <xref ref-type="bibr" rid="bib14">
       [14]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib79">
       [79]
      </xref>
      . More recently Cotton et al. demonstrated in an excellent investigation using domain-specific substrates and inhibitors, affinity differences between N- and C-terminal catalytic domains of about three orders of magnitude
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      .
     </p>
     <p>
      The membrane bound form of this enzyme seems to play an important role in the potentiation of the BK action. Inhibitors of this enzyme are used as drugs for treatment of different forms of hypertension and heart failure. For therapeutically used hormones this knowledge about potentiating compounds and their action mechanisms is very important. This knowledge can help to improve the therapeutic effect, to prevent not only an excessive dose, but also interaction with other drugs and side effects. On the other hand the therapeutic use of potentiating compounds requires the knowledge about the interaction with the hormone action on the molecular basis as well. As shown by Li et al. ACE may also act as a receptor for SARS coronavirus
      <xref ref-type="bibr" rid="bib47">
       [47]
      </xref>
      .
     </p>
     <p>
      With extensive therapeutical application of bradykinin potentiating compounds such as captopril
      <xref ref-type="bibr" rid="bib12">
       [12]
      </xref>
      , enalaprilat
      <xref ref-type="bibr" rid="bib64">
       [64]
      </xref>
      , ramiprilat
      <xref ref-type="bibr" rid="bib75">
       [75]
      </xref>
      , quinaprilat
      <xref ref-type="bibr" rid="bib41">
       [41]
      </xref>
      and lisinopril
      <xref ref-type="bibr" rid="bib6">
       [6]
      </xref>
      , studies of the molecular action mechanism have become more and more important. Many other proteases are also able to inactivate BK including the neutral endopeptidase (NEP, Neprolysin; E.C. 3.4.24.11)
      <xref ref-type="bibr" rid="bib42">
       [42]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib71">
       [71]
      </xref>
      , metalloendopeptidase (E.C. 3.4.25.15/16)
      <xref ref-type="bibr" rid="bib55">
       [55]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib58">
       [58]
      </xref>
      , aminopeptidase P (E.C. 3.4.11.9)
      <xref ref-type="bibr" rid="bib67">
       [67]
      </xref>
      , aminopeptidase N (E.C. 3.4.11.2)
      <xref ref-type="bibr" rid="bib63">
       [63]
      </xref>
      and carboxypeptidase M (E.C. 3.4.17.12)
      <xref ref-type="bibr" rid="bib72">
       [72]
      </xref>
      .
     </p>
     <p>
      Potentiation of BK action has also been studied in in vivo models by pharmacological tests on isolated organs and on the cellular level by biochemical methods. In the in vivo models, potentiation of BK action has been measured on the pressor response to intravenous BK in conscious rabbits
      <xref ref-type="bibr" rid="bib68">
       [68]
      </xref>
      or on the hypotensive effect in freely moving Wistar rats
      <xref ref-type="bibr" rid="bib65">
       [65]
      </xref>
      . Isolated organs such as the guinea pig ileum (GPI)
      <xref ref-type="bibr" rid="bib54">
       [54]
      </xref>
      , rat heart
      <xref ref-type="bibr" rid="bib34">
       [34]
      </xref>
      , rabbit jugular vein
      <xref ref-type="bibr" rid="bib17">
       [17]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib33">
       [33]
      </xref>
      , cerebral microvasculature (estimation of permeability)
      <xref ref-type="bibr" rid="bib58">
       [58]
      </xref>
      and porcine coronary arteries
      <xref ref-type="bibr" rid="bib76">
       [76]
      </xref>
      have been used for in vitro tests.
     </p>
     <p>
      Yet even at the onset of the search for the molecular mechanism of BK potentiation, certain contradictory findings have been observed. The inhibition of ACE by various peptide and nonpeptide compounds did not correlate well with the potentiating activity
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       [10]
      </xref>
      . Furthermore, the maximum of the BK-induced contraction of guinea pig ileum can be enhanced by potentiating compounds
      <xref ref-type="bibr" rid="bib77">
       [77]
      </xref>
      . Also the action evoked by enzymatically stable BK agonists can be potentiated in some test systems
      <xref ref-type="bibr" rid="bib78">
       [78]
      </xref>
      . Repeated exposure of porcine coronary arteries to BK has led to receptor desensitization. The addition of the potentiating compounds quinaprilat or angiotensin 1–7 fully restored the relaxant effect at a point when BK alone was no longer able to induce relaxation
      <xref ref-type="bibr" rid="bib76">
       [76]
      </xref>
      . At the molecular level the co-immunoprecipitation of ACE and the B
      <sub>
       2
      </sub>
      receptor with an anti receptor antibody clearly indicates an interaction of both partners on the cell membrane
      <xref ref-type="bibr" rid="bib50">
       [50]
      </xref>
      . Despite all these contradictory and to some degree confusing findings Regoli and coworkers
      <xref ref-type="bibr" rid="bib29">
       [29]
      </xref>
      and Dendorfer et al.
      <xref ref-type="bibr" rid="bib17">
       [17]
      </xref>
      have demonstrated that in their test systems (rabbit isolated aorta and venoconstriction) the potentiation by therapeutically used ACE inhibitors results exclusively from the inhibition of enzymatic BK degradation. Nevertheless, the group of Regoli found under influence of ACE inhibitors, a resensitization of the rabbit jugular vein
      <xref ref-type="bibr" rid="bib31">
       [31]
      </xref>
      and a change in the density of B
      <sub>
       2
      </sub>
      receptors in rat spinal cord
      <xref ref-type="bibr" rid="bib60">
       [60]
      </xref>
      .
     </p>
     <p>
      To understand the molecular basis for these discrepancies many approaches have been undertaken to elucidate the influence of potentiating compounds on the different bradykinin destroying enzymes, on the bradykinin receptors (BKR) and on signal pathways.
     </p>
     <p>
      Direct interaction of the potentiating compounds was postulated with the B
      <sub>
       1
      </sub>
      receptor
      <xref ref-type="bibr" rid="bib37">
       [37]
      </xref>
      . Phosphorylation of the receptor by protein kinase C leads to internalization
      <xref ref-type="bibr" rid="bib19">
       [19]
      </xref>
      (desensitization) and dephosphorylation by phosphatase SHP-2 to resensitization
      <xref ref-type="bibr" rid="bib18">
       [18]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib49">
       [49]
      </xref>
      . Bradykinin potentiating factors can influence both desensitization and resensitization, as well as the hetero-oligomerization of the B
      <sub>
       2
      </sub>
      receptor including the interaction with ACE
      <xref ref-type="bibr" rid="bib54">
       [54]
      </xref>
      and other degrading enzymes
      <xref ref-type="bibr" rid="bib15">
       [15]
      </xref>
      . At the level of signal pathways, a crosstalk with other pathways induced by other hormones
      <xref ref-type="bibr" rid="bib43">
       [43]
      </xref>
      or nonreceptor-mediated intracellular reactions
      <xref ref-type="bibr" rid="bib28">
       [28]
      </xref>
      have been observed.
     </p>
     <p>
      As initial experimentation on the potentiation of the bradykinin action was primarily performed on isolated smooth muscle organs, in the last decade the potentiating activity was mainly investigated on the affinity and density of the receptor
      <xref ref-type="bibr" rid="bib54">
       [54]
      </xref>
      , the intracellular mobilization of Ca
      <sup>
       2+
      </sup>
      <xref ref-type="bibr" rid="bib49">
       [49]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib54">
       [54]
      </xref>
      , the release of arachidonic acid
      <xref ref-type="bibr" rid="bib49">
       [49]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib54">
       [54]
      </xref>
      , of inositol phosphates
      <xref ref-type="bibr" rid="bib54">
       [54]
      </xref>
      , and of nitric oxide
      <xref ref-type="bibr" rid="bib37">
       [37]
      </xref>
      . Later studies on the molecular basis of bradykinin-evoked actions have been performed more and more on cell cultures instead of smooth muscles. These studies have used primarily Chinese hamster ovary cells (CHO cells) cotransfected with the B
      <sub>
       2
      </sub>
      receptor and ACE, ACE-mutants or neutral endopeptidase (NEP)
      <xref ref-type="bibr" rid="bib15">
       [15]
      </xref>
      . Endothelial cells have been used because they constitutively express the B
      <sub>
       2
      </sub>
      receptor and ACE
      <xref ref-type="bibr" rid="bib49">
       [49]
      </xref>
      .
     </p>
     <p>
      The aim of our experiments was to contribute to a better understanding of the potentiating mechanisms, and to prove or disprove postulated action mechanisms. For these studies we used three different systems: the smooth muscle contraction, transiently transfected COS-7 cells and polymorphonuclear leucocytes. We began to find differences between ACE inhibition and potentiation of the BK action. We were interested in determining the role of Ca
      <sup>
       2+
      </sup>
      -uptake from extracellular sources and its release from sarcoplasmatic reticulum for the potentiating action. We tested the direct interaction with the B
      <sub>
       2
      </sub>
      receptor in COS-7 cells and checked the influence of potentiating peptides on receptor dephosphorylation and selected signal transduction reactions.
     </p>
     <p>
      Since BK plays an important role in inflammatory processes we studied the potentiation on immunocompetent polymorphonuclear leucocytes. However it was not only our aim to verify or negate the contradictory opinions regarding the mechanism of bradykinin potentiation, we would also like to show that there simultaneously exist different mechanisms, depending on the assay and on the potentiating factors used.
     </p>
    </sec>
    <sec>
     <label>
      2
     </label>
     <title>
      Methods
     </title>
     <sec>
      <label>
       2.1
      </label>
      <title>
       Synthesis of peptides
      </title>
      <p>
       Boc-, Fmoc- and Ddz-amino acids were purchased from BACHEM (Switzerland) and ORPEGEN-Pharma (Germany). Boc-Pro-OCr-OH was synthesized according to the general procedure published by Gothe et al.
       <xref ref-type="bibr" rid="bib32">
        [32]
       </xref>
       . To form the HYCRAM™-linker the hydroxycrotonic ester was coupled to the aminomethyl resin Tentagel-S-NH
       <sub>
        2
       </sub>
       . The used resins were purchased from the following companies: amino methyl polystyrene, Tentagel-S-NH
       <sub>
        2
       </sub>
       and Wang resin from RAPP Polymere (Germany), and chlorotrityl resin from NOVA-Biochem (Germany). The peptides were synthesized on a PSS-80 automatic synthesizer (Applied Protein Technologies, USA) or on the semiautomatic synthesizer SP-650 (BACHEM, Switzerland). Each step was monitored by the Kaiser test. Couplings were carried out after neutralization by repeated washings (5–10 times) of the resin with 5% DIEA in DCM in a two-fold excess of N
       <sup>
        α
       </sup>
       -protected amino acid and diisopropylcarbodiimide (DIC) in DCM for 4 h; 2-(1H-benzotriazol-1-yl) 1,1,3,3-tetramethylguanidinium tetrafluoroborate (TBTU)/1-hydroxybenzotriazole (HOBt): Boc- or Fmoc- protected amino acids were used in a four-fold excess, solved in DMF or DCM/ DMF 1:1. TBTU and HOBt were applied in the same excess, diisopropylethylamine (DIEA) in a six-fold excess. The reaction time was between 4 and 12 h.
      </p>
      <p>
       Deprotecting procedures: Boc-deprotection was performed with TFA/DCM 1:1 without any scavenger in two steps, 5 min treatment followed by washing with DCM and second treatment for 20 min; Ddz-deprotection was carried out with 5% TFA in DCM in two steps, 5 and 20 min; Fmoc-deprotection was achieved with 20% piperidine in DMF in two steps, 5 and 20 min.
      </p>
     </sec>
     <sec>
      <label>
       2.2
      </label>
      <title>
       Potentiation of the BK-induced contraction of GPI
      </title>
      <p>
       The ileum (1.5 cm) of the guinea pigs was suspended in a 5 ml organ bath containing Tyrode solution at 37 °C. Isotonic contractions were recorded under a resting tension of 500 mg. BK was applied in a concentration of 1 × 10
       <sup>
        −8
       </sup>
       M that corresponded to an ED
       <sub>
        25
       </sub>
       to ED
       <sub>
        30
       </sub>
       of BK under these experimental conditions. Generally this effect was increased twice by BPP
       <sub>
        9α
       </sub>
       (20 nM) that was used as standard. The bradykinin potentiating peptides or the ACE inhibitors were given 5 min before application of BK. The potentiating effects of the analogues were calculated as per cent of the BK-induced contraction and compared with the effect caused by BPP
       <sub>
        9α
       </sub>
       (=1.0 or 100%) in the same experiment.
      </p>
     </sec>
     <sec>
      <label>
       2.3
      </label>
      <title>
       Ca
       <sup>
        2+
       </sup>
       -dependence of the potentiation of the BK-induced contraction of GPI
      </title>
      <p>
       To investigate the influence of Ca
       <sup>
        2+
       </sup>
       on the BK-potentiating action of BPP
       <sub>
        9α
       </sub>
       (20 nM BK, 20 nM BPP
       <sub>
        9α
       </sub>
       ), La
       <sup>
        3+
       </sup>
       (1.8 mM) was used as an inhibitor of the Ca
       <sup>
        2+
       </sup>
       influx in Ca
       <sup>
        2+
       </sup>
       -free or Ca
       <sup>
        2+
       </sup>
       -containing Tyrode solution. LaCl
       <sub>
        3
       </sub>
       was always given 1 min before or after the BK-induced contraction and before the application of BPP
       <sub>
        9α
       </sub>
       (see
       <xref ref-type="fig" rid="fig3">
        Fig. 3
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <label>
       2.4
      </label>
      <title>
       Inhibition of phosphatase activity
      </title>
      <p>
       Calyculin (100 nM) was used to estimate the involvement of BK-induced (20 nM BK) and potentiated (20 nM BK, 20 nM BPP
       <sub>
        9α
       </sub>
       ) contraction of the guinea pig ileum. Calyculin was applied before BPP
       <sub>
        9α
       </sub>
       was given at the maximum of the BK-induced contraction or 1 min before the BK- and BPP-induced effect was elicited (see
       <xref ref-type="fig" rid="fig6">
        Fig. 6
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <label>
       2.5
      </label>
      <title>
       Inhibition of isolated angiotensin I-converting enzyme
      </title>
      <p>
       Inhibitory activities were determined with an enzyme preparation from the guinea pig lung, using Benzoyl-Gly-His-Leu as the substrate. This method is described elsewhere
       <xref ref-type="bibr" rid="bib70">
        [70]
       </xref>
       .
      </p>
     </sec>
     <sec>
      <label>
       2.6
      </label>
      <title>
       Cell culture and transfection of COS-7 cells
      </title>
      <p>
       Cell culture and transfection of COS-7 cells have been described in detail
       <xref ref-type="bibr" rid="bib2">
        [2]
       </xref>
       . COS-7 cells (ATCC) were routinely grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal calf serum and antibiotics, and were kept in a humidified 5% CO
       <sub>
        2
       </sub>
       , 95% air atmosphere. Subconfluent cells were transfected in 24-well plates with BKR-B
       <sub>
        2
       </sub>
       -cDNA (1 μg cDNA/well) by the DEAE-dextran technique, and cells were used 48–72 h after transfection. Preparation of COS-7 membranes was done as described previously
       <xref ref-type="bibr" rid="bib57">
        [57]
       </xref>
       .
      </p>
     </sec>
     <sec>
      <label>
       2.7
      </label>
      <title>
       Receptor binding assay
      </title>
      <p>
       Competition binding studies were performed using [
       <sup>
        3
       </sup>
       H]BK (102 Ci/mmol, NEN Life Science Products, USA) and intact COS-7 cells (initial density (1–2) × 10
       <sup>
        5
       </sup>
       cells/well) in 24-well plates expressing the BKR-B
       <sub>
        2
       </sub>
       <xref ref-type="bibr" rid="bib56">
        [56]
       </xref>
       . Cells were incubated in binding buffer containing 0.8 nM of [
       <sup>
        3
       </sup>
       H]BK with different concentrations of BK in the absence or the presence of J526 (0.1 μM) or J527 (0.1 μM), or in increasing concentrations of J527 alone for 90 min at 4 °C. Non-specific binding was measured in the presence of 1 μM unlabeled BK. To estimate binding properties at 37 °C membranes of COS-7 cells were used. Membranes (0.15 mg/tube) were incubated with 0.8 nM of [
       <sup>
        3
       </sup>
       H]BK or with 0.8 nM of [
       <sup>
        3
       </sup>
       H]BK and 100 nM J526 for 20 min at 37 °C in binding buffer in the absence (total binding) or in the presence of 1 μM BK (non-specific binding). Thereafter, the samples were filtered through Whatman GF/B glass fiber filters pretreated with 0.1% (w/v) aqueous polyethylenimine. The filters were washed three times with 5 ml of ice-cold binding buffer, transferred into scintillation vials, dried and analyzed for bound radioactivity by scintillation counting.
      </p>
     </sec>
     <sec>
      <label>
       2.8
      </label>
      <title>
       Phosphatidylinositol turnover
      </title>
      <p>
       COS-7 cells expressing the BKR were grown in 24-well plates (5 × 10
       <sup>
        4
       </sup>
       to 10
       <sup>
        5
       </sup>
       cells/well) and labeled with 4 μCi/ml
       <italic>
        myo
       </italic>
       -[
       <sup>
        3
       </sup>
       H]inositol (10–25 Ci/mmol, NEN Life Science Products, USA) for 24 h. Cells were stimulated in DMEM without captopril with 3 × 10
       <sup>
        −8
       </sup>
       M BK for 5 min at 37 °C, or with 3 × 10
       <sup>
        −8
       </sup>
       M BK in the presence of J526 (0.1 μM), or with 3 × 10
       <sup>
        −8
       </sup>
       M BK in the presence of J527 (0.1 μM). Basal IP
       <sub>
        <italic>
         n
        </italic>
       </sub>
       was measured with J526 or J527 (0.1 μM), too. Preparation of stimulation and determination of the levels of inositol phosphates by anion exchange chromatography using AG-X8 as a resin were performed as recently described in detail
       <xref ref-type="bibr" rid="bib2">
        [2]
       </xref>
       .
      </p>
     </sec>
     <sec>
      <label>
       2.9
      </label>
      <title>
       Arachidonic acid release
      </title>
      <p>
       COS-7 cells were transfected and labeled with 0.4 μCi/ml [
       <sup>
        3
       </sup>
       H]arachidonic acid (60–100 Ci/mmol, NEN Life Science Products, USA) for 24 h as described previously
       <xref ref-type="bibr" rid="bib57">
        [57]
       </xref>
       . The cells were washed three times with label-free DMEM containing 0.5% (v/v) fetal calf serum and then stimulated in 0.5 ml in the same medium with 3 × 10
       <sup>
        −8
       </sup>
       M BK for 30 min in the absence or the presence of J526 (0.1 μM) or J527 (0.1 μM) at 37 °C. Assays were terminated by removing the medium from the cells. The medium was measured for [
       <sup>
        3
       </sup>
       H]arachidonic acid release by scintillation counting.
      </p>
     </sec>
     <sec>
      <label>
       2.10
      </label>
      <title>
       Preparation of human polymorphonuclear leukocytes (PMN)
       <xref ref-type="bibr" rid="bib62">
        [62]
       </xref>
      </title>
      <p>
       Heparinized venous blood from healthy volunteers was mixed with 1% dextran sulphate in 0.9% NaCl at a ratio of 1:1 (v/v) and left for 50 min at 37 °C for erythrocyte sedimentation to occur. The leukocyte-rich plasma was layered over an equal volume of Histopaque-1077, and the gradient was centrifuged for 30 min at 700 ×
       <italic>
        g
       </italic>
       . Contaminating erythrocytes were eliminated by lysis with ammonium chloride (0.98%), and the pure PMN were washed twice with Eagle‘s minimal essential medium (MEM) and resuspended (1 × 10
       <sup>
        6
       </sup>
       PMN/ml).
      </p>
     </sec>
     <sec>
      <label>
       2.11
      </label>
      <title>
       Chemotaxis assay
      </title>
      <p>
       Chemotaxis was quantified using the Boyden chamber technique as described previously
       <xref ref-type="bibr" rid="bib61">
        [61]
       </xref>
       . PMN were suspended in Eagle's MEM containing 20 mM HEPES (pH 7.3) and 5 × 10
       <sup>
        5
       </sup>
       /0.5 ml, pipetted into the top of Boyden chamber which were separated by a 3 μm pore filter (Sartorius SM 11302) from the lower part. Peptides were put into the lower stimulus compartment. Inhibitors or potentiating peptides were applied to the PMN for 15 min at 37 °C and then to the upper compartment of the chamber. After an incubation period of 3 h at 37 °C in an atmosphere of 5% CO
       <sub>
        2
       </sub>
       , 95% air at high humidity, the filters were fixed and stained with methylene blue. Using an image analyzer (Chemotaxis Analyzer HCA-100, HA-SOTEC, Rostock, Germany), the PMN were counted at every 10 μm interval from the original monolayer to the distal surface in 10 high power fields of each duplicate filter. An average locomotion index (LI
       <sub>
        <italic>
         m
        </italic>
        +
       </sub>
       ) was quantified and expressed as the migration index in comparison to the control (control = 1.0).
      </p>
     </sec>
     <sec>
      <label>
       2.12
      </label>
      <title>
       Statistical analysis
      </title>
      <p>
       Mostly the values are presented as means ± S.E.M. Statistical analysis was evaluated with the Student's
       <italic>
        t
       </italic>
       -test for independent samples or for paired samples, depending on the experimental protocol. Details are described in the legends for each figure.
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <sec>
      <label>
       3.1
      </label>
      <title>
       Synthesis of peptides
      </title>
      <p>
       BPP
       <sub>
        9α
       </sub>
       and a variety of analogues were synthesized according to the three different strategies in
       <xref ref-type="fig" rid="sch1">
        Scheme 1
       </xref>
       on the solid phase. To prevent dioxopiperazine formation, chlorotrityl resin or HYCRAM™ resin was used. In the case of Cl-trityl resin, cyclization of the C-terminal dipeptide was avoided by sterical hindrancy at the resin. Using the Boc-strategy with the HYCRAM™ resin prevents ring formation and thereby loss of loading. Syntheses on Wang resin provided very low yields. After removal from the resins all the peptides were purified by semipreparative HPLC and chemically characterized. Some of the analogues are prepared for photoaffinity labeling of the binding protein.
       <fig id="sch1">
        <label>
         Scheme 1
        </label>
        <caption>
         <p>
          Strategies for synthesis of BPP
          <sub>
           9α
          </sub>
          analogues using different linkers and resins (Wang resin, chlorotrityl resin, HYCRAM™ resin) and different protecting group combinations.
         </p>
        </caption>
        <graphic xlink:href="sc1">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.2
      </label>
      <title>
       Inhibition of the isolated angiotensin I-converting enzyme
      </title>
      <p>
       The inhibitory activities of all analogues listed in
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       were determined on isolated ACE from guinea pig lungs. As most organs, particularly guinea pig ileum, contain different BK degrading enzymes, we did not use an organ homogenate to estimate the inhibition of BK degradation. We used the isolated ACE to test the inhibition of hydrolysis of a synthetic tripeptide substrate by the potentiating peptides. As shown in
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       , distinct differences exist between potentiation of the BK-induced contraction of the guinea pig ileum and the inhibition of the isolated ACE.
       <table-wrap id="tbl1" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Analogues of the bradykinin potentiating peptide BPP
          <sub>
           9α
          </sub>
          (TEPROTIDE) with distinct differences between potentiation of the BK-induced contraction of the isolated guinea pig ileum (GPI) and inhibition of the isolated angiotensin I-converting enzyme (ACE)
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th align="left">
            Compound
           </th>
           <th align="left">
            Aminoacid sequence
           </th>
           <th align="left">
            Potentiation (%)
           </th>
           <th align="left">
            ACE-inhibition: IC
            <sub>
             50
            </sub>
            (M)
           </th>
           <th align="left">
            Quotient
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            BPP
            <sub>
             9α
            </sub>
           </td>
           <td align="left">
            Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            100
           </td>
           <td align="left">
            3 × 10
            <sup>
             −9
            </sup>
           </td>
           <td align="char">
            7.0
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Phe-Pro-Gln-Tyr-Pro-Pro
           </td>
           <td align="char">
            100
           </td>
           <td align="left">
            8 × 10
            <sup>
             −9
            </sup>
           </td>
           <td align="char">
            19
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Leu-Pro-Lys-Tyr-Pro-Pro
           </td>
           <td align="char">
            100
           </td>
           <td align="left">
            6 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            0.1 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Leu-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            90
           </td>
           <td align="left">
            1 × 10
            <sup>
             −5
            </sup>
           </td>
           <td align="char">
            2.5 × 10
            <sup>
             4
            </sup>
           </td>
          </tr>
          <tr>
           <td align="left" colspan="5">
           </td>
          </tr>
          <tr>
           <td align="left">
            [1-Pro]-BPP
            <sub>
             9α
            </sub>
           </td>
           <td align="left">
            Pro-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            115
           </td>
           <td align="left">
            5 × 10
            <sup>
             −10
            </sup>
           </td>
           <td align="char">
            1
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Arg-Pro-Gln-Ile-Ala-Pro
           </td>
           <td align="char">
            70
           </td>
           <td align="left">
            3 × 10
            <sup>
             −7
            </sup>
           </td>
           <td align="char">
            1 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Ala-Arg-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            75
           </td>
           <td align="left">
            3 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            93
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Leu-Pro-Leu-Ile-Pro-Pro
           </td>
           <td align="char">
            50
           </td>
           <td align="left">
            1 × 10
            <sup>
             −7
            </sup>
           </td>
           <td align="char">
            0.5 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Phe-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            90
           </td>
           <td align="left">
            5 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            0.1 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td align="left" colspan="5">
           </td>
          </tr>
          <tr>
           <td align="left">
            J527
           </td>
           <td align="left">
            Pro-Trp-Pro-Lys-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            70
           </td>
           <td align="left">
            3 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            0.1 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Lys-Pro-Lys-Ile-Pro-Pro
           </td>
           <td align="char">
            75
           </td>
           <td align="left">
            2 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            63
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Lys-Pro-Lys-Tyr-Pro-Pro
           </td>
           <td align="char">
            90
           </td>
           <td align="left">
            5 × 10
            <sup>
             −5
            </sup>
           </td>
           <td align="char">
            1.3 × 10
            <sup>
             5
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Leu-Pro-Lys-Ile-Pro-Pro
           </td>
           <td align="char">
            85
           </td>
           <td align="left">
            3 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            82
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Phe-Pro-Gln-Ile-Ala-Pro
           </td>
           <td align="char">
            70
           </td>
           <td align="left">
            3 × 10
            <sup>
             −6
            </sup>
           </td>
           <td align="char">
            1.0 × 10
            <sup>
             4
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Phe-Pro-Gln-Tyr-Ala-Pro
           </td>
           <td align="char">
            58
           </td>
           <td align="left">
            3 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            0.1 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Arg-Pro-Gln-Tyr-Pro-Pro
           </td>
           <td align="char">
            76
           </td>
           <td align="left">
            2 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            61
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pyr-Trp-Pro-Lys-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            65
           </td>
           <td align="left">
            2 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            72
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Arg-Pro-Lys-Ile-Pro-Pro
           </td>
           <td align="char">
            50
           </td>
           <td align="left">
            7 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            0.3 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            65
           </td>
           <td align="left">
            2 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            71
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Leu-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            40
           </td>
           <td align="left">
            7 × 10
            <sup>
             −6
            </sup>
           </td>
           <td align="char">
            4.0 × 10
            <sup>
             4
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Arg-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            55
           </td>
           <td align="left">
            7 × 10
            <sup>
             −6
            </sup>
           </td>
           <td align="char">
            3.0 × 10
            <sup>
             4
            </sup>
           </td>
          </tr>
          <tr>
           <td align="left" colspan="5">
           </td>
          </tr>
          <tr>
           <td align="left" colspan="5">
            Analogues and partialsequences with the photolabels ASA
            <xref ref-type="table-fn" rid="tbl1fn1">
             a
            </xref>
            and ABA
            <xref ref-type="table-fn" rid="tbl1fn2">
             b
            </xref>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            ABA-Pro-Trp-Pro-Phe-Pro-Gln-Tyr-Pro-Pro
           </td>
           <td align="char">
            93
           </td>
           <td align="left">
            1 × 10
            <sup>
             −7
            </sup>
           </td>
           <td align="char">
            0.3 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            ASA-Pro-Trp-Pro-Leu-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            110
           </td>
           <td align="left">
            3 × 10
            <sup>
             −7
            </sup>
           </td>
           <td align="char">
            0.7 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            ASA-Pro-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            90
           </td>
           <td align="left">
            6 × 10
            <sup>
             −9
            </sup>
           </td>
           <td align="char">
            16
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Lys(ASA)-Pro-Lys-Ile-Pro-Pro
           </td>
           <td align="char">
            99
           </td>
           <td align="left">
            1 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            23
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Lys-Pro-Lys(ASA)-Ile-Pro-Pro
           </td>
           <td align="char">
            103
           </td>
           <td align="left">
            8 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            0.2 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Lys(ABA)-Pro-Lys-Tyr-Pro-Pro
           </td>
           <td align="char">
            88
           </td>
           <td align="left">
            3 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            79
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Leu-Pro-Lys(ASA)-Ile-Pro-Pro
           </td>
           <td align="char">
            86
           </td>
           <td align="left">
            5 × 10
            <sup>
             −7
            </sup>
           </td>
           <td align="char">
            1.4 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            ABA-Pro-Trp-Pro-Phe-Pro-Gln-Tyr-Ala-Pro
           </td>
           <td align="char">
            20
           </td>
           <td align="left">
            1 × 10
            <sup>
             −5
            </sup>
           </td>
           <td align="char">
            1.1 × 10
            <sup>
             5
            </sup>
           </td>
          </tr>
          <tr>
           <td align="left" colspan="5">
           </td>
          </tr>
          <tr>
           <td align="left">
            J526
           </td>
           <td align="left">
            Pyr-Trp-Pro-Lys(ASA)-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            160
           </td>
           <td align="left">
            7 × 10
            <sup>
             −5
            </sup>
           </td>
           <td align="char">
            1.0 × 10
            <sup>
             5
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            ASA-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            110
           </td>
           <td align="left">
            6 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            0.1 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            ASA-Leu-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            70
           </td>
           <td align="left">
            8 × 10
            <sup>
             −6
            </sup>
           </td>
           <td align="char">
            2.6 × 10
            <sup>
             4
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            ASA-Arg-Pro-Gln-Ile-Pro-Pro
           </td>
           <td align="char">
            40
           </td>
           <td align="left">
            4 × 10
            <sup>
             −5
            </sup>
           </td>
           <td align="char">
            2.3 × 10
            <sup>
             5
            </sup>
           </td>
          </tr>
          <tr>
           <td align="left" colspan="5">
           </td>
          </tr>
          <tr>
           <td align="left" colspan="5">
            Analogues with the photolabel Bpa
            <xref ref-type="table-fn" rid="tbl1fn3">
             c
            </xref>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Bpa-Pro-Trp-Pro-Lys-Pro-Lys-Tyr-Pro-Pro
           </td>
           <td align="char">
            70
           </td>
           <td align="left">
            7 × 10
            <sup>
             −5
            </sup>
           </td>
           <td align="char">
            2.3 × 10
            <sup>
             5
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Bpa-Pro-Trp-Pro-Lys-Pro-Lys-Tyr(I)-Pro-Pro
           </td>
           <td align="char">
            75
           </td>
           <td align="left">
            5 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            0.2 × 10
            <sup>
             3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Bpa-Pro-Trp-Pro-Phe-Pro-Gln-Tyr-Ala-Pro
           </td>
           <td align="char">
            20
           </td>
           <td align="left">
            1 × 10
            <sup>
             −6
            </sup>
           </td>
           <td align="char">
            1.1 × 10
            <sup>
             4
            </sup>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Bpa-Pro-Trp-Pro-Arg-Pro-Gln-Tyr-Pro-Pro
           </td>
           <td align="char">
            72
           </td>
           <td align="left">
            2 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            65
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Bpa-Pro-Arg-Pro-Gln-Tyr-Pro-Pro
           </td>
           <td align="char">
            63
           </td>
           <td align="left">
            2 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            74
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td align="left">
            Pro-Trp-Pro-Bpa-Pro-Gln-Tyr-Pro-Pro
           </td>
           <td align="char">
            90
           </td>
           <td align="left">
            3 × 10
            <sup>
             −8
            </sup>
           </td>
           <td align="char">
            77
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           To quantify the difference between potentiation and inhibition we calculated a quotient from both activities. For the analogue with the highest ACE-inhibitory activity [1-Pro]-BPP
           <sub>
            9α
           </sub>
           the quotient was accounted to 1.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tbl1fn1">
          <label>
           a
          </label>
          <p>
           4-Azidosalicylic acid.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tbl1fn2">
          <label>
           b
          </label>
          <p>
           4-Azidobenzoic acid.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tbl1fn3">
          <label>
           c
          </label>
          <p>
           <italic>
            p
           </italic>
           -Benzoylphenylalanine.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p>
       To quantify this difference we calculated a quotient from both activities. For the analogue [1-Pro]-BPP
       <sub>
        9α
       </sub>
       this quotient was accounted to 1. Most distinct differences were found by nonapeptide analogues and partial sequences labeled with azidosalicylic acid (ASA). Some quotients reach 10
       <sup>
        5
       </sup>
       . Thus the compound J526 shows about 160% potentiation compared to BPP
       <sub>
        9α
       </sub>
       , but to enrich the same inhibition of ACE as the 1-Pro analogue a 10
       <sup>
        5
       </sup>
       higher concentration is required, resulting in a quotient of 10
       <sup>
        5
       </sup>
       .
      </p>
     </sec>
     <sec>
      <label>
       3.3
      </label>
      <title>
       Potentiation of the BK-induced contraction of the isolated guinea pig ileum
      </title>
      <p>
       One of the earliest pharmacological tests used for bradykinin was the contraction of the isolated guinea pig ileum (GPI). In our test the contraction of GPI can be potentiated by BPP
       <sub>
        9α
       </sub>
       and by the ACE inhibitor ramiprilat as well. Both potentiators enhance the isotonic measured contraction after 5 min preincubation (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       ). The pD
       <sub>
        2
       </sub>
       -values for BK were shifted in the presence of 20 nM BPP
       <sub>
        9α
       </sub>
       from 7.15 ± 0.11 (
       <italic>
        n
       </italic>
       = 8) to 7.84 ± 0.19 (
       <italic>
        n
       </italic>
       = 4) and by ramiprilat (20 nM) to 7.87 ± 0.22 (
       <italic>
        n
       </italic>
       = 4). Both potentiators are also able to shift the cumulative GPI contraction curves for the enzymatically more stable bradykinin analogue DArg-Arg-Pro-Hyp-Gly-Thi-Ser-Pro-ɛAbu(ßPh)-Arg
       <xref ref-type="bibr" rid="bib16">
        [16]
       </xref>
       to higher affinities. The pD
       <sub>
        2
       </sub>
       -value of this BK analogue was shifted by BPP
       <sub>
        9α
       </sub>
       (20 nM) from 6.65 ± 0.14 (
       <italic>
        n
       </italic>
       = 6) to 7.15 ± 0.18 (
       <italic>
        n
       </italic>
       = 3) and by ramiprilat to 7.16 ± 0.15 (
       <italic>
        n
       </italic>
       = 3).
       <fig id="fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Concentration–response curves to bradykinin on the guinea pig ileum without and after preincubation (5 min) of 20 nM ramiprilat (A) or 20 nM BPP
          <sub>
           9α
          </sub>
          (B). Contractions are expressed as a percentage of the maximum BK-induced response (10
          <sup>
           −8
          </sup>
          M BK) before addition of ramiprilat or bradykinin potentiating peptides. The values are accounted from one representative experiment, which was repeated three to eight times.
         </p>
        </caption>
        <graphic xlink:href="gr1">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.4
      </label>
      <title>
       Influence on the bradykinin B
       <sub>
        2
       </sub>
       receptor
      </title>
      <p>
       To study the influence of bradykinin potentiating peptides on the bradykinin B
       <sub>
        2
       </sub>
       receptor COS-7 cells were transfected with the gene of the human receptor. Expression, chemical and functional characterization of the expressed receptor is described in a preceding publication
       <xref ref-type="bibr" rid="bib56">
        [56]
       </xref>
       . Radioligand binding studies with tritium labeled bradykinin [
       <sup>
        3
       </sup>
       H]BK were performed on intact cells.
       <xref ref-type="fig" rid="fig2">
        Fig. 2
       </xref>
       shows the displacement curves of [
       <sup>
        3
       </sup>
       H]BK by BK alone and in the presence of the both potentiating nonapeptide analogues J526 and J527. Both peptides were used in such a concentration (0.1 μM) as necessary for the maximum potentiating effect on the isolated smooth muscle organ GPI. The potentiating peptides have no effect on the binding of bradykinin, indicating that the peptides used are neither able to enhance the affinity nor the number of active receptors. An unexpected finding is that analogue J527 is able to displace slightly [
       <sup>
        3
       </sup>
       H]BK in concentrations of 0.1 μM (20% displacement) to 1 μM (40% displacement) (not shown).
       <fig id="fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Competition curves of bradykinin (BK), BK with J526 (0.1 μM), or BK with J527 (0.1 μM) for specific binding of [
          <sup>
           3
          </sup>
          H]BK to COS-7 cells expressing the bradykinin B
          <sub>
           2
          </sub>
          receptor. Shown are representative experiments performed in quadruplicate determinations and repeated once with the same result.
         </p>
        </caption>
        <graphic xlink:href="gr2">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.5
      </label>
      <title>
       Influence of bradykinin potentiating peptides on signal pathways
      </title>
      <sec>
       <label>
        3.5.1
       </label>
       <title>
        Influence on Calcium uptake
       </title>
       <p>
        Lanthanium ions (La
        <sup>
         3+
        </sup>
        ) act as inhibitor of the uptake of Ca
        <sup>
         2+
        </sup>
        from extracellular space. We used La
        <sup>
         3+
        </sup>
        to estimate the influence of BPP
        <sub>
         9α
        </sub>
        on Ca
        <sup>
         2+
        </sup>
        uptake. BK induces the contraction of the GPI only in the presence of extracellular calcium ions. The lowest extracellular concentration of Ca
        <sup>
         2+
        </sup>
        necessary for a detectable contraction is 1.8 mM. In a Ca
        <sup>
         2+
        </sup>
        containing Tyrode buffer, BK induces the contraction of the isolated GPI, which can also be potentiated in the presence of 1.8 mM La
        <sup>
         3+
        </sup>
        (
        <xref ref-type="fig" rid="fig3">
         Fig. 3
        </xref>
        ). Bradykinin alone is unable to contract the GPI in the presence of La
        <sup>
         3+
        </sup>
        . The ileum contracts only after addition of BPP
        <sub>
         9α
        </sub>
        , as shown in part A of
        <xref ref-type="fig" rid="fig3">
         Fig. 3
        </xref>
        . Part B of this figure, reflecting the results in the Ca
        <sup>
         2+
        </sup>
        free Tyrode buffer, clearly underlines the important role of extracellular Ca
        <sup>
         2+
        </sup>
        for the BK-induced smooth muscle contraction. Part A also shows evidence that mobilization of intracellular Ca
        <sup>
         2+
        </sup>
        is necessary for the potentiation by the peptides.
        <fig id="fig3">
         <label>
          Fig. 3
         </label>
         <caption>
          <p>
           Effect of La
           <sup>
            3+
           </sup>
           (1.8 mM) on the potentiation of a BK-induced (20 nM) contraction of the guinea pig ileum by BPP
           <sub>
            9α
           </sub>
           (20 nM) in Tyrode-solution with (A) and without [Ca
           <sup>
            2+
           </sup>
           ] (B). The arrows indicate the addition of BK, BPP
           <sub>
            9α
           </sub>
           , lanthanium or calcium ions. W = wash period. Curves are examples of five separate experiments.
          </p>
         </caption>
         <graphic xlink:href="gr3">
         </graphic>
        </fig>
       </p>
      </sec>
      <sec>
       <label>
        3.5.2
       </label>
       <title>
        Influence on the phosphatidyinositol turnover
       </title>
       <p>
        Bradykinin induces the formation of inositol phosphates in COS-7 cells transiently expressing the BK receptor. Both analogues of the potentiating nonapeptide are not able to augment the BK-induced intracellular concentration of inositol phosphates. Rather it seems that J527 reduces the BK-induced IP
        <sub>
         <italic>
          n
         </italic>
        </sub>
        formation. The most striking result from
        <xref ref-type="fig" rid="fig4">
         Fig. 4
        </xref>
        is the significant enhancement of the basal level by both potentiating peptides in the absence of bradykinin, possibly indicating a nonreceptor-mediated pathway.
        <fig id="fig4">
         <label>
          Fig. 4
         </label>
         <caption>
          <p>
           Effect of BPP
           <sub>
            9α
           </sub>
           analogues J526 and J527 on basal level of inositol phosphate production in COS-7 cells transiently transfected with BKR-B
           <sub>
            2
           </sub>
           cDNA. Cells were prelabeled with 4 μCi/ml myo[
           <sup>
            3
           </sup>
           H]-inositol for 24 h and than stimulated with 3 × 10
           <sup>
            −8
           </sup>
           M bradykinin for 5 min in absence or in presence of J526 (0.1 μM) or J527 (0.1 μM). Inositol phosphate formation was determined in quadruplicates. Shown are the mean ± S.E.M. of four independent comparative experiments.
          </p>
         </caption>
         <graphic xlink:href="gr4">
         </graphic>
        </fig>
       </p>
      </sec>
      <sec>
       <label>
        3.5.3
       </label>
       <title>
        Influence on release of arachidonic acid
       </title>
       <p>
        Bradykinin triggers the release of [
        <sup>
         3
        </sup>
        H]-labeled arachidonic acid from labeled phospholipids, presumably through activation of phospholipase A
        <sub>
         2
        </sub>
        by a G
        <sub>
         α
        </sub>
        -protein. The level of arachidonic acid is significantly enhanced by BK as shown in
        <xref ref-type="fig" rid="fig5">
         Fig. 5
        </xref>
        . Both potentiating peptides J526 and J527 slightly, but significantly, enhance the BK-mediated release of labeled arachidonic acid. Without BK both peptides have no significant influence on the basal level.
        <fig id="fig5">
         <label>
          Fig. 5
         </label>
         <caption>
          <p>
           Influence of BPP
           <sub>
            9α
           </sub>
           analogues J526 and J527 on the BK-induced increase in arachidonic acid production in COS-7 cells which have transiently expressed the bradykinin B
           <sub>
            2
           </sub>
           receptor. Cells were prelabeled with 0.4 μCi/ml [
           <sup>
            3
           </sup>
           H]arachidonic acid for 24 h and stimulated with 3 × 10
           <sup>
            −8
           </sup>
           M BK for 30 min in absence or in presence of J526 (0.1 μM) or J527 (0.1 μM). Arachidonic acid release was six-fold determined. Results are expressed as the mean ± S.E.M.
          </p>
         </caption>
         <graphic xlink:href="gr5">
         </graphic>
        </fig>
       </p>
      </sec>
      <sec>
       <label>
        3.5.4
       </label>
       <title>
        Influence on protein phosphatases
       </title>
       <p>
        Desensitization and resensitization are processes at the receptor level elicited by cytosolic receptor phosphorylation, followed by internalization or dephosphorylation, which is followed by reintegration into the cell membrane. Dephosphorylation of cytosolic Ser- and Thr-residues of the BK receptor results from activated protein phosphatases. Calyculin is known as a potent inhibitor of the protein phosphatases 1 and 2A. We used this inhibitor to check the involvement of these phosphatases in the potentiation of bradykinin action. As
        <xref ref-type="fig" rid="fig6">
         Fig. 6
        </xref>
        illustrates calyculin has no influence on the potentiation of the BK-induced contraction. Application of calyculin, neither before nor after BK administration, changes the potentiating effects of BPP
        <sub>
         9α
        </sub>
        or ramiprilat.
        <fig id="fig6">
         <label>
          Fig. 6
         </label>
         <caption>
          <p>
           Influence of calyculin (100 nM) on the potentiation of a BK-induced (20 nM) contraction of the guinea pig ileum by BPP
           <sub>
            9α
           </sub>
           (20 nM). The arrows indicate the addition of BK, BPP
           <sub>
            9α
           </sub>
           and calyculin. W = wash period. Curves are examples of four to six separated experiments.
          </p>
         </caption>
         <graphic xlink:href="gr6">
         </graphic>
        </fig>
       </p>
      </sec>
     </sec>
     <sec>
      <label>
       3.6
      </label>
      <title>
       Influence of potentiating factor on the migration of polymorphonuclear leukocytes (PMN)
      </title>
      <p>
       Bradykinin stimulates the migration of PMN corresponding to its concentration gradient. This effect could be characterized as true chemotaxis. These cells contain both types of BK receptors, BKR-B
       <sub>
        1
       </sub>
       and BRK-B
       <sub>
        2
       </sub>
       , as demonstrated using BK agonists and antagonists in the migration assay
       <xref ref-type="bibr" rid="bib62">
        [62]
       </xref>
       . They also contain the complete system for synthesis and release of bioactive kinins. Degradation of BK proceeds in PMN mainly by the neutral endopeptidase NEP (E.C. 3.4.24.11). The BK-induced accelerated migration of PMN can be potentiated after preincubation (5 min) of the cells with the NEP inhibitor phosphoramidon (10
       <sup>
        −7
       </sup>
       M). The migration index (MI = 1.12 ± 0.03) of BK (10
       <sup>
        −8
       </sup>
       M) is significantly (
       <italic>
        p
       </italic>
       &lt; 0.5;
       <italic>
        t
       </italic>
       -test for paired samples;
       <italic>
        n
       </italic>
       = 12) enhanced in the presence of phosphoramidon (MI = 1.19 ± 0.03) (not shown).
      </p>
      <p>
       The migratory capacity of BK for PMN can also be potentiated by the ACE inhibitor ramiprilat. The migation index of BK (10
       <sup>
        −7
       </sup>
       M) without ramiprilat is MI = 1.30 ± 0.06, in the presence of ramiprilat (10 nM) MI = 1.69 ± 0.26, measured in six experiments (not shown).
      </p>
      <p>
       As shown in
       <xref ref-type="fig" rid="fig7">
        Fig. 7
       </xref>
       BPP
       <sub>
        9α
       </sub>
       can enhance the migration of PMN induced as well by BK and by the enzymatically stable BK agonist D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-Pro-ɛAbu(βPh)-Arg
       <xref ref-type="bibr" rid="bib16">
        [16]
       </xref>
       , but is unable to enhance the migratory activity of the nonpeptide agonist FR190997
       <xref ref-type="bibr" rid="bib4">
        [4]
       </xref>
       and the BKR-B
       <sub>
        1
       </sub>
       agonist desArg
       <sup>
        9
       </sup>
       -BK. BPP
       <sub>
        9α
       </sub>
       (10 nM) is able to potentiate the dose–response curve of the BK-induced migration of the PMN (
       <xref ref-type="fig" rid="fig8">
        Fig. 8
       </xref>
       A). It potentiates the BK-induced effect in a concentration-dependent way (
       <xref ref-type="fig" rid="fig8">
        Fig. 8
       </xref>
       B).
       <fig id="fig7">
        <label>
         Fig. 7
        </label>
        <caption>
         <p>
          Influence of BPP
          <sub>
           9α
          </sub>
          on BKR-B
          <sub>
           2
          </sub>
          and BKR-B
          <sub>
           1
          </sub>
          agonists-induced migration of polymorphonuclear leukocytes (PMN). Cells in the upper compartment of the chamber were preincubated (15 min) with BPP
          <sub>
           9α
          </sub>
          (10
          <sup>
           −8
          </sup>
          M). Bradykinin, the nonpeptide agonist FR190997 or desArg
          <sup>
           9
          </sup>
          -BK (10
          <sup>
           −10
          </sup>
          M) were given into the lower compartment. Results are expressed as migration index (control = 1.0) and represent mean ± S.E.M. of five to seven experiments.
         </p>
        </caption>
        <graphic xlink:href="gr7">
        </graphic>
       </fig>
       <fig id="fig8">
        <label>
         Fig. 8
        </label>
        <caption>
         <p>
          Effect of BPP
          <sub>
           9α
          </sub>
          on the BK-induced migration of human polymorphonuclear leukocytes (PMN) in Boyden chambers. (A) Concentration–response curves of BK without and in presence of 10 nM BPP
          <sub>
           9α
          </sub>
          . Cells in the upper compartment of the chamber were preincubated (15 min) with BPP
          <sub>
           9α
          </sub>
          and BK was given into the lower compartment. (B): The BK-induced (10
          <sup>
           −9
          </sup>
          M) migration is dose-dependently potentiated by BPP
          <sub>
           9α
          </sub>
          in concentrations of 10
          <sup>
           −8
          </sup>
          and 10
          <sup>
           −7
          </sup>
          M. Results are expressed as migration index (control = 1.0) and represent mean ± S.E.M. of 3–11 experiments. Values are significantly different from control values without BPP
          <sub>
           9α
          </sub>
          :
          <sup>
           **
          </sup>
          <italic>
           p
          </italic>
          &lt; 0.01,
          <sup>
           *
          </sup>
          <italic>
           p
          </italic>
          &lt; 0.05 (Student's
          <italic>
           t
          </italic>
          -test).
         </p>
        </caption>
        <graphic xlink:href="gr8">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p>
      The potentiating action, despite many long years of experimental research and investigation, remains a phenomenon not fully understood. Beginning with studies on the potentiation of smooth muscle contraction more than 30 years ago, the search has been extended to other organs such as the vascular system, to different bradykinin degrading enzymes, to immunocompetent cells, and in the last decade to molecular mechanisms at the level of the bradykinin receptors and signal pathways, primarily studied on cell cultures. Other potentiating peptides and peptidomimetics besides the oligopeptides isolated from snake venoms have been used in these studies.
     </p>
     <p>
      Generally, some of the contradictory findings and therefore explanations in the literature seem to result not only from the complexity of the system, but also from: the use of enzymatically not fully stable bradykinin agonists e.g. [Hyp
      <sup>
       3
      </sup>
      ,Tyr(Me)
      <sup>
       8
      </sup>
      ]-BK
      <xref ref-type="bibr" rid="bib31">
       [31]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib53">
       [53]
      </xref>
      , the species dependency of the bradykinin receptor, the very different protease compositions of the tissues and cell lines used in the different studies, and the different structural requirements for both catalytic centers of ACE. Furthermore, we have to keep in mind the different density of the BK receptors, their localization in microdomains in the plasma membrane, the presence of certain other hormone receptors, the different signal pathways in the used tissues and cells, a possible influence on G-protein independent signal transduction, on G-protein trafficking pattern in the cells and on activators or regulators of G-protein signaling
      <xref ref-type="bibr" rid="bib48">
       [48]
      </xref>
      . Additionally the potentiating effect can be differentiated into an unspecific and specific part. Consequently, the search for potentiation of hormone actions is strongly related to the very recent research on multifunctional signal proteins.
     </p>
     <sec>
      <label>
       4.1
      </label>
      <title>
       Distinct differences between potentiation of the BK-induced contraction of the isolated guinea pig ileum and the inhibition of the isolated angiotensin I-converting enzyme
      </title>
      <p>
       The isolation, chemical and functional characterization of oligopeptides taken from the venoms of different snakes provided lead structures for a number of potentiating peptides. Long ago these oligopeptides gave some evidence of different structural requirements for potentiation of smooth muscle contraction and inhibition of ACE. Our synthesized analogues and fragments of the highly active nonapeptide BPP
       <sub>
        9α
       </sub>
       show in some cases differences between potentiation and enzyme inhibition of more than five orders of magnitude. This result indicates strongly different structural requirements for both biological activities, and is inconsistent with the exclusive reduction of potentiating action to the inhibition of ACE, as discussed by Regoli and his coworkers
       <xref ref-type="bibr" rid="bib31">
        [31]
       </xref>
       and Dendorfer et al.
       <xref ref-type="bibr" rid="bib17">
        [17]
       </xref>
       . We might draw this conclusion despite the different sources for the isolated organs and the ACE. Since the BK receptor is species dependent, the human BKR-B
       <sub>
        2
       </sub>
       shares about 80% sequence homology with that of the guinea pig
       <xref ref-type="bibr" rid="bib20">
        [20]
       </xref>
       , whereas the ACE seems to be nearly species independent. Interestingly, the potentiating activity is much less influenced by amino acid replacements or modifications of the lead peptide BPP
       <sub>
        9α
       </sub>
       than the inhibition of ACE.
      </p>
      <p>
       From the analogues listed in
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       , it is clearly evident that the potentiation of GPI contraction is less sensitive to amino acid replacements and modifications in the peptide sequence than the inhibition of ACE. Thus potentiating activities vary between 160% and 20%, whereas the IC
       <sub>
        50
       </sub>
       values for ACE inhibition vary between 5 × 10
       <sup>
        −10
       </sup>
       and 7 × 10
       <sup>
        −5
       </sup>
       M. Both activities show no correlation. The estimated values indicate that the potentiating activity allows beside amino acid replacements, a shortening of the sequence as well as substitutions of the N-terminus or side chains by aromatic moieties. The inhibitory activity seems to depend on the whole sequence. The replacement of the basic amino acid Arg at position 4 by neutral aliphatic or aromatic amino acids influences the ACE inhibition only slightly, on the other hand the acylation of the Lys side chain at the same position by ASA reduces the IC
       <sub>
        50
       </sub>
       value by four orders of magnitude. According to Cotton et al.
       <xref ref-type="bibr" rid="bib11">
        [11]
       </xref>
       position 4 seems to be crucial for inhibitory activity. But, our results did not provide clear structure activity relationships.
      </p>
      <p>
       Discussing the potentiation of the BK-induced contraction of GPI we have to keep in mind that this tissue also contains other proteases than ACE involved in BK degradation. But this finding is not able to explain the strong differences between both activities as expressed in the ratio in
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       .
      </p>
     </sec>
     <sec>
      <label>
       4.2
      </label>
      <title>
       Direct interaction with the bradykinin receptors
      </title>
      <p>
       It is reasonable to assume an interaction of the potentiating peptides with the BK receptor. For this interaction certain possible mechanisms exist. At first, the potentiating factors could act like allosteric effectors stabilizing the active receptor conformation. Secondly, these factors could influence the phosphorylation and dephosphorylation of cytosolic parts of the receptor, resulting in desensitization and resenzitization of the receptor. A third possible mechanism consists in the influence of potentiating factors on receptor hetero-oligomerization. AbdAlla et al.
       <xref ref-type="bibr" rid="bib1">
        [1]
       </xref>
       found that both the active high affinity angiotensin receptor AT
       <sub>
        1
       </sub>
       and the BKR-B
       <sub>
        2
       </sub>
       are able to form heteromeric complexes in smooth muscle cells. Most importantly, this heterodimerization evokes a signal enhancement, a further possible useful explanation of the potentiating effect.
      </p>
      <p>
       For checking these possibilities we used COS-7 cells transiently transfected with the human BKR-B
       <sub>
        2
       </sub>
       . The displacement curves show no differences between the displacement of [
       <sup>
        3
       </sup>
       H]-BK by BK alone nor in the presence of potentiating peptides. This finding clearly demonstrates that the analogues of BPP
       <sub>
        9α
       </sub>
       used in this study do not act as allosteric effectors stabilizing the active receptor conformation. Because COS-7 cells do not contain ACE, a heterodimerization of the B
       <sub>
        2
       </sub>
       receptor with somatic ACE as demonstrated by Erdos and Marcic
       <xref ref-type="bibr" rid="bib19">
        [19]
       </xref>
       is impossible in our system. Our radioligand binding curves show no influence of the potentiating peptides on the receptor capacity, indicating that under the test conditions the number of intramembranal receptors was not changed. This result excludes an internalization or reintegration of the receptor under the influence of potentiating peptides. But, we would not exclude these processes after heterodimerization with ACE or with the angiotensin receptor.
      </p>
     </sec>
     <sec>
      <label>
       4.3
      </label>
      <title>
       Influence on signal pathways
      </title>
      <p>
       The contraction of smooth muscles requires calcium ions. Consequently the potentiation of BK-induced contraction of GPI depends on extracellular and intracellular Ca
       <sup>
        2+
       </sup>
       . In a variety of publications the enhancement of the intracellular Ca
       <sup>
        2+
       </sup>
       -level is used as a qualitative or quantitative proof of the potentiating action. Our results with the inhibition of Ca
       <sup>
        2+
       </sup>
       -uptake from extracellular sources by La
       <sup>
        3+
       </sup>
       indicates that the potentiation of BK-action requires mobilization of Ca
       <sup>
        2+
       </sup>
       from intracellular stores. On the other hand, in the beginning phase of the BK-evoked GPI contraction extracellular calcium is needed. Thus, our results with La
       <sup>
        3+
       </sup>
       agree well with the finding of Marcic et al.
       <xref ref-type="bibr" rid="bib49">
        [49]
       </xref>
       , who described the inhibition of resensitization of the BK receptor in CHO cells by La
       <sup>
        3+
       </sup>
       .
      </p>
      <p>
       The inositol phosphates (IP
       <sub>
        <italic>
         n
        </italic>
       </sub>
       ) formed in transiently with the B
       <sub>
        2
       </sub>
       receptor transfected COS-7 cells opens the Ca
       <sup>
        2+
       </sup>
       channels of the endoplasmatic reticulum leading to an increase of cytosolic Ca
       <sup>
        2+
       </sup>
       . But, both potentiating nonapeptides J526 and J527 are unable to enhance the BK-induced formation of IP
       <sub>
        <italic>
         n
        </italic>
       </sub>
       . Surprisingly, both potentiating peptides increase the basal level of IP
       <sub>
        <italic>
         n
        </italic>
       </sub>
       in the absence of BK. Possibly this may be due to an unspecific, nonreceptor-mediated part of the potentiating action.
      </p>
      <p>
       Contrary to the absent effect of both potentiating peptides on the BK-induced enhancement of inositol phosphates, the BK-induced release of arachidonic acid is significantly increased. Furthermore, contrary to the IP
       <sub>
        <italic>
         n
        </italic>
       </sub>
       formation, no influence of either potentiating peptides on the basal level could be found. We continue to be unable to explain the potentiation of arachidonic acid release because no effect on the receptor has been detected. The missing effect of calyculin on the potentiation might indicate that the inhibited phosphatases are not involved into resensitization.
      </p>
     </sec>
     <sec>
      <label>
       4.4
      </label>
      <title>
       Influence on migration of polymorphonuclear leukocytes
      </title>
      <p>
       Besides GPI and COS-7 cells the PMN represent our third system for studies about the potentiating mechanism. These cells constitutively express B
       <sub>
        1
       </sub>
       as well as B
       <sub>
        2
       </sub>
       receptors and have a cell specific set of proteases involved in BK degradation. In this system the potentiating nonapeptide BPP
       <sub>
        9α
       </sub>
       and ramiprilat accelerate the BK-induced migration. In contrast to Ignjatovic et al.
       <xref ref-type="bibr" rid="bib37">
        [37]
       </xref>
       , who found on other cells a concentration-dependent direct activation of the B
       <sub>
        1
       </sub>
       receptor in the absence of kinins, we could not detect any activity of the potentiating nonapeptide without administration of B
       <sub>
        1
       </sub>
       or B
       <sub>
        2
       </sub>
       agonists. Though the migratory activity of the proteolytic stabilized BK analogue J725
       <xref ref-type="bibr" rid="bib16">
        [16]
       </xref>
       is potentiated, the action of the nonpeptide agonist FR190997
       <xref ref-type="bibr" rid="bib4">
        [4]
       </xref>
       could not be accelerated by BPP
       <sub>
        9α
       </sub>
       and ramiprilat. It is difficult to explain this finding. In agreement with the weaker acceleration of the stabilized BK analogue, the effect of the NEP inhibitor phosphoramidon and the concentration-dependent potentiation induced by BPP
       <sub>
        9α
       </sub>
       , we might suppose that in this test system the potentiation occurs possibly exclusively by inhibition of the enzymatic BK degradation. But, we also have to consider a different mechanism for the peptide and nonpeptide agonist. This assumption is supported in that test by the strongly reduced intrinsic activity of the nonpeptide agonist FR190997 compared to BK itself.
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      5
     </label>
     <title>
      Conclusions
     </title>
     <p>
      During the last three decades many different and controversial explanations on the potentiating mechanism have been derived from experiments performed in vivo, in vitro and at the cellular level.
     </p>
     <p>
      The distinct and in some cases very significant differences between the inhibitory and potentiating activity of the synthesized BPP
      <sub>
       9α
      </sub>
      analogues clearly indicate, in our opinion, that on guinea pig ileum this mechanism cannot be exclusively reduced to enzyme inhibition. The observed differences even exceed the different structural requirements for N- and C-terminal catalytic centers of ACE. The experiments with La
      <sup>
       3+
      </sup>
      gave evidence that the potentiation of smooth muscle contraction requires extracellular Ca
      <sup>
       2+
      </sup>
      which is taken up through opened channels. The increase of the intracellular level of inositol phosphates, triggered by potentiating peptides, leads to an additional enhancement of the intracellular Ca
      <sup>
       2+
      </sup>
      concentration. Application of potentiating peptides to COS-7 cells which were transiently transfected with the B
      <sub>
       2
      </sub>
      receptor and did not contain endogenous ACE, shows no increase in receptor affinity or density. These results disprove the described suggestion of direct interaction of BPP with the BK receptor.
     </p>
     <p>
      The described receptor resensitization by potentiating peptides could result from dephosphorylation of the activated receptor. Our results obtained with the phosphatase inhibitor calyculin disprove the influence of BPP
      <sub>
       9α
      </sub>
      on the calyculin sensitive phosphatase. No difference between potentiation neither in the absence nor in the presence of the inhibitor could be observed.
     </p>
     <p>
      The release of arachidonic acid is one of the prerequisites for inflammatory processes. The potentiating peptides have no effect on the basal level but they significantly increase the BK-induced release in COS-7 cells. This result indicates the possible involvement of potentiating peptides in inflammatory processes without affecting ACE.
     </p>
     <p>
      Contrary to that mechanism the potentiation of the migratory activity of polymorphonuclear leucocytes seems to be nearly exclusively evoked by the ACE inhibition. On these B
      <sub>
       1
      </sub>
      and B
      <sub>
       2
      </sub>
      receptor containing cells no direct interaction with the B
      <sub>
       1
      </sub>
      receptor could be observed.
     </p>
     <p>
      Our results together with those from the literature may lead to the general conclusion that different potentiating factors can act on different organs, tissues and cells by different mechanisms. Furthermore, BPP can evoke both receptor-mediated and nonreceptor-mediated intracellular reactions. In our opinion the contradictory explanations describing the potentiation mechanism result on the one hand from the very high complexity of the kallikrein–kinin and renin–angiotensin systems and on the other hand from the different in vivo and in vitro tests used.
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AbdAlla
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lother
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Quitterer
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
        </person-group>
        <article-title>
         AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         407
        </volume>
        <issue>
         6800
        </issue>
        <year>
         2000
        </year>
        <fpage>
         94
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="pmid">
         10993080
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adomeit
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Graness
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gross
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Seedorf
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wetzker
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Liebmann
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin B(2) receptor-mediated mitogen-activated protein kinase activation in COS-7 cells requires dual signaling via both protein kinase C pathway and epidermal growth factor receptor transactivation
        </article-title>
        <source>
         Mol Cell Biol
        </source>
        <volume>
         19
        </volume>
        <issue>
         8
        </issue>
        <year>
         1999
        </year>
        <fpage>
         5289
        </fpage>
        <lpage>
         5297
        </lpage>
        <pub-id pub-id-type="pmid">
         10409720
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Akchunov
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Golubenko
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Sosnina
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of biological properties of inhibitors angiotensin-1-converting enzyme from the spider venom
         <italic>
          Latrodectus tredecimguttatus
         </italic>
        </article-title>
        <source>
         Agents Actions Suppl
        </source>
        <volume>
         38
        </volume>
        <issue>
         Pt 1
        </issue>
        <year>
         1992
        </year>
        <fpage>
         469
        </fpage>
        <lpage>
         474
        </lpage>
        <pub-id pub-id-type="pmid">
         1334626
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Asano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hatori
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sawai
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Johki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Inamura
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Kayakiri
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pharmacological characterization of a nonpeptide bradykinin B
         <sub>
          2
         </sub>
         receptor antagonist, FR165649, and agonist FR190997
        </article-title>
        <source>
         Br J Pharmacol
        </source>
        <volume>
         124
        </volume>
        <issue>
         3
        </issue>
        <year>
         1998
        </year>
        <fpage>
         441
        </fpage>
        <lpage>
         446
        </lpage>
        <pub-id pub-id-type="pmid">
         9647466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Auerswald
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Doleschel
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         On the potentiation of kinins by sulfhydrylic compounds
        </article-title>
        <source>
         Arch Int Pharmacodyn Ther
        </source>
        <volume>
         168
        </volume>
        <issue>
         1
        </issue>
        <year>
         1967
        </year>
        <fpage>
         188
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="pmid">
         4292761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brunner
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
         <name>
          <surname>
           Desponds
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Biollaz
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Keller
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Ferber
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Gavras
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects
        </article-title>
        <source>
         Br J Clin Pharmacol
        </source>
        <volume>
         11
        </volume>
        <issue>
         5
        </issue>
        <year>
         1981
        </year>
        <fpage>
         461
        </fpage>
        <lpage>
         467
        </lpage>
        <pub-id pub-id-type="pmid">
         6268131
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chaturvedi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Huelar
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Gunthorpe
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gofman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Krapf
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Apostol
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin analogs as inhibitors of angiotensin-converting enzyme
        </article-title>
        <source>
         Pept Res
        </source>
        <volume>
         6
        </volume>
        <issue>
         6
        </issue>
        <year>
         1993
        </year>
        <fpage>
         308
        </fpage>
        <lpage>
         312
        </lpage>
        <pub-id pub-id-type="pmid">
         8292848
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chi
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           S.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L.G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lo
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           W.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure–function studies on the bradykinin potentiating peptide from Chinese snake venom (Agkistrodon halys Pallas)
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         6
        </volume>
        <issue>
         Suppl 3
        </issue>
        <year>
         1985
        </year>
        <fpage>
         339
        </fpage>
        <lpage>
         342
        </lpage>
        <pub-id pub-id-type="pmid">
         3008123
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cintra
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Vieira
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Giglio
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Primary structure and biological activity of bradykinin potentiating peptides from
         <italic>
          Bothrops insularis
         </italic>
         snake venom
        </article-title>
        <source>
         J Protein Chem
        </source>
        <volume>
         9
        </volume>
        <issue>
         2
        </issue>
        <year>
         1990
        </year>
        <fpage>
         221
        </fpage>
        <lpage>
         227
        </lpage>
        <pub-id pub-id-type="pmid">
         2386615
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cirstea
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potentiation of some bradykinin effects by thiol compounds
        </article-title>
        <source>
         Br J Pharmacol
        </source>
        <volume>
         25
        </volume>
        <issue>
         2
        </issue>
        <year>
         1965
        </year>
        <fpage>
         405
        </fpage>
        <lpage>
         410
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cotton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hayashi
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cuniasse
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Vazeux
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ianzer
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           De Camargo
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         41
        </volume>
        <issue>
         19
        </issue>
        <year>
         2002
        </year>
        <fpage>
         6065
        </fpage>
        <lpage>
         6071
        </lpage>
        <pub-id pub-id-type="pmid">
         11994001
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cushman
          </surname>
          <given-names>
           D.W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           H.S.
          </given-names>
         </name>
         <name>
          <surname>
           Sabo
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ondetti
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         16
        </volume>
        <issue>
         25
        </issue>
        <year>
         1977
        </year>
        <fpage>
         5484
        </fpage>
        <lpage>
         5491
        </lpage>
        <pub-id pub-id-type="pmid">
         200262
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cushman
          </surname>
          <given-names>
           D.W.
          </given-names>
         </name>
         <name>
          <surname>
           Pluscec
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Weaver
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <name>
          <surname>
           Sabo
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Kocy
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of angiotensin-coverting enzyme by analogs of peptides from
         <italic>
          Bothrops jararaca
         </italic>
         venom
        </article-title>
        <source>
         Experientia
        </source>
        <volume>
         29
        </volume>
        <issue>
         8
        </issue>
        <year>
         1973
        </year>
        <fpage>
         1032
        </fpage>
        <lpage>
         1035
        </lpage>
        <pub-id pub-id-type="pmid">
         4354751
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deddish
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Marcic
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Jackman
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Skidgel
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         31
        </volume>
        <issue>
         4
        </issue>
        <year>
         1998
        </year>
        <fpage>
         912
        </fpage>
        <lpage>
         9177
        </lpage>
        <pub-id pub-id-type="pmid">
         9535414
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deddish
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Marcic
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jackman
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neprilysin inhibitors potentiate effects of bradykinin on b2 receptor
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         39
        </volume>
        <issue>
         2 Pt 2
        </issue>
        <year>
         2002
        </year>
        <fpage>
         619
        </fpage>
        <lpage>
         623
        </lpage>
        <pub-id pub-id-type="pmid">
         11882619
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dendorfer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wagemann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Reissmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dominiak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural requirements for B
         <sub>
          2
         </sub>
         -agonists with improved degradation stability
        </article-title>
        <source>
         Immunopharmacology
        </source>
        <volume>
         45
        </volume>
        <issue>
         1–3
        </issue>
        <year>
         1999
        </year>
        <fpage>
         199
        </fpage>
        <lpage>
         205
        </lpage>
        <pub-id pub-id-type="pmid">
         10615012
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dendorfer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Reissmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wolfrum
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Raasch
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Dominiak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         38
        </volume>
        <issue>
         1
        </issue>
        <year>
         2001
        </year>
        <fpage>
         142
        </fpage>
        <lpage>
         146
        </lpage>
        <pub-id pub-id-type="pmid">
         11463775
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Duchene
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Schanstra
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Pecher
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pizard
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Susini
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Esteve
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel protein–protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         277
        </volume>
        <issue>
         43
        </issue>
        <year>
         2002
        </year>
        <fpage>
         40375
        </fpage>
        <lpage>
         40383
        </lpage>
        <pub-id pub-id-type="pmid">
         12177051
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           Marcic
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kinins, receptors, kininases and inhibitors—where did they lead us?
        </article-title>
        <source>
         Biol Chem
        </source>
        <volume>
         382
        </volume>
        <issue>
         1
        </issue>
        <year>
         2001
        </year>
        <fpage>
         43
        </fpage>
        <lpage>
         47
        </lpage>
        <pub-id pub-id-type="pmid">
         11258670
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Farmer
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Powell
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wilkins
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cloning, sequencing and functional expression of a guinea pig lung bradykinin B2 receptor
        </article-title>
        <source>
         Eur J Pharmacol
        </source>
        <volume>
         346
        </volume>
        <issue>
         2/3
        </issue>
        <year>
         1998
        </year>
        <fpage>
         291
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="pmid">
         9652372
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alves
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
         <name>
          <surname>
           Henriques
          </surname>
          <given-names>
           O.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Peptide T, a novel bradykinin potentiator isolated from
         <italic>
          Tityus serrulatus
         </italic>
         scorpion venom
        </article-title>
        <source>
         Toxicon
        </source>
        <volume>
         31
        </volume>
        <issue>
         8
        </issue>
        <year>
         1993
        </year>
        <fpage>
         941
        </fpage>
        <lpage>
         947
        </lpage>
        <pub-id pub-id-type="pmid">
         8212046
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alves
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lucas
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Habermehl
          </surname>
          <given-names>
           G.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of a bradykinin potentiating peptide (BPP-S) isolated from
         <italic>
          Scaptocosa raptoria
         </italic>
         venom
        </article-title>
        <source>
         Toxicon
        </source>
        <volume>
         34
        </volume>
        <issue>
         5
        </issue>
        <year>
         1996
        </year>
        <fpage>
         599
        </fpage>
        <lpage>
         603
        </lpage>
        <pub-id pub-id-type="pmid">
         8783454
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Galle
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Raida
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Schrader
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lebrun
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Habermehl
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation: analysis and properties of three bradykinin-potentiating peptides (BPP-II, BPP-III, and BPP-V) from
         <italic>
          Bothrops neuwiedi
         </italic>
         venom
        </article-title>
        <source>
         J Protein Chem
        </source>
        <volume>
         17
        </volume>
        <issue>
         3
        </issue>
        <year>
         1998
        </year>
        <fpage>
         285
        </fpage>
        <lpage>
         289
        </lpage>
        <pub-id pub-id-type="pmid">
         9588953
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Henriques
          </surname>
          <given-names>
           O.B.
          </given-names>
         </name>
         <name>
          <surname>
           Lebrun
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Batista
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
         <name>
          <surname>
           Prezoto
          </surname>
          <given-names>
           B.C.
          </given-names>
         </name>
         <name>
          <surname>
           Andreoni
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new bradykinin-potentiating peptide (peptide P) isolated from the venom of
         <italic>
          Bothrops jararacussu
         </italic>
         (jararacucu tapete, urutu dourado)
        </article-title>
        <source>
         Toxicon
        </source>
        <volume>
         30
        </volume>
        <issue>
         1
        </issue>
        <year>
         1992
        </year>
        <fpage>
         33
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="pmid">
         1595077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mollring
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lebrun
          </surname>
          <given-names>
           F.L.
          </given-names>
         </name>
         <name>
          <surname>
           Raida
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Znottka
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Habermehl
          </surname>
          <given-names>
           G.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure and effects of a kinin potentiating fraction F (AppF) isolated from
         <italic>
          Agkistrodon piscivorus piscivorus
         </italic>
         venom
        </article-title>
        <source>
         Toxicon
        </source>
        <volume>
         33
        </volume>
        <issue>
         10
        </issue>
        <year>
         1995
        </year>
        <fpage>
         1313
        </fpage>
        <lpage>
         1319
        </lpage>
        <pub-id pub-id-type="pmid">
         8599182
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A bradykinin-potentiating factor (Bpf) present in the venom of
         <italic>
          Bothrops jararaca
         </italic>
        </article-title>
        <source>
         Br J Pharmacol
        </source>
        <volume>
         24
        </volume>
        <year>
         1965
        </year>
        <fpage>
         163
        </fpage>
        <lpage>
         169
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Bartelt
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Greene
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of bradykinin-potentiating peptides from
         <italic>
          Bothrops jararaca
         </italic>
         venom
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         9
        </volume>
        <issue>
         13
        </issue>
        <year>
         1970
        </year>
        <fpage>
         2583
        </fpage>
        <lpage>
         2593
        </lpage>
        <pub-id pub-id-type="pmid">
         4317874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferry
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Brehin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kamel
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Landry
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         G protein-dependent activation of mast cell by peptides and basic secretagogues
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         23
        </volume>
        <issue>
         8
        </issue>
        <year>
         2002
        </year>
        <fpage>
         1507
        </fpage>
        <lpage>
         1515
        </lpage>
        <pub-id pub-id-type="pmid">
         12182955
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fortin
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Gobeil
          </surname>
          <given-names>
           F.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Adam
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Regoli
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Marceau
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor?
        </article-title>
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         285
        </volume>
        <issue>
         1
        </issue>
        <year>
         2003
        </year>
        <fpage>
         H277
        </fpage>
        <lpage>
         H282
        </lpage>
        <pub-id pub-id-type="pmid">
         12649080
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Genin
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dopamine receptor modulation by a highly rigid spiro bicyclic peptidomimetic of Pro-Leu-Gly-NH
         <sub>
          2
         </sub>
        </article-title>
        <source>
         J Med Chem
        </source>
        <volume>
         36
        </volume>
        <issue>
         22
        </issue>
        <year>
         1993
        </year>
        <fpage>
         3481
        </fpage>
        <lpage>
         3483
        </lpage>
        <pub-id pub-id-type="pmid">
         7901418
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gobeil
          </surname>
          <given-names>
           F.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Halle
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Blais
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Regoli
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Studies on the angiotensin-converting enzyme and the kinin B2 receptor in the rabbit jugular vein: modulation of contractile response to bradykinin
        </article-title>
        <source>
         Can J Physiol Pharmacol
        </source>
        <volume>
         80
        </volume>
        <issue>
         2
        </issue>
        <year>
         2002
        </year>
        <fpage>
         153
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="pmid">
         11934258
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gothe
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Seyfahrt
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Schuhmann
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Agricola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Reissmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lifferth
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Combination of allyl protection and HYCRAM™-linker technology for the synthesis of peptides with problematical amino acids and sequences
        </article-title>
        <source>
         J Prakt Chem
        </source>
        <volume>
         341
        </volume>
        <year>
         1999
        </year>
        <fpage>
         369
        </fpage>
        <lpage>
         377
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hecker
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bara
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Busse
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potentiation of the biological efficacy of bradykinin by ACE inhibitors: a shift in the affinity of the B2 receptor?
        </article-title>
        <source>
         Immunopharmacology
        </source>
        <volume>
         33
        </volume>
        <issue>
         1–3
        </issue>
        <year>
         1996
        </year>
        <fpage>
         93
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         8856122
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Henriques
          </surname>
          <given-names>
           O.B.
          </given-names>
         </name>
         <name>
          <surname>
           de Deus
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin potentiating peptides isolated from alpha-casein tryptic hydrolysate
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <volume>
         36
        </volume>
        <issue>
         1
        </issue>
        <year>
         1987
        </year>
        <fpage>
         182
        </fpage>
        <lpage>
         184
        </lpage>
        <pub-id pub-id-type="pmid">
         3026403
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Higuchi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Murayama
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Saguchi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ohi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Fujita
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Camargo
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin-potentiating peptides and C-type natriuretic peptides from snake venom
        </article-title>
        <source>
         Immunopharmacology
        </source>
        <volume>
         44
        </volume>
        <issue>
         1/2
        </issue>
        <year>
         1999
        </year>
        <fpage>
         129
        </fpage>
        <lpage>
         135
        </lpage>
        <pub-id pub-id-type="pmid">
         10604536
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ianzer
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Konno
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Marques-Porto
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Vieira Portaro
          </surname>
          <given-names>
           F.C.
          </given-names>
         </name>
         <name>
          <surname>
           Stöcklin
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Martins de Camargo
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of five new bradykinin potentiating peptides (BPPs) from
         <italic>
          Bothrops jararaca
         </italic>
         crude venom by using electrospray ionization tandem mass spectrometry after a two-step liquid chromatography
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         25
        </volume>
        <issue>
         7
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1085
        </fpage>
        <lpage>
         1092
        </lpage>
        <pub-id pub-id-type="pmid">
         15245866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ignjatovic
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Brovkovych
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Skidgel
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of bradykinin B1 receptor by ACE inhibitors
        </article-title>
        <source>
         Int Immunopharmacol
        </source>
        <volume>
         2
        </volume>
        <issue>
         13/14
        </issue>
        <year>
         2002
        </year>
        <fpage>
         1787
        </fpage>
        <lpage>
         1793
        </lpage>
        <pub-id pub-id-type="pmid">
         12489793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ivanov
          </surname>
          <given-names>
           V.T.
          </given-names>
         </name>
         <name>
          <surname>
           Karelin
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Philippova
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Nazimov
          </surname>
          <given-names>
           I.V.
          </given-names>
         </name>
         <name>
          <surname>
           Pletnev
          </surname>
          <given-names>
           V.Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hemoglobin as a source of endogenous bioactive peptides: the concept of tissue-specific peptide pool
        </article-title>
        <source>
         Biopolymers
        </source>
        <volume>
         43
        </volume>
        <year>
         1997
        </year>
        <fpage>
         171
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="pmid">
         9216253
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kato
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin-potentiating peptides from the venom of
         <italic>
          Agkistrodon halys blomhoffii
         </italic>
        </article-title>
        <source>
         Experientia
        </source>
        <volume>
         25
        </volume>
        <issue>
         7
        </issue>
        <year>
         1969
        </year>
        <fpage>
         694
        </fpage>
        <lpage>
         695
        </lpage>
        <pub-id pub-id-type="pmid">
         5801778
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kato
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin-potentiating peptides from the venom of
         <italic>
          Agkistrodon halys blomhoffi
         </italic>
         . Isolation of five bradykinin potentiators and the amino acid sequences of two of them, potentiators B and C
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         10
        </volume>
        <issue>
         6
        </issue>
        <year>
         1971
        </year>
        <fpage>
         972
        </fpage>
        <lpage>
         980
        </lpage>
        <pub-id pub-id-type="pmid">
         4323853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klutchko
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Blankley
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Fleming
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Hinkley
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Werner
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Nordin
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure–activity relationships for non-sulfhydryl and sulfhydryl types
        </article-title>
        <source>
         J Med Chem
        </source>
        <volume>
         29
        </volume>
        <issue>
         10
        </issue>
        <year>
         1986
        </year>
        <fpage>
         1953
        </fpage>
        <lpage>
         1961
        </lpage>
        <pub-id pub-id-type="pmid">
         3020249
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koehne
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Schaper
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Graf
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kunkel
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neutral endopeptidase 24.11: its physiologic and possibly pathophysiologic role in inflammation with special effect on respiratory inflammation
        </article-title>
        <source>
         Allergy
        </source>
        <volume>
         53
        </volume>
        <issue>
         11
        </issue>
        <year>
         1998
        </year>
        <fpage>
         1023
        </fpage>
        <lpage>
         1042
        </lpage>
        <pub-id pub-id-type="pmid">
         9860235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kudoh
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kudoh
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Katagai
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Takazawa
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Insulin potentiates bradykinin-induced inositol 1,4,5-triphosphate in neonatal rat cardiomyocytes
        </article-title>
        <source>
         J Cardiovasc Pharmacol
        </source>
        <volume>
         39
        </volume>
        <issue>
         5
        </issue>
        <year>
         2002
        </year>
        <fpage>
         621
        </fpage>
        <lpage>
         627
        </lpage>
        <pub-id pub-id-type="pmid">
         11973404
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           L‘vov
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yukel‘son
          </surname>
          <given-names>
           L.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin-potentiating peptides from
         <italic>
          Echis multisquamatus
         </italic>
         venom
        </article-title>
        <source>
         Khim Prir Soedin
        </source>
        <volume>
         1
        </volume>
        <year>
         1995
        </year>
        <fpage>
         435
        </fpage>
        <lpage>
         440
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ladram
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Montagne
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bulant
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nicolas
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of structural requirements for TRH-potentiating peptide receptor binding by analogue design
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         15
        </volume>
        <issue>
         3
        </issue>
        <year>
         1994
        </year>
        <fpage>
         429
        </fpage>
        <lpage>
         433
        </lpage>
        <pub-id pub-id-type="pmid">
         7937314
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lebrun
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Lebrun
          </surname>
          <given-names>
           F.L.
          </given-names>
         </name>
         <name>
          <surname>
           Henriques
          </surname>
          <given-names>
           O.B.
          </given-names>
         </name>
         <name>
          <surname>
           Carmona
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Juliano
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Camargo
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of a new bradykinin potentiating octapeptide from gamma-casein
        </article-title>
        <source>
         Can J Physiol Pharmacol
        </source>
        <volume>
         73
        </volume>
        <issue>
         1
        </issue>
        <year>
         1995
        </year>
        <fpage>
         85
        </fpage>
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="pmid">
         7600458
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <issue>
         6965
        </issue>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liebmann
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         G protein-coupled receptors and their signaling pathways: classical therapeutical targets susceptible to novel therapeutic concepts
        </article-title>
        <source>
         Curr Pharm Des
        </source>
        <volume>
         10
        </volume>
        <issue>
         16
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1937
        </fpage>
        <lpage>
         1958
        </lpage>
        <pub-id pub-id-type="pmid">
         15180530
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marcic
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Deddish
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Jackman
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhancement of bradykinin and resensitization of its B2 receptor
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         33
        </volume>
        <issue>
         3
        </issue>
        <year>
         1999
        </year>
        <fpage>
         835
        </fpage>
        <lpage>
         843
        </lpage>
        <pub-id pub-id-type="pmid">
         10082496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marcic
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Deddish
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Skidgel
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           Minshall
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         275
        </volume>
        <issue>
         21
        </issue>
        <year>
         2000
        </year>
        <fpage>
         16110
        </fpage>
        <lpage>
         16118
        </lpage>
        <pub-id pub-id-type="pmid">
         10748135
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matsui
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Osajima
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preparation and characterization of novel bioactive peptides responsible for angiotensin I-converting enzyme inhibition from wheat germ
        </article-title>
        <source>
         J Pept Sci
        </source>
        <volume>
         5
        </volume>
        <issue>
         7
        </issue>
        <year>
         1999
        </year>
        <fpage>
         289
        </fpage>
        <lpage>
         297
        </lpage>
        <pub-id pub-id-type="pmid">
         10442764
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meki
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Nassar
          </surname>
          <given-names>
           A.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rochat
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A bradykinin-potentiating peptide (peptide K12) isolated from the venom of Egyptian scorpion
         <italic>
          Buthus occitanus
         </italic>
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         16
        </volume>
        <issue>
         8
        </issue>
        <year>
         1995
        </year>
        <fpage>
         1359
        </fpage>
        <lpage>
         1365
        </lpage>
        <pub-id pub-id-type="pmid">
         8745044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Minshall
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
         <name>
          <surname>
           Nedumgottil
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Igic
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           Rabito
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         21
        </volume>
        <issue>
         8
        </issue>
        <year>
         2000
        </year>
        <fpage>
         1257
        </fpage>
        <lpage>
         1264
        </lpage>
        <pub-id pub-id-type="pmid">
         11035213
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Minshall
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Nakamura
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rabito
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           R.P.
          </given-names>
         </name>
         <name>
          <surname>
           Marcic
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         81
        </volume>
        <issue>
         5
        </issue>
        <year>
         1997
        </year>
        <fpage>
         848
        </fpage>
        <lpage>
         856
        </lpage>
        <pub-id pub-id-type="pmid">
         9351459
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Molina
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Carmona
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Kouyoumdjian
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Borges
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Juliano
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Liver bradykinin-inactivating-endopeptidase is similar to the metalloendopeptidase (EC 3.4.24.15)
        </article-title>
        <source>
         Immunopharmacology
        </source>
        <volume>
         32
        </volume>
        <issue>
         1–3
        </issue>
        <year>
         1996
        </year>
        <fpage>
         176
        </fpage>
        <lpage>
         179
        </lpage>
        <pub-id pub-id-type="pmid">
         8796302
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Adomeit
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kaufmann
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Appelhans
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Passow
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Reissmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression and functional characterization of a pHis-tagged human bradykinin B2 receptor in COS-7 cells
        </article-title>
        <source>
         Biol Chem
        </source>
        <volume>
         381
        </volume>
        <issue>
         4
        </issue>
        <year>
         2000
        </year>
        <fpage>
         343
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="pmid">
         10839464
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mueller
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Liebmann
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Reissmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intramolecular signal transduction by the bradykinin B2 receptor
        </article-title>
        <source>
         Int Immunopharmacol
        </source>
        <volume>
         2
        </volume>
        <issue>
         13/14
        </issue>
        <year>
         2002
        </year>
        <fpage>
         1763
        </fpage>
        <lpage>
         1770
        </lpage>
        <pub-id pub-id-type="pmid">
         12489790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Norman
          </surname>
          <given-names>
           M.U.
          </given-names>
         </name>
         <name>
          <surname>
           Lew
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           A.I.
          </given-names>
         </name>
         <name>
          <surname>
           Hickey
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Metalloendopeptidases EC 3.4.24.15/16 regulate bradykinin activity in the cerebral microvasculature
        </article-title>
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         284
        </volume>
        <issue>
         6
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1942
        </fpage>
        <lpage>
         1948
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ondetti
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Sabo
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Pluscec
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Weaver
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <name>
          <surname>
           Kocy
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme inhibitors from the venom of
         <italic>
          Bothrops jararaca
         </italic>
         . Isolation, elucidation of structure, and synthesis
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         10
        </volume>
        <issue>
         22
        </issue>
        <year>
         1971
        </year>
        <fpage>
         4033
        </fpage>
        <lpage>
         4039
        </lpage>
        <pub-id pub-id-type="pmid">
         4334402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ongali
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Buck Hde
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cloutier
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Legault
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Regoli
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chronic effects of angiotensin-converting enzyme inhibition on kinin receptor binding sites in the rat spinal cord
        </article-title>
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         284
        </volume>
        <issue>
         6
        </issue>
        <year>
         2003
        </year>
        <fpage>
         H1949
        </fpage>
        <lpage>
         H1958
        </lpage>
        <pub-id pub-id-type="pmid">
         12586640
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paegelow
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Nachweis chemotaktischer Faktoren
        </chapter-title>
        <year>
         1991
        </year>
        <publisher-name>
         Gustav Fischer Verlag
        </publisher-name>
        <publisher-loc>
         Jena
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paegelow
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Trzeczak
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bockmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vietinghoff
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Migratory responses of polymorphonuclear leukocytes to kinin peptides
        </article-title>
        <source>
         Pharmacology
        </source>
        <volume>
         66
        </volume>
        <issue>
         3
        </issue>
        <year>
         2002
        </year>
        <fpage>
         153
        </fpage>
        <lpage>
         161
        </lpage>
        <pub-id pub-id-type="pmid">
         12372905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Papapetropoulos
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ryan
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Antonov
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Virmani
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Kolodgie
          </surname>
          <given-names>
           F.D.
          </given-names>
         </name>
         <name>
          <surname>
           Gerrity
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human aortic endothelial cell aminopeptidase N
        </article-title>
        <source>
         Immunopharmacology
        </source>
        <volume>
         32
        </volume>
        <issue>
         1–3
        </issue>
        <year>
         1996
        </year>
        <fpage>
         153
        </fpage>
        <lpage>
         156
        </lpage>
        <pub-id pub-id-type="pmid">
         8796295
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patchett
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Tristram
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wyvratt
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Taub
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new class of angiotensin-converting enzyme inhibitors
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         288
        </volume>
        <issue>
         5788
        </issue>
        <year>
         1980
        </year>
        <fpage>
         280
        </fpage>
        <lpage>
         283
        </lpage>
        <pub-id pub-id-type="pmid">
         6253826
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paula
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
         <name>
          <surname>
           Lima
          </surname>
          <given-names>
           C.V.
          </given-names>
         </name>
         <name>
          <surname>
           Britto
          </surname>
          <given-names>
           R.R.
          </given-names>
         </name>
         <name>
          <surname>
           Campagnole-Santos
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Khosla
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potentiation of the hypotensive effect of bradykinin by angiotensin-(1–7)-related peptides
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         20
        </volume>
        <issue>
         4
        </issue>
        <year>
         1999
        </year>
        <fpage>
         493
        </fpage>
        <lpage>
         500
        </lpage>
        <pub-id pub-id-type="pmid">
         10458520
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Piot
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guillochon
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ricart
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of a bradykinin-potentiating peptide from a bovine peptic hemoglobin hydrolysate
        </article-title>
        <source>
         FEBS Lett
        </source>
        <volume>
         299
        </volume>
        <issue>
         1
        </issue>
        <year>
         1992
        </year>
        <fpage>
         75
        </fpage>
        <lpage>
         79
        </lpage>
        <pub-id pub-id-type="pmid">
         1544478
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ryan
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Papapetropoulos
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ju
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Denslow
          </surname>
          <given-names>
           N.D.
          </given-names>
         </name>
         <name>
          <surname>
           Antonov
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Virmani
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aminopeptidase P is disposed on human endothelial cells
        </article-title>
        <source>
         Immunopharmacology
        </source>
        <volume>
         32
        </volume>
        <issue>
         1–3
        </issue>
        <year>
         1996
        </year>
        <fpage>
         149
        </fpage>
        <lpage>
         152
        </lpage>
        <pub-id pub-id-type="pmid">
         8796294
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schumann
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Seyfarth
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Greiner
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Paegelow
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Reissmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Synthesis and biological activities of new side chain and backbone cyclic bradykinin analogues
        </article-title>
        <source>
         J Pept Res
        </source>
        <volume>
         60
        </volume>
        <issue>
         2
        </issue>
        <year>
         2002
        </year>
        <fpage>
         128
        </fpage>
        <lpage>
         140
        </lpage>
        <pub-id pub-id-type="pmid">
         12102726
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sellitti
          </surname>
          <given-names>
           D.F.
          </given-names>
         </name>
         <name>
          <surname>
           Doi
          </surname>
          <given-names>
           S.Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         C-type natriuretic peptide (CNP) increases [
         <sup>
          125
         </sup>
         I]ANF binding to FRTL-5 rat thyroid cells by increasing ANF receptor affinity
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         15
        </volume>
        <issue>
         7
        </issue>
        <year>
         1994
        </year>
        <fpage>
         1249
        </fpage>
        <lpage>
         1253
        </lpage>
        <pub-id pub-id-type="pmid">
         7854977
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib70">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siems
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Heder
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Komissarowa
          </surname>
          <given-names>
           N.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Procedure for the determination of angiotensin converting enzyme
        </article-title>
        <source>
         Z Med Lab Diagn
        </source>
        <volume>
         26
        </volume>
        <issue>
         4
        </issue>
        <year>
         1985
        </year>
        <fpage>
         232
        </fpage>
        <lpage>
         234
        </lpage>
        <pub-id pub-id-type="pmid">
         2994310
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib71">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skidgel
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Erdos
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         25
        </volume>
        <issue>
         3
        </issue>
        <year>
         2004
        </year>
        <fpage>
         521
        </fpage>
        <lpage>
         525
        </lpage>
        <pub-id pub-id-type="pmid">
         15134871
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib72">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skidgel
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           McGwire
          </surname>
          <given-names>
           G.B.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Membrane anchoring and release of carboxypeptidase M: implications for extracellular hydrolysis of peptide hormones
        </article-title>
        <source>
         Immunopharmacology
        </source>
        <volume>
         32
        </volume>
        <issue>
         1–3
        </issue>
        <year>
         1996
        </year>
        <fpage>
         48
        </fpage>
        <lpage>
         52
        </lpage>
        <pub-id pub-id-type="pmid">
         8796265
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib73">
       <label>
        73
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sosnina
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Golubenko
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Akhunov
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kugaevskaia
          </surname>
          <given-names>
           E.V.
          </given-names>
         </name>
         <name>
          <surname>
           Eliseeva Iu
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Orekhovich
          </surname>
          <given-names>
           V.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin-potentiating peptides from the spider Latrodectus tredecimguttatus—inhibitors of carboxycathepsin and of a preparation of karakurt venom kininase
        </article-title>
        <source>
         Dokl Akad Nauk SSSR
        </source>
        <volume>
         315
        </volume>
        <issue>
         1
        </issue>
        <year>
         1990
        </year>
        <fpage>
         236
        </fpage>
        <lpage>
         239
        </lpage>
        <pub-id pub-id-type="pmid">
         1965800
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib74">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Steinmann
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The E.K. Frey–E. Werle Foundation of the Henning L. Voigt Family Award ceremony
        </article-title>
        <source>
         Braz J Med Biol Res
        </source>
        <volume>
         27
        </volume>
        <issue>
         8
        </issue>
        <year>
         1994
        </year>
        <fpage>
         1687
        </fpage>
        <lpage>
         1692
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib75">
       <label>
        75
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Teetz
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Geiger
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Henning
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Urbach
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Synthesis of a highly active angiotensin converting enzyme inhibitor: 2-[
         <italic>
          N
         </italic>
         -[(
         <italic>
          S
         </italic>
         )-1-ethoxycarbonyl-3-phenylpropyl]-
         <sc>
          l
         </sc>
         -alanyl]-(1
         <italic>
          S
         </italic>
         ,3
         <italic>
          S
         </italic>
         ,5
         <italic>
          S
         </italic>
         )-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)
        </article-title>
        <source>
         Arzneimittelforschung
        </source>
        <volume>
         34
        </volume>
        <issue>
         10B
        </issue>
        <year>
         1984
        </year>
        <fpage>
         1399
        </fpage>
        <lpage>
         1401
        </lpage>
        <pub-id pub-id-type="pmid">
         6097264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib76">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tom
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           de Vries
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Saxena
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
         <name>
          <surname>
           Danser
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bradykinin potentiation by angiotensin-(1–7) and ACE inhibitors correlates with ACE C- and N-domain blockade
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         38
        </volume>
        <issue>
         1
        </issue>
        <year>
         2001
        </year>
        <fpage>
         95
        </fpage>
        <lpage>
         99
        </lpage>
        <pub-id pub-id-type="pmid">
         11463767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib77">
       <label>
        77
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ufkes
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Aarsen
          </surname>
          <given-names>
           P.N.
          </given-names>
         </name>
         <name>
          <surname>
           van der Meer
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The mechanism of action of two bradykinin-potentiating peptides on isolated smooth muscle
        </article-title>
        <source>
         Eur J Pharmacol
        </source>
        <volume>
         44
        </volume>
        <issue>
         2
        </issue>
        <year>
         1977
        </year>
        <fpage>
         89
        </fpage>
        <lpage>
         97
        </lpage>
        <pub-id pub-id-type="pmid">
         195822
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib78">
       <label>
        78
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ufkes
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Visser
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Heuver
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Van der Meer
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure–activity relationships of bradykinin potentiating peptides
        </article-title>
        <source>
         Eur J Pharmacol
        </source>
        <volume>
         50
        </volume>
        <issue>
         2
        </issue>
        <year>
         1978
        </year>
        <fpage>
         119
        </fpage>
        <lpage>
         122
        </lpage>
        <pub-id pub-id-type="pmid">
         679977
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib79">
       <label>
        79
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Alhenc-Gelas
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Clauser
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The two homologous domains of human angiotensin I-converting enzyme are both catalytically active
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         266
        </volume>
        <issue>
         14
        </issue>
        <year>
         1991
        </year>
        <fpage>
         9002
        </fpage>
        <lpage>
         9008
        </lpage>
        <pub-id pub-id-type="pmid">
         1851160
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib80">
       <label>
        80
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamafuji
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Taniguchi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sakamoto
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The thiol enzyme from rat spleen that produces bradykinin potentiating peptide from rat plasma
        </article-title>
        <source>
         Immunopharmacology
        </source>
        <volume>
         32
        </volume>
        <issue>
         1–3
        </issue>
        <year>
         1996
        </year>
        <fpage>
         157
        </fpage>
        <lpage>
         159
        </lpage>
        <pub-id pub-id-type="pmid">
         8796296
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib81">
       <label>
        81
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Garreau
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Sannier
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Piot
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Opioid peptides derived from hemoglobin: hemorphins
        </article-title>
        <source>
         Biopolymers
        </source>
        <volume>
         43
        </volume>
        <issue>
         2
        </issue>
        <year>
         1997
        </year>
        <fpage>
         75
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="pmid">
         9216245
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       We thank I. Agricola and H. Rohde for skilful technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (Re 853/2-1 and Collaborative Research Center 436, Jena).
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Mol Sci
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int J Mol Sci
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       ijms
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Molecular Sciences
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1422-0067
      </issn>
      <publisher>
       <publisher-name>
        MDPI
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30634441
      </article-id>
      <article-id pub-id-type="pmc">
       6358887
      </article-id>
      <article-id pub-id-type="doi">
       10.3390/ijms20020239
      </article-id>
      <article-id pub-id-type="publisher-id">
       ijms-20-00239
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0001-7860-9770
        </contrib-id>
        <name>
         <surname>
          Sato
         </surname>
         <given-names>
          Teruki
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-ijms-20-00239">
         1
        </xref>
        <xref ref-type="aff" rid="af2-ijms-20-00239">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kadowaki
         </surname>
         <given-names>
          Ayumi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-ijms-20-00239">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0002-3146-2780
        </contrib-id>
        <name>
         <surname>
          Suzuki
         </surname>
         <given-names>
          Takashi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-ijms-20-00239">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ito
         </surname>
         <given-names>
          Hiroshi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2-ijms-20-00239">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Watanabe
         </surname>
         <given-names>
          Hiroyuki
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2-ijms-20-00239">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Imai
         </surname>
         <given-names>
          Yumiko
         </given-names>
        </name>
        <xref ref-type="aff" rid="af3-ijms-20-00239">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kuba
         </surname>
         <given-names>
          Keiji
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-ijms-20-00239">
         1
        </xref>
        <xref ref-type="corresp" rid="c1-ijms-20-00239">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1-ijms-20-00239">
       <label>
        1
       </label>
       Department of Biochemistry and Metabolic Science, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan;
       <email>
        satot@med.akita-u.ac.jp
       </email>
       (T.S.);
       <email>
        kadowakiayu@med.akita-u.ac.jp
       </email>
       (A.K.);
       <email>
        tksuzuki@iwate-med.ac.jp
       </email>
       (T.S.)
      </aff>
      <aff id="af2-ijms-20-00239">
       <label>
        2
       </label>
       Department of Cardiology, Akita University Graduate School of Medicine, Akita 010-8543, Japan;
       <email>
        hitomed2@gipc.akita-u.ac.jp
       </email>
       (H.I.);
       <email>
        hirow@doc.med.akita-u.ac.jp
       </email>
       (H.W.)
      </aff>
      <aff id="af3-ijms-20-00239">
       <label>
        3
       </label>
       Laboratory of Regulation of Intractable Infectious Diseases, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan;
       <email>
        y-imai@nibiohn.go.jp
       </email>
      </aff>
      <author-notes>
       <corresp id="c1-ijms-20-00239">
        <label>
         *
        </label>
        Correspondence:
        <email>
         kuba@med.akita-u.ac.jp
        </email>
        ; Tel.: +81-18-884-6074
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        09
       </day>
       <month>
        1
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <month>
        1
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       20
      </volume>
      <issue>
       2
      </issue>
      <elocation-id>
       239
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         30
        </day>
        <month>
         11
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         30
        </day>
        <month>
         12
        </month>
        <year>
         2018
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2019 by the authors.
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Apelin is an inotropic and cardioprotective peptide that exhibits beneficial effects through activation of the APJ receptor in the pathology of cardiovascular diseases. Apelin induces the expression of angiotensin-converting enzyme 2 (ACE2) in failing hearts, thereby improving heart function in an angiotensin 1–7-dependent manner. Whether apelin antagonizes the over-activation of the renin–angiotensin system in the heart remains elusive. In this study we show that the detrimental effects of angiotensin II (Ang II) were exacerbated in the hearts of aged apelin-gene-deficient mice. Ang II-mediated cardiac dysfunction and hypertrophy were augmented in apelin knockout mice. The loss of apelin increased the ratio of angiotensin-converting enzyme (ACE) to ACE2 expression in the Ang II-stressed hearts, and Ang II-induced cardiac fibrosis was markedly enhanced in apelin knockout mice. mRNA expression of pro-fibrotic genes, such as transforming growth-factor beta (TGF-β) signaling, were significantly upregulated in apelin knockout hearts. Consistently, treatment with the ACE-inhibitor Captopril decreased cardiac contractility in apelin knockout mice. In vitro, apelin ameliorated Ang II-induced TGF-β expression in primary cardiomyocytes, accompanied with reduced hypertrophy. These results provide direct evidence that endogenous apelin plays a crucial role in suppressing Ang II-induced cardiac dysfunction and pathological remodeling.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        apelin
       </kwd>
       <kwd>
        APJ receptor
       </kwd>
       <kwd>
        angiotensin II
       </kwd>
       <kwd>
        angiotensin-converting enzyme 2
       </kwd>
       <kwd>
        ACE inhibitor
       </kwd>
       <kwd>
        transforming growth-factor beta
       </kwd>
       <kwd>
        heart failure
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1-ijms-20-00239">
     <title>
      1. Introduction
     </title>
     <p>
      Apelin is an endogenous peptide ligand for dreceptor (or Aplnr) and has potent positive inotropic activity and vasodilatory action [
      <xref ref-type="bibr" rid="B1-ijms-20-00239">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="B2-ijms-20-00239">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B3-ijms-20-00239">
       3
      </xref>
      ]. APJ is a G protein-coupled receptor that shares significant homology with the angiotensin II type 1 receptor (AT1R) [
      <xref ref-type="bibr" rid="B4-ijms-20-00239">
       4
      </xref>
      ]. The apelin–APJ axis regulates cardiovascular functions including blood pressure, cardiac contractility, and fluid balance, and thereby exerts beneficial effects on cardiovascular systems [
      <xref ref-type="bibr" rid="B5-ijms-20-00239">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="B6-ijms-20-00239">
       6
      </xref>
      ]. Treatment with apelin peptide in vivo improves the cardiac contractility and output in myocardial infarcted rats and normal mice, and protects the heart from pressure overload, isoproterenol-induced injury, or ischemia reperfusion injury [
      <xref ref-type="bibr" rid="B7-ijms-20-00239">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B8-ijms-20-00239">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="B9-ijms-20-00239">
       9
      </xref>
      ]. In studies of apelin knockout and APJ knockout mice, we and others have demonstrated that the endogenous apelin–APJ axis regulates the heart contractility associated with aging, exercise, and pressure overload; in the absence of apelin or APJ expression, these mutant mice show contractile dysfunctions [
      <xref ref-type="bibr" rid="B8-ijms-20-00239">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="B10-ijms-20-00239">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="B11-ijms-20-00239">
       11
      </xref>
      ]. By contrast, APJ was identified as a dual receptor to mediate cardiac hypertrophy [
      <xref ref-type="bibr" rid="B12-ijms-20-00239">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="B13-ijms-20-00239">
       13
      </xref>
      ] via β-arrestin signaling [
      <xref ref-type="bibr" rid="B14-ijms-20-00239">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B15-ijms-20-00239">
       15
      </xref>
      ]. Thus, the precise role of endogenous apelin signaling in heart function remains elusive.
     </p>
     <p>
      Cardiac hypertrophy is an adaptive response to maintain cardiac function in the event of an increased workload, although prolonged cardiac hypertrophy can lead to heart failure via the ischemia of cardiomyocytes [
      <xref ref-type="bibr" rid="B16-ijms-20-00239">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="B17-ijms-20-00239">
       17
      </xref>
      ]. In addition, cardiac fibrosis adversely increases tissue stiffness and impairs ventricular function. Consistently, cardiac hypertrophy and the development of fibrosis correlate with the deterioration of myocardial function in heart failure [
      <xref ref-type="bibr" rid="B18-ijms-20-00239">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="B19-ijms-20-00239">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="B20-ijms-20-00239">
       20
      </xref>
      ]. Thus, cardiac hypertrophy and fibrosis are key features of heart failure, and apelin’s inotropic and protective roles in the heart are attractive as a potential therapeutic candidate for treating heart failure.
     </p>
     <p>
      Apelin has also been identified as a substrate for angiotensin-converting enzyme 2 (ACE2), which cleaves apelin with similar efficiency as its primary substrate angiotensin II (Ang II) [
      <xref ref-type="bibr" rid="B21-ijms-20-00239">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="B22-ijms-20-00239">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="B23-ijms-20-00239">
       23
      </xref>
      ]. ACE2 is a negative regulator of the renin–angiotensin system (RAS) that inactivates Ang II by converting it to angiotensin 1–7 (Ang 1–7) [
      <xref ref-type="bibr" rid="B21-ijms-20-00239">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="B22-ijms-20-00239">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="B23-ijms-20-00239">
       23
      </xref>
      ], whereas angiotensin-converting enzyme 1 (or ACE1) activates RAS by converting Ang I to Ang II. ACE2 was also identified as a regulator of heart failure [
      <xref ref-type="bibr" rid="B24-ijms-20-00239">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="B25-ijms-20-00239">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="B26-ijms-20-00239">
       26
      </xref>
      ], diabetic nephropathy [
      <xref ref-type="bibr" rid="B27-ijms-20-00239">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="B28-ijms-20-00239">
       28
      </xref>
      ], acute lung failure [
      <xref ref-type="bibr" rid="B29-ijms-20-00239">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="B30-ijms-20-00239">
       30
      </xref>
      ], and the SARS (severe acute respiratory syndrome) coronavirus receptor [
      <xref ref-type="bibr" rid="B31-ijms-20-00239">
       31
      </xref>
      ,
      <xref ref-type="bibr" rid="B32-ijms-20-00239">
       32
      </xref>
      ].
     </p>
     <p>
      Apelin-APJ signaling has been shown to counteract the effects of Ang II on AT1R in defined physiological and pathophysiological settings. For instance, in hypertensive rat models, the continuous infusion of Ang II downregulates apelin and APJ expression [
      <xref ref-type="bibr" rid="B33-ijms-20-00239">
       33
      </xref>
      ]. We have shown that Apelin upregulates ACE2 expression. Apelin-induced ACE2 downregulates Ang II signaling while enhancing Ang 1–7–Mas receptor signaling in aged or failing hearts [
      <xref ref-type="bibr" rid="B34-ijms-20-00239">
       34
      </xref>
      ]. On the other hand, it has been suggested that the counter-balancing effects of the apelin–APJ axis on Ang II–AT1R signaling are mediated by receptor dimerization. The APJ receptor physically interacts with AT1 receptors, and exogenous apelin negatively regulates Ang II–AT1R signaling in in vitro cell culture systems and in an in vivo atherosclerosis model [
      <xref ref-type="bibr" rid="B35-ijms-20-00239">
       35
      </xref>
      ]. However, whether endogenous apelin counteracts the over-activation of RAS in the heart remains unexplored.
     </p>
     <p>
      In this study, we aimed to determine the effects of endogenous apelin on Ang II-induced pathology in the heart. We showed that Ang II-mediated cardiac dysfunction, hypertrophy, and fibrosis were augmented in apelin knockout (Apelin KO) mice.
     </p>
    </sec>
    <sec id="sec2-ijms-20-00239">
     <title>
      2. Results
     </title>
     <sec id="sec2dot1-ijms-20-00239">
      <title>
       2.1. Apelin Depletion Does Not Affect Ang II-Induced Hypertension in Aged Mice
      </title>
      <p>
       We first examined whether Ang II levels were affected in Apelin KO mice by subjecting the plasma to an analysis of liquid chromatography with tandem mass-spectrometry (LC-MS/MS), also called a RAS fingerprint. However, Ang II levels were not significantly changed in aged Apelin KO mice (
       <xref ref-type="app" rid="app1-ijms-20-00239">
        Figure S1A,B
       </xref>
       ), though there was a trend of decreasing Ang 1–7/Ang II ratios (
       <xref ref-type="app" rid="app1-ijms-20-00239">
        Figure S1C,D
       </xref>
       ). We thus set out to directly examine the effects of Ang II signaling in Apelin KO mice, and we treated 12-month-old Apelin KO mice and wild type (WT) mice with Ang II or vehicle for 2 weeks using osmotic minipumps. In vehicle-treated Apelin KO mice, the blood pressure was slightly but significantly decreased compared with the WT mice (
       <xref ref-type="fig" rid="ijms-20-00239-f001">
        Figure 1
       </xref>
       A). When the mice were continuously injected with Ang II for 2 weeks, both WT and Apelin KO mice showed elevated blood pressure in a comparable manner, and there was no difference in hypertension between the mice (
       <xref ref-type="fig" rid="ijms-20-00239-f001">
        Figure 1
       </xref>
       A–C). Thus, endogenous apelin has little or no effects on Ang II-induced hypertension.
      </p>
     </sec>
     <sec id="sec2dot2-ijms-20-00239">
      <title>
       2.2. Ratio of ACE to ACE2 Was Upregulated in the Hearts of Apelin KO Mice
      </title>
      <p>
       Since the Apelin KO mice showed reduced ACE2 expression in the hearts of aged mice or mice with pressure overload stress to the left ventricle, we examined the cardiac expressions of ACE and ACE2 mRNAs. In vehicle-treated mice, ACE2 expression in the heart was downregulated by apelin depletion, whereas ACE expression was not altered (
       <xref ref-type="fig" rid="ijms-20-00239-f002">
        Figure 2
       </xref>
       A,B), consistent with previous results [
       <xref ref-type="bibr" rid="B34-ijms-20-00239">
        34
       </xref>
       ,
       <xref ref-type="bibr" rid="B36-ijms-20-00239">
        36
       </xref>
       ]. On the other hand, after Ang II treatment, Apelin KO mice showed a trend of decreased expression of ACE2 in the heart, but this did not reach statistical significance (
       <xref ref-type="fig" rid="ijms-20-00239-f002">
        Figure 2
       </xref>
       B). When we calculated the ratio of ACE to ACE2 expression, Apelin KO mice showed an increased ratio of ACE to ACE2 expression compared with WT mice after Ang II infusion as well as after vehicle treatment (
       <xref ref-type="fig" rid="ijms-20-00239-f002">
        Figure 2
       </xref>
       C). Thus, the loss of apelin enhances the cardiac effects of exogenous Ang II by shifting the balance of ACE and ACE2 toward the ACE dominant state.
      </p>
     </sec>
     <sec id="sec2dot3-ijms-20-00239">
      <title>
       2.3. Ang II Treatment Augments Heart Dysfunction in Aged Apelin KO Mice
      </title>
      <p>
       When cardiac function was assessed with echocardiography, the percent of fractional shortening (%FS) was decreased in aged Apelin KO mice treated with vehicle compared to the age-matched WT control mice that received vehicle treatment (
       <xref ref-type="fig" rid="ijms-20-00239-f003">
        Figure 3
       </xref>
       A,B,
       <xref ref-type="table" rid="ijms-20-00239-t001">
        Table 1
       </xref>
       ), which was consistent with our previous results [
       <xref ref-type="bibr" rid="B8-ijms-20-00239">
        8
       </xref>
       ]. After 2 weeks of continuous Ang II infusion, WT mice showed non-significant reduction of %FS compared with vehicle-treated WT mice (
       <xref ref-type="fig" rid="ijms-20-00239-f003">
        Figure 3
       </xref>
       A,B,
       <xref ref-type="table" rid="ijms-20-00239-t001">
        Table 1
       </xref>
       ). However, Ang II-treated Apelin KO mice showed a marked reduction of %FS compared with Ang II-treated WT mice (
       <xref ref-type="fig" rid="ijms-20-00239-f003">
        Figure 3
       </xref>
       A,B,
       <xref ref-type="table" rid="ijms-20-00239-t001">
        Table 1
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec2dot4-ijms-20-00239">
      <title>
       2.4. Loss of Apelin Exacerbates Ang II-Induced Cardiac Hypertrophy
      </title>
      <p>
       In echocardiography, the thickness of the interventricular septum (IVS) was significantly increased in Ang II-infused Apelin KO mice (
       <xref ref-type="fig" rid="ijms-20-00239-f003">
        Figure 3
       </xref>
       C), suggesting that Ang II-mediated cardiac hypertrophy was enhanced in Apelin KO mice. Consistently, Apelin KO mice with Ang II infusion showed a significantly increased heart weight to body weight (HW/BW) ratio, compared with Ang II-infused WT mice (
       <xref ref-type="fig" rid="ijms-20-00239-f003">
        Figure 3
       </xref>
       D,E).
      </p>
     </sec>
     <sec id="sec2dot5-ijms-20-00239">
      <title>
       2.5. Ang II Infusion Induces Cardiac Fibrosis in Aged Apelin KO Hearts
      </title>
      <p>
       We next examined cardiac fibrosis, which is the well-known outcome of enhanced Ang II signaling in the heart. Mild fibrosis of interstitial and perivascular areas were observed in Ang II-treated WT mouse hearts (
       <xref ref-type="fig" rid="ijms-20-00239-f004">
        Figure 4
       </xref>
       A). In contrast, Apelin KO mice with Ang II infusion exhibited massive cardiac fibrosis (
       <xref ref-type="fig" rid="ijms-20-00239-f004">
        Figure 4
       </xref>
       A). Quantitative analysis of fibrotic areas in the hearts showed that fibrotic areas in Ang II-treated Apelin KO mouse hearts were significantly larger than those in WT hearts with Ang II treatment (
       <xref ref-type="fig" rid="ijms-20-00239-f004">
        Figure 4
       </xref>
       B). Consistently, mRNA expression of the fibrosis-associated genes collagen 8a (
       <italic>
        Col8a
       </italic>
       ), transforming growth-factor beta 2 (
       <italic>
        Tgfb2
       </italic>
       ), and latent transforming growth-factor beta-binding protein 2 (
       <italic>
        Ltbp2
       </italic>
       ) were significantly increased in Ang II-treated Apelin KO mice compared with WT mice (
       <xref ref-type="fig" rid="ijms-20-00239-f004">
        Figure 4
       </xref>
       C–E), whereas in vehicle-treated Apelin KO mice those gene expressions showed a trend to decrease, but did not reach statistical significance. Thus, Ang II augments cardiac dysfunction, hypertrophy, and fibrosis in Apelin KO mice.
      </p>
     </sec>
     <sec id="sec2dot6-ijms-20-00239">
      <title>
       2.6. ACE Inhibitor Improves Impaired Contractility in Aged Apelin KO Hearts
      </title>
      <p>
       We further examined whether Ang II depletion by ACE inhibition affects cardiac dysfunction in aged Apelin KO mice. After 2 weeks of treatment with Captopril, an ACE inhibitor (ACE-i), WT and Apelin KO mice were subjected to echocardiography. The decreased percentage of fractional shortening (%FS) and an increased end-systolic diameter of the left ventricle (LVESD) in Apelin KO mice were significantly improved by ACE-i to levels similar to those of the WT mice (
       <xref ref-type="fig" rid="ijms-20-00239-f005">
        Figure 5
       </xref>
       A,B;
       <xref ref-type="table" rid="ijms-20-00239-t002">
        Table 2
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec2dot7-ijms-20-00239">
      <title>
       2.7. Apelin Antagonizes Ang II Effects in Primary Cardiomyocytes
      </title>
      <p>
       To determine whether Apelin antagonizes Ang II effects in vitro, we treated the isolated primary cardiomyocytes with Ang II, apelin-13, or both peptides. Ang II treatment induced hypertrophic growth of mouse cardiomyocytes, while apelin-13 did not affect the cell size (
       <xref ref-type="fig" rid="ijms-20-00239-f006">
        Figure 6
       </xref>
       A,B). Interestingly, combination treatment of Ang II and Apelin-13 reduced Ang II-mediated hypertrophy in cardiomyocytes (
       <xref ref-type="fig" rid="ijms-20-00239-f006">
        Figure 6
       </xref>
       A,B). Consistently, mRNA expression of brain natriuretic peptide (
       <italic>
        BNP
       </italic>
       ), atrial natriuretic factor (
       <italic>
        ANF
       </italic>
       ), and
       <italic>
        Tgfb2
       </italic>
       were upregulated by Ang II treatment, whereas apelin-13 significantly decreased the elevated expression of
       <italic>
        BNP
       </italic>
       ,
       <italic>
        ANF
       </italic>
       , and
       <italic>
        Tgfb2
       </italic>
       in Ang II-treated cells to the levels of control vehicle-treated cardiomyocytes (
       <xref ref-type="fig" rid="ijms-20-00239-f006">
        Figure 6
       </xref>
       C–E). Thus, apelin antagonizes Ang II-mediated hypertrophy and gene expression in cardiomyocytes.
      </p>
     </sec>
    </sec>
    <sec id="sec3-ijms-20-00239">
     <title>
      3. Discussion
     </title>
     <p>
      In this study, we demonstrated that endogenous Apelin improves exogenous Ang II-induced cardiac dysfunction and pathological remodeling, as well as antagonizing endogenous Ang II-mediated impairment of heart contractility in aged mice. We also showed that apelin suppresses cellular hypertrophy and pro-fibrotic gene expression in in vitro cardiomyocytes. These data provide direct evidence that endogenous apelin is crucial to antagonize the Ang II–AT1R axis in cardiac muscle cells.
     </p>
     <p>
      While endogenous apelin antagonizes Ang II-induced heart pathology and upregulates ACE2 expression, it is interesting to observe that Ang II-stimulated elevation of blood pressure was not further increased in Apelin KO mice but comparable to WT mice. This is a sharp contrast to the marked elevation of blood pressure in ACE2 knockout mice when treated with Ang II [
      <xref ref-type="bibr" rid="B37-ijms-20-00239">
       37
      </xref>
      ]. Although treatment with the apelin peptide antagonizes Ang II-stimulated blood pressure elevation [
      <xref ref-type="bibr" rid="B36-ijms-20-00239">
       36
      </xref>
      ], the physiological effects of endogenous apelin on the RAS seem to be biased to the heart. Consistently, our initial study of Apelin KO mice first identified the phenotype of cardiac dysfunction. In addition, ex vivo measurements of cardiac contractility showed that ACE-inhibitor treatment partly rescued the impaired contractility of Apelin KO mouse hearts (unpublished results), implicating that intrinsic cardiac RAS activation is causative of heart dysfunction. Despite numerous reports on the variety of functions of apelin, these evidences suggest that the heart is one of the major target organs for endogenous Apelin.
     </p>
     <p>
      The pathological response during the progression of heart failure involves myocyte hypertrophy and cardiac fibrosis, which is crucially mediated by Ang II signaling. In this study, we showed that apelin inhibits Ang II-induced cellular hypertrophy and pro-fibrotic gene expression in cardiomyocytes in vitro. The results can be explained by two mechanisms: one is apelin-mediated downregulation of Ang II–AT1R signaling in the levels of receptors or intracellular signaling [
      <xref ref-type="bibr" rid="B35-ijms-20-00239">
       35
      </xref>
      ], and the other is apelin-mediated downmodulation of the ACE/ACE2 ratio and subsequent Ang II downregulation [
      <xref ref-type="bibr" rid="B34-ijms-20-00239">
       34
      </xref>
      ]. While apelin suppresses Ang II-stimulated pro-fibrotic signaling in cardiomyocytes, such as the downregulation of TGF-β expression, it was postulated that apelin directly inhibits fibrogenic responses of fibroblasts. Apelin inhibits the TGF-β-induced activation of cardiac fibroblasts and collagen production through a sphingosine kinase 1 [
      <xref ref-type="bibr" rid="B38-ijms-20-00239">
       38
      </xref>
      ]. Recently, the tissue-specific deletion of the APJ receptor in endothelial cells or myocardial cells was reported [
      <xref ref-type="bibr" rid="B39-ijms-20-00239">
       39
      </xref>
      ]. In TAC (Transverse Aortic Constriction) pressure overload models, APJ deletion in endothelial cells increased cardiac fibrosis and decreased heart contractility, whereas the cardiomyocyte-specific deletion of APJ suppressed cardiac hypertrophy and improved heart function [
      <xref ref-type="bibr" rid="B40-ijms-20-00239">
       40
      </xref>
      ]. Therefore, the favorable effects of apelin in the heart are likely mediated through complex cellular interactions and signaling. Further analysis of other cell types in the heart, such as fibroblasts, neurons, or atrial cells would be warranted for a precise understanding of apelin signaling in the heart.
     </p>
     <p>
      Our current findings establish that endogenous apelin antagonizes the Ang II–AT1R axis in aged hearts. Apelin has been recently proposed to be an anti-aging peptide, which in mice extends the healthy life span and prevents sarcopenia, an aging-associated muscle weakness [
      <xref ref-type="bibr" rid="B41-ijms-20-00239">
       41
      </xref>
      ,
      <xref ref-type="bibr" rid="B42-ijms-20-00239">
       42
      </xref>
      ]. Currently the drugs targeting RAS, such as ACE inhibitors and angiotensin receptor blockers, are widely used in the clinic, but RAS inhibition per se does not have any inotropic affects and thus the efficacies on cardiac dysfunction in aged patients would be relatively limited. The development of therapeutic strategy to stimulate apelin-APJ signaling, which exerts positive inotrope and protective effects in the heart, would contribute to making a new class of cardiovascular medicine for aged societies.
     </p>
    </sec>
    <sec id="sec4-ijms-20-00239">
     <title>
      4. Materials and Methods
     </title>
     <sec id="sec4dot1-ijms-20-00239">
      <title>
       4.1. Mice
      </title>
      <p>
       Apelin knockout (apelin-/y) mice were generated as described [
       <xref ref-type="bibr" rid="B8-ijms-20-00239">
        8
       </xref>
       ] and backcrossed to C57/BL6J mice for more than 10 generations. Mice were genotyped by PCR and Southern blotting and maintained at the animal facilities of Akita University Graduate School of Medicine. All animal experiments conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Approval for the experiments were granted by the ethics review board of Akita University (a-1-2665, 16th March 2015).
      </p>
     </sec>
     <sec id="sec4dot2-ijms-20-00239">
      <title>
       4.2. Pharmacological Interventions
      </title>
      <p>
       For Ang II treatment, 12-month-old WT and Apelin KO mice were subcutaneously infused with either vehicle or Ang II (Sigma-Aldrich, St. Louis, MI, USA) at 1 mg/kg/day for 2 weeks by osmotic minipumps (Alzet model 1002, ALZET Corp., Cupertino, CA, USA). For ACE-inhibitor treatment, 12-months-old WT and Apelin KO male mice received either vehicle or Captopril (50 mg/L) in their drinking water. Two weeks after treatment, blood pressure measurement and echocardiography were performed and the mice were sacrificed for analysis.
      </p>
     </sec>
     <sec id="sec4dot3-ijms-20-00239">
      <title>
       4.3. Echocardiography and Blood Pressure Measurements
      </title>
      <p>
       Echocardiographic measurements were performed as previously described [
       <xref ref-type="bibr" rid="B43-ijms-20-00239">
        43
       </xref>
       ]. Briefly, after mice were anesthetized with isoflurane (1%)/oxygen, echocardiography was performed using Vevo770 (FUJIFILM, Tokyo, Japan) equipped with a 30-MHz linear transducer. %Fractional shortening (FS) was calculated as follows: FS = [(LVEDD − LVESD)/LVEDD] × 100. M-mode images were obtained for measurement of wall thickness and chamber dimensions with the use of the leading-edge conventions adapted by the American Society of Echocardiography. Blood pressure was measured in conscious mice by a programmable sphygmomanometer (BP-200, Softron Co. Ltd., Tokyo, Japan) using the tail cuff method after 5 days of daily training, as described previously [
       <xref ref-type="bibr" rid="B11-ijms-20-00239">
        11
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec4dot4-ijms-20-00239">
      <title>
       4.4. LC-MS/MS Analyses for Angiotensin Peptides
      </title>
      <p>
       Blood samples were collected with 50 units of heparin or with an optimized protease inhibitor cocktail. Plasma was kept at −80 °C until further measurement. Metabolomic profiling of Angiotensin peptides was conducted by Attoquant Diagnostics GmbH (Vienna, Austria) using technologies described previously [
       <xref ref-type="bibr" rid="B44-ijms-20-00239">
        44
       </xref>
       ]. To evaluate the activities of all RAS–peptide converting enzymes present in the plasma, we equilibrated the heparin plasma ex vivo by incubating it for 1 hour at 37 °C to obtain steady-state angiotensin peptide levels, followed by addition of a protease inhibitor cocktail (ex vivo RAS fingerprinting). Samples were then subjected to LC-MS/MS analysis using a reversed-phase analytic column (Acquity UPLC
       <sup>
        ®
       </sup>
       C18, Waters Co., Milford, MA, USA) operating in line with a XEVO TQ-S triple quadrupole mass spectrometer (Waters) as described [
       <xref ref-type="bibr" rid="B44-ijms-20-00239">
        44
       </xref>
       ]. For each peptide and corresponding internal standards, two different mass transitions were measured [
       <xref ref-type="bibr" rid="B44-ijms-20-00239">
        44
       </xref>
       ]. Ten angiotensin peptide metabolites could be simultaneously evaluated by this method: Ang I, Ang 1–9, Ang II, Ang III, Ang IV, Ang 1–7, Ang 1–5, Ang 2–7, Ang 3–7, and Ang 2–10.
      </p>
     </sec>
     <sec id="sec4dot5-ijms-20-00239">
      <title>
       4.5. Histology
      </title>
      <p>
       Heart tissues were fixed with 4% formalin and embedded in paraffin. Five μm-thick sections were prepared and stained with hematoxylin and eosin, or Masson’s trichrome.
      </p>
     </sec>
     <sec id="sec4dot6-ijms-20-00239">
      <title>
       4.6. Quantitative Real-Time PCR
      </title>
      <p>
       RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and cDNA synthesized using the PrimeScript RT reagent kit (TAKARA). Sequences of the forward and reverse primers of the genes studied are shown in
       <xref ref-type="app" rid="app1-ijms-20-00239">
        Supplementary Table S1
       </xref>
       . Real-time PCR was run in 96 well plates using a SYBR Premix ExTaq II (TAKARA Bio., Shiga, Japan) according to the instructions of the manufacturer. Relative gene expression levels were quantified by using the Thermal Cycler Dice Real Time System II software (TAKARA).
      </p>
     </sec>
     <sec id="sec4dot7-ijms-20-00239">
      <title>
       4.7. Primary Cardiomyocyte Cultures
      </title>
      <p>
       Mouse cardiomyocytes were isolated from prenatal mouse hearts of wild type mice as described previously [
       <xref ref-type="bibr" rid="B34-ijms-20-00239">
        34
       </xref>
       ]. Briefly, prenatal mice (E17.5) were removed from pregnant mice euthanized by cervical dislocation, and prenatal mouse hearts were harvested and rapidly minced in MSS buffer (30 mM HEPES, 120 mM NaCl, 4 mM Glucose, 2 mM KCl, 1 mM KH
       <sub>
        2
       </sub>
       PO
       <sub>
        4
       </sub>
       , pH 7.6). After digestion with collagenase (Wako, Osaka, Japan) for 45 min at 35 °C, cardiomyocytes were collected, pre-plated to exclude non-cardiomyocytes, and plated on gelatinized culture dishes or plates with DMEM/F-12 (Gibco, Palo Alto, CA, USA) supplemented with 10% fetal bovine serum (Equitech Bio, Inc. Kerrville, TX, USA).
      </p>
     </sec>
     <sec id="sec4dot8-ijms-20-00239">
      <title>
       4.8. Statistical Analyses
      </title>
      <p>
       Data are presented as mean values ± SEM. Statistical significance between two experimental groups was determined using Student’s two-tailed
       <italic>
        t
       </italic>
       -test. Comparisons of parameters among more than 3 groups were analyzed by one-way ANOVA, followed by Turkey’s post-hoc test.
       <italic>
        p
       </italic>
       &lt; 0.05 was considered significant.
      </p>
     </sec>
    </sec>
    <back>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We thank all members of our laboratories for technical assistance and helpful discussions.
      </p>
     </ack>
     <app-group>
      <app id="app1-ijms-20-00239">
       <title>
        Supplementary Materials
       </title>
       <p>
        Supplementary materials can be found at
        <uri xlink:href="http://www.mdpi.com/1422-0067/20/2/239/s1">
         http://www.mdpi.com/1422-0067/20/2/239/s1
        </uri>
        .
       </p>
       <supplementary-material content-type="local-data" id="ijms-20-00239-s001">
        <media xlink:href="ijms-20-00239-s001.pdf">
         <caption>
          <p>
           Click here for additional data file.
          </p>
         </caption>
        </media>
       </supplementary-material>
      </app>
     </app-group>
     <notes>
      <title>
       Author Contributions
      </title>
      <p>
       Conceptualization, K.K. and Y.I.; methodology, T.S. (Teruki Sato), A.K., and T.S. (Takashi Suzuki); validation, T.S. (Teruki Sato) and K.K.; formal analysis, T.S. (Teruki Sato); investigation, T.S. (Teruki Sato); data curation, T.S. (Teruki Sato); writing—original draft preparation, K.K. and T.S. (Teruki Sato); writing—review and editing, T.S. (Teruki Sato) and K.K.; supervision, H.W., H.I., Y.I., and K.K.; project administration, K.K.; funding acquisition, K.K.
      </p>
     </notes>
     <notes>
      <title>
       Funding
      </title>
      <p>
       K.K. is supported by the Kaken [17H04028] from Japanese Ministry of Science, the PRESTO from JST, Uehara Memorial Foundation, and Takeda Foundation. Y.I. is supported by the Kaken [17H06179], T. Sato is supported by the Kaken [18K15879].
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Conflicts of Interest
      </title>
      <p>
       The authors declare no conflict of interest.
      </p>
     </notes>
     <glossary>
      <title>
       Abbreviations
      </title>
      <array orientation="portrait">
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          ACE2
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          Angiotensin-Converting Enzyme 2
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          AT1R
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          Angiotensin Type 1 Receptor
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          RAS
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          Renin–Angiotensin System
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          TGF-β
         </td>
         <td align="left" colspan="1" rowspan="1" valign="middle">
          Transforming Growth-Factor β
         </td>
        </tr>
       </tbody>
      </array>
     </glossary>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1-ijms-20-00239">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tatemoto
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Hosoya
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Habata
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fujii
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Kakegawa
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           M.X.
          </given-names>
         </name>
         <name>
          <surname>
           Kawamata
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fukusumi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hinuma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kitada
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor
        </article-title>
        <source>
         Biochem. Biophy. Res. Commun.
        </source>
        <year>
         1998
        </year>
        <volume>
         251
        </volume>
        <fpage>
         471
        </fpage>
        <lpage>
         476
        </lpage>
        <pub-id pub-id-type="doi">
         10.1006/bbrc.1998.9489
        </pub-id>
        <pub-id pub-id-type="pmid">
         9792798
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2-ijms-20-00239">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kariyawasam
          </surname>
          <given-names>
           A.P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Osmond
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           George
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           O’Dowd
          </surname>
          <given-names>
           B.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of apelin, the ligand for the APJ receptor
        </article-title>
        <source>
         J. Neurochem.
        </source>
        <year>
         2000
        </year>
        <volume>
         74
        </volume>
        <fpage>
         34
        </fpage>
        <lpage>
         41
        </lpage>
        <pub-id pub-id-type="doi">
         10.1046/j.1471-4159.2000.0740034.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         10617103
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3-ijms-20-00239">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Szokodi
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Tavi
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Földes
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Voutilainen-Myllylä
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ilves
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tokola
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Pikkarainen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Piuhola
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rysä
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tóth
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2002
        </year>
        <volume>
         91
        </volume>
        <fpage>
         434
        </fpage>
        <lpage>
         440
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/01.RES.0000033522.37861.69
        </pub-id>
        <pub-id pub-id-type="pmid">
         12215493
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4-ijms-20-00239">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O’Dowd
          </surname>
          <given-names>
           B.F.
          </given-names>
         </name>
         <name>
          <surname>
           Heiber
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Heng
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Kennedy
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Petronis
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           George
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11
        </article-title>
        <source>
         Gene
        </source>
        <year>
         1993
        </year>
        <volume>
         136
        </volume>
        <fpage>
         355
        </fpage>
        <lpage>
         360
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0378-1119(93)90495-O
        </pub-id>
        <pub-id pub-id-type="pmid">
         8294032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5-ijms-20-00239">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ashley
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Powers
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kundu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Finsterbach
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Caffarelli
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Eichhorn
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Mahajan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo
        </article-title>
        <source>
         Cardiovasc. Res.
        </source>
        <year>
         2005
        </year>
        <volume>
         65
        </volume>
        <fpage>
         73
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cardiores.2004.08.018
        </pub-id>
        <pub-id pub-id-type="pmid">
         15621035
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6-ijms-20-00239">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Japp
          </surname>
          <given-names>
           A.G.
          </given-names>
         </name>
         <name>
          <surname>
           Cruden
          </surname>
          <given-names>
           N.L.
          </given-names>
         </name>
         <name>
          <surname>
           Barnes
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Gemeren
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Mathews
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Adamson
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
         <name>
          <surname>
           Denvir
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Megson
          </surname>
          <given-names>
           I.L.
          </given-names>
         </name>
         <name>
          <surname>
           Flapan
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute cardiovascular effects of apelin in humans: Potential role in patients with chronic heart failure
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         2010
        </year>
        <volume>
         121
        </volume>
        <fpage>
         1818
        </fpage>
        <lpage>
         1827
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/CIRCULATIONAHA.109.911339
        </pub-id>
        <pub-id pub-id-type="pmid">
         20385929
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7-ijms-20-00239">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gerns
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           Y.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Apelin protects myocardial injury induced by isoproterenol in rats
        </article-title>
        <source>
         Regul. Peptides
        </source>
        <year>
         2006
        </year>
        <volume>
         133
        </volume>
        <fpage>
         147
        </fpage>
        <lpage>
         154
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.regpep.2005.09.033
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8-ijms-20-00239">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Arab
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Maekawa
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leschnik
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Leibbrandt
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Markovic
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Schwaighofer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2007
        </year>
        <volume>
         101
        </volume>
        <fpage>
         e32
        </fpage>
        <lpage>
         e42
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/CIRCRESAHA.107.158659
        </pub-id>
        <pub-id pub-id-type="pmid">
         17673668
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9-ijms-20-00239">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xin
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Redington
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2011
        </year>
        <volume>
         301
        </volume>
        <fpage>
         H1471
        </fpage>
        <lpage>
         H1486
        </lpage>
        <pub-id pub-id-type="doi">
         10.1152/ajpheart.00097.2011
        </pub-id>
        <pub-id pub-id-type="pmid">
         21803944
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B10-ijms-20-00239">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Charo
          </surname>
          <given-names>
           D.N.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fajardo
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Kawana
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kundu
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sheikh
          </surname>
          <given-names>
           A.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Finsterbach
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Leeper
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ernst
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Endogenous regulation of cardiovascular function by apelin-APJ
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2009
        </year>
        <volume>
         297
        </volume>
        <fpage>
         H1904
        </fpage>
        <lpage>
         H1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1152/ajpheart.00686.2009
        </pub-id>
        <pub-id pub-id-type="pmid">
         19767528
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11-ijms-20-00239">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ishida
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hashimoto
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Hashimoto
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Nishiwaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Iguchi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Harada
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sugaya
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuzaki
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Shiota
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2004
        </year>
        <volume>
         279
        </volume>
        <fpage>
         26274
        </fpage>
        <lpage>
         26279
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M404149200
        </pub-id>
        <pub-id pub-id-type="pmid">
         15087458
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B12-ijms-20-00239">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Scimia
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hurtado
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ray
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Metzler
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Woods
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Purcell
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <name>
          <surname>
           Catalucci
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Akasaka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         APJ acts as a dual receptor in cardiac hypertrophy
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2012
        </year>
        <volume>
         488
        </volume>
        <fpage>
         394
        </fpage>
        <lpage>
         398
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature11263
        </pub-id>
        <pub-id pub-id-type="pmid">
         22810587
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13-ijms-20-00239">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murata
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ishida
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ishimaru
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Mizukami
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hamada
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Saito
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fukamizu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lactation is a Risk Factor of Postpartum Heart Failure in Mice with Cardiomyocyte-specific Apelin Receptor (APJ) Overexpression
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2016
        </year>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M115.699009
        </pub-id>
        <pub-id pub-id-type="pmid">
         27033703
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14-ijms-20-00239">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Capote
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mendez Perez
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Lymperopoulos
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         GPCR signaling and cardiac function
        </article-title>
        <source>
         Eur. J. Pharmacol.
        </source>
        <year>
         2015
        </year>
        <volume>
         763
        </volume>
        <fpage>
         143
        </fpage>
        <lpage>
         148
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ejphar.2015.05.019
        </pub-id>
        <pub-id pub-id-type="pmid">
         25981298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15-ijms-20-00239">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lymperopoulos
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Arrestins in the Cardiovascular System: An Update
        </article-title>
        <source>
         Prog. Mol. Biol. Transl. Sci.
        </source>
        <year>
         2018
        </year>
        <volume>
         159
        </volume>
        <fpage>
         27
        </fpage>
        <lpage>
         57
        </lpage>
        <pub-id pub-id-type="pmid">
         30340788
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B16-ijms-20-00239">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Garrison
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Savage
          </surname>
          <given-names>
           D.D.
          </given-names>
         </name>
         <name>
          <surname>
           Kannel
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Castelli
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
        </article-title>
        <source>
         New Engl. J. Med.
        </source>
        <year>
         1990
        </year>
        <volume>
         322
        </volume>
        <fpage>
         1561
        </fpage>
        <lpage>
         1566
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJM199005313222203
        </pub-id>
        <pub-id pub-id-type="pmid">
         2139921
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B17-ijms-20-00239">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Minamino
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Toko
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Miyauchi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Orimo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Akazawa
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tateno
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kayama
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Harada
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2007
        </year>
        <volume>
         446
        </volume>
        <fpage>
         444
        </fpage>
        <lpage>
         448
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature05602
        </pub-id>
        <pub-id pub-id-type="pmid">
         17334357
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18-ijms-20-00239">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Segura
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Frazier
          </surname>
          <given-names>
           O.H.
          </given-names>
         </name>
         <name>
          <surname>
           Buja
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fibrosis and heart failure
        </article-title>
        <source>
         Heart Failure Rev.
        </source>
        <year>
         2014
        </year>
        <volume>
         19
        </volume>
        <fpage>
         173
        </fpage>
        <lpage>
         185
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s10741-012-9365-4
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19-ijms-20-00239">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Targeting pathological remodeling: Concepts of cardioprotection and reparation
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         2000
        </year>
        <volume>
         102
        </volume>
        <fpage>
         1342
        </fpage>
        <lpage>
         1345
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/01.CIR.102.12.1342
        </pub-id>
        <pub-id pub-id-type="pmid">
         10993849
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20-ijms-20-00239">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schaper
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Froede
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Hein
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Buck
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hashizume
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Speiser
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Friedl
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bleese
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         1991
        </year>
        <volume>
         83
        </volume>
        <fpage>
         504
        </fpage>
        <lpage>
         514
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/01.CIR.83.2.504
        </pub-id>
        <pub-id pub-id-type="pmid">
         1991369
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21-ijms-20-00239">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Godbout
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gosselin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stagliano
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Donovan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Woolf
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Robison
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Jeyaseelan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
        </article-title>
        <source>
         Circ. Res.
        </source>
        <year>
         2000
        </year>
        <volume>
         87
        </volume>
        <fpage>
         E1
        </fpage>
        <lpage>
         E9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/01.RES.87.5.e1
        </pub-id>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22-ijms-20-00239">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Karran
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Christie
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2000
        </year>
        <volume>
         275
        </volume>
        <fpage>
         33238
        </fpage>
        <lpage>
         33243
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M002615200
        </pub-id>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23-ijms-20-00239">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vickers
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hales
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kaushik
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Dick
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gavin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Godbout
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Parsons
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2002
        </year>
        <volume>
         277
        </volume>
        <fpage>
         14838
        </fpage>
        <lpage>
         14843
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M200581200
        </pub-id>
        <pub-id pub-id-type="pmid">
         11815627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24-ijms-20-00239">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kozieradzki
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Scanga
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Oliveira-dos-Santos
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           da Costa
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is an essential regulator of heart function
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2002
        </year>
        <volume>
         417
        </volume>
        <fpage>
         822
        </fpage>
        <lpage>
         828
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature00786
        </pub-id>
        <pub-id pub-id-type="pmid">
         12075344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25-ijms-20-00239">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kassiri
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Butany
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Backx
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsushima
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Scholey
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Khokha
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice
        </article-title>
        <source>
         Cardiovasc. Res.
        </source>
        <year>
         2007
        </year>
        <volume>
         75
        </volume>
        <fpage>
         29
        </fpage>
        <lpage>
         39
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cardiores.2007.04.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         17499227
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26-ijms-20-00239">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ohishi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Katsuya
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ito
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ikushima
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kaibe
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tatara
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shiota
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sugano
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Takeda
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2006
        </year>
        <volume>
         47
        </volume>
        <fpage>
         718
        </fpage>
        <lpage>
         726
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/01.HYP.0000205833.89478.5b
        </pub-id>
        <pub-id pub-id-type="pmid">
         16505206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27-ijms-20-00239">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Herzenberg
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kassiri
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Reich
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Khokha
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Backx
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Scholey
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2006
        </year>
        <volume>
         168
        </volume>
        <fpage>
         1808
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.2353/ajpath.2006.051091
        </pub-id>
        <pub-id pub-id-type="pmid">
         16723697
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28-ijms-20-00239">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tikellis
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Bialkowski
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Pete
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sheehy
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes
        </article-title>
        <source>
         Diabetes
        </source>
        <year>
         2008
        </year>
        <volume>
         57
        </volume>
        <fpage>
         1018
        </fpage>
        <lpage>
         1025
        </lpage>
        <pub-id pub-id-type="doi">
         10.2337/db07-1212
        </pub-id>
        <pub-id pub-id-type="pmid">
         18235039
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29-ijms-20-00239">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wada
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Leong-Poi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 protects from severe acute lung failure
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2005
        </year>
        <volume>
         436
        </volume>
        <fpage>
         112
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature03712
        </pub-id>
        <pub-id pub-id-type="pmid">
         16001071
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30-ijms-20-00239">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ohto-Nakanishi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Trilogy of ACE2: A peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters
        </article-title>
        <source>
         Pharmacol. Therap.
        </source>
        <year>
         2010
        </year>
        <volume>
         128
        </volume>
        <fpage>
         119
        </fpage>
        <lpage>
         128
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.pharmthera.2010.06.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         20599443
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31-ijms-20-00239">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1267
        </pub-id>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32-ijms-20-00239">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         426
        </volume>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02145
        </pub-id>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33-ijms-20-00239">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iwanaga
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kihara
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Takenaka
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kita
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system
        </article-title>
        <source>
         J. Mol. Cell. Cardiol.
        </source>
        <year>
         2006
        </year>
        <volume>
         41
        </volume>
        <fpage>
         798
        </fpage>
        <lpage>
         806
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.yjmcc.2006.07.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         16919293
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34-ijms-20-00239">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sato
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kadowaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fukamizu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           P.P.
          </given-names>
         </name>
         <name>
          <surname>
           Kimura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ito
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Apelin is a positive regulator of ACE2 in failing hearts
        </article-title>
        <source>
         J. Clin. Investig.
        </source>
        <year>
         2013
        </year>
        <volume>
         123
        </volume>
        <fpage>
         5203
        </fpage>
        <lpage>
         5211
        </lpage>
        <pub-id pub-id-type="doi">
         10.1172/JCI69608
        </pub-id>
        <pub-id pub-id-type="pmid">
         24177423
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35-ijms-20-00239">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chun
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kojima
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kundu
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sheikh
          </surname>
          <given-names>
           A.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Leeper
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Pearl
          </surname>
          <given-names>
           N.E.
          </given-names>
         </name>
         <name>
          <surname>
           Patterson
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis
        </article-title>
        <source>
         J. Clin. Investig.
        </source>
        <year>
         2008
        </year>
        <volume>
         118
        </volume>
        <fpage>
         3343
        </fpage>
        <lpage>
         3354
        </lpage>
        <pub-id pub-id-type="doi">
         10.1172/JCI34871
        </pub-id>
        <pub-id pub-id-type="pmid">
         18769630
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36-ijms-20-00239">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schreiber
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Holditch
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Generous
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ikeda
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sustained ELABELA Gene Therapy in High Salt-Induced Hypertensive Rats
        </article-title>
        <source>
         Current Gene Ther.
        </source>
        <year>
         2017
        </year>
        <volume>
         16
        </volume>
        <fpage>
         349
        </fpage>
        <lpage>
         360
        </lpage>
        <pub-id pub-id-type="doi">
         10.2174/1566523217666161121111906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B37-ijms-20-00239">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gurley
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
         <name>
          <surname>
           Allred
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Le
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Griffiths
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Mao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Philip
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Haystead
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Breitbart
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Acton
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice
        </article-title>
        <source>
         J. Clin. Investig.
        </source>
        <year>
         2006
        </year>
        <volume>
         116
        </volume>
        <fpage>
         2218
        </fpage>
        <lpage>
         2225
        </lpage>
        <pub-id pub-id-type="doi">
         10.1172/JCI16980
        </pub-id>
        <pub-id pub-id-type="pmid">
         16878172
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B38-ijms-20-00239">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pchejetski
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Foussal
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Alfarano
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lairez
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Calise
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Guilbeau-Frugier
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Schaak
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Seguelas
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wanecq
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Valet
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1
        </article-title>
        <source>
         Eur. Heart J.
        </source>
        <year>
         2012
        </year>
        <volume>
         33
        </volume>
        <fpage>
         2360
        </fpage>
        <lpage>
         2369
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/eurheartj/ehr389
        </pub-id>
        <pub-id pub-id-type="pmid">
         22028387
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B39-ijms-20-00239">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Elabela, a new endogenous ligand of APJ, functions in embryos and adults organisms
        </article-title>
        <source>
         Acta Biochim. Biophys. Sin.
        </source>
        <year>
         2017
        </year>
        <pub-id pub-id-type="doi">
         10.1093/abbs/gmx014
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B40-ijms-20-00239">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parikh
          </surname>
          <given-names>
           V.N.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Woods
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Charo
          </surname>
          <given-names>
           D.N.
          </given-names>
         </name>
         <name>
          <surname>
           Grunwald
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Seo
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition
        </article-title>
        <source>
         Am. J. Physiol. Heart Circ. Physiol.
        </source>
        <year>
         2018
        </year>
        <volume>
         315
        </volume>
        <fpage>
         H348
        </fpage>
        <lpage>
         H356
        </lpage>
        <pub-id pub-id-type="doi">
         10.1152/ajpheart.00693.2017
        </pub-id>
        <pub-id pub-id-type="pmid">
         29775410
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B41-ijms-20-00239">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sato
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Sato
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kadowaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ishida
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yamaguchi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kimura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fukamizu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         ELABELA—APJ axis protects from pressure overload heart failure and Angiotensin II-induced cardiac damage
        </article-title>
        <source>
         Cardiovasc. Res.
        </source>
        <year>
         2017
        </year>
        <pub-id pub-id-type="doi">
         10.1093/cvr/cvx061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B42-ijms-20-00239">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           van Dijk
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice
        </article-title>
        <source>
         Science
        </source>
        <year>
         2017
        </year>
        <volume>
         357
        </volume>
        <fpage>
         707
        </fpage>
        <lpage>
         713
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.aam6607
        </pub-id>
        <pub-id pub-id-type="pmid">
         28663440
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B43-ijms-20-00239">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamaguchi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The CCR4-NOT deadenylase complex controls Atg7-dependent cell death and heart function
        </article-title>
        <source>
         Sci. Signal.
        </source>
        <year>
         2018
        </year>
        <volume>
         11
        </volume>
        <fpage>
         eaan3638
        </fpage>
        <pub-id pub-id-type="doi">
         10.1126/scisignal.aan3638
        </pub-id>
        <pub-id pub-id-type="pmid">
         29438013
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B44-ijms-20-00239">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wysocki
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gonzalez-Pacheco
          </surname>
          <given-names>
           F.R.
          </given-names>
         </name>
         <name>
          <surname>
           Salem
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Evora
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Garcia-Halpin
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Poglitsch
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Schuster
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Batlle
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Murine recombinant angiotensin-converting enzyme 2: Effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2
        </article-title>
        <source>
         Hypertension
        </source>
        <year>
         2012
        </year>
        <volume>
         60
        </volume>
        <fpage>
         730
        </fpage>
        <lpage>
         740
        </lpage>
        <pub-id pub-id-type="doi">
         10.1161/HYPERTENSIONAHA.112.198622
        </pub-id>
        <pub-id pub-id-type="pmid">
         22777933
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="ijms-20-00239-f001" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Blood pressure measurements in Ang II-treated mice. Wild type (WT) and apelin knockout (Apelin KO) mice at 12 months of age were continuously infused with either vehicle or angiotensin II (Ang II) for 2 weeks using osmotic minipumps (Ang II, 1 mg/kg/day) and measured for blood pressure using the tail-cuff method. Systolic (
        <bold>
         A
        </bold>
        ), diastolic (
        <bold>
         B
        </bold>
        ), and mean (
        <bold>
         C
        </bold>
        ) blood pressures are shown.
        <italic>
         n
        </italic>
        = 4–6 per group. All values are mean ± SEM. †
        <italic>
         p
        </italic>
        &lt; 0.1; *
        <italic>
         p
        </italic>
        &lt; 0.05; **
        <italic>
         p
        </italic>
        &lt; 0.01. ns: not significant.
       </p>
      </caption>
      <graphic xlink:href="ijms-20-00239-g001">
      </graphic>
     </fig>
     <fig id="ijms-20-00239-f002" orientation="portrait" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        mRNA expression of ACE and ACE2 in the heart. The heart tissues harvested from Ang II-treated WT and Apelin KO mice were subjected to qRT-PCR analysis to measure mRNA expression levels. mRNA expression of ACE (
        <bold>
         A
        </bold>
        ), ACE2 (
        <bold>
         B
        </bold>
        ), and the ratio of ACE expression to ACE2 expression (ACE/ACE2) (
        <bold>
         C
        </bold>
        ) are shown.
        <italic>
         n
        </italic>
        = 4–6 per group. All values are mean ± SEM. *
        <italic>
         p
        </italic>
        &lt; 0.05.
       </p>
      </caption>
      <graphic xlink:href="ijms-20-00239-g002">
      </graphic>
     </fig>
     <fig id="ijms-20-00239-f003" orientation="portrait" position="float">
      <label>
       Figure 3
      </label>
      <caption>
       <p>
        Measurements of heart function and cardiac hypertrophy in Ang II-treated mice. (
        <bold>
         A
        </bold>
        –
        <bold>
         C
        </bold>
        ) Echocardiography of WT and Apelin KO mice treated with either vehicle or Ang II (
        <italic>
         n
        </italic>
        = 4–6 per group). Representative pictures of echocardiography (
        <bold>
         A
        </bold>
        ), percent of fractional shortening (%FS) (
        <bold>
         B
        </bold>
        ), and the thickness of the end-diastolic interventricular septum (IVS) (
        <bold>
         C
        </bold>
        ) are shown. (
        <bold>
         D
        </bold>
        ) Histology of hearts stained with hematoxylin/eosin. (
        <bold>
         E
        </bold>
        ) Heart weight to body weight ratio (HW/BW) of WT and Apelin KO mice treated with either vehicle or Ang II (
        <italic>
         n
        </italic>
        = 4–6 per group). Bars indicates 1mm. All values are mean ± SEM. *
        <italic>
         p
        </italic>
        &lt; 0.05; **
        <italic>
         p
        </italic>
        &lt; 0.01. ns: not significant.
       </p>
      </caption>
      <graphic xlink:href="ijms-20-00239-g003">
      </graphic>
     </fig>
     <fig id="ijms-20-00239-f004" orientation="portrait" position="float">
      <label>
       Figure 4
      </label>
      <caption>
       <p>
        Cardiac fibrosis in Ang II-treated mice. (
        <bold>
         A
        </bold>
        ,
        <bold>
         B
        </bold>
        ) Histological analysis of cardiac fibrosis: Masson-trichrome staining (
        <bold>
         A
        </bold>
        ) and quantification of %fibrosis area (
        <bold>
         B
        </bold>
        ) in the hearts of Ang II or vehicle-treated WT and Apelin KO mice are shown (
        <italic>
         n
        </italic>
        = 4 per group). Bars indicates 200μm. (
        <bold>
         C
        </bold>
        –
        <bold>
         E
        </bold>
        ) Real-time PCR analysis for mRNA expression of pro-fibrotic genes collagen 8a (
        <italic>
         Col8a
        </italic>
        ) (
        <bold>
         C
        </bold>
        ), transforming growth-factor beta 2 (
        <italic>
         Tgfb2
        </italic>
        ) (
        <bold>
         D
        </bold>
        ), latent transforming growth-factor beta-binding protein 2 (
        <italic>
         Ltbp2
        </italic>
        ) (
        <bold>
         E
        </bold>
        ), normalized with 18S respectively (
        <italic>
         n
        </italic>
        = 4 per group). All values are mean ± SEM. *
        <italic>
         p
        </italic>
        &lt; 0.05.
       </p>
      </caption>
      <graphic xlink:href="ijms-20-00239-g004">
      </graphic>
     </fig>
     <fig id="ijms-20-00239-f005" orientation="portrait" position="float">
      <label>
       Figure 5
      </label>
      <caption>
       <p>
        Effects of ACE inhibition on cardiac contractility in Apelin KO mice. Echocardiography of WT and Apelin KO mice treated with either vehicle or the ACE-inhibitor Captopril (ACE-i) in drinking water for 2 weeks (
        <italic>
         n
        </italic>
        = 5–6 per group). %fractional shortening (
        <bold>
         A
        </bold>
        ) and diameter of end-systolic left ventricle (LVESD) (
        <bold>
         B
        </bold>
        ) are shown. All values are mean ± SEM. *
        <italic>
         p
        </italic>
        &lt; 0.05; **
        <italic>
         p
        </italic>
        &lt; 0.01.
       </p>
      </caption>
      <graphic xlink:href="ijms-20-00239-g005">
      </graphic>
     </fig>
     <fig id="ijms-20-00239-f006" orientation="portrait" position="float">
      <label>
       Figure 6
      </label>
      <caption>
       <p>
        Effects of apelin and Ang II peptides in mouse cardiomyocytes. (
        <bold>
         A
        </bold>
        –
        <bold>
         C
        </bold>
        ) Immunocytochemistry of primary mouse cardiomyocytes. Wild type mouse cardiomyocytes were treated with vehicle, 1 μM Ang II, 1 μM apelin, or a combination of both peptides, stained with α-actinin (red) and Hoechst (DNA, blue) and quantified. Representative pictures of cardiomyocytes (
        <bold>
         A
        </bold>
        ), measurements of cell diameter (
        <bold>
         B
        </bold>
        ), and cell area (
        <bold>
         C
        </bold>
        ) are shown. Bars indicates 20μm. Values are mean ± SEM of at least 5 fields per group in 3 independent experiments. (
        <bold>
         D
        </bold>
        –
        <bold>
         F
        </bold>
        ) Real-time PCR analysis for
        <italic>
         BNP
        </italic>
        ,
        <italic>
         ANF,
        </italic>
        and
        <italic>
         Tgfb2
        </italic>
        mRNA expression in cardiomyocytes (
        <italic>
         n
        </italic>
        = 4 independent experiments). All values are mean ± SEM. *
        <italic>
         p
        </italic>
        &lt; 0.05; **
        <italic>
         p
        </italic>
        &lt; 0.01; ***
        <italic>
         p
        </italic>
        &lt; 0.001.
       </p>
      </caption>
      <graphic xlink:href="ijms-20-00239-g006">
      </graphic>
     </fig>
     <table-wrap id="ijms-20-00239-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       ijms-20-00239-t001_Table 1
      </object-id>
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Echocardiography data of Apelin KO mice treated with Ang II. Values are means ± SEM. Abbreviations: (M) month; (HR) heart rate; (FS) fractional shortening; (EF) ejection fraction; (LVESD) left ventricular end-systolic diameter; (LVEDD) left ventricular end-diastolic diameter; (IVS) end-diastolic interventricular septum; (PWT) end-diastolic posterior wall thickness. *
        <italic>
         p
        </italic>
        &lt; 0.05 and **
        <italic>
         p
        </italic>
        &lt; 0.01 compared with control wild type mice with vehicle.
        <sup>
         #
        </sup>
        <italic>
         p
        </italic>
        &lt; 0.05 and
        <sup>
         ##
        </sup>
        <italic>
         p
        </italic>
        &lt; 0.01 compared to wild type mice with Ang II.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Wild Type + Vehicle
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Apelin KO + Vehicle
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Wild Type + Ang II
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Apelin KO + Ang II
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          N
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          age (M)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          HR (bpm)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          550.28 ± 24.63
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          550.47 ± 50.93
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          577.00 ± 38.03
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          557.67 ± 29.39
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          FS (%)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          49.83 ± 2.05
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          36.33 ± 6.57 **
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          44.20 ± 5.52
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          31.35 ± 2.20 ##
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          EF (%)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          81.30 ± 2.01
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          65.61 ± 9.08 **
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          75.46 ± 5.92
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          59.44 ± 3.30 ##
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LVESD (mm)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.10 ± 0.20
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.76 ± 0.36 **
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.19 ± 0.22
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.71 ± 0.31 #
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LVEDD (mm)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4.18 ± 0.36
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4.32 ± 0.13
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.92 ± 0.45
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.95 ± 0.38
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          IVS (mm)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.67 ± 0.02
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.71 ± 0.04
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.84 ± 0.03 **
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.91 ± 0.05 #
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          PWT (mm)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          0.79 ± 0.05
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          0.79 ± 0.04
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1.00 ± 0.07 **
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          0.95 ± 0.04
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="ijms-20-00239-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       ijms-20-00239-t002_Table 2
      </object-id>
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Echocardiography data of Apelin KO mice treated with an ACE inhibitor. Values are mean ± SEM. See
        <xref ref-type="table" rid="ijms-20-00239-t001">
         Table 1
        </xref>
        for abbreviations. The ACE inhibitor (ACE-i) Captopril was given in drinking water for 2 weeks before echocardiography. *
        <italic>
         p
        </italic>
        &lt; 0.05 and **
        <italic>
         p
        </italic>
        &lt; 0.01 compared with control wild type mice.
        <sup>
         #
        </sup>
        <italic>
         p
        </italic>
        &lt; 0.05 compared to vehicle treated Apelin KO mice.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Wild Type + Vehicle
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Apelin KO + Vehicle
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Wild Type + ACE-i
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Apelin KO + ACE-i
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          N
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          age (M)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          HR (bpm)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          476.20 ± 18.00
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          464.40 ± 11.50
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          480.60 ± 11.90
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          455.00 ± 15.90
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          FS (%)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          39.60 ± 0.81
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          29.60 ± 1.08 **
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          40.40 ± 1.29
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          39.25 ± 0.06
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LVESD (mm)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.26 ± 0.04
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.76 ± 0.02 *
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.16 ± 0.04
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.33 ± 0.02 #
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LVEDD (mm)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.74 ± 0.05
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.90 ± 0.05 *
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.76 ± 0.06
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.85 ± 0.06
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          PWT (mm)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          0.88 ± 0.02
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          0.72 ± 0.02 **
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          0.86 ± 0.02
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          0.83 ± 0.04 #
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Curr Opin Pharmacol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Curr Opin Pharmacol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Current Opinion in Pharmacology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1471-4892
      </issn>
      <issn pub-type="epub">
       1471-4973
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd. Published by Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       21215698
      </article-id>
      <article-id pub-id-type="pmc">
       3075309
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1471-4892(10)00179-7
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.coph.2010.12.002
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        ACE2, a promising therapeutic target for pulmonary hypertension
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Shenoy
         </surname>
         <given-names>
          Vinayak
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0005">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Qi
         </surname>
         <given-names>
          Yanfei
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0005">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Katovich
         </surname>
         <given-names>
          Michael J
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0010">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Raizada
         </surname>
         <given-names>
          Mohan K
         </given-names>
        </name>
        <email>
         mraizada@ufl.edu
        </email>
        <xref ref-type="aff" rid="aff0005">
         1
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0005">
       <label>
        1
       </label>
       Department of Physiology and Functional Genomics, University of Florida, Gainesville, FL, United States
      </aff>
      <aff id="aff0010">
       <label>
        2
       </label>
       Department of Pharmacodynamics, University of Florida, Gainesville, FL, United States
      </aff>
      <pub-date pub-type="pmc-release">
       <day>
        5
       </day>
       <month>
        1
       </month>
       <year>
        2011
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        4
       </month>
       <year>
        2011
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        5
       </day>
       <month>
        1
       </month>
       <year>
        2011
       </year>
      </pub-date>
      <volume>
       11
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       150
      </fpage>
      <lpage>
       155
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2010 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2010
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Pulmonary arterial hypertension (PAH) is a chronic lung disease with poor diagnosis and limited therapeutic options. The currently available therapies are ineffective in improving the quality of life and reducing mortality rates. There exists a clear unmet medical need to treat this disease, which necessitates the discovery of novel therapeutic targets/agents for safe and successful therapy. An altered renin–angiotensin system (RAS) has been implicated as a causative factor in the pathogenesis of PAH. Angiotensin II (Ang II), a key effector peptide of the RAS, can exert deleterious effects on the pulmonary vasculature resulting in vasoconstriction, proliferation, and inflammation, all of which contribute to PAH development. Recently, a new member of the RAS, angiotensin converting enzyme 2 (ACE2), was discovered. This enzyme functions as a negative regulator of the angiotensin system by metabolizing Ang II to a putative protective peptide, angiotensin-(1–7). ACE2 is abundantly expressed in the lung tissue and emerging evidence suggests a beneficial role for this enzyme against lung diseases. In this review, we focus on ACE2 in relation to pulmonary hypertension and provide proof of principle for its therapeutic role in PAH.
       </p>
      </abstract>
     </article-meta>
    </front>
    <sec id="sec0005">
     <title>
      Introduction
     </title>
     <p id="par0005">
      Pulmonary arterial hypertension (PAH) is a debilitating chronic disorder of the lungs characterized by sustained elevation of blood pressure in the pulmonary vasculature. The normal mean pulmonary arterial pressure in a healthy adult is about 14 mm Hg at rest. However, in PAH, the resting mean pulmonary arterial pressure measures over 25 mm Hg (and greater than 30 mm Hg during exercise) [
      <xref ref-type="bibr" rid="bib0005">
       1
      </xref>
      ]. PAH can either be of idiopathic origin with unknown etiology or, it can arise due to secondary medical conditions such as collagen vascular diseases, heart malformation or viral infections. Genetic and epigenetic risk factors have also been linked to PAH pathogenesis [
      <xref ref-type="bibr" rid="bib0010">
       2
      </xref>
      ]. Regardless of the cause, PAH is associated with endothelial dysfunction, vasoconstriction, and remodeling of the pulmonary vessels. Endothelial dysfunction is believed to be an early component of the pulmonary hypertensive process, creating an imbalance between vasodilator (nitric oxide (NO) and prostacyclin) and vasoconstrictor substances (endothelin, thromboxane A2 and serotonin) [
      <xref ref-type="bibr" rid="bib0015">
       3
       <sup>
        •
       </sup>
      </xref>
      ]. This imbalance leads to a cascade of events resulting in hyper-proliferation of pulmonary smooth muscle cells, activation of lung fibroblasts, induction of thrombotic mediators and release of inflammatory cytokines, all of which increase vascular resistance and pressure. One of the causal factors for endothelial dysfunction and vascular impairment is the renin–angiotensin system (RAS) [
      <xref ref-type="bibr" rid="bib0020">
       4
      </xref>
      ]. Activation of the classic ACE-AngII-AT1R axis of the RAS, comprising of angiotensin converting enzyme (ACE), the vasoactive peptide angiotensin II (Ang II), and its receptor AT1R, adversely affects pulmonary hemodynamics to cause PAH [
      <xref ref-type="bibr" rid="bib0025">
       5
      </xref>
      ]. Conversely, ACE2, the recently discovered homologue of ACE has been shown to oppose the detrimental effects of the ACE-AngII-AT1R axis on the cardio-pulmonary system [
      <xref ref-type="bibr" rid="bib0030">
       6
       <sup>
        ••
       </sup>
      </xref>
      ]. This review focuses on the role of ACE2 in the pathobiology of pulmonary hypertension and provides proof of concept that targeting of this enzyme can prove to be an effective therapeutic strategy for the treatment of PAH.
     </p>
    </sec>
    <sec id="sec0010">
     <title>
      Intrapulmonary renin–angiotensin system (RAS) — a critical component in PAH
     </title>
     <p id="par0010">
      The RAS is composed of a series of enzymatic reactions that lead to the generation of several angiotensin peptides. The cascade begins with the proteolytic cleavage of angiotensinogen by renin to yield the inactive precursor angiotensin I. Angiotensin I is further acted upon by ACE to form Ang II, a biologically active vasopeptide that mediates its effects via two distinct receptor subtypes — AT1R and AT2R. Stimulation of the AT1R causes vasoconstriction, cell proliferation, inflammation, and fibrosis, while activation of AT2R regulates opposing effects [
      <xref ref-type="bibr" rid="bib0035">
       7
      </xref>
      ]. Several new members of the RAS have recently been identified, which has expanded our understanding of this biological system. These new members include (pro) renin receptor [
      <xref ref-type="bibr" rid="bib0040">
       8
      </xref>
      ], angiotensin-(1–12) [
      <xref ref-type="bibr" rid="bib0045">
       9
      </xref>
      ], ACE2 [
      <xref ref-type="bibr" rid="bib0050">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0055">
       11
      </xref>
      ], angiotensin-(1–7) [
      <xref ref-type="bibr" rid="bib0060">
       12
      </xref>
      ], and the Mas receptor [
      <xref ref-type="bibr" rid="bib0065">
       13
      </xref>
      ]. All the major components of the RAS including renin, angiotensinogen, ACE, ACE2, AT1R, AT2R, and the Mas receptor are expressed in the lung tissue [
      <xref ref-type="bibr" rid="bib0025">
       5
      </xref>
      ]. It is relevant to point out that polymorphism in the genes encoding for angiotensinogen [
      <xref ref-type="bibr" rid="bib0070">
       14
      </xref>
      ], and ACE [
      <xref ref-type="bibr" rid="bib0075">
       15
      </xref>
      ], has been linked to the development of PAH. With regard to the ACE gene, an insertion–deletion polymorphism of 287 base pairs in intron 16 results in three distinct genotypes; DD(homozygous deletion allele), II(homozygous insertion allele), and ID heterozygotes [
      <xref ref-type="bibr" rid="bib0080">
       16
      </xref>
      ]. The deletion allele (DD) is associated with increased ACE activity, while the insertion allele (II) is associated with decreased ACE activity [
      <xref ref-type="bibr" rid="bib0085">
       17
      </xref>
      ]. The ACE DD genotype, accompanied by elevated circulating levels of Ang II, has been implicated in the development of PAH [
      <xref ref-type="bibr" rid="bib0090">
       18
      </xref>
      ]. Interestingly, the lungs of pulmonary hypertensive patients as well as animals with PAH express high levels of ACE, suggesting a causative role for this enzyme in disease pathogenesis [
      <xref ref-type="bibr" rid="bib0095">
       19
      </xref>
      ]. ACE is the primary enzyme responsible for Ang II production in the lungs. This Ang II peptide is a potent pulmonary vasoconstrictor with mitogenic actions [
      <xref ref-type="bibr" rid="bib0100">
       20
      </xref>
      ]. Both animal and clinical studies have shown that stimulation of the pulmonary smooth muscle cells with Ang II produces migratory, hypertrophic, and proliferative effects [
      <xref ref-type="bibr" rid="bib0105">
       21
      </xref>
      ]. Furthermore, Ang II initiates inflammatory processes and generates cellular reactive oxygen species (ROS), factors that contribute to the pathophysiology of PAH [
      <xref ref-type="bibr" rid="bib0110">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0115">
       23
      </xref>
      ]. Accumulating evidence also suggests that Ang II induces apoptosis of the lung parenchymal cells, leading to pulmonary hypertension [
      <xref ref-type="bibr" rid="bib0120">
       24
      </xref>
      ]. Collectively, these findings clearly indicate an active role for RAS in the pulmonary hypertensive process. However, pharmacological blockade with ACE inhibitors or AT1R antagonists has produced mixed results against PAH [
      <xref ref-type="bibr" rid="bib0125">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0130">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0135">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0140">
       28
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0145">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0150">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0155">
       31
      </xref>
      ], thus rendering their medical use somewhat controversial. Nevertheless, several lines of emerging evidence strongly suggest that the recently discovered ACE homologue, ACE2, either by itself or through its catalytic product Ang-(1–7) opposes the proliferative, hypertrophic, and fibrotic effects of Ang II [
      <xref ref-type="bibr" rid="bib0160">
       32
      </xref>
      ] in many organs, including the lungs, suggesting a plausible protective role against PAH.
     </p>
    </sec>
    <sec id="sec0015">
     <title>
      Pharmacology and tissue distribution of ACE2
     </title>
     <p id="par0015">
      ACE2 was discovered as a close homologue of ACE about a decade ago, by two independent research groups using distinct methodologies [
      <xref ref-type="bibr" rid="bib0050">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0055">
       11
      </xref>
      ]. It contains 805 amino acids and shares 42% sequence homology with the active site of ACE. However, unlike ACE, which is a dipeptidyl-peptidase, ACE2 is a mono-carboxypeptidase that cleaves a single amino acid from the C-terminal of its substrates. Ang II appears to be the main substrate for ACE2, and is effectively hydrolyzed to angiotensin-(1–7) [Ang-(1–7)]. Apelin-13, Apelin 36, Neurotensin 1–8, Dynorphin A (1–13), [des-Arg9]-Bradykinin, and [Lys-des-Arg9]-Bradykinin are the other known peptide targets for ACE2. ACE2 exists as a membrane-bound protein in the lungs, stomach, spleen, intestine, bone-marrow, kidney, liver, and the brain [
      <xref ref-type="bibr" rid="bib0165">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0170">
       34
      </xref>
      ]. Particularly, in the lungs, it is expressed on the vascular endothelium, type I and type II alveolar epithelial cells, the smooth muscle cells of the pulmonary vasculature, and in bronchial epithelia [
      <xref ref-type="bibr" rid="bib0175">
       35
      </xref>
      ]. Though, ACE2 exists primarily as a membrane-bound protein, a soluble form has been detected in both plasma and urine [
      <xref ref-type="bibr" rid="bib0180">
       36
      </xref>
      ].
     </p>
    </sec>
    <sec id="sec0020">
     <title>
      Contribution of ACE2 to lung pathophysiology
     </title>
     <p id="par0020">
      ACE2 has been suggested to play an important role in lung pathophysiology. Evidence for this comes from the following observations: first, decreased expression of ACE2 is associated with lung fibrosis in both human and experimental animals [
      <xref ref-type="bibr" rid="bib0185">
       37
      </xref>
      ]; second, lung overexpression of ACE2 attenuates monocrotaline-induced pulmonary hypertension [
      <xref ref-type="bibr" rid="bib0190">
       38
      </xref>
      ] and bleomycin-induced pulmonary fibrosis [
      <xref ref-type="bibr" rid="bib0195">
       39
      </xref>
      ]; third, ACE2 protects murine lungs from acute injury [
      <xref ref-type="bibr" rid="bib0200">
       40
      </xref>
      ] and respiratory distress syndrome [
      <xref ref-type="bibr" rid="bib0205">
       41
      </xref>
      ]; fourth, mutant ACE2 mice exhibit enhanced vascular permeability with declining lung function [
      <xref ref-type="bibr" rid="bib0210">
       42
      </xref>
      ]; fifth, reduced pulmonary ACE2 expression due to SARS-CoV infection results in lung failure [
      <xref ref-type="bibr" rid="bib0215">
       43
      </xref>
      ]; sixth, administration of recombinant ACE2 prevents the development of lung failure in ACE2 knockout mice [
      <xref ref-type="bibr" rid="bib0210">
       42
      </xref>
      ]; and seventh, ACE2 treatment reversed established PAH in BMPR2R899X mice (JA Johnson
      <italic>
       et al.
      </italic>
      , abstract in Am J Respir Crit Care Med 2010, 181:A6327). A recent report by Takahashi
      <italic>
       et al.
      </italic>
      [
      <xref ref-type="bibr" rid="bib0220">
       44
      </xref>
      ], also suggests that auto-antibodies to ACE2 may predispose patients with connective tissue diseases to PAH. All these observations substantiate the importance of ACE2 in lung pathophysiology.
     </p>
    </sec>
    <sec id="sec0025">
     <title>
      Protective role of ACE2 against PAH-induced cardiac remodeling
     </title>
     <p id="par0025">
      Remodeling of the right ventricle, characterized by myocyte hypertrophy and fibrosis, is often observed in pulmonary hypertensive patients [
      <xref ref-type="bibr" rid="bib0225">
       45
      </xref>
      ]. During the early stages of PAH, the remodeling process represents an adaptive response to compensate for the increased right ventricular workload. However, over time the right ventricle becomes thickened, enlarged, and dysfunctional, which can culminate in heart failure. In fact, right ventricular failure is the primary cause of death in patients with PAH [
      <xref ref-type="bibr" rid="bib0230">
       46
      </xref>
      ]. Zisman
      <italic>
       et al.
      </italic>
      , were the first investigators to report increased ACE2 activity and elevated angiotensin-(1–7) levels in the ventricles of PAH patients [
      <xref ref-type="bibr" rid="bib0235">
       47
      </xref>
      ]. It appears that upregulation of ACE2 and the subsequent increase in Ang-(1–7) levels may be a compensatory response to protect against tissue injury. This view is supported by several experimental studies, wherein administration of ACE2 or Ang-(1–7) exerted cardio-protective effects [
      <xref ref-type="bibr" rid="bib0240">
       48
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0245">
       49
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0250">
       50
      </xref>
      ]. Conversely, ACE2 deficiency resulted in increased incidence of cardiac death due to chronic pressure overload [
      <xref ref-type="bibr" rid="bib0255">
       51
      </xref>
      ]. Of particular relevance to pulmonary therapeutics is that lung overexpression of ACE2 prevented the development of right ventricular hypertrophy in animal models of PAH and lung fibrosis (
      <xref ref-type="fig" rid="fig0005">
       Figure 1
      </xref>
      ). Similar beneficial effects were also observed with endogenous activation of ACE2 using XNT (1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one) [
      <xref ref-type="bibr" rid="bib0030">
       6
       <sup>
        ••
       </sup>
      </xref>
      ]. Part of the protective mechanism of ACE2 may be related to decrease in the levels of Ang II and/or the ensuing increase in Ang-(1–7). Besides this, modulation of matrix metalloproteinases (MMPs) by ACE2, especially that of MMP-2 and MMP-9 may also be responsible for the anti-remodeling effects [
      <xref ref-type="bibr" rid="bib0260">
       52
      </xref>
      ]. It is well known that MMPs contribute to cardiac remodeling in PAH [
      <xref ref-type="bibr" rid="bib0265">
       53
      </xref>
      ]. Furthermore, ACE2 overexpression has been shown to inhibit hypoxia-induced collagen production by cardiac fibroblasts, highlighting the anti-fibrotic actions of ACE2 [
      <xref ref-type="bibr" rid="bib0270">
       54
      </xref>
      ].
      <fig id="fig0005">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Lentiviral mediated lung overexpression of ACE2 attenuates monocrotaline (MCT)-induced increase in right ventricular systolic pressure (RVSP) and prevents the development of right ventricular hypertrophy, expressed as the ratio of right ventricular weight (RV) to left ventricular + septum weight (LV + S).
        </p>
       </caption>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec id="sec0030">
     <title>
      Anti-proliferative effects on vascular smooth muscle cells
     </title>
     <p id="par0030">
      All the layers of the pulmonary vessel wall undergo structural and functional changes during PAH [
      <xref ref-type="bibr" rid="bib0275">
       55
      </xref>
      ]. These changes include proliferation of the vascular smooth muscle cells, intimal thickening and extension of smooth muscle into previously non-muscularized arterioles. Vascular remodeling reduces lumen diameter, thereby increasing pulmonary vascular resistance and pressure.
      <italic>
       In vitro
      </italic>
      studies have shown that decreased ACE2 level is associated with hyper-proliferation and enhanced migration of pulmonary smooth muscle cells, suggesting a vasoprotective role for ACE2 [
      <xref ref-type="bibr" rid="bib0280">
       56
      </xref>
      ]. These
      <italic>
       in vitro
      </italic>
      data were further confirmed by
      <italic>
       in vivo
      </italic>
      studies, wherein lung overexpression of ACE2 not only prevented vessel wall thickening but also attenuated muscularization of the pulmonary vessels [
      <xref ref-type="bibr" rid="bib0190">
       38
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0195">
       39
      </xref>
      ]. Administration of XNT, the synthetic ACE2 activator, also exerted similar beneficial effects on the pulmonary vasculature in an experimental model of PAH [
      <xref ref-type="bibr" rid="bib0030">
       6
       <sup>
        ••
       </sup>
      </xref>
      ].
     </p>
    </sec>
    <sec id="sec0035">
     <title>
      Effect on endothelial dysfunction, oxidative stress, and inflammation
     </title>
     <p id="par0035">
      Reduced bioavailability of NO, increased formation of ROS, and inflammation are hallmarks of PAH [
      <xref ref-type="bibr" rid="bib0285">
       57
      </xref>
      ]. Improvement of the aforementioned factors is essential for effective pulmonary hypertensive therapy. ACE2 is predominantly localized to the vascular endothelium and exerts vasodilatory actions [
      <xref ref-type="bibr" rid="bib0290">
       58
      </xref>
      ]. On the contrary, deficiency in ACE2 impairs endothelium-dependent vasorelaxation [
      <xref ref-type="bibr" rid="bib0295">
       59
      </xref>
      ], which underscores the importance of ACE2 in endothelial function. A stoichiometric balance between NO and superoxide is critical for maintaining normal vascular tone. It is well established that Ang II increases superoxide production by upregulating endothelial nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) resulting in vascular impairment. On the other hand, ACE2 has been shown to reduce Ang II mediated superoxide production [
      <xref ref-type="bibr" rid="bib0300">
       60
      </xref>
      ], thereby improving vascular function. Inflammatory cytokines (e.g., IL-1, IL-6, TNF-α and MCP-1) and growth factors (TGF-β) substantially contribute to the development and/or progression of PAH. In this regard, treatment with ACE2 or XNT has been shown to decrease the expression of pro-inflammatory cytokines in the lungs [
      <xref ref-type="bibr" rid="bib0030">
       6••
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0190">
       38
      </xref>
      ]. Also, this decrease in pro-inflammatory cytokine levels was accompanied by a concomitant increase in the anti-inflammatory cytokine, IL-10. Taken together, experimental evidence indicates a protective role for ACE2 against endothelial dysfunction, oxidative stress, and inflammation.
     </p>
    </sec>
    <sec id="sec0040">
     <title>
      Conclusions
     </title>
     <p id="par0040">
      In light of the limited efficacy of currently available treatment options for PAH therapy, development of novel therapeutic strategies is needed. In this regard, discovery of ACE2 seems to be relevant. As discussed above, ACE2 has been shown to exert a host of beneficial effects on the cardio-pulmonary system, resulting in the prevention of PAH (
      <xref ref-type="fig" rid="fig0010">
       Figure 2
      </xref>
      ). Thus, it appears that genetic approaches to increase ACE2 activity and/or the use of synthetic ACE2 activators may represent potential new therapies for effectively treating PAH.
      <fig id="fig0010">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         ACE2 exerts a host of actions on the cardio-pulmonary system that include prevention of endothelial dysfunction, reduction in pulmonary oxidative stress, attenuation of vascular impairment, anti-inflammatory, and anti-cardiac remodeling effects. All these properties are responsible for the protective role of ACE2 against pulmonary arterial hypertension.
        </p>
       </caption>
       <graphic xlink:href="gr2_lrg">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec id="sec0045">
     <title>
      References and recommended reading
     </title>
     <p id="par0045">
      Papers of particular interest, published within the period of review, have been highlighted as:
      <list id="lis0005" list-type="simple">
       <list-item id="lsti0005">
        <p id="par0050">
         • of special interest
        </p>
       </list-item>
       <list-item id="lsti0010">
        <p id="par0055">
         •• of outstanding interest
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <back>
     <ref-list id="bibl0005">
      <title>
       References
      </title>
      <ref id="bib0005">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Galie
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Torbicki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Barst
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Dartevelle
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Haworth
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Higenbottam
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Olschewski
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Peacock
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Pietra
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
        </article-title>
        <source>
         Eur Heart J
        </source>
        <volume>
         25
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2243
        </fpage>
        <lpage>
         2278
        </lpage>
        <pub-id pub-id-type="pmid">
         15589643
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loscalzo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic clues to the cause of primary pulmonary hypertension
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         345
        </volume>
        <year>
         2001
        </year>
        <fpage>
         367
        </fpage>
        <lpage>
         371
        </lpage>
        <pub-id pub-id-type="pmid">
         11484696
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        3•
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morrell
          </surname>
          <given-names>
           N.W.
          </given-names>
         </name>
         <name>
          <surname>
           Adnot
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Archer
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dupuis
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           MacLean
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           McMurtry
          </surname>
          <given-names>
           I.F.
          </given-names>
         </name>
         <name>
          <surname>
           Stenmark
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Thistlethwaite
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Weissmann
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cellular and molecular basis of pulmonary arterial hypertension
        </article-title>
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         54
        </volume>
        <year>
         2009
        </year>
        <fpage>
         S20
        </fpage>
        <lpage>
         S31
        </lpage>
        <pub-id pub-id-type="pmid">
         19555855
        </pub-id>
       </element-citation>
       <note>
        <p>
         This article comprehensively reviews the pathophysiological mechanisms involved in PAH.
        </p>
       </note>
      </ref>
      <ref id="bib0020">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luscher
          </surname>
          <given-names>
           T.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Endothelial dysfunction: the role and impact of the renin–angiotensin system
        </article-title>
        <source>
         Heart
        </source>
        <volume>
         84
        </volume>
        <issue>
         Suppl. 1
        </issue>
        <year>
         2000
        </year>
        <fpage>
         i20
        </fpage>
        <lpage>
         i22
        </lpage>
        <comment>
         [discussion i50]
        </comment>
        <pub-id pub-id-type="pmid">
         10956315
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marshall
          </surname>
          <given-names>
           R.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The pulmonary renin–angiotensin system
        </article-title>
        <source>
         Curr Pharm Des
        </source>
        <volume>
         9
        </volume>
        <year>
         2003
        </year>
        <fpage>
         715
        </fpage>
        <lpage>
         722
        </lpage>
        <pub-id pub-id-type="pmid">
         12570789
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <label>
        6••
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Shenoy
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Yamazato
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sriramula
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Francis
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Castellano
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Ostrov
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
         <name>
          <surname>
           Katovich
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Raizada
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         179
        </volume>
        <year>
         2009
        </year>
        <fpage>
         1048
        </fpage>
        <lpage>
         1054
        </lpage>
        <pub-id pub-id-type="pmid">
         19246717
        </pub-id>
       </element-citation>
       <note>
        <p>
         This is the first study that describes the use of a synthetic activator of ACE2 can prevent the development of PAH and associated cardio-pulmonary remodeling.
        </p>
       </note>
      </ref>
      <ref id="bib0035">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stroth
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Unger
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The renin–angiotensin system and its receptors
        </article-title>
        <source>
         J Cardiovasc Pharmacol
        </source>
        <volume>
         33
        </volume>
        <issue>
         Suppl. 1
        </issue>
        <year>
         1999
        </year>
        <fpage>
         S21
        </fpage>
        <lpage>
         S28
        </lpage>
        <comment>
         [discussion S41–3]
        </comment>
        <pub-id pub-id-type="pmid">
         10028950
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Delarue
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Burckle
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Bouzhir
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Giller
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Sraer
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin
        </article-title>
        <source>
         J Clin Invest
        </source>
        <volume>
         109
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1417
        </fpage>
        <lpage>
         1427
        </lpage>
        <pub-id pub-id-type="pmid">
         12045255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kato
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sasaki
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Minamino
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Eto
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kitamura
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and identification of proangiotensin-12, a possible component of the renin–angiotensin system
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <volume>
         350
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1026
        </fpage>
        <lpage>
         1031
        </lpage>
        <pub-id pub-id-type="pmid">
         17045572
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Godbout
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gosselin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stagliano
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Donovan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Woolf
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Robison
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Jeyaseelan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         87
        </volume>
        <year>
         2000
        </year>
        <fpage>
         E1
        </fpage>
        <lpage>
         E9
        </lpage>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Karran
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Christie
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         275
        </volume>
        <year>
         2000
        </year>
        <fpage>
         33238
        </fpage>
        <lpage>
         33243
        </lpage>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schiavone
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brosnihan
          </surname>
          <given-names>
           K.B.
          </given-names>
         </name>
         <name>
          <surname>
           Khosla
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1–7) heptapeptide
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         85
        </volume>
        <year>
         1988
        </year>
        <fpage>
         4095
        </fpage>
        <lpage>
         4098
        </lpage>
        <pub-id pub-id-type="pmid">
         3375255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Simoes e Silva
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Maric
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Machado
          </surname>
          <given-names>
           R.P.
          </given-names>
         </name>
         <name>
          <surname>
           de Buhr
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Heringer-Walther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Pinheiro
          </surname>
          <given-names>
           S.V.
          </given-names>
         </name>
         <name>
          <surname>
           Lopes
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Bader
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         100
        </volume>
        <year>
         2003
        </year>
        <fpage>
         8258
        </fpage>
        <lpage>
         8263
        </lpage>
        <pub-id pub-id-type="pmid">
         12829792
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Solari
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Puri
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic polymorphisms of angiotensin system genes in congenital diaphragmatic hernia associated with persistent pulmonary hypertension
        </article-title>
        <source>
         J Pediatr Surg
        </source>
        <volume>
         39
        </volume>
        <year>
         2004
        </year>
        <fpage>
         302
        </fpage>
        <lpage>
         306
        </lpage>
        <comment>
         [discussion 302–6]
        </comment>
        <pub-id pub-id-type="pmid">
         15017542
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kanazawa
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Okamoto
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Hirata
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yoshikawa
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         162
        </volume>
        <year>
         2000
        </year>
        <fpage>
         1235
        </fpage>
        <lpage>
         1238
        </lpage>
        <pub-id pub-id-type="pmid">
         11029323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications
        </article-title>
        <source>
         Drugs
        </source>
        <volume>
         62
        </volume>
        <year>
         2002
        </year>
        <fpage>
         977
        </fpage>
        <lpage>
         993
        </lpage>
        <pub-id pub-id-type="pmid">
         11985486
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rigat
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Hubert
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Alhenc-Gelas
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Cambien
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Corvol
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Soubrier
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
        </article-title>
        <source>
         J Clin Invest
        </source>
        <volume>
         86
        </volume>
        <year>
         1990
        </year>
        <fpage>
         1343
        </fpage>
        <lpage>
         1346
        </lpage>
        <pub-id pub-id-type="pmid">
         1976655
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0090">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abraham
          </surname>
          <given-names>
           W.T.
          </given-names>
         </name>
         <name>
          <surname>
           Raynolds
          </surname>
          <given-names>
           M.V.
          </given-names>
         </name>
         <name>
          <surname>
           Badesch
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
         <name>
          <surname>
           Wynne
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Groves
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Roden
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Lowes
          </surname>
          <given-names>
           B.D.
          </given-names>
         </name>
         <name>
          <surname>
           Zisman
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Voelkel
          </surname>
          <given-names>
           N.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics
        </article-title>
        <source>
         J Renin Angiotensin Aldosterone Syst
        </source>
        <volume>
         4
        </volume>
        <year>
         2003
        </year>
        <fpage>
         27
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         12692750
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0095">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Orte
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Polak
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Haworth
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Yacoub
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Morrell
          </surname>
          <given-names>
           N.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension
        </article-title>
        <source>
         J Pathol
        </source>
        <volume>
         192
        </volume>
        <year>
         2000
        </year>
        <fpage>
         379
        </fpage>
        <lpage>
         384
        </lpage>
        <pub-id pub-id-type="pmid">
         11054722
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0100">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lipworth
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dagg
          </surname>
          <given-names>
           K.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed
        </article-title>
        <source>
         Chest
        </source>
        <volume>
         105
        </volume>
        <year>
         1994
        </year>
        <fpage>
         1360
        </fpage>
        <lpage>
         1364
        </lpage>
        <pub-id pub-id-type="pmid">
         8181320
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0105">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morrell
          </surname>
          <given-names>
           N.W.
          </given-names>
         </name>
         <name>
          <surname>
           Upton
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Kotecha
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huntley
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yacoub
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Polak
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wharton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II activates MAPK and stimulates growth of human pulmonary artery smooth muscle via AT1 receptors
        </article-title>
        <source>
         Am J Physiol
        </source>
        <volume>
         277
        </volume>
        <year>
         1999
        </year>
        <fpage>
         L440
        </fpage>
        <lpage>
         L448
        </lpage>
        <pub-id pub-id-type="pmid">
         10484450
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0110">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vapaatalo
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Mervaala
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II and vascular inflammation
        </article-title>
        <source>
         Med Sci Monit
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         RA194
        </fpage>
        <lpage>
         RA205
        </lpage>
        <pub-id pub-id-type="pmid">
         15917731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0115">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schiffrin
          </surname>
          <given-names>
           E.L.
          </given-names>
         </name>
         <name>
          <surname>
           Touyz
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inflammation and vascular hypertrophy induced by angiotensin II: role of NADPH oxidase-derived reactive oxygen species independently of blood pressure elevation?
        </article-title>
        <source>
         Arterioscler Thromb Vasc Biol
        </source>
        <volume>
         23
        </volume>
        <year>
         2003
        </year>
        <fpage>
         707
        </fpage>
        <lpage>
         709
        </lpage>
        <pub-id pub-id-type="pmid">
         12740221
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0120">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zagariya
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ibarra-Sunga
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Gidea
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ang
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Deshmukh
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chaudhary
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Baraboutis
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Filippatos
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Uhal
          </surname>
          <given-names>
           B.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II induces apoptosis in human and rat alveolar epithelial cells
        </article-title>
        <source>
         Am J Physiol
        </source>
        <volume>
         276
        </volume>
        <year>
         1999
        </year>
        <fpage>
         L885
        </fpage>
        <lpage>
         L889
        </lpage>
        <pub-id pub-id-type="pmid">
         10330045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0125">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cassis
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rippetoe
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Soltis
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Painter
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Fitz
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Gillespie
          </surname>
          <given-names>
           M.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist
        </article-title>
        <source>
         J Pharmacol Exp Ther
        </source>
        <volume>
         262
        </volume>
        <year>
         1992
        </year>
        <fpage>
         1168
        </fpage>
        <lpage>
         1172
        </lpage>
        <pub-id pub-id-type="pmid">
         1527721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0130">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           W.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ts’ao
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Molteni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism
        </article-title>
        <source>
         Proc Soc Exp Biol Med
        </source>
        <volume>
         205
        </volume>
        <year>
         1994
        </year>
        <fpage>
         80
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         8115354
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0135">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kreutz
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Alfonso
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ganten
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Paul
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of losartan on right ventricular hypertrophy and cardiac angiotensin I-converting enzyme activity in pulmonary hypertensive rats
        </article-title>
        <source>
         Clin Exp Hypertens
        </source>
        <volume>
         18
        </volume>
        <year>
         1996
        </year>
        <fpage>
         101
        </fpage>
        <lpage>
         111
        </lpage>
        <pub-id pub-id-type="pmid">
         8822237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0140">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Molteni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Moulder
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           W.F.
          </given-names>
         </name>
         <name>
          <surname>
           Fish
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wolfe
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Brizio-Molteni
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Veno
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker
        </article-title>
        <source>
         Int J Radiat Biol
        </source>
        <volume>
         76
        </volume>
        <year>
         2000
        </year>
        <fpage>
         523
        </fpage>
        <lpage>
         532
        </lpage>
        <pub-id pub-id-type="pmid">
         10815633
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0145">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nadrous
          </surname>
          <given-names>
           H.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ryu
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Douglas
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Decker
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Olson
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis
        </article-title>
        <source>
         Chest
        </source>
        <volume>
         126
        </volume>
        <year>
         2004
        </year>
        <fpage>
         438
        </fpage>
        <lpage>
         446
        </lpage>
        <pub-id pub-id-type="pmid">
         15302729
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0150">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Otsuka
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Shiratori
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chiba
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Abe
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist
        </article-title>
        <source>
         Thorax
        </source>
        <volume>
         59
        </volume>
        <year>
         2004
        </year>
        <fpage>
         31
        </fpage>
        <lpage>
         38
        </lpage>
        <pub-id pub-id-type="pmid">
         14694243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0155">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Molteni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wolfe
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           W.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ts’ao
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Molteni
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Veno
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Fish
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Quintanilla
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Herndon
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Moulder
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis
        </article-title>
        <source>
         Curr Pharm Des
        </source>
        <volume>
         13
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1307
        </fpage>
        <lpage>
         1316
        </lpage>
        <pub-id pub-id-type="pmid">
         17506716
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0160">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Simoes
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent advances in the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axis
        </article-title>
        <source>
         Exp Physiol
        </source>
        <volume>
         93
        </volume>
        <year>
         2008
        </year>
        <fpage>
         519
        </fpage>
        <lpage>
         527
        </lpage>
        <pub-id pub-id-type="pmid">
         18310257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0165">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gembardt
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Sterner-Kock
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Imboden
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Spalteholz
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Reibitz
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Schultheiss
          </surname>
          <given-names>
           H.P.
          </given-names>
         </name>
         <name>
          <surname>
           Siems
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Walther
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents
        </article-title>
        <source>
         Peptides
        </source>
        <volume>
         26
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1270
        </fpage>
        <lpage>
         1277
        </lpage>
        <pub-id pub-id-type="pmid">
         15949646
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0170">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soler
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Barrios
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Oliva
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Batlle
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pharmacologic modulation of ACE2 expression
        </article-title>
        <source>
         Curr Hypertens Rep
        </source>
        <volume>
         10
        </volume>
        <year>
         2008
        </year>
        <fpage>
         410
        </fpage>
        <lpage>
         414
        </lpage>
        <pub-id pub-id-type="pmid">
         18775121
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0175">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamming
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Timens
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bulthuis
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lely
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Navis
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           van Goor
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
        </article-title>
        <source>
         J Pathol
        </source>
        <volume>
         203
        </volume>
        <year>
         2004
        </year>
        <fpage>
         631
        </fpage>
        <lpage>
         637
        </lpage>
        <pub-id pub-id-type="pmid">
         15141377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0180">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Epelman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Van Lente
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Francis
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Sen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin–angiotensin–aldosterone system
        </article-title>
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         52
        </volume>
        <year>
         2008
        </year>
        <fpage>
         750
        </fpage>
        <lpage>
         754
        </lpage>
        <pub-id pub-id-type="pmid">
         18718423
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0185">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Molina-Molina
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Abdul-Hafez
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Uhal
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Xaubet
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Uhal
          </surname>
          <given-names>
           B.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis
        </article-title>
        <source>
         Am J Physiol Lung Cell Mol Physiol
        </source>
        <volume>
         295
        </volume>
        <year>
         2008
        </year>
        <fpage>
         L178
        </fpage>
        <lpage>
         L185
        </lpage>
        <pub-id pub-id-type="pmid">
         18441099
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0190">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamazato
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Sriramula
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Francis
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yamazato
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bradford
          </surname>
          <given-names>
           C.N.
          </given-names>
         </name>
         <name>
          <surname>
           Shenoy
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         54
        </volume>
        <year>
         2009
        </year>
        <fpage>
         365
        </fpage>
        <lpage>
         371
        </lpage>
        <pub-id pub-id-type="pmid">
         19564552
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0195">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shenoy
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fraga-Silva
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Diez-Freire
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Dooies
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jun
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sriramula
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Mariappan
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Pourang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The angiotensin-converting enzyme 2/angiogenesis-(1–7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         182
        </volume>
        <year>
         2010
        </year>
        <fpage>
         1065
        </fpage>
        <lpage>
         1072
        </lpage>
        <pub-id pub-id-type="pmid">
         20581171
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0200">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice
        </article-title>
        <source>
         Exp Physiol
        </source>
        <volume>
         93
        </volume>
        <year>
         2008
        </year>
        <fpage>
         543
        </fpage>
        <lpage>
         548
        </lpage>
        <pub-id pub-id-type="pmid">
         18448662
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0205">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 in acute respiratory distress syndrome
        </article-title>
        <source>
         Cell Mol Life Sci
        </source>
        <volume>
         64
        </volume>
        <year>
         2007
        </year>
        <fpage>
         2006
        </fpage>
        <lpage>
         2012
        </lpage>
        <pub-id pub-id-type="pmid">
         17558469
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0210">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wada
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Leong-Poi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 protects from severe acute lung failure
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         436
        </volume>
        <year>
         2005
        </year>
        <fpage>
         112
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="pmid">
         16001071
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0215">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0220">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Haga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ishizaka
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Mimori
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases
        </article-title>
        <source>
         Arthritis Res Ther
        </source>
        <volume>
         12
        </volume>
        <year>
         2010
        </year>
        <fpage>
         R85
        </fpage>
        <pub-id pub-id-type="pmid">
         20470389
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0225">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bronicki
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Baden
          </surname>
          <given-names>
           H.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathophysiology of right ventricular failure in pulmonary hypertension
        </article-title>
        <source>
         Pediatr Crit Care Med
        </source>
        <volume>
         11
        </volume>
        <issue>
         2 Suppl.
        </issue>
        <year>
         2010
        </year>
        <fpage>
         S15
        </fpage>
        <lpage>
         S22
        </lpage>
        <pub-id pub-id-type="pmid">
         20216156
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0230">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bogaard
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Abe
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Vonk Noordegraaf
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Voelkel NF
          </surname>
         </name>
        </person-group>
        <article-title>
         The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension
        </article-title>
        <source>
         Chest
        </source>
        <volume>
         135
        </volume>
        <year>
         2009
        </year>
        <fpage>
         794
        </fpage>
        <lpage>
         804
        </lpage>
        <pub-id pub-id-type="pmid">
         19265089
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0235">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zisman
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Asano
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Dutcher
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ferdensi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Jenkin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bush
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
         <name>
          <surname>
           Bohlmeyer
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Perryman
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
         <name>
          <surname>
           Bristow
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         98
        </volume>
        <year>
         1998
        </year>
        <fpage>
         1735
        </fpage>
        <lpage>
         1741
        </lpage>
        <pub-id pub-id-type="pmid">
         9788827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0240">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huentelman
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Grobe
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Vazquez
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Stewart
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Mecca
          </surname>
          <given-names>
           A.P.
          </given-names>
         </name>
         <name>
          <surname>
           Katovich
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raizada
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats
        </article-title>
        <source>
         Exp Physiol
        </source>
        <volume>
         90
        </volume>
        <year>
         2005
        </year>
        <fpage>
         783
        </fpage>
        <lpage>
         790
        </lpage>
        <pub-id pub-id-type="pmid">
         16049057
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0245">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Der Sarkissian
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Grobe
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Narielwala
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Walter
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
         <name>
          <surname>
           Katovich
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Raizada
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         51
        </volume>
        <year>
         2008
        </year>
        <fpage>
         712
        </fpage>
        <lpage>
         718
        </lpage>
        <pub-id pub-id-type="pmid">
         18250366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0250">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grobe
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Mecca
          </surname>
          <given-names>
           A.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lingis
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shenoy
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Bolton
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Machado
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Speth
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Raizada
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Katovich
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7)
        </article-title>
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         292
        </volume>
        <year>
         2007
        </year>
        <fpage>
         H736
        </fpage>
        <lpage>
         H742
        </lpage>
        <pub-id pub-id-type="pmid">
         17098828
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0255">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ohishi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Katsuya
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ito
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ikushima
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kaibe
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tatara
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shiota
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sugano
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Takeda
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         47
        </volume>
        <year>
         2006
        </year>
        <fpage>
         718
        </fpage>
        <lpage>
         726
        </lpage>
        <pub-id pub-id-type="pmid">
         16505206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0260">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kassiri
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Basu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           P.P.
          </given-names>
         </name>
         <name>
          <surname>
           Scholey
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction
        </article-title>
        <source>
         Circ Heart Fail
        </source>
        <volume>
         2
        </volume>
        <year>
         2009
        </year>
        <fpage>
         446
        </fpage>
        <lpage>
         455
        </lpage>
        <pub-id pub-id-type="pmid">
         19808375
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0265">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohbayashi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Matrix metalloproteinases in lung diseases
        </article-title>
        <source>
         Curr Protein Pept Sci
        </source>
        <volume>
         3
        </volume>
        <year>
         2002
        </year>
        <fpage>
         409
        </fpage>
        <lpage>
         421
        </lpage>
        <pub-id pub-id-type="pmid">
         12370004
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0270">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grobe
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Der Sarkissian
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Stewart
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Meszaros
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Raizada
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Katovich
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts
        </article-title>
        <source>
         Clin Sci (Lond)
        </source>
        <volume>
         113
        </volume>
        <year>
         2007
        </year>
        <fpage>
         357
        </fpage>
        <lpage>
         364
        </lpage>
        <pub-id pub-id-type="pmid">
         17600530
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0275">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tuder
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Marecki
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Richter
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fijalkowska
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Flores
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathology of pulmonary hypertension
        </article-title>
        <source>
         Clin Chest Med
        </source>
        <volume>
         28
        </volume>
        <year>
         2007
        </year>
        <fpage>
         23
        </fpage>
        <lpage>
         42
        </lpage>
        <comment>
         vii
        </comment>
        <pub-id pub-id-type="pmid">
         17338926
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0280">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells
        </article-title>
        <source>
         Am J Physiol Lung Cell Mol Physiol
        </source>
        <volume>
         297
        </volume>
        <year>
         2009
        </year>
        <fpage>
         L631
        </fpage>
        <lpage>
         L640
        </lpage>
        <pub-id pub-id-type="pmid">
         19592460
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0285">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Budhiraja
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Tuder
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hassoun
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Endothelial dysfunction in pulmonary hypertension
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         109
        </volume>
        <year>
         2004
        </year>
        <fpage>
         159
        </fpage>
        <lpage>
         165
        </lpage>
        <pub-id pub-id-type="pmid">
         14734504
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0290">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rentzsch
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Todiras
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Iliescu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Popova
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Campos
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Oliveira
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Baltatu
          </surname>
          <given-names>
           O.C.
          </given-names>
         </name>
         <name>
          <surname>
           Santos
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bader
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         52
        </volume>
        <year>
         2008
        </year>
        <fpage>
         967
        </fpage>
        <lpage>
         973
        </lpage>
        <pub-id pub-id-type="pmid">
         18809792
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0295">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lovren
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Quan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Teoh
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Shukla
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Levitt
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Omran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stewart
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis
        </article-title>
        <source>
         Am J Physiol Heart Circ Physiol
        </source>
        <volume>
         295
        </volume>
        <year>
         2008
        </year>
        <fpage>
         H1377
        </fpage>
        <lpage>
         H1384
        </lpage>
        <pub-id pub-id-type="pmid">
         18660448
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0300">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gwathmey
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pendergrass
          </surname>
          <given-names>
           K.D.
          </given-names>
         </name>
         <name>
          <surname>
           Reid
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Diz
          </surname>
          <given-names>
           D.I.
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-(1–7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus
        </article-title>
        <source>
         Hypertension
        </source>
        <volume>
         55
        </volume>
        <year>
         2010
        </year>
        <fpage>
         166
        </fpage>
        <lpage>
         171
        </lpage>
        <pub-id pub-id-type="pmid">
         19948986
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack>
      <title>
       Acknowledgement
      </title>
      <p>
       This work was supported by
       <funding-source id="gs0005">
        N.I.H
       </funding-source>
       Grants HL 99980 and HL102033.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <?properties manuscript?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">
       7906255
      </journal-id>
      <journal-id journal-id-type="pubmed-jr-id">
       4217
      </journal-id>
      <journal-id journal-id-type="nlm-ta">
       Hypertension
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Hypertension
      </journal-id>
      <journal-title-group>
       <journal-title>
        Hypertension (Dallas, Tex. : 1979)
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0194-911X
      </issn>
      <issn pub-type="epub">
       1524-4563
      </issn>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25225202
      </article-id>
      <article-id pub-id-type="pmc">
       4231883
      </article-id>
      <article-id pub-id-type="doi">
       10.1161/HYPERTENSIONAHA.114.03743
      </article-id>
      <article-id pub-id-type="manuscript">
       NIHMS623642
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Angiotensin-II mediates ACE2 Internalization and Degradation through an Angiotensin-II type I receptor-dependent mechanism
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" equal-contrib="yes">
        <name>
         <surname>
          Deshotels
         </surname>
         <given-names>
          Matthew R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="yes">
        <name>
         <surname>
          Xia
         </surname>
         <given-names>
          Huijing
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sriramula
         </surname>
         <given-names>
          Srinivas
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lazartigues
         </surname>
         <given-names>
          Eric
         </given-names>
        </name>
        <xref ref-type="corresp" rid="CR1">
         *
        </xref>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Filipeanu
         </surname>
         <given-names>
          Catalin M.
         </given-names>
        </name>
        <xref ref-type="corresp" rid="CR1">
         *
        </xref>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
       </contrib>
      </contrib-group>
      <aff id="A1">
       <label>
        1
       </label>
       Department of Pharmacology &amp; Experimental Therapeutics and Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA, USA
      </aff>
      <aff id="A2">
       <label>
        2
       </label>
       Department of Pharmacology, College of Medicine, Howard University Washington, DC, USA
      </aff>
      <author-notes>
       <corresp id="CR1">
        <label>
         *
        </label>
        Co-corresponding authors: Dr. Eric Lazartigues: Phone: (504) 568-3210, Fax: (504) 568-2361,
        <email>
         elazar@lsuhsc.edu
        </email>
        and Dr. Catalin Filipeanu: Phone: (202) 806-6318, Fax: (202) 806-4453,
        <email>
         catalin.filipeanu@howard.edu
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
       <day>
        28
       </day>
       <month>
        8
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        15
       </day>
       <month>
        9
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        12
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        01
       </day>
       <month>
        12
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       64
      </volume>
      <issue>
       6
      </issue>
      <fpage>
       1368
      </fpage>
      <lpage>
       1375
      </lpage>
      <!--elocation-id from pubmed: 10.1161/HYPERTENSIONAHA.114.03743-->
      <abstract>
       <p id="P1">
        Angiotensin Converting Enzyme type 2 (ACE2) is a pivotal component of the renin-angiotensin system, promoting the conversion of Angiotensin (Ang)-II to Ang-(1-7). We previously reported that decreased ACE2 expression and activity contribute to the development of Ang-II-mediated hypertension in mice. The present study aimed to investigate the mechanisms involved in ACE2 down-regulation during neurogenic hypertension. In ACE2-transfected Neuro-2A cells, Ang-II treatment resulted in a significant attenuation of ACE2 enzymatic activity. Examination of the subcellular localization of ACE2 revealed that Ang-II treatment leads to ACE2 internalization and degradation into lysosomes. These effects were prevented by both the Ang-II type 1 receptor (AT
        <sub>
         1
        </sub>
        R) blocker losartan and the lysosomal inhibitor leupeptin. In contrast, in HEK293T cells, which lack endogenous AT
        <sub>
         1
        </sub>
        R, Ang-II failed to promote ACE2 internalization. Moreover, this effect could be induced after AT
        <sub>
         1
        </sub>
        R transfection. Further, co-immunoprecipitation experiments demonstrated that AT
        <sub>
         1
        </sub>
        R and ACE2 form complexes and these interactions were decreased by Ang-II treatment, which also enhanced ACE2 ubiquitination. In contrast, ACE2 activity was not changed by transfection of AT
        <sub>
         2
        </sub>
        or Mas receptors.
        <italic>
         In vivo
        </italic>
        , Ang-II-mediated hypertension was blunted by chronic infusion of leupeptin in wildtype C57Bl/6, but not in ACE2 knockout mice. Overall, this is the first demonstration that elevated Ang-II levels reduce ACE2 expression and activity by stimulation of lysosomal degradation through an AT
        <sub>
         1
        </sub>
        R-dependent mechanism.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        Post-transcriptional regulation
       </kwd>
       <kwd>
        proteasome
       </kwd>
       <kwd>
        autonomic nervous system
       </kwd>
       <kwd>
        renin-angiotensin system
       </kwd>
       <kwd>
        hypertension
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Antiviral Res
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Antiviral Res
      </journal-id>
      <journal-title-group>
       <journal-title>
        Antiviral Research
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0166-3542
      </issn>
      <issn pub-type="epub">
       1872-9096
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       16730806
      </article-id>
      <article-id pub-id-type="pmc">
       7114332
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0166-3542(06)00121-5
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.antiviral.2006.04.014
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ho
         </surname>
         <given-names>
          Tin-Yun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Shih-Lu
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Jaw-Chyun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Chia-Cheng
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hsiang
         </surname>
         <given-names>
          Chien-Yun
         </given-names>
        </name>
        <email>
         cyhsiang@mail.cmu.edu.tw
        </email>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Department of Biochemistry, China Medical University, Taichung, Taiwan
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Graduate Institute of Chinese Pharmaceutical, China Medical University, Taichung, Taiwan
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       Department of Microbiology, China Medical University, 91 Hsueh-Shih Road, Taichung 404, Taiwan
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ⁎
        </label>
        Corresponding author. Tel.: +886 4 22053366x8503; fax: +886 4 22053764.
        <email>
         cyhsiang@mail.cmu.edu.tw
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        15
       </day>
       <month>
        5
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        5
       </month>
       <year>
        2007
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        15
       </day>
       <month>
        5
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <volume>
       74
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       92
      </fpage>
      <lpage>
       101
      </lpage>
      <history>
       <date date-type="received">
        <day>
         9
        </day>
        <month>
         1
        </month>
        <year>
         2006
        </year>
       </date>
       <date date-type="accepted">
        <day>
         11
        </day>
        <month>
         4
        </month>
        <year>
         2006
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2006 Elsevier B.V. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2006
       </copyright-year>
       <copyright-holder>
        Elsevier B.V.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel coronavirus (SARS-CoV). SARS-CoV spike (S) protein, a type I membrane-bound protein, is essential for the viral attachment to the host cell receptor angiotensin-converting enzyme 2 (ACE2). By screening 312 controlled Chinese medicinal herbs supervised by Committee on Chinese Medicine and Pharmacy at Taiwan, we identified that three widely used Chinese medicinal herbs of the family
        <italic>
         Polygonaceae
        </italic>
        inhibited the interaction of SARS-CoV S protein and ACE2. The IC
        <sub>
         50
        </sub>
        values for Radix et Rhizoma Rhei (the root tubers of
        <italic>
         Rheum officinale
        </italic>
        Baill.), Radix Polygoni multiflori (the root tubers of
        <italic>
         Polygonum multiflorum
        </italic>
        Thunb.), and Caulis Polygoni multiflori (the vines of
        <italic>
         P. multiflorum
        </italic>
        Thunb.) ranged from 1 to 10 μg/ml. Emodin, an anthraquinone compound derived from genus
        <italic>
         Rheum
        </italic>
        and
        <italic>
         Polygonum
        </italic>
        , significantly blocked the S protein and ACE2 interaction in a dose-dependent manner. It also inhibited the infectivity of S protein-pseudotyped retrovirus to Vero E6 cells. These findings suggested that emodin may be considered as a potential lead therapeutic agent in the treatment of SARS.
       </p>
      </abstract>
      <kwd-group>
       <title>
        Abbreviations
       </title>
       <kwd>
        SARS, severe acute respiratory syndrome
       </kwd>
       <kwd>
        SARS-CoV, SARS coronavirus
       </kwd>
       <kwd>
        S, spike
       </kwd>
       <kwd>
        ACE2, angiotensin-converting enzyme 2
       </kwd>
       <kwd>
        HIV, human immunodeficiency virus
       </kwd>
       <kwd>
        ELISA, enzyme-linked immunosorbent assay
       </kwd>
       <kwd>
        <italic>
         E. coli
        </italic>
        ,
        <italic>
         Escherichia coli
        </italic>
       </kwd>
       <kwd>
        SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis
       </kwd>
       <kwd>
        PBS, phosphate-buffered saline
       </kwd>
       <kwd>
        BSA, bovine serum albumin
       </kwd>
       <kwd>
        IFA, immunofluorescence assay
       </kwd>
       <kwd>
        MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
       </kwd>
       <kwd>
        HSV, herpes simplex virus
       </kwd>
      </kwd-group>
      <kwd-group>
       <title>
        Keywords
       </title>
       <kwd>
        SARS coronavirus
       </kwd>
       <kwd>
        Spike protein
       </kwd>
       <kwd>
        Angiotensin-converting enzyme 2
       </kwd>
       <kwd>
        Emodin
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec>
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p>
      Severe acute respiratory syndrome (SARS) is a new human disease that results in progressive respiratory failure and death in close to 10% of infected individuals (
      <xref ref-type="bibr" rid="bib28">
       Ksiazek et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib35">
       Peiris et al., 2003
      </xref>
      ). The etiological agent, SARS coronavirus (SARS-CoV) (
      <xref ref-type="bibr" rid="bib14">
       Drosten et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib15">
       Fouchier et al., 2003
      </xref>
      ) contains a single-stranded plus-sense RNA genome about 30 kb in length that has a 5′-cap structure and a 3′-polyadenylation tract (
      <xref ref-type="bibr" rid="bib32">
       Marra et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib37">
       Rota et al., 2003
      </xref>
      ). The genomic organization is typical of coronaviruses, having 14 potential major open reading frames that encode replicase, spike (S), envelope, membrane, and nucleocapsid proteins in the same order as those of other coronaviruses (
      <xref ref-type="bibr" rid="bib44">
       Tan et al., 2005
      </xref>
      ).
     </p>
     <p>
      SARS-CoV S protein is a large type I membrane glycoprotein projection from viral envelope (
      <xref ref-type="bibr" rid="bib6">
       Bosch et al., 2003
      </xref>
      ). SARS-CoV S protein is responsible for binding to cellular receptors and for mediating the fusion of viral and host membranes (
      <xref ref-type="bibr" rid="bib39">
       Simmons et al., 2004
      </xref>
      ,
      <xref ref-type="bibr" rid="bib45">
       Tripet et al., 2004
      </xref>
      ). It also contains important virus-neutralizing epitopes that elicit neutralizing antibody in the host species (
      <xref ref-type="bibr" rid="bib20">
       Hofmann et al., 2004a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib40">
       Sui et al., 2004
      </xref>
      ). Furthermore, mutations in this gene dramatically affect the virulence, pathogenesis, and host cell tropism (
      <xref ref-type="bibr" rid="bib36">
       Petit et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib50">
       Yi et al., 2005
      </xref>
      ). Angiotensin-converting enzyme 2 (ACE2) has been identified as a functional receptor for SARS-CoV (
      <xref ref-type="bibr" rid="bib30">
       Li et al., 2003
      </xref>
      ). Soluble S fragment or ACE2 is able to block S protein-mediated infection (
      <xref ref-type="bibr" rid="bib21">
       Hofmann et al., 2004b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib33">
       Moore et al., 2004
      </xref>
      ). Monoclonal antibodies against S protein efficiently neutralize SARS-CoV
      <italic>
       in vitro
      </italic>
      and
      <italic>
       in vivo
      </italic>
      (
      <xref ref-type="bibr" rid="bib16">
       Greenough et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib40">
       Sui et al., 2004
      </xref>
      ). Moreover, vaccines that express the S protein induce T cell and neutralizing antibody responses, and protect animals from SARS-CoV infection (
      <xref ref-type="bibr" rid="bib10">
       Chen et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib49">
       Yang et al., 2004
      </xref>
      ). These findings clearly suggest that blocking the binding of the S protein with its cellular receptor can prevent virus entry.
     </p>
     <p>
      Recent reports indicate that human immunodeficiency virus protease inhibitors (lopinavir and ritonavir), an anti-psychotic drug (promazine), and an anti-parasitic drug (niclosamide) are effective inhibitors of SARS-CoV infection by inhibiting the SARS-CoV main proteinase (
      <xref ref-type="bibr" rid="bib7">
       Chan et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib46">
       Wu et al., 2004a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib53">
       Zhang and Yap, 2004
      </xref>
      ). Natural products, such as glycyrrhizin, baicalin, reserpine, luteolin, ginsenoside-Rb1 and aescin, also abolished SARS-CoV production
      <italic>
       in vitro
      </italic>
      ; however, the antiviral mechanisms of these compounds remained unclear (
      <xref ref-type="bibr" rid="bib8">
       Chen et al., 2004
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       Cinatl et al., 2003a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib47">
       Wu et al., 2004b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib51">
       Yi et al., 2004
      </xref>
      ). One of the logical targets of the viral life cycle to inhibit SARS-CoV replication is the step following entry of the infectious virion into the host cell. To discover inhibitors at this stage, we established a biotinylated enzyme-linked immunosorbent assay (ELISA) to evaluate the inhibitory effects of Chinese medicinal herbs on the S protein and ACE2 interaction. Herein we reported the finding that emodin, the likely active component from
      <italic>
       Rheum officinale
      </italic>
      and
      <italic>
       Polygonum multiflorum
      </italic>
      , blocked both the binding of S protein to ACE2 and the infectivity of S protein-pseudotyped retrovirus to Vero E6 cells.
     </p>
    </sec>
    <sec id="sec1">
     <label>
      2
     </label>
     <title>
      Materials and methods
     </title>
     <sec>
      <label>
       2.1
      </label>
      <title>
       Chemicals
      </title>
      <p>
       Emodin, rhein, and promazine hydrochloride were purchased from Sigma (St. Louis, MO, USA). Chrysin, anthraquinone, and 1,4-bis-(1-anthraquinonylamino)-anthraquinone were purchased from Aldrich (Germany). Emodin (MW = 270.24), rhein (MW = 284.22), chrysin (MW = 254.24), and 1,4-bis-(1-anthraquinonylamino)-anthraquinone (MW = 665.67) were dissolved in dimethyl sulfoxide at 37, 35, 33, and 50 mM, respectively. Anthraquinone (MW = 208.22) was dissolved in ethanol at 5 mM. Promazine hydrochloride (MW = 320.88) was dissolved in water at 1 M. All chemicals were protected from light and stored at −30 °C in small aliquots.
      </p>
     </sec>
     <sec>
      <label>
       2.2
      </label>
      <title>
       Purification and biotinylation of recombinant SARS-CoV S protein
      </title>
      <p>
       The SARS-CoV S gene was cloned into pET-28b(+) (Novagen, Madison, WI, USA) to an N-terminal fusion with six histidine residues. Recombinant S protein was expressed in
       <italic>
        Escherichia coli
       </italic>
       (
       <italic>
        E. coli
       </italic>
       ) BL21(DE3)pLysS strain. The expression and purification of recombinant SARS-CoV S protein were performed as described previously (
       <xref ref-type="bibr" rid="bib19">
        Ho et al., 2004
       </xref>
       ). Protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and quantified with a Bradford method (Bio-Rad, Hercules, CA, USA). Recombinant S protein was biotinylated as described previously (
       <xref ref-type="bibr" rid="bib18">
        Ho et al., 2006
       </xref>
       ). The unincorporated biotin was removed by centricon-10 filtration (Millipore, Bedford, MA, USA), and the biotinylated S protein was stored at 4 °C until further analysis.
      </p>
     </sec>
     <sec>
      <label>
       2.3
      </label>
      <title>
       Preparation of herb extracts
      </title>
      <p>
       Chinese medicinal herbs were gifts from Chuang Song Zong Pharmaceutical Co., Ltd (Kaohsiung, Taiwan). Plant sample was ground with the homogenizer to a fine powder. The aqueous extract was prepared by mixing 100 g of each herb powder with 500 ml of deionized water and shaking at 4 °C overnight. The extract was centrifuged at 10,000 ×
       <italic>
        g
       </italic>
       for 5 min, and the supernatant was evaporated under vacuum to dryness and resuspended in deionized water to a final concentration of 1 mg/ml. The extracts were stored at −20 °C in small aliquots.
      </p>
     </sec>
     <sec>
      <label>
       2.4
      </label>
      <title>
       Biotinylated ELISA
      </title>
      <p>
       The biotinylated ELISA was performed as described previously (
       <xref ref-type="bibr" rid="bib18">
        Ho et al., 2006
       </xref>
       ). Briefly, microtiter plates (MaxiSorp Nunc-Immum™ plates, Nunc, Denmark) were coated at 4 °C overnight with 50 μl of 0.2 ng/μl ACE2 (R&amp;D Systems, Minneapolis, MN, USA), rinsed with 200 μl washing buffer (0.5% Tween 20 in phosphate-buffered saline (PBS) (137 mM NaCl, 1.4 mM KH
       <sub>
        2
       </sub>
       PO
       <sub>
        4
       </sub>
       , 4.3 mM Na
       <sub>
        2
       </sub>
       HPO
       <sub>
        4
       </sub>
       , 2.7 mM KCl, pH 7.2)), and blocked with 200 μl blocking buffer (5% bovine serum albumin (BSA) in washing buffer) by incubating at 37 °C for 30 min. The absorbed protein in each well was challenged with 50 μl of 1 ng/μl biotinylated S protein and incubated at 37 °C for 1 h. After three washes with washing buffer, 50 μl diluted peroxidase-conjugated avidin was added to each well and incubated at 37 °C for 1 h. Following three washes, 50 μl chromogenic substrate, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (Sigma, St. Louis, MO, USA), was added to each well and incubated at 37 °C for 15 min. The absorbance was read at 405 nm in an ELISA plate reader (Anthos Labtec Instruments, Austria).
      </p>
      <p>
       For the competition assay, biotinylated S protein was mixed with various amounts of extracts and incubated at 37 °C with shaking. After a 2-h incubation, the mixture was added to wells, which were coated with ACE2, and incubated at 37 °C for 1 h. Following three washes, peroxidase-conjugated avidin and chromatic substrate were sequentially added. The absorbance was read at 405 nm in an ELISA plate reader. The percent inhibition was calculated by [1 − (OD value of mixture containing extract and S protein/OD value of mixture containing S protein only)] × 100. The IC
       <sub>
        50
       </sub>
       value was determined as the quantity of compound required to inhibit the interaction between S protein and ACE2 at 50%.
      </p>
     </sec>
     <sec>
      <label>
       2.5
      </label>
      <title>
       Immunofluorescence assay (IFA)
      </title>
      <p>
       Vero E6 cells (10
       <sup>
        4
       </sup>
       cells) were seeded in 24-well plates containing glass coverslips and incubated at 37 °C for 1 day. The coverslips were then rinsed with PBS, fixed with 3.7% PBS-buffered formaldehyde at room temperature for 30 min, and blocked with 1% BSA at 37 °C for 1 h. After four washes with PBS, biotin-labeled S protein was added to each coverslip and incubated at 4 °C overnight. Following four washes with PBS, diluted fluorescence-conjugated streptavidin (Chemicon, Temecula, CA, USA) was added and incubated at 37 °C for 90 min in the dark. The coverslips were then washed four times with PBS, placed onto glass slides, mounted with fluoromount G (Electron Microscopy Sciences, Hatfield, PA, USA), and observed under a confocal microscope (Leica, Germany).
      </p>
     </sec>
     <sec>
      <label>
       2.6
      </label>
      <title>
       Infection with S protein-pseudotyped retrovirus
      </title>
      <p>
       Recombinant retroviruses expressing a luciferase reporter gene and pseudotyped with S proteins were produced as described previously (
       <xref ref-type="bibr" rid="bib41">
        Sui et al., 2005
       </xref>
       ). Briefly, 293T cells were cotransfected with a plasmid pcDNA-spike encoding S protein, a plasmid pCMVΔR8.2 encoding HIV-1 Gag-Pol, and a plasmid pHIV-Luc encoding the firefly luciferase reporter gene under control of the HIV-1 long terminal repeat. Forty-eight hours later, viral supernatants were harvested, mixed with various amounts of compound, and incubated at 37 °C with shaking. After a 2-h incubation, the mixture was added to ACE2-expression Vero E6 cells in a 96-well plate. Forty-eight hours postinfection, cells were harvested and the luciferase activity was assayed as previously described (
       <xref ref-type="bibr" rid="bib23">
        Hsiang et al., 2005
       </xref>
       ). Relative infectivity is calculated as dividing the relative luciferase unit of compound/pseudovirus-infected cells by the relative luciferase unit of pseudovirus-infected cells.
      </p>
     </sec>
     <sec>
      <label>
       2.7
      </label>
      <title>
       3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
      </title>
      <p>
       Cell viability was monitored by MTT colorimetric assay. Briefly, cells were cultivated in 96-well culture plates. After a 24-h incubation at 37 °C, various amounts of compounds were added to confluent cell monolayers and incubated for another 24 h. One-tenth volume of 5 mg/ml MTT was then added to the culture medium. After a 4-h incubation at 37 °C, equal cell culture volume of 0.04 N HCl in isopropanol was added to dissolve the MTT formazan, and the absorbance value was measured at 570 nm using a microplate reader. Cell viability (%) was calculated by (OD of treated cells/OD of untreated cells) × 100.
      </p>
     </sec>
     <sec>
      <label>
       2.8
      </label>
      <title>
       Statistical analysis
      </title>
      <p>
       Data were presented as mean ± standard error. Student's
       <italic>
        t
       </italic>
       test was used for comparisons between two experiments. A value of
       <italic>
        p
       </italic>
       &lt; 0.05 was considered statistically significant.
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <sec>
      <label>
       3.1
      </label>
      <title>
       Recombinant S protein binds to ACE2 in a dose-dependent manner
      </title>
      <p>
       We established a biotinylated ELISA to evaluate the binding efficacy of S protein to ACE2. The 138-kDa recombinant S protein was expressed in soluble form in
       <italic>
        E. coli
       </italic>
       and purified to homogeneity (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       A). The recombinant S protein was biotinylated and its ability to interact with ACE2 coated on ELISA plates was evaluated. As shown in
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       B, the OD value increased as the amount of S protein increased, indicating that recombinant S protein bound to ACE2 in a dose-dependent manner.
       <fig id="fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Analysis of SARS-CoV S protein and ACE2 interaction. (A) SDS-PAGE analysis of recombinant SARS-CoV S protein. The preparations of uninduced
          <italic>
           E. coli
          </italic>
          (lane 2), induced
          <italic>
           E. coli
          </italic>
          (lane 3), and purified recombinant S protein (lane 4) were analyzed by 10% SDS-PAGE and stained by Coomassie brilliant blue. The molecular masses of protein standard (lane 1) are shown at the left. The location of the 138-kDa recombinant S protein is indicated by the arrow. (B) The binding ability of SARS-CoV S protein to ACE2 by biotinylated ELISA. The wells were coated with 1 ng of ACE2 and challenged with various amounts of biotin-labeled S protein. Following three washes, peroxidase-conjugated avidin and chromatic substrate were sequentially added. The absorbance was read at 405 nm in an ELISA plate reader. Values are mean ± standard error of three independent assays.
         </p>
        </caption>
        <graphic xlink:href="gr1">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.2
      </label>
      <title>
       Chinese medicinal herbs block the binding of S protein to ACE2
      </title>
      <p>
       To evaluate the inhibitory effects of Chinese medicinal herbs on the S protein and ACE2 interaction, we mixed 1 μg of aqueous herbal extracts with 0.05 μg biotin-labeled S protein, incubated the mixture at 37 °C for 2 h, and added to ACE2-coated wells. From a screen of 312 controlled Chinese medicinal herbs supervised by the Committee on Chinese Medicine and Pharmacy at Taiwan, we found that various herbal extracts inhibited the interaction (data not shown). We further divided these herbs into 32 families and compared their level of inhibition with the taxonomic characterization. As shown in
       <xref ref-type="fig" rid="fig2">
        Fig. 2
       </xref>
       , 25 out of 32 families significantly abolished the interaction between S protein and ACE2. Six families, including
       <italic>
        Nelumbonaceae
       </italic>
       ,
       <italic>
        Labiatae
       </italic>
       ,
       <italic>
        Magnoliaceae
       </italic>
       ,
       <italic>
        Oleaceae
       </italic>
       ,
       <italic>
        Lauraceae
       </italic>
       and
       <italic>
        Polygonaceae
       </italic>
       , blocked 60–90% of the binding of S protein to ACE2 at 1 μg. Among these families,
       <italic>
        Polygonaceae
       </italic>
       exhibited the highest inhibition on the S protein and ACE2 interaction, with the inhibitory percentage of 86.33 ± 4.55%.
       <fig id="fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Inhibitory effects of Chinese medicinal herbs on the interaction between SARS-CoV S protein and ACE2. Biotin-labeled S protein (0.05 μg) was mixed with 1 μg of aqueous extracts of herbs, and the mixtures were added to wells, which were coated with 1 ng of ACE2. The biotinylated ELISA was performed as described in Section
          <xref ref-type="sec" rid="sec1">
           2
          </xref>
          . Results are expressed as inhibition (%) described in Section
          <xref ref-type="sec" rid="sec1">
           2
          </xref>
          . Numbers in the brackets are the sum of herb species in the family. Values are mean ± standard error of three independent assays.
          <sup>
           *
          </sup>
          <italic>
           p
          </italic>
          &lt; 0.05,
          <sup>
           **
          </sup>
          <italic>
           p
          </italic>
          &lt; 0.01,
          <sup>
           ***
          </sup>
          <italic>
           p
          </italic>
          &lt; 0.001, compared with BSA.
         </p>
        </caption>
        <graphic xlink:href="gr2">
        </graphic>
       </fig>
      </p>
      <p>
       Three kinds of Chinese medicinal herbs belonging to
       <italic>
        Polygonaceae
       </italic>
       were further analyzed. Radix et Rhizoma Rhei (Da-Huang) is the root tuber of plant
       <italic>
        R. officinale
       </italic>
       Baill. Radix Polygoni multiflori (Ho-Shou-Wu) and Caulis Polygoni multiflori (Yeh-Chiao-Teng) are the root tuber and vine of plant
       <italic>
        P. multiflorum
       </italic>
       Thunb., respectively. Preincubation of these herbs with biotin-labeled S protein inhibited the binding of S protein to ACE2 in a dose-dependent manner (
       <xref ref-type="fig" rid="fig3">
        Fig. 3
       </xref>
       ). The IC
       <sub>
        50
       </sub>
       values for Radix et Rhizoma Rhei, Radix Polygoni multiflori, and Caulis Polygoni multiflori ranged from 1 to 10 μg/ml.
       <fig id="fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Inhibitory effects of Radix et Rhizoma Rhei, Radix Polygoni multiflori, and Caulis Polygoni multiflori on the SARS-CoV S protein and ACE2 interaction. Biotin-labeled S protein (0.05 μg) was mixed with various amounts of aqueous extracts from Radix et Rhizoma Rhei (A), Radix Polygoni multiflori (B) or Caulis Polygoni multiflori (C), and the mixtures were added to wells, which were coated with 1 ng of ACE2. The biotinylated ELISA was performed as described in Section
          <xref ref-type="sec" rid="sec1">
           2
          </xref>
          . Results are expressed as inhibition (%) described in Section
          <xref ref-type="sec" rid="sec1">
           2
          </xref>
          . Values are mean ± standard error of six independent assays.
         </p>
        </caption>
        <graphic xlink:href="gr3">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.3
      </label>
      <title>
       Emodin inhibits the interaction between S protein and ACE2
      </title>
      <p>
       As emodin (1,3,8-trihydroxy-6-methylanthraquinone), rhein (1,8-dihydroxy-3-carboxyl-9,10-anthraquinone), and chrysin (5,7-dihydroxyflavone) are produced in high levels in genus
       <italic>
        Rheum
       </italic>
       and
       <italic>
        Polygonum
       </italic>
       (
       <xref ref-type="bibr" rid="bib26">
        Koyama et al., 2003
       </xref>
       ,
       <xref ref-type="bibr" rid="bib34">
        Nonaka et al., 1977
       </xref>
       ), we investigated whether these compounds were responsible for blocking the binding of S protein to ACE2. Emodin and rhein belong to anthraquinone compounds, while chrysin belongs to a flavonoid compound (
       <xref ref-type="fig" rid="fig4">
        Fig. 4
       </xref>
       ). As shown in
       <xref ref-type="fig" rid="fig5">
        Fig. 5
       </xref>
       A, emodin blocked the binding of S protein to ACE2 in a dose-dependent manner. The IC
       <sub>
        50
       </sub>
       value of emodin is 200 μM. Preincubation of rhein with biotinylated S protein slightly inhibited the S protein and ACE2 interaction (
       <xref ref-type="fig" rid="fig5">
        Fig. 5
       </xref>
       B). Chrysin exhibited a weak inhibition on the S protein and ACE2 interaction at 400 μM; however, it significantly stimulated the binding of S protein to ACE2 at 50 μM (
       <xref ref-type="fig" rid="fig5">
        Fig. 5
       </xref>
       C). These results suggested that emodin was the likely active constituent of
       <italic>
        Rheum
       </italic>
       and
       <italic>
        Polygonum
       </italic>
       responsible for blocking the binding of S protein to ACE2.
       <fig id="fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          Chemical structures of compounds used in this study.
         </p>
        </caption>
        <graphic xlink:href="gr4">
        </graphic>
       </fig>
       <fig id="fig5">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Inhibitory effects of emodin, rhein, and chrysin on the interaction between SARS-CoV S protein and ACE2. Biotin-labeled S protein (0.05 μg) was mixed with various amounts of emodin (A), rhein (B) or chrysin (C), and the mixtures were added to wells, which were coated with 1 ng of ACE2. The biotinylated ELISA was performed as described in Section
          <xref ref-type="sec" rid="sec1">
           2
          </xref>
          . Results are expressed as inhibition (%) described in Section
          <xref ref-type="sec" rid="sec1">
           2
          </xref>
          . Values are mean ± standard error of six independent assays.
         </p>
        </caption>
        <graphic xlink:href="gr5">
        </graphic>
       </fig>
      </p>
      <p>
       Emodin is an anthraquinone compound consists of three cyclic rings. The anti-psychotic drug promazine, which has been shown to exhibit the significant effect in inhibiting the replication of SARS-CoV (
       <xref ref-type="bibr" rid="bib53">
        Zhang and Yap, 2004
       </xref>
       ), shared a similar structure with emodin (
       <xref ref-type="fig" rid="fig4">
        Fig. 4
       </xref>
       ). Therefore, we compared the inhibitory effects of emodin, promazine, and two other anthraquinone compounds on the S protein and ACE2 interaction. These compounds all showed inhibition on the binding of S protein to ACE2 (
       <xref ref-type="fig" rid="fig6">
        Fig. 6
       </xref>
       ); however, the inhibitory activities of anthraquinone and 1,4-bis-(1-anthraquinonylamino)-anthraquinone were not significant. As compared to emodin, promazine exhibited the highest inhibition; however, the differences between emodin and promazine were not significant. These findings suggested that emodin and promazine might be capable of inhibiting SARS-CoV infectivity by blocking the S protein and ACE2 interaction.
       <fig id="fig6">
        <label>
         Fig. 6
        </label>
        <caption>
         <p>
          Inhibitory effects of emodin and emodin-like compounds on the SARS-CoV S protein and ACE2 interaction. Biotin-labeled S protein (0.05 μg) was mixed with various amounts of emodin, promazine, anthraquinone or 1,4-bis-(1-anthraquinonylamino)-anthraquinone, and the mixtures were added to wells, which were coated with 1 ng of ACE2. The biotinylated ELISA was performed as described in Section
          <xref ref-type="sec" rid="sec1">
           2
          </xref>
          . Results are expressed as inhibition (%) described in Section
          <xref ref-type="sec" rid="sec1">
           2
          </xref>
          . Values are mean ± standard error of six independent assays.
         </p>
        </caption>
        <graphic xlink:href="gr6">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.4
      </label>
      <title>
       Emodin abolishes the infectivity of protein-pseudotyped retrovirus to Vero E6 cells
      </title>
      <p>
       The inhibitory potential of emodin on the SARS-CoV S protein and Vero E6 cell interaction was further evaluated by IFA. Emodin and promazine displayed no cytotoxicity in the concentration used in IFA. No cellular morphological change has been observed in emodin or promazine-treated cells. Vero E6 cells treated with BSA showed negative result, while cells treated with biotin-labeled S protein purified from
       <italic>
        E. coli
       </italic>
       or baculovirus showed the strong fluorescence (
       <xref ref-type="fig" rid="fig7">
        Fig. 7
       </xref>
       ). Treatment of Vero E6 cells with either emodin/biotinylated S protein or promazine/biotinylated S protein diminished the cell-associated fluorescence. These results indicated that emodin and promazine were able to block the S protein and Vero E6 cell interaction.
       <fig id="fig7">
        <label>
         Fig. 7
        </label>
        <caption>
         <p>
          Inhibitory effects of emodin and promazine on the interaction between SARS-CoV S protein and Vero E6 cells. Vero E6 cells were cultured on glass coverslips and treated with biotin-labeled S protein in the presence of various amounts of compounds. Recombinant S protein was purified from
          <italic>
           E. coli
          </italic>
          (A) or baculovirus (B). After a 16-h incubation at 4 °C, cells were stained with fluorescence-conjugated streptavidin and evaluated under a confocal microscope. Magnification, 400×.
         </p>
        </caption>
        <graphic xlink:href="gr7">
        </graphic>
       </fig>
      </p>
      <p>
       S protein-pseudotyped retrovirus infectivity was also used to evaluate the inhibitory potential of emodin. Vero E6 cells transfected with the plasmid encoding ACE2 were infected with S protein-pseudotyped retrovirus in the presence or absence of compounds. Emodin inhibited the S protein-pseudotyped retrovirus infectivity in a dose-dependent manner (
       <xref ref-type="fig" rid="fig8">
        Fig. 8
       </xref>
       ). The percent inhibition of emodin at 50 μM was 94.12 ± 5.90%. Because Vero cells treated with 50 μM emodin remained 82.4 ± 3.8% viability, the anti-SARS-CoV activity of emodin was not due to toxicity. Promazine also inhibited the S protein-pseudotyped retrovirus infectivity in a dose-dependent manner. Promazine exhibited the cytotoxicity effect at higher concentration (&gt;25 μM). Thus, the possibility that the antiviral activity of promazine was due to toxicity could not be excluded. However, the relative infectivity was 0.23 ± 0.2 when pseudovirus was treated with 5 μM promazine. At the same concentration, cell viability remained 95.6 ± 7.7% by MTT assay. Thus, the anti-SARS-CoV activity of promazine at 5 μM was not due to toxicity. Our findings indicated that emodin was a novel anti-SARS-CoV compound that was able to block the SARS-CoV S protein binding to Vero E6 cells.
       <fig id="fig8">
        <label>
         Fig. 8
        </label>
        <caption>
         <p>
          Inhibitory effects of emodin and promazine on the SARS-CoV S protein-pseudotyped retrovirus infectivity. S protein-pseudotyped retroviruses were mixed with various amounts of emodin and promazine, and then incubated at 37 °C with shaking. After a 2-h incubation, the mixtures were inoculated with Vero E6 cells transfected with the plasmid encoding ACE2. The luciferase activity of cell lysate was assayed 2 days postinfection. The cell viability was determined after a 24-h treatment with emodin or promazine. The bars and lines represent the relative infectivity and cell viability (%), respectively, described in Section
          <xref ref-type="sec" rid="sec1">
           2
          </xref>
          . Values are mean ± standard error of three independent assays.
          <sup>
           *
          </sup>
          <italic>
           p
          </italic>
          &lt; 0.05,
          <sup>
           **
          </sup>
          <italic>
           p
          </italic>
          &lt; 0.01, compared with untreated cells.
         </p>
        </caption>
        <graphic xlink:href="gr8">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p>
      Various clinically approved drugs, including nucleoside analogs, interferons, HIV protease inhibitors, anti-psychotic drug, anti-parasitic drug and antibiotics, have been screened for their anti-SARS-CoV effects (
      <xref ref-type="bibr" rid="bib11">
       Cinatle et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib43">
       Tan et al., 2004
      </xref>
      ,
      <xref ref-type="bibr" rid="bib46">
       Wu et al., 2004a
      </xref>
      ). Interferons and ribavirin exhibit anti-SARS-CoV effects at high concentrations; however, the significant cytotoxic effects of these compounds are also observed (
      <xref ref-type="bibr" rid="bib13">
       Cinatl et al., 2003b
      </xref>
      ). Promazine and niclosamide have been shown to exhibit significant effects in inhibiting the replication of SARS-CoV by abolishing the main proteinase activity (
      <xref ref-type="bibr" rid="bib53">
       Zhang and Yap, 2004
      </xref>
      ). In addition to clinically approved drugs, some components of traditional Chinese medicine are found to be effective inhibitors of SARS-CoV replication (
      <xref ref-type="bibr" rid="bib47">
       Wu et al., 2004b
      </xref>
      ). For examples, glycyrrhizin, the bioactive compounds of licorice root, is one of the first compounds found to be active against SARS-CoV
      <italic>
       in vitro
      </italic>
      (
      <xref ref-type="bibr" rid="bib12">
       Cinatl et al., 2003a
      </xref>
      ). Sinigrin, a phenolic compound derived from
      <italic>
       Isatis indigotica
      </italic>
      root, exhibits the anti-SARS-CoV potential by inhibiting SARS-CoV main proteinase activity (
      <xref ref-type="bibr" rid="bib31">
       Lin et al., 2005
      </xref>
      ). Baicaline, a flavonoid derived from
      <italic>
       Scutellaria baicalensis
      </italic>
      , inhibits SARS-CoV replication
      <italic>
       in vitro
      </italic>
      and
      <italic>
       in vivo
      </italic>
      (
      <xref ref-type="bibr" rid="bib8">
       Chen et al., 2004
      </xref>
      ). These findings might explain some beneficial effects of traditional Chinese medicine observed in SARS patients (
      <xref ref-type="bibr" rid="bib52">
       Zhang et al., 2004
      </xref>
      ). It also suggested the anti-SARS-CoV potential of natural products from Chinese medicinal herbs.
     </p>
     <p>
      By screening 312 herbs, we identified three widely used Chinese medicinal herbs of the family
      <italic>
       Polygonaceae
      </italic>
      exhibited the inhibitory efficacy on the SARS-CoV S protein and ACE2 interaction. Radix et Rhizoma Rhei is widely used in Southeast Asian folk medicine to alleviate liver and kidney damage (
      <xref ref-type="bibr" rid="bib1">
       Agarwal et al., 2000
      </xref>
      ,
      <xref ref-type="bibr" rid="bib3">
       Arosio et al., 2000
      </xref>
      ). Radix Polygoni multiflori and Caulis Polygoni multiflori are the most famous tonic traditional medicines in China and Japan, and clinically used for the treatment of coronary heart disease hyperlipidemia, neurosis, and other diseases commonly associated with aging (
      <xref ref-type="bibr" rid="bib48">
       Xiao et al., 1993
      </xref>
      ). Radix et Rhizoma Rhei has been shown to inhibit herpes simplex virus (HSV) infection by blocking both the attachment and penetration processes (
      <xref ref-type="bibr" rid="bib22">
       Hsiang et al., 2001
      </xref>
      ). Radix Polygoni multiflori and Caulis Polygoni multiflori have never been identified to exhibit the antiviral effects. In this study, we demonstrated that these herbs might be capable of inhibiting SARS-CoV infection by blockade of the binding of SARS-CoV S protein to cellular receptors.
     </p>
     <p>
      The genus
      <italic>
       Rheum
      </italic>
      and
      <italic>
       Polygonum
      </italic>
      are sources of a wide range of phenolic compounds, flavonoids, anthraquinone, stilbenes, and tannins (
      <xref ref-type="bibr" rid="bib34">
       Nonaka et al., 1977
      </xref>
      ). Anthraquinones, derived from the methanolic extract of Radix et Rhizoma Rhei, have been shown to disrupt the viral envelope, resulting in the abolishment of viral adsorption (
      <xref ref-type="bibr" rid="bib42">
       Sydiskis et al., 1991
      </xref>
      ). Several studies indicated that anthraquinones exhibited anti-HIV, anti-human cytomegalovirus, anti-HSV, and anti-Epstein-Barr virus activities (
      <xref ref-type="bibr" rid="bib4">
       Barnard et al., 1992
      </xref>
      ,
      <xref ref-type="bibr" rid="bib25">
       Konoshima et al., 1989
      </xref>
      ,
      <xref ref-type="bibr" rid="bib38">
       Schinazi et al., 1990
      </xref>
      ). Recent study further indicated that anthraquinone show antiviral activity but only emodin is a virucidal agent (
      <xref ref-type="bibr" rid="bib2">
       Alves et al., 2004
      </xref>
      ). Emodin is the active constituent deriving from genus
      <italic>
       Rheum
      </italic>
      and
      <italic>
       Polygonum
      </italic>
      . Emodin possesses antibacterial, diuretic, and vasorelaxant effects (
      <xref ref-type="bibr" rid="bib24">
       Huang et al., 1991
      </xref>
      ,
      <xref ref-type="bibr" rid="bib27">
       Koyama et al., 1988
      </xref>
      ,
      <xref ref-type="bibr" rid="bib54">
       Zhou and Chen, 1988
      </xref>
      ). It also exhibits anti-inflammatory, anti-proliferative, and anti-carcinogenic properties (
      <xref ref-type="bibr" rid="bib9">
       Chen et al., 2002
      </xref>
      ,
      <xref ref-type="bibr" rid="bib29">
       Kumar et al., 1998
      </xref>
      ). Emodin is suspected to exhibit its antiviral activity by inhibiting casein kinase 2, which is exploited by many viruses for the phosphorylation of proteins that are essential to their life cycle (
      <xref ref-type="bibr" rid="bib5">
       Battistutta et al., 2000
      </xref>
      ,
      <xref ref-type="bibr" rid="bib17">
       Guerra and Issinger, 1999
      </xref>
      ). It also has been demonstrated that emodin disrupted the lipid bilayer, resulting in the inactivation of enveloped virus (
      <xref ref-type="bibr" rid="bib42">
       Sydiskis et al., 1991
      </xref>
      ). In this study, we demonstrated that emodin was able to block the SARS-CoV S protein and ACE2 interaction. Preincubation of emodin with S protein or S protein-pseudotyped retrovirus also abolished the SARS-CoV and Vero E6 cell interaction. These findings suggested that in addition to disrupting the viral envelope, emodin might abolish SARS-CoV infection by competing the binding site of S protein with ACE2.
     </p>
     <p>
      Emodin is an anthraquinone compound consisting of three cyclic rings. Promazine, which has demonstrated anti-SARS-CoV effect, is also a phenolic compound consisting of three cyclic rings. Based on the structural similarity, we wondered whether other anthraquinones or phenolic compounds also exhibited the anti-SARS effects. By comparing the inhibitory efficacy of promazine, anthraquinone, 1,4-bis-(1-anthraquinonylamino)-anthraquinone with emodin, we found that anthraquinone and 1,4-bis-(1-anthraquinonylamino)-anthraquinone slightly inhibited the S protein and ACE2 interaction. Emodin and promazine blocked the S protein and ACE2 in a dose-dependent manner. These results suggested that the side chains but not the anthraquinone skeleton has a great impact on the S protein and ACE2 binding. These findings also indicated that promazine exhibited anti-SARS effect by inhibiting both the virus entry and protein processing.
     </p>
    </sec>
    <sec>
     <label>
      5
     </label>
     <title>
      Conclusion
     </title>
     <p>
      By screening 312 herbs, we identified three widely used Chinese medicinal herbs of the family
      <italic>
       Polygonaceae
      </italic>
      which inhibited the SARS-CoV S protein and ACE2 interaction. Emodin, the major components of the genus
      <italic>
       Rheum
      </italic>
      and
      <italic>
       Polygonum
      </italic>
      , is the likely active constituent responsible for blocking both the binding of SARS-CoV S protein to ACE2 and the infectivity of S protein-pseudotyped retrovirus to Vero E6 cells. These findings suggested that emodin was a novel anti-SARS-CoV compound and might be considered as a potential therapeutic agent in the treatment of SARS.
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="bib1">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agarwal
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Verma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antifungal activity of anthraquinone derivatives from
         <italic>
          Rheum emodi
         </italic>
        </article-title>
        <source>
         J. Ethnopharmacol.
        </source>
        <volume>
         72
        </volume>
        <year>
         2000
        </year>
        <fpage>
         43
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         10967452
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alves
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Pe′rez-Fons
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Estepa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Micol
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin
        </article-title>
        <source>
         Biochem. Pharmacol.
        </source>
        <volume>
         68
        </volume>
        <year>
         2004
        </year>
        <fpage>
         549
        </fpage>
        <lpage>
         561
        </lpage>
        <pub-id pub-id-type="pmid">
         15242821
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arosio
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Gagliano
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fusaro
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Parmeggiani
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tagliabue
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Galetti
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           DeCastri
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Moscheni
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Annoni
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aloe-Emodin quinone pretreatment reduces acute liver injury induced by carbon tetrachloride
        </article-title>
        <source>
         Pharmacol. Toxicol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2000
        </year>
        <fpage>
         229
        </fpage>
        <lpage>
         233
        </lpage>
        <pub-id pub-id-type="pmid">
         11129503
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Huffman
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           J.L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Wood
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
         <name>
          <surname>
           Sidwell
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <volume>
         17
        </volume>
        <year>
         1992
        </year>
        <fpage>
         63
        </fpage>
        <lpage>
         77
        </lpage>
        <pub-id pub-id-type="pmid">
         1310583
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Battistutta
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Sarno
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           DeMoliner
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Papinutto
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zanotti
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Pinna
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         275
        </volume>
        <year>
         2000
        </year>
        <fpage>
         29618
        </fpage>
        <lpage>
         29622
        </lpage>
        <pub-id pub-id-type="pmid">
         10882732
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           van der Zee
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           de Haan
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         77
        </volume>
        <year>
         2003
        </year>
        <fpage>
         8801
        </fpage>
        <lpage>
         8811
        </lpage>
        <pub-id pub-id-type="pmid">
         12885899
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
         <name>
          <surname>
           Que
          </surname>
          <given-names>
           T.L.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study
        </article-title>
        <source>
         Hong Kong Med. J.
        </source>
        <volume>
         9
        </volume>
        <year>
         2003
        </year>
        <fpage>
         399
        </fpage>
        <lpage>
         406
        </lpage>
        <pub-id pub-id-type="pmid">
         14660806
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.T.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           I.F.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <volume>
         31
        </volume>
        <year>
         2004
        </year>
        <fpage>
         69
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="pmid">
         15288617
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           W.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           F.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production
        </article-title>
        <source>
         Biochem. Pharmacol.
        </source>
        <volume>
         64
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1713
        </fpage>
        <lpage>
         1724
        </lpage>
        <pub-id pub-id-type="pmid">
         12445860
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ba
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Gettie
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           D.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         79
        </volume>
        <year>
         2005
        </year>
        <fpage>
         2678
        </fpage>
        <lpage>
         2688
        </lpage>
        <pub-id pub-id-type="pmid">
         15708987
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatle
          </surname>
          <given-names>
           J.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Michaelis
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hoever
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of antiviral therapy for severe acute respiratory syndrome
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <volume>
         66
        </volume>
        <year>
         2005
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         97
        </lpage>
        <pub-id pub-id-type="pmid">
         15878786
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chandra
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <year>
         2003
        </year>
        <fpage>
         2045
        </fpage>
        <lpage>
         2046
        </lpage>
        <pub-id pub-id-type="pmid">
         12814717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chandra
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of SARS with human interferons
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         362
        </volume>
        <year>
         2003
        </year>
        <fpage>
         293
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="pmid">
         12892961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gunther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           van der Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Brodt
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Panning
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Berger
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Burguiere
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Eickmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Escriou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Grywna
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kramme
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Manuguerra
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rickerts
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Sturmer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vieth
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Klenk
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Schmitz
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1967
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Schutten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Doornum
          </surname>
          <given-names>
           G.J.J.
          </given-names>
         </name>
         <name>
          <surname>
           van den Hoogen
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Stohr
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.M.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Koch's postulates fulfilled for SARS virus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         423
        </volume>
        <year>
         2003
        </year>
        <fpage>
         240
        </fpage>
        <pub-id pub-id-type="pmid">
         12748632
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Babcock
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hernandez
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           W.D.
          </given-names>
         </name>
         <name>
          <surname>
           Coccia
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Graziano
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Srinivasan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lowy
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Finberg
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ambrosino
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         191
        </volume>
        <year>
         2005
        </year>
        <fpage>
         507
        </fpage>
        <lpage>
         514
        </lpage>
        <pub-id pub-id-type="pmid">
         15655773
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guerra
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Issinger
          </surname>
          <given-names>
           O.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protein kinase CK2 and its role in cellular proliferation, development and pathology
        </article-title>
        <source>
         Electrophoresis
        </source>
        <volume>
         20
        </volume>
        <year>
         1999
        </year>
        <fpage>
         391
        </fpage>
        <lpage>
         408
        </lpage>
        <pub-id pub-id-type="pmid">
         10197447
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hsiang
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <volume>
         69
        </volume>
        <year>
         2006
        </year>
        <fpage>
         70
        </fpage>
        <lpage>
         76
        </lpage>
        <pub-id pub-id-type="pmid">
         16337697
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
         <name>
          <surname>
           Hsiang
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <volume>
         313
        </volume>
        <year>
         2004
        </year>
        <fpage>
         938
        </fpage>
        <lpage>
         947
        </lpage>
        <pub-id pub-id-type="pmid">
         14706633
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hattermann
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Marzi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gramberg
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Geiner
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Krumbiegel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kuate
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Uberla
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Niedrig
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         78
        </volume>
        <year>
         2004
        </year>
        <fpage>
         6134
        </fpage>
        <lpage>
         6142
        </lpage>
        <pub-id pub-id-type="pmid">
         15163706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Geier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Marzi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Krumbiegel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Peipp
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fey
          </surname>
          <given-names>
           G.H.
          </given-names>
         </name>
         <name>
          <surname>
           Gramberg
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <volume>
         319
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1216
        </fpage>
        <lpage>
         1221
        </lpage>
        <pub-id pub-id-type="pmid">
         15194496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsiang
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           I.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibitory effect of anti-pyretic and anti-inflammatory herbs on herpes simplex virus replication
        </article-title>
        <source>
         Am. J. Chin. Med.
        </source>
        <volume>
         29
        </volume>
        <year>
         2001
        </year>
        <fpage>
         459
        </fpage>
        <lpage>
         467
        </lpage>
        <pub-id pub-id-type="pmid">
         11789588
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsiang
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Morin inhibited 12-
         <italic>
          O
         </italic>
         -tetradecanoylphorbol-13-acetate-induced hepatocellular transformation via activator protein 1 signaling pathway and cell cycle progression
        </article-title>
        <source>
         Biochem. Pharmacol.
        </source>
        <volume>
         69
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1603
        </fpage>
        <lpage>
         1611
        </lpage>
        <pub-id pub-id-type="pmid">
         15896340
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           H.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chao
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vasorelaxants from Chinese herbs, emodin and scoparone, possess immunosuppressive properties
        </article-title>
        <source>
         Eur. J. Pharmacol.
        </source>
        <volume>
         198
        </volume>
        <year>
         1991
        </year>
        <fpage>
         211
        </fpage>
        <lpage>
         213
        </lpage>
        <pub-id pub-id-type="pmid">
         1830846
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Konoshima
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kozuka
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Koyama
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Okatani
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tagahara
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Studies on inhibitors of skin tumor promotion. VI. Inhibitory effects of quinones on Epstein-Barr virus activation
        </article-title>
        <source>
         J. Nat. Prod.
        </source>
        <volume>
         52
        </volume>
        <year>
         1989
        </year>
        <fpage>
         987
        </fpage>
        <lpage>
         995
        </lpage>
        <pub-id pub-id-type="pmid">
         2558164
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koyama
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Morita
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Kawanishi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Tagahara
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kobayashi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Capillary electrophoresis for simultaneous determination of emodin, chrysophanol, and their 8-beta-
         <sc>
          d
         </sc>
         -glucosides
        </article-title>
        <source>
         Chem. Pharm. Bull. (Tokyo)
        </source>
        <volume>
         51
        </volume>
        <year>
         2003
        </year>
        <fpage>
         418
        </fpage>
        <lpage>
         420
        </lpage>
        <pub-id pub-id-type="pmid">
         12672996
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koyama
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kelly
          </surname>
          <given-names>
           T.R.
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel type of potential anticancer agents derived from chrysophanol and emodin. Some structure–activity relationship studies
        </article-title>
        <source>
         J. Med. Chem.
        </source>
        <volume>
         31
        </volume>
        <year>
         1988
        </year>
        <fpage>
         283
        </fpage>
        <lpage>
         284
        </lpage>
        <pub-id pub-id-type="pmid">
         3339601
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Emery
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Comer
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Humphrey
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Shieh
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Guarner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Paddock
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Fields
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           DeRisi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           LeDuc
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Bellini
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dhawan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Aggarwal
          </surname>
          <given-names>
           B.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-κB activation, IκB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells
        </article-title>
        <source>
         Oncogene
        </source>
        <volume>
         17
        </volume>
        <year>
         1998
        </year>
        <fpage>
         913
        </fpage>
        <lpage>
         918
        </lpage>
        <pub-id pub-id-type="pmid">
         9780008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           F.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chao
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <volume>
         68
        </volume>
        <year>
         2005
        </year>
        <fpage>
         36
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="pmid">
         16115693
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marra
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Astell
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Holt
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brooks-Wilson
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Butterfield
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Khattra
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Asano
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Barber
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cloutier
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Coughlin
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Freeman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Girn
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Griffith
          </surname>
          <given-names>
           O.L.
          </given-names>
         </name>
         <name>
          <surname>
           Leach
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Mayo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           McDonald
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Montgomery
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
         <name>
          <surname>
           Pandoh
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Petrescu
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           A.G.
          </given-names>
         </name>
         <name>
          <surname>
           Schein
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Siddiqui
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Smailus
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Stott
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Plummer
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Andonov
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Artsob
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Bastien
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bernard
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           T.F.
          </given-names>
         </name>
         <name>
          <surname>
           Bowness
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Drebot
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fernando
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Flick
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Garbutt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gray
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Grolla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Meyers
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kabani
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Normand
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Stroher
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Tipples
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
         <name>
          <surname>
           Tyler
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vogrig
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Brunham
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Krajden
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Skowronski
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Upton
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Genome sequence of the SARS-associated coronavirus
        </article-title>
        <source>
         Science
        </source>
        <volume>
         300
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1399
        </fpage>
        <lpage>
         1404
        </lpage>
        <pub-id pub-id-type="pmid">
         12730501
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dorfman
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Coderre
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         78
        </volume>
        <year>
         2004
        </year>
        <fpage>
         10628
        </fpage>
        <lpage>
         10635
        </lpage>
        <pub-id pub-id-type="pmid">
         15367630
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nonaka
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Minami
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nishioka
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Studies on rhubarb (Rhei rhizoma). III. Stilbene glycosides
        </article-title>
        <source>
         Chem. Pharm. Bull. (Tokyo)
        </source>
        <volume>
         25
        </volume>
        <year>
         1977
        </year>
        <fpage>
         2300
        </fpage>
        <lpage>
         2305
        </lpage>
        <pub-id pub-id-type="pmid">
         589726
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yam
          </surname>
          <given-names>
           L.Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yee
          </surname>
          <given-names>
           W.K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           D.N.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           R.W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <collab>
          Members of the SARS Study Group
         </collab>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1319
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Petit
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Melancon
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chouljenko
          </surname>
          <given-names>
           V.N.
          </given-names>
         </name>
         <name>
          <surname>
           Colgrove
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Knipe
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kousoulas
          </surname>
          <given-names>
           K.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         341
        </volume>
        <year>
         2005
        </year>
        <fpage>
         215
        </fpage>
        <lpage>
         230
        </lpage>
        <pub-id pub-id-type="pmid">
         16099010
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Oberste
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Monroe
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Nix
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Campagnoli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Icenogle
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Penaranda
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bankamp
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Maher
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lowe
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Frace
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           DeRisi
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.D.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Burns
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Sanchez
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Liffick
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Holloway
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Limor
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McCaustland
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Olsen-Rasmussen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Gunther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pallansch
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bellini
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of a novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         Science
        </source>
        <volume>
         300
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1394
        </fpage>
        <lpage>
         1399
        </lpage>
        <pub-id pub-id-type="pmid">
         12730500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schinazi
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Babu
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Oswald
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Saalmann
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Cannon
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Eriksson
          </surname>
          <given-names>
           B.F.H.
          </given-names>
         </name>
         <name>
          <surname>
           Nasr
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anthraquinones as a new class of antiviral agents against human immunodeficiency virus
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <volume>
         13
        </volume>
        <year>
         1990
        </year>
        <fpage>
         265
        </fpage>
        <lpage>
         272
        </lpage>
        <pub-id pub-id-type="pmid">
         1697740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Reeves
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rennekamp
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Amberg
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Piefer
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bates
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U.S.A.
        </source>
        <volume>
         101
        </volume>
        <year>
         2004
        </year>
        <fpage>
         4240
        </fpage>
        <lpage>
         4245
        </lpage>
        <pub-id pub-id-type="pmid">
         15010527
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Murakami
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tallarico
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Olurinde
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bellini
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Marasco
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U.S.A.
        </source>
        <volume>
         101
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2536
        </fpage>
        <lpage>
         2541
        </lpage>
        <pub-id pub-id-type="pmid">
         14983044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Murakami
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Marasco
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         79
        </volume>
        <year>
         2005
        </year>
        <fpage>
         5900
        </fpage>
        <lpage>
         5906
        </lpage>
        <pub-id pub-id-type="pmid">
         15857975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sydiskis
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Owen
          </surname>
          <given-names>
           D.G.
          </given-names>
         </name>
         <name>
          <surname>
           Lohr
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Rosler
          </surname>
          <given-names>
           K.H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Blomster
          </surname>
          <given-names>
           R.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inactivation of enveloped viruses by anthraquinones extracted from plants
        </article-title>
        <source>
         Antimicrob. Agents Chemother.
        </source>
        <volume>
         35
        </volume>
        <year>
         1991
        </year>
        <fpage>
         2463
        </fpage>
        <lpage>
         2466
        </lpage>
        <pub-id pub-id-type="pmid">
         1810179
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           E.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           H.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Stanton
          </surname>
          <given-names>
           L.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         581
        </fpage>
        <lpage>
         586
        </lpage>
        <pub-id pub-id-type="pmid">
         15200845
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of viral proteins encoded by the SARS-coronavirus genome
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <volume>
         65
        </volume>
        <year>
         2005
        </year>
        <fpage>
         69
        </fpage>
        <lpage>
         78
        </lpage>
        <pub-id pub-id-type="pmid">
         15708633
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tripet
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Howard
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
         <name>
          <surname>
           Jobling
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
         <name>
          <surname>
           Hodges
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural characterization of the SARS-coronavirus spike S fusion protein core
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         279
        </volume>
        <year>
         2004
        </year>
        <fpage>
         20836
        </fpage>
        <lpage>
         20849
        </lpage>
        <pub-id pub-id-type="pmid">
         14996844
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jan
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           H.P.
          </given-names>
         </name>
         <name>
          <surname>
           Hwang
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chao
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide
        </article-title>
        <source>
         Antimicrob. Agents Chemother.
        </source>
        <volume>
         48
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2693
        </fpage>
        <lpage>
         2696
        </lpage>
        <pub-id pub-id-type="pmid">
         15215127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jan
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kuo
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Juan
          </surname>
          <given-names>
           H.F.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           H.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Brik
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           F.S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Small molecules targeting severe acute respiratory syndrome human coronavirus
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U.S.A.
        </source>
        <volume>
         101
        </volume>
        <year>
         2004
        </year>
        <fpage>
         10012
        </fpage>
        <lpage>
         10017
        </lpage>
        <pub-id pub-id-type="pmid">
         15226499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Xing
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunological aspects of Chinese medicinal plants as antiageing drugs
        </article-title>
        <source>
         J. Ethnopharmacol.
        </source>
        <volume>
         38
        </volume>
        <year>
         1993
        </year>
        <fpage>
         167
        </fpage>
        <lpage>
         175
        </lpage>
        <pub-id pub-id-type="pmid">
         8510465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Nabel
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         428
        </volume>
        <year>
         2004
        </year>
        <fpage>
         561
        </fpage>
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="pmid">
         15024391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ba
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           D.D.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         79
        </volume>
        <year>
         2005
        </year>
        <fpage>
         11638
        </fpage>
        <lpage>
         11646
        </lpage>
        <pub-id pub-id-type="pmid">
         16140741
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zuo
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Duan
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         78
        </volume>
        <year>
         2004
        </year>
        <fpage>
         11334
        </fpage>
        <lpage>
         11339
        </lpage>
        <pub-id pub-id-type="pmid">
         15452254
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.M.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of integrated traditional Chinese and Western medicine on SARS: a review of clinical evidence
        </article-title>
        <source>
         World J. Gastroenterol.
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         3500
        </fpage>
        <lpage>
         3505
        </lpage>
        <pub-id pub-id-type="pmid">
         15526373
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib53">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yap
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs
        </article-title>
        <source>
         Bioorg. Med. Chem.
        </source>
        <volume>
         12
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2517
        </fpage>
        <lpage>
         2521
        </lpage>
        <pub-id pub-id-type="pmid">
         15110833
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           X.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Biochemical study of Chinese rhubarb. XXII. Inhibitory effect of anthraquinone derivatives on Na
         <sup>
          +
         </sup>
         -K
         <sup>
          +
         </sup>
         -ATPase of the rabbit renal medulla and their diuretic action
        </article-title>
        <source>
         Acta Pharmacol. Sin.
        </source>
        <volume>
         23
        </volume>
        <year>
         1988
        </year>
        <fpage>
         17
        </fpage>
        <lpage>
         20
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We thank Prof. M. Farzan for providing plasmids for the construction of pseudovirus. We thank Miss Y.C. Wei for her technical assistance. This work was supported by grants from National Science Council (NSC 92-2751-B-039-001-Y and NSC 92-2751-B-039-005-Y) and China Medical University (CMU93-M-05 and CMU94-117), Taiwan, ROC.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Curr Hypertens Rep
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Curr. Hypertens. Rep
      </journal-id>
      <journal-title-group>
       <journal-title>
        Current Hypertension Reports
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1522-6417
      </issn>
      <issn pub-type="epub">
       1534-3111
      </issn>
      <publisher>
       <publisher-name>
        Current Science Inc.
       </publisher-name>
       <publisher-loc>
        New York
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       20556668
      </article-id>
      <article-id pub-id-type="pmc">
       2957877
      </article-id>
      <article-id pub-id-type="publisher-id">
       122
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/s11906-010-0122-6
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Targeting the Vasoprotective Axis of the Renin-Angiotensin System: A Novel Strategic Approach to Pulmonary Hypertensive Therapy
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bradford
         </surname>
         <given-names>
          Chastity N.
         </given-names>
        </name>
        <address>
         <email>
          cbradford@ufl.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ely
         </surname>
         <given-names>
          Debra R.
         </given-names>
        </name>
        <address>
         <email>
          elyd@ufl.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Raizada
         </surname>
         <given-names>
          Mohan K.
         </given-names>
        </name>
        <address>
         <email>
          mraizada@phys.med.ufl.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <aff id="Aff1">
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.15276.37
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000419368091
         </institution-id>
         <institution>
          Department of Physiology and Functional Genomics, College of Medicine,
         </institution>
         <institution>
          University of Florida,
         </institution>
        </institution-wrap>
        PO Box 100274, Gainesville, FL 32610 USA
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        17
       </day>
       <month>
        6
       </month>
       <year>
        2010
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <year>
        2010
       </year>
      </pub-date>
      <volume>
       12
      </volume>
      <issue>
       4
      </issue>
      <fpage>
       212
      </fpage>
      <lpage>
       219
      </lpage>
      <permissions>
       <copyright-statement>
        © Springer Science+Business Media, LLC 2010
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p>
        A decade has passed since the discovery of angiotensin-converting enzyme 2 (ACE2), a component of the ACE2–angiotensin (Ang)-(1-7)–Mas counterregulatory axis of the renin angiotensin system (RAS). ACE2 is considered an endogenous regulator of the vasoconstrictive, proliferative, fibrotic, and proinflammatory effects of the ACE–Ang II–angiotensin II type 1 receptor (AT
        <sub>
         1
        </sub>
        R) axis. Both animal and clinical studies have emerged to define a role for ACE2 in pulmonary arterial hypertension (PAH). There is scientific evidence supporting the concept that ACE2 maintains the RAS balance and plays a protective role in PAH. The activation of pulmonary ACE2 could influence the pathogenesis of PAH and serve as a novel therapeutic target in PAH. Current therapeutic strategies and interventions have limited success, and PAH remains a fatal disease. Thus, more research that establishes the novel therapeutic potential and defines the mechanism of the ACE2–Ang-(1-7)–Mas counterregulatory axis in PAH is needed.
       </p>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        ACE2
       </kwd>
       <kwd>
        Angiotensin-(1-7)
       </kwd>
       <kwd>
        Mas receptor
       </kwd>
       <kwd>
        Hypertension
       </kwd>
       <kwd>
        Cardiopulmonary diseases protection
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer Science+Business Media, LLC 2010
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1" sec-type="introduction">
     <title>
      Introduction
     </title>
     <p>
      Angiotensin (Ang)-converting enzyme 2 (ACE2) has been implicated in a number of physiologic and pathophysiologic processes. It is a novel homologue of ACE and a component of the counterregulatory axis of ACE. It is a monocarboxypeptidase, and it generates Ang-(1-7), another component of the renin-angiotensin system (RAS), which attenuates the vasoconstrictive, proliferative, fibrotic, and inflammatory effects of Ang II [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]. ACE2 cleaves a single residue from its substrate, Ang I, generating Ang-(1-9) and a single residue from another preferred substrate, Ang II, to generate Ang-(1-7). ACE2 also cleaves other peptide substrates such as des-arg-bradykinin, neurotensin, and kinetensin. ACE2 plays a pertinent role in the vasoprotective axis of the RAS, ACE2–Ang-(1-7)–Mas, as it counterbalances the vasoconstrictive, proliferative, and fibrotic actions of the ACE–Ang II–Ang II type 1 receptor (AT
      <sub>
       1
      </sub>
      R) axis [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ••].
     </p>
     <p>
      ACE2 is abundantly expressed in many cell types in the lung, such as Clara cells, type I and II alveolar epithelial cells, macrophages, endothelium, smooth muscle cells (SMCs) of blood vessels, and bronchial epithelia [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. Because the RAS components are widely expressed in the lung, the activation of pulmonary ACE2 could influence the pathogenesis of lung injury and serve as a novel therapeutic target in pulmonary arterial hypertension (PAH).
     </p>
     <p>
      PAH is a chronic disease of diverse etiology. Despite modern therapeutic advances, the World Health Organization functional class (WHO-FC) estimates median survival to be 6 months for WHO-FC IV, 2.5 years for WHO-FC III, and 6 years for WHO-FC I/II. Although targeted treatment, pleiotropic drug approaches, and novel progenitor-cell therapy provide symptomatic relief and prolong survival, PAH remains a fatal disease with no cure. Without proper therapy, chronic vasoconstriction, inflammation, and in situ thrombosis promote increased pulmonary vascular remodeling (PVR). Clinically, PAH is characterized by increased mean pulmonary arterial pressure (&gt;25 mm Hg at rest) and persistent elevation of pulmonary vascular resistance, which leads to the main cause of death in these patients, right-sided heart failure [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ].
     </p>
     <p>
      PAH can be heritable, and predisposing genetic and environmental risk factors may lead to an imbalance in counterregulatory mechanisms associated with pulmonary vascular remodeling, such as vasoconstriction/vasodilatation, proliferation/antiproliferation, and prothrombogenics/antithrombogenics. These imbalances initiate a cascade of pathophysiologic events in the lungs leading to PAH [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ••]; the exact pathogenesis of the disease is still unknown. Based upon the concept of homeostatic imbalance and multifactorial pathobiology, the mainstay of PAH treatment includes vasodilators, anticoagulants, calcium channel blockers, and endothelin receptor antagonists.
     </p>
     <p>
      The renin-angiotensin system (RAS) is a well-recognized player in endothelial dysfunction and vascular remodeling, but the precise involvement of this system’s members in the lung pathophysiology of PAH remains elusive. Thus, the discovery of ACE2 and the emerging counterregulatory concept of RAS is of great significance [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. The ACE–Ang II–AT
      <sub>
       1
      </sub>
      R axis promotes vasoconstriction, proliferation, and fibrosis, whereas the ACE2–Ang-(1-7)–Mas axis protects lungs. The ACE2–Ang-(1-7)–Mas axis intrinsically induces vasoprotective actions by counterregulating the ACE–Ang II–AT
      <sub>
       1
      </sub>
      R axis. This review focuses on the vasoprotective axis of the RAS as a potential target for therapeutic intervention in PAH. A conceptual breakthrough is urgently needed to develop a novel strategy for therapeutic intervention and management of PAH. Research establishing a role for ACE2 in lung pathophysiology is emerging.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      The Role of the RAS in Pulmonary Arterial Hypertension
     </title>
     <p>
      PAH is a chronic disease of diverse etiology, clinically characterized by increased pulmonary vascular resistance. Table
      <xref ref-type="table" rid="Tab1">
       1
      </xref>
      outlines the current classification of all forms of pulmonary hypertension (PH) [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ••]. Genetic mutations influence PAH development, and in the year 2000, mutations of the gene encoding bone morphogenetic protein receptor type II (BMPR-II), a transforming growth factor (TGF)-β superfamily receptor, were identified as the primary genetic mutation in some patients with PAH [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ].
      <table-wrap id="Tab1">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Classification of pulmonary hypertension
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <tbody>
         <tr>
          <td>
           1–Pulmonary arterial hypertension
          </td>
         </tr>
         <tr>
          <td>
           1.1 Idiopathic
          </td>
         </tr>
         <tr>
          <td>
           1.2 Heritable
          </td>
         </tr>
         <tr>
          <td>
           1.3 Drug/toxin-induced
          </td>
         </tr>
         <tr>
          <td>
           1.4 Associated with APAH
          </td>
         </tr>
         <tr>
          <td>
           1.5 Persistent pulmonary hypertension of the newborn
          </td>
         </tr>
         <tr>
          <td>
           1′–Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
          </td>
         </tr>
         <tr>
          <td>
           2–Pulmonary hypertension due to left heart disease
          </td>
         </tr>
         <tr>
          <td>
           3–Pulmonary hypertension due to lung diseases and/or hypoxemia
          </td>
         </tr>
         <tr>
          <td>
           4–Chronic thromboembolic pulmonary hypertension
          </td>
         </tr>
         <tr>
          <td>
           5–Pulmonary hypertension with unclear and/or multifactorial mechanisms
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         <italic>
          Adapted from
         </italic>
         Galie et al. [
         <xref ref-type="bibr" rid="CR6">
          6
         </xref>
         ••]
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p>
      PAH patients are often characterized by remodeling of small distal pulmonary arteries resulting in medial hypertrophy, intimal proliferation, adventitial thickening with moderate inflammatory infiltrates, plexiform lesions, and thrombotic lesions. This remodeling causes increased pulmonary vascular resistance resulting in a mean pulmonary arterial pressure greater than 25 mm Hg at rest. Persistent elevation of pulmonary vascular resistance leads to right heart failure and death [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ••]. PAH is a consequence of vascular effector imbalance, perturbations in the homeostasis of vasoconstrictors and vasodilators, growth inhibitors and mitogenic factors, and antithrombotic and prothrombotic factors [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ]. As a result of these findings, vasodilator, anticoagulant, antiplatelet, anti-inflammatory, and vascular remodeling therapies have been used for PAH treatment. Before current intervention strategies, life expectancy for adults with idiopathic PAH was less than 3 years from diagnosis; for children, it was less than 10 months [
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ]. There are complex strategies for treating PAH patients that include both supportive and specific drug therapy. Specific drug therapy often falls into three categories: vasodilators, calcium channel blockers, and endothelin receptor antagonists. The latest clinical trials have strategically targeted remodeling, including the testing of antiproliferative drugs in advanced human PAH.
     </p>
     <p>
      Both clinical and animal data suggest that intervention strategies that attenuate the actions of the ACE–Ang II–AT
      <sub>
       1
      </sub>
      R axis (i.e., angiotensin receptor blockers and/or ACE inhibitor therapy) and activate the ACE2–Ang-(1-7)–Mas axis (i.e., ACE2 activation or ACE2 viral transfer) are effective in attenuating and preventing maladaptive vascular remodeling associated with PAH. Because limiting AngII bioactivity remains the cornerstone of cardiovascular therapeutics, it is plausible that the same approach may be valid in pulmonary diseases [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ]. Pulmonary vascular fibrosis, hypertrophy, and vascular smooth muscle migration are regressed with ACE2. Thus, its discovery and role in lung pathophysiology are of great importance.
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      ACE2 and Its Role in Lung Diseases
     </title>
     <p>
      ACE2 was initially discovered as a receptor for severe acute respiratory syndrome (SARS) coronavirus and because of its sequence homology to ACE, the research community began to determine its localization and study its role in most model systems. It is a type I transmembrane protein, which contains a single metalloproteinase active site [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. ACE2 has been localized to human heart, kidney, coronary arteries, arterioles, vasa vasorum, testis, gastrointestinal tract, and lung. ACE2 is abundantly expressed in many cell types in the lung such as Clara cells, type I and II alveolar epithelial cells, macrophages, endothelium, SMCs, and bronchial epithelia. ACE2 is localized to endothelial cells, and expression is enhanced in the walls of newly muscularized pulmonary arteries [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ]. These data illustrate that ACE2, like ACE, is localized to the lung, the vasculature, and more specifically, to the endothelium, and thus exists as a potential therapeutic target. The literature also strongly supports a RAS imbalance in pulmonary disease and lung injury.
     </p>
     <sec id="Sec4">
      <title>
       ACE2 in Lung Injury
      </title>
      <p>
       ACE2 limits vasoproliferative, fibrotic, and hypertrophic actions of the RAS during lung injury. Both animal and human pulmonary studies reveal that a RAS imbalance may play an important role in pulmonary disease progression. In three different models of acute respiratory distress syndrome (ARDS), ACE2 knockout mice have severe lung disease, elevated serum and tissue Ang II levels, and increased collagen deposition. This loss of ACE in acute lung injury leads to leaky pulmonary blood vessels through AT
       <sub>
        1
       </sub>
       a receptor stimulation [
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
       ]. In a lung injury model induced by acid aspiration or sepsis, ACE2 deletion worsens the injury. Aortas from ACE2-deficient mice exhibit impaired endothelium-dependent vasodilation [
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ]. This RAS imbalance is further supported by literature revealing that severe lung failure on an ACE2 knockout background was rescued by ACE inactivation [
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
       ].
      </p>
      <p>
       The RAS imbalance is also evident in animal models of PH. Bleomycin-induced PH and pulmonary fibrosis are associated with decreased ACE2 activity. ACE2 is upregulated in response to hypoxia and illustrates a protective effect in severe acute lung failure. Activation of a key transcriptional factor during hypoxia,
       <inline-formula id="IEq1">
        <alternatives>
         <tex-math id="M1">
          \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\hbox{HIF}} - {1_\alpha } $$\end{document}
         </tex-math>
         <inline-graphic xlink:href="11906_2010_122_Article_IEq1.gif">
         </inline-graphic>
        </alternatives>
       </inline-formula>
       , increased ACE and decreased ACE2 [
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
       ]. Lenti-ACE2 tracheal injections prevent and partially reverse PH in a monocrotaline (MCT) model of PH [
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ].
      </p>
      <p>
       Targeting ACE2 may have additional beneficial effects, unlike the blockade of ACE and AT
       <sub>
        1
       </sub>
       Rs. Targeting ACE2 in PH is a novel strategy (Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       ), as ACE2 is a multifunctional enzyme with pleiotropic effects. It not only gives protection by degradation of Ang II, but it also produces the vasodilatory peptide, Ang-(1-7).
       <fig id="Fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Targeting the ACE2/Ang-(1-7)/Mas axis prevents and reverses pulmonary vascular pathology of pulmonary arterial hypertension. ACE—angiotensin-converting enzyme; Ang II—angiotensin II; AT
          <sub>
           1
          </sub>
          R—angiotensin II type 1 receptor; AT
          <sub>
           2
          </sub>
          R—angiotensin II type 2 receptor; BMPR-II—bone morphogenetic protein receptor type II; ERK1/2—extracellular signal-regulated protein kinase 1/2; NO—nitric oxide; TGF-β—transforming growth factor β
         </p>
        </caption>
        <graphic id="MO1" xlink:href="11906_2010_122_Fig1_HTML">
        </graphic>
       </fig>
      </p>
      <p>
       In animal models, the literature also strongly supports pharmacologic treatment of lung disease with ACE2. Because PVR occurs in PAH, studies that prevent, limit, or regress PVR are important for progress in the field. In a sepsis-induced ACE2 knockout model of acute lung injury, treatment with recombinant human ACE2 protein provided direct protection [
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
       ]. This study also suggests that Ang II, ACE, and AT
       <sub>
        1
       </sub>
       a receptor promote lung injury, whereas ACE2 and AT
       <sub>
        2
       </sub>
       receptor protect against lung injury. ACE2 overexpression improves endothelial cell migration and tube formation [
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ]. We have demonstrated in MCT-treated mice that pulmonary ACE2 overexpression via lentiviral vector both prevents and reverses the increases in right ventricular systolic pressure, significantly attenuates and partially reverses muscularization of pulmonary vessel, and increases the AT
       <sub>
        2
       </sub>
       R:AT
       <sub>
        1
       </sub>
       R mRNA ratio [
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ]. Our studies further reveal that activation of endogenous ACE2 by XNT (1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one) prevents pulmonary vascular remodeling in PH development [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ••]. XNT reversed cardiac hypertrophy, ventricular fibrosis, and renal interstitial fibrosis; prevented an increase in right ventricular systolic pressure (RVSP) and right ventricular hypertrophy; and attenuated vascular wall thickening and pulmonary fibrosis. XNT decreased proinflammatory cytokine levels, increased anti-inflammatory cytokine levels, and increased ACE2 activity. XNT had no adverse effects on systemic blood pressure. These effects are inhibited by an Ang-(1-7) antagonist, A779, demonstrating that ACE2 may produce beneficial effects via Ang-(1-7) [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ••]. Interestingly, ACE2 overexpression in the smooth muscle of spontaneously hypertensive stroke prone rats (SHRSP) resulted in increased aortic ACE2 activity, Ang-(1-7), and Ang II and improved vascular function [
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
       ]. Mas agonists, AVE0991, CGEM856, CGEM857, confer endothelium-dependent relaxation effects.
      </p>
      <p>
       Chronic and sustained imbalances that favor the ACE–Ang II–AT
       <sub>
        1
       </sub>
       R axis may promote the progression of lung disease. We believe that the beneficial effects of the system involve a shift from the vasoconstrictive, proliferative, and fibrotic axes to the vasoprotective axis of the RAS, and thus targeting the RAS in PH should be revisited, with ACE2 as the therapeutic target. Unlike ACE inhibitors and angiotensin-receptor blockers (ARBs), ACE2 is an endogenous regulator of the RAS. Therapy with ACE inhibitors and ARBs indirectly increases ACE2 and Ang-(1-7), but ACE2 activation would directly increase the enzyme to promote beneficial effects. Like ACE inhibitor and ARB therapy, ACE2 activation attenuates remodeling and fibrosis and affects the vascular relaxation properties of the endothelium. RAS intervention studies in PH are inconclusive, and the role of the ACE2–Ang-(1-7)–Mas axis activation in PH has not been confirmed with clinical trials.
      </p>
     </sec>
    </sec>
    <sec id="Sec5">
     <title>
      RAS Intervention and Pulmonary Hypertension: The Controversy of ACE Inhibitor/ARB Therapy
     </title>
     <p>
      It is evident that benchside pharmacologic inhibition of the RAS has translated to the bedside in the treatment of patients with hypertension, congestive heart failure, left ventricular dysfunction, pulmonary and systemic edema, diabetic nephropathy, cirrhosis of the liver, and scleroderma [
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ]. Although there is evidence in both clinical and animal studies supporting the contention that the RAS is involved in the development and progression of PAH, the use of ACE inhibitors in PAH remains controversial (Table
      <xref ref-type="table" rid="Tab2">
       2
      </xref>
      ).
      <table-wrap id="Tab2">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Efficacy of therapeutic RAS intervention in human and animal models of pulmonary arterial hypertension
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           RAS therapy
          </th>
          <th>
           Model/species
          </th>
          <th>
           Effect on PAH
          </th>
          <th>
           Study
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           ACE inhibitor (cilazapril)
          </td>
          <td>
           30 chronic congestive heart failure patients (NYHA III–IV) with PAH
          </td>
          <td>
           ↓ Mean pulmonary and capillary wedge pressures; ↑ flow-mediated vasodilation; ↑ left ventricular ejection fraction; improved functional class of patients
          </td>
          <td>
           Tavli and Gocer [
           <xref ref-type="bibr" rid="CR21">
            21
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           ACE inhibitor (captopril)
          </td>
          <td>
           15 patients with hypoxic PH due to chronic obstructive lung disease
          </td>
          <td>
           ↓ Systemic arterial pressure; did not reduce pulmonary vascular resistance
          </td>
          <td>
           Zieliński et al. [
           <xref ref-type="bibr" rid="CR24">
            24
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           ACE inhibitor (perindopril)
          </td>
          <td>
           Hypoxic rat model
          </td>
          <td>
           Did not restore pulmonary vascular function or attenuate pulmonary vascular resistance; modest effect on pulmonary artery pressure
          </td>
          <td>
           Jeffery and Wanstall [
           <xref ref-type="bibr" rid="CR18">
            18
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           AT
           <sub>
            1
           </sub>
           R antagonist (losartan)
          </td>
          <td>
           Smoke-induced PH rat model
          </td>
          <td>
           Attenuated pulmonary artery remodeling; ↓ RVSP elevation; ↓ Ang II accumulation; ↑ ACE2
          </td>
          <td>
           Han et al. [
           <xref ref-type="bibr" rid="CR19">
            19
           </xref>
           •]
          </td>
         </tr>
         <tr>
          <td>
           AT
           <sub>
            1
           </sub>
           R antagonist (telmisartan)
          </td>
          <td>
           MCT-treated rats
          </td>
          <td>
           ↓ RVSP elevation; ↓ RVH; ↓ fibrosis; ↓ RV dysfunction
          </td>
          <td>
           Okada et al. [
           <xref ref-type="bibr" rid="CR20">
            20
           </xref>
           ]
          </td>
         </tr>
         <tr>
          <td>
           ACE2 activator (XNT)
          </td>
          <td>
           MCT-treated rats
          </td>
          <td>
           ↓ RVSP elevation; ↓ RVH; ↓ fibrosis; ↓ RV dysfunction
          </td>
          <td>
           Ferreira et al. [
           <xref ref-type="bibr" rid="CR2">
            2
           </xref>
           ••]
          </td>
         </tr>
         <tr>
          <td>
           Pulmonary ACE2 overexpression via lentiviral vector
          </td>
          <td>
           MCT-treated mice
          </td>
          <td>
           Prevented and reversed RVSP; attenuated and partially reversed muscularization; ↑AT
           <sub>
            2
           </sub>
           R:AT
           <sub>
            1
           </sub>
           R mRNA
          </td>
          <td>
           Yamazato et al. [
           <xref ref-type="bibr" rid="CR14">
            14
           </xref>
           ]
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         <italic>
          ACE
         </italic>
         angiotensin-converting enzyme,
         <italic>
          Ang II
         </italic>
         angiotensin II,
         <italic>
          AT
         </italic>
         <sub>
          <italic>
           1
          </italic>
         </sub>
         <italic>
          R
         </italic>
         angiotensin II type 1 receptor,
         <italic>
          AT
         </italic>
         <sub>
          <italic>
           2
          </italic>
         </sub>
         <italic>
          R
         </italic>
         angiotensin II type 2 receptor,
         <italic>
          MCT
         </italic>
         monocrotaline,
         <italic>
          NYHA
         </italic>
         New York Heart Association,
         <italic>
          PAH
         </italic>
         pulmonary arterial hypertension,
         <italic>
          PH
         </italic>
         pulmonary hypertension,
         <italic>
          RAS
         </italic>
         renin-angiotensin system,
         <italic>
          RVH
         </italic>
         right ventricular hypertrophy,
         <italic>
          RVSP
         </italic>
         right ventricular systolic pressure,
         <italic>
          XNT
         </italic>
         1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <sec id="Sec6">
      <title>
       RAS Therapy in Animal Models of Pulmonary Hypertension
      </title>
      <p>
       Enalapril, another ACE inhibitor, was given concomitantly with MCT in a chronic PAH rat model fed a high-cholesterol diet [
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ]. This therapeutic intervention attenuated the development of PAH while preserving the expression of endothelial nitric oxide synthase (eNOS), demonstrating a role for RAS and NO in the development of PAH. In a hypoxic rat model of PAH, the dose-dependent effects of perindopril, an ACE inhibitor, on vascular remodeling did not restore pulmonary vascular function and had only a modest effect on pulmonary artery pressure [
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
       ]. Losartan, an AT
       <sub>
        1
       </sub>
       R antagonist, attenuated smoke-induced pulmonary artery remodeling, RVSP elevation, and Ang II accumulation, and increased ACE2 in rat lungs [
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       •]. Okada et al. [
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
       ] demonstrated that telmisartan, an AT
       <sub>
        1
       </sub>
       R antagonist, attenuated right ventricular (RV) remodeling via inhibition of RV hypertrophy, fibrosis, and dysfunction in MCT-treated male Wistar rats. Yet the acceleration time:ejection time ratio of pulmonary artery flow velocity was not significantly different than the ratio for controls. In clinical trials in human patients, ACE inhibitor therapy has been tested to treat PAH. Tavli et al. [
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
       ] conducted a small proof-of-concept trial in 30 PAH patients with stable chronic congestive heart failure and demonstrated that cilazapril, an ACE inhibitor, significantly decreased mean pulmonary and capillary wedge pressures. This drug also increased flow-mediated vasodilatation, improved left ventricular ejection fraction, and improved the functional class of patients. Both systemic and pulmonary arterial pressures were significantly decreased after 12  weeks of captopril treatment in 17 patients with high-altitude PH and mild-to-moderate systemic arterial hypertension [
       <xref ref-type="bibr" rid="CR22">
        22
       </xref>
       ]. Conversely, Bilan et al. [
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
       ] demonstrated in a 1-year placebo-controlled study of 41 PAH patients with scleroderma that enalapril did not alter LV systolic or diastolic function and heart diameter, and signs of PH were found in four of the patients. Zieliński et al. [
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
       ] demonstrated in 15 patients with hypoxic PH due to chronic obstructive lung disease that acute administration of captopril significantly decreased systemic arterial pressure but does not reduce PVR. In addition to blocking ACE and angiotensin receptors of the ACE–Ang II–AT
       <sub>
        1
       </sub>
       R axis, these inhibitors increase ACE2 and Ang-(1-7) expression levels in rats and humans [
       <xref ref-type="bibr" rid="CR25">
        25
       </xref>
       ]. In patients with primary PH, higher cardiac ACE2 activity and Ang-(1-7) levels provide cardioprotection; and in patients with pulmonary fibrosis, ACE2 expression is decreased [
       <xref ref-type="bibr" rid="CR26">
        26
       </xref>
       ]. These findings may indicate that ACE inhibition may be less effective in scleroderma and hypoxic PH or that it may be more effective in attenuation of remodeling when given earlier during the disease state. In addition to regressing remodeling, ACE inhibitors lower systemic blood pressure and therefore may not be beneficial for PH patients with right heart failure.
      </p>
     </sec>
    </sec>
    <sec id="Sec7">
     <title>
      The ACE2–Ang-(1-7)–Mas RAS Axis: Mechanism of Beneficial Effects
     </title>
     <p>
      There is a limited amount of evidence to support the mechanistic role of the ACE2–Ang-(1-7)–Mas axis. We do not completely understand how the ACE2–Ang-(1-7)–Mas axis protects the lungs from PH. Most of the literature has established that the Mas receptor is a G protein–coupled receptor, and its activation by Ang-(1-7) counteracts the actions of the ACE–Ang II–AT
      <sub>
       1
      </sub>
      R axis of the RAS system [
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      ]. Yet the mechanisms involved are still unclear. Like ACE2 its downstream targets, Ang-(1-7) and Mas, demonstrate its impact on endothelial function. Mas knockout mice exhibited impaired endothelial function and decreased NO and eNOS [
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ]. In cardiac myocytes from Mas-deficient mice, Mas deficiency impairs Ang-(1-7) signaling [
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      ].
     </p>
     <p>
      In a recent article, brain-selective ACE2 overexpression attenuated neurogenic hypertension, possibly through Mas and AT
      <sub>
       2
      </sub>
      R upregulation [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ]. Gallagher et al. [
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      •] reported that Ang-(1-7) prevented the Ang II–mediated reduction in ACE2 mRNA, and this was blocked by the Ang-(1-7) receptor antagonist [
      <sc>
       d
      </sc>
      -Ala
      <sup>
       7
      </sup>
      ]-ANG-(1-7) and mitogen-activated protein (MAP) kinase kinase inhibitor PD98059. They were also the first to demonstrate in vascular SMCs that MAP kinase-phosphatase pathway regulates ACE2 and maintains the balance between Ang II and Ang-(1-7). Ang-(1-7) functions through NO or prostaglandins and has antifibrotic and antioxidant properties. Gwathmey et al. [
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ••] were the first to demonstrate that Ang-(1-7) promotes the proteolytic conversion of Ang II by ACE2 within the nucleus to potentially endogenously modulate reactive oxygen species (ROS) production. Wang et al. [
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ] demonstrated that circulating Ang-(1-7) stimulated cardiac endothelial progenitor cell (EPC) proliferation benefiting myocardial infarction. Tallant et al. [
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
      ] suggest that Ang-(1-7) inhibits vascular growth through the release of prostacyclin, the prostacyclin-mediated production of cyclic adenosine monophosphate (cAMP), activation of cAMP-dependent protein kinase, and the attenuation of MAP kinase activation. These mechanistic studies have established that the ACE2–Ang-(1-7)–Mas receptor axis components exist within the nucleus and at every level of the vascular wall, poised to initiate and sustain a vasoprotective effect.
     </p>
    </sec>
    <sec id="Sec8">
     <title>
      Signaling of TGF-β and Bone Morphogenetic Proteins in Pulmonary Hypertension
     </title>
     <p>
      Ang II promotes growth, proliferation, and fibrosis. TGF-β upregulates ACE and downregulates ACE2. The TGF-β superfamily encompasses a large number of growth factors such as TGF-β ligands, activins, inhibins, and bone morphogenetic proteins (BMPs). BMPS are involved in vascular integrity and control of vascular cell proliferation [
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
      ]. Both TGF-β and BMP isoforms control endothelial cell and SMC proliferation, apoptosis, and extracellular matrix (ECM) secretion and deposition. BMPR-II and BMPR-1A plasma membrane protein expression is decreased in pulmonary endothelial cells in both heritable and sporadic PAH. BMPR-II has been localized to the endothelium and vascular SMCs of small pulmonary arteries [
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ]. Signal transduction studies reveal that BMP signals are mediated by type I and II receptors through downstream mediators, Smad1, Smad5, and Smad8. They form a complex with Smad4 and translocate into the nucleus. The function of BMPR-II is to mediate growth suppression and apoptosis in vasculature [
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      ]. Thus a loss of BMPR-II function may lead to the vasculopathy evident in PAH [
      <xref ref-type="bibr" rid="CR39">
       39
      </xref>
      ]. Late cultured EPCs from idiopathic PAH patients with BMPR-II mutation showed a hyperproliferative phenotype with impaired ability to form vascular networks [
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
      ].
     </p>
     <p>
      TGF-β signaling controls a number of functions: proliferation, migration, differentiation, apoptosis, ECM deposition, and secretion. Mutations in genes encoding either TGF-β or BMP signaling systems have been associated with PAH, and research suggests that abnormal TGF-β or BMP signaling is imbalanced in PAH [
      <xref ref-type="bibr" rid="CR41">
       41
      </xref>
      ]. Thus, TGF-β and BMP appear to play opposing roles (Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ) in maintenance and growth of pulmonary artery SMCs and endothelial cells [
      <xref ref-type="bibr" rid="CR42">
       42
      </xref>
      ]. Studies suggest an inhibitory effect of BMP signaling on pulmonary artery SMCs. Such cells from PAH patients are resistant to antiproliferative effects of BMP. TGF-β gain of proliferation and BMPR-II loss of growth suppression and inability to promote vascular SMC apoptosis may promote PAH development.
     </p>
     <p>
      Hong et al. [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ••] revealed increased RVSP and increased muscularization in
      <italic>
       Bmpr2
      </italic>
      knockout mice with incomplete penetrance. Reynolds et al. [
      <xref ref-type="bibr" rid="CR43">
       43
      </xref>
      ] demonstrated that overexpression of BMPR-II in a hypoxic rat model protects them against PAH development. BMPR-II heterozygous null mice have severe hypoxic PH with a decrease in eNOS expression and activity.
     </p>
     <p>
      TGF-β signaling is modulated in MCT rat models and the results are controversial. Some studies suggest that MCT inhibits signaling, and others suggest that MCT enhances signaling. Inhibition of activin-like kinase 5 (ALK5), a TGF-β type I receptor, prevents and reverses PAH [
      <xref ref-type="bibr" rid="CR44">
       44
      </xref>
      ]. In both hypoxic and MCT models, BMPR-II mRNA and protein expression are reduced, with increased TGF-β and Smad3 signaling in the MCT model and not in the hypoxic model. This increase in signaling, RVSP, and vascular remodeling in the MCT model was attenuated by ALK5 inhibition [
      <xref ref-type="bibr" rid="CR45">
       45
      </xref>
      ]. Reduction in BMPR-II signaling due to genetic or environmental cues may cause BMPR-II signaling to fall below a threshold that triggers PAH vasculopathy. An imbalance in TGF–β/BMP signaling promotes PAH development and progression.
     </p>
    </sec>
    <sec id="Sec9">
     <title>
      Future Directions
     </title>
     <p>
      Since its discovery in 2000, ACE2 has been investigated in the SARS coronavirus infection and in the cardiovascular, renal, central nervous, and pulmonary systems. The benefit of its overexpression and activation in PAH supports its use in a “proof of concept” preclinical trial. It will be interesting to discover the link between TGF-β, BMPR-II, and the ACE2–Ang-(1-7)–Mas axis because, regardless of the disease etiology, remodeling consists of intimal fibrosis, increased medial thickness, pulmonary arteriolar occlusion, and plexiform lesions. ACE2 has been shown to prevent fibrosis and other components of PVR. Therefore, ACE2 therapy may be effective at preventing disease progression in all forms of PH.
     </p>
     <p>
      Perturbation of BMP signaling is increased with missense mutations, and the knowledge of differences in disease severity and different BMPR-II mutations is critical to therapeutic design. Cilostazol, a phosphodiesterase III inhibitor, offers a synergistic benefit in ameliorating MCT-induced PAH in rats [
      <xref ref-type="bibr" rid="CR46">
       46
      </xref>
      ]. Rosuvastatin blunted the increase in RVSP but did not reduce mean arterial pressure in the Ren2 rat [
      <xref ref-type="bibr" rid="CR47">
       47
      </xref>
      ]. In a hypoxia-induced PH model, transplantation of Sca1+KDR+CXCR4+ cultured early EPCs failed to reverse vascular remodeling and changes in pulmonary hemodynamics, and intravenous administration of bone marrow cells failed to prevent an increase in RVSP and arterial muscularization, yet Raoul et al. [
      <xref ref-type="bibr" rid="CR48">
       48
      </xref>
      ] demonstrated that infusion of the same cells was effective in preventing MCT-induced PH. Zhao et al. [
      <xref ref-type="bibr" rid="CR49">
       49
      </xref>
      ] also showed that bone marrow–derived, endothelial-like progenitor cells were effective in preventing and reversing MCT-induced PH. Because pulmonary vascular remodeling encompasses: endothelial dysfunction, fibroblast and SMC activation, crosstalk between cells within the vascular wall, and recruitment of circulating progenitor cells, these may be potential therapeutic targets.
     </p>
     <p>
      In addition to targeting activation or overexpression of ACE2, the literature illustrates other possible novel targets for intervention: phosphodiesterase inhibitors, statins, L-arginine, antiplatelet agents, serotonin inhibitors, agents to alter ion channel function, gene therapy, elastase inhibitors, antiproliferative heparins, tyrosine kinase inhibitors, and bone marrow–derived endothelial progenitor cell treatment [
      <xref ref-type="bibr" rid="CR50">
       50
      </xref>
      ].
     </p>
     <p>
      The ACE–Ang II–AT
      <sub>
       1
      </sub>
      R axis of the RAS has been implicated in PAH, yet intervention studies using ACE inhibitors and ARBs remain controversial. Evidence targeting the ACE2–Ang-(1-7)–Mas axis of the RAS supports the idea that this axis antagonizes the proliferative, fibrotic, and hypertrophic effects of the ACE–Ang II–AT
      <sub>
       1
      </sub>
      R axis. In an effort to advance research efforts in PAH therapy, we must consider the efficacy of ACE2 activation in clinical trials, the use of subpressor doses of ACE inhibitors or ARBs in clinical trials, larger clinical trials, the efficacy of ACE inhibitors in regression of established lesions compared with new lesions, the timing of intervention, the identification of bone marrow cell types to treat PAH, and the development of animal models that reflect human PAH.
     </p>
    </sec>
    <sec id="Sec10" sec-type="conclusion">
     <title>
      Conclusions
     </title>
     <p>
      We need a novel strategic intervention, as PAH is a chronic, fatal disease. Current therapy addresses vasoconstrictor imbalance and endothelial dysfunction, but vasodilator therapy has yet to improve patient survival. Unlike epoprostenol, a prostacyclin analogue and potent vasodilator, most PAH therapies have not improved survival. Therefore, new therapies that target PVR are emerging. Increasing evidence supports the concept of an imbalance in various components of the RAS. Animal and human trials demonstrate that an imbalance that favors the ACE–Ang II–AT
      <sub>
       1
      </sub>
      R axis actions promotes proliferation, fibrosis, and growth. There is no current consensus for the efficacy of therapeutic PAH strategies such as ACEs or ARBs in human and animal models, yet the benefit of ACE2 overexpression and activation in lung is consistent. In PAH, ACE2 overexpression and activation exerts its effects via the ACE2–Ang-(1-7)–Mas axis, limiting the detrimental actions of the ACE–Ang II–AT
      <sub>
       1
      </sub>
      R axis and playing a protective role in PH. The exact mechanism of benefit remains elusive, but the benefit in both prevention and reversal studies in animal models is clear. Thus, activation of ACE2 is a novel and effective strategy for PAH that must be considered.
     </p>
    </sec>
    <back>
     <ack>
      <sec id="d29e832">
       <title>
        Disclosure
       </title>
       <p>
        No potential conflicts of interest relevant to this article were reported.
       </p>
      </sec>
     </ack>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref-list id="BSec1">
       <title>
        Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
       </title>
       <ref id="CR1">
        <label>
         1.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Grobe
           </surname>
           <given-names>
            JL
           </given-names>
          </name>
          <name>
           <surname>
            Mecca
           </surname>
           <given-names>
            AP
           </given-names>
          </name>
          <name>
           <surname>
            Lingis
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7)
         </article-title>
         <source>
          Am J Physiol Heart Circ Physiol
         </source>
         <year>
          2007
         </year>
         <volume>
          292
         </volume>
         <fpage>
          H736
         </fpage>
         <lpage>
          H742
         </lpage>
         <pub-id pub-id-type="doi">
          10.1152/ajpheart.00937.2006
         </pub-id>
         <pub-id pub-id-type="pmid">
          17098828
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR2">
        <label>
         2.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Ferreira
           </surname>
           <given-names>
            AJ
           </given-names>
          </name>
          <name>
           <surname>
            Shenoy
           </surname>
           <given-names>
            V
           </given-names>
          </name>
          <name>
           <surname>
            Yamazato
           </surname>
           <given-names>
            Y
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension
         </article-title>
         <source>
          Am J Respir Crit Care Med
         </source>
         <year>
          2009
         </year>
         <volume>
          179
         </volume>
         <fpage>
          1048
         </fpage>
         <lpage>
          1054
         </lpage>
         <pub-id pub-id-type="doi">
          10.1164/rccm.200811-1678OC
         </pub-id>
         <pub-id pub-id-type="pmid">
          19246717
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR3">
        <label>
         3.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Hamming
           </surname>
           <given-names>
            I
           </given-names>
          </name>
          <name>
           <surname>
            Cooper
           </surname>
           <given-names>
            ME
           </given-names>
          </name>
          <name>
           <surname>
            Haagmans
           </surname>
           <given-names>
            BL
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          The emerging role of ACE2 in physiology and disease
         </article-title>
         <source>
          J Pathol
         </source>
         <year>
          2007
         </year>
         <volume>
          212
         </volume>
         <fpage>
          1
         </fpage>
         <lpage>
          11
         </lpage>
         <pub-id pub-id-type="doi">
          10.1002/path.2162
         </pub-id>
         <pub-id pub-id-type="pmid">
          17464936
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR4">
        <label>
         4.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Donoghue
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <name>
           <surname>
            Hsieh
           </surname>
           <given-names>
            F
           </given-names>
          </name>
          <name>
           <surname>
            Baronas
           </surname>
           <given-names>
            E
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9
         </article-title>
         <source>
          Circ Res
         </source>
         <year>
          2000
         </year>
         <volume>
          87
         </volume>
         <fpage>
          E1
         </fpage>
         <lpage>
          E9
         </lpage>
         <pub-id pub-id-type="pmid">
          10969042
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR5">
        <label>
         5.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Hong
           </surname>
           <given-names>
            KH
           </given-names>
          </name>
          <name>
           <surname>
            Lee
           </surname>
           <given-names>
            YJ
           </given-names>
          </name>
          <name>
           <surname>
            Lee
           </surname>
           <given-names>
            E
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Genetic ablation of the
          <italic>
           BMPR2
          </italic>
          gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension
         </article-title>
         <source>
          Circulation
         </source>
         <year>
          2008
         </year>
         <volume>
          118
         </volume>
         <fpage>
          722
         </fpage>
         <lpage>
          730
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/CIRCULATIONAHA.107.736801
         </pub-id>
         <pub-id pub-id-type="pmid">
          18663089
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR6">
        <label>
         6.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Galie
           </surname>
           <given-names>
            N
           </given-names>
          </name>
          <name>
           <surname>
            Hoeper
           </surname>
           <given-names>
            MM
           </given-names>
          </name>
          <name>
           <surname>
            Humbert
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
         </article-title>
         <source>
          Eur Heart J
         </source>
         <year>
          2009
         </year>
         <volume>
          30
         </volume>
         <fpage>
          2493
         </fpage>
         <lpage>
          2537
         </lpage>
         <pub-id pub-id-type="doi">
          10.1093/eurheartj/ehp297
         </pub-id>
         <pub-id pub-id-type="pmid">
          19713419
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR7">
        <label>
         7.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Thomson
           </surname>
           <given-names>
            JR
           </given-names>
          </name>
          <name>
           <surname>
            Machado
           </surname>
           <given-names>
            RD
           </given-names>
          </name>
          <name>
           <surname>
            Pauciulo
           </surname>
           <given-names>
            MW
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family
         </article-title>
         <source>
          J Med Genet
         </source>
         <year>
          2000
         </year>
         <volume>
          37
         </volume>
         <fpage>
          741
         </fpage>
         <lpage>
          745
         </lpage>
         <pub-id pub-id-type="doi">
          10.1136/jmg.37.10.741
         </pub-id>
         <pub-id pub-id-type="pmid">
          11015450
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR8">
        <label>
         8.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Farber
           </surname>
           <given-names>
            HW
           </given-names>
          </name>
          <name>
           <surname>
            Loscalzo
           </surname>
           <given-names>
            J
           </given-names>
          </name>
         </person-group>
         <article-title>
          Pulmonary arterial hypertension
         </article-title>
         <source>
          N Engl J Med
         </source>
         <year>
          2004
         </year>
         <volume>
          351
         </volume>
         <fpage>
          1655
         </fpage>
         <lpage>
          1665
         </lpage>
         <pub-id pub-id-type="doi">
          10.1056/NEJMra035488
         </pub-id>
         <pub-id pub-id-type="pmid">
          15483284
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR9">
        <label>
         9.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Runo
           </surname>
           <given-names>
            JR
           </given-names>
          </name>
          <name>
           <surname>
            Loyd
           </surname>
           <given-names>
            JE
           </given-names>
          </name>
         </person-group>
         <article-title>
          Primary pulmonary hypertension
         </article-title>
         <source>
          Lancet
         </source>
         <year>
          2003
         </year>
         <volume>
          361
         </volume>
         <fpage>
          1533
         </fpage>
         <lpage>
          1544
         </lpage>
         <pub-id pub-id-type="doi">
          10.1016/S0140-6736(03)13167-4
         </pub-id>
         <pub-id pub-id-type="pmid">
          12737878
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR10">
        <label>
         10.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Lovren
           </surname>
           <given-names>
            F
           </given-names>
          </name>
          <name>
           <surname>
            Pan
           </surname>
           <given-names>
            Y
           </given-names>
          </name>
          <name>
           <surname>
            Quan
           </surname>
           <given-names>
            A
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis
         </article-title>
         <source>
          Am J Physiol Heart Circ Physiol
         </source>
         <year>
          2008
         </year>
         <volume>
          295
         </volume>
         <fpage>
          H1377
         </fpage>
         <lpage>
          H1384
         </lpage>
         <pub-id pub-id-type="doi">
          10.1152/ajpheart.00331.2008
         </pub-id>
         <pub-id pub-id-type="pmid">
          18660448
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR11">
        <label>
         11.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Morrell
           </surname>
           <given-names>
            NW
           </given-names>
          </name>
          <name>
           <surname>
            Morris
           </surname>
           <given-names>
            KG
           </given-names>
          </name>
          <name>
           <surname>
            Stenmark
           </surname>
           <given-names>
            KR
           </given-names>
          </name>
         </person-group>
         <article-title>
          Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension
         </article-title>
         <source>
          Am J Physiol
         </source>
         <year>
          1995
         </year>
         <volume>
          269
         </volume>
         <fpage>
          H1186
         </fpage>
         <lpage>
          H1194
         </lpage>
         <pub-id pub-id-type="pmid">
          7485548
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR12">
        <label>
         12.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Imai
           </surname>
           <given-names>
            Y
           </given-names>
          </name>
          <name>
           <surname>
            Kuba
           </surname>
           <given-names>
            K
           </given-names>
          </name>
          <name>
           <surname>
            Rao
           </surname>
           <given-names>
            S
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Angiotensin-converting enzyme 2 protects from severe acute lung failure
         </article-title>
         <source>
          Nature
         </source>
         <year>
          2005
         </year>
         <volume>
          436
         </volume>
         <fpage>
          112
         </fpage>
         <lpage>
          116
         </lpage>
         <pub-id pub-id-type="doi">
          10.1038/nature03712
         </pub-id>
         <pub-id pub-id-type="pmid">
          16001071
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR13">
        <label>
         13.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Zhang
           </surname>
           <given-names>
            R
           </given-names>
          </name>
          <name>
           <surname>
            Wu
           </surname>
           <given-names>
            Y
           </given-names>
          </name>
          <name>
           <surname>
            Zhao
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells
         </article-title>
         <source>
          Am J Physiol Lung Cell Mol Physiol
         </source>
         <year>
          2009
         </year>
         <volume>
          297
         </volume>
         <fpage>
          L631
         </fpage>
         <lpage>
          L640
         </lpage>
         <pub-id pub-id-type="doi">
          10.1152/ajplung.90415.2008
         </pub-id>
         <pub-id pub-id-type="pmid">
          19592460
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR14">
        <label>
         14.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Yamazato
           </surname>
           <given-names>
            Y
           </given-names>
          </name>
          <name>
           <surname>
            Ferreira
           </surname>
           <given-names>
            AJ
           </given-names>
          </name>
          <name>
           <surname>
            Hong
           </surname>
           <given-names>
            KH
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer
         </article-title>
         <source>
          Hypertension
         </source>
         <year>
          2009
         </year>
         <volume>
          54
         </volume>
         <fpage>
          365
         </fpage>
         <lpage>
          371
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/HYPERTENSIONAHA.108.125468
         </pub-id>
         <pub-id pub-id-type="pmid">
          19564552
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR15">
        <label>
         15.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Rentzsch
           </surname>
           <given-names>
            B
           </given-names>
          </name>
          <name>
           <surname>
            Todiras
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <name>
           <surname>
            Iliescu
           </surname>
           <given-names>
            R
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function
         </article-title>
         <source>
          Hypertension
         </source>
         <year>
          2008
         </year>
         <volume>
          52
         </volume>
         <fpage>
          967
         </fpage>
         <lpage>
          973
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/HYPERTENSIONAHA.108.114322
         </pub-id>
         <pub-id pub-id-type="pmid">
          18809792
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR16">
        <label>
         16.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Harrison-Bernard
           </surname>
           <given-names>
            LM
           </given-names>
          </name>
         </person-group>
         <article-title>
          The renal renin-angiotensin system
         </article-title>
         <source>
          Adv Physiol Educ
         </source>
         <year>
          2009
         </year>
         <volume>
          33
         </volume>
         <fpage>
          270
         </fpage>
         <lpage>
          274
         </lpage>
         <pub-id pub-id-type="doi">
          10.1152/advan.00049.2009
         </pub-id>
         <pub-id pub-id-type="pmid">
          19948673
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR17">
        <label>
         17.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Kanno
           </surname>
           <given-names>
            S
           </given-names>
          </name>
          <name>
           <surname>
            Wu
           </surname>
           <given-names>
            YJ
           </given-names>
          </name>
          <name>
           <surname>
            Lee
           </surname>
           <given-names>
            PC
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats
         </article-title>
         <source>
          Circulation
         </source>
         <year>
          2001
         </year>
         <volume>
          104
         </volume>
         <fpage>
          945
         </fpage>
         <lpage>
          950
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/hc3401.093155
         </pub-id>
         <pub-id pub-id-type="pmid">
          11514384
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR18">
        <label>
         18.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Jeffery
           </surname>
           <given-names>
            TK
           </given-names>
          </name>
          <name>
           <surname>
            Wanstall
           </surname>
           <given-names>
            JC
           </given-names>
          </name>
         </person-group>
         <article-title>
          Perindopril, an angiotensin converting enzyme inhibitor, in pulmonary hypertensive rats: comparative effects on pulmonary vascular structure and function
         </article-title>
         <source>
          Br J Pharmacol
         </source>
         <year>
          1999
         </year>
         <volume>
          128
         </volume>
         <fpage>
          1407
         </fpage>
         <lpage>
          1418
         </lpage>
         <pub-id pub-id-type="doi">
          10.1038/sj.bjp.0702923
         </pub-id>
         <pub-id pub-id-type="pmid">
          10602319
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR19">
        <label>
         19.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Han
           </surname>
           <given-names>
            SX
           </given-names>
          </name>
          <name>
           <surname>
            He
           </surname>
           <given-names>
            GM
           </given-names>
          </name>
          <name>
           <surname>
            Wang
           </surname>
           <given-names>
            T
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: possible involvement of angiotensin-converting enzyme-2
         </article-title>
         <source>
          Toxicol Appl Pharmacol
         </source>
         <year>
          2010
         </year>
         <volume>
          245
         </volume>
         <fpage>
          100
         </fpage>
         <lpage>
          107
         </lpage>
         <pub-id pub-id-type="doi">
          10.1016/j.taap.2010.02.009
         </pub-id>
         <pub-id pub-id-type="pmid">
          20178811
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR20">
        <label>
         20.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Okada
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <name>
           <surname>
            Harada
           </surname>
           <given-names>
            T
           </given-names>
          </name>
          <name>
           <surname>
            Kikuzuki
           </surname>
           <given-names>
            R
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats
         </article-title>
         <source>
          J Pharmacol Sci
         </source>
         <year>
          2009
         </year>
         <volume>
          111
         </volume>
         <fpage>
          193
         </fpage>
         <lpage>
          200
         </lpage>
         <pub-id pub-id-type="doi">
          10.1254/jphs.09112FP
         </pub-id>
         <pub-id pub-id-type="pmid">
          19809219
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR21">
        <label>
         21.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Tavli
           </surname>
           <given-names>
            T
           </given-names>
          </name>
          <name>
           <surname>
            Gocer
           </surname>
           <given-names>
            H
           </given-names>
          </name>
         </person-group>
         <article-title>
          Effects of cilazapril on endothelial function and pulmonary hypertension in patients with congestive heart failure
         </article-title>
         <source>
          Jpn Heart J
         </source>
         <year>
          2002
         </year>
         <volume>
          43
         </volume>
         <fpage>
          667
         </fpage>
         <lpage>
          674
         </lpage>
         <pub-id pub-id-type="doi">
          10.1536/jhj.43.667
         </pub-id>
         <pub-id pub-id-type="pmid">
          12558130
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR22">
        <label>
         22.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Niazova
           </surname>
           <given-names>
            ZA
           </given-names>
          </name>
          <name>
           <surname>
            Batyraliev
           </surname>
           <given-names>
            TA
           </given-names>
          </name>
          <name>
           <surname>
            Aikimbaev
           </surname>
           <given-names>
            KS
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          High-altitude pulmonary hypertension: effects of captopril on pulmonary and systemic arterial pressures
         </article-title>
         <source>
          J Hum Hypertens
         </source>
         <year>
          1996
         </year>
         <volume>
          10
         </volume>
         <issue>
          Suppl 3
         </issue>
         <fpage>
          S141
         </fpage>
         <lpage>
          S142
         </lpage>
         <pub-id pub-id-type="pmid">
          8872846
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR23">
        <label>
         23.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Bilan
           </surname>
           <given-names>
            A
           </given-names>
          </name>
          <name>
           <surname>
            Chibowska
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <name>
           <surname>
            Makaruk
           </surname>
           <given-names>
            B
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): echocardiographic substudy—three months follow-up
         </article-title>
         <source>
          Adv Exp Med Biol
         </source>
         <year>
          1999
         </year>
         <volume>
          455
         </volume>
         <fpage>
          279
         </fpage>
         <lpage>
          283
         </lpage>
         <pub-id pub-id-type="pmid">
          10599355
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR24">
        <label>
         24.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Zielinski
           </surname>
           <given-names>
            J
           </given-names>
          </name>
          <name>
           <surname>
            Hawrylkiewicz
           </surname>
           <given-names>
            I
           </given-names>
          </name>
          <name>
           <surname>
            Gorecka
           </surname>
           <given-names>
            D
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Captopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale
         </article-title>
         <source>
          Chest
         </source>
         <year>
          1986
         </year>
         <volume>
          90
         </volume>
         <fpage>
          562
         </fpage>
         <lpage>
          565
         </lpage>
         <pub-id pub-id-type="doi">
          10.1378/chest.90.4.562
         </pub-id>
         <pub-id pub-id-type="pmid">
          3530649
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR25">
        <label>
         25.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Chappell
           </surname>
           <given-names>
            MC
           </given-names>
          </name>
          <name>
           <surname>
            Pirro
           </surname>
           <given-names>
            NT
           </given-names>
          </name>
          <name>
           <surname>
            Sykes
           </surname>
           <given-names>
            A
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme
         </article-title>
         <source>
          Hypertension
         </source>
         <year>
          1998
         </year>
         <volume>
          31
         </volume>
         <fpage>
          362
         </fpage>
         <lpage>
          367
         </lpage>
         <pub-id pub-id-type="pmid">
          9453329
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR26">
        <label>
         26.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Li
           </surname>
           <given-names>
            X
           </given-names>
          </name>
          <name>
           <surname>
            Molina-Molina
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <name>
           <surname>
            Abdul-Hafez
           </surname>
           <given-names>
            A
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis
         </article-title>
         <source>
          Am J Physiol Lung Cell Mol Physiol
         </source>
         <year>
          2008
         </year>
         <volume>
          295
         </volume>
         <fpage>
          L178
         </fpage>
         <lpage>
          L185
         </lpage>
         <pub-id pub-id-type="doi">
          10.1152/ajplung.00009.2008
         </pub-id>
         <pub-id pub-id-type="pmid">
          18441099
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR27">
        <label>
         27.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Kostenis
           </surname>
           <given-names>
            E
           </given-names>
          </name>
          <name>
           <surname>
            Milligan
           </surname>
           <given-names>
            G
           </given-names>
          </name>
          <name>
           <surname>
            Christopoulos
           </surname>
           <given-names>
            A
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor
         </article-title>
         <source>
          Circulation
         </source>
         <year>
          2005
         </year>
         <volume>
          111
         </volume>
         <fpage>
          1806
         </fpage>
         <lpage>
          1813
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/01.CIR.0000160867.23556.7D
         </pub-id>
         <pub-id pub-id-type="pmid">
          15809376
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR28">
        <label>
         28.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Santo
           </surname>
           <given-names>
            RA
           </given-names>
          </name>
          <name>
           <surname>
            Castro
           </surname>
           <given-names>
            CH
           </given-names>
          </name>
          <name>
           <surname>
            Gava
           </surname>
           <given-names>
            E
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice
         </article-title>
         <source>
          Hypertension
         </source>
         <year>
          2006
         </year>
         <volume>
          47
         </volume>
         <fpage>
          996
         </fpage>
         <lpage>
          1002
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/01.HYP.0000215289.51180.5c
         </pub-id>
         <pub-id pub-id-type="pmid">
          16567589
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR29">
        <label>
         29.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Dias-Peixoto
           </surname>
           <given-names>
            MF
           </given-names>
          </name>
          <name>
           <surname>
            Santos
           </surname>
           <given-names>
            RA
           </given-names>
          </name>
          <name>
           <surname>
            Gomes
           </surname>
           <given-names>
            ER
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes
         </article-title>
         <source>
          Hypertension
         </source>
         <year>
          2008
         </year>
         <volume>
          52
         </volume>
         <fpage>
          542
         </fpage>
         <lpage>
          548
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/HYPERTENSIONAHA.108.114280
         </pub-id>
         <pub-id pub-id-type="pmid">
          18695148
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR30">
        <label>
         30.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Feng
           </surname>
           <given-names>
            Y
           </given-names>
          </name>
          <name>
           <surname>
            Xia
           </surname>
           <given-names>
            H
           </given-names>
          </name>
          <name>
           <surname>
            Cai
           </surname>
           <given-names>
            Y
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Brain-selective overexpression of human angiotensin-converting enzyme type 2 attenuates neurogenic hypertension
         </article-title>
         <source>
          Circ Res
         </source>
         <year>
          2010
         </year>
         <volume>
          106
         </volume>
         <fpage>
          373
         </fpage>
         <lpage>
          382
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/CIRCRESAHA.109.208645
         </pub-id>
         <pub-id pub-id-type="pmid">
          19926873
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR31">
        <label>
         31.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Gallagher
           </surname>
           <given-names>
            PE
           </given-names>
          </name>
          <name>
           <surname>
            Ferrario
           </surname>
           <given-names>
            CM
           </given-names>
          </name>
          <name>
           <surname>
            Tallant
           </surname>
           <given-names>
            EA
           </given-names>
          </name>
         </person-group>
         <article-title>
          MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides
         </article-title>
         <source>
          Am J Physiol Cell Physiol
         </source>
         <year>
          2008
         </year>
         <volume>
          295
         </volume>
         <fpage>
          C1169
         </fpage>
         <lpage>
          C1174
         </lpage>
         <pub-id pub-id-type="doi">
          10.1152/ajpcell.00145.2008
         </pub-id>
         <pub-id pub-id-type="pmid">
          18768926
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR32">
        <label>
         32.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Gwathmey
           </surname>
           <given-names>
            TM
           </given-names>
          </name>
          <name>
           <surname>
            Pendergrass
           </surname>
           <given-names>
            KD
           </given-names>
          </name>
          <name>
           <surname>
            Reid
           </surname>
           <given-names>
            SD
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Angiotensin-(1-7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus
         </article-title>
         <source>
          Hypertension
         </source>
         <year>
          2010
         </year>
         <volume>
          55
         </volume>
         <fpage>
          166
         </fpage>
         <lpage>
          171
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/HYPERTENSIONAHA.109.141622
         </pub-id>
         <pub-id pub-id-type="pmid">
          19948986
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR33">
        <label>
         33.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Wang
           </surname>
           <given-names>
            LW
           </given-names>
          </name>
          <name>
           <surname>
            Fu
           </surname>
           <given-names>
            XL
           </given-names>
          </name>
          <name>
           <surname>
            Clough
           </surname>
           <given-names>
            R
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis?
         </article-title>
         <source>
          Radiat Res
         </source>
         <year>
          2000
         </year>
         <volume>
          153
         </volume>
         <fpage>
          405
         </fpage>
         <lpage>
          410
         </lpage>
         <pub-id pub-id-type="doi">
          10.1667/0033-7587(2000)153[0405:CACEIP]2.0.CO;2
         </pub-id>
         <pub-id pub-id-type="pmid">
          10761000
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR34">
        <label>
         34.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Wang
           </surname>
           <given-names>
            Y
           </given-names>
          </name>
          <name>
           <surname>
            Qian
           </surname>
           <given-names>
            C
           </given-names>
          </name>
          <name>
           <surname>
            Roks
           </surname>
           <given-names>
            A
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction
         </article-title>
         <source>
          Circ Heart Fail
         </source>
         <year>
          2010
         </year>
         <volume>
          3
         </volume>
         <fpage>
          286
         </fpage>
         <lpage>
          293
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/CIRCHEARTFAILURE.109.905968
         </pub-id>
         <pub-id pub-id-type="pmid">
          20103774
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR35">
        <label>
         35.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Tallant
           </surname>
           <given-names>
            EA
           </given-names>
          </name>
          <name>
           <surname>
            Clark
           </surname>
           <given-names>
            MA
           </given-names>
          </name>
         </person-group>
         <article-title>
          Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7)
         </article-title>
         <source>
          Hypertension
         </source>
         <year>
          2003
         </year>
         <volume>
          42
         </volume>
         <fpage>
          574
         </fpage>
         <lpage>
          579
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/01.HYP.0000090322.55782.30
         </pub-id>
         <pub-id pub-id-type="pmid">
          12953014
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR36">
        <label>
         36.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Fujiwara
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <name>
           <surname>
            Yagi
           </surname>
           <given-names>
            H
           </given-names>
          </name>
          <name>
           <surname>
            Matsuoka
           </surname>
           <given-names>
            R
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (
          <italic>
           BMPR2
          </italic>
          ) in children with pulmonary arterial hypertension
         </article-title>
         <source>
          Circ J
         </source>
         <year>
          2008
         </year>
         <volume>
          72
         </volume>
         <fpage>
          127
         </fpage>
         <lpage>
          133
         </lpage>
         <pub-id pub-id-type="doi">
          10.1253/circj.72.127
         </pub-id>
         <pub-id pub-id-type="pmid">
          18159113
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR37">
        <label>
         37.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Atkinson
           </surname>
           <given-names>
            C
           </given-names>
          </name>
          <name>
           <surname>
            Stewart
           </surname>
           <given-names>
            S
           </given-names>
          </name>
          <name>
           <surname>
            Upton
           </surname>
           <given-names>
            PD
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor
         </article-title>
         <source>
          Circulation
         </source>
         <year>
          2002
         </year>
         <volume>
          105
         </volume>
         <fpage>
          1672
         </fpage>
         <lpage>
          1678
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/01.CIR.0000012754.72951.3D
         </pub-id>
         <pub-id pub-id-type="pmid">
          11940546
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR38">
        <label>
         38.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Nakaoka
           </surname>
           <given-names>
            T
           </given-names>
          </name>
          <name>
           <surname>
            Gonda
           </surname>
           <given-names>
            K
           </given-names>
          </name>
          <name>
           <surname>
            Ogita
           </surname>
           <given-names>
            T
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2
         </article-title>
         <source>
          J Clin Invest
         </source>
         <year>
          1997
         </year>
         <volume>
          100
         </volume>
         <fpage>
          2824
         </fpage>
         <lpage>
          2832
         </lpage>
         <pub-id pub-id-type="doi">
          10.1172/JCI119830
         </pub-id>
         <pub-id pub-id-type="pmid">
          9389748
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR39">
        <label>
         39.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Long
           </surname>
           <given-names>
            L
           </given-names>
          </name>
          <name>
           <surname>
            Crosby
           </surname>
           <given-names>
            A
           </given-names>
          </name>
          <name>
           <surname>
            Yang
           </surname>
           <given-names>
            X
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease
         </article-title>
         <source>
          Circulation
         </source>
         <year>
          2009
         </year>
         <volume>
          119
         </volume>
         <fpage>
          566
         </fpage>
         <lpage>
          576
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/CIRCULATIONAHA.108.821504
         </pub-id>
         <pub-id pub-id-type="pmid">
          19153267
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR40">
        <label>
         40.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Toshner
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <name>
           <surname>
            Voswinckel
           </surname>
           <given-names>
            R
           </given-names>
          </name>
          <name>
           <surname>
            Southwood
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension
         </article-title>
         <source>
          Am J Respir Crit Care Med
         </source>
         <year>
          2009
         </year>
         <volume>
          180
         </volume>
         <fpage>
          780
         </fpage>
         <lpage>
          787
         </lpage>
         <pub-id pub-id-type="doi">
          10.1164/rccm.200810-1662OC
         </pub-id>
         <pub-id pub-id-type="pmid">
          19628780
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR41">
        <label>
         41.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Humbert
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <name>
           <surname>
            Morrell
           </surname>
           <given-names>
            NW
           </given-names>
          </name>
          <name>
           <surname>
            Archer
           </surname>
           <given-names>
            SL
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Cellular and molecular pathobiology of pulmonary arterial hypertension
         </article-title>
         <source>
          J Am Coll Cardiol
         </source>
         <year>
          2004
         </year>
         <volume>
          43
         </volume>
         <issue>
          12 Suppl S
         </issue>
         <fpage>
          13S
         </fpage>
         <lpage>
          24S
         </lpage>
         <pub-id pub-id-type="doi">
          10.1016/j.jacc.2004.02.029
         </pub-id>
         <pub-id pub-id-type="pmid">
          15194174
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR42">
        <label>
         42.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Newman
           </surname>
           <given-names>
            JH
           </given-names>
          </name>
          <name>
           <surname>
            Phillips
           </surname>
           <given-names>
            JA
           </given-names>
           <suffix>
            3rd
           </suffix>
          </name>
          <name>
           <surname>
            Loyd
           </surname>
           <given-names>
            JE
           </given-names>
          </name>
         </person-group>
         <article-title>
          Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies
         </article-title>
         <source>
          Ann Intern Med
         </source>
         <year>
          2008
         </year>
         <volume>
          148
         </volume>
         <fpage>
          278
         </fpage>
         <lpage>
          283
         </lpage>
         <pub-id pub-id-type="pmid">
          18283205
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR43">
        <label>
         43.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Reynolds
           </surname>
           <given-names>
            AM
           </given-names>
          </name>
          <name>
           <surname>
            Xia
           </surname>
           <given-names>
            W
           </given-names>
          </name>
          <name>
           <surname>
            Holmes
           </surname>
           <given-names>
            MD
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension
         </article-title>
         <source>
          Am J Physiol Lung Cell Mol Physiol
         </source>
         <year>
          2007
         </year>
         <volume>
          292
         </volume>
         <fpage>
          L1182
         </fpage>
         <lpage>
          L1192
         </lpage>
         <pub-id pub-id-type="doi">
          10.1152/ajplung.00020.2006
         </pub-id>
         <pub-id pub-id-type="pmid">
          17277049
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR44">
        <label>
         44.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Zaiman
           </surname>
           <given-names>
            AL
           </given-names>
          </name>
          <name>
           <surname>
            Podowski
           </surname>
           <given-names>
            M
           </given-names>
          </name>
          <name>
           <surname>
            Medicherla
           </surname>
           <given-names>
            S
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension
         </article-title>
         <source>
          Am J Respir Crit Care Med
         </source>
         <year>
          2008
         </year>
         <volume>
          177
         </volume>
         <fpage>
          896
         </fpage>
         <lpage>
          905
         </lpage>
         <pub-id pub-id-type="doi">
          10.1164/rccm.200707-1083OC
         </pub-id>
         <pub-id pub-id-type="pmid">
          18202349
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR45">
        <label>
         45.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Morty
           </surname>
           <given-names>
            RE
           </given-names>
          </name>
          <name>
           <surname>
            Nejman
           </surname>
           <given-names>
            B
           </given-names>
          </name>
          <name>
           <surname>
            Kwapiszewska
           </surname>
           <given-names>
            G
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension
         </article-title>
         <source>
          Arterioscler Thromb Vasc Biol
         </source>
         <year>
          2007
         </year>
         <volume>
          27
         </volume>
         <fpage>
          1072
         </fpage>
         <lpage>
          1078
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/ATVBAHA.107.141200
         </pub-id>
         <pub-id pub-id-type="pmid">
          17347486
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR46">
        <label>
         46.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Sun
           </surname>
           <given-names>
            CK
           </given-names>
          </name>
          <name>
           <surname>
            Lee
           </surname>
           <given-names>
            FY
           </given-names>
          </name>
          <name>
           <surname>
            Sheu
           </surname>
           <given-names>
            JJ
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Early combined treatment with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats
         </article-title>
         <source>
          J Pharmacol Exp Ther
         </source>
         <year>
          2009
         </year>
         <volume>
          330
         </volume>
         <fpage>
          718
         </fpage>
         <lpage>
          726
         </lpage>
         <pub-id pub-id-type="doi">
          10.1124/jpet.109.154328
         </pub-id>
         <pub-id pub-id-type="pmid">
          19528354
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR47">
        <label>
         47.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            DeMarco
           </surname>
           <given-names>
            VG
           </given-names>
          </name>
          <name>
           <surname>
            Habibi
           </surname>
           <given-names>
            J
           </given-names>
          </name>
          <name>
           <surname>
            Whaley-Connell
           </surname>
           <given-names>
            AT
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat
         </article-title>
         <source>
          Am J Physiol Heart Circ Physiol
         </source>
         <year>
          2009
         </year>
         <volume>
          297
         </volume>
         <fpage>
          H1128
         </fpage>
         <lpage>
          H1139
         </lpage>
         <pub-id pub-id-type="doi">
          10.1152/ajpheart.00048.2009
         </pub-id>
         <pub-id pub-id-type="pmid">
          19633211
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR48">
        <label>
         48.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Raoul
           </surname>
           <given-names>
            W
           </given-names>
          </name>
          <name>
           <surname>
            Wagner-Ballon
           </surname>
           <given-names>
            O
           </given-names>
          </name>
          <name>
           <surname>
            Saber
           </surname>
           <given-names>
            G
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Effects of bone marrow-derived cells on monocrotaline- and hypoxia-induced pulmonary hypertension in mice
         </article-title>
         <source>
          Respir Res
         </source>
         <year>
          2007
         </year>
         <volume>
          8
         </volume>
         <fpage>
          8
         </fpage>
         <pub-id pub-id-type="doi">
          10.1186/1465-9921-8-8
         </pub-id>
         <pub-id pub-id-type="pmid">
          17263874
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR49">
        <label>
         49.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Zhao
           </surname>
           <given-names>
            YD
           </given-names>
          </name>
          <name>
           <surname>
            Courtman
           </surname>
           <given-names>
            DW
           </given-names>
          </name>
          <name>
           <surname>
            Deng
           </surname>
           <given-names>
            Y
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease
         </article-title>
         <source>
          Circ Res
         </source>
         <year>
          2005
         </year>
         <volume>
          96
         </volume>
         <fpage>
          442
         </fpage>
         <lpage>
          450
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/01.RES.0000157672.70560.7b
         </pub-id>
         <pub-id pub-id-type="pmid">
          15692087
         </pub-id>
        </element-citation>
       </ref>
       <ref id="CR50">
        <label>
         50.
        </label>
        <element-citation publication-type="journal">
         <person-group person-group-type="author">
          <name>
           <surname>
            Newman
           </surname>
           <given-names>
            JH
           </given-names>
          </name>
          <name>
           <surname>
            Fanburg
           </surname>
           <given-names>
            BL
           </given-names>
          </name>
          <name>
           <surname>
            Archer
           </surname>
           <given-names>
            SL
           </given-names>
          </name>
          <etal>
          </etal>
         </person-group>
         <article-title>
          Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop
         </article-title>
         <source>
          Circulation
         </source>
         <year>
          2004
         </year>
         <volume>
          109
         </volume>
         <fpage>
          2947
         </fpage>
         <lpage>
          2952
         </lpage>
         <pub-id pub-id-type="doi">
          10.1161/01.CIR.0000132476.87231.6F
         </pub-id>
         <pub-id pub-id-type="pmid">
          15210611
         </pub-id>
        </element-citation>
       </ref>
      </ref-list>
     </ref-list>
    </back>
   </article>
   <article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Bioorg Med Chem Lett
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Bioorg. Med. Chem. Lett
      </journal-id>
      <journal-title-group>
       <journal-title>
        Bioorganic &amp; Medicinal Chemistry Letters
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0960-894X
      </issn>
      <issn pub-type="epub">
       1464-3405
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd. Published by Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       18078750
      </article-id>
      <article-id pub-id-type="pmc">
       7126659
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0960-894X(07)01358-3
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.bmcl.2007.11.048
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Thiol-based angiotensin-converting enzyme 2 inhibitors: P
        <sup>
         1
        </sup>
        modifications for the exploration of the S
        <sup>
         1
        </sup>
        subsite
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Deaton
         </surname>
         <given-names>
          David N.
         </given-names>
        </name>
        <email>
         david.n.deaton@gsk.com
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          Enoch N.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Graham
         </surname>
         <given-names>
          Kevin P.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gross
         </surname>
         <given-names>
          Jeffrey W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Miller
         </surname>
         <given-names>
          Aaron B.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Strelow
         </surname>
         <given-names>
          John M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Molecular Discovery Research, Screening &amp; Compound Profiling, GlaxoSmithKline, Upper Providence, PA 19426, USA
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Molecular Discovery Research, Computational and Structural Chemistry, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ⁎
        </label>
        Corresponding author. Tel.: +1 919 483 6270; fax: +1 919 315 0430.
        <email>
         david.n.deaton@gsk.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        19
       </day>
       <month>
        11
       </month>
       <year>
        2007
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <day>
        15
       </day>
       <month>
        1
       </month>
       <year>
        2008
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        19
       </day>
       <month>
        11
       </month>
       <year>
        2007
       </year>
      </pub-date>
      <volume>
       18
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       732
      </fpage>
      <lpage>
       737
      </lpage>
      <history>
       <date date-type="received">
        <day>
         13
        </day>
        <month>
         9
        </month>
        <year>
         2007
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         12
        </day>
        <month>
         11
        </month>
        <year>
         2007
        </year>
       </date>
       <date date-type="accepted">
        <day>
         14
        </day>
        <month>
         11
        </month>
        <year>
         2007
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2007 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2007
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="graphical">
       <title>
        Graphical abstract
       </title>
       <p>
        Screening of a metalloprotease library led to the identification of a thiol-based dual ACE/NEP inhibitor as a potent ACE2 inhibitor. Modifications of the P
        <sup>
         1
        </sup>
        benzyl moiety led to improvements in ACE2 potency as well as to increased selectivity versus ACE and NEP.
       </p>
       <fig id="d32e1261" position="anchor">
        <graphic xlink:href="fx1">
        </graphic>
       </fig>
      </abstract>
      <abstract>
       <p>
        Screening of a metalloprotease library led to the identification of a thiol-based dual ACE/NEP inhibitor as a potent ACE2 inhibitor. Modifications of the P
        <sup>
         1
        </sup>
        benzyl moiety led to improvements in ACE2 potency as well as to increased selectivity versus ACE and NEP.
       </p>
      </abstract>
      <kwd-group>
       <title>
        Keywords
       </title>
       <kwd>
        Angiotensin-converting enzyme 2
       </kwd>
       <kwd>
        Metalloproteases
       </kwd>
       <kwd>
        Protease inhibitors
       </kwd>
       <kwd>
        Thiols
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     Angiotensin-converting enzyme 2 (ACE2) is a recently identified clan MA, family M2 monocarboxypeptidase with highest homology to the dicarboxypeptidase angiotensin-converting enzyme (ACE, EC 3.4.15.1).
     <xref ref-type="bibr" rid="bib1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="bib2">
      2
     </xref>
     This membrane-associated and secreted metalloprotease is expressed in heart, kidney, testes, intestine, and lung, and has been implicated in cardiovascular disease, kidney disease, obesity, and lung disease.
     <xref ref-type="bibr" rid="bib3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="bib4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="bib5">
      5
     </xref>
    </p>
    <p>
     ACE2 processes angiotensin I and the AT
     <sub>
      1
     </sub>
     and AT
     <sub>
      2
     </sub>
     receptor agonist angiotensin II to produce angiotensin (1–9) and the
     <italic>
      mas
     </italic>
     receptor agonist angiotensin (1–7), respectively, but its exact role in the renin-angiotensin system (RAS) needs to be clarified. One group has reported that C57BL/6 ACE2 (−/−) mice exhibit a severe reduction in cardiac contractility, which is rescued in the ACE (−/−)/ACE2 (−/−) double knockout.
     <xref ref-type="bibr" rid="bib6">
      <sup>
       6
      </sup>
     </xref>
     In contrast, another group has disclosed that ACE2 (−/−) mice of 129/SvEv, C57BL/6, and mixed background do not exhibit cardiac contractility defects, but have increased susceptibility to angiotensin II-induced hypertension.
     <xref ref-type="bibr" rid="bib7">
      <sup>
       7
      </sup>
     </xref>
     While, a third group has revealed that male ACE (−/Y) mice are more susceptible to heart failure and death after transverse aortic constriction than their normal littermates.
     <xref ref-type="bibr" rid="bib8">
      <sup>
       8
      </sup>
     </xref>
     Supporting a role for ACE2 in cardiac function, transgenic mice overexpressing ACE2 in the heart have lower mean arterial pressure with rare focal myocyte vacuolization, myofibril splaying, and nuclear enlargement. Many of these mice develop terminal ventricular fibrillation with lethal arrhythmias.
     <xref ref-type="bibr" rid="bib9">
      <sup>
       9
      </sup>
     </xref>
    </p>
    <p>
     Furthermore, male ACE2 (−/Y) mice, but not female ACE2 (−/−) mice, also accumulate fibrillar collagen in the renal glomerular mesangium, leading to development of glomerulosclerosis of the kidneys.
     <xref ref-type="bibr" rid="bib10">
      <sup>
       10
      </sup>
     </xref>
     In addition, ACE2 (−/−) mice exhibit lower body weights than wild type mice with reduced fat mass.
     <xref ref-type="bibr" rid="bib11">
      <sup>
       11
      </sup>
     </xref>
     Moreover, ACE2 is also utilized by the severe acute respiratory syndrome (SARS) coronavirus as the receptor for infection.
     <xref ref-type="bibr" rid="bib12">
      <sup>
       12
      </sup>
     </xref>
     ACE2 (−/−) mice are resistant to SARS corona virus infection.
     <xref ref-type="bibr" rid="bib13">
      <sup>
       13
      </sup>
     </xref>
     Finally, ACE2 (−/−) mice have enhanced vascular permeability, increased lung edema, and worsened lung function in several murine acute respiratory distress syndrome (ARDS) models.
     <xref ref-type="bibr" rid="bib14">
      <sup>
       14
      </sup>
     </xref>
     With the many potential functions of ACE2, small molecule inhibitors of this enzyme could be utilized to help further define the physiological roles of this protease.
    </p>
    <p>
     ACE2 belongs to the zinc metalloprotease family and it has been reported that classical ACE inhibitors such as captopril and lisinopril do not attenuate ACE2 enzyme activity. As part of a strategy to discover lead molecules for an ACE2 inhibitor program, a directed screen of ACE2 versus a set of metalloprotease inhibitors from the GlaxoSmithKline compound collection was performed. Surprisingly, although confirming that classical ACE inhibitors like captopril were inactive in the screen, the thiol acid
     <bold>
      1a
     </bold>
     was identified as a potent ACE2 inhibitor (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 86 nM).
     <xref ref-type="bibr" rid="bib15">
      <sup>
       15
      </sup>
     </xref>
     This biphenyl analog
     <bold>
      1a
     </bold>
     is a known dual ACE and M13 metalloprotease neutral endopeptidase (neprilysin, NEP, EC 3.4.24.11) inhibitor (ACE
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 30 nM, NEP
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.1 nM).
     <xref ref-type="bibr" rid="bib16">
      <sup>
       16
      </sup>
     </xref>
     It also inhibits the M14 metalloprotease carboxypeptidase A1 (CpA, EC 3.4.17.1,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1,200 nM). Speculating that the thiol functioned as a binding group for the active site zinc and that the carboxylic acid served as a recognition element for the enzyme’s monocarboxypeptidase activity, the benzyl and methylene
     <italic>
      p
     </italic>
     -biphenyl moieties were surmised to be the P
     <sup>
      1
     </sup>
     and
     <inline-formula>
      <mml:math altimg="si1.gif" id="M1" overflow="scroll">
       <mml:mrow>
        <mml:msup>
         <mml:mrow>
          <mml:mi mathvariant="normal">
           P
          </mml:mi>
         </mml:mrow>
         <mml:mrow>
          <mml:msup>
           <mml:mrow>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
           <mml:mrow>
            <mml:mo>
             ′
            </mml:mo>
           </mml:mrow>
          </mml:msup>
         </mml:mrow>
        </mml:msup>
       </mml:mrow>
      </mml:math>
     </inline-formula>
     substituents. With this premise, the structure activity relationships of the P
     <sup>
      1
     </sup>
     position of the lead inhibitor were explored with the goal of improving potency and reducing ACE and NEP inhibitory activity.
     <fig id="d32e1426">
      <graphic xlink:href="fx2">
      </graphic>
     </fig>
    </p>
    <p>
     The thiol analogs
     <bold>
      1a
     </bold>
     –
     <bold>
      1s
     </bold>
     were prepared as depicted in
     <xref ref-type="fig" rid="fig4">
      Scheme 1
     </xref>
     . The acids
     <bold>
      3a
     </bold>
     –
     <bold>
      3s
     </bold>
     were activated in situ via the carbodiimide, converted into the activated esters with the aza-hydroxybenzotriazole, and then coupled to the amine hydrochloride
     <bold>
      4
     </bold>
     to produce the fully protected amides. Subsequent hydrolysis of the methyl ester, as well as the thioacetate, with lithium hydroxide afforded the thiol acids
     <bold>
      1a
     </bold>
     –
     <bold>
      1s
     </bold>
     .
     <xref ref-type="bibr" rid="bib17">
      <sup>
       17
      </sup>
     </xref>
     <fig id="fig4">
      <label>
       Scheme 1
      </label>
      <caption>
       <p>
        Reagents and conditions: (a)
        <bold>
         2c
        </bold>
        and
        <bold>
         2e
        </bold>
        , X
        <private-char description="bond, double bond" name="E00C">
         <glyph-data format="PBM" id="pc-E00C" resolution="300" x-size="12" y-size="9">
          000000000000
000000000000
000000000000
111111111111
000000000000
111111111111
000000000000
000000000000
000000000000
         </glyph-data>
        </private-char>
        S, AcCl, NEt
        <sub>
         3
        </sub>
        , dioxane, 0 °C to rt, 15–37%; (b)
        <bold>
         2k
        </bold>
        ,
        <bold>
         2m
        </bold>
        , and
        <bold>
         2n
        </bold>
        , X
        <private-char description="bond, double bond" name="E00C">
         <glyph-ref glyph-data="pc-E00C">
         </glyph-ref>
        </private-char>
        O, AcSH, DIAD, PPh
        <sub>
         3
        </sub>
        , THF, 0 °C to rt, 24–67%; (c)
        <bold>
         2a
        </bold>
        –
        <bold>
         2b
        </bold>
        ,
        <bold>
         2d
        </bold>
        ,
        <bold>
         2f
        </bold>
        –
        <bold>
         2j
        </bold>
        ,
        <bold>
         2l
        </bold>
        ,
        <bold>
         2o
        </bold>
        –
        <bold>
         2s
        </bold>
        , X
        <private-char description="bond, double bond" name="E00C">
         <glyph-ref glyph-data="pc-E00C">
         </glyph-ref>
        </private-char>
        NH, HBr, NaNO
        <sub>
         2
        </sub>
        , H
        <sub>
         2
        </sub>
        O, 0 °C, 25–80%; (d) AcS
        <sup>
         −
        </sup>
        K
        <sup>
         +
        </sup>
        , DMF, 0 °C to rt, 11–72%; (e) EDC, HOAt,
        <italic>
         i
        </italic>
        -Pr
        <sub>
         2
        </sub>
        NEt, CH
        <sub>
         2
        </sub>
        Cl
        <sub>
         2
        </sub>
        , 48–96%; (f) LiOH·H
        <sub>
         2
        </sub>
        O, THF, H
        <sub>
         2
        </sub>
        O, 30–94%.
       </p>
      </caption>
      <graphic xlink:href="gr4">
      </graphic>
     </fig>
    </p>
    <p>
     The thiol acids
     <bold>
      3a
     </bold>
     –
     <bold>
      3s
     </bold>
     were produced by three different routes. Acids
     <bold>
      3c
     </bold>
     and
     <bold>
      3e
     </bold>
     were prepared by reaction of the commercially available thiols
     <bold>
      2c
     </bold>
     and
     <bold>
      2e
     </bold>
     (X
     <private-char description="bond, double bond" name="E00C">
      <glyph-ref glyph-data="pc-E00C">
      </glyph-ref>
     </private-char>
     S) with acetyl chloride. In contrast, the acids
     <bold>
      3k
     </bold>
     ,
     <bold>
      3m
     </bold>
     , and
     <bold>
      3n
     </bold>
     were produced from the alcohols
     <bold>
      2k
     </bold>
     ,
     <bold>
      2m
     </bold>
     , and
     <bold>
      2n
     </bold>
     (X
     <private-char description="bond, double bond" name="E00C">
      <glyph-ref glyph-data="pc-E00C">
      </glyph-ref>
     </private-char>
     O) via the Mitsunobu reaction with thioacetic acid.
     <xref ref-type="bibr" rid="bib18">
      <sup>
       18
      </sup>
     </xref>
     Alternatively, the acids
     <bold>
      3a
     </bold>
     –
     <bold>
      3b
     </bold>
     ,
     <bold>
      3d
     </bold>
     ,
     <bold>
      3f
     </bold>
     –
     <bold>
      3j
     </bold>
     ,
     <bold>
      3l
     </bold>
     , and
     <bold>
      3o
     </bold>
     –
     <bold>
      3s
     </bold>
     were synthesized from the commercially available amino acids
     <bold>
      2a
     </bold>
     –
     <bold>
      2b
     </bold>
     ,
     <bold>
      2d
     </bold>
     ,
     <bold>
      2f
     </bold>
     –
     <bold>
      2j
     </bold>
     ,
     <bold>
      2l
     </bold>
     , and
     <bold>
      2o
     </bold>
     –
     <bold>
      2s
     </bold>
     (X
     <private-char description="bond, double bond" name="E00C">
      <glyph-ref glyph-data="pc-E00C">
      </glyph-ref>
     </private-char>
     NH), by diazotization of the amines to afford the bromides, then subsequent displacement of the bromides, by potassium thioacetate, with stereochemical inversion. Some stereochemical erosion, presumably resulting from formation of the α-lactone before nucleophilic trapping, resulted during the Mitsunobu and diazotization reaction steps, but after coupling with the amine
     <bold>
      4
     </bold>
     , the minor diastereomer could be removed via chromatography.
    </p>
    <p>
     The structure/activity relationships of P
     <sup>
      1
     </sup>
     analogs are depicted in
     <xref ref-type="table" rid="tbl1">
      Table 1
     </xref>
     . The (R) isomer
     <bold>
      1b
     </bold>
     derived from
     <sc>
      l
     </sc>
     -phenylalanine displays the P
     <sup>
      1
     </sup>
     benzyl substituent in the unnatural configuration. This orientation of the P
     <sup>
      1
     </sup>
     substituent was detrimental to the ACE2 inhibitory activity of diastereomer
     <bold>
      1b
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1400 nM) as well as that of ACE (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 520 nM). This loss in inhibition is not surprising, since nature has evolved proteases to recognize the natural configuration of physiological peptide substrates. In contrast, NEP (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.3 nM) accommodated the alternate configuration with no loss in potency.
     <table-wrap id="tbl1" position="float">
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Inhibition of human ACE2, ACE, NEP, and CpA
        <inline-graphic xlink:href="fx3.gif">
        </inline-graphic>
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th>
          #
         </th>
         <th>
          R
          <sup>
           1
          </sup>
         </th>
         <th>
          R
          <sup>
           2
          </sup>
         </th>
         <th>
          ACE2
          <italic>
           K
          </italic>
          <sub>
           i App
          </sub>
          <xref ref-type="table-fn" rid="tblfn1">
           a
          </xref>
          (nM)
         </th>
         <th>
          ACE
          <italic>
           K
          </italic>
          <sub>
           i App
          </sub>
          <xref ref-type="table-fn" rid="tblfn2">
           b
          </xref>
          (nM)
         </th>
         <th>
          NEP
          <italic>
           K
          </italic>
          <sub>
           i App
          </sub>
          <xref ref-type="table-fn" rid="tblfn3">
           c
          </xref>
          (nM)
         </th>
         <th>
          CpA
          <italic>
           K
          </italic>
          <sub>
           i App
          </sub>
          <xref ref-type="table-fn" rid="tblfn4">
           d
          </xref>
          (nM)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td>
          <bold>
           1a
          </bold>
         </td>
         <td>
          CH
          <sub>
           2
          </sub>
          Ph
         </td>
         <td>
          H
         </td>
         <td>
          86
         </td>
         <td>
          30
         </td>
         <td>
          1.1
         </td>
         <td>
          1200
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1b
          </bold>
         </td>
         <td>
          H
         </td>
         <td>
          CH
          <sub>
           2
          </sub>
          Ph
         </td>
         <td>
          1400
         </td>
         <td>
          520
         </td>
         <td>
          1.3
         </td>
         <td>
          310
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1c
          </bold>
         </td>
         <td>
          H
         </td>
         <td>
          H
         </td>
         <td>
          320
         </td>
         <td>
          16
         </td>
         <td>
          13
         </td>
         <td>
          1700
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1d
          </bold>
         </td>
         <td>
          Me
         </td>
         <td>
          H
         </td>
         <td>
          6.9
         </td>
         <td>
          21
         </td>
         <td>
          23
         </td>
         <td>
          14,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1e
          </bold>
         </td>
         <td>
          Me
         </td>
         <td>
          Me
         </td>
         <td>
          2300
         </td>
         <td>
          3400
         </td>
         <td>
          730
         </td>
         <td>
          &gt;50,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1f
          </bold>
         </td>
         <td>
          Et
         </td>
         <td>
          H
         </td>
         <td>
          1.4
         </td>
         <td>
          8.6
         </td>
         <td>
          0.80
         </td>
         <td>
          9,300
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1g
          </bold>
         </td>
         <td>
          <italic>
           n
          </italic>
          -Bu
         </td>
         <td>
          H
         </td>
         <td>
          1.8
         </td>
         <td>
          9.3
         </td>
         <td>
          1.2
         </td>
         <td>
          8900
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1h
          </bold>
         </td>
         <td>
          <italic>
           i
          </italic>
          -Pr
         </td>
         <td>
          H
         </td>
         <td>
          1.5
         </td>
         <td>
          200
         </td>
         <td>
          13
         </td>
         <td>
          17,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1i
          </bold>
         </td>
         <td>
          (R)-s-Bu
         </td>
         <td>
          H
         </td>
         <td>
          1.5
         </td>
         <td>
          490
         </td>
         <td>
          27
         </td>
         <td>
          11,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1j
          </bold>
         </td>
         <td>
          (S)-s-Bu
         </td>
         <td>
          H
         </td>
         <td>
          1.6
         </td>
         <td>
          200
         </td>
         <td>
          2.4
         </td>
         <td>
          15,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1k
          </bold>
         </td>
         <td>
          Cyb
         </td>
         <td>
          H
         </td>
         <td>
          2.4
         </td>
         <td>
          620
         </td>
         <td>
          5.4
         </td>
         <td>
          12,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1l
          </bold>
         </td>
         <td>
          Cyp
         </td>
         <td>
          H
         </td>
         <td>
          1.8
         </td>
         <td>
          700
         </td>
         <td>
          38
         </td>
         <td>
          12,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1m
          </bold>
         </td>
         <td>
          Cyh
         </td>
         <td>
          H
         </td>
         <td>
          65
         </td>
         <td>
          13,000
         </td>
         <td>
          1300
         </td>
         <td>
          12,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1n
          </bold>
         </td>
         <td>
          Ph
         </td>
         <td>
          H
         </td>
         <td>
          84
         </td>
         <td>
          &gt;10,000
         </td>
         <td>
          410
         </td>
         <td>
          &gt;50,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1o
          </bold>
         </td>
         <td>
          <italic>
           i
          </italic>
          -Bu
         </td>
         <td>
          H
         </td>
         <td>
          1.4
         </td>
         <td>
          3.2
         </td>
         <td>
          0.28
         </td>
         <td>
          11,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1p
          </bold>
         </td>
         <td>
          CH
          <sub>
           2
          </sub>
          <italic>
           t
          </italic>
          -Bu
         </td>
         <td>
          H
         </td>
         <td>
          7.1
         </td>
         <td>
          2,700
         </td>
         <td>
          2.6
         </td>
         <td>
          22,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1q
          </bold>
         </td>
         <td>
          CH
          <sub>
           2
          </sub>
          Cyh
         </td>
         <td>
          H
         </td>
         <td>
          420
         </td>
         <td>
          840
         </td>
         <td>
          130
         </td>
         <td>
          17,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1r
          </bold>
         </td>
         <td>
          CH
          <sub>
           2
          </sub>
          β-Np
         </td>
         <td>
          H
         </td>
         <td>
          550
         </td>
         <td>
          210
         </td>
         <td>
          140
         </td>
         <td>
          32,000
         </td>
        </tr>
        <tr>
         <td>
          <bold>
           1s
          </bold>
         </td>
         <td>
          (CH
          <sub>
           2
          </sub>
          )
          <sub>
           2
          </sub>
          Ph
         </td>
         <td>
          H
         </td>
         <td>
          860
         </td>
         <td>
          93
         </td>
         <td>
          2.6
         </td>
         <td>
          5,000
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="tblfn1">
        <label>
         a
        </label>
        <p>
         Inhibition of recombinant human ACE2 activity in a fluorescence assay using 0.4 nM ACE2, 30 μM MCA-Tyr-Val-Ala-Asp-Ala-Pro-Lys(DNP)-OH as substrate in 1 μM Zn(OAc)
         <sub>
          2
         </sub>
         , 100 μM TCEP, 50 mM Hepes, 300 μM CHAPS, and 300 mM NaCl at pH = 7.5. The average percent coefficient of variance for the
         <italic>
          K
         </italic>
         <sub>
          i App
         </sub>
         values was 45%.
        </p>
       </fn>
      </table-wrap-foot>
      <table-wrap-foot>
       <fn id="tblfn2">
        <label>
         b
        </label>
        <p>
         Inhibition of recombinant human ACE activity in a fluorescence assay using 0.5 nM ACE, 10 μM MCA-Ala-Ser-Asp-Lys-Dap(DNP)-OH as substrate in 1 μM Zn(OAc)
         <sub>
          2
         </sub>
         , 100 μM TCEP, 50 mM Hepes, 300 μM CHAPS, and 300 mM NaCl at pH = 7.5. The average percent coefficient of variance for the
         <italic>
          K
         </italic>
         <sub>
          i App
         </sub>
         values was 58%.
        </p>
       </fn>
      </table-wrap-foot>
      <table-wrap-foot>
       <fn id="tblfn3">
        <label>
         c
        </label>
        <p>
         Inhibition of recombinant human NEP activity in a fluorescence assay using 0.15 nM NEP, 2 μM FAM-Gly-Pro-Leu-Gly-Leu-Phe-Ala-Arg-Lys(TAMRA)-NH
         <sub>
          2
         </sub>
         as substrate in 1 μM Zn(OAc)
         <sub>
          2
         </sub>
         , 100 μM TCEP, 50 mM Hepes, 300 μM CHAPS, and 300 mM NaCl at pH = 7.5. The average percent coefficient of variance for the
         <italic>
          K
         </italic>
         <sub>
          i App
         </sub>
         values was 43%.
        </p>
       </fn>
      </table-wrap-foot>
      <table-wrap-foot>
       <fn id="tblfn4">
        <label>
         d
        </label>
        <p>
         Inhibition of recombinant human CpA activity in a fluorescence assay using 37 nM CpA, 30 μM Abz-Gly-Gly-Nph-OH as substrate in 1 μM Zn(OAc)
         <sub>
          2
         </sub>
         , 100 μM TCEP, 50 mM Hepes, 300 μM CHAPS, and 300 mM NaCl at pH = 7.5. The average percent coefficient of variance for the
         <italic>
          K
         </italic>
         <sub>
          i App
         </sub>
         values was 38%.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
    </p>
    <p>
     Complete removal of the P
     <sup>
      1
     </sup>
     moiety caused a modest loss in inhibitory potency versus ACE2 (H,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 320 nM). This decrease in potency could arise from reduced van der Waals interactions due to the lack of a P
     <sup>
      1
     </sup>
     substituent, the increased entropic cost for the inhibitor to bind to the protease given the inhibitor’s increased rotational freedom, or a combination of these factors. In contrast to the D-isomer
     <bold>
      1b
     </bold>
     , the ACE activity (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 16 nM) of the glycine-like analog
     <bold>
      1c
     </bold>
     was not affected by elimination of the P
     <sup>
      1
     </sup>
     element, while NEP potency (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 13 nM) of
     <bold>
      1c
     </bold>
     decreased by over an order of magnitude.
    </p>
    <p>
     The alanine-derived analog
     <bold>
      1d
     </bold>
     (Me,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 6.9 nM) decreases rotational freedom and was an even more potent ACE2 inhibitor than the starting lead
     <bold>
      1a
     </bold>
     , while increasing selectivity versus both ACE (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 21 nM) and NEP (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 23 nM). In contrast, the geminal dimethyl analog
     <bold>
      1e
     </bold>
     (ACE2
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 2300 nM) decreased inhibitory potency versus not only ACE2, but also ACE (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 3,400 nM) and NEP (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 730 nM). Similar to the methyl analog
     <bold>
      1d
     </bold>
     , the linear P
     <sup>
      1
     </sup>
     ethyl and
     <italic>
      n
     </italic>
     -butyl analogs
     <bold>
      1f
     </bold>
     (Et,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.4 nM) and
     <bold>
      1g
     </bold>
     (
     <italic>
      n
     </italic>
     -Bu,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.8 nM) were also potent ACE2 inhibitors, but these extensions in P
     <sup>
      1
     </sup>
     also increased activity versus ACE (
     <bold>
      1f
     </bold>
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 8.6 nM,
     <bold>
      1g
     </bold>
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 9.3 nM) and even more so versus NEP (
     <bold>
      1f
     </bold>
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 0.80 nM,
     <bold>
      1g
     </bold>
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.2 nM).
    </p>
    <p>
     With the hope of improving the selectivity of these thiol-based inhibitors versus ACE and NEP, the effect of branching along the P
     <sup>
      1
     </sup>
     side chain of this inhibitor class was explored. Branching along the P
     <sup>
      1
     </sup>
     chain was well tolerated in the S
     <sup>
      1
     </sup>
     subsite of ACE2. The α-branched
     <italic>
      iso
     </italic>
     -propyl
     <bold>
      1h
     </bold>
     (
     <italic>
      i
     </italic>
     -Pr,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.5 nM), (R)-
     <italic>
      sec
     </italic>
     -butyl
     <bold>
      1i
     </bold>
     ((R)-
     <italic>
      s
     </italic>
     -Bu,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.5 nM), (S)-
     <italic>
      sec
     </italic>
     -butyl
     <bold>
      1j
     </bold>
     ((S)-
     <italic>
      s
     </italic>
     -Bu,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.6 nM), cyclobutyl
     <bold>
      1k
     </bold>
     (Cyb,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 2.4 nM), and cyclopentyl
     <bold>
      1l
     </bold>
     (Cyp,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.8 nM) analogs and the β-branched
     <italic>
      iso
     </italic>
     -butyl
     <bold>
      1o
     </bold>
     (
     <italic>
      i
     </italic>
     -Bu,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.4 nM) and
     <italic>
      neo
     </italic>
     -pentyl
     <bold>
      1p
     </bold>
     (CH
     <sub>
      2
     </sub>
     <italic>
      t
     </italic>
     -Bu,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 7.1 nM) analogs maintained their ACE2 inhibition. Only the bulkier branched analogs, like the α-branched cyclohexyl
     <bold>
      1m
     </bold>
     (Cyh,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 65 nM) and phenyl
     <bold>
      1n
     </bold>
     (Ph,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 84 nM), the β-branched methylene cyclohexyl
     <bold>
      1q
     </bold>
     (CH
     <sub>
      2
     </sub>
     Cyh,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 420 nM) and methylene β-naphthyl
     <bold>
      1r
     </bold>
     (CH
     <sub>
      2
     </sub>
     β-Np,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 550 nM), and the γ-branched ethylene phenyl
     <bold>
      1s
     </bold>
     ((CH
     <sub>
      2
     </sub>
     )
     <sub>
      2
     </sub>
     Ph,
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 860 nM), were too large to be accommodated by the ACE2 S
     <sup>
      1
     </sup>
     subsite.
    </p>
    <p>
     In contrast, α-branching of the P
     <sup>
      1
     </sup>
     moiety was poorly tolerated by the ACE S
     <sup>
      1
     </sup>
     subsite, resulting in substantial decreases in ACE inhibitory activity for the α-branched
     <italic>
      iso
     </italic>
     -propyl
     <bold>
      1h
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 200 nM), (R)-
     <italic>
      sec
     </italic>
     -butyl
     <bold>
      1i
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 490 nM), (S)-
     <italic>
      sec
     </italic>
     -butyl
     <bold>
      1j
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 200 nM), cyclobutyl
     <bold>
      1k
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 620 nM), cyclopentyl
     <bold>
      1l
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 700 nM), cyclohexyl
     <bold>
      1m
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 13,000 nM), and phenyl
     <bold>
      1n
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = &gt;10,000 nM) analogs. The S
     <sup>
      1
     </sup>
     subsite of NEP is more accepting of α-branching in P
     <sup>
      1
     </sup>
     substituents than the ACE enzyme, but less liberal than ACE2. The α-branched
     <italic>
      iso
     </italic>
     -propyl
     <bold>
      1h
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 13 nM), (R)-
     <italic>
      sec
     </italic>
     -butyl
     <bold>
      1i
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 27 nM), (S)-
     <italic>
      sec
     </italic>
     -butyl
     <bold>
      1j
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 2.4 nM), cyclobutyl
     <bold>
      1k
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 5.4 nM), cyclopentyl
     <bold>
      1l
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 38 nM), cyclohexyl
     <bold>
      1m
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1300 nM), and phenyl
     <bold>
      1n
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 410 nM) analogs lost some inhibitory activity versus NEP relative to the ethyl analog
     <bold>
      1f
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 0.80 nM). Thus, α-branching at the P
     <sup>
      1
     </sup>
     group enhanced selectivity for ACE2 protease inhibition relative to ACE and NEP. The (R)-
     <italic>
      sec
     </italic>
     -butyl analog
     <bold>
      1i
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.5 nM) has 330-fold selectivity versus ACE and 18-fold selectivity versus NEP, while the cyclopentyl
     <bold>
      1l
     </bold>
     (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.8 nM) has 390-fold selectivity versus ACE and 21-fold selectivity versus NEP.
    </p>
    <p>
     In comparison to α-branching, both ACE and NEP S
     <sup>
      1
     </sup>
     subsites were more permissive to β-branching in P
     <sup>
      1
     </sup>
     groups. Thus, the
     <italic>
      iso
     </italic>
     -butyl
     <bold>
      1o
     </bold>
     analog is not only a potent ACE2 inhibitor (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 1.4 nM), but also a low nanomolar ACE (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 3.2 nM) and subnanomolar NEP inhibitor (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 0.28 nM). ACE is less tolerant of bulky β-branching, with the
     <italic>
      neo
     </italic>
     -pentyl
     <bold>
      1p
     </bold>
     analog exhibiting potent dual ACE2 (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 7.1 nM) and NEP (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 2.6 nM) inhibition with good selectivity over ACE (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 2700 nM). Larger β-branched substituents like the methylene cyclohexyl
     <bold>
      1q
     </bold>
     (ACE2
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 420 nM, ACE
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 840 nM, NEP
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 130 nM) and methylene β-naphthyl
     <bold>
      1r
     </bold>
     (ACE2
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 550 nM, ACE
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 210 nM, NEP
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 140 nM) attenuate inhibitory activity at all three enzymes. Finally, as the ethylene phenyl analog
     <bold>
      1
     </bold>
     <bold>
      s
     </bold>
     shows, like ACE2 (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 860 nM), ACE (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 93 nM) was less tolerant of γ-branching in P
     <sup>
      1
     </sup>
     groups, while NEP (
     <italic>
      K
     </italic>
     <sub>
      i App
     </sub>
     = 2.6 nM) accepted it. None of these thiol-based inhibitors was a potent inhibitor of CpA.
    </p>
    <p>
     A model of the thiol
     <bold>
      1i
     </bold>
     <xref ref-type="bibr" rid="bib19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="bib20">
      20
     </xref>
     docked into the active site of ACE2 based on the recent X-ray crystal structure
     <xref ref-type="bibr" rid="bib21">
      <sup>
       21
      </sup>
     </xref>
     is shown in
     <xref ref-type="fig" rid="fig1">
      Figure 1
     </xref>
     . It provides insight into the SAR of the thiol series. In addition to binding to the imidazole nitrogens of
     <sup>
      374
     </sup>
     His and
     <sup>
      378
     </sup>
     His and the carboxylate of
     <sup>
      402
     </sup>
     Glu, the active site zinc coordinates the thiol of the inhibitor. Also, the terminal carboxylate of the inhibitor forms electrostatic interactions with the guanidine of
     <sup>
      273
     </sup>
     Arg and accepts hydrogen bonds from the imidazoles of
     <sup>
      345
     </sup>
     His and
     <sup>
      505
     </sup>
     His. Moreover, the carbonyl of
     <sup>
      346
     </sup>
     Pro accepts a hydrogen bond from the amide nitrogen of the inhibitor, while the amide carbonyl is stabilized by a hydrogen bond to
     <sup>
      515
     </sup>
     Tyr. Furthermore, the
     <inline-formula>
      <mml:math altimg="si2.gif" id="M2" overflow="scroll">
       <mml:mrow>
        <mml:msup>
         <mml:mrow>
          <mml:mi mathvariant="normal">
           P
          </mml:mi>
         </mml:mrow>
         <mml:mrow>
          <mml:msup>
           <mml:mrow>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
           <mml:mrow>
            <mml:mo>
             ′
            </mml:mo>
           </mml:mrow>
          </mml:msup>
         </mml:mrow>
        </mml:msup>
       </mml:mrow>
      </mml:math>
     </inline-formula>
     methylene biphenyl substituent of
     <bold>
      1i
     </bold>
     forms significant lipophilic interactions with the quite large
     <inline-formula>
      <mml:math altimg="si3.gif" id="M3" overflow="scroll">
       <mml:mrow>
        <mml:msup>
         <mml:mrow>
          <mml:mi mathvariant="normal">
           S
          </mml:mi>
         </mml:mrow>
         <mml:mrow>
          <mml:msup>
           <mml:mrow>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
           <mml:mrow>
            <mml:mo>
             ′
            </mml:mo>
           </mml:mrow>
          </mml:msup>
         </mml:mrow>
        </mml:msup>
       </mml:mrow>
      </mml:math>
     </inline-formula>
     channel composed of the lengthwise canal between the two subdomains, including residues
     <sup>
      274
     </sup>
     Phe,
     <sup>
      276
     </sup>
     Thr,
     <sup>
      346
     </sup>
     Pro,
     <sup>
      367
     </sup>
     Asp,
     <sup>
      370
     </sup>
     Leu,
     <sup>
      371
     </sup>
     Thr, and
     <sup>
      374
     </sup>
     His. This biphenyl substituent is hypothesized to occupy a different part of this large pocket than the carboxyl inhibitor co-crystallized in 1R4L. The P
     <sup>
      1
     </sup>
     (R)-
     <italic>
      sec
     </italic>
     -butyl group of the inhibitor forms van der Waals interactions with the S
     <sup>
      1
     </sup>
     pocket composed of
     <sup>
      347
     </sup>
     Thr,
     <sup>
      504
     </sup>
     Phe,
     <sup>
      510
     </sup>
     Tyr, and
     <sup>
      514
     </sup>
     Arg. As shown in the close-up of the S
     <sup>
      1
     </sup>
     subsite depicted in
     <xref ref-type="fig" rid="fig2">
      Figure 2
     </xref>
     ,
     <sup>
      510
     </sup>
     Tyr forms part of a pocket which the α-branched methyl of the P
     <sup>
      1
     </sup>
     (R)-
     <italic>
      sec
     </italic>
     -butyl group occupies. Larger substituents are disfavored as they would require movement of the phenol side chain of
     <sup>
      510
     </sup>
     Tyr. Thus, this model agrees with the SAR, since the S
     <sup>
      1
     </sup>
     subsite can tolerate cyclobutyl and cyclopentyl substituents, but is less accepting of a cyclohexyl group.
     <fig id="fig1">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        A model of the thiol compound
        <bold>
         1i
        </bold>
        bound to the active site of ACE2 based on a X-ray co-crystal structure of a carboxylate inhibitor bound to ACE2 (PDB code 1R4L). The ACE2 carbons are colored cyan with inhibitor
        <bold>
         1i
        </bold>
        carbons colored green. The semi-transparent gray surface represents the molecular surface, while hydrogen bonds are depicted as yellow dashed lines. Several residues were removed for visual clarity. This figure was generated using PYMOL version 1.0 (Delano Scientific,
        <ext-link ext-link-type="uri" xlink:href="http://www.pymol.org">
         <underline>
          www.pymol.org
         </underline>
        </ext-link>
        ).
       </p>
      </caption>
      <graphic xlink:href="gr1">
      </graphic>
     </fig>
     <fig id="fig2">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        A close up of the P
        <sup>
         1
        </sup>
        pocket of the model of the thiol compound
        <bold>
         1i
        </bold>
        bound to the active site of ACE2 based on a X-ray co-crystal structure (PDB code 1R4L). The ACE2 carbons are colored cyan with inhibitor
        <bold>
         1i
        </bold>
        carbons colored green.
        <sup>
         510
        </sup>
        Tyr is colored in orange to highlight its putative role in the selectivity of
        <bold>
         1i
        </bold>
        . The semi-transparent gray surface represents the molecular surface. This figure was generated using PYMOL version 1.00 (Delano Scientific,
        <ext-link ext-link-type="uri" xlink:href="http://www.pymol.org">
         <underline>
          www.pymol.org
         </underline>
        </ext-link>
        ).
       </p>
      </caption>
      <graphic xlink:href="gr2">
      </graphic>
     </fig>
    </p>
    <p>
     A model of the inhibitor
     <bold>
      1i
     </bold>
     <xref ref-type="bibr" rid="bib19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="bib20">
      20
     </xref>
     docked into the active site of ACE, focusing on the S
     <sup>
      1
     </sup>
     subsite, based on the X-ray structure of lisinopril with ACE,
     <xref ref-type="bibr" rid="bib22">
      <sup>
       22
      </sup>
     </xref>
     is shown in
     <xref ref-type="fig" rid="fig3">
      Figure 3
     </xref>
     . From the model, it is apparent that the methyl group of the (R)-
     <italic>
      sec
     </italic>
     -butyl P
     <sup>
      1
     </sup>
     moiety of inhibitor
     <bold>
      1i
     </bold>
     bumps into the enzyme, helping explain the 330-fold selectivity for ACE2 versus ACE. The branching nature of
     <sup>
      518
     </sup>
     Val (atom CG1) makes this portion of the S
     <sup>
      1
     </sup>
     pocket smaller than in ACE2.
     <sup>
      518
     </sup>
     Val is the homologous residue in ACE to
     <sup>
      510
     </sup>
     Tyr in ACE2. This
     <sup>
      510
     </sup>
     Tyr to
     <sup>
      518
     </sup>
     Val substitution from ACE2 to ACE and resulting alteration of the S
     <sup>
      1
     </sup>
     pocket volume helps explain the reduced ability of ACE to accommodate α-branching in P
     <sup>
      1
     </sup>
     substituents.
     <fig id="fig3">
      <label>
       Figure 3
      </label>
      <caption>
       <p>
        A model of the thiol compound
        <bold>
         1i
        </bold>
        bound to the active site of ACE using the X-ray co-crystal structure of ACE and lisinopril (PDB code 1O86). The ACE carbons are colored magenta with inhibitor
        <bold>
         1i
        </bold>
        carbons colored green.
        <sup>
         518
        </sup>
        Val is colored orange to highlight its hypothesized role in the selectivity of
        <bold>
         1i
        </bold>
        . The semi-transparent gray surface represents the molecular surface. This figure was generated using PYMOL version 1.00 (Delano Scientific,
        <ext-link ext-link-type="uri" xlink:href="http://www.pymol.org">
         <underline>
          www.pymol.org
         </underline>
        </ext-link>
        ).
       </p>
      </caption>
      <graphic xlink:href="gr3">
      </graphic>
     </fig>
    </p>
    <p>
     Although X-ray structures of NEP co-crystallized with a thiol-based inhibitor (PDB code 1Y8J)
     <xref ref-type="bibr" rid="bib23">
      <sup>
       23
      </sup>
     </xref>
     and an analog with a
     <inline-formula>
      <mml:math altimg="si4.gif" id="M4" overflow="scroll">
       <mml:mrow>
        <mml:msup>
         <mml:mrow>
          <mml:mi mathvariant="normal">
           P
          </mml:mi>
         </mml:mrow>
         <mml:mrow>
          <mml:msup>
           <mml:mrow>
            <mml:mn>
             1
            </mml:mn>
           </mml:mrow>
           <mml:mrow>
            <mml:mo>
             ′
            </mml:mo>
           </mml:mrow>
          </mml:msup>
         </mml:mrow>
        </mml:msup>
       </mml:mrow>
      </mml:math>
     </inline-formula>
     bi-phenyl moiety (PDB code 1R1H)
     <xref ref-type="bibr" rid="bib24">
      <sup>
       24
      </sup>
     </xref>
     are available, as NEP belongs to a different metalloprotease family (M13 vs M2), no reasonable model of these thiol inhibitors bound to NEP could be determined to help explain the increase in NEP selectivity of α-branched P
     <sup>
      1
     </sup>
     analogs. Likely protein movement to accommodate potent NEP inhibitors like
     <bold>
      1o
     </bold>
     is required. The movement of multiple amino acid residues in proteins is difficult to predict accurately.
    </p>
    <p>
     In summary, a series of α-thiol amide-based inhibitors of ACE2 with varied substituents at the P
     <sup>
      1
     </sup>
     position were synthesized. Inhibitors containing linear alkyl P
     <sup>
      1
     </sup>
     moieties were some of the more potent analogs in the ACE2 enzymatic assay. The smaller α-branched P
     <sup>
      1
     </sup>
     substituents, exemplified by inhibitors
     <bold>
      1i
     </bold>
     and
     <bold>
      1l
     </bold>
     , maintained similar potencies, and increased selectivity versus ACE and NEP. Information gained from these studies has proven to be useful in the design of other ACE2 inhibitors. These inhibitors will be reported in due course. Furthermore, a potent pan ACE/ACE2/NEP inhibitor
     <bold>
      1o
     </bold>
     and a potent dual ACE2/NEP inhibitor
     <bold>
      1p
     </bold>
     have been identified. These tools may prove useful in further defining the roles these proteases play in the RAS cascade.
    </p>
    <back>
     <ref-list>
      <title>
       References and notes
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Godbout
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gosselin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stagliano
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Donovan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Woolf
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Robison
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Jeyaseelan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Breitbart
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Acton
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <source>
         Circ. Res.
        </source>
        <volume>
         87
        </volume>
        <year>
         2000
        </year>
        <fpage>
         e1
        </fpage>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Karran
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Christie
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         275
        </volume>
        <year>
         2000
        </year>
        <fpage>
         33238
        </fpage>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Danilczyk
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <source>
         Circ. Res.
        </source>
        <volume>
         98
        </volume>
        <year>
         2006
        </year>
        <fpage>
         463
        </fpage>
        <pub-id pub-id-type="pmid">
         16514079
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <source>
         Curr. Opin. Pharm.
        </source>
        <volume>
         6
        </volume>
        <year>
         2006
        </year>
        <fpage>
         271
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tallant
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
        </person-group>
        <source>
         Future Cardiol.
        </source>
        <volume>
         2
        </volume>
        <year>
         2006
        </year>
        <fpage>
         335
        </fpage>
        <pub-id pub-id-type="pmid">
         19804091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kozieradzki
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Scanga
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Oliveira-dos-Santos
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           da Costa
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Scholey
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Manoukian
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Backx
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yagil
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <source>
         Nature
        </source>
        <volume>
         417
        </volume>
        <year>
         2002
        </year>
        <fpage>
         822
        </fpage>
        <pub-id pub-id-type="pmid">
         12075344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gurley
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
         <name>
          <surname>
           Allred
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Le
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Griffiths
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Mao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Philip
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Haystead
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Breitbart
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Acton
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Rockman
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Coffman
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
        </person-group>
        <source>
         J. Clin. Invest.
        </source>
        <volume>
         116
        </volume>
        <year>
         2006
        </year>
        <fpage>
         2218
        </fpage>
        <pub-id pub-id-type="pmid">
         16878172
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ohishi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Katsuya
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ito
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ikushima
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kaibe
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tatara
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shiota
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sugano
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Takeda
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rakugi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ogihara
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <source>
         Hypertension
        </source>
        <volume>
         47
        </volume>
        <year>
         2006
        </year>
        <fpage>
         718
        </fpage>
        <pub-id pub-id-type="pmid">
         16505206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wakimoto
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Maguire
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Acton
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hales
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Stagliano
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fairchild-Huntress
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lorenz
          </surname>
          <given-names>
           J.N.
          </given-names>
         </name>
         <name>
          <surname>
           Kadambi
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Berul
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Breitbart
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
        </person-group>
        <source>
         J. Mol. Cell. Cardiol.
        </source>
        <volume>
         35
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1043
        </fpage>
        <pub-id pub-id-type="pmid">
         12967627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Herzenberg
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kassiri
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Reich
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Khokha
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Backx
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Scholey
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
        </person-group>
        <source>
         Am. J. Path.
        </source>
        <volume>
         168
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1808
        </fpage>
        <pub-id pub-id-type="pmid">
         16723697
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <mixed-citation id="bib11-2" publication-type="other">
        Acton, S. L.; Ocain, T. D.; Gould, A. E.; Dales, N. A.; Guan, B.; Brown, J. A.; Patane, M.; Kadambi, V. J.; Solomon, M.; Stricker-Krongrad, A.; PCT Int. Appl. WO 039997,
        <bold>
         2002
        </bold>
       </mixed-citation>
       <mixed-citation id="bib11-3" publication-type="other">
        <italic>
         Chem. Abstr.
        </italic>
        <bold>
         2002,
        </bold>
        <italic>
         136
        </italic>
        , 402027.
       </mixed-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Leibbrandt
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wada
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Slutsky
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <source>
         Nat. Med.
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         875
        </fpage>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wada
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Leong-Poi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Fukamizu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           C.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Hein
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Uhlig
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Slutsky
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <source>
         Nature
        </source>
        <volume>
         436
        </volume>
        <year>
         2005
        </year>
        <fpage>
         112
        </fpage>
        <pub-id pub-id-type="pmid">
         16001071
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deaton
          </surname>
          <given-names>
           D.N.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           E.N.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Gross
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
         <name>
          <surname>
           Strelow
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Sotiropoulou
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Pampalakis
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Arampatzidou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <source>
         5th General Meeting of the International Proteolysis Society
        </source>
        <year>
         2007
        </year>
        <publisher-name>
         International Proteolysis Society
        </publisher-name>
        <publisher-loc>
         Patras, Greece
        </publisher-loc>
        <fpage>
         444
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bhagwat
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Fink
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gude
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Qiao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sakane
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Berry
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ghai
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
        </person-group>
        <source>
         Bioorg. Med. Chem. Lett.
        </source>
        <volume>
         5
        </volume>
        <year>
         1995
        </year>
        <fpage>
         735
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <note>
        <p>
         Hydrolyses were performed under an argon atmosphere. When hydrolyses were carried out with reactions open to the atmosphere, varying amounts of disulfide products were isolated, likely from aerobic oxidation. The enzyme assays contain a reducing agent, tris-(2-chloroethyl)-phosphate (TCEP), to prevent oxidation of the thiols to disulfides during the assays. Dilutions of 10 mM stock solutions of the thiols
         <bold>
          1a
         </bold>
         –
         <bold>
          1s
         </bold>
         to final assay concentrations were done with 50% aqueous acetonitrile just prior to protease inhibition studies. Under these standard conditions, both the thiols and their corresponding disulfides showed enzyme inhibitory activity. Presumably, the disulfides were reduced to their corresponding thiols by TCEP during the pre-incubation period, before substrates were added. In contrast, if the assays were performed without TCEP, the disulfides were completely inactive, while the potencies of the thiols were attenuated, probably because of partial aerobic oxidation to their corresponding disulfides during the pre-incubation period.
        </p>
       </note>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <note>
        <p>
         Alcohols
         <bold>
          2m
         </bold>
         and
         <bold>
          2n
         </bold>
         are commercially available. Alcohol
         <bold>
          2k
         </bold>
         was prepared from cyclobutane methanol in three steps. First, oxidation of the alcohol with pyridinium chlorochromate afforded the aldehyde. Then, reaction of the aldehyde with trimethylsilyl cyanide and
         <italic>
          N
         </italic>
         -methyl morpholine N-oxide provided the silyl protected cyanohydrin. Finally, hydrochloric acid catalyzed hydrolysis of the cyanohydrin yielded the hydroxyacid
         <bold>
          2k
         </bold>
         .
        </p>
       </note>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Charifson
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
        </person-group>
        <source>
         Practical Application of Computer-Aided Drug Design
        </source>
        <year>
         1997
        </year>
        <publisher-name>
         Marcel Dekker
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         243
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <note>
        <p>
         The ‘grow’ algorithm within the MVP program was used to dock the inhibitor into the active site beginning from the carboxylic acid group.
        </p>
       </note>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Towler
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Staker
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Prasad
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Menon
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Parsons
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ryan
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Fisher
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Dales
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Patane
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Pantoliano
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
        </person-group>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         279
        </volume>
        <year>
         2004
        </year>
        <fpage>
         17996
        </fpage>
        <pub-id pub-id-type="pmid">
         14754895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Natesh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Schwager
          </surname>
          <given-names>
           S.L.U.
          </given-names>
         </name>
         <name>
          <surname>
           Sturrock
          </surname>
          <given-names>
           E.D.
          </given-names>
         </name>
         <name>
          <surname>
           Acharya
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
        </person-group>
        <source>
         Nature
        </source>
        <volume>
         421
        </volume>
        <year>
         2003
        </year>
        <fpage>
         551
        </fpage>
        <pub-id pub-id-type="pmid">
         12540854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sahli
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Frank
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Schweizer
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Diederich
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Blum-Kaelin
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Aebi
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Boehm
          </surname>
          <given-names>
           H.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Oefner
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Dale
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
        </person-group>
        <source>
         Helv. Chim. Acta
        </source>
        <volume>
         88
        </volume>
        <year>
         2005
        </year>
        <fpage>
         731
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oefner
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Roques
          </surname>
          <given-names>
           B.P.
          </given-names>
         </name>
         <name>
          <surname>
           Fournie-Zaluski
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Dale
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
        </person-group>
        <source>
         Acta Crystallogr. D: Biol. Crystallogr.
        </source>
        <volume>
         60
        </volume>
        <year>
         2004
        </year>
        <fpage>
         392
        </fpage>
        <pub-id pub-id-type="pmid">
         14747736
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec sec-type="supplementary-material">
      <title>
       Supplementary data
      </title>
      <p>
       <supplementary-material content-type="local-data" id="d32e2773">
        <caption>
         <title>
          Supplementary data
         </title>
        </caption>
        <media xlink:href="mmc1.doc">
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack>
      <title>
       Acknowledgment
      </title>
      <p>
       The authors would like to thank Rob I. West for helpful discussions.
      </p>
     </ack>
     <fn-group>
      <fn fn-type="supplementary-material" id="d32e2761">
       <p>
        Supplementary data associated with this article can be found, in the online version, at
        <ext-link ext-link-type="doi" xlink:href="10.1016/j.bmcl.2007.11.048">
         doi:10.1016/j.bmcl.2007.11.048
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
  </pmc-articleset>
 </body>
</html>